cytarabine has been researched along with Acute Myelogenous Leukemia in 3877 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1116 (28.79) | 18.7374 |
| 1990's | 610 (15.73) | 18.2507 |
| 2000's | 508 (13.10) | 29.6817 |
| 2010's | 1138 (29.35) | 24.3611 |
| 2020's | 505 (13.03) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, TH; Kessel, D; Khilanani, P | 2 |
| Choi, SJ; Choi, SU; Han, SY; Kim, YC; Lee, SD; Moon, MJ | 1 |
| Bell-Horwath, TR; Li, G; Merino, EJ; Mulloy, JC; Thowfeik, FS; Vadukoot, AK; Wunderlich, M | 1 |
| Atallah, G; Aycinena, A; Basham, S; Bellamacina, C; Burger, MT; Castillo, J; Chan, J; Chen, MY; Dai, Y; Ding, Y; Feucht, P; Fritsch, C; Garcia, PD; Ginn, E; Han, W; Holash, J; Huh, K; Kauffmann, A; Lambert, A; Lan, J; Langowski, JL; Lindvall, MK; Mathur, M; Muller, K; Nishiguchi, G; Pfister, E; Simmons, R; Tamez, V; Vanasse, KG; Wang, Y; Zang, R; Zavorotinskaya, T; Zhang, Y | 1 |
| Chen, Y; Guo, H; Jin, J; Jin, Q; Li, B; Li, T; Lin, G; Ling, J; Lu, S; Lu, T; Wang, Y; Wang, Z; Yang, T; Yao, C; Yuan, H; Zhang, L; Zhi, Y | 1 |
| Feng, R; Li, J; Liu, H; Ning, S; Pei, L; Sun, J; Wang, T; Xing, B; Zhao, Y; Zhu, X | 1 |
| Braniecki, M; Gok Yavuz, B; Hwang, J; Quigley, JG; Singh, N; Tsoukas, MM | 1 |
| Anderson, E; Cox, C; Gynn, LE; May, JE; Robinson, G; Upstill-Goddard, G; Wexler, SA | 1 |
| Advani, AS; Becker, PS; Bixby, DL; DeAngelo, DJ; Feldman, EJ; Jonas, BA; Liesveld, JL; Magnani, JL; Marlton, P; O'Dwyer, ME; Thackray, HM | 1 |
| Almlöf, I; Calderón-Montaño, JM; Centio, A; Erkers, T; Estruch, M; Friedrich, S; Gad, H; Garnett, MJ; Göktürk, C; Helleday, T; Henriksson, M; Heshmati, Y; Höglund, A; Koolmeister, T; Lehmann, S; Nagesh Danda, A; Östling, P; Pham, TM; Rasti, A; Sandvall, T; Sanjiv, K; Scobie, M; Seashore-Ludlow, B; Struyf, N; Theilgaard-Mönch, K; Tsuber, V; Våtsveen, TK; Visnes, T; Walfridsson, J; Wallner, O; Warpman Berglund, U; Wiita, E | 1 |
| Ariti, C; Burnett, AK; Clark, RE; Copland, M; Dennis, M; Gilkes, A; Hemmaway, C; Hills, RK; Knapper, S; Mehta, P; Radia, R; Russell, N; Thomas, IF; Upton, L | 1 |
| Daver, N; DiNardo, C; Konopleva, M; Saxena, K | 1 |
| Alakel, N; Bornhäuser, M; Chemnitz, J; Döhner, H; Döhner, K; Fransecky, L; Gaidzik, V; Germing, U; Götze, KS; Haas, R; Hänel, M; Hanoun, M; Henning, L; Heuser, M; Holderried, TAW; Holtick, U; Jehn, CF; Kaiser, U; Kobbe, G; Koch, K; Kraus, S; Krause, SW; Kriege, O; Krüger, W; Lauseker, M; Middeke, JM; Morgner, A; Neuerburg, C; Platzbecker, U; Rautenberg, C; Röhnert, MA; Röllig, C; Sauer, T; Schäfer-Eckart, K; Schetelig, J; Schliemann, C; Scholl, S; Schröder, J; Schroeder, T; Severmann, J; Sockel, K; Stelljes, M; Stölzel, F; Thol, F; Unglaub, JM; Verbeek, M; Vucinic, V; Wagner-Drouet, E; Wass, M | 1 |
| Fleischmann, M; Frietsch, JJ; Glaser, A; Hammersen, J; Hilgendorf, I; Hochhaus, A; Mühleck, R; Sayer, HG; Schnetzke, U; Scholl, S; Schrenk, K | 1 |
| Kubal, T; Lee, J; Li, W; McCarthy, K; Richter, K | 1 |
| Garcia-Manero, G; Jabbour, EJ; Jain, N; Kantarjian, HM; Ravandi, F; Welch, MA; Wierda, WG | 1 |
| He, Y; Li, X; Long, B; Sun, Y; Wen, R; Zhang, J; Zhang, X | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Leiby, BE; Schmucker, AM; Wilde, L | 1 |
| Chen, Q; Chen, Y; Hu, J; Li, J; Li, X; Mao, Y; Shen, Y; Sheng, Y; Wang, L; Weng, X; Wu, J; Wu, M; You, J; Zhang, Y; Zhao, H; Zheng, Y | 1 |
| Augeri, S; Aydin, S; Bracci, C; D'Ardia, S; Ferrero, E; Funaro, A; Marchisio, S; Massaia, M; Ortolan, E; Yakymiv, Y | 1 |
| Caldwell, KJ; Farrar, JE; Federico, SM; Hu, Y; Lei, S; Lewis, S; Nichols, KE; Onciu, M; Ribeiro, RC; Rubnitz, JE; Salek, M; Takemoto, CM; Triplett, BM; Wlodarski, MW; Zhang, J | 1 |
| Anthony, S; Bearss, D; Bergua Burgues, JM; Bhatnagar, B; Bhatt, VR; Castillo, TBD; Dalovisio, A; Dillon, R; Douglas Smith, B; Esteve, J; Fine, G; Frankfurt, O; Lee, DJ; Lin, TL; Litzow, MR; Mehta, P; Montesinos, P; Nazha, A; Schriber, J; Vicente, MV; Vigil, CE; Wang, ES; Yair Levy, M; Yee, K; Zeidner, JF | 1 |
| Alonzo, TA; Aplenc, R; de Bont, ESJM; Gamis, AS; Gerbing, RB; Hoff, FW; Horton, TM; Jenkins, GN; Kolb, EA; Kornblau, SM; Meshinchi, S; Qiu, Y; van Dijk, AD | 1 |
| Gai, Y; Lin, H; Liu, F; Liu, S; Lv, J; Su, Y; Wang, G; Wang, Y; Zhao, Q | 1 |
| Alric, C; Bérard, E; Bertoli, S; Bidet, A; de Grande, AC; Delabesse, E; Dumas, PY; Galtier, J; Klein, E; Lechevalier, N; Leguay, T; Luquet, I; Pigneux, A; Récher, C; Rieu, JB; Sarry, A; Tavitian, S; Vergez, F; Vial, JP | 1 |
| Coombs, CC; DeZern, AE; Foster, MC; Gojo, I; Ivanova, A; Jamieson, K; Knaus, HA; Levis, MJ; Luznik, L; Mazziotta, F; McKinnon, KP; Montgomery, ND; Moore, D; Mukhopadhyay, R; Prince, GT; Serody, JS; Smith, BD; Van Deventer, H; Vincent, BG; Webster, JA; Wilkinson, AD; Zeidner, JF | 1 |
| Kaspers, GJL; Kipng'etich, M; Klein, K; Langat, S; Mostert, S; Njuguna, F; Olbara, G; van Weelderen, RE; Vik, TA | 1 |
| Álamo, P; Alba-Castellón, L; Aviñó, A; Casanova, I; Cedó, L; Eritja, R; Falgàs, A; Gallardo, A; García-León, A; Mangues, R; Núñez, Y; Pallarès, V; Sánchez-García, L; Serna, N; Sierra, J; Unzueta, U; Vázquez, E; Villaverde, A | 1 |
| Kuo, DJ; Le Floch, N; Spies, JM; Wong, V | 1 |
| Michaelis, LC | 1 |
| Luger, SM | 3 |
| Itsumi, M; Kajikawa, M; Kato, H; Kawai, C; Kitakaze, K; Kuribayashi, F; Miyano, K; Okamoto, S; Yamauchi, A | 1 |
| Thol, F | 2 |
| Guo, Z; Liu, L; Liu, P; Ren, X; Wang, F; Xu, W; Xu, Y; Zhang, H; Zhang, S; Zheng, L | 1 |
| Burnett, A; Dennis, M; Hills, R; Kjeldsen, L; Russell, N | 1 |
| Arnan, M; Bargay, J; Bataller, A; Brunet, S; Castaño-Díez, S; Coll, R; Colomer, D; Costa, D; de Llano, MPQ; Diaz-Beyá, M; Escoda, L; Esteban, D; Esteve, J; Gallardo, D; Garcia-Guiñon, A; Garrido, A; Guijarro, F; López-Guerra, M; Merchan, BM; Mozas, P; Nomdedéu, JF; Oliver-Caldés, A; Oñate, G; Pratcorona, M; Rivero, A; Rozman, M; Salamero, O; Sampol, A; Sierra, J; Tormo, M; Vall-Llovera, F; Vives, S; Zamora, L | 1 |
| Cai, H; Ekblom, M; Johansson, AS; Kondo, M; Qian, H; Sandhow, L; Sasaki, T; Tryggvason, K; Ungerstedt, J; Walfridsson, J; Xiao, P; Zawacka-Pankau, J | 1 |
| Shimony, S; Stahl, M; Stone, RM | 1 |
| Rowe, JM | 4 |
| Al-Mansour, Z; Alonzo, TA; Aplenc, R; Cao, X; Cogle, C; Elsayed, AH; Gamis, A; Kolb, EA; Lamba, JK; Meshinchi, S; Mitra, AK; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, J; Wu, H | 1 |
| DiNardo, CD; Pollyea, DA | 1 |
| Jordheim, LP | 1 |
| Assis-Mendonça, GR; Bueno, MLP; da Silva, JAF; Duarte, ASS; Ferro, KP; Pericole, FV; Rego, EM; Roversi, FM; Saad, STO; Shiraishi, RN; Torello, CO | 1 |
| Akahoshi, Y; Gomyo, A; Kako, S; Kameda, K; Kanda, Y; Kawamura, M; Kawamura, S; Kimura, SI; Kusuda, M; Matsumi, S; Misaki, Y; Nakamura, Y; Nakasone, H; Okada, Y; Sato, M; Takeshita, J; Tamaki, M; Tanihara, A; Wada, H; Yoshimura, K; Yoshino, N | 1 |
| Chen, Q; Chen, X; Liu, J; Luo, W; Sun, H; Zhou, G | 1 |
| Kuang, P; Liu, T; Qin, Y | 1 |
| Cai, X; Geng, L; Han, Y; Liu, H; Liu, X; Sun, Z; Tang, B; Tong, J; Wang, L; Wang, X; Xue, L; Zhang, L; Zhao, N; Zheng, C; Zhou, L; Zhu, W; Zhu, X | 1 |
| Fleischmann, M; Frietsch, JJ; Hammersen, J; Hilgendorf, I; Hochhaus, A; Prims, F; Schnetzke, U; Scholl, S; Schrenk, K; Thiede, C | 1 |
| Strickland, SA; Vey, N | 1 |
| Casasnovas, NM; Castells, G; Manzaneque, A; Muntañola, A | 1 |
| Dunham, N; Fan, H; Garrett-Bakelman, FE; Prajapati, SC | 1 |
| Argüello, RJ; Aroua, N; Avet-Loiseau, H; Boet, E; Bosc, C; Bousard, A; Cabon, F; Cognet, G; Farge, T; Fournié, JJ; Fovez, Q; Gadaud, N; Gotanègre, M; Jarrou, L; Joffre, C; Kaoma, T; Kaphan, E; Kluza, J; Larrue, C; Marine, JC; Mazzotti, C; Mouchel, PL; Nicot, N; Picard, M; Poillet-Perez, L; Polley, N; Rambow, F; Récher, C; Sabatier, M; Sahal, A; Saland, E; Sarry, JE; Stuani, L; Su, X; Tamburini, J; Tiong, IS; Tosolini, M; Vergez, F; Wang, Y; Wei, AH | 1 |
| Chen, L; Chen, P; Hou, D; Huang, H; Li, D; Lin, X; Wang, B; Wang, X; You, R; Zhang, B; Zheng, X | 1 |
| Cao, Y; Han, C; Li, L; Shen, J; Yu, X | 1 |
| Castillo, TBD; Delgado, A; Duan, Y; Enjeti, AK; Garbayo Guijarro, B; Gimenez Conca, A; Girshova, L; Guvenc, B; Hsiao, HH; Lee, JH; Llamas, C; Martelli, MP; Miyamoto, T; Olivera, LJE; Sanford, D; Tomuleasa, C | 1 |
| Aldrich, J; Alvarado, Y; Borthakur, G; Daver, N; DiNardo, C; Garcia-Manero, G; Kadia, T; Ohanian, M; Patel, K; Pemmaraju, N; Ravandi, F; Senapati, J; Shoukier, M; Wang, X | 1 |
| Bhojwani, D; Brown, P; Burke, MJ; Chang, BH; Chi, YY; Colace, SI; Florendo, E; Gossai, N; Heimbruch, K; Hermiston, ML; Heym, K; Hutchinson, RJ; Huynh, VT; Kaplan, JA; Malvar, J; Mody, R; O'Brien, TA; Place, AE; Pommert, L; Pulakanti, K; Rao, S; Schafer, ES; Shaw, PH; Sposto, R; Stelloh, C; Wayne, A; Ziegler, DS | 1 |
| Cheng, S; Ding, X; Gao, L; Hu, S; Hu, Y; Li, B; Li, Z; Ling, J; Lu, J; Lu, Q; Pan, J; Ribeiro, RC; Wang, J; Wang, Y; Xiao, P; Zheng, J | 1 |
| Chen, CY; Cui, ZL; Fu, Y; Gao, ZX; Liu, F; Ma, S; Zhang, L; Zhou, MR | 1 |
| Bai, J; Pei, Z; Song, Q; Wang, H; Wang, J; Wu, H; Zhang, B | 1 |
| Lancet, J; Ravandi, F | 1 |
| Babushok, DV; Carulli, A; Frey, NV; Freyer, CW; Gill, SI; Graveno, ME; Hexner, EO; Loren, AW; Luger, SM; Mangan, BL; Martin, ME; McCurdy, SR; Nietupski, R; Perl, AE; Porter, DL; Pratz, KW | 1 |
| Chen, J; Fang, Q; Gong, B; Gong, X; Gu, R; Jin, J; Li, Y; Lin, D; Liu, B; Liu, K; Liu, Y; Mi, Y; Qiu, S; Song, Z; Wang, J; Wang, Y; Wei, H; Wei, S; Yang, M; Zhang, G; Zhang, J; Zhou, C | 1 |
| Bagnoli, JW; Enard, W; Hellmann, I; Herold, T; Jayavelu, AK; Jeremias, I; Jurinovic, V; Mann, M; Richter, D; Valtierra-Gutiérrez, IA; Vick, B; Zeller, C | 1 |
| Bai, H; Duan, J; Fu, W; Li, Y; Liang, X; Peng, Y; Yu, W; Zhang, Q | 1 |
| Bui, CN; Conca, AG; Del Castillo, TB; Delgado, A; Duan, Y; Enjeti, AK; Girshova, L; Guijarro, BG; Guvenc, B; Hsiao, HH; Ito, T; Lee, JH; Llamas, C; Martelli, MP; Olivera, LJE; Sanford, D; Tomuleasa, C | 1 |
| Bewersdorf, JP; Goshua, G; Huntington, SF; Patel, KK; Podoltsev, NA; Shallis, RM; Zeidan, AM | 1 |
| Feng, Y; Guryanova, OA; Kaur, P; Shabashvili, DE; Venugopal, K | 1 |
| Anderson, R; Ghiraldeli, L; Pardee, TS; Pladna, K | 1 |
| Guo, H; Lu, W; Shi, J; Zhang, Y; Zhang, Z; Zhu, J | 1 |
| Gao, W; Hu, J; Jiang, J; Wan, M; Wang, L | 1 |
| Anderson, R; Bhave, RR; Chou, JW; Dralle, S; Ellis, LR; Howard, DS; Isom, S; Lyerly, S; Manuel, M; Miller, LD; Pardee, TS; Pladna, KM; Powell, BL; Schramm, NJ | 1 |
| Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
| Ando, J; Delgado, A; Duan, Y; Eto, T; Garbayo Guijarro, B; Imada, K; Ishikawa, Y; Ito, T; Katsuoka, Y; Kawakami, Y; Kiyoi, H; Kizaki, M; Komeno, T; Kondo, T; Llamas, C; Miyamoto, T; Mori, A; Morita, T; Morita, Y; Nakayama, M; Satake, A; Takezako, N; Taneike, I; Uoshima, N; Watanabe, J; Yamamoto, K; Yoshida, C | 1 |
| Huang, ZP; Liu, M; Zhang, JZ | 2 |
| DU, CK; Lu, Y | 1 |
| Huleihel, M; Kapelushnik, J; Khaleel, B; Lunenfeld, E | 2 |
| Beckermann, BM; Catalani, O; Cavenagh, J; Deeren, D; Fenaux, P; Genevray, M; Girshova, L; Jamois, C; Konopleva, MY; Krauter, J; Martinelli, G; Montesinos, P; Muehlbauer, S; Mundt, K; Ott, M; Ottmann, O; Petrini, M; Pigneux, A; Rambaldi, A; Recher, C; Rodriguez-Veiga, R; Röllig, C; Schäfer, JA; Taussig, D; Vey, N; Wei, AH; Yoon, SS | 1 |
| Borthakur, G; Brandt, M; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Kim, K; Konopleva, M; Loghavi, S; Pemmaraju, N; Pierce, S; Rausch, CR; Ravandi, F; Sasaki, K; Short, NJ; Tang, G; Yilmaz, M | 1 |
| Chen, R; Li, L; Li, X; Sun, J; Xie, M; Xie, W; Yang, X; Ye, X; Zheng, X; Zhu, J; Zhu, L; Zhu, M | 1 |
| Ahmed, SO; Aljurf, M; Alotaibi, S; Mohty, M; Niederwieser, D; Sanz, J | 1 |
| Azarnoush, S; Dhunputh, C; Ducassou, S; Leverger, G; Merched, M; Pasquet, M; Petit, A; Strullu, M | 1 |
| Faderl, S; Goldberg, SL; Lancet, JE; Lin, TL; Newell, LF; Ryan, RJ; Uy, GL; Wieduwilt, MJ | 1 |
| Gong, P; Jing, Y; Wang, Y; Waxman, S; Yin, C; Zhang, J; Zhang, Z; Zhao, L | 1 |
| Benjamin, K; Bui, CN; Devine, J; DiNardo, CD; Fiedler, W; Fracchiolla, N; Ivanov, V; Jonas, BA; Kamalakar, R; Kim, I; Mendes, W; Montesinos, P; Novak, J; Ofran, Y; Panayiotidis, P; Pejsa, V; Potluri, J; Pratz, KW; Recher, C; Schuh, AC; Stevens, D; Turgut, M; Wei, AH; Wei, X; Yamamoto, K; Yeh, SP | 1 |
| Al-Antary, ET; Edwards, H; Ge, Y; Gupte, A; Ravindranath, Y; Taub, JW | 1 |
| Ben Khoud, M; Brinster, C; Figeac, M; Leprêtre, F; Mopin, A; Quesnel, B; Sebda, S; Villenet, C | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Liu, Z; Xiang, B; Zeng, Q | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M | 1 |
| Barthélémy, A; Berthon, C; Cheok, M; Farfariello, V; Guillemette, A; Idziorek, T; Jouy, N; Labiad, O; Laguillaumie, MO; Lemonnier, L; Lewuillon, C; Peyrouze, P; Quesnel, B; Shaik, FA; Tarhan, MC; Titah, S; Touil, Y | 1 |
| Elonen, E; Huhtala, H; Itälä-Remes, M; Jantunen, E; Kairisto, V; Kauppila, M; Koistinen, P; Koivunen, E; Kolonen, A; Kuittinen, T; Nousiainen, T; Ollikainen, H; Pelliniemi, TT; Penttilä, K; Porkka, K; Pyörälä, M; Räty, R; Rauhala, A; Rimpiläinen, J; Rintala, H; Ruutu, T; Säily, M; Sankelo, M; Silvennoinen, R; Sinisalo, M; Volin, L | 1 |
| Fang, QY; Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Qiu, SW; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, CX; Zhang, GJ; Zhou, CL | 1 |
| Fang, YJ; Huang, J; Li, HM; Sun, XY; Wang, YP; Xue, Y | 1 |
| Li, LC; Wang, JD; Yang, SS; Zeng, QF; Zheng, F; Zhou, Z | 1 |
| Bay, JO; Béné, MC; Bertrand, P; Bonmati, C; Carré, M; Darrouzain, F; Gallego-Hernanz, MP; Gyan, E; Hérault, O; Hunault, M; Lioure, B; Peterlin, P; Picou, F; Pigneux, A; Récher, C; Ternant, D; Vallet, N | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Jiang, Y; Ye, Z | 1 |
| Byrne, J; Chromik, J; de Botton, S; DiNardo, CD; Döhner, H; Doronin, V; Fathi, AT; Frankfurt, O; Hasan, M; Kim, HJ; Koprivnikar, J; Laille, E; Larson, RA; Martin-Regueira, P; Montesinos, P; Ommen, H; Papayannidis, C; Pigneux, A; Salamero, O; Schuh, AC; Semochkin, S; Thol, F; Thomas, X; Vidriales, MB; Vyas, P; Wei, AH; Yu, X | 1 |
| Bhojwani, D; Burke, MJ; Chao, K; Colace, SI; Doan, A; Gossai, NP; Guinipero, T; Hilsenbeck, SG; Hinson, A; Jo, E; Kaplan, JA; Otterson, D; Pommert, L; Schafer, ES; Stevens, AM; Wayne, AS | 1 |
| Amit, O; Apel, A; Bar-On, Y; Frisch, A; Moshe, Y; Nachmias, B; Ofran, Y; Raanani, P; Ram, R; Shargian, L; Shimony, S; Vainstein, V; Wolach, O; Yeshurun, M | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Chen, D; Elliott, MA; Gangat, N; Hogan, WJ; Hook, CC; Ketterling, RP; Litzow, MR; Mangaonkar, A; Pardanani, A; Patnaik, MS; Shah, M; Tefferi, A; Viswanatha, D | 1 |
| Adès, L; Ayaka, P; Benaksas, C; Berrou, J; Boissel, N; Braun, T; Chat, L; Chauvel, C; Clappier, E; Dal Bello, R; Di Feo, G; Dombret, H; Duchmann, M; Fenouille, N; Itzykson, R; Joudinaud, R; Kim, R; Ling, F; Pacchiardi, K; Pardieu, B; Pasanisi, J; Preudhomme, C; Puissant, A; Raffoux, E; Sodaro, G; Vaganay, C; Vasseur, L | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Chan, O; Deutsch, Y; Eatrides, J; Jain, AG; Komrokji, R; Kuykendall, A; Lancet, J; Lee, D; Padron, E; Sallman, D; Sweet, K; Talati, C | 1 |
| Aumann, S; Frisch, A; Gatt, ME; Gross Even-Zohar, N; Gural, A; Leiba, R; Nachmias, B; Ofran, Y; Shaulov, A; Vainstein, V; Zimran, E; Zohar, Y; Zuckerman, T | 1 |
| Balasubramanian, P; Das, S; Ijee, S; Kumar, S; Stallon Illangeswaran, RS; Velayudhan, SR | 1 |
| Alsdorf, WH; Bokemeyer, C; Brauneck, F; Fiedler, W; Ghandili, S; Karagiannis, P; Klingler, F; Modemann, F; Wolschke, C | 1 |
| Batinic, D; Batinic, J; Bedalov, A; Dembitz, V; Lalic, H; Smoljo, T; Tomic, B; Visnjic, D | 1 |
| Dai, Z; Fan, S; Hu, H; Jiao, Q; Li, J; Liang, Y; Lv, XB; Sun, J; Tang, X; Wang, M; Yan, J; Yu, B; Yuan, X; Zhang, C; Zhang, F; Zhang, Z | 1 |
| Chen, Y; Fang, Q; Hu, T; Ni, M; Pan, C; Wang, J; Wang, W; Zhang, S; Zhang, T | 1 |
| Ball, BJ; Koller, PB; Pullarkat, V | 1 |
| Cao, Y; Chen, J; Chen, L; Li, X; Ren, J; Wu, J; Zhang, Y | 1 |
| Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE | 1 |
| Srinivasan, S | 1 |
| Anzai, N; Arai, Y; Atsuta, Y; Fukuda, T; Hiramoto, N; Kanda, J; Kawamura, K; Kimura, T; Konuma, T; Mizuno, S; Murata, M; Nakamae, H; Onizuka, M; Ota, S; Ozawa, Y; Sawa, M; Shimomura, Y; Takahashi, S; Takami, A; Tanaka, M; Yanada, M | 1 |
| Abernathy, KM; Byrne, M; Chen, H; Gatwood, KS; Perciavalle, MA; Zakhari, MM | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Budagaga, Y; Haddad, A; Haddad, M; Hofman, J; Laštovičková, L; Morell, A; Novotná, E; Portillo, R; Vagiannis, D; Wsól, V; Zhang, Y | 1 |
| Agrawal, N; Ahmed, R; Bansal, N; Bhurani, D; Halder, R; Mehta, P; Rainchwar, S; Singh, R; Verma, M | 1 |
| Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X | 1 |
| Angona, A; Arnan, M; Bargay, J; Coll, R; Cruz, D; Díaz-Santa, J; Díez, I; Esteve, J; Gallardo, D; Garcia, A; Garrido, A; González-Bártulos, M; Lloveras, N; Osca, G; Pratcorona, M; Rodríguez-Romanos, R; Salamero, O; Sampol, A; Sierra, J; Sitges, M; Talarn, C; Tormo, M; Tuset, E; Vall-Llovera, F; Vila, J; Vives, S; Zamora, L | 1 |
| Bakhshi, S; Batra, A; Bisht, R; Chaudhary, S; Dubashi, B; Ganesan, TS; Kayal, S; Kumar, H; Radhakrishnan, V; Rajaraman, S; Shenoy, PK; Thampy, C | 1 |
| Annageldiyev, C; Cabot, MC; Claxton, DF; Conaway, MR; Costa-Pinheiro, P; Deering, TG; Feith, DJ; Fox, TE; Golla, U; Kester, M; Khokhlatchev, AV; Loughran, TP; Sharma, A; Shaw, JJP; Tan, SF; Ung, J | 1 |
| Balsat, M; Barraco, F; Ducastelle-Leprêtre, S; Fossard, G; Ghesquières, H; Gilis, L; Hayette, S; Heiblig, M; Huet, S; Labussière-Wallet, H; Larcher, MV; Loron, S; Meur, GL; Michallet, M; Plesa, A; Renault, M; Sujobert, P; Thérèse, RM; Thomas, X; Tigaud, I | 1 |
| Anagnostopoulos, A; Bergeron, J; Champion, R; Chyla, B; DiNardo, CD; Fiedler, W; Hou, JZ; Ivanov, V; Jiang, Q; Kim, I; Laribi, K; McDonald, A; Mendes, W; Montesinos, P; Murthy, V; Novak, J; Pagoni, M; Panayiotidis, P; Sun, Y; Ting, SB; Wang, J; Wei, AH; Yamauchi, T | 1 |
| Beeler-Marfisi, J; Bienzle, D; Calvalido, J; Matsuyama, A; Mutsaers, AJ; Richardson, D; Wood, RD | 1 |
| Guo, S; Ji, C; Ji, M; Jia, R; Li, G; Li, P; Lu, F; Ma, D; Sun, T; Sun, Y; Xia, Y; Xue, F; Yan, S; Ye, J; Zang, S; Zhang, J | 1 |
| Dong, CX; Hou, YF; Huang, YJ; Kang, JM; Qi, K; Yang, LH; Zhang, JH; Zhang, YF | 1 |
| Bao, X; Carter, J; Dombkowski, A; Edwards, H; Ge, Y; Hege Hurrish, K; Hüttemann, M; Kalpage, HA; Kim, S; Li, J; Li, X; Ma, J; Qiao, X; Su, Y; Taub, JW; Wang, G | 1 |
| Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T | 1 |
| Foutouhi, S; Kiuru, M; Simmons, E; Tartar, DM | 1 |
| Chen, Y; Deng, K; Ju, W; Li, L; Ni, W; Wang, L | 1 |
| Asubonteng, K; Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Prebet, T | 1 |
| Assouline, S; Desjardins, P; Fournier, PA; Leber, B; Leitch, HA; Lembo, PMC; Paulson, K; Sanford, D | 1 |
| Chang, K; Guan, F; Li, H; Li, X; Lu, Y; Xie, C | 1 |
| Chiba, S; Hattori, K; Kato, T; Kurita, N; Maruyama, Y; Nanmoku, T; Nishikii, H; Obara, N; Sakamoto, T; Sakata-Yanagimoto, M; Suehara, Y; Tsuboi, Y; Yokoyama, Y; Yoshida, C | 1 |
| Anthony, DC; Bonal, DM; Butera, J; Castillo-Martin, M; Chorzalska, A; Dubielecka, PM; Hopkins, K; Liang, O; Melcher, D; Oakes, A; Olszewski, AJ; Pardo, M; Petersen, M; Quesenberry, P; Reagan, J; Rintels, P; Schorl, C; So, EY; Treaba, DO; Zhao, TC | 1 |
| Björn, N; Gréen, H; Jakobsen, I; Lotfi, K; Sundkvist, M | 1 |
| Billingham, L; Craddock, C; Dillon, R; Fox, S; Freeman, S; Hemmaway, C; Homer, E; Jackson, A; Knapper, S; Leahy, J; Mamwell, A; Maycock, S; Ommen, HB; Potter, N; Russell, N; Thomas, C; Wei, A | 1 |
| Angenendt, L; Bartscht, T; Berdel, AF; Berdel, WE; Bischoff, M; Butterfass-Bahloul, T; Gerss, J; Hentrich, M; Kewitz, T; Koch, R; Krug, U; Lenz, G; Mikesch, JH; Peceny, R; Schliemann, C; Serve, H; Spiekermann, K; Steffen, B | 1 |
| Baell, J; Bruedigam, C; Bullinger, L; Bywater, MJ; Cooper, E; Cooper, L; Godfrey, W; Haldar, R; Huang, F; Jacquelin, S; Janardhanan, Y; Jin, J; Lane, SW; Ling, VY; Straube, J; Tavakoli Shirazi, P; Tey, SK; Zhao, Y | 1 |
| Ariti, C; Burnett, AK; Cheng, P; Copland, M; De Santo, C; Dennis, M; Knapper, SK; McMullin, MF; Mehta, P; Mussai, F; Russell, NH; Scarpa, U; Stavrou, V; Sydenham, M; Thomas, IF; Upton, L | 1 |
| Bazinet, A; Borthakur, G; Chien, KS; Darbaniyan, F; Daver, NG; DiNardo, CD; Garcia-Manero, G; Hammond, D; Jabbour, EJ; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Montalban-Bravo, G; Pemmaraju, N; Pierce, SA; Ravandi, F; Sasaki, K; Venugopal, S | 1 |
| Chen, X; Gao, XH; Hao, HL; Huang, C; Li, J; Li, JY; Li, Y; Liu, JY; Tu, CQ; Wang, DW; Wang, RC; Xiong, X; Yang, J; Yang, YB; Yuan, J; Zhang, XX; Zhang, XY; Zheng, CF; Zou, LL | 1 |
| Aloyz, R; Fooks, K; Galicia-Vazquez, G; Gife, V; Hulea, L; Johnson, NA; Luo, V; Mercier, FE; Nouhi, Z; Orthwein, A; Poon, WWL; Rys, RN; Schcolnik-Cabrera, A | 1 |
| Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A | 1 |
| Matthews, A; Pratz, KW | 1 |
| Ball, B; Baron, J; Famulare, C; Fazal, S; Goldberg, AD; Griffiths, EA; Przespolewski, A; Sanikommu, SR; Stahl, M; Sweet, K; Talati, C; Thompson, JE; Thota, S; Vachhani, P; Waksal, J; Wang, ES | 1 |
| Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H | 1 |
| Dabaja, BS; Fang, PQ; Nasr, L; Short, NJ; Wu, SY | 1 |
| Stone, RM | 5 |
| Cao, S; Chai, X; Fang, Q; Feng, C; Hu, T; Hu, X; Pan, C; Shang, Q; Wang, J; Yang, T; Zhang, X; Zheng, L | 1 |
| Abuasab, T; Alvarado, Y; Borthakur, G; Brandt, MA; Daver, N; DiNardo, C; Haddad, FG; Kadia, T; Kantarjian, H; Pemmaraju, N; Ravandi, F; Senapati, J | 1 |
| Frisch, A; Ofran, Y; Rowe, JM | 1 |
| Al-Kali, A; Alkhateeb, HB; Atherton, P; Begna, K; Gangat, N; Hashmi, S; He, R; Litzow, M; Palmer, J; Patnaik, M; Tibes, R | 1 |
| Bo, J; Dou, L; Gao, C; Gao, X; Li, H; Liu, D; Lu, N; Wang, L; Wei, Y; Wu, Y; Zhang, R; Zhu, C | 1 |
| Chen, J; Chen, L; Fu, W; Gao, L; Hu, Y; Lu, G; Ni, X; Tang, G; Xu, L; Yang, J | 1 |
| Cairoli, R; Di Virgilio, R; Ferrara, F; Furneri, G; Veggia, B | 1 |
| Cai, H; Han, S; He, J; Li, S; Lin, X; Liu, Y; Shi, Y; Wang, X; Xiu, M | 1 |
| Alonzo, TA; Aplenc, R; Cao, X; Elsayed, AH; Klco, JM; Kolb, EA; Lamba, JK; Ma, X; Marrero, RJ; Meshinchi, S; Pounds, SB; Ribeiro, RC; Ries, RE; Rubnitz, JE; Wu, H | 1 |
| Al-Ali, HK; Aul, C; Balleisen, L; Berdel, WE; Cross, M; Dörken, B; Dreger, P; Eimermacher, H; Florschütz, A; Giagounidis, A; Hähling, D; Hegenbart, U; Hehlmann, R; Heinicke, T; Heyn, S; Hiddemann, W; Hirt, C; Hochhaus, A; Hoffmann, VS; Jentzsch, M; Junghanss, C; Kahl, C; Kiehl, M; Krahl, R; Krämer, A; Krug, U; Lang, T; Lengfelder, E; Maschmeyer, G; Mügge, LO; Müller-Tidow, C; Naumann, R; Niederwieser, D; Oldenkott, B; Opitz, B; Peter, N; Pfirrmann, M; Pönisch, W; Reifenrath, K; Sauerland, C; Sayer, H; Schliemann, C; Scholl, S; Schulze, A; Schütte, W; Schwind, S; Serve, H; Späth, C; Staib, P; Vucinic, V; Wolf, HH; Wörmann, B; Zojer, N | 1 |
| Mehmood, T; Zhang, XE | 1 |
| Chang, YJ; Gong, LZ; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Liu, XH; Qin, YZ; Ruan, GR; Tang, FF; Wang, J; Wang, Y; Yu, WJ; Zhao, XS; Zhu, XL | 1 |
| Hou, JX; Hu, YM; Li, SZ; Lin, D; Liu, KQ; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL | 1 |
| Angenendt, L; Berdel, WE; Kessler, T; Kuron, D; Lenz, G; Mesters, R; Mikesch, JH; Pohlmann, A; Schliemann, C; Stelljes, M | 1 |
| Wang, D; Wang, G; Wang, Y; Wu, S; Yang, H | 1 |
| Huang, X; Jin, J; Lou, Y; Ma, L; Mao, L; Ren, Y; Tong, H; Wang, H; Wang, Y; Wu, J; Xu, H; Yang, M; Yao, Y; Ye, X; Zhang, Y; Zhou, Y; Zhu, HH | 1 |
| Appelbaum, J; Curley, N; Estey, EH; Gooley, T; Halpern, AB; Hendrie, PC; Kopmar, NE; Lim, J; Percival, MM; Russell, K; Schonhoff, K; Scott, BL; Shaw, C; Walter, RB | 1 |
| Balasubramanian, P; David, E; Illangeswaran, RSS; Janet, NB; Jebanesan, DZP; Mathews, V; Rajamani, BM; Sivakumar, KK; Velayudhan, SR; Vidhyadharan, RT | 1 |
| Chang, LS; Chiou, JT; Hong, YC; Hsu, CC; Lee, YC | 1 |
| Christakopoulos, GE; Inaba, H; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Smith, J; Takemoto, CM; Walker, KN; Wang, L; Zheng, Y | 1 |
| Assouline, S; Bergeron, J; Borden, KLB; Cocolakis, E; Culjkovic-Kraljacic, B; Gasiorek, J; Lambert, C; Szlachtycz, D; Yee, K; Zakaria, C | 1 |
| Bica, V; Boettcher, M; Fischer, T; Graziosi, S; Latini, S; Massacci, G; Mougiakakos, D; Perfetto, L; Pugliese, GM; Sacco, F; Venafra, V | 1 |
| Bhalla, KN; Birdwell, CE; Das, K; Daver, N; Davis, JA; DiNardo, CD; Fiskus, W; Kadia, TM; Kantarjian, H; Loghavi, S; McGeehan, GM; Mill, CP; Ruan, X; Sasaki, K; Su, X; Takahashi, K | 1 |
| Ando, J; Asada, N; Dobashi, N; Honda, H; Iida, H; Ishizawa, K; Miyamoto, T; Mukai, H; Nishimura, Y; Okubo, S; Shinagawa, A; Soshin, T; Takada, S; Tsutsui, A; Usuki, K; Yamamoto, K; Yoshida, C | 1 |
| Albano, F; Attolico, I; Carluccio, P; Contento, C; Delia, M; Di Gennaro, D; Gagliardi, VP; Musto, P | 1 |
| Jain, A; Lemoli, RM; Montesinos, P | 1 |
| Jiao, Z; Li, F; Li, Y; Wu, X; Zhang, J | 1 |
| Asby, R; Dembitz, V; Dillingh, LS; Gallipoli, P; Giotopoulos, G; Helgason, GV; Huntly, BJP; James, SC; Kranc, KR; Madrigal, P; Magee, AMS; Mapperley, C; Philippe, C; Prehn, JHM; Rattigan, KM; Rouault-Pierre, K; Tzelepis, K; van de Lagemaat, LN; Vassiliou, GS; Woodley, K | 1 |
| Bhojwani, D; Dao, J; Doan, A; Freyer, DR; Gaynon, P; Hadar, AJ; Huang, HKT; Kovach, AE; Malvar, J; Orgel, E; Parekh, C; Posch, LC; Raca, G; Rushing, T; Stokke, J | 1 |
| Chang, J; Jin, J; Shen, YJ; Wang, HF; Ye, XN; Zhang, Y; Zhu, HH; Zhu, L | 1 |
| Bhansali, RS; Kuo, EJ; Lai, C; Lin, RJ; Mannis, G | 1 |
| Chen, T; Deng, X; Gao, L; Kong, P; Li, J; Rao, J; Tan, X; Yao, H; Yin, X; Zhang, C; Zhang, X | 1 |
| Gao, XN; Jing, Y; Li, MY; Li, YF; Liu, DH; Su, YF; Wang, A; Wang, J; Wang, YZ; Xu, L; Zhang, LL; Zheng, X | 1 |
| Arnold, C; Batten, LM; Betteridge, S; Canham, J; Cavenagh, J; Dennis, M; Dillon, R; Freeman, SD; Gilkes, A; Hemmaway, C; Hinson, EL; Kleeman, M; Knapper, S; Kottaridis, P; Mehta, P; Othman, J; Overgaard, UM; Potter, N; Russell, NH; Villiers, W; Wilhelm-Benartzi, C; Wych, J | 1 |
| Atchley, E; Derkach, A; DeWolf, S; Galera, PK; Glass, J; Roshal, M; Shah, R; Stump, SE; Weis, TM; Xiao, W | 1 |
| Bennett, JM; Cripe, LD; Fernandez, HF; Foran, JM; Ketterling, RP; Lai, C; Lazarus, HM; Levine, RL; Litzow, MR; Luger, SM; Paietta, E; Racevskis, J; Rowe, JM; Sun, Z; Tallman, MS; Zhang, Y | 1 |
| Basara, N; Benner, A; Bullinger, L; Cocciardi, S; Döhner, H; Döhner, K; Fiedler, W; Fransecky, L; Gaidzik, VI; Ganser, A; Götze, K; Greil, R; Hertenstein, B; Heuser, M; Kapp-Schwoerer, S; Koller, E; Krauter, J; Krzykalla, J; Kühn, MWM; Leis, C; Lübbert, M; Machherndl-Spandl, S; Martens, UM; Mayer, K; Nachbaur, D; Paschka, P; Ringhoffer, M; Saadati, M; Samra, MA; Schleicher, J; Schlenk, RF; Schrade, A; Schroeder, T; Thol, F; Wattad, M; Weber, D; Wulf, G | 1 |
| Chen, J; Chen, S; Han, Y; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D; Xu, Y; Xue, S; Yao, Y; Yu, Z; Zhang, Y | 1 |
| Bisht, S; Brossart, P; Feldmann, G; Hahn-Ast, C; Mayer, K; Serries, M | 1 |
| Aláez, C; Amigo, ML; Barciela, LA; Belmonte, DG; Benavente, C; Bergua Burgués, JM; Bernal, T; Callejas, M; Cervero, C; Concepción, VN; de la Fuente Burguera, A; de LaIglesia, A; de Miguel Llorente, D; Figuera, A; Foncillas, MA; García Pérez, MJ; García-Fortes, M; García-Noblejas, A; Garrido, A; Gómez Correcha, K; González, LL; Jordá, RC; Lavilla Rubira, E; Leonardo, AA; López-Lorenzo, JL; Lorente de Uña, S; Martínez, P; Martínez-Chamorro, C; Martínez-Cuadrón, D; Mena Durán, AV; Montesinos, P; Moreno, AF; Pérez-Encinas, MM; Rad, G; Riaza, R; Roca, JR; Rodríguez-Macías, G; Roldán, A; Salamero, O; Vall-Llovera, F; Zarzuela, MP | 1 |
| Fang, JP; Huang, K; Li, Y; Liao, XY; Qiu, KY; Xu, HG; Zhou, DH | 1 |
| Hu, C; Huang, J; Huang, X; Jin, J; Li, C; Li, X; Lin, X; Ma, Z; Mao, S; Qian, Y; Wang, J; Wei, W; Ye, W; Yin, X; Zhou, Y; Zhu, B | 1 |
| de Witte, T; Muus, P | 1 |
| Ji, C; Jia, L; Li, G; Liu, J; Ma, D; Song, Y; Yang, H; Yang, X; Ye, F; Ye, J; Zheng, D; Zhou, Q; Zhou, Y | 1 |
| Cahill, K; Chen, C; Fulton, N; Han, D; He, C; Liang, G; Odenike, O; Stock, W; Wang, L; You, Q; Zhang, W | 1 |
| Azab, M; Brandwein, J; Demeter, J; Döhner, H; Döhner, K; Fenaux, P; Gercheva-Kyuchukova, L; Gobbi, M; Griffiths, E; Hao, Y; Issa, JJ; Jedrzejczak, WW; Kantarjian, H; Keer, H; Krauter, J; Kropf, PL; Mayer, J; Min, YH; Miyazaki, Y; Novak, J; Ojeda-Uribe, M; Robak, T; Roboz, GJ; Thomas, X; Yee, K; Yeh, SP | 1 |
| Feng, B; Fu, JF; Kan, WJ; Li, J; Li, JN; Liu, MM; Luo, GH; Song, N; Tu, YT; Wang, HL; Wei, G; Wu, WB; Xu, GY; Xu, R; Zhou, YB | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Carulli, A; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Lai, C; Loren, AW; Luger, SM; Maillard, IP; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Skuli, S; Stadtmauer, EA | 1 |
| Abkowitz, JL; Appelbaum, JS; Becker, PS; Cassaday, RD; Estey, EH; Garcia, KA; Ghiuzeli, MC; Halpern, AB; Hendrie, PC; Keel, SB; Oehler, VG; Orozco, JJ; Othus, M; Percival, MM; Rodríguez-Arbolí, E; Scott, BL; Walter, RB | 1 |
| Cenin, DA; Donald Harvey Iii, R; Kovacsovics, T; Kurish, HP; Lee, JS; Li, BKT; Lo, M; Patel, S; Prelewicz, S; Schlafer, D; Wagner, CB; Walchack, R; Wasef, B; Ying, J | 1 |
| Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ | 1 |
| Kaspers, GJL; Klein, K; Njuguna, F; Olbara, G; van Weelderen, RE; Vik, TA; Wijnen, NE | 1 |
| Akashi, K; Egashira, N; Ieiri, I; Ishida, S; Kato, K; Kawashiri, T; Mochizuki, E; Nakamura, H; Ochiai, H; Ozawa, N; Uchida, M; Yonemitsu, H | 1 |
| Cao, L; Hong, M; Jiang, ZQ; Li, JY; Liu, WJ; Qian, SX; Sun, Q; Zhu, Y | 1 |
| Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY | 1 |
| Abbas, HA; Andreeff, M; Basyal, M; Borthakur, G; Dara, SI; Daver, N; DiNardo, CD; Garcia-Manero, G; Ishizawa, J; Issa, GC; Jabbour, EJ; Kantarjian, HM; Khoury, J; Kornblau, SM; Li, L; Loghavi, S; Muftuoglu, M; Naqvi, K; Pemmaraju, N; Pourebrahim, R; Ravandi, F; Senapati, J; Short, NJ; Yilmaz, M | 1 |
| Cheng, J; Li, L; Lu, J; Wang, S; Yang, J; Zhang, S; Zhao, L; Zhou, L | 1 |
| Chen, Y; Deng, Y; Ding, B; He, Z; Song, L; Tao, S; Wang, C; Yu, L; Zhou, D | 1 |
| Álvarez, N; Ayala, R; Carreño-Tarragona, G; García-Vicente, R; Garrido-García, V; Giménez, A; Linares, M; Martínez-López, J; Morales, ML; Ortiz-Ruiz, A; Reyes-Palomares, A; Rodríguez-García, A; Sánchez, R; Vincelle-Nieto, Á | 1 |
| Agarwal, N; Ahmed, R; Bansal, N; Bhurani, D; Halder, R; Mirgh, SP; Shaikh, MR; Singh, B; Singh, R | 1 |
| Chang, WI; MacDonell-Yilmaz, RE; Moynihan, L; Sampino, EV; Sprinz, PG | 1 |
| Darwish, C; Farina, K; Tremblay, D | 1 |
| Broe, A; Lambova, A; Legg, A; Levy, J; Medalla, G | 1 |
| Arcese, W; Ciceri, F; Gedde-Dahl, T; Gorin, NC; Labopin, M; Lanza, F; Maertens, J; Meijer, E; Mohty, M; Montoro, J; Pabst, T; Pérez-Simón, JA; Sanz, J; Schaap, N; Van Gorkom, G; Versluis, J; Vrhovac, R | 1 |
| Das, PK; Padhi, S; Panigrahi, C; Tikare, N | 1 |
| Almuina, NM; Andrew, G; Burns, S; Cahalin, P; Dennis, M; Freeman, SD; Gallagher, KME; Gilkes, A; Hills, RK; Jakobsen, NA; Kennedy, A; King, S; Knapper, S; Mehta, P; Metzner, M; Moore, R; Russell, NH; Sellar, RS; Thomas, A; Thomas, I; Vyas, P; Weber, D | 1 |
| Fredman, D; Gafter-Gvili, A; Raanani, P; Sherban, A; Shimony, S; Stahl, M; Wolach, O; Yeshurun, M | 1 |
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
| Chen, H; Chen, Y; Guo, W; Li, S; Li, Y; Liu, L; Liu, M; Lv, S; Peng, S; Wu, M; Xing, Y; Yi, Z; Zhang, L; Zhu, S | 1 |
| Bataller, A; Borthakur, G; Bose, P; Champlin, R; Daver, N; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Islam, R; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Marx, KR; Molica, M; Pemmaraju, N; Rausch, CR; Ravandi, F; Shpall, E; Tidwell, RS; Wang, S; Ylimaz, M | 1 |
| Deotare, U; Fulford, A; Ho, J; Lazo-Langner, A; Sljivic, I; Xenocostas, A | 1 |
| Chen, G; Chen, P; Chen, X; Liu, Y | 1 |
| Abe, Y; Ishida, T; Kasai, Y; Kasuya, Y; Kikuchi, T; Nomura, M; Norihama, Y; Oda, Y; Ogura, M; Sato, K; Takei, T; Tsukada, N | 1 |
| Cai, D; Hou, D; Huang, H; Liao, X; Lin, L; Liu, J; Tan, M; Wang, J; Wang, X; You, R; Zhang, S; Zheng, X | 1 |
| Ichinohe, T; Inaba, T; Kashimoto, N; Mino, T; Naka, K; Ueshima, T; Ureshino, H; Yamaguchi, T | 1 |
| Betts, KA; Bui, CN; Dua, A; Lachaine, J; Li, X; Pratz, K; Schuh, AC; Song, J; Suh, HS | 1 |
| Bravo, J; Cais, A; Godavarthy, PS; Hoeller, F; Huntly, BJP; Kahler, A; Kowarz, E; Krack, T; Krause, DS; Kumar, R; Llavona, P; Marschalek, R; Meduri, E; Minciacchi, VR; Münch, C; Nowak, D; Pampaloni, F; Paulini, L; Pereira, RS; Stark, T; Tascher, G; Zanetti, C | 1 |
| Cagnin, S; Peroni, E; Randi, ML; Rosato, A | 1 |
| Chen, Y; Huang, P; Li, H; Luo, X; Su, Q; Zhang, P | 1 |
| Gou, J; He, H; Liu, B; Liu, Z; Tang, X; Wang, P; Yin, T; Zhang, J; Zhang, Y | 1 |
| Chen, S; Han, Y; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D; Xu, Y; Xue, S; Zhang, K; Zhang, X; Zhang, Y | 1 |
| Huang, B; Liu, J; Wang, XL; Wang, XZ; Yang, Y; Yao, F; Yu, X; Zhong, F | 1 |
| Bonmati, C; Campidelli, A; D'Aveni-Piney, M; Divoux, M; Kicki, C; Notarantonio, AB; Pagliuca, S; Roth-Guépin, G; Rubio, MT | 1 |
| Ban, C; Deng, W; Sun, X; Wu, X; Wu, Z; Xu, R; Zhao, Q | 1 |
| Sasaki, K | 1 |
| Cao, S; Dong, Y; Tao, Q; Wang, J; Zhang, Q | 1 |
| Hsu, HJ; Wang, CY; Wu, MJ; Wu, PS; Yen, JH | 1 |
| Adès, L; Fenaux, P; Sébert, M | 1 |
| Jiang, B; Sun, WX | 1 |
| Dong, Y; Hu, J; Li, J; Li, X; Li, Y; Ren, R; Wu, W; Zhang, Y; Zhu, H | 1 |
| Robak, T; Wolska-Washer, A | 1 |
| Addona, G; Altura, R; Chen, H; Chen, L; Cho, J; Cristescu, R; Follmer, N; Javaid, S; Kariv, I; Kerr, K; Machacek, M; Mansueto, MS; Muise, ES; Nicholson, B; Xu, H | 1 |
| Berda-Haddad, Y; Ciccolini, J; Costello, R; Donnette, M; Fanciullino, R; Farnault, L; Giocanti, M; Hau, LTT; Lacarelle, B; Ouafik, L; Solas, C; Venton, G | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
| Chung, W; Cui, J; Han, J; Heo, JY; Jang, Y; Ju, X; Kim, SJ; Kweon, GR; Lee, MJ; Lee, YL; Ryu, MJ; Son, JH; Song, IC | 1 |
| Alfayez, M; Daver, N; Kadia, T; Kantarjian, H; Ravandi-Kashani, F | 1 |
| Adaeva, R; Battipaglia, G; Bonnin, A; Brissot, E; Debureaux, PE; Delhommeau, F; Duléry, R; Hirsch, P; Isnard, F; Labopin, M; Lapusan, S; Legrand, O; Malard, F; Mamez, AC; Mohty, M; Vekhoff, A | 1 |
| Goldsmith, SR; Lovell, AR; Schroeder, MA | 1 |
| Baclig, NV; Becker, PS; Buckley, SA; Cassaday, RD; Estey, EH; Gernsheimer, TB; Halpern, AB; Hartley, GA; Hendrie, PC; Howard, NP; Keel, SB; Oehler, VG; Orozco, JJ; Othus, M; Percival, MM; Scott, BL; Shustov, AR; Walter, RB; Welch, VL | 1 |
| Alonso Domínguez, JM; Arquero, T; Atance, M; Chamizo, C; Piris, MA; Prieto-Torres, L; Requena, L; Rodriguez-Pinilla, SM; Salgado, RN; Soto, C | 1 |
| Koning, JL; Kuo, DJ; Murshed, F; Wong, V | 1 |
| Deotare, U; Deschner, M; Phua, C; Saini, L; Xenocostas, A | 1 |
| Duan, XL; Hua, J; Luan, J; Ma, CC; Xiao, TW | 1 |
| Altini, M; Bolognese, A; Bravaccini, S; Catalano, L; Cerchione, C; De Giorgi, U; De Nisco, M; Di Rorà, AGL; Dora Iula, V; Manfra, M; Marra, N; Martinelli, G; Martinelli, V; Pagano, F; Pane, F; Pedatella, S; Picardi, M; Pugliese, N; Ronconi, S; Simonetti, G | 1 |
| Aragüés, M; Chicharro, P; Fraga, J; Llamas-Velasco, M; Reolid, A; Rodríguez-Jiménez, P | 1 |
| Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J | 1 |
| Akl, H; Bene, MC; Bourgeais, J; Brossaud, J; Dakik, H; Domenech, J; El-Sabban, M; Foucault, A; Gallay, N; Gouilleux, F; Gyan, E; Hamard, S; Herault, O; Hleihel, R; Kouzi, F; Le Nail, LR; Mazurier, F; Picou, F; Ravalet, N; Rouleux-Bonnin, F; Roux, B; Zibara, K | 1 |
| Bian, Y; Huang, C; Ma, S; Ma, W; Miao, L; Miao, M; Xia, F; Yu, D | 1 |
| Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J | 1 |
| Bruserud, Ø; Fredly, HK; Gjertsen, BT; Grønningsæter, IS; Hatfield, KJ | 1 |
| Bodzenta, E; Bolkun, L; Brzozowski, K; Czemerska, M; Giebel, S; Gromek, T; Grosicki, S; Grzybowska-Izydorczyk, O; Helbig, G; Hellman, A; Holowiecki, J; Hus, M; Kloczko, J; Knopinska-Posluszny, W; Krawczynska, A; Kuydowicz, M; Lech-Maranda, E; Nowicki, M; Patkowska, E; Piekarska, A; Pluta, A; Razny, M; Robak, T; Sobas, M; Stelmach, P; Stepka, K; Szmigielska-Kaplon, A; Warzocha, K; Wawrzyniak, E; Wierzbowska, A; Wojcik, K; Wrobel, T | 1 |
| Aldoss, I; Marcucci, G | 1 |
| Prakash, L; Prakash, S; Roy Choudhury, J; Yoon, JH | 1 |
| Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R | 1 |
| Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB | 1 |
| Chen, G; Gong, D; Huang, S; Jing, Y; Li, Y; Lv, N; Wang, L; Wang, N; Xiong, Q; Xu, Q; Yu, L; Zhou, W | 2 |
| Bonizzoni, E; Cascavilla, N; Celio, L; Dargenio, M; Di Renzo, N; Greco, G; Mannina, D; Matera, R; Mazza, P; Melillo, L; Merenda, A; Musso, M; Pastore, D; Pavone, V; Porretto, F | 1 |
| Byerly, L; Manning, N; Mizukawa, B; Mulloy, JC; O'Brien, E; Perentesis, JP; Sabulski, A; Sexton, C; Wunderlich, M | 1 |
| Chen, K; Jiang, H; Li, H; Shao, JB; Yang, JW; Zhang, N; Zhu, JS | 1 |
| Breccia, M; Capria, S; Foa, R; Jabbour, E; Kadia, TM; Molica, M; Trisolini, S | 1 |
| Abboud, CN; Abboud, R; Chendamarai, E; DiPersio, JF; Ghobadi, A; Pusic, I; Rettig, MP; Riedell, PA; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Chiarella, M; Cortes, JE; Goldberg, SL; Hogge, D; Kolitz, JE; Lancet, JE; Louie, AC; Ritchie, EK; Ryan, RJ; Strickland, SA; Stuart, RK; Villa, KF | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Borthakur, G; Boyer, AD; Huang, R; Huang, X; Ji, D; Jiang, M; Li, F; Luan, S; Tang, G; Xu, Q; You, MJ; Zhang, Z | 1 |
| Akria, L; Ben Yakar, R; Flaishon, L; Gengrinovitch, S; Henig, I; Hoffman, R; Horowitz, NA; Koren-Michowitz, M; Lavi, N; Nudelman, O; Ofran, Y; Ram, R; Rowe, JM; Tavor, S; Tessler, S; Yeganeh, S; Zuckerman, T | 1 |
| Au-Yeung, R; Kwong, YL; Sim, JPY | 1 |
| Derman, BA; Larson, RA | 1 |
| Bacher, U; Mansouri Taleghani, B; Novak, U; Oppliger Leibundgut, E; Pabst, T; Sula, M | 1 |
| Ballen, K; Bhatt, S; Brunner, A; Burgess, M; Carr, SA; DeAngelo, DJ; Ebert, BL; Fell, G; Garcia, JS; Keshishian, H; Letai, A; Medeiros, BC; Neuberg, D; Sperling, AS; Stone, RM; Yilma, B | 1 |
| DiNardo, CD; Richard-Carpentier, G | 1 |
| Arthur, C; Coyle, L; Enjeti, A; Fay, K; Greenwood, M; Jeffrey, A; Katsioulas, V; Kerridge, I; Mackinlay, N; Nalpantidis, A; Shortt, J; Stevenson, W; Yip, E | 1 |
| Anderson, JT; Baker, SD; Fu, Q; Hu, S; Sparreboom, A | 1 |
| Kasner, MT | 1 |
| Abu Samra, M; Basara, N; Benner, A; Bentz, M; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Girschikofsky, M; Götze, K; Greil, R; Hertenstein, B; Heuser, M; Horst, HA; Kapp-Schwoerer, S; Kindler, T; Koller, E; Krauter, J; Krzykalla, J; Leis, C; Lübbert, M; Martens, U; Mayer, K; Nachbaur, D; Paschka, P; Schleicher, J; Schlenk, RF; Schroeder, T; Thol, F; Wattad, M; Weber, D; Wulf, G | 1 |
| Albertella, M; Bankar, A; Bethell, R; Bylund, J; Eneroth, A; Gronda, M; Hurren, R; Kavanagh, S; Kylefjord, H; Maclean, N; Minden, MD; Moses, S; Norin, S; Pinho, P; Rizoska, B; Rraklli, V; Rydergård, C; Schimmer, AD; Siriwardena, TP; Targett-Adams, P; Wang, X | 1 |
| Amrein, PC; Attar, E; Ballen, KK; Behnan, T; Bergeron, MK; Bertoli, C; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Duong, VH; Emadi, A; Fathi, AT; Foster, JE; Graubert, TA; Hasserjian, RP; Hobbs, G; Hock, H; Lescinskas, C; Lesho, P; Macrae, M; Mann, ML; McAfee, SL; McGregor, K; Moran, JA; Narayan, R; Neuberg, DS; Preffer, FI; Rae, J; Ramos, AY; Som, TT; Story, JL; Vartanian, MK; Wey, MC | 1 |
| Oliai, C; Schiller, G | 1 |
| Choi, JY; Kang, MG; Kim, HY; Lee, WS; Shin, JK; Song, HN | 1 |
| Bang, SM; Byun, JM; Hong, J; Kim, I; Koh, Y; Lee, J; Lee, JO; Shin, DY; Suh, KJ; Yoon, SS | 1 |
| Ojha, S; Ooi, MG | 1 |
| Baughn, LB; Blackburn, PR; Chen, D; Dalovisio, A; Greipp, PT; Haferlach, C; Hoppman, NL; Huang, L; Johnson, SH; Ketterling, RP; Oliveira, JL; Peterson, JF; Pitel, BA; Smadbeck, JB; Vasmatzis, G; Wood, AJ | 1 |
| Chen, L; Hu, N; Wang, C; Zhao, H | 2 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Cao, S; Cheng, C; Liu, H; Xiao, F; Yuan, F; Zhou, G | 1 |
| Hadjibabaie, M; Radmehr, M; Rahmani, H; Solduzian, M | 1 |
| Axelsson, H; Branca, RM; Bunten, SS; Coggins, SA; Grandér, D; Hed Myrberg, I; Helleday, T; Henter, JI; Herold, N; Heyman, M; Kim, B; Kutzner, J; Lee, S; Lehmann, S; Lehtiö, J; Lundbäck, T; Mäkelä, P; Mermelekas, G; Paulin, CB; Pokrovskaja Tamm, K; Qian, H; Rassidakis, GZ; Rasti, A; Rudd, SG; Sandhow, L; Sanjiv, K; Schaller, T; Schinazi, RF; Suman, S; Tao, S; Tsesmetzis, N; Walfridsson, J; Warpman-Berglund, U; Wiita, E; Zhang, SM | 1 |
| Ferrara, F | 2 |
| Feng, A; Masadeh, M; Murali, AR | 1 |
| A von dem Borne, P; Bargetzi, M; Biemond, BJ; Breems, DA; Chalandon, Y; Cloos, J; de Jongh, E; de Weerdt, O; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, JJJW; Jaspers, A; Jongen-Lavrencic, M; Klein, SK; Löwenberg, B; Maertens, J; Manz, M; Michaux, L; Ossenkoppele, GJ; Pabst, T; Stuessi, G; Tick, L; Valk, P; van der Klift, M; van der Poel, MWM; van der Velden, WJFM; van Marwijk Kooy, M; van Norden, Y; van Rhenen, A; Vekemans, MC | 1 |
| Gale, RP; Gong, B; Gong, X; Gu, R; Li, W; Li, Y; Lin, D; Liu, B; Liu, K; Liu, Y; Mi, Y; Qiu, S; Song, Z; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhao, X; Zhou, C | 1 |
| Asghari, H; Lancet, J | 1 |
| Brossart, P; Glasmacher, A; Hahn-Ast, C; Mayer, K; Schmidt-Wolf, IGH; Schwab, K; von Lilienfeld-Toal, M | 1 |
| Artz, AS; Cahill, KE; Fulton, N; Godley, LA; Green, M; Jain, N; Kadri, S; Karimi, YH; Karrison, TG; Larson, RA; Le Beau, MM; Liu, H; McNerney, ME; Odenike, O; Segal, J; Stock, W; Thirman, MJ; Weiner, H | 1 |
| Becker, PS; Buckley, SA; Estey, EH; Halpern, AB; Hendrie, PC; Oehler, VG; Othus, M; Palmieri, R; Percival, MM; Scott, BL; Walter, RB | 1 |
| Blaise, D; Bonnet, S; Bouchacourt, B; Charbonnier, A; Collignon, A; d'Incan, E; Gelsi-Boyer, V; Hospital, MA; Mohty, B; Mozziconacci, MJ; Rey, J; Saillard, C; Vey, N; Zemmour, C | 1 |
| Gong, L; Huang, X; Jia, J; Jiang, H; Jiang, Q; Lai, Y; Liu, K; Liu, X; Lu, R; Lu, S; Ruan, G; Shi, H; Wang, J; Wang, Y; Wu, Y; Xu, L; Yan, C; Zhang, X; Zhao, X | 1 |
| Bloomfield, CD; Blum, W; Bucci, D; Eisfeld, AK; Geyer, S; Kohlschmidt, J; Kolitz, JE; Larson, RA; Laumann, K; Marcucci, G; Mrózek, K; Pardee, TS; Stock, W; Stone, RM; Uy, GL; Wang, ES; Zhao, W | 1 |
| An, Q; Chiarella, M; Larson, ML; Lin, TL; Louie, AC; Roboz, GJ; Rubenstein, SE; Schiller, GJ; Solomon, SR | 1 |
| Antunovic, P; Cammenga, J; Deneberg, S; Derolf, ÅR; Eriksson, A; Höglund, M; Juliusson, G; Lazarevic, V; Lehmann, S; Lorenz, F; Möllgård, L; Ölander, E; Österroos, A; Uggla, B; Wennström, L | 1 |
| Borthakur, G; Bueso-Ramos, C; Class, CA; Cortes, JE; Daver, N; DiNardo, CD; Do, KA; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Khoury, JD; Konopleva, M; Montalban-Bravo, G; Naqvi, K; Patel, K; Pierce, S; Ravandi, F; Routbort, M; Sasaki, K; Short, NJ; Takahashi, K | 1 |
| Gerber, JM; Patel, SA | 1 |
| Bashey, A; Holland, HK; Morris, LE; Solh, MM; Solomon, SR; Zhang, X | 1 |
| Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Mizuno, T; Nakadate, H; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yoshimura, S | 1 |
| Abbenante, MC; Arpinati, M; Baccarani, M; Baldazzi, C; Bertamini, L; Bochicchio, MT; Bonifazi, F; Caso, L; Cavo, M; Cristiano, G; Curti, A; de Polo, S; Fontana, MC; Marconi, G; Martinelli, G; Nanni, J; Olivi, M; Ottaviani, E; Paolini, S; Papayannidis, C; Parisi, S; Ragaini, S; Sartor, C; Sessa, M; Talami, A; Testoni, N | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Burnett, A; Stone, R | 1 |
| Arnan, M; Bargay, J; Coll, R; Cruz, D; Díaz-Santa, J; Escoda, L; Esteve, J; Gallardo, D; Garcia, A; Garrido, A; Heras, I; Lloveras, N; Moret, C; Osca, G; Pratcorona, M; Quiñones, T; Rodríguez-Romanos, R; Salamero, O; Sampol, A; Sierra, J; Tormo, M; Vives, S | 1 |
| Bohannon, L; Brander, D; Chan, C; Chao, N; de Castro, C; Diehl, L; Dillon, LW; Erba, H; Gadi, VK; Galal, A; Hourigan, CS; Jauhari, S; LeBlanc, T; Li, Z; Lyu, J; Meyer, E; Nixon, AB; Rao, AV; Rizzieri, DA; Shelby, R; Siamakpour-Reihani, S; Staats, J; Stefanovic, A; Sung, AD; Wong, HY; Xie, J | 1 |
| Aplenc, R | 1 |
| Advani, AS; Appelbaum, FR; Ganapathi, MK; Ganapathi, RN; Godwin, JE; Koegle, ER; List, AF; McDonough, S; Michelson, AP; Othus, M; Petersdorf, SH; Radich, JP; Willman, CL | 1 |
| Anagnostopoulos, A; Bergeron, J; Chyla, B; DiNardo, CD; Fiedler, W; Gopalakrishnan, S; Hayslip, J; Hou, JZ; Hu, Y; Ivanov, V; Jiang, Q; Kim, I; Laribi, K; McDonald, A; Mendes, W; Montesinos, P; Murthy, V; Novak, J; Pagoni, M; Panayiotidis, P; Samoilova, O; Stevens, DA; Wei, AH; Yamauchi, T | 1 |
| Honda, S; Katayama, O; Kawano, R; Morita, T; Nagamatsu, K; Narahara, H; Nishida, Y; Ogata, M; Sakata, M; Shirao, K; Takano, K; Yanai, Y; Yoshida, N | 1 |
| Huang, L; Hui, Y; Li, Y; Mao, X; Shang, Z; Wang, Y; Wang, Z; Wei, J; Xiao, M; Zhang, D; Zheng, L | 1 |
| Beachamp, Z; Bossé, R; Brown, R; Cline, C; Cogle, CR; Collins, B; Hawkins, KE; Hiemenz, J; Hsu, J; May, WS; Moreb, JS; Norkin, M; Pettiford, LC; Turner, D; Uckun, F; Wingard, JR; Wise, E | 1 |
| Hong, M; Li, JY; Miao, Y; Qian, SX; Qiu, HR; Sun, Q; Yang, H; Zhu, H; Zhu, Y | 1 |
| Barbachano, Y; Cole, S; Coppola, P; Flores, B; Freire, J; Hemmings, R; Koenig, J; Lapveteläinen, T; Márcia, S; Penttilä, K; Pignatti, F; Roige, SD; Tzogani, K | 1 |
| Bradley, T; Watts, JM | 1 |
| Capelli, D; Chiarucci, M; Discepoli, G; Fiorentini, A; Leoni, P; Menotti, D; Olivieri, A; Poloni, A; Saraceni, F | 1 |
| Bossis, G; Brockly, F; Cartron, G; Gâtel, P; Hicheri, Y; Pastore, M; Piechaczyk, M; Reynes, C | 1 |
| Bertrand, Y; Girard, S; Marceau-Renaut, A; Penel-Page, M; Plesa, A; Renard, C | 1 |
| Bewersdorf, JP; Davidoff, AJ; Giri, S; Gore, SD; Huntington, SF; Ma, X; Neparidze, N; Podoltsev, NA; Shallis, RM; Wang, R; Wang, X; Zeidan, AM; Zhang, C | 1 |
| Agrawal, V; Arain, S; Cahill, K; Calip, GS; Christian, S; Esen, A; Griffin, S; Khan, I; Konig, H; Odenike, O; Patel, P; Quigley, JG; Shergill, A; Stock, W; Sweiss, K | 1 |
| Bewersdorf, JP; Diadamo, A; Gowda, L; Podoltsev, NA; Shallis, RM; Siddon, A; Zeidan, AM | 1 |
| Aasebø, E; Bartaula-Brevik, S; Bruserud, Ø; Grønningsæter, IS; Hatfield, KJ; Reikvam, H; Tvedt, TH | 1 |
| Chang, LX; Chen, X; Chen, XJ; Guo, Y; Liu, F; Liu, TF; Ruan, M; Yang, WY; Zhang, L; Zhao, BB; Zhu, XF | 1 |
| Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L | 1 |
| Dohner, H; Fischer, T; Jost, F; Sager, S; Schalk, E; Weber, D | 1 |
| Apel, A; Cohen, Y; Danylesko, I; Ganzel, C; Gino-Moor, S; Gural, A; Koren-Michowitz, M; Moshe, Y; Nachmias, B; Ofran, Y; Pasvolsky, O; Peretz, G; Ram, R; Rowe, JM; Vainstein, V; Wolach, O; Yeganeh, S; Yerushalmi, R; Zektser, M | 1 |
| Chen, Q; Jiang, N; Sun, YF; Zhang, B; Zhang, XM | 1 |
| Bertoli, S; Besson, A; Cartel, M; David, L; Didier, C; Gotanègre, M; Manenti, S; Mansat-De Mas, V; Mouchel, PL; Sarry, JE | 1 |
| Boswell, HS; Calin, GA; Chen, F; Gilca, M; Griffin, S; Guo, B; Konig, H; Niculite, C; Petrusca, D; Rice, S; Rogozea, A; Wu, X | 1 |
| Acharya, S; Baryawno, N; Bullinger, L; Chattophadhyay, S; Churchill, M; Cobert, J; Das, S; Doench, J; Huang, C; Hutchinson, JN; Keibler, MA; Lee, D; Logan, DJ; Mercier, F; Mukherjee, S; Rizzo, WB; S'aulis, D; Saez, B; Scadden, DT; Scadden, EW; Schreiber, S; Sharda, A; Stephanopoulos, G; Sykes, DB; van Gastel, N; Viswanathan, V; Yu, VWC; Yusuf, RZ | 1 |
| Fan, Z; Jin, Y; Li, L; Liu, W; Zhang, JY; Zhao, M; Zhou, Y | 1 |
| Cerny, J; Lazarus, HM; Litzow, M; Rowe, JM; Rybka, W; Strickland, SA; Tallman, MS; Wang, XV | 1 |
| Kanaya, M; Kondo, T | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Deeren, D | 1 |
| Apperley, JF; Bain, BJ; Brown, L; Hastings, A; Nadal-Melsio, E | 1 |
| Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X | 1 |
| Luo, ZQ; Pan, PJ | 1 |
| Li, TT; Ran, XH; Sun, L; Wang, LJ; Wu, XF | 1 |
| Åbacka, H; Granchi, C; Hagström-Andersson, AK; Hansen, JS; Huang, P; Hyrenius-Wittsten, A; Lindkvist-Petersson, K; Minutolo, F; Poli, G; Tuccinardi, T; Venskutonytė, R | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Basak, GW; Drozd-Sokolowska, J; Dwilewicz-Trojaczek, J; Gierej, B; Halaburda, K; Karakulska-Prystupiuk, E; Sachs, W; Tormanowska, M; Urbanowska, E; Wiktor-Jedrzejczak, W | 1 |
| Cheng, X; Fu, C; Huang, F; Jia, X; Meng, Y; Shao, G; Wang, L; Wang, T; Wang, X; Wu, H; Yang, T | 1 |
| Baker, R; Burt, R; Farah, N; Ibrahim, AR; Kottaridis, PD | 1 |
| Aroua, N; Azuaje, F; Bardotti, M; Bellvert, F; Boet, E; Bonnefoy, N; Bosc, C; de Toni, F; Farge, T; Gandarillas, S; Ghisi, M; Gotanègre, M; Gwilliam, R; Hosseini, M; Jarrou, L; Joffre, C; Kaoma, T; Larrue, C; Laurent, C; Mazed, F; Mouchel, PL; Nicolau-Travers, ML; Nicot, N; Picard, M; Portais, JC; Récher, C; Sabatier, M; Saland, E; Sarry, JE; Stuani, L; Syrykh, C; Tamburini, J; Vergez, F | 1 |
| Liu, C; Shao, Z; Sun, Y; Wu, C | 1 |
| Candoni, A; Chan, G; Cortes, JE; Ferdinand, R; Fiedler, W; Heidel, FH; Heuser, M; Leber, B; Ma, WW; Montesinos, P; O'Brien, T; O'Connell, A; Pollyea, DA; Robak, T; Sekeres, MA; Smith, BD | 1 |
| Bakhshi, S; Chopra, A; Ganguly, S; Garg, A; Vishnubhatla, S | 1 |
| Allen, K; Castellino, SM; Cooper, TM; Keller, FG; Metts, JL; Minson, KA; Monroe, C; Sabnis, HS; Woods, WG | 1 |
| Dorn, J; Drecoll, E; Frejno, M; Heinzlmeir, S; Helm, D; Hogrebe, A; Kleigrewe, K; Kuster, B; Kvasnicka, HM; Meng, C; Mergner, J; Oellerich, T; Ruprecht, B; Samaras, P; Scheich, S; Serve, H; Weichert, W; Wilhelm, M; Zecha, J | 1 |
| Bell, TJ; Bhattacharyya, H; Cappelleri, JC; Cortes, JE; Hoang, CJ; Johnson, C; Kwon, Y; Solem, CT | 1 |
| Jia, Y; Jiang, XY; Liang, H; Liu, W; Yi, XP; Zeng, H; Zhan, HE; Zhao, L; Zhao, XL; Zheng, QL; Zhou, HY | 1 |
| Beutel, G; Eder, M; Gabdoulline, R; Gohring, G; Heuser, M; Koenecke, C; Krauter, J; Markel, D; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Trummer, A | 1 |
| Bhatnagar, B; Koenig, KL; Sahasrabudhe, KD; Sigmund, AM | 1 |
| Chien, KS; Garcia-Manero, G; Montalban-Bravo, G | 1 |
| Den Haese, J; Elmeliegy, M; Jusko, WJ; Talati, C; Wetzler, M | 1 |
| Cheong, JW; Chung, H; Hyun, SY; Jang, JE; Kim, JS; Kim, SJ; Kong, JH; Lee, JI; Min, YH; Na, EJ; Shim, KY | 1 |
| Bhatnagar, B; Blachly, JS; Blum, WG; Byrd, JC; Crosswell, HE; Lin, TL; Liu, J; Long, L; Mims, AS; Minden, MD; Munugalavadla, V; Oellerich, T; Orwick, S; Pan, Y; Rao, AV; Serve, H; Walker, AR; Zhang, D | 1 |
| Estey, EH | 2 |
| Backhaus, D; Bill, M; Brauer, D; Goldmann, K; Grimm, J; Jentzsch, M; Niederwieser, D; Platzbecker, U; Schulz, J; Schwind, S | 1 |
| Arber, DA; Erba, HP | 1 |
| Herold, N | 1 |
| Egan, PC; Farmakiotis, D; Ingham, R; Reagan, JL; Vale, CA | 1 |
| Dang, FT; Wan, YM; Yang, J; Yang, QJ; Zheng, J | 1 |
| Chen, G; Fang, M; Gao, S; Gao, X; Li, X; Li, Y; Liu, H; Liu, Z; Luo, J; Ma, Y; Shen, J; Sun, K; Wang, L; Wang, X; Wei, X; Yang, L; Yu, L; Zhang, Y; Zhou, W | 1 |
| Chan, G; Cortes, JE; Lin, S; Ruiz-Garcia, A; Shaik, N | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Horibe, K; Iwamoto, S; Kinoshita, A; Koh, K; Kosaka, Y; Kudo, K; Miyachi, H; Moritake, H; Nakahata, T; Nakayama, H; Saito, AM; Shimada, A; Taga, T; Takahashi, H; Tawa, A; Terui, K; Tomizawa, D; Watanabe, T | 1 |
| Oniashvilli, N; Pasvolsky, O; Raanani, P; Rozovski, U; Rubinstein, M; Sela-Navon, M; Shargian-Alon, L; Wolach, O; Yahav, D; Yeshurun, M | 1 |
| Anderson, JT; Baker, SD; Buelow, DR; Gibson, AA; Goodwin, EA; Hu, S; Lamba, JK; Pounds, SB; Shi, L; Sparreboom, A | 1 |
| Albert, M; Carroll, M; Chen, Z; Delwel, R; Goswami, S; Guzman, ML; Kawabata, KC; Mason, CE; Melnick, A; Meydan, C; Roboz, GJ; Sugita, M; Wouters, BJ; Wyman, S; Yip, W; Zong, H | 1 |
| Baclig, NV; Buckley, SA; Cassaday, RD; Estey, EH; Gernsheimer, TB; Halpern, AB; Hartley, GA; Hendrie, PC; Howard, NP; Othus, M; Percival, MM; Scott, BL; Walter, RB; Welch, VL | 1 |
| Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W | 1 |
| Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
| Archetti, S; Bellotti, D; Bertoli, D; Borlenghi, E; Carbone, C; Cattaneo, C; Cerqui, E; Crippa, C; Dalceggio, D; Farina, M; Gramegna, D; Oberti, M; Pagani, C; Passi, A; Rossi, G; Schieppati, F; Sciumé, M; Soverini, G; Tucci, A | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Cafaro, A; Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Martinelli, G; Masini, C; Silimbani, P; Simonetti, G | 1 |
| Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Gottardi, M; Martinelli, G; Padella, A; Simonetti, G; Sperotto, A | 1 |
| Candoni, A; Clark, RE; Cortes, JE; Heuser, M; Leber, B; Montesinos, P; Vyas, P; Zeidan, AM | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y | 1 |
| Chacim, S; Mariz, JM; Tavares, M | 1 |
| Bankar, A; Bolster, L; Brandwein, JM; Hallett, D; Hamilton, M; Karkhaneh, M; Liew, E; Patterson, J; Saini, L; Taparia, M; Van Slyke, T; Wu, C; Zhu, N | 1 |
| Alati, C; Audisio, E; Bertani, G; Bilio, A; Caizzi, M; Candoni, A; Carnevale-Schianca, F; Cerrano, M; Cignetti, A; Clavio, M; D'Ardia, S; Dargenio, M; Ferrara, F; Fianchi, L; Fracchiolla, N; Galimberti, S; Gottardi, M; Grimaldi, F; Guolo, F; Gurreri, C; Lemoli, RM; Minetto, P; Morselli, M; Musto, P; Pagano, L; Pasciolla, C; Pavesi, F; Pietrantuono, G; Rizzuto, G; Rondoni, M; Rossi, G; Scappini, B; Scattolin, AM; Tafuri, A; Zappasodi, P | 1 |
| Becker, PS; Godwin, CD; Halpern, AB; Othus, M; Palmieri, R; Percival, MM; Walter, RB | 1 |
| Hosono, N; Negoro, E; Nishi, R; Okura, M; Shigemi, H; Yamauchi, T | 1 |
| Chen, J; Gong, B; Gong, X; Gu, R; Jin, J; Li, Y; Lin, D; Liu, B; Liu, K; Liu, Y; Mi, Y; Qiu, S; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhang, J; Zhao, X; Zhou, C | 1 |
| Abe, K; Dowsett, L; Hutchins, K; Wada, R | 1 |
| Qi, W; Song, B; Sun, L; Xu, X; Yan, X; Zhao, D | 1 |
| Dai, XB; Gao, HQ; Hua, HY; Li, J; Sun, XM; Wang, ZQ; Wu, S; Xu, ZQ; Zhang, Y; Zhao, Y; Zhou, Y; Zhu, WY; Zhu, XJ | 1 |
| Candoni, A; Clavio, M; Dennis, M; Giannini, B; Gibellini, D; Gilkes, A; Isidori, A; Loscocco, F; Mianulli, AM; Musuraca, G; Navari, M; Piccaluga, PP; Rocchi, M; Sensi, A; Visani, G; Zuffa, E | 1 |
| Chen, L; Kang, J; Liu, L; Ren, S; Tao, Y; Zhang, H | 1 |
| Azar, MM; Pischel, L; Ringer, M | 1 |
| Arellano, M; Baer, MR; Ball, B; Blum, W; Borate, U; Boyiadzis, M; Brennan, T; Burd, A; Byrd, JC; Chen, T; Collins, R; Deininger, M; Druker, B; Duong, VH; Foran, J; Foster, MC; Heerema, NA; Kovacsovics, T; Levine, RL; Lin, TL; Litzow, M; Marcus, S; Miller, M; Mims, AS; Odenike, O; Olin, R; Patel, P; Rosenberg, L; Ruppert, AS; Schiller, G; Severson, E; Shoben, AB; Stefanos, M; Stein, EM; Stock, W; Traer, E; Vergilio, JA; Vietz, C; Walker, A; Yocum, A | 1 |
| Daver, N; DiNardo, CD; Fathi, AT; Pollyea, DA; Vyas, P; Wei, AH | 1 |
| Bewersdorf, JP; Giri, S; Stahl, M; Tallman, MS; Wang, R; Williams, RT; Zeidan, AM | 1 |
| Andreeff, M; Daver, N; DiNardo, CD; Franquiz, MJ; Garcia-Manero, G; Hwang, H; Issa, GC; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Montalban-Bravo, G; Ning, J; Patel, KP; Ravandi, F; Short, NJ; Takahashi, K | 1 |
| Galinsky, I; Hoang, CJ; McBride, A; Newman, MJ; Paul, S; Relias, V; Ryan, JC; Saneeymehri, S; Stanislaus, G; Tobin, J | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Alsdorf, W; Blohm, ME; Bokemeyer, C; Fiedler, W; Hecher, K; Karagiannis, P; Oelrich, J; Singer, D; Tallarek, AC; Waizenegger, JS; Wolschke, C | 1 |
| Gangat, N; Tefferi, A | 1 |
| Akbar, MW; Demirkol Canli, S; Gure, AO; Haznedaroglu, IC; Isbilen, M; Kucukkaraduman, B; Malkan, UY; Okay, M; Sayinalp, N; Turk, C; Turk, S; Ucar, G | 1 |
| Diao, S; DiNardo, C; DiPippo, AJ; Konopleva, M; Maiti, A; Nichols, ED; Ning, J; Qiao, W | 1 |
| Ma, DD; Molloy, TJ; Röllig, C; Stölzel, F; Tursky, ML; Vu, TT; Wang, KW | 1 |
| Abraham, M; Aharon, A; Al-Rawi, AN; Altman, JK; Andreeff, M; Bohana-Kashtan, O; Borthakur, G; Bueso-Ramos, C; Cortes, JE; DiPersio, JF; Foley-Comer, A; Foran, J; Glicko-Kabir, I; Kadosh, SE; Lustig, TM; Nagler, A; Oberkovitz, G; Ofran, Y; Peled, A; Pemmaraju, N; Pereg, Y; Rowe, JM; Samara, E; Shaw, S; Shimoni, A; Showel, MM; Sorani, E; Tallman, MS; Uy, GL; Vainstein-Haras, A | 1 |
| Bollaert, E; Demoulin, JB; Essaghir, A; Graux, C; Havelange, V; Lenglez, S; Michaux, L; Saussoy, P; Schoemans, H; Valk, PJM; Vandewalle, V | 1 |
| Chen, EC; Garcia, JS | 1 |
| Boenisch, O; Bokemeyer, C; Fiedler, W; Ghandili, S; Ittrich, H; Jarczak, D; Karagiannis, P; Kluge, S; Lütgehetmann, M; Modemann, F; Pfefferle, S; Roedl, K; Rohde, H; Schmiedel, S; Sonnemann, P; Weisel, K; Wichmann, D | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Anderson, LD; Awan, F; Bergstrom, CP; Chen, W; Chung, S; Collins, R; Dahiya, S; Kansagra, A; Madanat, Y; Patel, P; Ramakrishnan, P; Rizvi, S; Vusirkala, M; Yan, J; Zhang, CC; Zhu, H | 1 |
| Assouline, S; Blotner, S; Chen, LC; Dickinson, MJ; Drummond, MW; Higgins, B; Jukofsky, L; Kasner, M; Kelly, KR; Lee, JH; Martinelli, G; Monnet, A; Muehlbauer, S; Nichols, G; Ott, M; Papayannidis, C; Pierceall, WE; Seiter, K; Simon, S; Vey, N; Yee, K; Yoon, SS; Zhi, J | 1 |
| Chiang, T; Miller, C; Seabury, R; Triesel, K | 1 |
| Cao, L; Chen, SS; Hong, M; Li, JY; Qian, SX; Qiao, C; Sun, Q; Wu, WZ; Xie, Y | 1 |
| Pi, Y; Ren, H; Wang, B; Wang, L | 1 |
| Appelbaum, FR; Estey, EH; Walter, RB | 1 |
| Burnett, AK; Clark, RE; Drummond, M; Freeman, S; Hills, RK; Huntly, B; Kell, J; Kjeldsen, L; Knapper, S; McMullin, MF; Russell, NH; Spearing, R; Thomas, IF | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Gu, W; Hua, X; Ling, Y; Wang, B; Yan, F; Yang, B; Zhang, J | 1 |
| Fang, Q; Liu, P; Ma, D; Pan, C; Wang, J; Wang, P | 1 |
| Chen, TC; Liao, PW; Teng, CJ; Wang, RC | 1 |
| Gecks, T; Hilgendorf, I; Hochhaus, A; Malouhi, A; Schnetzke, U; Scholl, S; Sinn, K; Voigt, M; Zinke, J | 1 |
| Chen, XJ; Chen, YM; Guo, Y; Liu, F; Liu, LP; Liu, TF; Liu, XM; Quan Qi, B; Ruan, M; Yang, WY; Zhang, AL; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Fang, Q; Gong, B; Gong, X; Gu, R; Jin, J; Li, Y; Lin, D; Liu, B; Liu, K; Liu, X; Liu, Y; Ma, Y; Mi, Y; Qiu, S; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhang, J; Zhou, C | 1 |
| Battle, L; Dusza, SW; Markova, A; Moy, A; Park, JH; Stoll, JR; Tallman, MS; Taylor, J | 1 |
| Tallman, MS; Waksal, JA | 1 |
| Cheng, Q; Chu, X; Ding, M; Gao, L; Guo, F; He, L; Ma, Y; Pan, M; Ye, L; Yu, G; Yuan, T; Zhu, M | 1 |
| Feld, J; Navada, SC; Silverman, LR | 1 |
| Hoover, A; Modi, A; Wiese, S; Zimmerman, JAO | 1 |
| Algarra, L; Ayala, R; Bergua, JM; Calasanz, MJ; Falantes, JF; Gil, C; Herrera, P; Labrador, J; Lavilla, E; Lopez, JL; Martinez, P; Martínez-Cuadrón, D; Martinez-Lopez, J; Montesinos, P; Paiva, B; Prosper, F; Ramos, F; Salamero, O; San-Miguel, JF; Sanz, MÁ; Sayas, MJ; Serrano, J; Simoes, C; Tormo, M; Vidriales, MB; Villar, S; Vives, S | 1 |
| Benitez, LL; Bixby, DL; Burke, PW; Marini, BL; Ochs, MA; Perissinotti, AJ; Pettit, KM | 1 |
| Ades, L; Auberger, P; Bertoli, S; Bonmati, C; Caulier, A; Chevallier, P; Chiche, E; Cluzeau, T; Dumas, PY; Genthon, A; Hicheri, Y; Joris, M; Legrand, O; Lejeune, C; Loschi, M; Micol, JB; Mohty, M; Pasquier, F; Peterlin, P; Pigneux, A; Raffoux, E; Rahmé, R; Recher, C; Roth-Guepin, G; Thomas, X; Vey, N | 1 |
| Lin, N; Wang, L | 1 |
| Newman, MJ | 1 |
| Baron, J; Cronin, TL; Elshoury, A; Freyer, CW; Griffiths, EA; Ji, W; Muppidi, MR; Ontiveros, EP; Przespolewski, A; Thompson, JE; Thota, S; Wang, ES | 1 |
| Heaney, ML; Sarkaria, SM | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Altvater, B; Angenendt, L; Berdel, AF; Berdel, WE; Hemmerle, T; Kessler, T; Lenz, G; Mikesch, JH; Neri, D; Rossig, C; Schäfers, M; Schliemann, C; Stelljes, M | 1 |
| Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S | 1 |
| Bao, X; Dou, J; Guo, M; Li, L; Mei, F; Xu, H; Xue, R; Zhang, Y; Zhao, F; Zheng, D | 1 |
| Chen, L; Liu, H; Liu, L; Ren, S; Tao, Y; Zhang, H | 1 |
| Benitez, LL; Bixby, DL; Boyer, D; Burke, PW; Lee, W; Marini, BL; Perissinotti, AJ; Pettit, K; Reid, JH | 1 |
| Bremer, E; Huls, G; Lourens, HJ; Visser, N; Wiersma, VR | 1 |
| Choi, EJ; Choi, Y; Kim, H; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Park, HS; Park, JH | 1 |
| Du, J; Fang, P; Liang, H; Liu, W; Zeng, H; Zhang, K; Zhao, L; Zhao, T; Zhou, C | 1 |
| Burzdikaite, P; Dapkeviciute, A; Daukelaite, G; Davainis, L; Griskevicius, L; Maneikis, K; Pugaciute, B; Ringeleviciute, U; Staras, V; Zucenka, A | 1 |
| Chang, C; Fang, Y; Guo, J; Jia, Y; Shi, L; Wu, D; Wu, L; Zhang, Z; Zhao, Y | 1 |
| Al-Malki, M; Aldoss, I; Ali, H; Aribi, A; Arslan, S; Artz, A; Budde, E; Dadwal, S; Forman, S; Khaled, S; Koller, P; Marcucci, G; Nakamura, R; Ngo, D; Pullarkat, V; Salhotra, A; Sandhu, K; Snyder, DS; Stein, A; Zhang, J | 1 |
| Appelbaum, F; Erba, H; Estey, E; Garcia-Manero, G; Godwin, J; Othus, M; Stirewalt, D; Weick, J | 1 |
| Cortes, JE; Faderl, S; Hogge, DE; Kolitz, JE; Lancet, JE; Lin, TL; Rizzieri, DA; Ryan, DH; Ryan, RJ; Schiller, GJ; Solomon, SR; Uy, GL; Wieduwilt, MJ | 1 |
| Bell, T; Brown, A; Cappelleri, JC; Chan, G; Daniele, P; Tremblay, G | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Chan, G; Cortes, JE; Fiedler, W; Heuser, M; Hoang, CJ; Leber, B; Ma, WW; Merchant, A; Montesinos, P; O'Brien, T; O'Connell, A; Papayannidis, C; Pérez-Simón, JA; Sekeres, MA; Smith, BD; Zeremski, M | 1 |
| Konopleva, M; Saxena, K | 1 |
| Perl, AE | 2 |
| Jayandharan, GR; Krishnan, UM; Rajagopal, P | 1 |
| Etzler, J; Grandits, AM; Grebien, F; Hackl, H; Heller, G; Heyes, E; Nguyen, CH; Schlerka, A; Sill, H; Stoiber, D; Wieser, R | 1 |
| Bomalaski, JS; Chen, TY; Cho, SF; Feng, X; Hsiao, HH; Hsu, YT; Johnston, A; Kao, HW; Kuo, MC; Liu, TC; Liu, YC; Tsai, HJ | 1 |
| Chen, A; Cheng, C; Cheng, S; Fan, J; Fan, L; Fang, F; Gao, L; He, H; Hu, S; Hu, Y; Jiang, S; Li, J; Ling, J; Lu, J; Pan, J; Ribeiro, RC; Wang, QF; Wang, Y; Xiao, P; Yao, Y; Zheng, X | 1 |
| Anantha, M; Bally, MB; Chen, KTJ; Leung, AWY; Militao, GGC; Witzigmann, D | 1 |
| Abedi, M; Hoeg, RT; Jonas, BA; Krishnan, R; Moskoff, BN; Rosenberg, AS; Tenold, ME; Tuscano, JM | 1 |
| Benitez, LL; Bixby, DL; Burke, PW; Clark, SM; Crain, M; Filtz, M; Griffin, S; Kadia, T; Klaus, J; Marini, BL; Olson, M; Perissinotti, AJ; Pettit, K; Ratermann, K; Rausch, CR; Treptow, C | 1 |
| Zhang, X | 1 |
| Chandra Sekaran, U; Grove, CS | 1 |
| Apel, A; Basood, M; Canaani, J; Duek, A; Frisch, A; Ganzel, C; Gural, A; Hellman, I; Koren-Michowitz, M; Leibovitch, C; Moshe, Y; Ofran, Y; Stemer, G; Wolach, O; Zektser, M | 1 |
| Cammann, SK; Lloyd, RS; McCullough, AK; Minko, IG; Moellmer, SA; Owen, N | 1 |
| Charles, A; Copson, KM; DeAngelo, DJ; Flamand, Y; Haydu, JE; Lindsley, RC; Luskin, MR; Neuberg, D; Stone, RM; Vedula, RS; Versluis, J | 1 |
| Ambrusko, S; Andolina, JR; Barth, M; Boulware, R; Comito, M; Fraint, E; Fries, C; Monteleone, P; Vargas, A | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Guerra, V; Jabbour, EJ; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, M; Levis, M; Ohanian, M; Pemmaraju, N; Pierce, S; Pinsoy, MR; Ravandi, F; Swaminathan, M; Wierda, WG; Xiao, L | 1 |
| Chai-Adisaksopha, C; Hantrakool, S; Norasetthada, L; Piriyakhuntorn, P; Rattanathammethee, T; Rattarittamrong, E; Tangchitpianvit, K; Tantiworawit, A | 1 |
| Cappelleri, JC; Heeg, B; Mamolo, C; Mokgokong, R; Muresan, B; Palaka, A; Soikkeli, F | 1 |
| Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Chen, HM; Hsiao, FY; Huang, HH; Ko, BS; Wang, CY | 1 |
| An, L; Chu, X; Li, L; Liu, Y; Wang, J; Wang, L; Xu, J | 1 |
| Özcan, G; Uçakhan, ÖÖ | 1 |
| Ariti, C; Burnett, A; Clark, RE; Copland, M; Dennis, M; Greaves, P; Hemmaway, C; Hills, R; Russell, N; Severinsen, MT; Thomas, I | 1 |
| Emadi, A; Faderl, S; Finn, L; Garcia, R; Jacoby, MA; Male, HJ; Powell, BL; Saba, NS; Seiter, K | 1 |
| Fujita, H; Hagiwara, Y; Hakamada, K; Hara, Y; Kanda, T; Kubota, S; Mitsuhashi, Y; Miura, T; Morohashi, H; Ogasawara, H; Sakamoto, Y; Sato, K; Umemura, K | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Alonzo, TA; Aplenc, R; Brodersen, LE; Gamis, AS; Gerbing, RB; Guest, E; Hirsch, B; Kolb, EA; Loken, MR; Meshinchi, S; Pollard, JA; Raimondi, SC | 1 |
| Aguiñiga-Sánchez, I; Fajardo-Orduña, GR; Ledesma-Martínez, E; Mora-García, ML; Santiago-Osorio, E; Weiss-Steider, B | 1 |
| Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME | 1 |
| Bai, H; Dong, H; Gu, N; Kong, F; Liu, F; Ma, M; Sun, Q; Wang, C; Xu, H; Zhang, Y | 1 |
| Niu, L; Wang, XL; Wang, YN; Wei, T; Xi, YM; Yang, MY | 1 |
| Chiou, SS; Lin, PC; Shieh, TM; Shih, YH; Tseng, YH; Yang, RC | 1 |
| Cao, S; Chen, XP; Cheng, C; Jiang, ZP; Yuan, F; Zhang, W; Zhao, XL; Zhou, G; Zhou, HH | 1 |
| Graff, JP; Karnati, T; Lee, D; Omofoye, OA; Shahlaie, K | 1 |
| Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S | 1 |
| Borthakur, G; Kantarjian, H | 1 |
| Azimi, A; Goroshchuk, O; Jafari, R; Kolosenko, I; Kunold, E; Palm-Apergi, C; Pirmoradian, M; Vidarsdottir, L | 1 |
| Plesa, A; Thomas, X | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Carroll, AJ; Eisfeld, AK; Jacobson, S; Kohlschmidt, J; Kolitz, JE; Larson, RA; Marcucci, G; Mrózek, K; Stock, W; Stone, RM; Stuart, RK; Sutamtewagul, G; Thakuri, M; Vij, R; Walker, AR; Wang, ES; Yin, J | 1 |
| Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Ryan, RJ; Uy, GL | 1 |
| Davainis, L; Griskevicius, L; Maneikis, K; Peceliunas, V; Pileckyte, R; Staras, V; Trociukas, I; Vaitekenaite, V; Zucenka, A; Zvirblis, T | 1 |
| Fleischmann, M; Frietsch, JJ; Glaser, A; Hammersen, J; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schnetzke, U; Scholl, S; Schrenk, K | 1 |
| Gergis, U; Grosso, D | 1 |
| Asou, N; Dobashi, N; Honda, H; Ichikawa, S; Iida, H; Ishizawa, K; Jiang, Q; Komatsu, N; Kuroda, J; Kurokawa, M; Matsumura, I; Mendes, W; Miyamoto, T; Miyazaki, Y; Okubo, S; Takada, S; Usuki, K; Wei, A; Yamauchi, T; Yoshida, C | 1 |
| Alvarado, Y; Bivins, CA; Borthakur, G; Daver, NG; DiNardo, CD; Guerrero, JA; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Konopleva, MY; Maduike, RE; Maiti, A; Montalbano, KS; Ning, J; Pemmaraju, N; Pierce, S; Qiao, W; Rausch, CR; Ravandi, F; Short, NJ; Vaughan, K; Wade, A; Yilmaz, M | 1 |
| Hosono, N; Ida, N; Kuze, A; Negoro, E; Yamauchi, T | 1 |
| Schuh, AC; Tang, K; Yee, KW | 1 |
| Li, H; Wang, G; Wen, X; Zhou, L | 1 |
| Balsat, M; Barraco, F; Baudouin, A; Cadassou, O; Ducastelle, S; Elhamri, M; Fossard, G; Gutrin, J; Hayette, S; Heiblig, M; Labussière, H; Larcher, MV; Plesa, A; Roumier, C; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Andresen, C; Glinka, A; He, L; Hübschmann, D; Jeremias, I; Lee, H; Müller-Decker, K; Niehrs, C; Pabst, C; Sun, R | 1 |
| Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
| Daraskevicius, J; Everatt, V; Maneikis, K; Ringeleviciute, U; Vaitekenaite, V; Zucenka, A | 1 |
| Bencharef, H; Dassouli, D; Guennoun, B; Hda, N; Lamchahab, M; Oukkache, B; Quessar, A; Sraidi, S | 1 |
| Gerds, AT; Mukherjee, S | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Gupta, A; Patnaik, MM; Viswanatha, DS | 1 |
| Binner, M; Bornhäuser, M; Bray, LJ; Körner, Y; von Bonin, M; Werner, C | 1 |
| Bhalla, K; Boddu, PC; Cortes, JE; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Ohanian, M; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Verstovsek, S; Wierda, WG | 1 |
| Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC | 1 |
| Ang, AL; Ho, LP; Ng, HJ; Ong, SY; Yeo, PM | 1 |
| Carroll, M; DeNizio, JE; Kohli, RM; Nabel, CS | 1 |
| Chen, M; Liu, H; Liu, L; Ren, S; Zhang, H; Zhang, J | 1 |
| Koyama, T; Shinki, H; Tsunaka, M | 1 |
| Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T | 1 |
| Balakrishnan, VS | 1 |
| Aroua, N; Barreira, Y; Bosc, C; Boutzen, H; Broin, N; Carroll, M; Cassant-Sourdy, S; Castellano, R; Collette, Y; Danet-Desnoyers, G; David, M; de Toni, F; Delhommeau, F; Duchamp, O; Farge, T; Féliu, V; Fraisse, M; Gales, L; Garmy-Susini, BH; Griessinger, E; Hirsch, P; Hosseini, M; Iacovoni, J; Kaoma, T; Larrue, C; Linares, LK; Montersino, C; Nicolau-Travers, ML; Palama, T; Perry, R; Portais, JC; Récher, C; Saland, E; Sarry, A; Sarry, JE; Scotland, S; Selak, M; Serhan, N; Stuani, L; Sugita, M; Tavitian, S; Vallar, L; Vergez, F | 1 |
| Duyster, J; Engelhardt, M; Felthaus, J; Follo, M; Greil, C; Klingner, K; Schnerch, D; Schüler, J; Wäsch, R; Wider, D | 1 |
| Guo, W; Huang, J; Huang, S; Huang, X; Jin, J; Li, C; Li, X; Ma, Z; Xu, Y; Yan, X; Yu, M; Zhou, Y | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Gao, WH; Hu, YM; Huang, PP; Li, HM; Li, JF; Li, SZ; Liu, CH; Liu, QG; Mi, YC; Wu, LH; Xu, N; Yu, JY; Zheng, YL | 1 |
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
| Cai, HC; Cao, XX; Chen, M; Duan, MH; Feng, J; Han, B; Han, X; Li, J; Wang, SJ; Yang, C; Zhang, L; Zhang, W; Zhang, Y; Zhou, DB; Zhu, TN; Zhuang, JL | 1 |
| Inoue, Y; Isobe, Y; Kato, M; Matsunawa, M; Miura, I; Nishio, Y; Sakai, H; Sato, K; Suzuki, Y; Tomita, N; Tsuruoka, Y; Uchida, A; Uemura, Y; Yokoi, S | 1 |
| Liu, P; Zhang, H; Zhou, S | 1 |
| Abraham, A; Balasubramanian, P; Karathedath, S; Krishnamurthy, P; Mathews, V; Musheer Aalam, SM; Rajamani, BM; Varatharajan, S; Velayudhan, SR | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Sato, K; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Benner, A; Bentz, M; Brossart, P; Döhner, H; Döhner, K; Fiedler, W; Ganser, A; Göhring, G; Götze, K; Heil, G; Held, G; Hertenstein, B; Horst, HA; Jaramillo, S; Kindler, T; Kirchen, H; Köhne, CH; Koller, E; Krauter, J; Kremers, S; Kündgen, A; Lübbert, M; Martin, H; Nachbaur, D; Raghavachar, A; Runde, V; Russ, G; Salih, HR; Salwender, H; Schlenk, RF; Wattad, M; Weber, D; Wulf, G | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Caruso, S; Catania, MR; Cerchione, C; Chiurazzi, F; Della Pepa, R; Giordano, C; Iula, DV; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Simeone, L | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Ali, AM; Cooley, SA; DiPersio, JF; Miller, JS; Rashidi, A; Romee, R; Shanley, R; Ustun, C; Vij, KR; Weisdorf, DJ; Westervelt, P | 1 |
| Aliño, SF; Bosó, V; Herrero, MJ; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Moscardó, F; Poveda, JL; Sanz, MÁ | 1 |
| Aliño, SF; Boluda, B; Bosó, V; Cervera, J; Herrero, MJ; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Moscardó, F; Poveda, JL; Rodríguez-Veiga, R; Rojas, L; Sanz, MÁ; Sendra, L | 1 |
| Catalano, J; Cummings, N; Hills, R; McManus, J; Sadawarte, S; Tan, P; Tiong, IS; Wei, A | 1 |
| Fleury, A; Freiwald, M; Fritsch, H; Haug, K; P Solans, B; Trocóniz, IF | 1 |
| Shand, JC | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; de Witte, T; Döhner, H; Döhner, K; Ehninger, G; Ganser, A; Geyer, S; Klisovic, RB; Krauter, J; Larson, RA; Laumann, K; Lo-Coco, F; Mandrekar, SJ; Marcucci, G; Medeiros, BC; Niederwieser, D; Prior, TW; Sanford, BL; Sanz, MA; Schlenk, RF; Serve, H; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Wei, A | 1 |
| Chidini, G; Cortelezzi, A; Dambrosi, F; Fracchiolla, NS; Gianelli, U; Guidotti, F; Merlo, D; Ossola, MW; Sciumè, M | 1 |
| Chen, L; Guo, P; Jia, P; Li, J; Li, X; Tong, J; Zhang, Y | 1 |
| Berghold, A; Greinix, HT; Magina, KN; Neumeister, P; Pregartner, G; Sill, H; Wölfler, A; Zebisch, A | 1 |
| Schimmer, AD | 1 |
| Buxhofer-Ausch, V; Geissler, K; Girschikofsky, M; Gleixner, K; Herndlhofer, S; Hoermann, G; Jaeger, U; Knoebl, P; Kundi, M; Machherndl-Spandl, S; Poehnl, R; Sliwa, T; Sperr, WR; Strecker, K; Valent, P; Weltermann, A | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L | 2 |
| Blijlevens, NMA; Kox, M; Leijte, GP; Pickkers, PP; Scheffer, GJ; Timmermans, K | 1 |
| Beute, WK; Harrison, JS; Studzinski, GP; Wang, X | 1 |
| Killian-Benigno, C; Kuo, DJ | 1 |
| Miyawaki, S | 3 |
| Cuglievan, B; Garces, S; Menegaz, BA; Rytting, ME | 1 |
| Chen, K; Deng, M; Deng, S; Li, J; Li, P; Li, Y; Wang, Y; Xu, B; Zhang, L; Zhou, Y | 1 |
| Kang, Q; Londoño-Joshi, A; Malek, SN; Parkin, B; Rhim, AD; Tewari, M | 1 |
| Gu, MJ; Kim, MJ; Kim, MK; Kim, YK | 1 |
| Cen, J; Chen, S; Pan, J; Shao, H; Wu, C; Yang, Q | 1 |
| Albano, F; Carluccio, P; Casieri, P; Delia, M; Mestice, A; Pasciolla, C; Pastore, D; Ricco, A; Rossi, AR; Specchia, G | 1 |
| Ali Baig, MF; Khan, BA; Siddiqui, N | 1 |
| Blackford, AL; Doyle, LA; Gojo, I; Huntoon, CJ; Karnitz, LM; Karp, JE; Kaufmann, SH; Kinders, R; Litzow, M; Morris, L; Patnaik, M; Rosner, GL; Smith, BD; Tibes, R; Wang, L; Webster, JA | 1 |
| Di Raimondo, F; Ferrara, F; Fuligni, F; Isidori, A; Loscocco, F; Paolini, S; Piccaluga, PP; Rocchi, M; Spina, E; Visani, A; Visani, G; Zammit, V | 1 |
| Murphy, T; Yee, KWL | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Chen, SN; Fu, ZZ; Li, WY; Qiu, HY; Sun, AN; Wang, Y; Wu, DP | 1 |
| Tiong, IS; Wei, AH | 2 |
| Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M | 1 |
| Hu, K; Liu, W; Lyons, A; Song, Z; Yang, X; Zhai, S | 1 |
| Alino, SF; Herrero, MJ; Martinez-Cuadron, D; Megias-Vericat, JE; Montesinos, P; Poveda, JL; Sanz, MA | 1 |
| Altuntaş, F; Ayyildiz, MO; Bekdemir, F; Çakar, MK; Dal, MS; Dogu, MH; Hacioglu, SK; Ilkkiliç, K; Karakus, A; Kaya, AH; Korkmaz, S; Merdin, A; Tekgündüz, E | 1 |
| Chantzi, E; Eriksson, A; Fryknäs, M; Gullbo, J; Gustafsson, M; Höglund, M; Larsson, R; Nygren, P | 1 |
| Cascone, I; Celani, R; Cimini, AM; Clemente, E; Colotti, G; Courty, J; De Cola, A; De Laurenzi, V; Destouches, D; Dhez, AC; Di Matteo, A; Federici, L; Franceschini, M; Ippoliti, R; Raineri, F; Vallée, B | 1 |
| Amrein, PC; Attar, EC; Avigan, D; Ballen, KK; Brunner, AM; DeAngelo, DJ; Ebert, BL; Fathi, AT; Hobbs, GS; Luptakova, K; McMasters, M; Rosenblatt, J; Sperling, AS; Steensma, DP; Stone, RM; Stroopinsky, D; Wadleigh, M; Washington, A; Werner, L | 1 |
| Grassinger, J; Hart, C; Herr, W; Iberl, S; Müller, G; Schelker, RC | 1 |
| Cao, HX; Miao, CF; Sun, L; Tang, P; Yan, L; Zhang, LR | 1 |
| Foran, JM | 1 |
| Abarrategi, A; Blackwood, E; Bonnet, D; Di Tullio, A; Grey, W; Gribben, J; Mian, S; Rouault-Pierre, K; Stewart, A | 1 |
| Capparelli, EV; Lancet, JE; Louie, A; Nikanjam, M; Schiller, G | 1 |
| Auvrignon, A; Baruchel, A; Bertrand, Y; Felix, A; Fenneteau, O; Gandemer, V; Leblanc, T; Leverger, G; Michel, G; Nelkem, B; Paillard, C; Petit, A; Ragu, C; Rohrlich, PS; Schmitt, C; Sirvent, A | 1 |
| Al Harthy, M; Gondek, LP; Murray, JC; Pallazola, VA; Webster, J; Zimmerman, SL | 1 |
| Kim, M; Williams, S | 2 |
| Evans, AG; Goorha, S; Hobbs, ALV; Leonard, JM; Mills, EL; Seligson, ND | 1 |
| Al-Ali, HK; Beach, CL; Butrym, A; Candoni, A; Cavenagh, J; Del Castillo, TB; Döhner, H; Dombret, H; Falantes, J; Jang, JH; Kumar, R; Minden, MD; Récher, C; Sandhu, I; Schuh, AC; Selleslag, D; Seymour, JF; Songer, S; Stone, RM; Weaver, J; Wierzbowska, A | 1 |
| Becker, PS; Chiarella, MT; Estey, EH; Hendrie, PC; Louie, AC; McDaniel, EN; Medeiros, BC; Orlowski, KF; Othus, M; Percival, MM; Scott, BL; Walter, RB | 1 |
| Akashi, K; Aoki, T; Fujisaki, T; Harada, M; Henzan, H; Hidaka, M; Matsue, K; Miyamoto, T; Nagafuji, K; Ogawa, R; Takase, K; Taniguchi, S; Teshima, T; Uchida, N | 1 |
| Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Bixby, DL; Crouch, A; Marini, BL; Nachar, VR; Perissinotti, AJ; Scappaticci, GB; Talpaz, M; Uebel, JR; Vulaj, V | 1 |
| Baldus, CD; Bamopoulos, SA; Berdel, WE; Blum, H; Bohlander, SK; Bräundl, K; Görlich, D; Graf, A; Greif, PA; Hartmann, L; Hellmann, I; Herold, T; Hiddemann, W; Jurinovic, V; Kerbs, P; Konstandin, NP; Krebs, S; Ksienzyk, B; Mattes, R; Metzeler, KH; Neumann, M; Pastore, F; Schneider, S; Schumacher, D; Spiekermann, K; Stief, SM; Vosberg, S; Wolf, S; Wörmann, BJ; Zellmeier, E | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Lancet, JE; Talati, C | 1 |
| Duan, M; Liang, G; Xu, X; Zhang, L | 1 |
| Berdel, WE; Bornhäuser, M; Ehninger, G; Einsele, H; Fetscher, S; Gabrecht, M; Hänel, M; Heits, F; Herbst, R; Kaiser, U; Krämer, A; Kramer, M; Krümpelmann, U; Kullmer, J; Link, H; Mantovani-Löffler, L; Mohr, B; Neuhaus, T; Platzbecker, U; Ritter, B; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Schmitz, N; Schuler, US; Serve, H; Thiede, C | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Baccarani, M; Candoni, A; Fanin, R; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Martinelli, G; Papayannidis, C; Simeone, E; Visani, G | 1 |
| DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH | 1 |
| Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M | 1 |
| Bejanyan, N; Defor, T; Eckfeldt, C; He, F; Kurtzweil, A; Parker, S; Rashidi, A; Sapkota, S; Ustun, C; Warlick, E; Weisdorf, D | 1 |
| Aragon-Miguel, R; Burillo-Martinez, S; Calleja-Algarra, A; Ortiz-Romero, PL; Prieto-Barrios, M; Rodriguez-Peralto, JL; Tous-Romero, F; Velasco-Tamariz, V; Zarco-Olivo, C | 1 |
| Chen, F; Fu, B; Fu, G; Li, X; Peng, J; Zhao, X | 1 |
| Barghout, SH; Chan, SM; Claudio, J; Gronda, M; Gupta, V; Heath, E; Hurren, R; Kamel-Reid, S; Kavanagh, S; Khalaf, D; Liyanage, SU; Lutynski, A; Maze, D; Minden, MD; Rostom, A; Rydlewski, A; Schimmer, AD; Schuh, AC; Sibai, H; Siriwardena, TP; Stockley, TL; Sukhai, M; Yee, K; Zhang, T | 1 |
| Amrolia, P; Breslin, P; Cummins, M; De La Fuente, J; Gassas, A; Gibson, B; Hiwarkar, P; Hough, R; James, B; Lawson, S; Patrick, K; Petterson, T; Potter, M; Shenton, G; Sivaprakasam, P; Skinner, R; Slatter, M; Veys, P; Vora, A; Wynn, R | 1 |
| Li, Z; Liu, H; Lu, W; Shi, J; Wan, Y; Wei, Y; Yang, S; Yu, Y; Zhai, Y; Zhao, W | 1 |
| Borschel, L; Bourquin, JP; Creutzig, U; Dworzak, M; Klingebiel, T; Klusmann, JH; Lehrnbecher, T; Rasche, M; Reinhardt, D; Zimmermann, M | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Chen, Y; Guan, MX; Hu, X; Hui, L; Jiang, L; Mei, S; Meng, W; Xue, S; Yang, Y | 1 |
| Braun, JT; Fesler, MJ; Freter, CE; Lionberger, JM; Petruska, PJ; Reddy, DV; Schoen, MW; Woelich, SK | 1 |
| Accordi, B; Anselmi, L; Barozzi, P; Basso, G; Bertacchini, J; Chiarini, F; D'Avella, D; Forghieri, F; Frasson, C; Khosravi, A; Luppi, M; Marmiroli, S; Martelli, AM; Najmaldin, S; Rahim, F | 1 |
| Bai, J; Chen, Z; Cheng, T; Li, Y; Sheng, M; Xing, W; Yang, FC; Zhang, M; Zhang, P; Zhou, Y | 1 |
| Burnett, AK; Cahalin, P; Cavenagh, JD; Couzens, S; Dillon, R; Freeman, SD; Gilkes, A; Grimwade, D; Hills, RK; Jones, G; Khan, N; Khwaja, A; Nielsen, OJ; Russell, NH; Thomas, I; Upton, L; Virgo, P | 1 |
| Carabasi, M; Carroll, M; Filicko-O'Hara, J; Flomenberg, N; Frey, NV; Hexner, EO; Jeschke, GR; Kasner, MT; Loren, AW; Luger, SM; Mangan, JK; Mick, R; Perl, AE; Wagner, JL; Weiss, M | 1 |
| Hong, M; Huang, J; Li, J; Lian, Y; Qian, S; Wu, Y; Zhang, X; Zhao, H; Zhao, X; Zhu, Y | 1 |
| Cao, S; Cen, LN; Chen, P; Chen, SP; Chen, XP; Liu, H; Liu, YL; Yan, H; Zeng, H; Zhang, DY; Zhao, XL; Zhou, G; Zhu, KW | 1 |
| Baer, MR; El Chaer, F; Law, JY; Mohindra, P; Singh, ZN; Zou, Y | 1 |
| Huang, WB; Li, MW; Lin, P; Wang, W; Yang, XN; Yao, HY | 1 |
| Becktell, K; Burke, MJ; Houser, K | 1 |
| Bester, AC; Chavez, A; Church, GM; Clohessy, JG; Lee, JD; Lee, YR; Monteleone, E; Nachmani, D; Pandolfi, PP; Provero, P; Rinn, JL; Sauvageau, M; Victor, J; Vora, S | 1 |
| Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Sanz, MÁ | 1 |
| Erfurt-Berge, C; Krause, SW; Schröder, SD | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Cheng, H; Fei, X; Gu, J; He, J; Tian, Z; Wang, J; Wang, X; Xue, S; Yang, F; Yang, Y; Yin, Y; Zhang, S; Zhang, W; Zhao, J | 1 |
| Coltoff, A; Houldsworth, J; Keyzner, A; Mascarenhas, J; Renteria, AS | 1 |
| Brayer, J; Rose, A | 1 |
| Houssou, B; Lamchahab, M; Massi, R; Oukkache, B; Quessar, A | 1 |
| Feng, YF; Fu, CC; Han, Y; Li, WY; Ma, X; Qiu, HY; Sun, AN; Tang, XW; Wu, DP | 1 |
| Hanmantgad, M; Liu, B; Liu, D; Narurkar, R; Song, Y; Zafar, W | 1 |
| Acton, G; Carella, AM; Cortes, JE; Craig, AR; Craig, MD; Egyed, M; Fox, JA; Horst, HA; Jabbour, E; Kantarjian, HM; Klimek, VM; Krug, U; Lancet, JE; Pigneux, A; Ravandi, F; Récher, C; Ritchie, EK; Sayar, H; Schiller, GJ; Smith, JA; Strickland, SA; Stuart, RK; Vey, N; Ward, R | 1 |
| Bhatnagar, N; Jones, H; Wan Ariffin, E | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Chabane, K; Charlot, C; Courtois, L; Grange, B; Hayette, S; Huet, S; Lours, C; Mosnier, I; Paubelle, E; Salles, G; Simonet, T; Subtil, F; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Briot, T; Lagarce, F; Roger, E; Thépot, S | 1 |
| Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF | 1 |
| Bochtler, T; Bug, G; Döhner, H; Garin-Chesa, P; Krämer, A; Krug, U; Liu, D; Lübbert, M; Müller-Tidow, C; Ottmann, OG; Schlenk, RF; Taube, T; Voss, F | 1 |
| Adachi, S; Hasegawa, D; Hiramatsu, H; Horibe, K; Iwamoto, S; Kiyokawa, N; Miyachi, H; Saito, AM; Taga, T; Tanaka, S; Tomizawa, D | 1 |
| Berard, E; Bertoli, S; Gadaud, N; Huguet, F; Huynh, A; Luquet, I; Récher, C; Sarry, A; Tavitian, S | 1 |
| Boileau, M; Eppert, K; Frison, H; Laverdière, I; Minden, MD; Mitchell, A; Neumann, AL; Ng, SWK; Wang, JCY | 1 |
| Boer, J; Bowman, K; Burke, K; Covington, M; Diamond, S; Dostalik Roman, V; Feng, H; Hall, L; Hollis, G; Huber, R; Koblish, H; Lambert, QT; Li, YL; Marando, C; Margulis, A; Reuther, GW; Scherle, P; Shin, N; Vaddi, K; Wang, K; Wang, Q; Wynn, R; Xue, CB; Yao, W; Yeleswaram, S; Zhang, K | 1 |
| Dotson, JL; Jamil, MO | 1 |
| Chen, RA; Chen, Y; Ji, YR; Li, GH; Liu, C; Liu, L; Qin, WW; Wang, WQ; Zhou, NC | 1 |
| Pollyea, DA; Sharma, P | 1 |
| Bernardi, M; Borlenghi, E; Calvello, C; Castagnola, C; Cazzola, M; Cerqui, E; Da Vià, M; Ferretti, VV; Fracchiolla, N; Fumagalli, M; Mancini, V; Marbello, L; Ravano, E; Rocca, B; Rossi, G; Zappasodi, P | 1 |
| Chen, YB; Dey, BR; Fathi, AT; Hobbs, G | 1 |
| Cao, S; Chen, P; Chen, SP; Chen, XP; Liu, H; Liu, YL; Yan, H; Yang, J; Zeng, H; Zhang, DY; Zhao, XL; Zhou, G; Zhu, KW | 1 |
| Banerjee, K; Bixby, DL; Chiarella, M; Cortes, JE; Hoering, A; Hogge, D; Kolitz, JE; Lancet, JE; Lin, TL; Louie, AC; Medeiros, BC; Newell, LF; Ritchie, EK; Ryan, DH; Schiller, GJ; Solomon, SR; Stone, RM; Strickland, SA; Stuart, RK; Uy, GL; Wieduwilt, MJ | 1 |
| Ding, Y; Du, J; Gong, BF; Gong, TJ; Huang, WR; Jia, ZL; Jiang, EL; Li, BZ; Li, J; Liao, AJ; Liu, SC; Lu, N; Mao, YY; Sun, Y; Tan, YH; Wang, JX; Wei, H | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Konopleva, M; Letai, A | 1 |
| Killock, D | 1 |
| Cortes, JE; Rytting, ME; Short, NJ | 1 |
| Cao, X; Crews, KR; Elsayed, AH; Gandhi, V; Lamba, JK; Plunkett, W; Pounds, SB; Ribeiro, RC; Rubnitz, JE | 1 |
| Almakadi, M; Aslostovar, L; Bhatia, M; Boyd, AL; Collins, TJ; Foley, R; Julian, JA; Kim, RB; Leber, B; Leong, DP; Levine, MN; Tirona, RG; Xenocostas, A | 1 |
| Chen, Y; Gan, D; Hu, J; Huang, Q; Lin, D; Luo, X | 1 |
| Song, Q; Sun, L; Wang, LJ; Wu, XF; Zhuang, W | 1 |
| Hu, DZ; Li, YY; Tian, C | 1 |
| Blackford, AL; Bose, P; Doyle, LA; Foster, MC; Gocke, CD; Gojo, I; Karp, JE; Lancet, JE; Levy, MY; Little, RF; Litzow, MR; Morris, LE; Rosner, GL; Smith, BD; Strickland, SA; Tibes, R; Wright, JJ; Zeidner, JF | 2 |
| Anderson, E; Bone, H; Heywood, J; Mayer, L; Mehta, P; Rees, B; Reynolds, D; Robinson, G; Salisbury, V | 1 |
| Bourgeais, J; Debeissat, C; Domenech, J; Ducrocq, E; Ferrié, E; Foucault, A; Gallay, N; Gyan, E; Haddaoui, L; Hérault, O; Maciejewski, A; Picou, F; Ravalet, N; Vallet, N | 1 |
| Haack, K; Henderson, PT; Jonas, BA; Malfatti, MA; Pan, CX; Scharadin, TM; Turteltaub, KW | 1 |
| Crawford, SY; Hedlund, NG; Hynes, DM; Isgor, Z; Powell, LM; Rondelli, D; Zwanziger, J | 1 |
| Han, AR; Hwang, HS; Kim, HJ; Lee, JY; Min, WS; Park, GS | 1 |
| Cai, J; Chen, F; Li, X; Liu, J; Sheng, X; Xiao, F; Xu, L; Yin, T; Zhong, H | 1 |
| Sweet, K; Talati, C | 1 |
| Che, F; Gui, C; Huang, J; Wang, C; Zhang, L | 1 |
| Aksu, S; Buyukasık, Y; Ciftciler, R; Demiroglu, H; Goker, H; Haznedaroglu, IC; Malkan, UY; Okay, M; Ozcebe, O; Sayınalp, N | 1 |
| Inoue, A; Mori, A; Suzuki, R; Takitani, K; Tamai, H; Yamazaki, S | 1 |
| Al-Ali, HK; Beach, CL; Bullinger, L; Del Castillo, TB; Döhner, H; Dolnik, A; Dombret, H; MacBeth, KJ; Minden, MD; Santini, V; Seymour, JF; Skikne, BS; Songer, S; Stone, RM; Tang, L; Tu, N; Vyas, P | 1 |
| Amler, S; Baumgartner, A; Beelen, D; Behringer, DM; Biersack, H; Bohlander, SK; Braess, B; Braess, J; Buske, C; De Wit, M; Dufour, A; Faldum, A; Fiegl, M; Gaska, T; Görlich, D; Graeven, U; Hiddemann, W; Hindahl, H; Kiehl, MG; Ko, YD; Koch, R; Korsten, S; Kreuzer, KA; Lablans, M; Lengfelder, E; Lindemann, HW; Ludwig, WD; Massenkeil, G; Meckenstock, G; Medgenberg, D; Peceny, R; Roemer, E; Sauerland, C; Schiel, X; Schneider, S; Schwerdtfeger, R; Spaeth-Schwalbe, E; Spiekermann, K; Staib, P; Subklewe, M; Trenn, G; Unterhalt, M; Uppenkamp, MJ; Wörmann, B; Zinngrebe, B | 1 |
| Dührsen, U; Hanoun, M; Noppeney, R; Westhus, J | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Gao, L; Gong, L; Li, J; Qiu, H; Shen, R; Shi, Z; Sun, H; Tian, Z; Yang, L; Zhang, G | 1 |
| Chen, Q; Gurumurthy, A; Huang, S; Khoury, JD; Li, H; Qiu, Y; Shimada, K; Tang, M; Xu, B; Yan, B | 1 |
| Harada, K; Ikegawa, S; Kobayashi, T; Ohashi, K; Sasaki, S; Sekiya, N | 1 |
| Gourd, E | 1 |
| Bae, S; Costa, LJ; Erba, HP; Jamy, O; Papadantonakis, N | 1 |
| Deng, T; Jiang, L; Wang, D; Xiao, Y | 1 |
| Anderson, JE; Appelbaum, FR; Erba, HP; Estey, EH; Garcia-Manero, G; Godwin, JE; Othus, M; Stirewalt, DL; Walter, RB; Weick, JK; Wood, BL | 1 |
| Appelbaum, FR; Erba, HP; Estey, E; Garcia-Manero, G; Nand, S; Othus, M; Sekeres, MA | 1 |
| Hale, G; Kussman, A; Oshrine, B; Petrovic, A; Shyr, D | 1 |
| Chen, J; Chen, L; Cheng, H; Gao, L; Hu, XX; Li, HM; Luo, YR; Ni, X; Song, XM; Tang, GS; Wang, JM; Wang, ZW; Xia, XX; Yang, D; Yang, JM; Zhang, WP; Zhou, H | 1 |
| Andreeff, M; Chng, WJ; Henter, JI; Herold, N; Kantarjian, HM; Khoury, JD; Medeiros, LJ; Myrberg, IH; Ng, CH; Ng, SB; Rassidakis, GZ; Ravandi, F; Rudd, SG; Schaller, T; Tsesmetzis, N; Xagoraris, I; Yan, B | 1 |
| Luo, W; Ni, X; Wei, J; Yu, H; Zou, X | 1 |
| Bahashwan, S; Bay, JO; Berger, MG; Douge, A; Guièze, R; Hermet, E; Lemal, R; Moluçon-Chabrot, C; Ravinet, A; Tchirkov, A; Tournilhac, O; Veronese, L; Veyrat-Masson, R | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Beadle, JR; He, R; Hostetler, KY; Khoury, H; Minden, MD; Schimmer, A | 1 |
| Becker, H; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Götze, KS; Greil, C; Heuser, M; Janning, M; Kebenko, M; Könecke, C; Krauter, J; Lübbert, M; Neuhaus, B; Papkalla, A; Paschka, P; Reimer, P; Schlenk, RF; Thol, F; Verbeek, M; Wattad, M | 1 |
| Bhattacharyya, S; Bonifacio, G; Duchesneau, E; Guerin, A; Joseph, G; Li, N; Ndife, B; Stein, E; Vudumula, U; Xie, J | 1 |
| Bérard, E; Bertoli, S; Delabesse, E; Huguet, F; Picard, M; Récher, C; Sarry, A; Tavitian, S; Vergez, F | 1 |
| Andreeff, M; Arai, H; Kaga, N; Kikkawa, M; Konopleva, M; Miida, T; Ruvolo, V; Saitoh, K; Sekihara, K; Spagnuolo, PA; Tabe, Y; Taka, H; Yamatani, K; Yang, H | 1 |
| Al Yacoub, R; Cronin, TL; Griffiths, EA; Miller, A; Ontiveros, EP; Thompson, JE; Vachhani, P; Wang, ES; Zhang, F | 1 |
| Bug, G; Döhner, H; Fiedler, W; Goeldner, RG; Hilbert, J; Krämer, A; Krug, U; Lübbert, M; Müller-Tidow, C; Ottmann, OG; Schlenk, RF; Taube, T; Westermann, J | 1 |
| Ashaye, AO; Cappelleri, JC; Fahrbach, K; Khankhel, Z; Lang, K; Mamolo, C; Mokgokong, R; Orme, ME; Xu, Y | 1 |
| Lancet, JE | 1 |
| Castelli, G; Labbaye, C; Ottone, T; Pasquini, L; Pelosi, E; Quaranta, MT; Saulle, E; Spinello, I; Testa, U; Voso, MT | 1 |
| Ballesteros, J; Bergua, J; Colorado, M; García-Boyero, R; Gil, C; Gorrochategui, J; Hernández-Campo, P; Herrera, P; Jiménez-Bravo, S; Lavilla, E; Linares Gómez, M; López, JA; Martínez-Cuadrón, D; Martínez-López, J; Montesinos, P; Moscardó, F; Pérez-Oteyza, J; Pérez-Simón, JA; Primo, D; Rodríguez, G; Rojas, JL; Sanz, M; Serrano, J; Tormo, M; Troconiz, I; Vidriales, MB; Villoria, J; Vives, S | 1 |
| Abughanimeh, O; Bahaj, W; Foxworth, J; Gaur, R; Qasrawi, A; Qasrawi, L | 1 |
| Howell, G; Oliai, C; Schiller, G | 1 |
| Danilenko, M; Harrison, JS; Nachliely, M; Studzinski, GP; Wang, X | 1 |
| Blair, HA | 1 |
| Lv, T; Tian, X; Wang, L; Xu, J; Yuan, G | 1 |
| Abdalla, K; Abrar, MB; AlAzmi, AA; Elimam, N; Jastaniah, W; Mustafa, O | 1 |
| Alfayez, M; Boddu, PC; Borthakur, G; Cortes, J; Daver, NG; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Konopleva, M; Naqvi, K; Pierce, S; Ravandi, F; Short, NJ; Yilmaz, M | 1 |
| Banerjee, A; Bateman, DA; Blumenthal, GM; Farrell, AT; Fu, W; Gao, X; Gieser, G; Goldberg, KB; Janoria, KG; Krauss, AC; Li, L; Liu, J; Manning, ML; Patel, P; Pazdur, R; Przepiorka, D; Shen, YL; Sheth, CM; Shord, SS | 1 |
| Chan, G; Cortes, JE; DesJardins, P; Fiedler, W; Heidel, FH; Hellmann, A; Heuser, M; Laird, AD; Ma, WW; Montesinos, P; O'Connell, A; Ottmann, O; Pollyea, DA; Robak, T; Shaik, MN; Smith, BD; Zeremski, M | 1 |
| Banerjee, K; Gibbons, JA; Marier, JF; Vasilinin, G; Wang, Q | 1 |
| Abedin, SM; Akpan, I; Altman, JK; Arslan, AD; Beauchamp, EM; Blyth, GT; Eklund, EA; Fischietti, M; Fish, EN; Frankfurt, O; Goo, YA; Lantz, C; Nelson, A; Platanias, LC; Radecki, SG; Thomas, PM; Yang, A | 1 |
| Imataki, O; Kadowaki, N; Kubo, H; Kubo, YH; Uemura, M | 1 |
| de Bock, GH; de Bont, E; de Haas, V; De Moerloose, B; Dedeken, L; Denys, B; Kaspers, G; Lammens, T; Reedijk, A; Te Loo, M; Uyttebroeck, A; Van Damme, A; van den Heuvel-Eibrink, MM; Van der Werff-Ten Bosch, J; Zsiros, J | 1 |
| Friedler, S; Huleihel, M; Kapilushnik, J; Lunenfeld, E; Meese, E; Michailov, Y | 1 |
| Ansai, SI; Hoashi, T; Ichiyama, S; Kanda, N; Komatsu, T; Nagai, K; Saeki, H; Yamada, Y | 1 |
| Chen, J; Chen, R; Chen, X; Gu, L; Pan, C; Shen, S; Tang, J; Tang, Y; Xue, H | 1 |
| Jordan, CT; Pollyea, DA | 1 |
| Benitez, LL; Bixby, DL; Brown, J; Burke, PW; Cheung, E; Marini, BL; Perissinotti, AJ; Pettit, KM; Scappaticci, GB | 1 |
| Hoy, SM | 1 |
| Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Poveda, JL; Sanz, MÁ | 1 |
| Kontopoulou, E; Kunz, F; Reinhardt, D; Reinhardt, K; Soldierer, M; Strachan, S; Thakur, BK | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Kako, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Kimura, SI; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Toda, Y; Yamamoto, C; Yamasaki, R | 1 |
| Baskhaeva, GA; Davidiva, JO; Drokov, MY; Dvirnik, VN; Fidarova, ZT; Galtseva, IV; Gavrilina, OA; Kokhno, AV; Kulikov, SM; Kuzmina, LA; Kuznetsova, SA; Lobaova, TI; Loukianova, IA; Obukhova, TN; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Sudarikov, AB; Troitskaya, VV; Vasilyeva, VA | 1 |
| Banck, JC; Görlich, D | 1 |
| Cook, JR; Nomani, L; Rogers, HJ | 1 |
| Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T | 1 |
| Chung, KC; Deger, KA; Fisher, V; Hogge, D; Howell, TA; Koetter, K; Louie, AC; Matza, LS; Yeager, AM | 1 |
| Arnold, AJ; Gilmour, GS; Koch, MW | 1 |
| Flores-Jiménez, JA; González-Ramella, O; Pimentel-Morales, MA; Vega-Cortés, D; Zambrano-Velarde, MÁ | 1 |
| Penning, TM; Trippier, PC; Verma, K; Zang, T | 1 |
| Malhotra, P; Sahu, KK; Yanamandra, U | 1 |
| Ding, H; Flatten, KS; Hess, AD; Huehls, AM; Karnitz, LM; Kaufmann, SH; Kelly, RL; Kohorst, MA; Pratz, KW; Vincelette, ND; Webster, J | 1 |
| Gibson, B; Huang, F; Kearns, P; Moreno, L; Nakahara, S; Nemat, S; Nysom, K; Parasrampuria, DA; Reinhardt, D; Zhou, W; Zwaan, CM | 1 |
| Gasparetto, M; Minhajuddin, M; Pei, S; Seligman, P; Smith, CA; Stevens, B | 1 |
| Clauwaert, M; Depuydt, P; Druwé, P | 1 |
| Chien, HF; Hu, CY; Ko, YC; Lin, LI; Liu, ZH; Ou, DL; Tien, HF | 1 |
| Beck, A; Hunter, H; Jackson, S; Sheridan, D | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Hu, Y; Huang, H; Jin, A; Jin, M; Luo, Y; Tan, Y; Wei, G; Wu, W; Yang, L; Yu, J | 1 |
| Dabek, MT; Heinzmann, T; Johann, P; Kulozik, A; Kunz, J; Westhoff, J | 1 |
| Agarwal, S; Chyla, B; Enjeti, A; Fakouhi, KM; Fiedler, W; Hayslip, J; Hong, WJ; Hou, JZ; Humerickhouse, R; Lee, S; Lin, TL; Popovic, R; Roboz, GJ; Salem, AH; Savona, M; Strickland, SA; Tiong, IS; Walter, RB; Wei, AH; Xu, T | 1 |
| Ali, S; Barbachano, Y; Bjerrum, OW; Dunmore, HM; Gisselbrecht, C; Hay, JL; Hovgaard, D; Karres, D; Nagercoil, N; Pignatti, F; Salmonsson, T; Sarac, SB | 1 |
| Li, LJ; Yu, K; Zhang, JY | 1 |
| Chang, YT; Ghiaur, G; Hernandez, D; Jones, RJ; Su, M | 1 |
| Cao, S; Chen, P; Chen, X; Li, X; Liu, Y; Wang, S; Yan, H; Yuan, X; Zeng, H; Zhang, D; Zhao, X; Zhou, G; Zhu, K | 1 |
| Abel, GA; Amrein, P; Brunner, AM; DeAngelo, DJ; El-Jawahri, A; Fathi, A; Foster, J; Greer, JA; Hobbs, G; Horick, NK; LeBlanc, TW; Markovitz, N; Steensma, DP; Stone, RM; Temel, JS; Traeger, L; VanDusen, H; Wadleigh, M; Waldman, L | 1 |
| Shea, LK; Uy, GL | 1 |
| Passweg, JR | 1 |
| Amin, S; Cabot, MC; Claxton, DF; Conaway, MR; Desai, D; Doi, K; Dunton, W; Feith, DJ; Fox, TE; Kester, M; Liu, X; Loughran, TP; Morad, SAF; Tan, SF; Wang, HG | 1 |
| Andreassen, PR; Bu, J; Chen, W; Dong, Y; Feng, X; Hayashi, Y; Huang, G; Huang, R; Ju, Z; Wang, J; Wang, QF; Xiao, Z; Xu, Z; Yan, X; Zhan, D; Zhang, Y; Zhao, T; Zhao, X; Zhou, Y | 1 |
| Duffield, AS; Hamaker, M; Li, L; Small, D; Wu, M | 1 |
| Guo, X; Zhang, X | 2 |
| Aurelius, J; Ewald Sander, F; Hellstrand, K; Kiffin, R; Martner, A; Möllgård, L; Nilsson, S; Thorén, FB | 1 |
| Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W | 1 |
| Cao, YP; Li, JG; Zhang, JL | 1 |
| Bhise, NS; Cao, X; Elsayed, AH; Lamba, JK; Pounds, S | 1 |
| Chung, HJ; Han, SH; Hur, M; Kim, H; Lee, MH; Moon, HW; Yoon, S; Yun, YM | 1 |
| Adami, F; de Carvalho, LEW; Do Carmo Almeida, TC; Filho, VCB; Fonseca, FLA; Puty, TC; Sarraf, JS | 1 |
| By, K; Del Valle, PL; Farrell, AT; Goldberg, KB; Leong, R; Liu, C; Norsworthy, KJ; Pazdur, R; Przepiorka, D; Shen, YL; Sheth, CM; Subramaniam, S; Zhuang, L | 1 |
| Ali, NA; Dhulipala, VC; Djulbegovic, B; Extermann, MT; Kim, J; Komrokji, R; Kuykendall, A; Lancet, JE; Reljic, T; Sehovic, M; Sweet, K; Talati, C | 1 |
| Amadori, S; Baron, F; Bosi, A; Bourhis, JH; Cannella, L; de Witte, T; Efficace, F; Fabbiano, F; Fazi, P; Ferrero, D; Halkes, CJM; La Sala, E; Marie, JP; Martinelli, G; Muus, P; Petti, MC; Sborgia, M; Suciu, S; Trisolini, S; van der Velden, WJFM; Vignetti, M; Willemze, R; Wittnebel, S; Zittoun, RA | 1 |
| Baker, SD; Buelow, DR; Cotton, A; Dang, J; Drenberg, CD; Fu, Q; Gruber, TA; Guy, RK; Hu, S; Inaba, H; Jeon, JY; Li, M; Orwick, SJ; Pioso, M; Ribeiro, RC; Rubnitz, JE; Shelat, A | 1 |
| Alvarez, D; Banerjee, K; Callahan, T; Liboiron, BD; Lin, TL; Louie, AC; Mayer, LD; Michaelis, LC; Newell, LF; Pentikis, HS; Rubenstein, E; Stuart, RK; Wang, Q | 1 |
| Furevik, SMV; Haugse, R; Herfindal, L; Myklebust, NN; Singh, A | 1 |
| Assaraf, YG; Berman, B; Levin, M; Stark, M | 1 |
| Baker, SD; Behbehani, G; Bhatnagar, B; Blachly, J; Blum, W; Buelow, DR; Byrd, JC; Garzon, R; Jeon, JY; Klisovic, RB; Mims, AS; Phelps, M; Vasu, S; Walker, AR; Zhao, Q | 1 |
| Choudhary, D; Doval, D; Khandelwal, V; Kumar Sharma, S; Kumar, M | 1 |
| Bakhshi, R; Bakhshi, S; Pramanik, R; Singh, A; Tyagi, A; Vishnubhatla, S | 1 |
| Amin, S; Annageldiyev, C; Bhattacharya, P; Claxton, D; Desai, D; Dovat, S; Feith, DJ; Gowda, K; Iyer, S; Loughran, TP; Patel, T; Sharma, A; Tan, SF | 1 |
| Flaishon, L; Rowe, JM; Stone, A; Yakar, RB; Zukerman, T | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Candoni, A; Cerrano, M; Crisà, E; D'Ardia, S; Dubbini, MV; Ferrero, D; Zannier, ME | 1 |
| Blum, W; LaPlant, B; Larson, RA; Mandrekar, SJ; Marcucci, G; Stone, RM; Uy, GL; Yin, J | 1 |
| Maakaron, JE; Mims, AS | 1 |
| DiNardo, C; Guerra, VA; Konopleva, M | 1 |
| Jin, J; Mao, LP; Meng, HT; Qian, JJ; Qian, WB; Tong, HY; Wang, L; Yu, WJ; Zhang, Y | 1 |
| Alary, AS; Bouscary, D; Deau, B; Fontenay, M; Hermine, O; Kosmider, O; Mondesir, J; Sibon, D; Suarez, F; Tamburini, J; Willems, L | 1 |
| Inoue, D; Nishijima, K; Takahashi, J; Yoshida, Y | 1 |
| Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS | 1 |
| Cai, R; Cheng, J; Liu, B; Ma, J; Yang, J; Yu, D; Zuo, Y | 1 |
| Abou Dalle, I; Andreeff, M; Borthakur, G; Bose, P; Cortes, J; Daver, N; DiNardo, C; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Loghavi, S; Naqvi, K; Nogueras González, GM; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, NJ; Yalniz, F; Yilmaz, M | 1 |
| Danilenko, M; Dawod, A; Harrison, JS; Nachliely, M; Studzinski, GP; Wang, X | 1 |
| Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH | 1 |
| Fischer, T; Jost, F; Rinke, K; Sager, S; Schalk, E | 1 |
| Stirrups, R | 1 |
| Kawamata, N; Umezawa, Y | 1 |
| Dama, P; Fulton, N; Kline, J; Liu, H; Tang, M | 1 |
| Ast, AM; Blenc, AM; Cogle, CR; Drusbosky, LM; Ge, Y; Geddes, T; Lipten, SD; Madlambayan, GJ; Maywood, M; Miller, R; Ostrov, DA; Pezeshkian, MB; Pompeu, Y; Salgado, AD; Vijay, V; Vue, GS | 1 |
| Caputo, VS; Gmucova, H; Holubova, M; Jindra, P; Leba, M; Lysak, D | 1 |
| Fathi, AT | 1 |
| Jing, Y; Li, Y; Lv, N; Wang, L; Xu, Q; Yu, L | 1 |
| Ballerini, F; Cagnetta, A; Cea, M; Clavio, M; Colombo, N; Gobbi, M; Guolo, F; Lemoli, RM; Marcolin, R; Miglino, M; Minetto, P; Todiere, A | 1 |
| Aroua, N; Bosc, C; Bossis, G; Farge, T; Gotanègre, M; Guyonnet-Dupérat, V; Hosseini, M; Jarrou, L; Larrue, C; Mouchel, PL; Piechaczyk, M; Récher, C; Rezvani, HR; Sabatier, M; Saland, E; Sarry, JE; Zaghdoudi, S | 1 |
| Cumpston, A; Kanate, AS; Vos, J; Walchack, R | 1 |
| Guo, W; Huang, X; Jin, J; Li, F; Li, X; Mao, S; Yu, M | 1 |
| He, R; Li, J; Liu, X; Pan, R; Wang, C | 1 |
| Anyang, BN; Baer, MR; Beumer, JH; Carrier, F; Espinoza-Delgado, I; Fang, HB; Gojo, I; Lapidus, R; Ross, DD; Sadowska, M; Srivastava, RK; Tan, M | 1 |
| Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Qin, YZ; Zhang, XH; Zhu, HH | 1 |
| Aplenc, R; Bagatell, R; Fisher, BT; Huang, YS; Kavcic, M; Lee, GE; Li, Y; Seif, AE; Tasian, SK; Torp, K; Vujkovic, M; Walker, DM | 1 |
| Audisio, E; D'Ardia, S; Di Bello, C; Di Celle, PF; Frairia, C; Inghirami, G; Marmont, F; Messa, E; Pich, A; Riera, L; Sismondi, F; Toppino, D; Vitolo, U | 1 |
| Chen, H; Hu, J; Hu, L; Jiang, M; Li, B; Li, Y; Lou, X; Ning, H; Wang, J; Xu, C; Yu, Z | 1 |
| Ham, JC; Ruijs, GJ; van Marwijk Kooy, MR | 1 |
| Sperr, WR; Ustun, C; Valent, P; Weisdorf, D; Wiernik, A | 1 |
| Chen, X; Gao, L; Kong, P; Li, Y; Liu, Y; Su, Y; Wang, C; Wang, Q; Wang, S; Wen, Q; Yuan, Z; Zeng, Y; Zhang, C; Zhang, X; Zhang, Y | 1 |
| Campana, D; Cao, X; Cox, NJ; Crews, KR; Dolan, ME; Gamazon, ER; Gorsic, L; Hartford, CM; Hulur, I; Im, HK; Lamba, JK; Mitra, AK; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, JE; Stark, AL; Welsh, M; Wheeler, HE; Wong, SS; Zhang, W | 1 |
| Ammannagari, N; Kaewpoowat, Q; Patel, A; Ratanapo, S | 1 |
| Kerisit, K; Lin, C; Shlapak, D; Stumpf, B; Wang, A | 1 |
| Negoro, E; Shigemi, H; Ueda, T; Uzui, K; Yamauchi, T; Yoshida, A | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Appelbaum, FR; Brandwein, J; Erba, HP; Kopecky, KJ; Larson, RA; Nevill, T; Petersdorf, SH; Slovak, M; Stenke, L; Stiff, PJ; Stuart, RK; Tallman, MS; Walter, RB; Willman, C | 1 |
| Chen, B; Ouyang, J; Wang, J; Xu, JY; Yang, YG; Zhang, QG; Zhou, M; Zhou, RF | 1 |
| Jin, J; Mai, W; Mao, L; Meng, H; Qian, J; Qian, W; Tong, H; Tong, Y; Yu, W | 1 |
| Li, XY; Li, Y; Wang, X | 1 |
| Ando, K; Bay, JO; Giagounidis, A; Gröpper, S; Jabbour, EJ; Kantarjian, HM; Martinelli, G; Owen, K; Papayannidis, C; Pike, L; Quintás-Cardama, A; Schmitt, N; Stockman, PK; Wei, A | 1 |
| Bowers, DC; Heym, KM; Pelfrey, L; Thienprayoon, R | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Brunner, AM; Chen, YB; Drapkin, BJ; Fathi, AT; Feng, Y; McAfee, SL; Neuberg, DS; Sadrzadeh, H | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Ehninger, G; Einsele, H; Hänel, M; Ho, AD; Illmer, T; Kramer, M; Krause, SW; Mayer, J; Neubauer, A; Parmentier, S; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Schmitz, N; Serve, H; Stölzel, F; Thiede, C | 1 |
| Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
| Kamimura, S; Kojima, H; Moritake, H; Nunoi, H; Sawa, D; Shimonodan, H; Yamada, A | 1 |
| Hagihara, K; Hino, M; Inaba, A; Koh, H; Nagata, Y; Nakamae, H; Nakane, T; Nakao, Y; Nanno, S; Nishimoto, M; Okamura, H; Sakabe, M; Shimono, T | 1 |
| Andreeff, M; Chen, Y; Croce, C; Garzon, R; Jacamo, R; Konopleva, M | 1 |
| Andreadis, C; Giacomini, KM; Kubo, M; Matsuda, K; Mefford, JA; Percival, ME; Singh, N; Stecula, A; Takahashi, A; Witte, JS; Yang, K; Yee, SW | 1 |
| Alonzo, TA; Cesano, A; Cohen, AC; Dahl, GV; Gamis, A; Gayko, U; Gerbing, R; Hackett, J; Lacayo, NJ; Louie, B; Meshinchi, S; Purvis, N; Putta, S; Ravindranath, Y; Rosen, DB; Westfall, M | 1 |
| Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, S; Machishima, T; Nakasone, H; Nishida, J; Okuda, S; Sakamoto, K; Sato, M; Tanihara, A; Terasako, K; Wada, H; Yamasaki, R; Yamazaki, R | 1 |
| Aquino, S; Avenoso, D; Ballerini, F; Bergamaschi, M; Clavio, M; Colombo, N; Cruciani, F; De Astis, E; Ghiggi, C; Gobbi, M; Grasso, R; Guolo, F; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G | 1 |
| Creutzig, U; Dworzak, MN; Reinhardt, D; Ritter, J; Schellong, G; Zimmermann, M | 1 |
| Brychtova, Y; Doubek, M; Dusek, J; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M | 1 |
| Castaigne, S; Celli-Lebras, K; Chevret, S; Dombret, H; Fenaux, P; Gachard, N; Gardin, C; Malfuson, JV; Merabet, F; Micol, JB; Pautas, C; Preudhomme, C; Quesnel, B; Sarkozy, C; Terré, C; Thomas, X; Turlure, P | 1 |
| Fischer, T; Heidel, FH; Jentsch-Ullrich, K; Krogel, C; Luehr, H; Schalk, E; Schnoeder, TM; Wolleschak, D | 1 |
| Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Oliver, SD; Owen, K; Ribrag, V; Rousselot, P; Sekeres, MA; Stockman, PK | 1 |
| Andreeff, M; Hatanaka, Y; Hsu, FJ; Jin, L; Konopleva, M; Miida, T; Shi, YX; Shikami, M; Tabe, Y; Zeng, Z | 1 |
| Advani, AS; Earl, M; Gallagher, EM; Kalaycio, ME; Kusick, KN; Maciejewski, JP; Mukherjee, S; Sekeres, MA; Tiu, RV; Wenzell, CM; Yeh, JY | 1 |
| Ali, S; Bowen, D; Burnett, AK; Hills, RK; Hunter, AE; Knapper, S; McMullin, MF; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Feng, L; Ma, LN; Sheng, GY; Wang, CM; Wang, YC; Wei, YW; Yin, CY | 1 |
| Falk, IJ; Fyrberg, A; Gréen, H; Hermanson, M; Höglund, M; Lotfi, K; Nahi, H; Palmqvist, L; Paul, E; Rosenquist, R; Stockelberg, D; Wei, Y | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Choi, S; Cortes, J; Daver, N; Du, M; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Nazha, A; Pemmaraju, N; Ravandi, F | 1 |
| DiNardo, CD; Gandhi, VV; O'Brien, S; Ravandi, F | 1 |
| He, GS; He, XF; Ji, CF; Jin, ZM; Liu, LM; Ma, X; Sun, AN; Wu, DP; Xue, SL; Yang, Y; Zhang, YM | 1 |
| Dailey, ME; Gorgan, MA; Mar, N; Vredenburgh, JJ | 1 |
| Burnett, AK; Gibson, BE; Hills, RK; Hunter, AE; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Singh-Rambiritch, S; Wood, NH | 1 |
| Ichikawa, M; Kobayashi, T; Kurokawa, M; Nannya, Y | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Berdel, WE; Frey, K; Giovannoni, L; Gutbrodt, KL; Klapper, W; Neri, D; Pabst, T; Schliemann, C | 1 |
| Bowman, WP; Campana, D; Coustan-Smith, E; Dahl, G; Inaba, H; O'Hear, C; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shi, L; Taub, JW | 1 |
| Blum, W; Byrd, JC; Chan, KK; Devine, SM; Grever, MR; Huynh, L; Kefauver, C; Klisovic, RB; Liu, Z; Marcucci, G; Xie, Z; Zwiebel, JA | 1 |
| Campana, D; Cao, X; Crews, KR; Dolan, ME; Downing, J; Gandhi, V; Hartford, C; Lamba, JK; Mitra, AK; Plunkett, W; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, JE | 1 |
| Handa, H; Hatsumi, N; Jimbo, T; Miyawaki, S; Nojima, Y; Saitoh, T; Sakura, T; Shimizu, H; Takada, S | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Beyene, J; Bowes, L; Brossard, J; Cellot, S; Dix, D; Ethier, MC; Gillmeister, B; Johnston, D; Lewis, V; Michon, B; Mitchell, D; Portwine, C; Price, V; Silva, M; Stobart, K; Sung, L; Yanofsky, R; Zelcer, S | 1 |
| Alloush, H; Anderson, E; Conway, M; Fitzgerald, SP; Lamont, J; Martin, A; Mehta, P; O'Malley, K; Reid, C; Ruddock, M; Salisbury, V; Smith, JG; Smith, MA | 1 |
| Bergua, J; Carpio, C; Herrera, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Oriol, A; Rodríguez-Veiga, R; Salamero, O; Sanz, J; Sanz, MA; Vidriales, B; Vives, S | 1 |
| Andreeff, M; Blake, N; Cardone, MH; Carlson, NE; Elashoff, M; Huang, X; Konopleva, M; Kornblau, SM; Lena, R; Pierceall, WE | 1 |
| Advani, A; Elson, P; Kalaycio, M; Kendeigh, C; Maciejewski, JP; Mohan, S; Mukherjee, S; Ornstein, MC; Saunthararajah, Y; Sekeres, MA; Tiu, RV | 1 |
| Geethakumari, PR; Nair, SG | 1 |
| Azzarà, A; Benedetti, E; Buda, G; Caracciolo, F; Carulli, G; Fontanelli, G; Galimberti, S; Orciuolo, E; Petrini, M; Rocco, M | 1 |
| Beelen, D; Berdel, WE; Braess, J; Büchner, T; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Reichle, A; Rieger, C; Sauerland, C; Schiel, X; Schöndube, D; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B | 1 |
| Chang, CS; Hsiao, HH; Hsu, JF; Lin, SF; Liu, TC; Liu, YC; Lu, PL; Wu, CH | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Chromik, J; Fulda, S; Safferthal, C; Serve, H | 1 |
| Amadori, S; Buccisano, F; Isidori, A; Loscocco, F; Manduzio, P; Maurillo, L; Sparaventi, G; Venditti, A; Visani, G | 1 |
| Baker, SD; Buck, SA; Caldwell, JT; Chen, W; Drenberg, C; Edwards, H; Ge, Y; Inaba, H; Taub, JW; Xie, C; Xu, X | 1 |
| Bergeland, T; Blau, IW; Gianella-Borradori, A; Gjertsen, BT; Huguet-Rigal, F; Jacobsen, TF; Johansen, M; Kindler, T; Krauter, J; Krug, U; Rizzieri, D; Schlenk, RF; Thomas, X; Vey, N | 1 |
| Medeiros, BC | 1 |
| Aldoss, I; Haider, M; Ji, L; Pullarkat, V | 1 |
| Amadori, S; Beksac, M; Berneman, Z; Bron, D; Camera, A; Cantore, N; Cilloni, D; de Witte, T; Fabbiano, F; Fazi, P; Fillet, G; Guimaraes, JE; Hagemeijer, A; Halkes, CJ; Jansen, J; Labar, B; Lefrère, F; Leoni, P; Luppi, M; Magro, D; Mancini, M; Mandelli, F; Marie, JP; Marijt, EW; Meert, L; Melillo, L; Meloni, G; Mistrik, M; Mitra, ME; Muus, P; Nobile, F; Sborgia, M; Selleslag, DL; Sica, S; Specchia, G; Suciu, S; Thomas, X; Trisolini, SM; Venditti, A; Vignetti, M; Willemze, R | 1 |
| Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K | 1 |
| Ravandi, F | 2 |
| Sekeres, MA | 1 |
| Döhner, K; Paschka, P | 1 |
| Asano, S; Ebihara, Y; Jo, N; Kato, S; Kawamata, T; Konuma, T; Mochizuki, S; Ohno, N; Oiwa-Monna, M; Ooi, J; Takahashi, S; Tojo, A; Uchimaru, K; Yokoyama, K; Yuji, K | 1 |
| Aronow, BJ; Bhat, B; Cancelas, JA; Chaubey, A; Chen, J; Gebelein, B; Grimes, HL; Guzman, ML; Horman, SR; Jegga, AG; Jordan, CT; Marcucci, G; Mulloy, JC; Phelan, JD; Velu, CS; Wunderlich, M; Zeleznik-Le, NJ | 1 |
| Chen, CC; Chen, MF; Chen, PT; Chen, YY; Chou, HJ; Huang, CE; Lee, KD; Lu, CH; Lung, J; Tsai, PS | 1 |
| Andreeff, M; Burks, JK; Carter, BZ; Huang, X; Jacamo, R; Kornblau, SM; Mak, DH; Mak, PY; Mu, H; Ruvolo, P; Ruvolo, V; Shi, Y; Wei, W | 1 |
| Arnold, R; Bilger, K; Blaise, D; Bunjes, D; Chevallier, P; Cornelissen, JJ; Craddock, C; Fegueux, N; Goker, H; Kuball, J; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Schouten, HC; Sengeloev, H; Socie, G; Vindelov, L; Yeshurun, M | 1 |
| Boada, M; Díaz, L; Grille, S; Guadagna, R; Guillermo, C; Irigoin, V; Stevenazzi, M | 1 |
| Ma, WL; Meng, W; Wang, NS; Wei, M; Zheng, WL | 1 |
| Castaigne, S; Farhat, H; Garcia, I; Ghez, S; Merabet, F; Pilorge, S; Preudhomme, C; Rabian, F; Raggueneau, V; Renneville, A; Rigaudeau, S; Rousselot, P; Sarkozy, C; Taksin, AL; Terré, C | 1 |
| Cardenas-Turanzas, M; Champlin, R; Ciurea, S; Cornelison, AM; Cortes, J; Daver, N; de Lima, M; Garcia-Manero, G; Ghanem, H; Giralt, S; Jabbour, E; Kantarjian, H; Khouri, I; Mathisen, M; Oran, B; Popat, U; Ravandi, F | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Baer, MR; Bär, C; Becker, H; Bloomfield, CD; Bucci, D; Bundschuh, R; Byrd, JC; Caligiuri, MA; Carroll, AJ; Carter, TH; Curfman, JP; Eisfeld, AK; Frankhouser, D; Garzon, R; Kohlschmidt, J; Kolitz, JE; Maharry, K; Marcucci, G; Mendler, JH; Metzeler, KH; Mrózek, K; Nicolet, D; Plass, C; Powell, BL; Schwind, S; Stone, RM; Volinia, S; Wetzler, M; Whitman, SP; Wu, YZ; Yan, P | 1 |
| Allen, SL; Bakan, CE; Benson, DM; Bloomfield, CD; Caligiuri, MA; Deangelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vij, R | 1 |
| Abkowitz, JL; Buckley, SA; Estey, EH; Othus, M; Vainstein, V; Walter, RB | 1 |
| Fang, Q; Hu, X; Li, Y; Ma, D; Sun, J; Wang, J; Wang, P; Zhang, Y; Zhou, S | 1 |
| Anderson, CM; de Magalhaes Silverman, M; Hoffman, HT; Hoover, AC; Smith, MC; Syrbu, SI | 1 |
| Bergua, JM; Chevassut, T; Duarte, R; Gianella-Borradori, A; Hals, PA; Jacobsen, TF; Johansen, M; Knapper, S; Rasch, W; Salamero, O; Smith, M | 1 |
| Cui, J; Gao, S; Han, W; Li, W; Liu, X; Su, L; Tan, Y; Yu, P | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Caraci, MR; Di Raimondo, F; Ferrara, F; Fuligni, F; Gazzola, A; Isidori, A; Laginestra, MA; Loscocco, F; Paolini, S; Piccaluga, PP; Pileri, SA; Riccardi, C; Rocchi, M; Rossi, M; Sparaventi, G; Visani, A; Visani, G | 1 |
| Asou, N; Handa, H; Hatta, Y; Honda, S; Iriyama, N; Kobayashi, Y; Maeda, T; Miyawaki, S; Miyazaki, Y; Naoe, T; Ohnishi, K; Ohtake, S; Sakamaki, H; Sakura, T; Sato, S; Takahashi, M; Taki, T; Taniwaki, M; Yamaguchi, S | 1 |
| Kim, I; Kwon, JH; Lee, JS; Lee, YG; Park, S; Yoon, SS | 1 |
| Robak, T; Wierzbowska, A | 2 |
| Andreeff, M; Arana Yi, C; Borthakur, G; Brandt, M; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Levis, M; Luthra, R; O'Brien, S; Pierce, S; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Chung, NG; Jang, W; Kim, M; Lee, JW | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Kearns, P; Leonard, SM; Perry, T; Woodman, CB | 1 |
| Tohyama, K | 1 |
| Anjos-Afonso, F; Bonnet, D; Gribben, J; Griessinger, E; Lassailly, F; Pizzitola, I; Rouault-Pierre, K; Taussig, D; Vargaftig, J | 1 |
| Arthur, C; Berrak, E; Delaunay, J; Jones, M; Kantarjian, HM; Li, Y; Mayer, J; Mazur, G; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Adès, L; Santini, V | 1 |
| Jang, JH; Jung, CW; Jung, HA; Kim, K; Kim, SJ; Maeng, CH; Park, S | 1 |
| Bae, SH; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM | 1 |
| Brito-Ramirez, AS; Cantú-Rodríguez, OG; Gomez-Almaguer, D; Gutiérrez-Aguirre, H; Herrera-Garza, JL; Jaime-Pérez, JC; Pinzon-Uresti, MA | 1 |
| Elnoshokaty, EH; Elsayed, GM; Moneer, MM; Nassar, HR; Zaher, A | 1 |
| Jin, Z; Lin, G; Liu, L; Ma, A; Si, Y; Sun, Y; Wang, L; Wu, D; Zhang, X; Zhang, Y; Zhao, G | 1 |
| Bochtler, T; Dietrich, S; Dreger, P; Ho, AD; Krämer, A; Luft, T; Radujkovic, A; Schöning, T | 1 |
| Bekele, N; Borthakur, G; Estey, E; Jabbour, EJ; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, WK; Ravandi-Kashani, F; Tsimberidou, AM | 1 |
| Cabrera, JR; de Laiglesia, A; de Pablo, R; Dorado, N; Forés, R; García-Marco, JA; Lario, A; Piris, M; Regidor, C; Vilches, C | 1 |
| Chen, D; Gao, Y; Hu, Z; Ji, C; Lin, S; Liu, S; Luo, Y; Peng, L; Shao, K; Shen, J; Shen, Y; Wen, X; Wu, D; Ye, B; Yu, Q; Zhang, Y; Zheng, Z; Zhou, Y | 1 |
| Amsellem, S; Bourhis, JH; Chouaib, S; Mallavialle, A; Nanbakhsh, A; Pochon, C | 1 |
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Cooper, M; Cortes, JE; Damon, LE; Feldman, EJ; Hogge, DE; Kolitz, JE; Komrokji, R; Kovacsovics, TJ; Lancet, JE; Louie, AC; Solomon, SR; Tallman, MS; Yeager, AM | 1 |
| Nishi, R; Shigemi, H; Ueda, T; Uzui, K; Yamauchi, T | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Al Sheikha, D; Bryant, A; Jayaswal, V; Lim, TK; Ma, DD; Palma, CA; Vu, TT | 1 |
| Chen, C; Xu, W; Yang, J | 1 |
| Fix, P; Fricke, HJ; Glaser, A; Hochhaus, A; La Rosée, P; Schnetzke, U; Scholl, S; Schrenk, K; Spies-Weisshart, B | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| Cui, J; Guo, R; Hoffman, AR; Hu, JF; Li, W; Sun, J; Wang, G; Wang, H | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Du, Y; Ji, C; Ji, M; Li, P; Lu, F; Ma, D; Sun, X; Wang, H; Zang, S; Zhang, J | 1 |
| Fujiki, A; Hirashima, Y; Hosoi, H; Imamura, T; Sakamoto, K; Yano, M; Yoshida, H | 1 |
| Alonzo, TA; Cooper, TM; Gamis, AS; Gerbing, RB; Horton, TM; Loken, MR; Meshinchi, S; Perentesis, JP; Razzouk, BI; Taub, JW; Whitlock, JA | 1 |
| de Revel, T; Eddou, H; Jennane, S; Konopacki, J; Mahtat, EM; Malfuson, JV; Souleau, B | 1 |
| Hong, SK; Kim, EC; Sung, JY | 1 |
| Wiernik, PH | 2 |
| Brossart, P; Brugger, W; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, VI; Göttlicher, M; Götze, K; Greil, R; Heil, G; Held, G; Horst, HA; Kirchen, H; Köhne, CH; Koller, E; Kremers, S; Matzdorff, A; Nachbaur, D; Paschka, P; Raghavachar, A; Ringhoffer, M; Schlenk, RF; Tassara, M; Wattad, M; Wulf, G | 1 |
| Frankfurt, O; Grewal, DS; Holland, PM; Pyatetsky, D | 1 |
| Altman, JK; Arellano, M; Foss, Ø; Gianella-Borradori, A; Giles, FJ; Gobbi, M; Hills, R; Jacobsen, TF; Montesinos, P; O'Connell, C; Pigneux, A; Roboz, GJ; Rosenblat, T; Solomon, SR; Vetrhusand, S; Vey, N | 1 |
| Chen, J; Chen, L; Gao, L; Gong, S; Hu, X; Liu, M; Lu, S; Ni, X; Qiu, H; Song, X; Wang, J; Wang, L; Xu, S; Xu, X; Yang, J; Zhang, W | 1 |
| Fanin, R; Geromin, A; Medeot, M; Patriarca, F; Sperotto, A; Tiribelli, M | 1 |
| Avery, S; Fedele, PL; Haas, M; Patil, S; Spencer, A; Wei, A | 1 |
| Amri, A; Assouline, S; Becker, MW; Bergeron, J; Borden, KL; Cerchietti, L; Cocolakis, E; Cormack, G; Culjkovic-Kraljacic, B; Gendron, P; Jaquith, JB; Jordan, CT; Leber, B; Miller, WH; Morris, SJ; Pei, S; Romeo, AA; Zahreddine, HA | 1 |
| Barisone, E; Berger, M; Cesaro, S; De Matteo, A; Locatelli, F; Menna, G; Messina, C; Micalizzi, C; Morello, W; Parasole, R; Pession, A; Petruzziello, F; Poggi, V; Testi, AM; Varotto, S | 1 |
| Jackson, AE; Witzig, TE | 1 |
| Adams, HJ; Kwee, TC | 1 |
| Bolognia, J; Marks, P; Podoltsev, N; Zhang, B | 1 |
| Baik, H; Bossis, G; Boutzen, H; Brockly, F; Kaoma, T; Kifagi, C; Manenti, S; Pelegrin, M; Piechaczyk, M; Récher, C; Ristic, M; Saland, E; Salem, T; Sarry, JE; Vallar, L; Vergez, F | 1 |
| Fiedler, W; Janning, M | 1 |
| Desjonqueres, A; Eveillard, M | 1 |
| Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Buck, SA; Caldwell, JT; Edwards, H; Ge, Y; Taub, JW | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Estey, EE; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Koller, C; Luthra, R; O'Brien, S; Patel, K; Ravandi, F; Wang, X | 1 |
| Anoun, S; Benchekroun, S; Lamchahab, M; Oukkache, B; Qachouh, M; Quessar, A | 1 |
| Deng, D; Huang, L; Li, H; Liu, Z; Mo, Z; Xiao, Q; Yang, X; Ye, B; Ye, F; Zhang, B | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Ahn, KS; Cheong, HS; Koh, Y; Lee, C; Shin, HD; Yoon, SS | 1 |
| Brandwein, JM; Döhner, H; Döhner, K; Fiedler, W; Fouillard, L; Fritsch, H; Haaland, A; Krämer, A; Lepretre, S; Lübbert, M; Maertens, J; Müller-Tidow, C; Ottmann, OG; Raffoux, E; Reman, O; Schlenk, RF; Taube, T; Turlure, P; Voss, F | 1 |
| Appelbaum, FR; Burnett, AK; Cahn, JY; Castaigne, S; Chevret, S; Chilton, L; Delaunay, J; Dombret, H; Estey, EH; Hills, RK; Ifrah, N; Moorman, AV; Othus, M; Petersdorf, S; Récher, C | 1 |
| He, H; Li, X; Li, XP; Li, Y; Liu, ZG; Liu, ZQ; Wang, Y; Xu, YJ; Yin, JY; Zhai, M; Zhang, Y; Zhou, F; Zhou, HH | 1 |
| Aldayel, AS; Konoplev, S; Medeiros, LJ; Rich, A; Sun, J; Yin, CC | 1 |
| Castaigne, S; Cayuela, JM; Chevret, S; Dombret, H; Hayette, S; Lambert, J; Nibourel, O; Pautas, C; Preudhomme, C; Renneville, A; Rousselot, P; Terré, C | 1 |
| Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C | 1 |
| Dai, M; Fan, Z; Feng, R; Huang, F; Jiang, Q; Li, X; Liu, Q; Sun, J; Wei, Q; Wei, Y; Xie, M; Zhang, Y | 1 |
| Cao, X; Dong, W; Ling, Y; Liu, D; Wang, B; Yang, B | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Ohanian, M; Pierce, S; Ravandi, F; Rozovski, U | 1 |
| Aumann, NK; Bailey, NJ; Beckmann, DA; Kurata, M; Largaespada, DA; Liska, CR; Melrose, EG; Moriarity, BS; Rahrmann, EP; Rathe, SK; Stoltenberg, CB | 1 |
| Bradstock, KF; Collins, M; Cull, G; Di Iulio, J; Enno, A; Hahn, U; Lewis, ID; Link, E; Marlton, P; Schwarer, A; Seymour, JF; Szer, J | 1 |
| Ang, AL; Goh, YT; Kam, G; Loh, Y; Wong, GC; Yiu, R; Yueh, LL | 1 |
| Bodaghi, B; Chapiro, E; Charlotte, F; LeHoang, P; Maloum, K; Nguyen-Khac, F; Thepot, S; Touitou, V | 1 |
| Baer, MR; Becker, H; Bloomfield, CD; Bundschuh, R; Carroll, AJ; Carter, TH; Curfman, JP; Eisfeld, AK; Frankhouser, D; Kohlschmidt, J; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mendler, JH; Metzeler, KH; Moore, JO; Mrózek, K; Nicolet, D; Niederwieser, C; Powell, BL; Schwind, S; Stone, RM; Volinia, S; Whitman, SP; Wu, YZ; Yan, P | 1 |
| Aotsuka, N; Asano, S; Atsuta, Y; Kanamori, H; Kato, K; Kato, S; Konuma, T; Kozai, Y; Nagamura-Inoue, T; Ogawa, H; Ohashi, K; Onishi, Y; Ooi, J; Suzuki, R; Takahashi, S; Uchida, N; Yamaguchi, H | 1 |
| Anderson, E; Salisbury, V | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Caldwell, JT; Ge, Y; Taub, JW | 1 |
| Akin, I; Baumann, S; Behnes, M; Borggrefe, M; Faust, M; Goranova, D; Heidenreich, D; Hofmann, WK; Huseynov, A; Klein, S; Nolte, F | 1 |
| Kantarjian, H | 1 |
| Allan, JM; Cole, M; Fordham, SE; Irving, JA | 1 |
| Chen-Liang, TH; Florensa, L; Jerez, A; Ortuño, FJ | 1 |
| Chen, J; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Wei, J; Yu, W | 1 |
| Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y | 1 |
| Berdel, WE; Braess, J; Buechner, T; Greif, PA; Heinecke, A; Hiddemann, W; Krug, U; Ksienzyk, B; Mellert, G; Pastore, F; Sauerland, CM; Schneider, S; Spiekermann, K; Woermann, B; Zellmeier, E | 1 |
| Gong, B; Gong, X; Li, W; Mi, Y; Sun, M; Wang, J; Wei, H; Zhao, X | 1 |
| Antonenas, V; Bishop, DC; Gottlieb, DJ; Johnston, AJ; Kwan, JM | 1 |
| Dujovny, T; Edel, Y; Goldvaser, H; Raanani, P; Shepshelovich, D; Wolach, O | 1 |
| Apel, A; Avigdor, A; Koren-Michowitz, M; Maayan, H; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R | 1 |
| Caldwell, JT; Edwards, H; Ge, Y; Taub, JW; Wang, G; Xie, C | 1 |
| He, C; Mao, ZJ; Singleton, TP; Su, G; Tan, D; Wei, L; Yin, B; Zhao, W; Zheng, Y | 1 |
| Drokov, MIu; Galstian, GM; Kessel'man, SA; Kliasova, GA; Kulikov, SM; Kuz'mina, LA; Obukhova, TN; Paramonova, EV; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Troitskaia, VV; Vasil'eva, VA | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Gan, SL; Liu, YF; Sun, H; Tian, DH; Xie, XS; Xing, HZ | 1 |
| Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y | 1 |
| Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A | 1 |
| Chen, T; Craig, AR; Cripe, LD; Fox, JA; Hawtin, R; Karp, JE; Lancet, JE; Leavitt, RD; Maris, MB; Michelson, GC; Ravandi, F; Roboz, GJ; Stuart, RK | 1 |
| Abraham, A; Balasubramanian, P; Devasia, AJ; Karathedath, S; Mathews, V; Varatharajan, S | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Gao, Z; Gong, R; Ma, L; Tian, W; Wang, T; Zhu, Q | 1 |
| DeFilippis, EM; Gaan, J; Garshick, M; Harp, J | 1 |
| Assouline, S; Bergeron, J; Borden, KL; Caplan, S; Cocolakis, E; Culjkovic-Kraljacic, B; Lambert, C; Lau, CJ; Miller, WH; Zahreddine, HA | 1 |
| Creutzig, U; Kaspers, GL; Reinhardt, D; Semmler, J; Zimmermann, M | 1 |
| Cong, YW; Cui, Y; Dong, B; Jing, Y; Liu, XL; Luo, QL; Shan, YJ; Shen, X; Wang, LS; Xiao, H; Xing, S; Xiong, GL; Yang, M; Yu, ZY; Zhang, YF | 1 |
| Fozza, C | 1 |
| Basso, G; Beqiri, V; Bisio, V; Buldini, B; Fagioli, F; Locatelli, F; Manara, E; Masetti, R; Pession, A; Pigazzi, M; Putti, MC; Rizzari, C; Rondelli, R; Tregnago, C | 1 |
| Chen, C; Chen, Y; Ding, Y; Fu, J; Liang, A; Lu, H; Wang, W; Wu, H; Zhang, W; Zou, S | 1 |
| Azevedo, MC; Buccheri, V; Chamone, DA; Dorlhiac-Llacer, PE; Velloso, ED | 1 |
| Barrett, AJ; Dutra, A; Hensel, NF; Ito, S; Keyvanfar, K; Larochelle, A; Liu, P; Melenhorst, JJ; Miner, S; Muranski, P; Pak, E; Rezvani, K | 1 |
| Azevedo, MM; Castro, I; Correia-Neves, M; Fernandes, Â; Ludovico, P; Paiva, A; Pereira, O; Sampaio-Marques, B | 1 |
| Lan, FM; Li, HM | 1 |
| Gong, B; Gong, X; Li, W; Li, Y; Lin, D; Liu, B; Liu, K; Liu, Y; Lu, Y; Mi, Y; Sun, M; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhao, X; Zhou, C | 1 |
| Abkowitz, JL; Appelbaum, FR; Becker, PS; Estey, EH; Forman, SJ; Gardner, KM; Hendrie, PC; Medeiros, BC; Othus, M; Pagel, JM; Parks, C; Scott, BL; Stein, AS; Walter, RB; Wood, BL | 1 |
| Ho, A; Lao, Z; Wong, GC; Yiu, R | 1 |
| Aliño, SF; Bosó, V; Herrero, MJ; Megías-Vericat, JE; Montesinos, P; Moscardó, F; Poveda, JL; Rojas, L; Sanz, MÁ | 1 |
| Chen, J; He, H; Li, X; Liu, Z; Qian, C; Xu, X; Yin, J; Zhai, M; Zhang, Y; Zhou, H | 1 |
| Erba, HP | 1 |
| Hu, R; Li, YC; Wu, B; Yang, W; Yao, K; Zhang, GJ; Zhang, R | 1 |
| Stone, RM; Wolach, O | 1 |
| Baczyńska, D; Butrym, A; Kuliczkowski, K; Mazur, G; Rybka, J; Tukiendorf, A | 1 |
| Grimwade, D; Kayser, S; Schlenk, RF; Walter, RB; Yosuico, VE | 1 |
| Bahl, A; Bakhshi, S; Gupta, R; Kumar, L; Kumar, R; Raina, V; Sharma, A | 1 |
| Burnett, AK; Cahalin, P; Clark, RE; Hemmaway, C; Hills, RK; Khwaja, A; Milligan, D; Panoskaltsis, N; Russell, N | 1 |
| Becker, PS; Chen, TL; Dean, C; Estey, EH; Hendrie, PC; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Shadman, M; Shannon-Dorcy, K; Walter, RB | 1 |
| Bar-Natan, M; Douer, D; Herscovici, C; Itchaki, G; Raanani, P; Ram, R; Shpilberg, O; Tallman, MS; Wolach, O; Yeshurun, M | 1 |
| Brunet, S; Clapés, V; Guardia, R; Oriol, A; Piernas, S; Ribera, JM; Sierra, J; Subirà, M; Vives, S | 1 |
| Choi, JH; Kim, ES; Kim, S; Lee, YY; Park, BB; Won, YW; Yoon, JS | 1 |
| Curti, A; Jandus, C; Lecciso, M; Ochsenbein, A; Riether, C; Romero, P; Salomé, B; Trabanelli, S | 1 |
| Beggs, A; Cheng, P; De Santo, C; Egan, S; Higginbotham-Jones, J; Kearns, P; Lo, A; Loke, J; Mussai, F; Ng, M; Odintsova, E; Perry, T; Pratt, G; U, KP | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Wang, X | 1 |
| Allen, SL; Damon, L; Egyed, M; Erba, HP; Horst, HA; Jang, JH; Lundberg, AS; Masszi, T; Mazzola, E; Neuberg, D; Pigneux, A; Powell, B; Rizzieri, D; Sekeres, MA; Selleslag, D; Solomon, SR; Stone, RM; Stuart, RK; Tallman, MS; Venugopal, P; Warzocha, K; Wetzler, M | 1 |
| Amaki, J; Ando, K; Aoyama, Y; Hara, R; Ichiki, A; Kawada, H; Kawai, H; Kojima, M; Machida, S; Miyamoto, M; Ogawa, Y; Ohmachi, K; Onizuka, M; Sato, A; Shirasugi, Y; Toyosaki, M | 1 |
| Arruda, A; Dzneladze, I; Gabra, M; Greenberg, SA; Hakem, A; He, R; Ibrahimova, N; Langlois, C; Löwenberg, B; Minden, MD; Rashid, A; Salmena, L; Sharobim, MH; Son, MH; Valk, PJ; Woolley, JF | 1 |
| Boyson, CA; Chen-Kiang, S; Di Liberto, M; Dorn, DC; Hannah, J; Huang, X; Moore, MA; Yang, C; Zhou, P | 1 |
| Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y | 1 |
| Fujisawa, S; Iseki, K; Kondo, T; Ohya, H; Shibayama, Y; Teshima, T | 1 |
| Alonzo, TA; Aplenc, R; Bagatell, R; Fisher, BT; Gamis, A; Gerbing, RB; Hall, M; Huang, YS; Li, Y; Luger, S; Miller, TP; Rubin, D; Seif, AE; Sung, L; Torp, K; Troxel, AB | 1 |
| Abdel-Wahab, O; Estey, EH; Fernandez, HF; Gönen, M; Lee, JW; Levine, RL; Othus, M; Paietta, EM; Patel, J; Racevskis, J; Sun, Z; Tallman, MS; Walter, RB | 1 |
| Roboz, GJ | 3 |
| Bao, L; Huang, X; Jia, J; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Wang, J; Yang, S; Zhang, Y; Zhao, T; Zhu, H | 2 |
| Madias, JE | 1 |
| Menon, MP; Vidholia, A | 1 |
| Burnett, AK; Clark, RE; Dennis, M; Dignum, H; Hemmaway, C; Hills, RK; Kjeldsen, L; McMullin, MF; Milligan, D; Panoskaltsis, N; Russell, N; Thomas, IF | 1 |
| Ford, LA; Gandhi, S; Griffiths, EA; Gupta, N; Miller, A; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X | 1 |
| Mizuki, M; Morio, K; Sozu, T; Uejima, E | 1 |
| Burnett, AK; Cahalin, P; Cavenagh, J; Clark, RE; Dennis, M; Friis, L; Hills, RK; Kell, J; Kjeldsen, L; McMullin, MF; Milligan, D; Russell, NH; Thomas, IF | 1 |
| Brill, JM; DiPersio, JF; Erba, HP; Larson, RA; Luger, SM; Rouits, E; Sorensen, JM; Tallman, MS; Vuagniaux, G; Zanna, C | 1 |
| Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C | 1 |
| Becker, PS; Buckley, SA; Dean, C; Estey, EH; Gooley, TA; Hendrie, P; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Smith, K; Walter, RB; Wood, BL | 1 |
| Aifantis, I; Antony-Debre, I; Baljevic, M; Barreyro, L; Cavatore, M; Cimmino, L; de Stanchina, E; Hatlen, M; Hricik, T; Jiang, Y; Levine, RL; Mason, C; Melnick, A; Meydan, C; Nimer, SD; Paietta, E; Pandey, S; Rapaport, F; Robertson, A; Shank, K; Shih, AH; Socci, N; Steidl, U; Sun, Y; Tallman, M; Viale, A; Wei, C; Woods, B | 1 |
| Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Burnett, AK; Hills, R; Lazenby, M; Zabkiewicz, J | 1 |
| Asano, S; Ishii, H; Kato, S; Konuma, T; Oiwa-Monna, M; Takahashi, S; Tojo, A | 1 |
| Bae, SH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Kakiuchi, S; Kawamoto, S; Matsuoka, H; Minami, H; Yakushijin, K; Yamamoto, K | 1 |
| Augustin, E; Beffinger, M; Konicz, S; Laskowska, K; Polewska, J; Skwarska, A; Wojtczyk, A | 1 |
| Kang, HR; Kang, MG; Kim, JY; Lim, KH; Park, HK | 1 |
| Barckhausen, C; Brendel, C; Huynh, M; Illmer, T; Krause, M; Mernberger, M; Millahn, A; Neubauer, A; Ross, P; Stabla, K; Stiewe, T; Teichler, S | 1 |
| Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
| Aulitzky, W; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Lange, T; Maschmeyer, G; Morgner, A; Neugebauer, S; Niederwieser, D; Peter, N; Pönisch, W; Schäfer-Eckart, K; Schetelig, J; Schulze, A; Thiel, A; Wilhelm, M | 1 |
| Choi, CW; Kang, KW; Kim, BS; Kim, DS; Kim, SJ; Lee, SR; Park, Y; Sung, HJ | 2 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Lei, B; Liu, J; Ma, XR; Wang, FX; Wang, J; Wang, JL; Xu, Y; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Cao, Z; Gong, BF; Gong, XY; Gu, RX; Li, W; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhao, XL; Zhou, CL | 1 |
| Cho, KM; Hwang, SY; Kim, HJ; Kim, NY; Kim, TS; Kim, YK; Lee, TH; Song, JH | 1 |
| Hotinski, AK; Lewis, ID; Ross, DM | 1 |
| Baumann, S | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, M; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stray, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Ding, C; Jiao, W; Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Koyakutty, M; Menon, D; Menon, KN; Mony, U; Nair, MS; Nair, SV; Pavithran, K; Sidharthan, N | 1 |
| Ali, S; Craddock, C; Culligan, DJ; Embleton, ND; Jones, GL; Marsden, PJ; Russell, N | 1 |
| Abraham, A; Balasubramanian, P; Chandy, M; George, B; Janet, NB; Jayavelu, AK; Karathedath, S; Lakshmi, KM; Mathews, V; Mohanan, E; Philip, C; Shaji, RV; Srivastava, A; Srivastava, VM; Varatharajan, S; Viswabandya, A; Zhang, W | 1 |
| Chen, CY; Hu, CY; Lai, YL; Lin, LI; Lin, YM; Lu, JW; Ou, DL; Tien, HF | 1 |
| De Castro, CM; Griffin, PT; Komrokji, RS; Lancet, JE; List, AF; Melchert, M; Rizzieri, DA | 1 |
| Su, YZ; Sun, NT; Wang, CB; Zhou, Y | 1 |
| Busfield, SJ; Cummings, N; Lee, EM; Lewis, ID; Lock, RB; Lopez, AF; McCall, MN; McManus, JF; Powell, JA; Ramshaw, HS; Vairo, G; Wei, A; Yee, D | 1 |
| Ahmed, T; Berenzon, D; Dralle, S; Ellis, LR; Holwerda, S; Isom, S; Klepin, HD; Lyerly, S; Manuel, M; Pardee, TS; Powell, BL | 1 |
| Brunet, S; Castro, N; Chillón, MC; Díez-Campelo, M; González, M; Herrera, P; López, J; Mateo, M; Mateos, MV; Montesinos, P; Ocio, EM; Olave, MT; Oriol, A; Pérez-Simón, JA; Prieto-Conde, MI; San Miguel, JF; Sanz, MÁ; Vidriales, MB | 1 |
| Chi, J; Costeas, P; Liu, L; Nian, Q; Wang, L; Wei, C; Xiao, Q; Yang, Z | 1 |
| Fujimaki, K; Fujisawa, S; Fujita, H; Hagihara, M; Ishigatsubo, Y; Kanamori, H; Kawasaki, R; Koharazawa, H; Maruta, A; Sakai, R; Tachibana, T; Taguchi, J; Tanaka, M; Tomita, N; Yamazaki, E | 1 |
| Ashton, JM; Balys, M; Becker, MW; Calvi, LM; Eberhardt, A; Mendler, JH; Myers, JR; Sivagnanalingam, U; Wang, N | 1 |
| Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K | 1 |
| Alebouyeh, M; Faranoush, M; Hedayati Asl, AA; Mehrvar, A; Niktoreh Mofrad, N; Reinhardt, D; Tashvighi, M | 1 |
| Cogle, CR; Drusbosky, L; Gars, E; McGee, C; Meacham, A; Scott, EW; Trujillo, A; Wise, E | 1 |
| Delabesse, E; Hospital, MA; Larrue, C; Manenti, S; Mansat-De Mas, V; Récher, C; Saland, E; Sarry, JE; Serhan, N; Tamburini, J; Vergez, F | 1 |
| Cheong, JW; Eom, JI; Jang, JE; Jeung, HK; Kim, JS; Kim, Y; Kim, YS; Min, YH | 1 |
| Chai, Q; Chen, S; Fang, Q; Lin, X; Wang, J; Zhang, Y; Zhao, J; Zhe, N | 1 |
| Kopeček, J; Shami, PJ; Yang, J; Zhang, R; Zhou, Y | 1 |
| Abhyankar, S; Aljitawi, O; Bivona, C; Bray, WM; Ganguly, S; Grauer, D; Henry, D; Lin, TL; McGuirk, J; Rockey, M; Singh, A | 1 |
| Bornhäuser, M | 1 |
| Acton, G; Carella, AM; Cortes, J; Craig, AR; Craig, MD; Damon, L; Derigs, HG; Erba, HP; Fox, JA; Gaidano, G; Havelange, V; Heuser, M; Hogge, D; Horst, HA; Jabbour, E; Kantarjian, HM; Klimek, VM; Lancet, JE; Maertens, J; Mehta, C; Odenike, O; Pigneux, A; Powell, BL; Ravandi, F; Recher, C; Ritchie, EK; Roboz, GJ; Sayar, H; Schiller, GJ; Smith, JA; Strickland, SA; Stuart, RK; Thomas, X; Vey, N; Ward, R; Wei, A | 1 |
| Archer, K; Aust, M; Beckta, J; Dumur, C; Ginder, GD; Grant, S; Hawkins, E; Podder, S; Rahmani, M; Sperlazza, J; Wang, SZ; Zu Zhu, S | 1 |
| Desai, U; Jain, N; Mirza, S; Rawal, R; Shah, K | 1 |
| Auboeuf, D; Balsat, M; Campos, L; Cheok, M; Cros, E; Dumontet, C; El-Hamri, M; Flandrin-Gresta, P; Guyotat, D; Koering, C; Michallet, M; Mohamed, AM; Mortada, H; Mortreux, F; Nibourel, O; Nicolini, F; Payen-Gay, L; Pinatel, C; Preudhomme, C; Solly, F; Thenoz, M; Thomas, X; Wattel, E | 1 |
| Kun, Y; Rong, Z; Ying, Y; Yingchun, L; Zhuogang, L | 1 |
| Baty, J; Chang, GS; Christopher, M; Demeter, RT; DiPersio, JF; Duncavage, EJ; Fronick, C; Fulton, R; Graubert, TA; Griffith, M; Griffith, OL; Heath, SE; Helton, NM; Hundal, J; Ketkar-Kulkarni, S; Klco, JM; Kulkarni, S; Lamprecht, TL; Larson, DE; Ley, TJ; Link, DC; Magrini, V; Mardis, ER; Miller, CA; O'Laughlin, M; Ozenberger, BA; Payton, JE; Petti, A; Radich, JP; Shen, D; Spencer, DH; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Blanco-Prieto, MJ; Castello-Cros, R; Cirauqui, C; Estella-Hermoso de Mendoza, A; Imbuluzqueta, E; Odero, MD; Pippa, R | 1 |
| Culen, M; Dvorakova, D; Horky, O; Jeziskova, I; Mayer, J; Racil, Z; Semerad, L; Sustkova, Z; Weinbergerova, B | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Harrison, JS; Studzinski, GP; Wang, X | 3 |
| Bezerra, MA; Bezerra, MF; de Assis, RA; de Mello, MR; Duarte, BK; Fernandes, E; Lima, AS; Lorand-Metze, I; Lucena-Araujo, AR; Machado, CG; Oliveira, MM; Pagnano, K; Ramos, CF; Souto, FR | 1 |
| Briz, O; Díez-Martín, JL; Macias, RI; Marin, JJ; Rodríguez-Macias, G | 1 |
| Horinek, A; Korabecna, M; Koutova, L; Lysak, D; Pazourkova, E; Pospisilova, S; Sterbova, M; Svobodova, I | 1 |
| Ahn, KS; Doo Shin, H; Hyo Kim, L; Kim, HL; Koh, Y; Lee, C; Sub Cheong, H; Yoon, SS | 1 |
| Lynch, RC; Medeiros, BC | 1 |
| Baker, SD; Bhise, N; Cao, X; Cogle, CR; Crews, KR; Downing, JR; Lamba, JK; Pounds, S; Raimondi, SC; Ribeiro, RC; Rubnitz, JE | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Ben-Haroush, A; Even-Or, E; Stein, J; Yahel, A; Yaniv, I | 1 |
| Bloomfield, CD; Döhner, H; Weisdorf, DJ | 1 |
| Tan, H; Wang, C; Xie, B; Xu, J; Yu, B; Zheng, R | 1 |
| Chen, B; Ouyang, J; Xu, P; Zhou, D | 1 |
| Carter, BZ; Dai, M; Ding, B; Jiang, L; Jiang, X; Liang, S; Liu, Q; Meng, F; Wang, Z; Ye, J; Yin, C; Yu, G; Zhang, Y; Zhao, Q; Zhong, Q | 1 |
| Jia, X; Li, N; Li, Y; Wang, J; Xie, S | 1 |
| Han, AR; Kim, HJ; Kim, SH; Lee, JY; Min, WS; Park, G | 1 |
| Amadori, S; Baron, F; Bron, D; de Witte, T; Halkes, C; Meert, L; Muus, P; Selleslag, D; Suciu, S; Willemze, R | 1 |
| Herrington, JD; Jirasek, MA | 1 |
| Al-Ali, HK; Behre, G; Franke, GN; Hochhaus, A; Jentzsch, M; Klink, A; Niederwieser, D; Pfrepper, C; Sayer, HG; Schenk, T; Schwind, S | 1 |
| Ahn, MS; Choi, JH; Choi, YW; Jeong, SH; Kang, SY; Lee, HW; Park, JS | 1 |
| Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Ai, H; Fan, R; Fu, Y; Hu, J; Liu, S; Mi, R; Song, Y; Wang, P; Wang, X; Wei, X; Yin, Q; Zhou, J; Zhu, X | 1 |
| Barker, JA; Bixby, D; Marini, BL; Perissinotti, AJ | 1 |
| Fang-Lin, L; Hao, L; Ling-Ling, W; Lu-Qun, W; Ming, H; Xiang-Xin, L; Xue-Liang, C | 1 |
| Ando, K; Asai, S; Damdinsuren, A; Ito, M; Jin, G; Matsushita, H; Miyachi, H; Tanaka, M; Tsukamoto, H | 1 |
| Chen, J; Liu, Y; Shen, Y; Wu, D | 1 |
| Chen, J; Chen, L; Fu, W; Gao, L; Hu, X; Lü, S; Ni, X; Qiu, H; Song, X; Wang, J; Wang, L; Xi, H; Xu, X; Yang, J; Zhang, W | 1 |
| Jamy, O; Martin, MG; Wiedower, E | 1 |
| Baldus, CD; Berdel, WE; Brümmendorf, TH; Butterfaß-Bahloul, T; Dugas, M; Ehninger, G; Eveslage, M; Frickhofen, N; Gerss, J; Giagounidis, A; Görner, M; Götze, K; Hänel, M; Herr, W; Kaiser, U; Kaufmann, M; Kiani, A; Kiehl, M; Koschmieder, A; Koschmieder, S; Krause, SW; Krug, U; Kunzmann, V; Link, H; Müller-Tidow, C; Naumann, R; Neubauer, A; Noppeney, R; Peceny, R; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schmitz, N; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Thiem, U; Tschanter, P; Wagner, R | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Hubáček, J; Indrák, K; Jarošová, M; Marschalek, R; Meyer, C; Szotkowski, T; Zimmermannová, O; Zuna, J | 1 |
| Borg, K; Calbecka, M; Czekalska, S; Ejduk, A; Florek, I; Gadomska, G; Gajkowska-Kulik, J; Giebel, S; Grosicki, S; Haus, O; Holowiecki, J; Jakobczyk, M; Jazwiec, B; Jedrzejczak, WW; Karabin, K; Kata, D; Kielbinski, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Libura, J; Libura, M; Matiakowska, K; Paluszewska, M; Pawelczyk, M; Piatkowska-Jakubas, B; Skotnicki, A; Solarska, I; Warzocha, K; Wierzbowska, A; Zawada, M | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Alonzo, T; Auvrignon, A; Balwierz, W; Beverloo, HB; Bongers, M; Cloos, J; Creutzig, U; De Moerloose, B; Dworzak, M; Forestier, E; Fynn, A; Gibson, B; Harrison, CJ; Hirsch, B; Johnston, D; Kaspers, G; Klein, K; Lee, V; Pession, A; Popa, A; Raimondi, S; Reedijk, A; Reinhardt, D; Rubnitz, J; Salgado, C; Taga, T; Tawa, A; Zapotocky, M; Zeller, B; Zimmerman, M | 1 |
| Chen, A; Hu, S; Wang, QF; Yang, J | 1 |
| Bokemeyer, C; Degwert, N; Fiedler, W; Klokow, M; Latuske, E; Stamm, H; Vohwinkel, G; Wellbrock, J | 1 |
| Spagnuolo, P | 1 |
| Aliño, SF; Bosó, V; Herrero, MJ; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Moscardó, F; Poveda, JL; Rojas, L; Sanz, MÁ | 1 |
| Cabanillas, F; Cheah, CY; Chihara, D; Fayad, LE; Goy, A; Hagemeister, FB; Kantarjian, H; Kwak, LW; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, ML; Westin, JR; Younes, A | 1 |
| Brennig, S; Buchegger, T; Hetzel, M; Lachmann, N; Moritz, T; Schambach, A | 1 |
| Baker, SD; Drenberg, CD; Evans, WE; Gibson, AA; Hu, S; Li, L; Orwick, SJ; Paugh, SW; Pounds, SB; Ribeiro, RC; Rubnitz, JE; Shi, L; Sparreboom, A | 1 |
| Gou, H; Hu, X; Lu, X; Peng, W; Shang, M; Song, X; Ye, Y; Ying, B; Zhang, J; Zhao, Z; Zhou, J; Zhou, Y | 1 |
| Hu, HL; Huang, YJ; Li, J; Liu, J; Sun, WJ; Xi, XQ; Zhao, HX | 1 |
| Dai, M; Fan, Z; Huang, F; Jiang, Q; Li, Y; Lin, D; Liu, Q; Nie, D; Sun, J; Xiao, Y; Xuan, L; Zhang, Y | 1 |
| Ando, S; Fukayama, M; Gonoi, W; Higo, T; Ishida, M; Kobayashi, T; Kurokawa, M; Nakamura, F; Ohtomo, K; Okuma, H; Ushiku, T; Yamazaki, S | 1 |
| Imada, K; Kitagawa, T; Mori, M; Onaka, T; Yonezawa, A | 1 |
| Gronda, M; Hurren, R; Minden, MD; Rotin, LE; Schimmer, AD; Slassi, M; Wang, X | 1 |
| Brandwein, J; Gül-Uludağ, H; Jiang, H; Kucharski, C; Kutsch, O; Landry, B; Parmar, MB; Plianwong, S; Uludağ, H; Zak, Z | 1 |
| Andreeff, M; Borthakur, G; Cortes, J; DiNardo, C; Estrov, Z; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Takahashi, K | 1 |
| Buckley, SA; Estey, EH; Godwin, CD; Othus, M; Powell, MA; Walter, RB | 1 |
| Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 2 |
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Chen, J; Hu, J; Huang, H; Huang, X; Jin, J; Li, J; Li, Y; Liang, Y; Ma, J; Sun, Y; Wang, C; Wang, J; Wang, L; Wu, D; Xiao, Y; Yu, K | 1 |
| Chen, CC; Chen, YY; Chou, HJ; Gau, JP; Huang, CE; Lung, J; Tsai, YH; Yang, MH; You, JY | 1 |
| Baker, SD; Buelow, DR; Drenberg, CD; Gibson, AA; Hu, S; Li, L; Orwick, SJ; Schuetz, JD; Sparreboom, A | 1 |
| Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH | 1 |
| Aul, C; Balleisen, L; Beelen, D; Berdel, WE; Braess, J; Büchner, T; Eimermacher, H; Gale, RP; Giagounidis, A; Görlich, D; Grüneisen, A; Haferlach, C; Haferlach, T; Hehlmann, R; Heinecke, A; Hiddemann, W; Kern, W; Köpcke, W; Krug, U; Lengfelder, E; Ludwig, WD; Maschmeyer, G; Müller-Tidow, C; Rasche, H; Reichle, A; Sauerland, MC; Schliemann, C; Schnittger, S; Serve, H; Spiekermann, K; Staib, P; Stelljes, M; Thiel, E; Wörmann, BJ | 1 |
| Bainschab, A; Greinix, HT; Krause, R; Quehenberger, F; Sill, H; Wölfler, A; Zebisch, A | 1 |
| Ding, J; Jing, Y; Wang, HX; Wang, LJ; Yang, H; Yu, L; Zhu, CY | 1 |
| Cheong, JW; Eom, JI; Jeung, HK; Kim, Y; Min, YH | 1 |
| Brady, WE; Dickey, NM; Ford, LA; Griffiths, EA; L Bashaw, H; Sperrazza, J; Tan, W; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Qin, YZ; Zhu, HH | 1 |
| Fang, L; Hu, N; Lin, Y; Pan, L; Qin, T; Qu, S; Ru, K; Wang, J; Xiao, Z; Xing, R; Xu, Z; Zhang, H; Zhang, Y | 1 |
| Fan, C; Huang, J; Jin, J; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Yu, W | 1 |
| Çelik, Y; Maden, M; Pamuk, G; Ünlü, E | 1 |
| Bolster, L; Brandwein, J; Ghosh, S; Hamilton, M; Larratt, L; Liew, E; Mant, M; Patterson, JM; Peters, A; Ritchie, B; Saini, L; Sandhu, I; Turner, R; Wu, C; Zhu, N | 1 |
| Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Wang, J; Wen, L; Yang, SM; Zhao, T; Zhu, HH | 1 |
| Benner, A; Döhner, H; Döhner, K; Fiedler, W; Ganser, A; Götze, K; Haase, D; Horst, HA; Hütter-Krönke, ML; Kirchen, H; Köhne, CH; Koller, E; Krauter, J; Kremers, S; Matzdorff, AC; Moessner, M; Petzer, AL; Rummel, M; Salwender, H; Schlenk, RF; Schmidt-Wolf, IG; Theobald, M; Weber, D | 1 |
| Appelbaum, FR; Erba, H; Estey, E; Godwin, J; Mukherjee, S; Othus, M; Petersdorf, S; Sekeres, MA | 1 |
| Chen, JY; Dai, XB; Jiang, PJ; Ni, HW; Sun, XM; Zhang, WX | 1 |
| Cheng, H; Gao, L; Hu, X; Liu, N; Tang, G; Wang, C; Wang, J; Wang, L | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M | 1 |
| Gui, R; Li, M; Li, Z; Song, Y; Wei, X; Zhang, Y; Zhao, H; Zhou, J; Zu, Y | 1 |
| Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J | 1 |
| Amador-Barciela, ML; Barrios, M; Benavente, C; Bergua, JM; Fernández-Abellán, P; García, R; García-Huerta, AJ; Herrera-Puente, P; Martinez-Cuadrón, D; Martínez-Sánchez, MP; Montesinos, P; Pérez-Encinas, M; Prieto-Fernandez, J; Riaza-Grau, R; Rodríguez-Macias, G; Rodríguez-Veiga, R; Sanz, MA; Sayas, MJ; Serrano, J; Simiele, A | 1 |
| Candelaria, M; Corrales-Alfaro, C; Díaz-Chavez, J; Gutiérrez-Hernández, O; Herrera, LA; Labardini-Méndez, J; Vidal-Millán, S | 1 |
| Baker, SD; Buaboonnam, J; Drenberg, CD; Fan, Y; Guy, RK; Hu, S; Li, L; Orwick, SJ; Rubnitz, J; Shelat, AA | 1 |
| Adam, H; Colle, J; Costello, R; Fanciullino, R; Farnault, L; Ivanov, V; Labiad, Y; Mercier, C; Suchon, P; Venton, G | 1 |
| Chao, Z; Chen, XM; Deng, CX; DU, X; Huang, X; Lai, PL; Li, MM; Liao, PJ; Ling, W; Lu, ZS; Wan, CC; Wang, YL; Weng, JY; Wu, SJ; Zhong, LY; Zou, XL | 1 |
| DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY | 1 |
| Ahmed, N; Baskind, P; Liu, D; Seiter, K; Shaikh, A | 1 |
| Ito, N; Ito, R; Kageyama, Y; Kawakami, K; Nagaharu, K; Yamaguchi, T | 1 |
| Batár, P; Illés, Á; Kiss, A; Mezei, G; Miltényi, Z; Rejtő, L; Reményi, G; Simon, Z; Szász, R; Telek, B; Udvardy, M; Ujj, Z | 1 |
| Akiyama, K; Aoki, T; Arakawa, Y; Hanada, R; Ikeda, Y; Koh, K; Mori, M; Sekinaka, Y | 1 |
| DeAngelo, DJ; Ravandi, F; Stein, EM | 1 |
| Dolberg, OJ; Ellis, M; Hellmann, I; Huitema, AD; Krashin, E; Rosing, H | 1 |
| Baumann, FT; Bloch, W; Elter, T; Garthe, A; Hallek, M; Hartig, P; Joisten, N; Oberste, M; Schenk, A; Wolf, F; Zimmer, P | 1 |
| Collin, M; Creasey, T; Jones, GL | 1 |
| Kong, PY; Ma, YY; Shen, ZH; Zeng, DF; Zhang, X | 1 |
| Gao, J; Gao, YN; Li, MH; Wang, JX; Wang, XM; Xu, QZ; Yang, WZ; Yuan, WP | 1 |
| Liu, ZW; Wang, DZ; Yang, XF; Zhu, YN | 1 |
| Baer, MR; Doshi, KA; Huszar, D; Natarajan, K; Perrotti, D; Rassool, FV; Tron, AE; Trotta, R | 1 |
| Appelbaum, FR; Becker, PS; Bernstein, ID; Cicconi, L; Dahlberg, A; Delaney, C; Estey, EH; Milano, F; Nicoud, I; Othus, M; Sandhu, V | 1 |
| Chang, CL; Chi, HS; Cho, YU; Jang, S; Jo, SY; Kim, HH; Kim, IS; Lee, EY; Park, CJ; Park, SH; Yi, J | 1 |
| Botzenhardt, U; Bullinger, L; Deshayes, K; Döhner, H; Döhner, K; Fulda, S; Lueck, SC; Russ, AC; Schlenk, RF; Vucic, D; Zobel, K | 1 |
| Gomyo, H; Imoto, S; Kajimoto, K; Koizumi, T; Mizuno, I; Murayama, T; Sugimoto, T; Tobinai, K | 1 |
| Ahn, KS; Cheong, HS; Kim, HL; Kim, JH; Koh, Y; Lee, C; Shin, HD; Yoon, SS | 1 |
| Aoi, M; Kitamura, K; Sakurada, H; Sugimura, Y; Tachi, T; Teramachi, H; Yamamura, M; Yuge, M | 1 |
| Fukushima, N; Hayakawa, F; Jamieson, C; Kakiuchi, S; Kiyoi, H; Kuwatsuka, Y; Minami, Y; Naoe, T | 1 |
| Adams, J; Albrecht, H; Basnet, SK; Diab, S; Islam, S; Li, P; Milne, R; Wang, S; Yu, M | 1 |
| Chen, Y; Hu, J; Liu, T; Yang, T; Yang, X; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Fernandez, HF | 1 |
| Kataoka, K; Koya, J; Kurokawa, M; Morita, K; Nakazaki, K; Sato, T; Sumitomo, Y; Tsuruta-Kishino, T | 1 |
| Fox, JA; Jamieson, GC; Poi, M; Strickland, SA | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Wang, FX; Wang, JL; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Alzghari, SK; Cable, CT; Herrington, JD; Seago, SE | 1 |
| Duan, MH; Feng, J; Han, X; Li, J; Tian, LP; Yang, C; Zhang, L; Zhang, M; Zhang, W; Zhang, Y; Zhou, DB | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Fancourt, C; Gojo, I; Johnson-Levonas, AO; Jones, MB; Kantarjian, H; Knox, CD; Lam, R; Minden, MD; Patel, PS; Patnaik, MM; Ravandi, F; Rose, S; Tibes, R | 1 |
| Gómez-Cortés, C; Guerrero-Rivera, S; Gutiérrez-Espíndola, GR; Medrano-Contreras, J; Meillón-García, LA; Pérez-Rocha, JF; Talavera-Piña, JO; Terreros-Muñoz, E | 1 |
| Andersson, C; Blom, K; Eriksson, A; Gustafsson, MG; Haglund, C; Höglund, M; Kashif, M; Larsson, R; Österroos, A | 1 |
| Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL | 1 |
| Ali, S; Burnett, AK; Burns, S; Cahalin, P; Clark, RE; Dennis, M; Freeman, S; Hills, RK; Kell, J; Milligan, D; Nielsen, OJ; Pocock, C; Russell, NH | 1 |
| Bertoli, S; Cartel, M; Cazaux, C; David, L; Delabesse, E; Deshaies, D; Didier, C; Fernandez-Vidal, A; Grgurevic, S; Hoffmann, JS; Larrue, C; Lepage, B; Manenti, S; Prade, N; Récher, C; Sarry, JE | 1 |
| Chen, HR; Dou, LP; Fang, MY; Gao, XN; Gong, D; Hu, LD; Jing, Y; Ke, XY; Li, HH; Li, W; Li, YH; Liu, F; Liu, H; Luo, JM; Ma, YG; Shen, JL; Wang, HX; Wang, JW; Wang, QS; Wang, Z; Yang, QM; Yu, L | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Cortes, J; Daver, N; DiNardo, C; Estrov, Z; Garcia-Manero, G; Huang, X; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Pierce, S; Ravandi, F; Wang, S; Wang, X | 1 |
| An, X; Cai, J; Huang, L; Li, QX; Liu, J; Wang, D; Wang, N; Wery, JP; Zhang, L; Zhou, D; Zhou, J | 1 |
| Cheng, H; Hu, X; Li, R; Lv, S; Song, X; Wang, J; Wang, L; Yang, J; Zhang, W | 1 |
| Jiang, Q; Li, L; Sun, J; Xie, M; Xie, W; Yang, X; Ye, X; Zheng, Y; Zhu, J; Zhu, L; Zhu, M | 1 |
| Angenendt, L; Berdel, WE; Butterfass-Bahloul, T; Edemir, S; Gerss, J; Kewitz, T; Knoblauch, N; Krug, U; Mikesch, JH; Müller-Tidow, C; Sauer, T; Schliemann, C; Urban, M; Vehring, K; Wiebe, S | 1 |
| Ding, K; Fu, R; Li, L; Liu, H; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y | 1 |
| Fridle, C; Manz, MG; Medinger, M; Pabst, T; Passweg, J; Seipel, K; Wilk, MC | 1 |
| Chen, SJ; Chen, WL; Chen, Z; Cheng, Z; Jia, W; Liu, J; Ni, Y; Qu, C; Rajani, C; Su, M; Wang, YY; Wei, R; Xia, L; Xie, G; Zhao, A; Zhao, L | 1 |
| Amadori, S; Baron, F; de Witte, T; Halkes, CJ; Marie, JP; Meert, L; Meloni, G; Muus, P; Pruijt, H; Ramadan, SM; Selleslag, D; Suciu, S; Venditti, A; Vignetti, M; Willemze, R; Wittnebel, S | 1 |
| Andreeff, M; Borthakur, G; Piya, S | 1 |
| Kobos, R; LaQuaglia, MP; Modak, S; Pandit-Taskar, N; Sait, S | 1 |
| Bonfigli, S; Careddu, MG; Coppola, L; Dessì, L; Dore, F; Dore, S; Fozza, C; Giannico, DB; Longinotti, M; Longu, F; Nieddu, RM; Pardini, S; Podda, L; Sotgiu, G | 1 |
| Aumann, NK; Bailey, NJ; Jones, JM; Kurata, M; Largaespada, DA; Moriarity, BS; Rathe, SK; Veldhuijzen, GW | 1 |
| Bittenbring, J; Ganser, A; Hallek, M; Huynh, A; Kröger, N; Labopin, M; Malard, F; Michallet, M; Mohty, M; Nagler, A; Savani, BN; Schmid, C; Stuhler, G; Tischer, J | 1 |
| Aittokallio, T; Eldfors, S; Heckman, C; Kallioniemi, O; Karjalainen, R; Kontro, M; Kumar, A; Majumder, MM; Malani, D; Murumägi, A; Ojamies, P; Pemovska, T; Porkka, K; Wennerberg, K; Wolf, M; Yadav, B | 1 |
| Beltrão, EI; Benicio, MT; Bezerra, MA; Bezerra, MF; Coelho-Silva, JL; Lucena-Araujo, AR; Machado, CG; Nascimento, JC; Rego, EM; Rocha, CR | 1 |
| Horne, DA; Kowolik, CM; Lin, M; Overman, LE; Xie, J | 1 |
| Basso, G; Bisio, V; Di Giacomo, D; Di Meglio, A; Leszl, A; Locatelli, F; Manara, E; Masetti, R; Mecucci, C; Minuzzo, S; Pession, A; Pigazzi, M; Rondelli, R; Salsi, V; Togni, M; Tregnago, C; Zampini, M; Zappavigna, V | 1 |
| Chen, XP; Li, X; Liu, ZQ; Pang, FM; Tan, D; Tang, J; Wen, L; Xie, P; Yan, H; Zhang, W; Zhou, HH | 1 |
| Studzinski, GP; Zheng, R | 1 |
| Agrawal-Singh, S; Berdel, WE; Dugas, M; Ehninger, G; Göllner, S; Hansen, K; Herold, S; Jeremias, I; Klein, HU; Köhler, G; Lerdrup, M; Müller, LP; Müller-Tidow, C; Oellerich, T; Pabst, C; Pan, KT; Rohde, C; Sauer, T; Schenk, T; Serve, H; Spiekermann, K; Stölzel, F; Tavor, S; Thiede, C; Urlaub, H; Vick, B; Wickenhauser, C; Zelent, A | 1 |
| Gullbo, J; Haglund, C; Hassan, SB; Höglund, M; Larsson, R; Strese, S; Velander, E | 1 |
| Andresen, V; Bruserud, Ø; Gjertsen, BT; Omsland, M | 1 |
| Baldauf, HM; Berdel, WE; Bohnenberger, H; Cinatl, J; Comoglio, F; Cremer, A; Ferreirós, N; Flick, R; Geisslinger, G; Hansmann, ML; Hartmann, W; Hornung, V; Kaderali, L; Keppler, OT; Lohmeyer, J; Martin, M; Michaelis, M; Oellerich, T; Schliemann, C; Schneider, C; Schwarz, SM; Serve, H; Stegmann, L; Ströbel, P; Thomas, D; Wardelmann, E; Yakunin, AF | 1 |
| Barraco, F; Ducastelle-Leprêtre, S; Labussière-Wallet, H; Nicolini, FE; Paubelle, E; Plesa, A; Salles, G; Thomas, X; Wattel, E | 1 |
| Chen, R; Hao, JP; Tuerxun, N; Zhao, SY | 1 |
| Edwards, H; Ge, Y; Taub, JW; Wang, G; Xie, C; Zhao, J | 1 |
| Fischer, M; Fleischmann, M; Hilgendorf, I; Hochhaus, A; Schnetzke, U; Scholl, S; Spies-Weisshart, B; Walther, M | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Bergeron, M; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Fathi, AT; Fishman, KM; Foster, J; Graubert, TA; Hermance, NM; Hobbs, G; Joseph, C; Manning, AL; McGregor, KL; Neuberg, DS; Perry, AM; Ramos, AY; Sadrzadeh, H; Silver, R; Som, TT; Supko, J; Wander, SA | 1 |
| Axelsson, H; Bladh, J; Bulli, L; Calderón-Montaño, JM; Grandér, D; Hagenkort, A; Helleday, T; Henter, JI; Herold, N; Heshmati, Y; Heyman, M; Höglund, A; Jemth, AS; Kogner, P; Kutzner, J; Lehmann, S; Ljungblad, L; Loseva, O; Lundbäck, T; Myrberg, IH; Page, BD; Paulin, CB; Rassidakis, G; Rudd, SG; Sanjiv, K; Schaller, T; Sundin, M; Tamm, KP; Tesi, B; Uhlin, M; Valerie, NC; Walfridsson, J; Warpman-Berglund, U; Wiita, E | 1 |
| de Melo Campos, P; Favaro, P; Lopes, MR; Machado-Neto, JA; Pereira, JK; Saad, ST; Traina, F | 1 |
| Butrym, A; Czemerska, M; Giebel, S; Golos, A; Grosicki, S; Holowiecka-Goral, A; Holowiecki, J; Katarzyna Budziszewska, B; Kloczko, J; Kuliczkowski, K; Kyrcz-Krzemien, S; Lange, A; Madry, K; Mordak-Domagala, M; Piszcz, J; Pluta, A; Razny, M; Robak, T; Sulek, K; Szydlo, R; Warzocha, K; Wawrzyniak, E; Wierzbowska, A; Wiktor-Jedrzejczak, W; Wrzesien-Kus, A; Zwolinska, M | 1 |
| Clavio, M; Gobbi, M; Guolo, F; Lemoli, RM; Miglino, M; Minetto, P | 1 |
| Cahill, MR; Cotter, TG; Darcy, R; Guo, J; McKenna, SL; O'Driscoll, CM; Russell, EG | 1 |
| Gill, S | 1 |
| Broekhuizen, R; Court, F; Ernst, D; García, P; González, A; Macanas-Pirard, P; Montecinos, VP; Nervi, B; Ocqueteau, M; Oyanadel, C; Ramirez, P | 1 |
| Chu, R; Edwards, H; Epshteyn, V; Ge, Y; Li, X; Lin, H; Luedtke, DA; Ma, J; Su, Y; Taub, JW; Wang, G; Wang, Y; Wang, Z; Zhao, J | 1 |
| Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y | 1 |
| Banús-Mulet, A; Cornet-Masana, JM; Díaz-Beyá, M; Esteve, J; Etxabe, A; Lara-Castillo, MC; Nomdedeu, M; Pratcorona, M; Risueño, RM; Torrente, MA | 1 |
| Baker, SD; Blum, W; Drenberg, CD; Du, G; Gibson, AA; Gruber, TA; Hu, S; Li, L; Nies, AT; Pabla, N; Pounds, SB; Rhinehart, DP; Schwab, M; Shi, L; Sparreboom, A | 1 |
| Berthon, C; Cahn, JY; Caillot, D; Castaigne, S; Celli-Lebras, K; Chevret, S; de Botton, S; Dombret, H; Hermine, O; Ifrah, N; Lemasle, E; Marolleau, JP; Pigneux, A; Preudhomme, C; Raffoux, E; Recher, C; Reman, O; Simon, M; Terré, C; Thomas, X; Vey, N | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Hayashi, Y; Horibe, K; Iwamoto, S; Miyamura, T; Mizutani, S; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D | 1 |
| Abu Ghanimeh, M; Abughanimeh, O; Qasem, A; Qasrawi, A | 1 |
| Brower, V | 1 |
| Abboud, CN; Andreeff, M; DiPersio, JF; Eades, W; Fletcher, TR; Jacoby, MA; Konopleva, MY; McFarland, K; Reineck, T; Rettig, MP; Shannon, W; Stockerl-Goldstein, K; Stone, RM; Uy, GL; Westervelt, P | 1 |
| Ashton, S; Barry, ST; Caddy, J; Curtis, NJ; Derbyshire, N; Floc'h, N; Harris, E; Hattersley, M; Jacobs, VN; Maratea, K; Odedra, R; Pease, EJ; Pilling, JE; Taylor, P; Trueman, D; Wen, S | 1 |
| Finn, LE; Foran, JM; Hess, AD; Karp, JE; Kaufmann, SH; Knorr, KL; Smith, BD | 1 |
| Jawad, M; Mony, U; Pallis, M; Russell, N; Seedhouse, C | 1 |
| Huang, J; Jiang, DZ; Jin, J; Liu, H; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Tong, HY; Tong, Y; Wang, L | 1 |
| Borthakur, G; Bueso-Ramos, C; Estey, E; Kantarjian, H; Ravandi, F; Yanada, M | 1 |
| Browne, P; Giles, F; O'Rafferty, C; Swords, R | 1 |
| Abboud, CN; Martin, MG | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Breitenbuecher, F; Fischer, T; Heidel, F; Hoehn, Y; Huber, C; Kasper, S; Kindler, T; Lipka, DB; Markova, B | 1 |
| Blum, W; Byrd, JC; Chan, K; Devine, S; Grever, MR; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Marcucci, G; Pang, J; Vukosavljevic, T; Wei, X; Xie, Z; Zwiebel, JA | 1 |
| Bloomfield, CD; Larson, RA; Liu, ET; Maharry, K; Marcucci, G; Mayer, RJ; Mrózek, K; Neubauer, A; Paschka, P; Thiede, C | 1 |
| Baer, MR; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Kolitz, JE; Langer, C; Larson, RA; Maharry, K; Marcucci, G; Mrózek, K; Paschka, P; Powell, BL; Ruppert, AS; Whitman, SP; Zhao, W | 1 |
| Enjoji, M; Hamaguchi, H; Kawachi, Y; Kurisu, A; Kusakabe, M; Maruyama, H; Matsuki, M; Nagano, H; Nagata, K; Ohtsukasa, S; Taki, K | 1 |
| Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Thomas, DA; Verstovsek, S | 1 |
| Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR | 1 |
| Benesch, M; Bergloeff, J; Gruber, A; Lackner, H; Moser, A; Schwinger, W; Sommer, C; Sovinz, P; Urban, C | 1 |
| Attarian, H; Ghadiany, M; Hajifathali, A; Khosravi, A; Molanaee, S | 1 |
| Bai, CH; Kim, YD; Song, SY; Woo, HJ | 1 |
| Amadori, S; Ammatuna, E; Arcese, W; Buccisano, F; Cerretti, R; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Lo Coco, F; Maurillo, L; Neri, B; Ottaviani, L; Panetta, P; Quaresima, M; Rizzo, M; Sarlo, C; Spagnoli, A; Venditti, A; Venditti, D | 1 |
| Baker, N; Bosi, A; Dansey, R; Herrmann, R; Kassis, J; Lazzarino, M; Noga, SJ; Sierra, J; Szer, J; Thomas, X | 1 |
| Candoni, A; Chiarvesio, A; Damiani, D; Fanin, R; Malagola, M; Martinelli, G; Michelutti, A; Piccaluga, PP; Russo, D; Simeone, E; Tiribelli, M; Toffoletti, E | 1 |
| Brandt, M; Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; Medeiros, LJ; O'Brien, S; Pierce, S; Tsimberidou, AM; Wen, S | 1 |
| Ito, T; Nakazawa, H; Saida, T; Uhara, H | 1 |
| Fang, BJ; Li, HY; Li, YF; Liu, YY; Song, YP; Wang, P; Wei, XD; Yue, H; Zhang, LN; Zhang, YL; Zhu, XH | 1 |
| Fladmark, KE; Gjertsen, BT; Hovland, R; Oveland, E; Selheim, F; Wergeland, L | 1 |
| Casper, J; Freund, M; Hilgendorf, I; Junghanss, C; Kahl, C; Leithaeuser, M; Steiner, B; Wolff, D | 1 |
| Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B | 1 |
| Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
| Advani, A; Kalaycio, M; Pohlman, B; Rybicki, L; Sekeres, M; Sobecks, R; Tripp, B | 1 |
| Baruchel, A; Bertrand, Y; Boutard, P; Brethon, B; Bruno, B; Chevret, S; Dalle, JH; de Lumley, L; Jérome, C; Leblanc, T; Nelken, B; Oudot, C; Yakouben, K | 1 |
| Dumontet, C; Jordheim, LP; Nguyen-Dumont, T; Tavtigian, SV; Thomas, X | 1 |
| Asagoe, K; Matsuzawa, Y; Sakoda, H; Sugahara, H; Togashi, Y | 1 |
| Corallo, CE; Coutsouvelis, J | 1 |
| Chi, HS; Jang, S; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, SS; Lee, YS; Lim, SN; Park, CJ; Ryu, SG; Seol, M; Yun, SC | 1 |
| Allen-Bard, S; Carlin, R; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Mazumdar, M; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Wittenberg, B | 1 |
| Advani, AS; Copelan, EA; Elson, P; Estey, E; Faderl, S; Kalaycio, ME; Kantarjian, HM; Sekeres, MA | 1 |
| Ehninger, G; Hiddemann, W; Illmer, T; Karsch, C; Kiani, A; Lindner, LH; Ostermann, H; Platzbecker, U; Schleyer, E; Würfel, M | 1 |
| Avet-Loiseau, H; Chevallier, P; Delaunay, J; Dmytruk, N; Garand, R; Girault, S; Guillaume, T; Harousseau, JL; Hunault, M; Ifrah, N; Milpied, N; Mohty, M; Pigneux, A; Turlure, P | 1 |
| Belloc, F; Jeanneteau, M; Lacombe, F; Mahon, FX; Milpied, N; Pigneux, A; Reiffers, J; Uhalde, M | 1 |
| Cao, XM; Chen, YX; He, AL; Liu, J; Ma, XR; Zhang, WG | 1 |
| Alonso, N; Arranz, R; Blanes, M; Conde, E; Deben, G; Fernández de Sevilla, A; Fernández-Abellán, P; Morgades, M; Nicolás, C; Ribera, JM; Rodríguez, MJ; Sánchez, E; Sancho, JM | 1 |
| Borthakur, G; Estey, EH; Faderl, S; Gandhi, VV; Garcia-Manero, G; Kantarjian, H; Pierce, S; Plunkett, WK; Ravandi, F; Wang, X | 1 |
| Fujita, N; Inaba, T; Nakatani, T; Nishimura, H; Saito, J; Uchiyama, H; Yamamoto, M; Yamane, Y | 1 |
| Alonzo, TA; Bhatla, D; Conner, H; Davies, SM; Geiger, H; Gerbing, RB; Mehta, PA; Meshinchi, S; Perentesis, J; Ross, JA; Zamzow, T; Zhai, X | 1 |
| Ando, K; Kawada, H; Murayama, H; Nakamura, N; Ogawa, Y; Ohmachi, K; Suzuki, R; Tsuboi, K | 1 |
| Jones, RL; Kulkarni, S; Mehta, J; Morgan, G; Potter, M; Powles, R; Saso, R; Singhal, S; Sirohi, B; Smith, K; Swansbury, GJ; Treleaven, J | 1 |
| Chen, ZC; Li, QB; Li, WM; Xia, LH; You, Y; Zhou, H; Zou, P | 1 |
| Brandwein, JM; Gupta, V; Howson-Jan, K; Leber, BF; MacAlpine, K; Minden, MD; Moore, M; Schimmer, AD; Schuh, AC; Wright, J; Yee, KW | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Jiang, SY; Li, BS; Xie, XT; Yang, LL | 1 |
| Li, Y; Liao, A; Liu, Z; Qi, L; Shao, H; Wang, H; Yang, W; Zhang, J | 1 |
| Baer, MR; Duran, GE; Fielding, R; Lancet, JE; List, AF; Marcelletti, JF; Multani, PS; Sikic, BI | 1 |
| Hanafusa, T; Kobayashi, K; Nakayama, S; Takubo, T; Tsuji, M; Yokote, T | 1 |
| Dorn, DC; Kou, CA; Moore, MA; Png, KJ | 1 |
| Chen, CC; Gau, JP; Lan, C; Lee, KD; Lin, JT; Liu, JM; Lo, WH; Lu, CH; Yang, CF; You, JY; Yu, YB | 1 |
| Alexander, C; Bashford, J; Jefferies, PD; Lee, GA; Whitehead, K | 1 |
| Baurmann, H; Beelen, DW; Berdel, WE; Bohlander, S; Braess, J; Büchner, T; Buske, C; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Ludwig, WD; Oruzio, D; Peceny, R; Reichle, A; Sauerland, C; Schiel, X; Schmid, C; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B | 1 |
| Demir, M; Oztürk, E; Pamuk, GE; Taşçi, M | 1 |
| Abboud, CN; Augustin, K; Cashen, A; DiPersio, JF; Luo, J; Martin, MG; Procknow, E; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Bellaaj, H; Elloumi, M; Kallel, C; Kammoun, H; Kassar, O; Sandi, HS | 1 |
| Cafro, AM; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Nosari, AM; Ricci, F; Tedeschi, A | 1 |
| Bae, SH; Joo, YD; Kim, H; Lee, JH; Lee, KH; Lee, WS; Mo Ryoo, H; Park, JH | 1 |
| Tallman, M | 1 |
| Karp, J | 1 |
| Burns, LA; D'Orazio, JA; Farhoudi, N; Kesler, MV; McBride, MT | 1 |
| Chia, HY; Koh, LP; Liu, TC; Poon, LM; Tan, LK | 1 |
| Assa'ad, A; Burns, K; Hershey, GK; Johnson, T; Lierl, MB; Metz, KA; Seidu, L | 1 |
| Boeck, S; Braess, J; Christ, B; Hausmann, A; Hiddemann, W; Metzeler, KH; Ostermann, H; Parhofer, KG; Stemmler, HJ | 1 |
| Chen, LJ; Li, JY; Lu, H; Lu, RN; Qian, SX; Qiu, HX; Sheng, RL; Wu, HX; Xu, W | 1 |
| Horacek, JM; Jakl, M; Jebavy, L; Pudil, R | 1 |
| Ayres, M; Beck, JF; Chen, ZS; Ehninger, G; Gandhi, V; Grube, M; Guo, Y; Illmer, T; Jedlitschky, G; Köck, K; Kroemer, HK; Kruh, GD; Ritter, CA; Schaich, M; Siegmund, W | 1 |
| Abe, D; Adachi, S; Asai, K; Daifu, T; Izawa, K; Kato, I; Matubara, H; Nakahata, T; Tokumasu, M; Umeda, K; Uryu, K; Watanabe, K | 1 |
| Adams, JA; Liu Yin, JA; Morris, KL | 1 |
| Kim, HJ; Kim, SH; Kim, TS; Kweon, SH; Lee, TH; Song, JH | 1 |
| Archer, LE; Damon, LE; Hurd, D; Larson, RA; Linker, CA; Owzar, K; Powell, B | 1 |
| Burnett, AK; Dennis, M; Goldstone, A; Hills, RK; McMullin, MF; Milligan, D; Pallis, M; Prentice, A; Russell, N; Sellwood, E; Wheatley, K | 1 |
| Aimiuwu, J; Blum, W; Chan, KK; Chen, P; Grever, MR; Klisovic, R; Liu, S; Liu, Z; Marcucci, G; Pang, J; Xie, Z | 1 |
| Chang, H; He, C; Liu, T; Xiang, B; Xu, CG; Xu, J | 1 |
| Borrego, L; Guillermo, N; Hernández-Machín, B; Montenegro, T; Peñate, Y | 1 |
| Giles, FJ | 1 |
| Buyukasik, Y; Goker, H; Ozcebe, OI; Sayinalp, N; Serefhanoglu, S | 1 |
| Aktas, B; Demirer, T; Ensari, A; Kurt, OK; Topcuoglu, P | 1 |
| Britt-Marie, F; Curt, P; Frost, BM; Gudmar, L; Hasle, H; Hellebostad, M; Henrik, H; Josefine, P; Jukka, K; Kanerva, J; Kjeld, S; Lönnerholm, G; Marit, H; Palle, J; Petersson, C; Schmiegelow, K | 1 |
| Chang, CK; He, Q; Li, X; Song, LQ; Su, JY; Wu, LY; Xu, L; Zhang, X; Zhou, LY | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Gondo, H; Kawatani, E; Kishikawa, Y; Kuwahara, N; Matsuishi, E; Mori, D; Osoegawa, K; Sankoda, C | 1 |
| Iwasaki, H; Kishi, S; Negoro, E; Takagi, K; Ueda, T; Urasaki, Y; Yamauchi, T; Yoshida, A | 1 |
| Bommana, V; Irani, F; Kasmani, R; Kumar, B; Mahajan, K; Mian, A | 1 |
| Borthakur, G; Cortes, JE; Estey, EE; Faderl, S; Jain, N; Kantarjian, H; Lin, E; O'Brien, S; Pierce, S; Ravandi, F | 1 |
| Leroux, JC; Simard, P | 1 |
| Cho, D; Kim, HJ; Kim, SH; Kim, TS; Lee, IK; Song, JH | 1 |
| Bulut, N; Dransfeld, CL; Ehninger, G; Kramer, M; Mahlknecht, U; Schaich, M; Thiede, C | 1 |
| Tallman, MS | 1 |
| Boissel, N; Dombret, H; Preudhomme, C | 1 |
| Kumar, V; Pal, J; Shrivastav, A | 1 |
| Bian, S; Fu, M; Lin, D; Liu, J; Mi, Y; Wang, J; Wang, Y; Yu, W | 1 |
| Abebe, L; Einzig, A; Lee, SH; Paietta, E; Wiernik, PH | 1 |
| Betancourt-García, RD; Castro, J; Fernández, AC; Fradera, J; López-Enríquez, A; Pacheco, E | 1 |
| Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Ikezoe, T; Nishioka, C; Yang, J; Yokoyama, A | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, SJ; Zhu, BG | 1 |
| Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF | 1 |
| Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM | 1 |
| Dutka, M; Flont, M; Gawronski, K; Giebel, S; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Konopka, L; Kuliczkowski, K; Lech-Maranda, E; Paluszewska, M; Palynyczko, G; Piatkowska-Jakubas, B; Robak, T; Seweryn, M; Skotnicki, A; Sokolowski, J; Sulek, K; Szpila, T; Warzocha, K; Wegrzyn, J; Zdziarska, B | 1 |
| Antholine, WE; Batey, RA; Datti, A; Dick, J; Dick, JE; Eberhard, Y; Gronda, M; Hurren, R; McDermott, SP; Schimmer, AD; Venugopal, A; Wang, X; Wood, TE; Wrana, J | 1 |
| Hamamoto, K; Hanada, R; Horibe, K; Imaizumi, M; Kigasawa, H; Kobayashi, R; Kudo, K; Morimoto, A; Nakayama, H; Tabuchi, K; Tawa, A; Tsuchida, M; Tsuchiya, S; Tsukimoto, I; Yabe, H | 1 |
| Heinrich, MC; Kampa, KM; Schittenhelm, MM; Yee, KW | 1 |
| Du, X; Huang, ZL; Li, QH; Lin, W; Lu, ZS; Weng, JY; Wu, SJ; Zhong, LY | 1 |
| Chen, L; Hou, J; Huang, C; Lü, S; Song, X; Wang, J; Yang, J; Zhang, W | 1 |
| Chang, C; He, Q; Li, X; Pu, Q; Song, L; Su, J; Wu, L; Xu, L; Zhang, X | 1 |
| Abadjian, GA; Aftimos, PG; El Karak, FR; Ghosn, MG; Haddad, AC; Nassar, MN | 1 |
| Hackanson, B; Lübbert, M; Rückert, A | 1 |
| Chai, JY; Wei, N; Zheng, WQ | 1 |
| Albitar, M; Boskovic, D; Brandwein, J; Cahill, A; DeAngelo, D; Giles, F; Kell, J; O'Brien, S; Pigneux, A; Robak, T; Seiter, K; Staib, P; Stock, W; Stuart, R; Tallman, M; Thomas, X; Vey, N | 1 |
| Erikci, AA; Ozturk, A; Sayan, O; Tekgunduz, E | 1 |
| Carrier, M; Cencic, R; Minden, M; Pelletier, J; Porco, JA; Trnkus, A | 1 |
| Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M | 1 |
| Bergeron, A; Boissel, N; Chagnon, K; Dombret, H; Raffoux, E; Tazi, A | 1 |
| Asou, N; Eto, K; Horikawa, K; Kugimiya, MH; Mitsuya, H; Nishimura, S; Shimomura, T; Suzushima, H; Tsuda, H; Wada, N; Yamasaki, H | 1 |
| Allen, SL; Bennett, JM; Budman, DR; Capizzi, RL; Kolitz, JE; Lundberg, AS | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Dalinghaus, M; de Vries, AC; Kroon, AA; van den Heuvel-Eibrink, MM; van Dongen, JC | 1 |
| Carlsson, M; Holm, C; Koranyi, G; Moberg, J | 1 |
| Bennett, JM; Cripe, LD; Dewald, GW; Gore, SD; Lazarus, HM; Lee, SJ; Litzow, MR; Othus, M; Paietta, EM; Rowe, JM; Tallman, MS | 1 |
| Abboud, CN; Augustin, KM; Cashen, AF; Dipersio, JF; Goyal, S; Hladnik, L; Martin, MG; Monahan, RS; Reichley, RM; Stockerl-Goldstein, K; Tiwari, D; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Appelbaum, FR; Chauncey, TR; Chen, IM; Dakhil, SR; Erba, HP; Gundacker, H; Kopecky, KJ; List, AF; Shadman, M; Slovak, ML; Willman, CL | 1 |
| Armistead, PM; Champlin, R; de Lima, M; Estey, E; Giralt, S; Kantarjian, H; Pierce, S; Qiao, W; Ravandi, F; Thall, PF; Wang, X | 1 |
| Hong, M; Li, JY; Li, Q; Lu, H; Qian, SX; Qiu, HX; Sheng, WY; Wu, HX; Xu, W; Zhang, R | 1 |
| Qin, TJ; Wang, JY; Xiao, ZJ; Xu, ZF; Zhou, CL | 1 |
| Lamba, JK | 2 |
| Byrd, JC; Chan, KK; Golan, S; Huynh, L; Jin, Y; Koh, CG; Lee, LJ; Lee, RJ; Liu, S; Marcucci, G; Muthusamy, N; Pang, J; Talmon, Y; Yang, J; Yang, X; Yu, B | 1 |
| Asai, S; Jin, G; Matsushita, H; Miyachi, H; Nosaka, T; Ono, R; Takahashi, S; Tsukamoto, H; Yahata, T | 1 |
| Ozawa, K | 1 |
| Nagai, T | 1 |
| Wakita, A | 1 |
| Cotta, CV; Khan, G; Pohlman, B; Sweetenham, J; Wesolowski, R | 1 |
| Höglund, M; Paul, C; Prenkert, M; Tidefelt, U; Tina, E | 1 |
| Eilers, M; Illmer, T; Meyer, M; Neubauer, A; Roth, P; Rübsamen, D; Slany, R; Stabla, K; Stiewe, T | 1 |
| Gharabaghi, F; Leahy, TR; Punnett, AS; Richardson, SE; Wadhwa, A | 1 |
| Kurokawa, M; Nagai, S; Nannya, Y; Takahashi, T | 1 |
| Matsumura, I | 1 |
| Miyazaki, Y | 1 |
| Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T | 1 |
| Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ | 1 |
| Chao, TY; Huang, TC | 1 |
| FUJIMOTO, H; HIASA, Y; HORIUCHI, N; KIMURA, S; MASUDA, K; MATSUSHITA, T; NAKAMURA, S; SHICHIJO, K; SHINOMIYA, S; TAKAHASHI, K; TAKEICHI, T; TAMAKI, Y; YAMANAKA, C | 1 |
| Berry, D; Borthakur, G; Faderl, S; Ferrajoli, A; Huang, X; Issa, JP; Kantarjian, H; Morris, G; Ravandi, F; Torma, R | 1 |
| Schiffer, CA | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Wu, HX; Xu, W | 1 |
| Burnett, AK; Duncombe, A; Gibson, B; Goldstone, AH; Hills, RK; McMullin, MF; Milligan, DW; Prentice, AG; Wheatley, K | 1 |
| Imanishi, D; Imoto, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Miyazaki, Y; Morita, Y; Naoe, T; Ohnishi, K; Ohno, R; Tanimoto, M; Yagasaki, F | 1 |
| Ahn, HS; Cho, B; Chung, NG; Hwang, TJ; Im, HJ; Kang, HJ; Kim, HK; Koo, HH; Kook, H; Lee, DH; Park, HJ; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH | 1 |
| Asou, N; Handa, H; Kageyama, S; Kishimoto, Y; Kiyoi, H; Maeda, Y; Matsuda, S; Miyawaki, S; Miyazaki, Y; Nagai, T; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okada, M; Okumura, H; Takahashi, M; Takeuchi, J; Yagasaki, F | 1 |
| Asou, N; Emi, N; Honda, S; Kishimoto, Y; Matsuda, S; Mitani, K; Miyawaki, S; Miyazaki, Y; Ogawa, Y; Ohno, R; Ohtake, S; Sakamaki, H; Takahashi, M; Yagasaki, F | 1 |
| Dessalvi, P; Di Tucci, AA; Emanuele, A; Pettinau, M; Romani, C | 1 |
| Cho, EK; Lee, JH; Park, J; Shin, DB; Sym, SJ; Yi, HS | 1 |
| Chen, H; Deisseroth, A; Farrell, A; He, K; Justice, R; Kane, R; Pazdur, R; Sridhara, R | 1 |
| Filanovsky, K; Shtalrid, M; Shvidel, L | 1 |
| Bencini, S; Bosi, A; Gianfaldoni, G; Longo, G; Mannelli, F; Ponziani, V; Vannucchi, AM | 1 |
| Li, Y; Zhang, R; Zhang, XH | 1 |
| Cetin, CB; Ergene, U; Ozbalci, D | 1 |
| Dvoráková, D; Gáliková, J; Lemez, P; MacWhannell, A; Michalová, K; Stejskal, J; Zemanová, Z | 1 |
| Ahn, JS; Bae, SH; Bang, SM; Choi, SJ; Chung, JS; Hong, DS; Jo, DY; Joo, YD; Jung, CW; Kim, HJ; Kim, I; Kim, SH; Kim, SJ; Lee, JH; Lee, JL; Lee, KH; Min, YH; Shin, HJ; Sohn, SK; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Dedhar, S; Hogge, DE; Muranyi, AL | 1 |
| Cortes, J; Faderl, S; Freireich, E; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Ravandi, F; Verma, D; Vu, K | 1 |
| Aziz, A; Gosbell, IB; Sanghavi, R; Varghese, B | 1 |
| Andreeff, M; Bekele, BN; Borthakur, G; Brandt, M; Byrd, A; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, HM; Konopleva, MY; Levis, M; Luthra, R; O'Brien, S; Pierce, SR; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Borthakur, G; Estey, EE | 1 |
| Abou Shamaa, LA; El-Naggar, AA; Mahmoud, BF; Salama, MA | 1 |
| Becher, J; Guthoff, R; Guthoff, T; Meinhardt, B; Tietze, B | 1 |
| van der Jagt, RH | 1 |
| Adachi, S; Asami, K; Endo, M; Goto, H; Hanada, R; Hara, J; Hori, T; Horibe, K; Horikoshi, Y; Hosoya, R; Ikuta, K; Kikuta, A; Kobayashi, R; Koike, K; Mugishima, H; Nagatoshi, Y; Nishimura, S; Ohara, A; Ohta, S; Sugita, K; Tsukimoto, I; Tsurusawa, M; Watanabe, A | 1 |
| Adiguzel, U; Erkayhan, G; Sari, A; Unal, S | 1 |
| Kato, J; Mori, T; Murata, M; Okamoto, S; Ono, Y; Shimizu, T; Sugita, K; Yamane, A | 1 |
| Bergua, J; Brunet, S; de la Serna, J; de Lisa, E; Díaz-Mediavilla, J; González, J; González, JD; Holowiecka, A; Krsnik, I; Lowenberg, B; Manso, F; Milone, G; Montesinos, P; Ossenkoppele, G; Rayón, C; Ribera, JM; Rivas, C; Rojas, R; Rubio, V; Sanz, MA | 1 |
| Bradstock, K | 1 |
| Catania, R; De Grandi, C; Di Cataldo, A; La Spina, M; Lo Nigro, L; Palmucci, S | 1 |
| Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B | 1 |
| Rogers, BB | 1 |
| Betts, DR; Bourquin, JP; Bradtke, J; Creutzig, U; Dworzak, MN; Haas, OA; Reinhardt, D; Sander, A; Stary, J; von Neuhoff, C; Zemanova, Z; Zimmermann, M | 1 |
| Aulitzky, W; Bodenstein, H; Bornhäuser, M; Ehninger, G; Gramatzki, M; Kramer, M; Mohr, B; Oelschlaegel, U; Platzbecker, U; Röllig, C; Schaich, M; Schuler, U; Soucek, S; Stölzel, F; Stuhlmann, R; Thiede, C; von Bonin, M; Wandt, H; Wermke, M | 1 |
| Airewele, G; Bowman, WP; Campana, D; Cao, X; Coustan-Smith, E; Dahl, G; Degar, B; Downing, JR; Inaba, H; Lacayo, NJ; Leung, W; Meshinchi, S; Onciu, M; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Taub, J | 1 |
| Benaissa, S; Estrov, Z; Kantarjian, H; Liu, X; Matsuda, A; Plunkett, W; Wang, Y | 1 |
| Bene, MC; Berthou, C; Cahn, JY; Dreyfus, F; Escoffre-Barbe, M; Fegueux, N; Harousseau, JL; Himberlin, C; Hunault-Berger, M; Ifrah, N; Jourdan, E; Lioure, B; Lissandre, S; Luquet, I; Milpied, N; Pigneux, A; Recher, C; Reiffers, J; Sauvezie, M; Witz, F | 1 |
| Choi, MJ; Kim, HO; Kim, HS; Park, YM | 1 |
| Largaespada, DA; Rathe, SK | 1 |
| Capobianchi, A; Capria, S; Cardarelli, L; Foà, R; Gentile, G; Gianfelici, V; Martino, P; Meloni, G; Trisolini, SM | 1 |
| Cheong, SK; Leong, CF; Maha, A; Seow, HF | 1 |
| Allen, SL; Baer, MR; Bloomfield, CD; DeAngelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vardiman, JW; Vij, R | 1 |
| Chen, B; Chen, N; Cheng, L; Ding, J; Feng, J; Gao, F; Li, Y; Lu, Z; Qian, J; Xia, G; Zhong, Y | 1 |
| Jin, J | 1 |
| Cheong, JW; Eom, JI; Jeung, HK; Jung, HI; Kim, SJ; Min, YH | 1 |
| Elonen, E; Itälä-Remes, M; Jantunen, E; Kinnunen, U; Koistinen, P; Nousiainen, T; Ohtonen, P; Räty, R; Remes, K; Silvennoinen, R; Syrjälä, H | 1 |
| Barraco, F; Cannas, G; Chelghoum, Y; Derbel, O; Elhamri, M; Le, QH; Michallet, M; Nicolas-Virelizier, E; Nicolini, F; Thomas, X; Troncy, J | 1 |
| Advani, A; Bejanyan, N; Copelan, E; Fu, AZ; Fu, R; Kalaycio, M; Lazaryan, A; Maciejewski, JP; Sekeres, MA; Sobecks, R | 1 |
| Rheingold, SR; Seif, AE; Sutter, JA | 1 |
| Bae, JY; Kim, BK; Kim, HK; Kim, I; Koh, Y; Lee, DS; Park, MH; Park, S; Park, SS; Song, EY; Yoon, SS | 1 |
| Eskew, A; Grier, DD; McLean, TW; White, T | 1 |
| Bocchia, M; Crupi, R; Defina, M; Gozzetti, A; Lauria, F; Pietrini, A; Raspadori, D; Rondoni, M | 1 |
| Kantarjian, H; O'Brien, S | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Fong, C; Tong, M | 1 |
| Alam, F; Chin, KJ | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Jeha, S; Kantarjian, H; Ouzounian, S; Pierce, S; Ravandi, F; Rytting, M | 1 |
| Cortes, J; Faderl, S; Freireich, EJ; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Ravandi, F; Shan, J; Wierda, W | 1 |
| Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S | 1 |
| Allen, S; Galinsky, I; Hurd, D; Kolitz, JE; Larson, RA; Marcucci, G; Moser, B; Sanford, B; Schulman, P; Stock, W; Stone, RM; Vij, R | 1 |
| Asou, N; Fujieda, A; Fujita, H; Handa, H; Honda, S; Kimura, Y; Kiyoi, H; Miyamura, K; Miyawaki, S; Miyazaki, Y; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okumura, H; Sakamaki, H; Shinagawa, K; Takahashi, M; Taniwaki, M; Usui, N; Yagasaki, F; Yamane, T | 1 |
| Advani, A; Brady, AK; Copelan, E; Earl, M; Fu, AZ; Kalaycio, M; Saunthararajah, Y; Sekeres, MA; Sobecks, R | 1 |
| Asou, N; Horikawa, K; Kawakita, T; Mitsuya, H; Nanri, T; Nosaka, K; Takatsu, N; Tsuji, T | 1 |
| Jabbour, E; Kadia, T; Parikh, SA | 1 |
| Cho, BS; Cho, SG; Choi, SM; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Habert, MO; Hannequin, D; Hitzel, A; Lepretre, S; Martinaud, O; Modzelewski, R; Tilly, H; Vera, P | 1 |
| Cutlan, JE; Geddes, ER; Hymes, SR; Polder, K; Torres-Cabala, CA | 1 |
| Chang, YH; Cho, EH; Hong, SI; Hong, YJ; Kang, HJ; Kim, M; Lee, JK; Lee, JW | 1 |
| Jeraj, R; Juckett, MB; Nickles, RJ; Perlman, SB; Vanderhoek, M | 1 |
| Baer, MR; Becker, H; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Carter, TH; Holland, KB; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Margeson, D; Metzeler, KH; Moore, JO; Mrózek, K; Powell, BL; Radmacher, MD; Schwind, S; Whitman, SP; Wu, YZ | 1 |
| Cros-Perrial, E; Demangel, D; Dreano, M; Dumontet, C; Herveau, S; Jordheim, LP; Keime, C; Plesa, A; Vendrell, JA | 1 |
| Chanel, S; Divgi, CR; Heaney, ML; Jurcic, JG; Larson, SM; McDevitt, MR; Morgenstern, A; Mulford, DA; Panageas, KS; Pandit-Taskar, N; Rosenblat, TL; Scheinberg, DA; Sgouros, G | 1 |
| Alizadeh, AA; Berube, C; Coutre, S; Gotlib, J; Ho, M; Kohrt, HE; Liedtke, M; Majeti, R; Medeiros, BC; Owen, T; Patel, S; Pollyea, DA | 1 |
| Doan, T; Fisher, PG; Lacayo, N; Liao, YJ | 1 |
| Fintelmann, RE; Jeng, BH; Qian, Y; Skalet, A | 1 |
| Buck, SA; Edwards, H; Ge, Y; Matherly, LH; Rubnitz, JE; Stout, ML; Taub, JW; Xie, C; Xu, X; Yu, Q; Zhou, H | 1 |
| Alloush, HM; Anderson, E; Angell, JE; Hill, PJ; Martin, AD; Mehta, P; Ruddock, MW; Salisbury, VC; Smith, JG; Smith, MA | 1 |
| Brandt, M; Cortes, J; de Lima, M; Faderl, S; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Santos, FP; Shan, J; Verstovsek, S | 1 |
| Briel, J; Gocke, CD; Hess, AD; Kanakry, CG; Karp, JE; Kos, F; Levitsky, H; Luznik, L; Meyer, C; Smith, BD; Thoburn, C | 1 |
| Andreeff, M; Borthakur, G; Byrd, AL; Carter, BZ; Estey, E; Kantarjian, H; Konopleva, M; Mak, DH; Morris, SJ | 1 |
| Arnoulet, C; Blaise, D; Charbonnier, A; D'incan, E; Devillier, R; Esterni, B; Etienne, A; Prebet, T; Romeo, E; Vey, N | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ | 1 |
| Appelbaum, FR | 1 |
| Deremer, D; Dobbins, R; Eisa, N; El-Geneidy, M; Hall, P; Jillella, A; Lewis, G; Ustun, C | 1 |
| Teh, TC; Wei, A | 1 |
| Fernandez, HF; George, TJ; Ho, VQ; Kharfan-Dabaja, MA; Komrokji, RS; Lancet, JE; List, AF; Pinilla-Ibarz, J; Price, SL; Wetzstein, GA | 1 |
| Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C | 1 |
| Dührsen, U; Dürig, J; Ebeling, P; Eisele, L; Günther, F; Nabring, J | 1 |
| Chen, S; Li, W; Qiu, H; Sun, A; Wang, Y; Wu, D | 1 |
| Berdel, WE; Braess, J; Büchner, T; Ehninger, G; Haferlach, C; Haferlach, T; Heinecke, A; Hiddemann, W; Koschmieder, A; Koschmieder, S; Kramer, M; Krug, U; Müller-Tidow, C; Rohde, C; Röllig, C; Sauerland, MC; Schaich, M; Serve, H; Spiekermann, K; Thiede, C; Wörmann, B | 1 |
| Burnett, AK; Coles, SJ; Knapper, S; Walsby, EJ | 1 |
| Chen, X; Du, W; He, Y; Huang, S; Li, X; Liu, W; Xiao, H; Yang, L; Zhang, J; Zheng, J | 1 |
| Burnett, A; Hewamana, S; Jenkins, C; Krige, D; Pepper, C | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Liu, J; Ma, XR; Wang, FX; Zhang, WG | 1 |
| Farah, RA; Farhat, HZ; Jalkh, KS; Kadri, AM; Sayad, PE | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Asou, N; Fujieda, A; Fujisawa, S; Handa, H; Honda, S; Kimura, Y; Kiyoi, H; Miyamura, K; Miyawaki, S; Miyazaki, Y; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Sakamaki, H; Sakura, T; Shinagawa, K; Takahashi, M; Taniwaki, M; Usui, N; Yagasaki, F; Yamane, T | 1 |
| Burnett, AK; Lazenby, M; Pepper, C; Walsby, E | 1 |
| Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L | 1 |
| Guo, XN; Li, JM; Shen, ZX; Sheng, XM; Sun, H; Wang, X; Wang, YY; Zhang, JL; Zhang, RY | 1 |
| Damm, F; Ganser, A; Göhring, G; Görlich, K; Heil, G; Heuser, M; Krauter, J; Schäfer, I; Schlegelberger, B; Thol, F; Wagner, K | 1 |
| Kiel, PJ; Rosenbeck, L | 1 |
| Chen, SJ; Chen, Z; Liang, Y; Liu, P; Mi, JQ; Ren, R; Shi, L; Wang, YY; Wu, CF; Xiong, SM; Zhao, LJ | 1 |
| Agura, E; Berryman, RB; Cooper, B; Fay, J; Holmes, H; Li, S; Maisel, C; Saracino, G; Tadic-Ovcina, M; Vance, E | 1 |
| Allen, SL; Asatiani, E; Feldman, EJ; Kolitz, JE; Lancet, JE; List, AF; Louie, AC; Mayer, LD; Ritchie, EK; Roboz, GJ; Swenson, C | 1 |
| Hedvat, CV; Park, JH; Tallman, MS | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Baer, MR; Bloomfield, CD; Caligiuri, MA; George, SL; Kolitz, JE; Larson, RA; Moore, JO; Mrózek, K; Powell, BL; Sanford, BL; Stone, RM | 1 |
| Baurmann, H; Braess, J; Buechner, T; Haferlach, C; Hahn, J; Haude, KH; Hiddemann, W; Holler, E; Kolb, HJ; Oruzio, D; Schleuning, M; Schlimok, G; Schmid, C; Schwerdtfeger, R; Spiekermann, K; Tischer, J | 1 |
| Buck, SA; Edwards, H; Ge, Y; Xie, C; Xu, X; Zhou, H | 1 |
| Akiyama, N; Ayabe, T; Kawasugi, K; Nishi, R; Oka, Y; Shirafuji, N; Shirasaki, R; Shirota, M; Taguchi, A; Tashiro, H; Umezawa, K | 1 |
| Du, QF; Huang, BT; Liu, XL; Luo, XJ; Wang, Y; Wei, YQ; Xu, LL; Xu, N; Yang, J; Yu, J; Zeng, QC; Zhang, JF | 1 |
| Abahssain, H; Chelghoum, Y; Dumontet, C; Elhamri, M; Gougounon, A; Michallet, M; Plesa, A; Rigollet, L; Thomas, X; Tigaud, I | 1 |
| Biemond, BJ; de Greef, GE; Ferrant, A; Gratwohl, A; Graux, C; Gregor, M; Löwenberg, B; Maertens, J; Ossenkoppele, GJ; Pabst, T; Schaafsma, MR; Schanz, U; Schouten, HC; Sonneveld, P; Theobald, M; van Putten, W; Vellenga, E; Verdonck, LF | 1 |
| Aiba, K; Dobashi, N; Ogasawara, Y; Saito, T; Sugiyama, K; Takahara, S; Takei, Y; Usui, N; Yahagi, Y; Yamaguchi, Y; Yano, S; Yokoyama, H | 1 |
| Huang, J; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, JJ; Qian, WB; Song, YP; Tong, HY; Tong, Y; Xu, WL | 1 |
| Jenkins, A; Kell, J; Lane, C; Patel, AK; Sheehan, W | 1 |
| Agrawal, AK; Golden, C; Guo, H | 1 |
| Shen, ZX | 1 |
| Juliusson, G | 1 |
| Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł | 1 |
| Baker, SD; Campana, D; Cao, X; Crews, KR; Downing, JR; Gandhi, V; Lamba, JK; Lamba, V; Plunkett, W; Pounds, SB; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE | 1 |
| Amri, A; Arguello, M; Borden, K; Cormack, G; Kraljacic, BC | 1 |
| Kwong, YL; Lee, HK; Leung, AY; Liu, HS; Sim, J; Tse, E; Yip, SF | 1 |
| Andrews, C; Baer, MR; Barcos, M; Baumann, H; Block, AW; Ford, LA; Nowak, NJ; Sait, SN; Tighe, S; Wang, ES; Wetzler, M | 1 |
| Alvaro, MG; Baraldi, A; Ciravegna, G; Corsetti, MT; De Paoli, L; Gatto, S; Levis, A; Perticone, S; Pietrasanta, D; Pini, M; Primon, V; Salvi, F; Tonso, A; Zallio, F | 1 |
| Bowen, D; Burnett, AK; Cahalin, P; Craig, J; Hills, RK; Hunter, A; Kell, J; McMullin, MF; Milligan, D; Russell, N; Wheatley, K; Yin, J | 1 |
| Ravindranath, Y; Taub, JW | 2 |
| Choi, Y; Jeon, M; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, YJ; Lee, YS; Seol, M; Sym, SJ; Yun, SC | 1 |
| Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S | 1 |
| Chen, J; Gu, L; Liu, Y; Pan, C; Tang, J; Xue, H | 1 |
| Baer, MR; Barcos, M; Block, AW; Ford, LA; Hyland, AJ; Licht, AS; Sait, SN; Varadarajan, R; Wang, ES; Wetzler, M | 1 |
| Bastida, J; Carretero, G; Medina, C; Santana, N; Valerón-Almazán, P; Vilar, J | 1 |
| Agarwal, N; Gupta, N; Kapoor, R; Kumar, S; Mahapatra, M; Mishra, P; Rathi, S; Saxena, R; Seth, T | 1 |
| Higa, T; Horikoshi, Y; Itoh, M; Iwai, A; Kanegane, H; Kogawa, K; Ogawa, A; Okada, M; Saiwakawa, Y; Shimomura, Y; Taga, T; Tsurusawa, M; Ueyama, J; Watanabe, A; Yamanaka, J | 1 |
| Kuendgen, A | 1 |
| Aulitzky, W; Bodenstein, H; Bornhäuser, M; Ehninger, G; Ho, A; Kaufmann, M; Krämer, A; Kramer, M; Mohr, B; Oelschlaegel, U; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Schmitz, N; Soucek, S; Stuhlmann, R; Thiede, C; Tischler, J; Wandt, H | 1 |
| Appelbaum, FR; Medeiros, BC; Othus, M | 1 |
| Mathisen, MS | 1 |
| Kami, M; Mori, J; Tsubokura, M | 1 |
| Appelbaum, FR; Becker, P; Estey, E; Hendrie, P; Knoebel, RW; McQuary, A; Petersdorf, S | 1 |
| Carew, JS; Choy, G; Espitia, CM; Giles, FJ; Kelly, KR; Nawrocki, ST; Padmanabhan, S; Taverna, P | 1 |
| Boissel, N; Bourhis, JH; Castaigne, S; Chelghoum, Y; de Botton, S; de Revel, T; Dombret, H; Elhamri, M; Fenaux, P; Gardin, C; Hicheri, Y; Michallet, M; Pautas, C; Preudhomme, C; Quesnel, B; Raffoux, E; Reman, O; Renneville, A; Terré, C; Thomas, X | 1 |
| Advani, A; Copelan, E; Ebrahem, Q; Gu, X; Hu, Z; Kalaycio, M; Link, KA; Maciejewski, J; Mahfouz, RZ; Mulloy, JC; Negrotto, S; Ng, KP; Radivoyevitch, T; Saunthararajah, Y; Sekeres, M; Sobecks, R | 1 |
| Burchert, A; Neubauer, A; Wilhelm, C | 1 |
| Campana, D; Cao, X; Crews, KR; Dolan, ME; Downing, J; Feldberg, T; Gandhi, V; Ghodke, Y; Hartford, C; Lamba, JK; Mitra, AK; Plunkett, W; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, JE | 1 |
| Bautista, F; Del Mar Andres, M; Fernandez-Navarro, JM; Moreno, L; Tasso, M; Verdeguer, A | 1 |
| Brunet, S; Bueno, J; Duarte, R; Esteve, J; Guardia, R; Llorente, A; Martínez-Cuadrón, D; Montesinos, P; Ribera, JM; Sánchez-Ortega, I; Sanz, MA; Sierra, AJ; Tormo, M; Torres, JP; Valcárcel, D | 1 |
| Arellano, M; Bhalla, K; Heffner, LT; Hutcherson, D; Khoury, HJ; Langston, A; Lima, L; McLemore, M; Neely, J; Pan, L; Tighiouart, M; Winton, E | 1 |
| Baer, MR; Ball, ED; Borthakur, G; Cortes, J; Dipersio, J; Fernandez, HF; Goodman, M; Kantarjian, H; Kolitz, JE; Wetzler, M | 1 |
| Bozoglan, H; Ergene, U; Yoleri, L | 1 |
| Burnett, AK; Hills, RK | 1 |
| Dym, H; Movahed, R | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Battiwalla, M; Ford, LA; Hahn, TE; McCarthy, PL; Tan, W; Wallace, PK; Wang, ES; Wetzler, M; Wilding, GE; Zeidan, A | 1 |
| Solis, EC | 1 |
| Bakhshi, S; Singhal, M | 1 |
| Hsiao, PF; Lin, J; Wu, YH | 1 |
| Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO | 1 |
| Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA | 1 |
| Katayama, Y; Murayama, SY; Myoken, Y; Sugata, T | 1 |
| Berdel, WE; Brunnberg, U; Büchner, T; Dührsen, U; Dürk, HA; Ehninger, G; Kessler, T; Kosch, M; Koschmieder, S; Krug, U; Mesters, RM; Mohr, M; Müller-Tidow, C; Noppeney, R; Sauerland, MC; Schulz, C; Serve, H | 1 |
| Cannas, G; Chelghoum, Y; Ducastelle, S; Dumontet, C; Elhamri, M; Labussière, H; Michallet, M; Nicolini, F; Thomas, X; Tigaud, I | 1 |
| Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Carillio, G; Kropp, M; Levato, L; Molica, S; Piro, E | 1 |
| Bradstock, KF; Muirhead, J; Paul, E; Seymour, JF; van der Jagt, A; Wei, A | 1 |
| Chang, C; He, Q; Li, X; Pu, Q; Su, J; Wu, L; Zhang, X | 1 |
| Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Harrington, E; Hendrie, PC; Kantarjian, HM; Pagel, JM; Petersdorf, SH; Pierce, S; Shan, J; Shustov, AR; Stirewalt, DL; Storer, B | 1 |
| Bauer, M; Bullinger, L; Döhner, H; Döhner, K; Holzmann, K; Kestler, HA; Lang, KM; Lück, SC; Rücker, FG; Russ, AC; Sander, S; Schlenk, RF | 1 |
| Beutel, G; Buchholz, S; Dammann, E; Eder, M; Ganser, A; Krauter, J; Stadler, M; Trummer, A | 1 |
| De Graaf, SS; Gibson, BE; Harrison, CJ; Howman, AJ; Webb, DK; Wheatley, K | 1 |
| Bowles, KM; Heasman, SA; Macewan, DJ; Rushworth, SA; Zaitseva, L | 1 |
| Baer, MR; Barcos, M; Block, AW; Ford, LA; Hyland, AJ; Lee, HJ; Licht, AS; Sait, SN; Wang, ES; Wetzler, M | 1 |
| Aquino, S; Ballerini, F; Beltrami, G; Bergamaschi, M; Cagnetta, A; Carella, AM; Clavio, M; Colombo, N; Ghiggi, C; Ghiso, A; Gobbi, M; Grasso, R; Lucchetti, MV; Miglino, M; Mitscheunig, L; Pica, G; Pierri, I; Sessarego, M; Vignolo, L | 1 |
| Bourquin, JP; Corbacioglu, S; Creutzig, U; Dworzak, MN; Reinhardt, D; Sander, A; Schrauder, A; Stary, J; Teigler-Schlegel, A; von Neuhoff, C; Zimmermann, M | 1 |
| Bain, BJ; Innes, A; May, PC; Pavlů, J | 1 |
| Fleckman, P; George, E; Yeh, I | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, MN; Kremens, B; Lehrnbecher, T; Reinhardt, D; Sander, A; Schmid, I; Starý, J; Steinbach, D; von Neuhoff, C; von Stackelberg, A; Vormoor, J; Zimmermann, M | 1 |
| Cho, B; Im, SA; Park, GS; Yun, DY | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Andreeff, M; Brandt, M; Cortes, J; Faderl, S; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Luthra, R; Patel, K; Pierce, S; Ravandi, F; Wang, X | 1 |
| Braunagel, D; Dransfeld, CL; Ehninger, G; Kramer, M; Mahlknecht, U; Schaich, M | 1 |
| Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM | 1 |
| Burke, AC; Giles, FJ | 1 |
| Fang, LW; Hu, NB; Pan, LJ; Qin, TJ; Wang, JZ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Fang, B; Li, Y; Liu, Y; Song, Y; Zhou, J | 1 |
| Berthon, C; Castaigne, S; Chantepie, S; Chevret, S; Dombret, H; Farhat, H; Gardin, C; Kammoun, L; Pautas, C; Raffoux, E; Reman, O; Rousselot, P | 1 |
| Cai, Z; Chiao, JW; Huang, H; Liu, D; Ni, W; Wei, G | 1 |
| Eyre, T; Grech, H; King, AJ; Rangarajan, D; Sampson, R | 1 |
| Fan, HM; Gill, D; Keane, C; Lane, S; McMillan, NA; Mollee, P; Murphy, R; Saunders, N; Spurr, T | 1 |
| Fondaw, MB; Khaled, YA; Reddy, VS; Shroff, SK; Ward, DE | 1 |
| Estey, E | 2 |
| Feldman, EJ | 1 |
| Abdelhamid, E; Berthon, C; Castaigne, S; Gardin, C; Gruson, B; Helevaut, N; Nibourel, O; Preudhomme, C; Renneville, A; Rousselot, P; Soua, Z | 1 |
| Portell, CA; Rogers, HJ; Sekeres, MA; Tiu, RV | 1 |
| Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D | 1 |
| Altman, J; Carlson-Leuer, K; Coyle, K; Frankfurt, O; Mehta, J; Newman, D; Rademaker, AW; Tallman, MS; Trifilio, SM | 1 |
| Bornhäuser, M; Ehninger, G; Hasford, J; Kramer, M; Pfirrmann, M; Röllig, C; Schaich, M; Thiede, C | 1 |
| Bender, B; Friberg, LE; Honoré, PH; Jensen, MK; Krogh-Madsen, M; Nielsen, OJ | 1 |
| Giles, F; Jacobsen, TF; O'Brien, S; Ravandi, F; Rizzieri, D; Swords, R | 1 |
| Borthakur, G; Cortes, J; Eghtedar, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Avilia, S; Battipaglia, G; Camera, A; Caranci, F; Morelli, E; Perna, F | 1 |
| Burnett, AK | 1 |
| Amoh, Y; Katsuoka, K; Mukai, H; Niiyama, S; Watarai, A | 1 |
| Albert, DH; Carlson, DM; Dudley, M; Enschede, S; Glaser, K; Hogge, D; Koh, LP; Li, X; McKeegan, E; Pradhan, R; Stock, W; Wang, ES; Yee, K | 1 |
| Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X | 1 |
| Fukushima, T; Haba, T; Morinaga, K; Nakao, S; Origasa, H; Sugiyama, T; Ueda, M; Ueda, T; Umehara, H; Urasaki, Y; Yamaguchi, M | 1 |
| Baturin, D; DeGregori, J; Fosmire, S; Gao, D; Gearheart, CM; Kim, J; Patel, PR; Porter, CC; Tan, AC; van Linden, A; Zaberezhnyy, V | 1 |
| Levis, M | 1 |
| Abbas, S; Abraham, A; Ahmed, R; Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A; Varatharajan, S; Zhang, W | 1 |
| Chiba, S; Enami, T; Hasegawa, Y; Nanmoku, T; Obara, N; Okoshi, Y; Suzukawa, K; Yokoyama, Y | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
| Qiu, HY; Sun, AN; Wang, WJ | 1 |
| Barnard, MR; Chang, H; Chuang, WY; Sun, CF | 1 |
| Kaspers, GJ | 1 |
| Arai, H; Handa, T; Iso, H; Maki, K; Mitani, K; Nakamura, Y; Sasaki, K; Tadokoro, J; Takahashi, W; Tokita, K; Tsurumi, S | 1 |
| Bruserud, O; Fredly, H; Gjertsen, BT; Reikvam, H | 1 |
| Barisone, E; Berger, M; Fagioli, F; Galletto, C; Manicone, R; Masetti, R; Pession, A; Quarello, P; Rivetti, E | 1 |
| Bargetzi, M; Biemond, B; Graux, C; Jacky, E; Legdeur, MC; Löwenberg, B; Maertens, J; Ossenkoppele, GJ; Pabst, T; Passweg, J; Schouten, HC; Sonneveld, P; Theobald, M; van Putten, W; Vekemans, MC; Vellenga, E; Verdonck, L | 1 |
| Cheong, JW; Kim, JS; Kim, SJ; Kim, Y; Min, YH; Yoon, S | 1 |
| Carew, JS; Ecsedy, J; Espitia, CM; Giles, FJ; Kelly, KR; Nawrocki, ST; Padmanabhan, S; Yang, JJ; Zhang, M | 1 |
| Buck, SA; Edwards, H; Ge, Y; Lograsso, SB; Matherly, LH; Taub, JW; Xie, C | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Kawabata, H; Kawanami, T; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Okazaki, T; Sakai, T; Satoh, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Garcia-Manero, G; Sampath, D | 1 |
| Berkowitz, J; Bernard, L; Hogge, DE; Kim, HP; Nitta, J | 1 |
| Anesi, GL; Attar, EC; Fathi, AT; Levine, D | 1 |
| Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Creutzig, U; Klusmann, JH; Kolenova, A; Neuhoff, C; Pekrun, A; Reinhardt, D; Reinhardt, K; Rössig, C; Sander, A; Sauerbrey, A; von Stackelberg, A | 1 |
| Huang, TS; Lin, HW; Shih, SR; Yao, M | 1 |
| Letendre, L; Tefferi, A | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Aliberti, S; Demurtas, A; Stacchini, A | 1 |
| Afrose, S; Ara, T; Islam, MS; Khan, MA; Rahman, MH | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Freireich, EJ; Garcia-Manero, G; Kadia, TM; Kantarjian, H; Kornblau, S; Luthra, R; Pierce, S; Ravandi, F | 1 |
| Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N | 1 |
| Arnoulet, C; Autret, A; Blaise, D; Charbonnier, A; D'incan, E; Etienne, A; Fürst, S; Jean, E; Prébet, T; Rey, J; Vey, N | 1 |
| Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E | 1 |
| Avigan, D; Collins, R; Craig, M; Faderl, S; Ganguly, S; Goldberg, S; Greiner, J; Hari, P; Huebner, D; Jagasia, M; Kantarjian, HM; Kovacsovics, T; Maris, M; Ravandi, F; Recher, C; Rizzieri, D; Schiller, G; Seiter, K; Stuart, R; Vasconcelles, M; Vey, N; Wang, ES; Wetzler, M | 1 |
| Forsch, S; Janssens, U; Niedeggen, A; Staib, P | 1 |
| Hwang, SY; Kim, HJ; Kim, TS; Kim, YK; Kweon, SH; Lee, TH; Min, WS; Song, JH | 1 |
| Barriga, FM; Besa, P; Broekhuizen, R; Cautivo, K; DiPersio, JF; Gidi, V; Holt, M; Kalergis, AM; Leisewitz, A; Leisewitz, F; Macanas-Pirard, P; Montecinos, VP; Nervi, B; Ocqueteau, M; Ramirez, P; Rettig, M; Riquelme, E; Swett, P | 1 |
| Bhatia, M; Brown, ED; Collins, TJ; Fiebig-Comyn, A; Fischer-Russell, D; Foley, R; Giacomelli, AO; Graham, M; Hassell, JA; Laronde, S; Leber, B; Lee, JB; Lee, JH; Levadoux-Martin, M; Malig, M; McNicol, JD; Risueño, RM; Russell, J; Sachlos, E; Shapovalova, Z; Trus, MR; Xenocostas, A | 1 |
| Burnett, AK; Cavanagh, J; Culligan, D; Hills, RK; Kell, J; Milligan, D; Russell, NH; Virchis, A; Wheatley, K | 1 |
| Bartolesi, AM; Fanci, R; Pecile, P; Pini, G | 1 |
| Ahn, KS; Kim, IW; Kim, KI; Kim, TK; Oh, JM; Shin, WG; Yoon, SS | 1 |
| Bowman, WP; Campana, D; Cao, X; Dahl, G; Inaba, H; Jenkins, L; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Taub, JW | 1 |
| Arthur, C; Buckstein, R; Cermak, J; Chou, WC; Delaunay, J; Dmoszynska, A; Faderl, S; Gau, JP; Kantarjian, HM; Kuo, CY; Lysák, D; Mayer, J; Mazur, G; Minden, M; Oriol, A; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Bergeland, T; Berry, DA; Dennis, M; Giles, FJ; Jacobsen, TF; Krug, UO; O'Brien, S; Ravandi, F; Rizzieri, DA; Sekeres, MA; Staudacher, K; Venditti, A; Vey, N | 1 |
| Goozner, M | 1 |
| Appelbaum, FR; Geraghty, DE; Godwin, JE; Ho, PA; Kutny, M; Meshinchi, S; Ostronoff, F; Othus, M; Petersdorf, SH; Radich, JP; Stirewalt, DL; Willman, CL | 1 |
| Alibhai, SM; Brandwein, JM; Breunis, H; Buckstein, R; Gupta, V; Li, M; Minden, MD; Mohamedali, H; Timilshina, N; Tomlinson, G | 1 |
| Colovic, M; Floros, KV; Gourgiotis, D; Pavlovic, S; Scorilas, A; Thomadaki, H; Tosic, N | 1 |
| Cao, XS; Wang, B; Yang, B | 1 |
| Carraway, HE; Dorcy, KS; Doyle, LA; Drye, DM; Estey, EH; Garrett-Mayer, E; Gladstone, DE; Gore, SD; Greer, JM; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Othus, M; Pagel, JM; Pratz, KW; Rudek, MA; Showel, MM; Smith, BD; Wright, JJ | 1 |
| Imada, K; Kitagawa, T; Mori, M; Onaka, T; Sasaki, Y; Yamamoto, K; Yonezawa, A | 1 |
| Avery, S; Coutsouvelis, J; Lee, D; Low, M; Opat, S; Patil, S; Salem, H; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| Rashidi, A; Roullet, MR | 1 |
| Bozkurt, C; Dogru, M; Kocaoglu, AC; Ozmen, S | 1 |
| Tang, W; Wang, L; Zhao, BB | 1 |
| Ritchie, EK | 1 |
| Grove, LE; Jurcic, JG; Lancet, JE; Sandalic, L; Sekeres, MA; Sievers, EL; Wood, BL | 1 |
| Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B | 1 |
| Alonzo, TA; Aplenc, R; Gamis, AS; Gerbing, RB; Sung, L | 1 |
| Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C | 1 |
| Creutzig, U; Reinhardt, D; Sander, A; Von Neuhoff, C | 1 |
| Ganesan, P; Majhi, U; Rajendranath, R; Sagar, TG; Udupa, K | 1 |
| Burnett, AK; Craddock, CF; Dufva, IH; Freeman, S; Hills, RK; Hunter, AE; Kell, J; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Hunnisett-Dritz, D | 1 |
| Flatten, KS; Hess, AD; Karnitz, LM; Karp, JE; Kaufmann, SH; Koh, BD; Parry, D; Peterson, KL; Schenk, EL; Smith, BD | 1 |
| Chen, BA; Cheng, L; Ding, JH; Feng, JF; Li, YF; Lu, ZH; Qian, J; Schultz, M; Wang, XM; Xia, GH; Xu, K; Xu, PP | 1 |
| Bo, L; Chen, F; Fang, Y; Fu, J; Li, Y; Liang, A; Lu, H; Zhang, H; Zhu, D | 1 |
| Hwang, YY; Kwong, YL; Trendell-Smith, NJ; Yeung, CK | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Goto, T; Ishibashi, M; Okamura, S; Tanimoto, K | 1 |
| Hwang, YY; Kwong, YL; Leung, RY; Tsui, P | 1 |
| Pardee, TS | 1 |
| Emadi, A; Karp, JE | 1 |
| Esfahani, A; Ghorbanihaghjo, A; Ghoreishi, Z; Nikanfar, A; Sanaat, Z | 1 |
| Guo, M; Hu, KX; Qiao, JH; Sun, QY; Wang, YR; Yu, CL | 1 |
| Gotoh, M; Ito, Y; Mihara, M; Miyawaki, S; Naoe, T; Ohnishi, K; Ohtake, S; Ohyashiki, K; Takada, S; Wakita, A | 1 |
| Ahn, KS; Huh, IS; Kim, IW; Kim, KI; Oh, JM; Park, T; Yoon, JH; Yoon, SS | 1 |
| Bowen, D; Burnett, AK; Dignum, H; Hills, RK; Hunter, AE; Kell, WJ; McMullin, MF; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Berdel, WE; Büchner, T; Döhner, H; Döhner, K; Ehninger, G; Ganser, A; Hasford, J; Hehlmann, R; Heil, G; Heinecke, A; Hiddemann, W; Hoelzer, D; Hoffmann, VS; Krahl, R; Kramer, M; Krauter, J; Krug, U; Niederwieser, DW; Pfirrmann, M; Sauerland, MC; Schaich, M; Schlenk, RF; Scholl, S; Späth, D | 1 |
| Chen, L; Wei, XD; Yin, QS | 1 |
| Aoshima, T; Fujimaki, K; Fujisawa, S; Fujita, H; Hagihara, M; Hattori, Y; Inoue, Y; Machida, S; Miyazaki, K; Nakajima, Y; Numata, A; Onizuka, M; Sakai, R; Shirasugi, Y; Tanaka, E; Tanaka, M; Watanabe, S; Yamazaki, E | 1 |
| Appelbaum, FR; Burnett, AK; Estey, EH; Kantarjian, HM; Larson, RA; Lo-Coco, F; Ravandi, F; Schiffer, CA | 1 |
| Aviv, F; Gibstein, L; Kirsner, I; Naparstek, E; Rahamim, E; Rozovski, U; Sarid, N; Tavor, S | 1 |
| Anchukova, LV; Bondarenko, SN; Gavrilova, LV; Ialykomov, IV; Kaplanov, KD; Kaporskaia, TS; Kliasova, GA; Kokhno, AV; Kondakova, EV; Konstantinova, TS; Kravchenko, SK; Kulikov, SM; Kuz'mina, LA; Lapin, VA; Moskov, VI; Parovichnikova, EN; Pristupa, AS; Ryzhko, VV; Samoĭlova, OS; Savchenko, VG; Shaforostova, II; Sokolov, AN; Troitskaia, VV; Volodicheva, EM; Zagoskina, TP | 1 |
| Ahn, HK; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, KH; Kim, SH; Kim, YK; Lee, KO; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, CH; Park, J; Sohn, SK | 1 |
| Chen, X; Guo, H; Li, G; Li, J; Li, L; Ren, F; Tan, Y; Wang, H | 1 |
| Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W | 1 |
| Cunha, BA; Desai, A; Staszewski, H | 1 |
| Ando, S; Hashino, S; Higashiyama, A; Imamura, M; Kahata, K; Okada, K; Onozawa, M; Takahata, M; Tanaka, J | 1 |
| Krema, H; Pavlin, CJ; Santiago, RA; Schuh, A | 1 |
| Cheong, JW; Hong, DS; Joo, YD; Kim, BK; Kim, CS; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Koh, Y; Lee, HK; Lee, JH; Lee, KH; Lee, SM; Min, YH; Park, E; Park, MR; Park, S; Park, SK; Sohn, SK; Won, JH; Yoon, SS | 1 |
| Colovic, N; Djunic, I; Djurasinovic, V; Jankovic, G; Palibrk, V; Suvajdzic, N; Tomin, D; Vidovic, A; Virijevic, M | 1 |
| Carraway, HE; Flatten, KS; Freshwater, T; Gladstone, DE; Gore, SD; Greer, JM; Horowitz, JA; Isaacs, R; Karp, JE; Kaufmann, SH; Levis, MJ; Loechner, S; Mackey, K; McDevitt, MA; Parry, DA; Peterson, K; Pratz, KW; Schneider, P; Showel, MM; Smith, BD; Sorge, C; Thomas, BM | 1 |
| Alachkar, H; Becker, H; Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Dorrance, AM; Eiring, AM; Fehniger, TA; Garzon, R; Hickey, CJ; Lee, LJ; Maharry, K; Marcucci, G; Mishra, A; Mrózek, K; Nicolet, D; Perrotti, D; Radomska, HS; Santhanam, R; Schwind, S; Vij, R; Walker, A; Whitman, SP; Wu, LC; Wu, YZ; Zhao, X | 1 |
| Bleeker, N; Das, SG; Hermanson, DL; Kelekar, A; Li, Y; Lowman, X; Xing, C | 1 |
| Brierley, CK; DeAngelo, DJ; Morgan, EA; Odejide, OO; Sprague, JR; Steensma, DP | 1 |
| Barton, B; Bednarik, J; Cerny, J; Evens, AM; Fortier, N; Hao, S; Hutchinson, L; Kroll-Desrosiers, A; Nath, R; O'Rourke, E; Raffel, GD; Ramanathan, M; Rosmarin, AG; Shanahan, L; Walsh, WV; Woda, B; Yu, H | 1 |
| Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES | 1 |
| Ferrara, F; Musto, P | 1 |
| Bertz, H; Finke, J; Lübbert, M; Müller, MJ | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Angelucci, E; Biagiotti, C; Borin, L; Bosi, A; Caracciolo, F; Cutini, I; Fanci, R; Gianfaldoni, G; Longo, G; Mannelli, F; Pogliani, EM; Romani, C; Scappini, B; Simonetti, F; Susini, MC | 1 |
| Lichtman, MA | 1 |
| Garcia-Manero, G | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Bradley, AM; Buie, LW; Deal, AM; van Deventer, H | 1 |
| Abrahamsson, J; Forestier, E; Gustafsson, B; Ha, SY; Hasle, H; Heilmann, C; Heldrup, J; Jahnukainen, K; Jónsson, ÓG; Lausen, B; Palle, J; Wareham, NE; Zeller, B | 1 |
| Armstrong, SA; Bullinger, L; Delwel, R; Döhner, K; Feng, Z; Figueroa, ME; Krivtsov, AV; Kung, AL; Melnick, AM; Sinha, AU; Stubbs, MC; Valk, PJ | 1 |
| Bruserud, Ø; Gjertsen, BT; McCormack, E; Mujić, M; Osdal, T | 1 |
| Blatt, K; Bradner, JE; Cerny-Reiterer, S; Gleixner, KV; Herrmann, H; Horny, HP; Müllauer, L; Shi, J; Sperr, WR; Vakoc, CR; Valent, P; Zuber, J | 1 |
| Chen, F; Fan, Z; Feng, R; Guo, X; Huang, F; Liu, X; Meng, F; Shi, P; Xu, B; Zha, J | 1 |
| Bradstock, K; Burnett, AK; Hills, RK; Ling, V; Seymour, JF; Wei, A | 1 |
| Handrup, MM; Hasle, H; Johannsen, KH; Lausen, B; Schrøder, H | 1 |
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Löwenberg, B | 1 |
| Chen, H; Liu, J; Liu, L; Liu, M; Shi, B; Ye, L; Yu, L; Zhang, Y | 1 |
| Berdel, WE; Brandts, CH; Büchner, T; Bug, G; Dührsen, U; Ehninger, G; Gerss, J; Koschmieder, A; Koschmieder, S; Krug, U; Müller-Tidow, C; Noppeney, R; Röllig, C; Schaich, M; Schwammbach, D; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Tidow, N | 1 |
| Flaig, M; Grahovac, M; Maximiliane Ehmann, L; Reibke, R; Wollenberg, A | 1 |
| Aleinikova, O; Armendariz, H; Bertrand, Y; Creutzig, U; Dworzak, M; Gibson, BE; Ha, SY; Hasle, H; Hovi, L; Kaspers, GJ; Leverger, GG; Maschan, A; Razzouk, BI; Reinhardt, D; Rizzari, C; Smisek, P; Smith, O; Stark, B; Tamminga, RY; Zimmermann, M | 1 |
| Negoro, E; Nishi, R; Takemura, H; Ueda, T; Yamauchi, T | 1 |
| Béné, MC; Berthon, C; Blanchet, O; Boissel, N; Bulabois, CE; Cayuela, JM; Chevret, S; Cornillet, P; Delabesse, E; Delaunay, J; Dombret, H; Guardiola, P; Ifrah, N; Jourdan, E; Lioure, B; Luquet, I; Pautas, C; Pigneux, A; Preudhomme, C; Raffoux, E; Recher, C; Renneville, A; Terré, C; Thomas, X; Vey, N | 1 |
| Béné, MC; Bories, P; Bouscary, D; Cahn, JY; Chapuis, N; Chevallier, P; Delepine, R; Demur, C; Dreyfus, F; Ifrah, N; Lacombe, C; Lamy, T; Leguay, T; Mayeux, P; Merlat, A; Park, S; Prebet, T; Recher, C; Saint Marcoux, F; Tamburini, J; Vey, N; Witz, F | 1 |
| Chou, FS; Mizukawa, B; Mulloy, JC; Saunthararajah, Y; Sexton, C; Shrestha, M; Wunderlich, M | 1 |
| Burnett, AK; Knapper, S; Lazenby, M; Pepper, CJ; Walsby, EJ | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Hassanein, M; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Attal, M; Bérard, E; Bertoli, S; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Duchayne, E; Huguet, F; Huynh, A; Laurent, G; Lauwers-Cances, V; Mansat-De Mas, V; Récher, C; Sarry, A; Tavitian, S; Vergez, F | 1 |
| Chen, L; Mi, R; Wei, X; Yin, Q | 1 |
| Kambhampati, SP; Kannan, RM; Lesniak, WG; Mishra, MK; Sk, UH; Zhang, F | 1 |
| Freeman, C; Giles, FJ; Keane, N; Swords, R | 1 |
| Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D | 1 |
| Alexander, HD; Humphreys, MW; Kettle, PJ; McGrattan, P | 1 |
| Fenske, N; Morgan, MB; Sakalosky, PE | 1 |
| Anastasi, J; Baer, MR; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Kolitz, JE; Larson, RA; Minderman, H; O'Loughlin, KL; Powell, BL; Schiffer, CA | 1 |
| Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ | 1 |
| Hoagland, HC; Hogan, WJ; Kaufmann, SH; Letendre, L; Litzow, MR; Pruthi, RK; Tefferi, A | 1 |
| Arceci, RJ; Loeb, DM | 2 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Björeman, M; Björkholm, M; Gahrton, G; Grimfors, G; Gruber, A; Hast, R; Killander, A; Lerner, R; Liliemark, J; Mattson, S; Oberg, G; Paul, C; Simonsson, B; Stalfelt, AM; Stenke, L; Tidefelt, U; Udén, AM | 1 |
| Ikeda, Y; Matsuzaki, M; Sakemi, T; Sano, M | 1 |
| Archer, KJ; Bloomfield, CD; Carroll, AJ; Farag, SS; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Stone, RM; Vardiman, JW | 1 |
| Wood, RA | 1 |
| Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X | 1 |
| Amess, JA; Bradburn, M; Carter, M; Dalley, CD; Lillington, DL; Lister, TA; Rohatiner, AZ | 1 |
| Castel, V; Dini, G; Fagioli, F; Ferrant, A; Frassoni, F; Labopin, M; Locatelli, F; Meloni, G; Messina, C; Ortega, J; Pession, A; Shaw, PJ; Sociè, G; Yaniv, I | 1 |
| Cetkovská, P; Cetkovský, P; Pizinger, K | 1 |
| Bruyere, H; Copland, M; Hogge, DE; Horsman, DE; Lavoie, JC; Le, A; Nantel, SH; Nevill, TJ; Seftel, MD; Shepherd, JD; Sutherland, HJ; Toze, CL | 1 |
| Arai, H; Arai, Y; Gunji, H; Handa, T; Maki, K; Mitani, K; Nakamura, F; Nakamura, Y; Saito, K; Tadokoro, J | 1 |
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Douglas, RS; Goldstein, SM; Nichols, C | 1 |
| Alvarado, Y; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A | 1 |
| Bolaños-Meade, J; Buddharaju, LN; Chen, TT; Guo, C; Karp, JE; Rapoport, AP; Sarkodee-Adoo, CB; Tidwell, ML | 1 |
| Dansako, H; Fujii, N; Fujita, S; Kaneda, K; Kojima, K; Shinagawa, K; Tanimoto, M; Yano, T; Yasukawa, M; Yoshida, C | 1 |
| Adil, SN; Burney, IA; Kakepoto, GN; Khurshid, M; Zaki, S | 1 |
| Li, Y; Liang, Y; Qin, H; Yang, Y; Zeng, L | 1 |
| Isaev, VG; Savchenko, VG; Sokolov, AN | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D | 1 |
| Disis, ML; Ginsburg, AS; Salazar, LG; True, LD | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Auvrignon, A; Bastard, C; Blaise, D; Castaigne, S; Dastugue, N; Delaunay, J; Dombret, H; Fenaux, P; Fière, D; Harousseau, JL; Lamy, T; Leblanc, T; Leverger, G; Mugneret, F; Pigneux, A; Reiffers, J; Rigal-Huguet, F; Van den Akker, J; Vey, N; Witz, F | 1 |
| Marinakis, T; Papaioannou, M; Sakellari, I; Skandali, A; Stavroyianni, N; Tiniakou, M; Tsimberidou, AM; Viniou, N; Yataganas, X | 1 |
| Go, RS; Johnston, KL | 1 |
| Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T | 1 |
| Bernard, M; Berthou, C; Campos, L; de Crémoux, P; Delain, M; Drenou, B; Falkenrodt, A; Fernandes, J; Garnache, F; Guilhot, F; Harousseau, JL; Hunault-Berger, M; Kara-Slimane, F; Lioure, B; Moreau, P; Mounier, C; Mugneret, F; Solary, E; Witz, B | 1 |
| Buquicchio, C; Carluccio, P; Greco, G; Liso, A; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G | 1 |
| Chen, J; Gu, L; Pan, C; Tang, J; Xue, H; Zhao, H | 1 |
| Beyan, C; Cetin, T; Kaptan, K; Nevruz, O | 1 |
| Crum, NF; Fehl, FC; Graham, BS; Higginbottom, PA | 1 |
| Chen, Y; He, M; Li, H; Wu, Y; Xiang, Z; Yu, D; Yue, B | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Inatomi, Y; Miyashita, T; Miyauchi, J; Shen, L; Toyama, K; U, M; Wu, Z | 1 |
| Apostolidou, E; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Tsimberidou, A | 1 |
| Kumagawa, M; Nagano, M; Suzuki, K; Suzumiya, J; Takamatsu, Y; Tamura, K | 1 |
| Adams, MT; Alonzo, TA; Arceci, RJ; Buckley, J; Buxton, AB; Dusenbery, K; Gamis, A; Masterson, M; Vik, T; Warkentin, P; Wells, RJ; Whitlock, JA | 1 |
| Akiyama, T; Fujimi, A; Hirayama, Y; Kato, J; Kawano, Y; Kobune, M; Kohda, K; Kuroda, H; Matsunaga, T; Miyake, K; Niitsu, Y; Sakamaki, S; Sato, T; Takemoto, N; Takimoto, R; Tanaka, I | 1 |
| Chelghoum, Y; Elhamri, M; Le, QH; Michallet, M; Revesz, D; Thomas, X | 1 |
| Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Jedrzejczak, W; Kowal, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Maj, S; Robak, T; Skotnicki, A; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Boogaerts, M; Daenen, S; de Greef, G; Ferrant, A; Fey, M; Gmür, J; Gratwohl, A; Huijgens, P; Kovacsovics, T; Löwenberg, B; Schouten, H; Sonneveld, P; Theobald, M; van Putten, W; Verdonck, L | 1 |
| Chiba, H; Hirayama, Y; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
| Debatin, KM; Eckhoff, S; Meyer, LH; Mohr, A; Stahnke, K | 1 |
| Benchekroun, S; Harif, M; Qachouh, M; Quessar, A | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Udvardy, M | 1 |
| Furuta, GT; Glickman, J; Köhler, H; Nurko, S | 1 |
| Ogawa, M | 1 |
| Fuchigami, K; Fukushima, T; Hata, T; Honda, M; Jinnai, I; Kuriyama, K; Miyazaki, Y; Togami, K; Tomonaga, M; Yamasaki, J | 1 |
| Akin, U; Haluk, K; Hamdi, A; Ismet, A; Meral, B; Osman, I | 1 |
| Aul, C; Berdel, WE; Büchner, T; Fonatsch, C; Frickhofen, N; Gruneisen, A; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Lengfelder, E; Löffler, H; Ludwig, WD; Maschmeyer, G; Mesters, RM; Sauerland, MC; Schoch, C; Serve, HL; Staib, P; Wörmann, B | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Ronconi, S; Rondoni, M; Visani, G | 1 |
| Blijlevens, N; de Pauw, B; Donnelly, P; Levenga, H; Shirango, H; Verweij, P | 1 |
| Fujii, S; Kikuchi, T; Miyata, A | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Araki, H; Hoshino, N; Katayama, N; Lorenzo V, F; Miyashita, H; Nishii, K; Ohishi, K; Sakakura, M; Shiku, H; Sugimoto, Y; Usui, E | 1 |
| Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E | 1 |
| Almqvist, A; Anttila, P; Elonen, E; Jantunen, E; Koistinen, P; Koivunen, E; Koponen, A; Mikkola, M; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Pulli, T; Remes, K; Ruutu, T; Sarkkinen, R; Silvennoinen, R; Timonen, T; Vanhatalo, S | 1 |
| Takeshita, A | 1 |
| Baran, W; Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jagoda, K; Jakubas, B; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Konopka, L; Kuliczkowski, K; Kyrcz-Krzemien, S; Marianska, B; Paluszewska, M; Pluta, A; Robak, T; Skotnicki, A; Stella-Holowiecka, B; Sulek, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Abrahams, A; Eggener, SE; Keeler, TC | 1 |
| Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G | 1 |
| Cunningham, MT; Davis, MK; Imkie, M; Persons, DL | 1 |
| Akercan, F; Cagirgan, S; Donmez, A; Mgoyi, L; Ozkinay, E; Vural, F; Yucebilgin, MS | 1 |
| Biesma, DH; Daenen, SM; Delforge, M; Graveland, WJ; Löwenberg, B; Muus, P; Noordhuis, P; Ossenkoppele, GJ; Peters, GJ; Schaafsma, MR; Selleslag, D; Sonneveld, P; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH | 1 |
| Grandage, VL; Jakupovic, I; Khwaja, A; Linch, DC | 1 |
| Masquelier, M; Vitols, S | 1 |
| Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM | 1 |
| Bolaños-Meade, J; Gojo, I; Guo, C; Karp, JE | 1 |
| Berthaud, P; Cahn, JY; Chevalier, MP; Guibon, O; Guilhot, F; Harousseau, JL; Lioure, B; Loos, C; Witz, B; Witz, F | 1 |
| Bloomfield, CD; Byrd, JC; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Ruppert, AS; Stamberg, J; Sterling, LJ; Vardiman, JW | 1 |
| Berdel, WE; Büchner, T; Hiddemann, W | 1 |
| Appelbaum, FR; Banker, DE; Li, HY; Mayer, SJ; Willman, CL; Zager, RA | 1 |
| Chen, H; Gocke, CD; Gojo, I; Greer, J; Guo, C; Karp, JE; Morris, L; Pili, R; Qian, D; Tidwell, M; Zwiebel, J | 1 |
| d'Adamo, F; Delfini, C; Guiducci, B; Leopardi, G; Mele, A; Nicolini, G; Piccaluga, P; Sparaventi, G; Visani, G | 1 |
| Fonatsch, C; Geissler, K; Jäger, U; Knöbl, P; Lechner, K; Piribauer, M; Schwarzinger, I; Sperr, WR; Thalhammer-Scherrer, R; Valent, P; Wimazal, F | 1 |
| Baumann, MA; Bernstein, JM; Kumar, G; Waibel, JS | 1 |
| Altundag, K; Babaoglu, MO; Bozkurt, A; Elkiran, T; Karadag, O; Saikawa, Y; Yasar, U | 1 |
| Kamijo, A; Kyuma, Y; Maruta, A; Nishimura, S | 1 |
| Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M | 1 |
| Bargay, J; Berlanga, J; Brunet, S; Bueno, J; Esteve, J; Granena, A; Guardia, R; Juliá, A; Martí, JM; Montserrat, E; Ribera, JM; Sierra, J | 1 |
| Abe, S; Funato, T; Harigae, H; Sasaki, T | 1 |
| Jordan, CT | 1 |
| Canpinar, H; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekuzman, G | 1 |
| Camps, A; de la Rubia, J; Jarque, I; Jiménez, C; Lorente, P; Lorenzo, I; Martín, G; Martínez, J; Moscardó, F; Sanz, G; Sanz, MA | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Abdalla, SH; Bain, BJ; Foot, N; Wrench, D | 1 |
| Creutzig, U; Dworzak, M; Lehrnbecher, T; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Amirkhosravi, A; Eifrig, B; Fiedler, W; Francis, JL; Hossfeld, DK; Langer, F; Loges, S; Meyer, T | 1 |
| Jain, S; Kumari, S; Lal, V; Mahi, S; Malhotra, P; Varma, S | 1 |
| Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M | 1 |
| Kiyoi, H; Kohno, S; Miyazaki, M; Nabeshima, T; Noda, Y; Senzaki, K | 1 |
| Cooper, T; Gandhi, V; Kantarjian, H; Plunkett, W | 1 |
| Maruyama, Y; Satoh, Y; Takahashi, T; Tsujisaki, M; Yoshimoto, M | 1 |
| Alymara, V; Bourantas, KL; Chaidos, A; Tsiara, S; Tzouvara, E; Vartholomatos, G | 1 |
| Bennett, JM; Cassileth, PA; Dewald, GW; Lazarus, HM; Lee, SJ; Litzow, MR; Miller, KB; Paietta, E; Rowe, JM; Stadtmauer, EA; Tallman, MS | 1 |
| Dumontet, C; Fernandez-Calotti, P; Galmarini, CM; Giordano, M; Jordheim, LP | 1 |
| Bradstock, KF; Di Iulio, J; Grigg, AP; Hui, C; Juneja, SK; Kimber, R; McQuillan, A; Reynolds, J; Smith, C | 1 |
| Chaoui, D; Legrand, O; Marie, JP; Peffault De Latour, R | 1 |
| Balaian, L; Ball, ED | 1 |
| Andreeff, M; Brandwein, J; Carter, BZ; Chun, K; Gronda, M; Houghten, RA; Mawji, IA; Messner, H; Minden, MD; Nefzi, A; Ostresh, J; Pinilla, C; Pond, GR; Reed, JC; Schimmer, AD; Schober, WD; Schuh, AC; Wang, Z; Wells, RA; Welsh, K | 1 |
| Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G | 1 |
| Arlander, SJ; Dai, NT; Erlichman, C; Eyck, CJ; Flatten, K; Heldebrant, MP; Karnitz, LM; Karp, JE; Kaufmann, SH; Loegering, D; Mesa, RA; Powell, HL; Smith, BD; Vroman, BT | 1 |
| Attal, M; Bauduer, F; Blaise, D; Bordessoule, D; Cailleres, S; Dastugue, N; Fegueux, N; Gastaut, JA; Jourdan, E; Legros, L; Marit, G; Molina, L; Pigneux, A; Rigal-Huguet, F; Vey, N; Zerazhi, H | 1 |
| Borkhardt, A; Bruch, J; Fuchs, U; Metzler, M; Perez, AV; Wilda, M; Woessmann, W | 1 |
| Karp, JE; Smith, BD | 3 |
| Böhm, A; Fonatsch, C; Geissler, K; Gisslinger, H; Jäger, U; Knöbl, P; Kyrle, PA; Lechner, K; Piribauer, M; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Albitar, M; Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Kornblau, S; Mattiuzzi, GN; O'Brien, SM; Thomas, D; Tsimberidou, AM; Verstovsek, S; Wierda, W | 1 |
| Ehninger, G; Fredersdorf, A; Illmer, T; Neubauer, A; Schaich, M; Stadler, S; Thiede, C | 1 |
| Creutzig, U; Diekamp, S; Dworzak, M; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Kawauchi, K; Ogasawara, T; Yasuyama, M | 1 |
| Chan, GW; Miller, KB; Winer, ES | 1 |
| Koistinen, P; Savolainen, ER; Siitonen, T | 1 |
| Schinköthe, T; Staib, P; Strunk, T; Tiehen, J | 1 |
| Califano, C; D'Arco, AM; Danise, P; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B | 1 |
| Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N | 1 |
| Da, WM; Li, HH; Wang, QS; Wang, SH; Wu, XX; Zhao, Y; Zhu, HY | 1 |
| Bueso-Ramos, C; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Shan, J; Verstovsek, S | 1 |
| Burnett, AK; Crump, M; Dugan, M; Ferrant, A; Fey, MF; Knauf, WU; Löwenberg, B; Ossenkoppele, GJ; Piccaluga, PP; Selleslag, D; Shepherd, J; Sonneveld, P; Theobald, M; van der Holt, B; Vellenga, E; Verhoef, GE | 1 |
| Anagnostopoulos, A; Fassas, A | 1 |
| Kara, B; Kara, IO; Paydas, S; Sahin, B | 1 |
| Agoliati, G; Ahmed, T; Arshad, M; Galvin-Parton, P; Liu, D; Qureshi, A; Seiter, K | 1 |
| Armaganidis, A; Kopterides, P; Lignos, M; Mentzelopoulos, S; Pappa, V | 1 |
| DU, X; Huang, ZL; Li, QH; Lin, W; Luo, CW; Zhong, LY | 1 |
| Chi, HS; Choi, SJ; Jang, S; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Ryu, SG; Seol, M | 1 |
| Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
| Jacobs, P; Wood, L | 1 |
| Dick, JE; Khoury, H; Meng, YS; Minden, MD | 1 |
| Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Tischer, J | 1 |
| Hassan, HT; Lu, C | 1 |
| Lamm, RD; McCarthy, PM; Sade, RM | 1 |
| Extermann, M; Luong, D; Naing, A | 1 |
| Alpay, R; Disel, U; Paydas, S; Tuncer, I; Yavuz, S | 1 |
| Barbier, M; Bignon, J; Boutonnat, J; Colle, PE; Faussat, AM; Marie, JP; Ronot, X; Thierry, J; Wdzieczak-Bakala, J | 1 |
| Ahn, BM; Baek, JH; Jeon, SB; Kim, DH; Kim, JG; Lee, KB; Moon, JH; Sohn, SK; Sung, WJ | 1 |
| Albertioni, F; Löfgren, C; Paul, C | 1 |
| Broekhuizen, AJ; Creutzig, U; Gibson, BE; Hubeek, I; Kaspers, GJ; Peters, GJ; Sargent, J | 1 |
| Frei-Lahr, DA; Hall, PD; Niedermeier, DM | 1 |
| Ao, ZF; Chen, BA; Gao, F; Shen, HL; Xia, W; Xu, WL; Zhang, YN | 1 |
| Aul, C; Balleisen, L; Berdel, WE; Büchner, T; Eimermacher, H; Grüneisen, A; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Kienast, J; Lengfelder, E; Mesters, RM; Rasche, H; Reichle, A; Sauerland, MC; Schnittger, S; Schoch, C; Schumacher, A; Serve, HL; Staib, P; Wörmann, B | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Schmidt-Wolf, IG; Schwerdtfeger, R | 1 |
| Asou, N; Emi, N; Honda, S; Kishimoto, Y; Matsuda, S; Matsushima, T; Mitani, K; Miyawaki, S; Miyazaki, Y; Ogawa, Y; Ohno, R; Ohtake, S; Sakamaki, H; Takahashi, M; Yagasaki, F | 1 |
| Armitage, ES; Balasis, M; Bali, P; Bhalla, K; Boyapalle, S; Fiskus, W; Greedy, B; Guo, F; Kumaraswamy, S; Lawrence, N; Pranpat, M; Rocha, K | 1 |
| Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Alakavuklar, M; Firat, D; Kansu, E; Kars, A; Koc, Y; Tekuzman, G | 1 |
| Bonaccorso, R; Citarrella, P; Ciulla, A; Di Marco, P; Di Salvo, V; Gebbia, V; Mansueto, S; Tambone Reyes, M; Tinnirello, D | 1 |
| Abboud, CN; Bechelli, J; Lancet, JE; Liesveld, JL; Lu, C; Phillips, G; Rosell, KE | 1 |
| Bauer, KS; Bible, K; Briel, J; Colevas, AD; Garimella, TS; Gojo, I; Gore, SD; Greer, J; Karp, JE; Kaufmann, S; Passaniti, A; Ross, DD; Smith, BD; Tidwell, ML; Wright, JJ | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Donelli, A; Ferrari, A; Giacobbi, F; Imovilli, A; Luppi, M; Morselli, M; Narni, F; Potenza, L; Riva, G; Temperani, P; Torelli, G | 1 |
| Alimena, G; Bongarzoni, V; Borza, PA; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Latagliata, R; Mandelli, F; Mecarocci, S; Mengarelli, A; Morano, SG; Petti, MC | 1 |
| Ahmed, T; Arshad, M; Baskind, P; Feldman, E; Liu, D; Naseer, N; Qureshi, A; Seiter, K; Shi, Q; Walia, T | 1 |
| Gujral, S; Gupta, S; Kelkar, R; Maheshwari, A; Parikh, P; Tongaonkar, H | 1 |
| Mashita, T; Mitsuda, M; Shimoda, T; Takahashi, Y; Yoshioka, H | 1 |
| Caballero, D; Mateos, JJ; Perez, E; San Miguel, JF; Sanz-Rodriguez, C; Vazquez, L | 1 |
| Burnett, AK; Craig, JI; Littlewood, T; Milligan, DW; Wheatley, K | 1 |
| Choudhry, VP; Dixit, A; Kannan, M; Mahapatra, M; Saxena, R | 1 |
| Asano, S; Fukuno, K; Iseki, T; Konuma, T; Ooi, J; Takahashi, S; Tojo, A; Tomonari, A; Tsukada, N; Uchiyama, M | 1 |
| Auvrignon, A; Baruchel, A; Brethon, B; Cayuela, JM; Lapillonne, H; Leverger, G | 1 |
| Collisson, E; Emmanouilides, C; Lashkari, A; Lowe, T; Paquette, R; Schiller, G; Territo, M | 1 |
| Asano, S; Iseki, T; Konuma, T; Nakaoka, T; Ooi, J; Takahashi, S; Takasugi, K; Tojo, A; Tomonari, A; Tsukada, N; Uchiyama, M | 1 |
| Bruserud, Ø; Ersvaer, E; Gjertsen, BT; Kalland, KH; Ryningen, A; Vintermyr, OK; Øyan, AM | 1 |
| Bian, SG; Liu, SH; Meng, QX; Mi, YC; Wang, JX; Xue, YP; Yu, WJ; Zhao, YZ | 1 |
| Abou-Jawde, RM; Advani, A; Kalaycio, M; Pohlman, B; Rybicki, L; Sekeres, M; Sobecks, R | 1 |
| Belch, A; Gluck, S; Larratt, L; Robinson, KS; Sheridan, D; Shustik, C; Stewart, K; Van Der Jagt, R; Wells, G; Yetisir, E | 1 |
| Aisa, Y; Arai, M; Enoki, S; Ikeda, Y; Mori, T; Nakazato, T; Okamoto, S; Yamazaki, R | 1 |
| Gu, C; Wells, RA; Ye, T | 1 |
| Estey, EH; Kern, W | 1 |
| Belevtsev, MV; Buglova, SE; Shman, TV | 1 |
| Chen, ZM; Huang, J; Jiang, DZ; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Tong, HY; Tong, Y; Wang, L; Xu, WL | 1 |
| Matsuda, K; Matsui, K; Shinohara, K; Tanaka, Y; Yamashita, K | 1 |
| Czyzewski, K; Styczynski, J; Wysocki, M | 1 |
| Hatoum, HA; Hudaib, AR; Mahfouz, RA; Otrock, ZK; Shamseddine, AI; Taher, AT | 1 |
| Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Mun, YC; Seong, CM; Shin, HJ; Yang, DH | 1 |
| Martin, PL; McLean, TW; White, MS | 1 |
| Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I | 1 |
| Higashihara, M; Kimura, H; Miyata, A; Mori, M; Ohta, M; Oshimi, K; Sunami, K; Yagasaki, F | 1 |
| Asai, O; Dobashi, N; Kobayashi, T; Osawa, H; Saito, T; Takei, Y; Usui, N; Yamaguchi, Y; Yamazaki, H; Yano, S | 1 |
| Meehan, SA; Polsky, D; Scharf, S; Srivastava, M | 1 |
| Lane, SW; Marlton, P; Mollee, PN | 1 |
| Appelbaum, FR; Banker, DE; Beran, M; Chen, W; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Jackson, CE; Kornblau, SM; Lemker, E; Shen, D; Stirewalt, D; Verstovsek, S | 1 |
| Bouscary, D; Dômont, J; Goldwasser, F; Martinez, V; Mir, O | 1 |
| Ifrah, N; Leboucher, B; Pellier, I; Rachieru, P; Rialland, X | 1 |
| Chen, J; Chen, SJ; Chen, Z; Gao, L; Gu, LJ; Kang, H; Liu, P; Shen, ZX; Wang, L; Wang, ZY; Weng, XQ; Xie, J; Yan, M; Zhang, DE; Zhang, FX; Zhou, GB | 1 |
| Du, X; Ke, XY; Liu, Y; Lu, ZS; Lv, JQ; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM | 1 |
| Hasz, DE; Largaespada, DA; Le Beau, MM; Rathe, SK; Tsai, ML; Yin, B | 1 |
| Iwasaki, H; Kawai, Y; Kishi, S; Takemura, H; Ueda, T; Urasaki, Y; Yamamoto, S; Yamauchi, T; Yoshida, A | 1 |
| Bortul, R; Evangelisti, C; Grafone, T; Martelli, AM; Martinelli, G; McCubrey, JA; Papa, V; Tabellini, G; Tazzari, PL | 1 |
| Alfaro, EM; Alonso, CN; Baro, C; Corral, Mdel P; Felice, MS; Gallego, MS; Rossi, J; Solé, F; Villa, O | 1 |
| Bleyer, A | 1 |
| Braess, J; Fiegl, M; Hiddemann, W | 1 |
| Hara, T; Kanemura, N; Kasahara, S; Moriwaki, H; Oyama, M; Sawada, M; Tsurumi, H; Yamada, T | 1 |
| Grigoriyan, A; Homer, R; Manthous, CA; Molina, J; Rishi, A | 1 |
| Ishizawa, K | 1 |
| Fujisawa, S; Kobayashi, M; Matsuoka, T; Naito, K | 1 |
| Ishitani, K; Kida, M; Koike, K; Kuroda, H; Matsunaga, T; Neda, H; Niitsu, Y; Nobuoka, A; Sakamaki, S; Terui, T; Watanabe, H | 1 |
| Baxter, H; Di Iulio, J; Juneja, S; Leahy, M; Manoharan, A; Matthews, J; Reynolds, J | 1 |
| Altintas, A; Cil, T; Isikdogan, A; Kaplan, MA; Pasa, S | 1 |
| Lange, BJ; Reilly, AF | 1 |
| Capelli, D; Discepoli, G; Leoni, P; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Troiani, E | 1 |
| Aribi, A; Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Kebriaei, P; O'Brien, S; Pierce, S; Ravandi, F; Thomas, D | 1 |
| Boveri, E; Castagnola, C; Castello, A; Magrini, U | 1 |
| Breda, L; Chiarelli, F; De Sanctis, S; Di Marzio, D; La Barba, G; Rollo, V | 1 |
| Chatterjee, T; Choudhry, DR; Choudhry, VP; Dixit, A; Kannan, M; Mahapatra, M; Mishra, P; Saxena, R | 1 |
| Ammirante, M; Arra, C; Bisogni, R; d' Avenia, M; Lamberti, A; Petrella, A; Romano, MF; Rosati, A; Spugnini, E; Turco, MC; Venuta, S | 1 |
| Biondi, A; Campbell, M; De Lorenzo, P; De Rossi, G; Felice, M; Ferster, A; Hann, I; Hovi, L; Janka, G; LeBlanc, T; Li, CK; Mann, G; Pieters, R; Rubnitz, J; Schrappe, M; Silverman, L; Stary, J; Suppiah, R; Szczepanski, T; Valsecchi, MG; Vora, A | 1 |
| Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ | 1 |
| Berdel, WE; Brunnberg, U; Büchner, T; Kessler, T; Krug, U; Mesters, RM; Mohr, B; Mohr, M; Müller-Tidow, C; Sauerland, C; Schliemann, C; Serve, H | 1 |
| Bolam, S; Deben, G; Fernández-Abellán, P; Giménez, E; Palomera, L; Parker, A; Pascual, T; Piñana, JL; Ribera, JM; Sánchez-García, E; Sancho, JM | 1 |
| Appelbaum, FR; Balcerzak, SP; Dakhil, SR; Head, DR; Karnad, AB; Petersdorf, SH; Rankin, C; Terebelo, HR; Willman, CL | 1 |
| Alghzaly, AA; Alkindi, S; Muralitharan, S; Pathare, AV; Raeburn, JA; Udayakumar, AM | 1 |
| Caracciolo, F; Focosi, D; Galimberti, S; Papineschi, F; Petrini, M | 1 |
| Avcu, F; Baran, Y; Gündüz, U; Gür, B; Kaya, P; Ural, AU | 1 |
| Hao, Y; Li, R; Xiao, Z; Xue, H; Yu, M; Zhang, L | 1 |
| Cao, XM; Chen, YX; He, AL; Liu, J; Liu, SH; Ma, XR; Wang, FX; Wang, JL; Zhang, WG; Zhao, WH | 1 |
| Caira, M; Fianchi, L; Gianfaldoni, G; Leone, G; Leoni, F; Pagano, L; Rutella, S; Scardocci, A; Storti, S; Valentini, CG; Voso, MT | 1 |
| Moshaver, B; Ossenkoppele, GJ; Schuurhuis, GJ; van der Pol, MA; Westra, AH; Zweegman, S | 1 |
| Haferlach, C; Haferlach, T; Schnittger, S; Weisser, M | 1 |
| Abruzzo, LV; Bobadilla, D; Cortes, J; Gibbons, DL; Kantarjian, H; Quintás-Cardama, A; Slovak, ML | 1 |
| Adachi, T; Hayakawa, F; Iwasaki, T; Kurahashi, S; Narimatsu, H; Sawamoto, A; Sugimoto, T; Sugiura, I; Suzuki, H | 1 |
| Fukai, F; Kodama, H; Matsunaga, T; Miura, S; Nagaya, T; Nakane, Y; Niitsu, Y; Owaki, T; Takayama, T; Takimoto, R; Tanaka, M | 1 |
| Dastugue, N; Huguet, F; Ifrah, N; Jourdan, E; Perreau, V; Pigneux, A; Reiffers, J; Salmi, LR; Sotto, JJ; Vey, N | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
| Dölken, G; Flieger, D; Glasmacher, A; Hahn-Ast, C; Kirchner, H; von Lilienfeld-Toal, M | 1 |
| Ahmed, P; Akhtar, F; Akhtar, FM; Chaudhry, QU; Kamal, MK; Khan, B; Raza, S; Satti, TM; Ullah, K | 1 |
| Grosicki, S; Hołowiecki, J; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Seferynska, I; Skotnicki, AB; Warzocha, K; Zdziarska, B | 1 |
| Büchner, T; Creutzig, U; Döhner, H; Reinhardt, D; Sauerland, MC; Schlenk, RF; Zimmermann, M | 1 |
| Cebula, B; Giebel, S; Grosicki, S; Hołowiecki, J; Kiełbiński, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Kłoczko, J; Piatkowska-Jakubas, B; Pluta, A; Robak, T; Skotnicki, AB; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A; Zawilska, K | 1 |
| Li, F; Li, HH; Wang, QS; Wang, SH; Yu, L; Zhao, Y | 1 |
| Cheng, YQ; DU, LJ; Fu, R; Gao, S; Guan, J; Jiang, HJ; Li, LJ; Liang, Y; Liu, CY; Liu, H; Liu, WH; Qu, W; Ruan, EB; Shao, ZH; Song, J; Song, WX; Song, Y; Wang, GJ; Wang, J; Wang, XM; Zhang, LT; Zhang, RL; Zou, P | 1 |
| Contra, T; Fernández-Plaza, S; González-Vicent, M; Lassaletta, A; Madero, L; Sevilla, J | 1 |
| Arana-Yi, C; Baer, MR; Barcos, M; Block, AW; Ford, LA; Sait, SN | 1 |
| Chi, HS; Choi, SJ; Im, HJ; Jang, S; Jun, KR; Lee, JH; Lee, KH; Moon, HN; Park, CJ; Seo, JJ | 1 |
| Delaney, SM; Dolan, ME; Gajria, D; Karrison, TG; Larson, RA; Odenike, OM; Ratain, MJ; Stock, W | 1 |
| Gibson, B; Rubnitz, JE; Smith, FO | 1 |
| Fujisawa, S; Fujita, A; Hyo, R; Ishigatsubo, Y; Kuwabara, H; Tomita, N; Yamazaki, E | 1 |
| Jooss, K; Li, B; Lin, JM; Rimmer, E; VanRoey, M | 1 |
| Bian, S; Liu, S; Meng, Q; Mi, Y; Wang, J; Xue, Y; Yu, W; Zhao, Y | 1 |
| Chi, HS; Cho, YU; Lee, JH; Lee, SG; Park, CJ; Seo, EJ | 1 |
| Asai, T; Chiba, S; Hangaishi, A; Kurokawa, M; Suzuki, HI; Tamaki, Z | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D | 1 |
| Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
| Gale, RE; Khwaja, A; Kottaridis, PD; Linch, DC; Matsuda, S; Mead, AJ | 1 |
| Hwang, SY; Kim, HJ; Kim, SH; Kim, TS; Song, JH | 1 |
| Bouyer, C; Doyen, J; Italiano, A; Peyrade, F; Thyss, A | 1 |
| Al Shaer, L; Burnett, A; Gilkes, A; Mills, K; Rowntree, C; Tonks, A; Walsby, E; Walsh, V | 1 |
| Borthakur, G; Estey, E; Garcia-Manero, G; Kantarjian, H; Ravandi, F; Yanada, M | 1 |
| Chen, FP; Chen, YJ; Li, XL; Shu, YG; Wu, DS; Zhang, LQ; Zhao, XL | 1 |
| Branquet, D; Clapson, P; Harket, A; Saint-Blancard, P; Soler, C | 1 |
| Arruga, F; Bracco, E; Carturan, S; Catalano, R; Cilloni, D; Defilippi, I; Iacobucci, I; Martinelli, G; Messa, E; Messa, F; Morotti, A; Nicoli, P; Panuzzo, C; Pautasso, M; Rosso, V; Saglio, G | 1 |
| Chu, SJ; Hsu, WH; Tsai, WC; Tsao, YT | 1 |
| Araújo, AG; dos Santos, GA; Falcão, RP; Garcia, AB; Jácomo, RH; Lima, AS; Lucena-Araujo, AR; Panepucci, RA; Rego, EM; Santana-Lemos, BA | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Kurahashi, S; Narimatsu, H; Sugimoto, T; Sugiura, I; Yamamoto, F | 1 |
| Angelucci, E; Dessalvi, P; Murru, R; Pettinau, M; Romani, C | 1 |
| Aisner, J; Collazo, C; Dutta, J; Gharibo, M; Gounder, M; Lin, Y; Nazar, A; Rubin, EH; Saleem, A; Saraiya, B; Schaar, D; Shih, W; Strair, RK; Zimmerman, L | 1 |
| Atra, AA; Baothman, A; Elimam, NA; Kassar, A; Khattab, TM; Zayed, A | 1 |
| Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y | 1 |
| Asou, N; Hata, H; Horikawa, K; Hoshino, K; Matsuno, F; Mitsuya, H; Miyake, H; Nosaka, K; Takatsu, N; Tatetsu, H | 1 |
| Kell, J | 1 |
| Kale, VP; Sharma, MB; Vaidya, AA | 1 |
| Aisa, Y; Hibi, T; Ikeda, Y; Kato, J; Kubo, A; Mori, T; Okamoto, S; Shigematsu, N; Shimizu, T; Watanabe, R; Yajima, T; Yamazaki, R | 1 |
| Aoki, FY; Bow, EJ; Sitar, DS | 1 |
| Comijn, EM; Hubeek, I; Kaspers, GJ; Merriman, RL; Padron, JM; Peters, GJ; Van der Wilt, CL | 1 |
| Hong, M; Li, JY; Lu, H; Lu, SF; Shen, WY; Wang, LX; Yang, H; Zhang, JF | 1 |
| Virgolini, L | 1 |
| Bhalla, K; Grant, S; Nayak, R | 1 |
| Berchtold, W; Cavalli, F; Fopp, M; Gratwohl, A; Imbach, P; Maurice, P; Sauter, C; Tschopp, L; von Fliedner, V | 1 |
| Bielawiec, M; Kłoczko, J; Zuch, A | 1 |
| Ihle, R; Stobbe, H | 1 |
| Anger, G; Fink, R; Herold, M; Höche, D | 1 |
| Arlin, Z; Burchenal, JH; Clarkson, B; Comacho, E; Dowling, M; Drapkin, RL; Dufour, P; Gee, TS; Kempin, S; McKenzie, S; Mertelsmann, R; Oettgen, HF; Passe, S; Thaler, HT; To, L | 1 |
| Flemans, RJ; Hayhoe, FG; Li, YS; Matthews, JG; Rees, JK; Swirsky, DM | 1 |
| Duraj, M; Holowiecka, B; Holowiecki, J; Japa, J; Jarczok, K; Krawczyk, M; Rudzka, E | 1 |
| Boccia, R; Champlin, R; Elashoff, R; Foon, K; Gale, RP; Jacobs, A; Zighelboim, J | 1 |
| Go, B; Gordon, DS; Meyer, L; Raney, MR; Vogler, WR; Winton, EF | 1 |
| Curtis, JE; McCulloch, EA; Motoji, T; Smith, LJ | 1 |
| Attadia, V; Cimino, R; Maio, M; Pinto, A; Zappacosta, S | 1 |
| Obrecht, JP | 1 |
| Duraj, M; Hołowiecka, B; Hołowiecki, J; Jarczok, K; Kniewska, I; Krawczyk, M; Kuśnierczyk, J; Opala, G; Rudzka, E; Stańczuk, M | 1 |
| Baehner, R; Chard, R; Hammond, D; Higgins, G; Movassaghi, N; Pyesmany, A; Sather, H | 1 |
| Flynn, TC; Harrist, TJ; Loss, RW; Moschella, SL; Murphy, GF | 1 |
| Arimori, S; Nagao, T | 1 |
| Benjamin, RS; Bodey, GP; Brown, NS; Carter, CJ; Freireich, EJ; Hester, J; Ho, DH; McCredie, K | 1 |
| Lindner, HJ; Linker, H; Schaefer, HE | 1 |
| Grianti, C; Izzi, T; Moretti, L; Muretto, P | 1 |
| Yamada, K | 1 |
| Hagenbeek, A; Löwenberg, B; Sizoo, W | 1 |
| Fibbe, WE; Willemze, R; Zwaan, FE | 2 |
| Burke, PJ; Karp, JE; Vaughan, WP | 4 |
| Curtis, JE; Elhakim, TM; Hasselback, R; McCulloch, EA; Messner, HA | 1 |
| Cuttner, J; Holland, JF; Paciucci, PA | 2 |
| Batten, E; Eridani, S; Sawyer, B | 1 |
| Lefante, J; Stein, RS; Vogler, WR | 1 |
| Akao, Y; Hiraiwa, A; Naito, K; Naoe, T; Tahara, T; Yamaguchi, H; Yoshikawa, H; Yoshikawa, S | 1 |
| Hehlmann, R; Thiel, E; Walther, B; Zönnchen, B | 1 |
| Growe, GH; Mangal, AK | 1 |
| Aubuchon, JP; Levine, RL; Salinsky, MC; Schutta, HS | 1 |
| Hansen, RM; Heuer, DK; Ritch, PS | 1 |
| Rohrig, KE | 1 |
| Ambinder, E; Button, G; Cuttner, J; Holland, JF; Meyer, RJ; Norton, L | 1 |
| Brodin, B; Liedén, G; Malm, C; Vikrot, O | 1 |
| Hess, CE; Stewart, FM | 1 |
| Chen, SC; Chu, JY; Demello, D; Gale, GB; O'Connor, DM | 1 |
| Johnston, A; Lister, TA; Piall, EM; Slevin, ML; Turner, P; Woollard, RC | 1 |
| Frauer, HM; Link, H; Waller, HD; Wilms, K | 1 |
| Himori, T; Ohnuma, T; Wakui, A | 2 |
| Kobayashi, M; Tahara, T | 1 |
| Camitta, BM; Coral, FS; Gelber, RD; Mayer, RJ; Rosenthal, DS; Weinstein, HJ | 1 |
| Evans, WE; Sinkule, JA | 1 |
| Biron, GL; Clément, S; Gosselin, BY; Lapointe, Y; Laurin, S; Maheu, M | 1 |
| Ishigami, S; Kubota, Y; Masaoka, T; Nakamura, H; Shibata, H; Takubo, T; Tanaka, T; Ueda, T; Yoshitake, J | 2 |
| Cooper, B; Kitchens, LW; Murray, C | 1 |
| Aguirre, J; Avilés, A; Cervera, J; Pizzuto, J; Ramos, E | 1 |
| Andrey, C; Beris, P; Chapuis, B; de Loes, S; Maurice, P; Plancherel, C | 1 |
| Bhalla, K; Cadman, E; Grant, S; Rauscher, F | 1 |
| Baccarani, M; Bandini, G; Cavazzini, G; Fanin, R; Tura, S; Zaccaria, A | 1 |
| Lihou, MG; Smith, PJ | 2 |
| Emi, N; Kawashima, K; Ohoshima, K; Satake, T; Sugihara, T; Takeyama, H; Yano, K | 1 |
| Marie, JP; Mathieu, M; Thevenin, D; Viguie, F; Zittoun, R | 1 |
| Killmann, SA; Nielsen, HR | 1 |
| Gerecke, D; Hirschmann, WD; Kress, M | 1 |
| Manoharan, A | 3 |
| Bell, AJ; Hamblin, TJ; Mufti, GJ; Oscier, DG | 1 |
| Kalliomäki, JL; Korvenranta, H; Meurman, L; Nikoskelainen, J; Rajamäki, A; Söderström, KO; Toivanen, A | 1 |
| Kochupillai, V; Raina, V | 1 |
| Greenberg, PL; Mackintosh, FR; Schrier, SL; Schwartz, RS | 1 |
| Kato, Y; Kawashima, K; Ohno, R; Yamada, K | 1 |
| Aherne, GW; Harvey, VJ; Johnston, A; Lister, TA; Piall, EM; Slevin, ML | 1 |
| Ishikura, H; Izumi, Y; Mochizuki, T; Park, YH; Sawada, H; Uchino, H; Usui, T; Wano, M; Yamagishi, M | 1 |
| Fassas, A; Kartalis, G; Klearchou, N; Mantalenakis, S; Sinacos, Z; Tsatalas, K | 1 |
| Arita, N; Kajiwara, S; Kono, H; Ohmori, T; Tabei, R | 1 |
| Anger, B; Ganser, A; Heimpel, H; Hoelzer, D; Seifried, E | 1 |
| Hossfeld, DK; Weh, HJ; Zschaber, R | 1 |
| Kawamura, S; Maekawa, I; Miyake, T; Sasaki, H | 1 |
| Bernard, P; Boisseau, MR; Broustet, A; Dachary, D; Lacombe, F; Reiffers, J | 1 |
| Wiley, JS; Woodruff, RK | 1 |
| De Bock, R; Haanen, C; Jehn, U | 1 |
| Bloch, A; Craig, RW; Frankfurt, OS; Sakagami, H; Takeda, K | 1 |
| Barlogie, B; Freireich, EJ; Haq, M; Johnston, DA; Keating, MJ; Maddox, AM | 1 |
| Bentwich, Z; Berrebi, A; Frumkin, A; Green, L; Hurwitz, N; Levin, S; Shalev, Y | 1 |
| Boyd, A; Cheng, ZM; Leyden, M; Manoharan, A; Sullivan, J | 1 |
| Egan, EM; Kufe, D; Munroe, D; Spriggs, D | 1 |
| Ishige, K; Oguro, M; Takagi, T | 1 |
| Cantini, E; Yanes, B | 1 |
| Markham, M | 1 |
| Summerfield, GP | 1 |
| Gustavsson, A; Olofsson, T | 1 |
| Lavelle, CL; Morry, R | 1 |
| Kufe, DW; Luisi-DeLuca, C; Mitchell, T; Spriggs, D | 1 |
| Kato, Y; Kawashima, K; Kodera, Y; Morishima, Y; Nagura, E; Ogura, M; Ohno, R; Sugihara, T; Suzuki, H; Watanabe, E | 1 |
| Asano, Y; Hozumi, M; Suzuki, K; Tomoyasu, S; Tsuruoka, N; Yokoyama, S | 1 |
| Murase, T; Ogata, H; Oheda, Y; Okamoto, S; Toyama, K; Yoshida, T | 1 |
| Christensson, B; Engsted, L; Gyllenhammar, H; Lindström, P; Ost, A | 1 |
| Watts, WJ | 1 |
| Apperley, J; Boughton, BJ; Franklin, IM; Knight, D | 1 |
| Bauer, KA; Rosenberg, RD | 1 |
| Leclerc, JM; Momparler, RL | 1 |
| Dohy, H; Kamada, N; Kuramoto, A; Maehama, S; Mandai, K; Oguma, N; Tahara, E; Takimoto, Y; Tanaka, K | 1 |
| Brugués, R; Del Cañizo, MC; Ríos, A; Rozman, C | 1 |
| Barnett, M; Hamilton, C; Lister, A; Richards, M | 1 |
| Ambriz-Fernández, R; Avilés-Miranda, A; García-Vela, E; Monroy-Arellano, L; Pizzuto, J | 1 |
| Lotem, J; Michalewicz, R; Sachs, L | 1 |
| Leyden, MJ; Manoharan, A; Sullivan, J | 1 |
| McCulloch, EA | 1 |
| Beris, P; Chapuis, B | 1 |
| Miller, MA | 1 |
| Catovsky, D; Galton, DA; Goldman, JM; Islam, A | 1 |
| Lie, SO; Slördahl, SH | 1 |
| Ben-Ishay, Z; Borenstein, A; Prindull, G; Sharon, S | 2 |
| Colly, LP; Hagenbeek, A; van Bekkum, DW | 2 |
| Ahlbom, G; Jensen, MK; Leegaard, OF | 1 |
| Chen, PM; Chiang, BN; Chiou, TJ; Chiu, CF; Tzeng, CH | 1 |
| Dan, K; Gomi, S; Horikoshi, H; Kuwabara, T; Nomura, T; Ogata, K; Ohki, I | 1 |
| Andrey, C; Beris, P; Chapuis, B; Helg, C; Rieder, A | 1 |
| Kubota, Y; Masaoka, T; Nakamura, H; Oguma, S; Shibata, H; Takubo, T; Tani, Y; Ueda, T | 1 |
| Chen, JR; Lin, SF; Liu, HW | 1 |
| Alarcón Zurita, C; Alvarez Carmona, A; de la Vega Bueno, E; del Potro Gómez, E; Díaz Mediavilla, J; Guerra Moyano, JL; Krsnik Castelló, I; Llorente Pérez, L; Martínez Martínez, R; Rodríguez Vázquez, M | 1 |
| Epstein, J; Preisler, HD | 1 |
| Flexner, JM; Kayser, J; Stein, RS | 1 |
| Auclerc, G; Auclerc, MF; Caro, J; Daubrisson, A; Degos, L; Jacquillat, GI; Marty, M; Schaison, G; Weil, M | 1 |
| Baker, MA; Carter, WH; Taub, RN | 1 |
| Brecher, M; Browman, G; Early, AP; Higby, DJ; McBride, JA; Preisler, HD | 1 |
| Aderka, D; Berliner, S; Pinkhas, J; Santo, M; Shaklai, M; Shoenfeld, Y; Weinberger, A | 1 |
| Ambrosetti, A; Cetto, G; Chilosi, M; Perona, G; Pizzolo, G | 1 |
| Dandona, P; Freedman, DB; Hoffbrand, AV; Prentice, HG; Shannon, M | 1 |
| Amess, JA; Bell, R; Birkhead, BG; Dhaliwal, HS; Ford, JM; Henry, G; Lister, TA; Malpas, JS; Rohatiner, AZ; Slevin, ML | 1 |
| Barbui, T; Bassan, R; Battista, R; Capnist, G; Chisesi, T; Cortelazzo, S; D'Emilio, A; Dini, E; Rodeghiero, F; Viero, P | 1 |
| Griffin, J; Kufe, D; Major, P; Munroe, D | 1 |
| Caillou, B; D'Hubert, E; De Vassal, F; Dorval, T; Gaget, H; Goldschmidt, E; Hayat, M; Jasmin, C; Lemaigre, G; Machover, D; Mathé, G; Michalski, B; Misset, JL; Rappaport, H; Ribaud, P; Schwarzenberg, L; Tourani, JM | 1 |
| Barrat, H; Blum, F; Cloup, M; Colbert, N; Duhamel, G; Gorin, NC; Lasfargues, G; Najman, A; Treisser, A | 1 |
| Crum, ED; Forman, WB; Rassiga, AL; Schwartz, HJ | 1 |
| Bhaduri, S; Heimpel, H; Hoelzer, D; Krieger, D; Kubanek, B; Kurrle, E; Vanek, E | 1 |
| Geissler, M; Jain, NC; Weller, RE | 1 |
| Berthier, R; Hollard, D; Leger, J; Michallet, M; Sotto, JJ | 1 |
| Broustet, A; Raynal, F; Reiffers, J | 1 |
| Giannoulis, NE; Johansson, NO; Reizenstein, P | 1 |
| Berger, NA; Klahr, C; Phillips, GL; Presant, CA | 1 |
| Camitta, BM; Coral, FS; Frei, E; Mayer, RJ; Nathan, DG; Rosenthal, DS; Weinstein, HJ | 1 |
| Kuliszkiewicz-Janus, M | 1 |
| Flexner, JH; Graber, SE; Stein, RS | 1 |
| Tisman, G; Wu, SJ | 1 |
| Preisler, HD | 1 |
| Daly, PA; Schiffer, CA; Wiernik, PH | 1 |
| Clodfelter, K; Foon, KA; Gale, RP; Yale, C | 1 |
| Balcar-Boroń, A; Nowaczyk-Michalak, A; Pytel-Dabrowska, T | 1 |
| Daher, O; Flatau, E; Kohn, D; Zuckerman, F | 1 |
| Bunch, C; Potter, CG | 1 |
| Grahame-Smith, DG; Harris, AL | 2 |
| Ballard, JO; Dougherty, JB; Eyster, ME; Gevirtz, NR; Hamilton, RW; Patel, SB; Shaikh, BS | 1 |
| Apel, D; Maj, S; Pawelski, S; Sobczyńska, Z; Sylwestrowicz, T; Zdziechowska, H; Zywicka-Lopaciuk, H | 1 |
| Krykowski, E; Mazurowa, A; Olszańska-Skorek, T; Polkowska-Kulesza, E; Płuzańska, A; Robak, T | 1 |
| Blom, J; Taylor, G | 1 |
| Ascari, E; Cresci, R; Mazzini, G; Montecucco, CM; Riccardi, A | 1 |
| Bauters, F; Goudemand, M; Huart, JJ; Jouet, JP; Jude, B; Toussaint, B | 1 |
| De Vries, EG; De Vries-Hospers, HG; Haaxma-Reiche, H; Houwen, B; Mulder, NH | 1 |
| Chubb, S; Hug, V; Keating, MJ; Plunkett, W | 1 |
| Buick, RN | 1 |
| Barlogie, B; Chubb, S; Plunkett, W | 1 |
| Bloomfield, CD; Peterson, BA | 2 |
| Cline, MJ; Foon, KA; Gale, RP; Zighelboim, J | 1 |
| Buick, RN; Curtis, JE; McCulloch, EA; Messner, HA; Senn, JS | 1 |
| Bunch, C; Grahame-Smith, DG; Harris, AL; Potter, CG | 1 |
| Biernacka, I; Brzuchowska, W; Grazybek-Hryncewicz, K; Kotlarek-Haus, S; Kuliczkowski, K; Luczkiewicz-Mulczykowa, A | 1 |
| Harris, AL | 2 |
| Beardsley, GP; Egan, EM; Kufe, DW; Major, PP; Minden, MD | 1 |
| Foon, KA; Gale, RP; Yale, C; Zighelboim, J | 1 |
| Benjamin, RS; Bodey, GP; Freireich, EJ; Keating, MJ; McCredie, KB; Smith, TL; Zander, A | 1 |
| Bodey, GP; Freireich, EJ; Gehan, E; Gutterman, JU; Hersh, EM; Keating, MJ; McCredie, KB; Smith, TL | 1 |
| Cooperman, BS; Klinger, HP | 1 |
| Hess, CE; Joyce, RA | 1 |
| Kondrak, R; Wedrychowicz, A | 1 |
| Challis, DR; Lowenthal, RM; Menon, C | 1 |
| Hirano, M; Ino, T; Matsui, T; Morishita, Y; Nakamura, K; Ono, Y; Saito, M; Shigemura, H; Shimizu, S | 1 |
| Omura, GA | 2 |
| Kanter, PM; Preisler, HD; Schwartz, HS | 1 |
| Aherne, GW; Johnston, A; Lister, TA; Piall, EM; Slevin, ML; Sweatman, MC | 1 |
| Begg, CB; Bennett, JM | 1 |
| Buick, RN; Chang, LJ; Curtis, JE; McCulloch, EA; Messner, HA | 1 |
| Barlogie, B; Dosik, GM; Freireich, EJ; Johnston, D; Mellard, D | 1 |
| Bank, A; Blom, J; Bloomfield, CD; Brunner, K; Carey, RW; Cooper, MR; Ellison, RR; Falkson, G; Glidewell, OJ; Gottlieb, A; Haurani, F; Henry, P; Hoagland, HC; Holland, JF; Hutchison, JL; James, GW; Kaan, SK; Kung, F; McIntyre, OR; Nawabi, IW; Nissen, NI; Obrecht, JP; Prager, D; Preisler, HD; Rai, KR; Ramanan, SV; Silver, RT; Weinberg, V; Wiernik, P | 1 |
| Epstein, J; Preisler, H | 1 |
| Fülle, HH; Koeppen, KM; Rühl, H; Schwerdtfeger, R | 1 |
| Coral, FS; Frei, E; Mayer, RJ; Nathan, DG; Rosenthal, DS; Weinstein, HJ | 1 |
| Jarowski, CI; Saper, CB | 1 |
| Jones, SP; Paterson, AR; Sawyer, WH; Wiley, JS | 1 |
| Hamami, T; Haruyama, H; Ijichi, H; Isemura, T; Nakagawa, M; Nakajima, Y; Shimazaki, C; Ura, Y | 1 |
| Curtis, JE; Germanson, TP; McCulloch, EA; Messner, HA; Senn, JS | 1 |
| Early, AP; Preisler, HD; Rustum, YM; Slocum, H | 1 |
| Adachi, T; Hamasaki, K; Hara, M; Kimura, I; Kitajima, K; Kohi, F; Lai, M; Sanada, H; Takahashi, I; Takaoka, K; Tokioka, M; Uchida, K; Watanabe, S; Yorimitsu, S | 1 |
| Daniel, MT; Degos, L; Housset, M | 1 |
| Ekert, H; Matthews, RN; Paton, CM; Toogood, IR; Waters, KD | 1 |
| Bodey, GP; Estey, EH; Freireich, EJ; Keating, MJ; McCredie, KB | 1 |
| Berenberg, J; Cooper, MR; Cornell, C; Dosik, H; Ellison, RR; Falkson, G; Frelick, R; Glidewell, O; Gottlieb, A; Green, M; Haurani, F; Henderson, E; Henry, P; Hoagland, C; Holland, JF; Hutchison, JL; James, GW; Leone, L; Levy, R; Nissen, N; Raich, P; Silver, RT; Steinberg, D; Wiernik, P; Yates, J | 1 |
| Oishi, N; Uphouse, WJ | 1 |
| Colpin, G; Keuning, JJ; Willemze, R; Zwaan, FE | 2 |
| Krol, TC; O'Keefe, P | 1 |
| Cadman, E; Grant, S; Rauscher, F | 1 |
| Bodey, GP; Freireich, EJ; Gehan, EA; Keating, MJ; McCredie, KB; Smith, T | 2 |
| Hasegawa, K; Hida, K; Kano, Y; Kasahara, T; Okamura, J; Sakamoto, S; Sasaki, H; Takaku, F; Tsukada, T | 1 |
| Bezwoda, WR; de Souza, JJ; Jetham, D; Sonnendecker, EW | 1 |
| Beswick, W; Chesterman, CN; Firkin, FC; Garson, OM; Januszewicz, E; Keating, MJ; Penington, DG | 1 |
| Breitman, TR; Ferrero, D; Gallo, E; Ruscetti, FW; Tarella, C | 1 |
| Bodey, GP; Freireich, EJ; Gehan, E; Keating, MJ; McCredie, KB; Smith, TL | 1 |
| Cozzi, E; Dakhil, S; Doan, K; Ensminger, W; Gyves, J; Liepman, M; Niederhuber, J; Wheeler, R | 1 |
| Kinsella, IA; Lawlor, E; McCann, SR; Temperley, IJ | 1 |
| Whittaker, JA | 2 |
| Fehr, J; Frick, P; Gmuer, J; Honegger, H; Martz, G; Sauter, C | 1 |
| Büchner, T; Emmerich, B; Fischer, JT; Fülle, HH; Heinecke, A; Hossfeld, DK; Koeppen, KM; Labedzki, L; Löffler, H; Nowrousian, MR; Pfreundschuh, M; Pralle, H; Rühl, H; Urbanitz, D; Wendt, FC | 1 |
| Henderson, ES | 3 |
| Aherne, GW; Johnston, A; Lister, TA; Piall, EM; Slevin, ML | 1 |
| Sullivan, MP | 1 |
| Bell, R; Dhaliwal, HS; Henry, GP; Lister, TA; Rohatiner, AZ; Slevin, ML | 1 |
| Marie, JP; Pochat, L; Pommier, Y; Zittoun, R | 1 |
| Marie, JP; Zittoun, R | 1 |
| Gerecke, D; Gross, R | 1 |
| Gottlieb, JE; Pauker, SG | 1 |
| Adachi, T; Endo, Y; Fujimoto, S; Hara, M; Kimura, I; Kitajima, K; Kohi, F; Lai, M; Oda, Y; Ohmoto, E; Sanada, H; Takahashi, I; Takaoka, K; Tokioka, M; Uchida, K; Watanabe, S; Yorimitsu, S | 1 |
| Drenthe-Schonk, AM; Haanen, CA; Holdrinet, RS; Linssen, PC; Pennings, AH; Plas, AM; van Egmond, J; Vierwinden, G; Wessels, JM | 1 |
| Brecher, M; Browman, G; Early, AP; Freeman, A; Preisler, HD; Raza, A; Walker, IR | 1 |
| Coccia, PF; Dehner, LP; Kersey, JH; Kim, TH; Krivit, W; Nesbit, ME; Ramsay, NK; Woods, WG | 1 |
| Haas, RJ; Helmig, M; Prentl, E | 1 |
| Dabich, L | 1 |
| Krieger, O; Lutz, D; Nowotny, H; Waldner, R | 1 |
| Stuart, J | 1 |
| Mihich, E | 1 |
| Barros, CA; Birman, V; Cavagnaro, F; Dragosky, MO; Dupont, J; Eppinger-Helft, M; Garay, G; Macchi, A; Muriel, FS; Pavlovsky, S; Scaglione, C; Suarez, A | 1 |
| Moloney, WC; Rosenthal, DS | 2 |
| Kondrat'eva, NA; Kovaleva, LG; Kruglova, GV; Makhonova, LA; Volkova, MA | 1 |
| Bagarry-Liégey, D; Carcassonne, Y; Ciardelli, P; Favre, R; Gastaut, JA; Imbert, C; Meyer, G; Sebahoun, G | 1 |
| Gordon, D; Jarrell, R; Knospe, W; Lefante, J; Omura, GA; Silberman, H; Vogler, WR | 1 |
| Chang, LJ; Izaguirre, CA; McCulloch, EA; Smith, LJ | 1 |
| Gale, RP | 2 |
| Lister, TA; Rohatiner, AZ | 1 |
| Andreeff, M; Gabrilove, J; Gordon, M; Jakubowski, A; Schuster, S; Shieh, JH; Tafuri, A; Vincent, M | 1 |
| Dardenne, M; de Witte, T; Fenaux, P; Hayat, M; Jaksic, B; Peetermans, M; Selleslag, D; Strijckmans, P; Suciu, S; Zittoun, R | 1 |
| Büchner, T; Hiddemann, W; Jahns-Streubel, G; Reuter, C; Schleyer, E; Unterhalt, M; Wörmann, B | 1 |
| Ehninger, G; Fackler-Schwalbe, E; Freund, M; Heil, G; Hoelzer, D; Link, H; Mitrou, PS; Ohl, S; Steinke, B; Wandt, H | 1 |
| Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U | 1 |
| Kaya, H; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Tanaka, N; Yoshida, T | 1 |
| Deguchi, M; Kitazawa, S; Maeda, S; Mochizuki, M; Ohara, N; Ohta, T; Takeuchi, S | 1 |
| Clark, SC; Inatomi, Y; Miyauchi, J; Shimizu, K; Toyama, K | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Abe, A; Hayatsu, K; Murakawa, E; Nagai, K; Sekiya, M | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P | 1 |
| Andreeff, M; Chen, R; Clarkson, BD; Gulati, SC; Lemoli, RM; Tafuri, A | 1 |
| Ayscue, L; Flasshove, M; Heit, W; Mitchell, BS; Schütte, J; Seeber, S; Strumberg, D; Tirier, C | 1 |
| Akashi, K; Harada, M; Inaba, S; Niho, Y; Takamatsu, Y; Teshima, T | 1 |
| De Witte, T; Muus, P; Preijers, F; Raymakers, R; Van der Lely, N; Wessels, J | 1 |
| Löwenberg, B; Sonneveld, P; te Boekhorst, PA | 1 |
| Manfori, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Bassini, A; Celeghini, C; Gibellini, D; Manfroi, S; Ottaviani, E; Pagliarini, C; Tosi, P; Tura, S; Visani, G; Zauli, G | 1 |
| Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Saito, K; Sakuma, H; Tsunogake, S; Waga, K; Yamada, K; Yamato, H | 1 |
| Aoki, S; Goto, T; Koyama, S; Shibata, A; Takahashi, H | 1 |
| Aoyagi, M; Enokihara, H; Koike, T; Nakamura, Y; Saito, K; Tsunogake, S; Watanabe, K; Yamada, K; Yamato, H; Yoshida, M | 1 |
| Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Noguchi, M; Saito, K; Sakuma, H; Waga, K; Yamada, K; Yamato, H | 1 |
| Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Hagemeijer, A; Hoebee, B; Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Bartolucci, AA; Moore, JO; Omura, GA; Stagg, M; Volger, WR; Weiner, RS | 1 |
| Arimura, M; Danno, Y; Fujimoto, K; Hata, T; Kuriyama, K; Mori, H; Saito, M; Tawara, M; Tushima, H; Yamamura, M | 1 |
| Miura, T; Moriwaki, H; Muto, Y; Nakamura, N; Oyama, M; Sawada, M; Takahashi, T; Tomoda, T; Tsurumi, H; Yamada, T | 1 |
| Godwin, J | 1 |
| Dittus, RS; Freund, DA | 1 |
| Aulitzky, WE; Bemb, W; Huber, C; Kolbe, K; Peschel, C; Schönbohn, H; Schuler, M | 1 |
| Anastasi, J; Hayashi, Y; McGavran, L; Nucifora, G; Roulston, D; Rowley, JD; Rudinsky, R; Tsuchida, M; Zeleznik-Le, N | 1 |
| Arie, Y; Hirai, M; Kikukawa, M; Kodo, H; Kumakawa, T; Mizutani, R; Mori, M; Murai, Y; Nakamura, N; Tsutsumi, H | 1 |
| Braess, J; Hiddemann, W; Kaufmann, C; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M; Wilde, S | 1 |
| Schiller, G | 1 |
| Björkholm, M; Gahrton, G; Grimfors, G; Gruber, A; Hast, R; Järnmark, M; Juliusson, G; Killander, A; Kimby, E; Liliemark, J | 1 |
| Fujihara, M; Kyo, T; Myoken, Y; Sugata, T | 1 |
| Castellano, A; Christiansen, N; D'Atri, S; Franchi, A; Frankel, S; Lu, K; Papa, G; Piccioni, D; Rustum, YM; Tuorto, V | 1 |
| August, CS; Bayever, E; Bunin, N; D'Angio, GJ; Goldwein, JW; Kamani, N | 1 |
| Belloc, F; Bernard, P; Boisseau, MR; Cony-Makhoul, P; Dumain, P; Lacombe, F; Puntous, M; Reiffers, J | 1 |
| Basara, N; Bosković, D; Colović, M; Radosević-Radojković, N; Rolović, Z | 1 |
| Aronica, G; Bruno, A; Buccisano, F; Caravita, T; Del Poeta, G; Masi, M; Pisani, F; Stasi, R; Tribalto, M; Venditti, A | 1 |
| Amess, JA; Davis, CL; Gupta, RK; Leahy, M; Lim, J; Love, S; MacCallum, PK; Oza, AM; Rohatiner, AZ; Whelan, JS | 1 |
| Bleiberg, I; Fabian, I; Kashman, Y; Lishner, M; Rudi, A; Shur, I | 1 |
| Abe, T; Hirao, A; Kawano, Y; Okamoto, Y; Saito, S; Sato, J; Shimizu, T; Suzue, T; Takaue, Y; Watanabe, T | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Heimpel, H; Heit, W; Huber, C; Kolbe, K; Maschmeyer, G; Mitrou, PS | 1 |
| Nakamura, T; Takauji, R; Tohyama, K; Ueda, T | 1 |
| Löwenberg, B; Sonneveld, P; te Boekhorst, PA; Vlastuin, M | 1 |
| Aizawa, S; Gotoh, A; Kawanishi, Y; Kimura, Y; Kurosawa, K; Miyazawa, K; Ohtaka, M; Toyama, K; Yoshikawa, O | 1 |
| Ashihara, E; Fujita, N; Goto, H; Hirata, T; Inaba, T; Nakagawa, M; Ohkawa, K; Oku, N; Shimazaki, C | 1 |
| De Felice, L; Mascolo, MG; Petrucci, MT; Petti, MC; Tafuri, A; Valentini, T | 1 |
| Advani, SH; Basade, M; Kulkarni, S | 1 |
| Arana, JI; Arrizabalaga, JI; Barrenetxea, JI; García, JC; Montes, PM; Rumoroso, JR | 1 |
| Cancelas, JA; Cerveró, C; García-Laraña, J; Hernández-Jodra, M; Lasa, E; López-Jimenez, J; Megido, M; Pérez-Oteyza, J; Sastre, JL; Zamora, C | 1 |
| Mizuta, K; Okuma, M; Sawada, H; Sawai, H; Takeda, Y; Tashima, M; Toi, T | 1 |
| Appelbaum, FR; Bigelow, CL; Files, JC; Grever, M; Head, D; Kopecky, K; Lipschitz, DA | 1 |
| Desforges, JF; Frenette, PS; Miller, KB; Rabson, A; Schenkein, DP; Slapack, CA | 1 |
| Berg, DT; Dodge, RK; George, SL; Lee, EJ; Moore, JO; Paciucci, PA; Powell, BL; Schiffer, CA; Schulman, P; Stone, RM | 1 |
| Hu, ZB; Li, M; McCulloch, EA; Minden, MD; Miyamoto, N; Yang, GS | 1 |
| Conry, JA; Dinndorf, PA; Kapur, S; Mott, SH; Packer, RJ; Pranzatelli, MR; Quinones, RR; Vezina, LG | 1 |
| Eguchi, H; Ikuno, Y; Inada, H; Ishii, E; Koga, H; Matuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Ueda, K | 1 |
| Bolaños, F; Candelaria, M; Hurtado, R; Labardini, JR; Majluf, A; Vargas, F | 1 |
| Chan, CH; Chan, J; Chan, LC; Chan, TK; Chiu, E; Chu, YC; Kwong, YL; Liang, R; Lie, A; Yeung, YM | 1 |
| Berman, E | 2 |
| McCulloch, EA; Minden, MD; Wang, C; Yang, GS | 1 |
| McCulloch, EA; Minden, MD; Yang, GS | 1 |
| Damasio, E; de Witte, T; Labar, B; Leoni, F; Mandelli, F; Papa, G; Resegotti, L; Visani, G; Willemze, R; Zittoun, RA | 1 |
| Jensen, MK; Pedersen, G; Pedersen, JO; Stentoft, J | 1 |
| Banavali, SD; Gaskins, F; Li, YQ; Preisler, HD; Raza, A; Venu, G; Yin, M | 1 |
| Bradbury, DA; Keith, FJ; Russell, NH; Zhu, YM | 1 |
| D'Onofrio, G; Di Mario, A; Etuk, B; Leone, G; Salutari, P; Sica, S | 1 |
| Bishop, JF; Cobcroft, R; Dodds, A; Herrman, R; Joshua, DE; Laidlaw, CR; Ma, D; Matthews, JP; Szer, J; Young, G | 1 |
| He, XP; Tang, XD; Yang, K | 1 |
| Reilly, JT; Snowden, JA; Wodziński, MA | 1 |
| Fukuda, T; Kakihara, T; Kishi, K; Kobayashi, T; Shibata, A; Uchiyama, M | 1 |
| Antin, JH; Miller, KB; Mitus, AJ; Parsons, SK; Ryan, HF; Schenkein, DP; Wheeler, C | 1 |
| Ohno, R | 2 |
| Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML | 1 |
| Imai, A; Kawabata, I; Morishita, S; Tamaya, T | 1 |
| Bhalla, K; Bullock, G; Huang, Y; Ibrado, AM; Mahoney, ME; Ponnathpur, V; Ray, S; Tang, C | 1 |
| Abella, E; de Planque, MM; Eisenbrey, AB; Karanes, C; Lum, LG; Ratanatharathorn, V; Ravindranath, Y; Schultz, KR; Sensenbrenner, LL; Uberti, JP | 1 |
| Armstrong, SG; Benger, AM; Browman, GP; McKay, KL; Meyer, RM; Singh, G | 1 |
| Bernell, P; Hast, R; Kimby, E | 1 |
| Byrd, RL; Cairo, MS; Cornelius, AS; Feusner, J; Gold, SH; Krill, CE; Ruymann, FB; Wells, RJ; White, ML | 1 |
| Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B | 1 |
| Artlich, A; Gortner, L; Kruse, K; Möller, J; Schwinger, E; Tschakaloff, A | 1 |
| Mittelman, M; Yarmolowski, A; Zeidman, A | 1 |
| Bartolucci, AA; Martelo, O; McCarley, DL; Moore, J; Omura, GA; Stagg, M; Vogler, WR | 1 |
| Archimbaud, E; Auzanneau, G; Bordessoule, D; Castaigne, S; Dupriez, B; Fenaux, P; Legros, M; Simon, M; Tertian, G; Tilly, H | 1 |
| Barra, Y; Carcassonne, Y; Iliadis, A; Ressayre, C; Riva-Lavieille, C | 1 |
| Atamer, MA; Büyükkeçeci, F; Keskin, A; Tombuloğlu, M | 1 |
| Cedrych, I; Hołowiecka, B; Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wacławik, A; Wojciechowska, M; Wojnar, J | 1 |
| Bow, EJ; Cheang, MS; Clinch, JJ; Kilpatrick, MG; Scott, BA | 1 |
| Jensen, MK; Johansen, P; Stentoft, J | 1 |
| Hahn, JS; Kim, SE; Ko, YW; Lee, SJ; Lee, ST; Min, YH | 1 |
| Vogler, WR | 2 |
| Aikawa, K; Furukawa, T; Gotoh, J; Ishibashi, T; Maruyama, Y; Shichishima, T; Shiga, Y; Yamagiwa, A | 1 |
| Aul, C; Burk, M; Gogolin, F; Heyll, A; Meckenstock, G; Runde, V; Söhngen, D; Winkelmann, M; Wolf, HH; Zahner, J | 1 |
| Estey, EH; Freireich, EJ; Ghaddar, HM; Kantarjian, HM; Keating, MJ; Pierce, S; Plunkett, W | 1 |
| Eppinger-Helft, M; Fernandez, I; Garcia Martinez, MA; Gonzalez Llaven, J; Ibarra, S; López-Hernández, M; Marin, A; Pavlovsky, S; Rubio, ME; Sobrevilla, P | 1 |
| Cooper, B; Meyer, W; Nemunaitis, J; Riley, C; Taylor, E | 1 |
| Crist, WM; Pratt, CB; Pui, CH; Rivera, GK; Santana, VM | 1 |
| Denoeux, JP; Desablens, B; Dierick, A; Labeille, B; Lok, C; Ruto, F; Torri, O | 1 |
| Niitsu, N; Shikoshi, K; Takada, M; Umeda, M | 1 |
| Preisler, H | 1 |
| Aoki, Y; Inoue, T; Irie, S; Kikuno, K; Okamoto, S; Shimane, M; Takada, M; Takahashi, S; Tanosaki, R; Tojo, A | 1 |
| Caracciolo, F; Carulli, G; Conte, A; Grassi, B; Mattii, L; Petrini, M; Sabbatini, A | 1 |
| Djaldetti, M; Floru, S; Mittelman, M | 1 |
| Gandhi, V | 1 |
| Kent, AB; Weinstein, RS | 1 |
| Kanno, M; Kobayashi, K; Matano, S; Matuda, T; Nakamura, S; Ohtake, S; Okabe, Y; Okumura, H; Takeda, Y; Yoshida, T | 1 |
| Griggs, JJ; Henley, SE; Rowe, JM | 1 |
| Liu, HC; Lou, FD; Meng, FY; Wang, YZ; Zhou, Q | 1 |
| García, R; Gomis, F; Guinot, M; Jarque, I; Palau, J; Pérez-Sirvent, ML; Sanz, GF; Sanz, MA; Sempere, A; Senent, L | 1 |
| Chubachi, A; Imai, H; Miura, AB; Miura, I; Nimura, T; Takahashi, N | 1 |
| Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J | 1 |
| Forsblom, AM; Gahrton, G; Hellström-Lindberg, E; Kock, Y; Lindberg, G; Ost, A; Robèrt, KH | 2 |
| Jehn, U | 2 |
| Lundström, U; Pesonen, E; Pihkala, J; Saarinen, UM; Salmo, M; Siimes, MA; Virkola, K; Virtanen, K | 1 |
| Balcar-Boroń, A; Kurylak, A; Pilecki, O; Wysocki, M | 1 |
| Aguado, MJ; Angós, JA; Gutiérrez, M; Moreno, JA; Romero, MS | 1 |
| Kaletin, GI; Pirogova, NA; Volkova, MA | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohhashi, Y; Yamada, K | 1 |
| Banavali, S; Banerjee, M; Gopal, V; Larson, R; Li, YQ; Preisler, H; Raza, A; Yin, M | 1 |
| Björkholm, M; Gruber, A; Liliemark, EK; Liliemark, J; Peterson, C; Pettersson, B | 1 |
| Champlin, R; Gajewski, J; Ho, W; Lee, M; Nimer, S; Schiller, G; Territo, M | 2 |
| Friedland, S; Loya, N; Shapiro, A | 1 |
| Hossfeld, DK; Shi, G; Weh, HJ | 1 |
| He, HT; Wang, XT | 1 |
| Baker, M; Bhalla, K; Grant, S | 1 |
| Baruchel, A; Deméocq, F; Guillot, T; Leblanc, T; Lemerle, S; Leverger, G; Nelken, B; Schaison, G; Vannier, JP | 1 |
| Daenen, S; Huijgens, PC; Löwenberg, B; Sonneveld, P; van Putten, WL; van Veldhoven, M; Verdonck, LF; Verhoef, G | 1 |
| Estey, EH; Kantarjian, H; Keating, M | 1 |
| Cerutti, I; Fernández-Barbieri, MA; Gomel, M; Kvicala, R; Matus-Ridley, M; Negri-Aranguren, P; Rosso, A; Sackmann-Muriel, F; Santarelli, MT | 1 |
| Ameling, C; Auf der Landwehr, U; Büchner, T; Hiddemann, W; Reuter, C; Rolf, C; Schleyer, E; Wörmann, B; Zühlsdorf, M | 1 |
| Abe, Y; Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Arimori, S; Fukuda, R; Ichikawa, Y; Kawada, H; Komatsuda, M; Masumoto, A; Nagao, T; Watanabe, S; Yonekura, S | 1 |
| McCulloch, EA; Rayappa, C | 1 |
| Tanaka, M | 1 |
| Boogaerts, M; Bosly, A; Carli, MG; Castoldi, G; Cuneo, A; Demuynck, H; Doyen, C; Ferrant, A; Michaux, JL; Piva, N | 1 |
| Bloch, A | 1 |
| Fujimura, T; Iwabuchi, A; Kawakubo, K; Kodama, A; Ohyashiki, JH; Ohyashiki, K; Toyama, K | 1 |
| Chen, LM; Huang, SH; Hwang, WS; Tseng, MT; Wang, CC | 1 |
| Bailey, CC; Curzon, ME; Duggal, MS; Hart, P; O'Sullivan, EA | 1 |
| Delmer, A; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 2 |
| Bennett, J; Browman, GP; Goldberg, J; Kukla, C; Larson, RA; Miller, KA; Preisler, HD; Raza, A; Rustum, YM; Vogler, R | 1 |
| Babacan, E; Bökesoy, I; Cavdar, AO; Gözdaşoğlu, S; Pamĭr, A; Sunguroğlu, A; Tanindi, S; Türker, A; Unal, E; Yavuz, G | 1 |
| An, E; Gomi, S; Inokuchi, K; Ito, T; Miyake, K; Ogata, K; Ohki, I; Tanabe, Y; Yamada, T; Yokose, N | 1 |
| Advani, SH; Gopal, R; Hegde, UP; Iyer, RS; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Saikia, TK | 1 |
| Filippi, C; Garbe, L; Garnier, G; Gratecos, N; Michiels, JF; Pesce, A; Poitou, G; Rosenthal, E; Taillan, B; Vinti, H | 1 |
| Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Barnett, MJ; Elmongy, MB; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD | 1 |
| Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P | 1 |
| Amess, JA; Davis, CL; Evans, ML; Gupta, RK; Leahy, M; Lim, J; MacCallum, PK; Price, CG; Rohatiner, AZ; Whelan, JS | 1 |
| Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 2 |
| Carella, AM; Carlier, P; Iacopino, P; Liso, V; Mirto, S; Montillo, M; Pagano, L; Pungolino, E; Resegotti, L; Stasi, R | 1 |
| Horoupian, DS; Vogel, H | 1 |
| Björkholm, M; Gruber, A; Knochenhauer, E; Liliemark, J; Peterson, C; Pettersson, B | 1 |
| Archimbaud, E; Auzanneau, G; Cordonnier, C; Fenaux, P; Leblond, V; Marie, JP; Reiffers, J; Tilly, H; Travade, P; Troussard, X | 1 |
| Akatsuka, J; Furukawa, T; Nakazawa, S; Nishimura, K; Ohira, M; Okawa, Y; Sugita, K; Tsuchida, M | 1 |
| Bruno, A; Coppetelli, U; Cox, C; Del Poeta, G; Franchi, A; Masi, M; Piccioni, D; Stasi, R; Tribalto, M; Venditti, A | 1 |
| Ikeda, K; Inoo, M; Murao, S; Murata, M; Nagai, M; Sasaki, K; Takahara, J; Tasaka, T; Tokuda, M | 1 |
| Heinemann, V; Jehn, U | 3 |
| Barnett, MJ; Klingemann, HG; Nantel, SH; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ | 1 |
| Estey, EH; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Aul, C; Balleisen, L; Bartholomäus, A; Becker, K; Bettelheim, P; Hiddemann, W; Lathan, B; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R | 2 |
| Fujiyama, Y; Hiramitu, Y; Hodohara, K; Hosoda, S; Kitoh, K; Sugiura, H; Sumiyoshi, K | 1 |
| Harousseau, JL | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Yamada, K | 1 |
| Amadori, S; Aricò, M; Comelli, A; Giuliano, M; Madon, E; Mandelli, F; Masera, G; Rondelli, R; Testi, AM; Zanesco, L | 1 |
| Bauters, F; Detourmignies, L; Fenaux, P; Laï, JL; Wattel, E | 1 |
| de Witte, T; Delmer, A; Ferrini, PR; Mandelli, F; Rio, B; Stryckmans, P; Tura, S; Vekhof, A; Willemze, R; Zittoun, R | 1 |
| Hansz, J; Kozłowska-Skrzypczak, M; Sawiński, K | 1 |
| Archimbaud, E; Thomas, X | 2 |
| Chucrallah, A; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Estey, EH; Simon, RM; Thall, PF | 1 |
| Berman, E; Golde, DW; Maslak, PG; Scheinberg, DA; Tyson, D; Weiss, MA; Yao, TJ | 1 |
| Groenewegen, A; Löwenberg, B; Sonneveld, P; Vellenga, E; Wielenga, JJ | 1 |
| Bow, EJ; Cheang, MS; Loewen, R; Schacter, B | 1 |
| Ino, Y; Moriwaki, H; Murakami, N; Muto, Y; Tsurumi, H; Yamada, T | 1 |
| Amadori, S; Cenacchi, A; Latagliata, R; Mandelli, F; Manfroi, S; Petti, MC; Spadea, A; Tosi, P; Tura, S; Visani, G | 1 |
| Baldicchi, L; Corneo, GM; Mangiagalli, M; Miccolis, IR; Pioltelli, P; Pogliani, EM | 1 |
| Gibney, MD; Nelson-Adesokan, P; Penneys, NS | 1 |
| Falk, RE; Fuerst, MM; Giles, FJ; Kusuanco, DA; Lawrence, GN; Lim, SW; Look, RM | 1 |
| Chau, WK; Chiu, CF; Ho, CH; Hsu, HC; Tan, TD; Tseng, CS | 1 |
| DeLima, M; Estey, E; Ghaddar, H; Pierce, S | 1 |
| Schiller, GJ | 1 |
| Nakamura, T; Ueda, T; Yamauchi, T | 1 |
| Baranov, AE; Fleischman, EW; Frenkel, MA; Gordeeva, AA; Konstantinova, LN; Kulagina, OE; Volkova, MA | 1 |
| Ben-Bassat, I; Berkowicz, M; Carter, A; Chetrit, A; Haddad, N; Raanani, P; Ramot, B; Shpilberg, O; Sofer, O; Tatarski, I | 1 |
| Attal, M; Berthaud, P; Broustet, A; Danel, P; Fabères, C; Gastaut, JA; Hollard, D; Huguet, F; Hurteloup, P; Lepeu, G; Maraninchi, D; Marit, G; Mercier, M; Michallet, M; Molina, L; Pris, J; Reiffers, J; Stoppa, AM; Tellier, Z | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Hu, ZB; McCulloch, EA; Minden, MD | 1 |
| Fey, MF; Hardegger, TP; Tobler, A; von Rohr, A | 1 |
| Gandhi, V; Loughlin, S; Plunkett, W; Zwelling, LA | 1 |
| Anderlini, P; Estey, EH; Freireich, EJ; Ghaddar, HM; Kantarjian, HM; Keating, MJ; O'Brien, S; Pierce, S; Smith, TL | 1 |
| Imanaka, F; Kouzai, K; Okuhara, T; Takimoto, Y | 1 |
| Cadiou, M; de Witte, T; Hayat, M; Mandelli, F; Peetermans, M; Petti, MC; Solbu, G; Stryckmans, P; Suciu, S; Thaler, J; Willemze, R; Zittoun, R | 1 |
| Hedley, DW; McCulloch, EA | 1 |
| Brack, N; Ehninger, G; Fackler-Schwalbe, I; Freund, M; Geer, T; Gramatzki, M; Hübner, G; Link, H; Löffler, B; Ohl, S; Poliwoda, H; Queisser, W; Raab, M; Schneider, B; Schneider, C; Schönrock-Nabulsi, P; Wandt, H | 1 |
| Ishida, Y; Ito, T; Kuriya, S; Miyairi, Y; Murai, K; Narigasawa, Y; Shimosegawa, K; Utsugisawa, T | 1 |
| Dabadghao, S; Dennison, D; Srivastava, A | 1 |
| Chai, A; Forman, SJ; Lee, J; Lipsett, J; Margolin, KA; Molina, A; Nademanee, A; Niland, J; O'Donnell, MR; Parker, PM; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Vora, N | 1 |
| Jowitt, SN; Yin, JA | 1 |
| Kearns, P; Majumdar, G; Partridge, F; Richardson, W; Wilcox, R | 1 |
| Estey, E; Kuschel, B | 1 |
| Ma, L; Qiao, Z; Wang, C; Yang, L; Zhang, H; Zhang, J | 1 |
| Dardenne, M; De Witte, T; Hayat, M; Kurstjens, R; Labar, B; Muus, P; Ribeiro, M; Roozendaal, K; Selleslag, D; Solbu, G; Suciu, S; Zittoun, R | 1 |
| Cao, DC; Higashigawa, M; Hori, H; Ido, M; Kawasaki, H; Komada, Y; Kuwabara, H; Ohkubo, T; Sakurai, M | 1 |
| Nishikawa, K | 1 |
| Saito, K | 1 |
| Andreeff, HM; Beran, M; Estey, E; Gandhi, V; Kantarjian, HM; Koller, CA; Kornblau, SM; O'Brien, S; Plunkett, W | 1 |
| Bhalla, K; Bullock, G; Huang, Y; Ibrado, AM; Krajewski, S; Ray, S; Reed, JC | 1 |
| Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC | 1 |
| Avvisati, G; Capria, S; Giona, F; Mandelli, F; Meloni, G; Micozzi, A; Vignetti, M | 1 |
| Curtis, JE; McCulloch, EA; Minden, MD; Minkin, S | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Wakita, M; Yamaguchi, T | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohashi, Y; Yamada, K | 1 |
| Chen, TP; Chen, TY; Chen, YC; Lin, SF; Tsao, CJ; Yao, M | 1 |
| Ahn, HS; Cho, KS; Choi, YM; Chung, TJ; Hwang, TJ; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, HS; Kim, JS; Lee, KS; Park, HS; Park, JW; Song, HS | 1 |
| Kidd, P; Quien, ET; Saidi, P; Sandhaus, L; Strair, R; Wallach, B | 1 |
| Hagiwara, S; Miwa, A; Nagai, M; Soda, Y; Takaku, F; Takezako, N; Togawa, A; Yuo, A | 1 |
| Hirakawa, S; Kato, M; Nakayama, M; Shikoshi, K; Takata, M; Tanaka, M; Umeda, M | 1 |
| Ahmed, T; Darzynkiewicz, Z; Feldman, EJ; Halicka, HD; Lake, D; Seiter, K; Traganos, F | 1 |
| Insiripong, S; Thaisamakr, S | 1 |
| Chaibi, P; de Revel, T; Dombret, H; Gardin, C; Micléa, JM; Nédellec, G; Rousselot, P; Turlure, P | 1 |
| Amadori, S; Andrizzi, C; Meloni, G; Moleti, ML; Orsini, E; Petti, MC; Pinto, RM; Vignetti, M | 1 |
| Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M | 1 |
| Enomoto, S; Ishida, Y; Ito, S; Ito, T; Kaneko, J; Kuriya, S; Miyairi, Y; Murai, K; Narigasawa, Y; Numaoka, H; Ono, Y; Shimosegawa, K; Sugawara, T; Utsugisawa, T | 1 |
| Pallister, CJ; Singer, CR; Smith, JG; Smith, MA | 1 |
| Degenhardt, F; Ganser, A; Geissler, RG; Hertenstein, B; Karthaus, M; Prahst, A | 1 |
| Abe, F; Fujii, H; Maruyama, S; Yosizawa, K | 1 |
| Badjou, R; Bernier, M; Bron, D; Crombez, P; Stryckmans, P; Trenschel, R; Verhest, A | 1 |
| Fujimoto, T; Gushiken, T; Horikoshi, Y; Ishida, Y; Kawakami, K; Kawamura, N; Kikuta, A; Koizumi, S; Maeda, H; Mimaya, J; Mugishima, H; Ohta, S; Oka, T; Okada, N; Sekine, I; Shimizu, H; Utsumi, J; Watanabe, A; Yamamura, Y | 1 |
| Beguin, Y; Bury, J; Fillet, G; Forget, P; Sautois, B | 1 |
| Olavarria, E; Prieto, E; Roman, A | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Yamaguchi, T | 1 |
| Elonen, E; Hänninen, A; Järventie, G; Kätkä, K; Koistinen, P; Koivunen, E; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Remes, K; Ruutu, T; Timonen, T; Volin, L | 1 |
| Appelbaum, FR; Chen, IM; Godwin, J; Head, DR; Kopecky, KJ; Leith, CP; McConnell, T; Slovak, ML; Willman, CL | 1 |
| Lee, M; Schiller, G | 1 |
| Sundström, GM; Wahlin, A | 1 |
| Kane, D; Keating, S; McCann, S; Mulcahy, F | 1 |
| Campbell, J; De La Serna, J; Diaz-Mediavilla, J; Francisco Tomás, J; García de Paredes, ML; Grande, C; Solano, C | 1 |
| Gau, JP; Ho, KC; Lin, TH; Yang, Y; Young, JH | 1 |
| Daibata, M; Ido, E; Kubonishi, I; Kuzume, T; Miyoshi, I; Murakami, K; Taguchi, H | 1 |
| Backway, KL; Chow, S; Hedley, DW; McCulloch, EA | 1 |
| Hall, JL; Hamblin, TJ; Myint, H; Ross, FM | 1 |
| Fujimoto, T | 1 |
| Aoki, H; Iinuma, M; Miyata, Y; Takeyama, H; Watanabe, E; Yamada, H; Yamamoto, Y | 1 |
| Björkholm, M; Engervall, P; Kalin, M | 1 |
| Fujimoto, T; Hirota, T; Horikoshi, Y; Kamitamari, A; Katano, N; Kawamura, N; Mimaya, J; Tsuji, Y; Tsurusawa, M; Yanai, M | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Anand, KP; Jaiprakash, MP; Kasthuri, AS; Kumar, R | 1 |
| Tu, YL; Xi, YR; Zhao, XH | 1 |
| Lee, M; Lill, M; Miller, T; Mittal-Henkle, A; Paquette, R; Sawyers, C; Schiller, G; Territo, M | 1 |
| Barnett, MJ; Dalal, BI; Horsman, DE; Klingemann, HG; Naiman, SC; Nantel, SH; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ; Sutherland, HJ; Wu, V | 1 |
| Alpdoğan, O; Alpdoğan, TB; Bayik, M; Demirçay, Z; Gürbüz, O; Kurtkaya, O; Yücelten, D | 1 |
| Ikeda, K; Ikeda, T; Kawachi, Y; Kuwajima, Y; Mori, M; Nishihara, T; Sasaki, K; Setsu, K; Takahara, J; Uchida, T | 1 |
| Goldstone, AH; Harvey, D; Johnson, S; Nokes, TJ | 1 |
| Rayon, C | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Cuttner, J; Davis, RB; Gottlieb, A; Holland, JF; Martelo, O; Paciucci, PA | 1 |
| Hengge, UR; Schultewolter, T; Uppenkamp, T | 1 |
| Curtis, D; Fairley, C; Spelman, D; Szer, J; Ugoni, A; Vujovic, O; Woolley, I | 1 |
| Ahmed, I; Chen, KR; Gibson, LE; Nakayama, H | 1 |
| Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S | 1 |
| Lasorella, A; Mastrangelo, S; Riccardi, A; Riccardi, R; Servidei, T | 1 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, CA; Kornblau, SM; O'Brien, S | 1 |
| Ryo, R; Saigo, K; Sugimoto, T; Yamaguchi, N | 1 |
| Hoagland, HC; Letendre, L; Litzow, MR; Noel, P; Tefferi, A | 1 |
| Corrado, C; Desmery, P; Dignani, C; Fernández, I; Juni, M; Martinez Rolón, J; Michelet, M; Milone, G; Pavlovsky, S | 1 |
| Diehl, V; Knöppel-Schwark, S; Lathan, B; Schwonzen, M; Staib, P; Steinmetz, HT; Tesch, H; Voliotis, D; Wickramanayake, PD | 1 |
| Amemiya, Y; Furukawa, Y; Hoshino, M; Imagawa, S; Izumi, T; Kawano, C; Kirito, K; Komatsu, N; Kuribara, R; Miura, Y; Miyazato, A; Muroi, K; Omine, K; Otsuki, T; Shimizu, R; Suzuki, T; Tabata, M; Takahashi, H; Takatoku, M; Terui, Y; Tomizuka, H; Toshima, M; Tsunoda, J; Uchida, M; Yoshida, M | 1 |
| Burton, CS; Grichnik, JM; Miller, WS; Moore, JO; Shea, CR; Sumner, WT | 1 |
| Qiau, Z; Wang, C; Yang, L | 1 |
| Asami, K; Eguchi, H; Hatae, Y; Hirota, T; Iwai, A; Katano, N; Koizumi, S; Kono, Y; Matusita, T; Miyawaki, T; Mugisima, H; Nakayama, M; Nisikawa, K; Osima, K; Sekine, I; Simokawa, T; Suzumiya, J; Tanaka, A; Tsuchiya, T; Tsurusawa, M; Utumi, J; Yamamoto, Y; Yamamura, Y; Yanase, T; Yokota, S | 1 |
| Barua, A; Rahman, J; Rashid, MA; Sayeed, MA; Yunus, AB | 1 |
| Arthur, DC; Bloomfield, CD; Heinonen, K; Lawrence, D; MacCallum, J; Mrózek, K; Pettenati, MJ; Qumsiyeh, MB; Schiffer, CA; Stamberg, J; Verma, RS | 1 |
| Ito, T; Konishi, H; Maesako, Y; Mori, S; Ueda, Y; Yagiri, Y | 1 |
| Calista, D; Landi, C | 1 |
| Alfaro, E; Casak, S; Cygler, A; Felice, MS; Fraquelli, L; Gallego, M; Pérez, LE; Quinteros, R; Sackmann-Muriel, F; Zubizarreta, P | 1 |
| Almqvist, A; Elonen, E; Hänninen, A; Jansson, SE; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Nousiainen, T; Pelliniemi, TT; Rajamäki, A; Remes, K; Ruutu, T; Timonen, T; Vilpo, J; Volin, L | 1 |
| Estey, E; Gandhi, V; Xu, YZ | 1 |
| Akiba, J; Fuyama, S; Hayashi, T; Kosugi, S; Maeda, K; Sasaki, H; Satoh, S; Suzuki, K; Tajima, K; Yahagi, A | 1 |
| Kanellopoulou, G; Stamatellos, G; Stamatopoulos, K; Vaiopoulos, G; Yataganas, X | 1 |
| Jacky, E; Sauter, C; Taverna, C | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D; Zaja, F | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Borleri, G; Buelli, M; D'emilio, A; Lerede, T; Personeni, A; Raimondi, R; Rodeghiero, F | 1 |
| Furukawa, Y; Kitani, T; Tsukaguchi, M | 1 |
| Asai, O; Dobashi, N; Kato, A; Katori, M; Kobayashi, T; Kuraishi, Y; Maki, N; Nagamine, M; Ogihara, A; Saito, T; Tajima, N; Usui, N; Watanabe, H; Yamazaki, H; Yano, S | 1 |
| Fusaoka, T; Kataoka, A; Tunamoto, K; Wakazono, Y | 1 |
| Delmer, A; Marie, JP | 1 |
| Montes, A; Nandi, A; Powles, RL; Talbot, DC; Teh, WL | 1 |
| Beran, M; Estey, E; Jeha, S; Kantarjian, H; Keating, M; O'Brien, S; Rios, MB; Vitek, L; Zurlo, MG | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| Bump, EA; Hedley, DW; Sheng-Tanner, X | 1 |
| Lehman, S; Löfgren, C; Möllgård, L; Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Hara, T; Moriwaki, H; Oyama, M; Sawada, M; Tsurumi, H; Yamada, T | 1 |
| Kanamaru, A; Miyawaki, S; Mizoguchi, H; Nakamura, T; Ohashi, Y; Ohno, R; Tomonaga, M; Tsukagoshi, S; Yoshida, S | 1 |
| Hiraoka, A; Kuraishi, Y; Ogawa, M; Okabe, K; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| Jabłoński, M; Machaczka, M; Rucińska, M; Skotnicki, AB | 1 |
| Cid, A; de la Rubia, J; Jarque, I; Jiménez, C; Larrea, L; López, A; Martín, G; Martínez, JA; Sanz, GF; Sanz, MA | 1 |
| Abe, T; Bai, A; Hasegawa, Y; Hori, M; Kojima, H; Komeno, T; Nagasawa, T; Nara, N; Ninomiya, H | 1 |
| Belch, AR; Chlumecky, V; Gati, WP; Larratt, LM; Mant, MJ; Paterson, AR; Turner, AR | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Chang, J; Fujita, Y; Jones, L; Kasper, C; Morgenstern, GR; Scarffe, JH | 1 |
| Cho, SG; Kim, CC; Lee, JH; Lee, KS; Lee, SY; Moon, H | 1 |
| Helm, KF; Long, D; Williams, JV | 1 |
| Mosher, D; Stein, JH; Vidarsson, B; Woods, T | 1 |
| Clarridge, J; Nachamkin, I; Osborne, J; Patel, JB; Schuster, MS; Waddington, M | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Keating, M; Vey, N | 1 |
| Khoubian, F; Lee, M; Paquette, R; Sawyers, C; Schiller, G; Territo, M | 1 |
| Loy, BA; Martin, AW; Tecimer, C | 1 |
| Al Bahar, S; Bavishi, K; Pandita, R; Savani, B | 1 |
| Hann, IM; McCarthy, AJ; Oakhill, A; Pitcher, LA | 1 |
| Hu, XF; Juneja, S; Kantharidis, P; Lee, G; Parkin, JD; Rischin, D; Rossi, R; Slater, A; Zalcberg, JR | 1 |
| Aul, C; Büchner, T; Fonatsch, C; Gassmann, W; Haase, D; Haferlach, T; Heinecke, A; Heyll, A; Hiddemann, W; Hossfeld, D; Lengfelder, E; Löffler, H; Ludwig, WD; Maschmeyer, G; Sauerland, MC; Schoch, C; Wörmann, B | 1 |
| Fenaux, P; Munck, JN; Rerat, K; Ulusakarya, A; Vantelon, JM | 1 |
| Fort, JA; Smith, LD | 1 |
| Ballerini, F; Beltrami, G; Canepa, L; Carrara, P; Cavaliere, M; Celesti, L; Clavio, M; Gatto, S; Gobbi, M; Lanza, L; Miglino, M; Pierri, I; Pietrasanta, D; Quintino, S; Varese, P | 1 |
| Byrne, JL; Dasgupta, E; Forman, K; Haynes, AP; Mitchell, D; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Benito, L; Delgado, I; García Alonso, L; García Vela, JA; Martin, M; Monteserin, MC; Oña, F; Somolinos, N | 1 |
| Andreeva, SV | 1 |
| Aoba, M; Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Matsuzaki, M; Mohri, H; Murata, T; Tanaka, M; Togawa, J | 1 |
| Kiss, I; Tomasek, J | 1 |
| Kuraishi, Y; Masaoka, T; Mizoguchi, H; Ogawa, M; Okabe, K; Saito, H; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| Asou, N; Emi, N; Hiraoka, A; Jinnai, I; Kageyama, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Minami, S; Minato, K; Miyawaki, S; Murakami, H; Naoe, T; Oh, H; Ohno, R; Omoto, E; Saito, K; Sakamaki, H; Takahashi, I; Tanimoto, M; Tomonaga, M; Tsubaki, K; Ueda, T; Yamada, O; Yoshida, M | 1 |
| Aydinok, Y; Cetingül, N; Kantar, M; Kavakli, K; Oniz, H | 1 |
| Abgrall, JP; Brice, P; Brion, A; Caillot, D; Cordonnier, C; Desablens, B; Dreyfus, F; Fenaux, P; Gratecos, N; Guerci, A; Hecquet, B; Hoang-Ngoc, L; Ifrah, N; Janvier, M; Leporrier, M; Lioure, B; Milpied, N; Pignon, B; Rochant, H; Sadoun, A; Solary, E; Stoppa, AM; Tilly, H; Veil, A; Wattel, E | 1 |
| Advani, R; Covelli, A; Davis, E; Dugan, K; Greenberg, P; Litchman, M; Lum, B; Milligan, D; Paietta, E; Ramek, J; Rowe, JM; Saba, H; Sikic, B; Tallman, M; Villena, J; Visani, G; Wiernik, PH | 1 |
| Filipits, M; Geissler, K; Jäger, U; Lechner, K; Pirker, R; Pohl, G; Scheper, RJ; Stranzl, T; Suchomel, RW | 1 |
| Balkham, SE; Elgie, AW; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C | 1 |
| Diehl, V; Dimski, T; Lathan, B; Pantke, B; Schinköthe, T; Staib, P; Voliotis, D; Wiedenmann, S | 1 |
| de Witte, T; Muus, P; Raymakers, R; Smeets, M; van der Lely, N | 1 |
| Elgie, AW; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Chimishkian, K; Gurova, K; Litvinova, E; Mentkevich, G | 1 |
| Pallis, M; Russell, NH; Syan, J | 1 |
| Borrione, P; Ciaiolo, C; Ferrero, D; Ortolano, B; Pileri, A; Pugliese, A | 1 |
| Baer, MR; Bloomfield, CD; Byrd, JC; Carroll, A; Davey, F; Dodge, RK; Edwards, C; Mayer, RJ; Moore, JO; Qumsiyeh, M; Schiffer, CA; Stamberg, J | 1 |
| Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB | 1 |
| Abboud, B; Chahine, G; Ferran, F | 1 |
| Hinrichs, SH; Iwen, PC; Lackner, RP; McCarthy, DI; Rinaldi, MG; Sigler, L; Sutton, DA; Tarantolo, S | 1 |
| Prince, HM; Speed, BR; Westerman, DA | 1 |
| Gujral, S; Kochupillai, V; Kumar, L; Mohanti, BK; Wadhwa, J | 1 |
| Hu, ZB; McCulloch, EA; Minden, MD; Stahl, J | 1 |
| Ahmed, T; Burke, HB; Darzynkiewicz, Z; Deptala, A; Dorota Halicka, H; Feldman, EJ; Goff, H; Hoang, A; Kancherla, R; Pozzuoli, M; Seiter, K; Traganos, F | 1 |
| Braess, J; Büchner, T; Haferlach, T; Hiddemann, W; Kern, W; Schoch, C; Unterhalt, M; Wörmann, B | 1 |
| D'Souza, S; Lindberg, M | 1 |
| Hamaguchi, H; Hara, M; Kikuchi, M; Makino, S; Mori, M; Nisimura, H; Okabe, K; Saburi, Y; Sato, H; Tamura, K; Tanimoto, M; Tomiyama, J; Urabe, A | 1 |
| Bodalski, J; Bolanowski, W; Nowak, K; Stolarska, M; Zalewska-Szewczyk, B | 1 |
| Burnett, AK; Kell, J | 1 |
| Aloe Spiriti, MA; Betrò, P; Breccia, M; D'Elia, GM; Latagliata, R; Luzi, G; Montefusco, E; Petti, MC; Pulsoni, A; Spadea, A | 1 |
| Akiyama, Y; Eguchi, M; Hayashi, Y; Hosoi, G; Ishii, E; Kato, K; Koike, K; Kojima, S; Nishimura, S; Ohara, A; Okamura, J; Okimoto, Y; Sako, M; Sato, T; Tsukimoto, I; Ueda, K; Yazaki, M; Yoshikawa, T | 1 |
| Frost, BM; Gustafsson, G; Larsson, R; Lönnerholm, G; Nygren, P | 1 |
| Aird, W; Amrein, P; MacNeill, K; Neuberg, D; Shulman, LN; Sternberg, DW; Thompson, L | 1 |
| Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y | 1 |
| Kuriyama, K | 2 |
| Ezaki, K; Hasegawa, A; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Okamoto, M; Tsuzuki, M | 1 |
| Aoyagi, A; Aoyagi, M; Arai, H; Arai, Y; Furusawa, S; Gunnji, H; Handa, T; Inoue, F; Kawagoe, Y; Kitsukawa, Y; Nakamura, Y; Saito, K; Tadokoro, J; Takahashi, W; Tsurumi, S; Waga, K; Yamamoto, K | 1 |
| Gáliková, J; Haas, T; Lemez, P | 1 |
| Mori, M | 2 |
| Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E | 1 |
| Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H | 1 |
| Chiba, K; Fukuhara, T; Hirano, T; Kakinoki, Y; Kurosawa, M; Maekawa, I; Miyake, T; Mori, A; Morioka, M; Noto, S; Okabe, M; Suzuki, S; Toyoshima, T; Tsutsumi, Y | 1 |
| Bisogni, R; Del Vecchio, L; Lamberti, A; Pagnini, D; Romano, MF; Storti, G; Tassone, P; Turco, MC; Venuta, S | 1 |
| Bian, S; Luo, M; Xue, Y | 1 |
| Adler, S; Andric, T; Creech, S; Galvez, A; Gezer, S; Gregory, SA; Hsu, W; Jajeh, A; Larson, RA; Loew, J; Preisler, HD; Slivnick, D; Venugopal, P | 1 |
| Hatake, K; Kobayashi, T; Kuriyama, K; Minami, S; Miyawaki, S; Ohno, R; Omoto, E; Saito, K; Tamura, J; Tanimoto, M | 1 |
| Bruno, AP; d'Orgeix, AT; Laurent, G; Lautier, D; Quillet-Mary, A | 1 |
| Bergmann, L; Blaise, D; Bosi, A; Cahn, JY; Cornelissen, J; De Witte, T; Ferrant, A; Frassoni, F; Gorin, NC; Labopin, M; Reiffers, J; Sierra, J; Visani, G | 1 |
| Alster, Y; Ben-Tal, O; Lowenstein, A; Schwartz, J | 1 |
| Bruserud, O; Ernst, P; Foss, B; Gjertsen, BT; Tjønnfjord, G | 1 |
| Arnaout, MK; Behm, FG; Belt, JR; Crom, WR; Mirro, J; Radomski, KM; Raimondi, SC; Ribeiro, RC; Santana, VM; Srivastava, DK; Tong, X | 1 |
| Amouri, A; Bouaouina, N; Chatti, S; Chehata, S; Ennabli, S; Laatiri, MA; Saad, A | 1 |
| Amess, JA; Arnott, S; Barbui, T; Bassan, R; Bradburn, MJ; Carter, M; Lister, TA; Personen, A; Raimondi, R; Rodeghiero, F; Rohatiner, AZ | 1 |
| Bruserud, O; Ernst, P | 1 |
| Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A | 1 |
| Beelen, DW; Brittinger, G; Flasshove, M; Kemmeries, G; Meusers, P; Noppeney, R; Roggenbuck, U; Scheulen, ME; Schütte, J; Seeber, S; Sohrab, S | 1 |
| Bloomfield, CD; Caligiuri, MA; Marcucci, G | 1 |
| Higashi, Y; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Anami, K; Ayukawa, H; Eguchi, H; Hara, T; Ikuno, Y; Inada, H; Ishii, E; Matsuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Sugimoto, T; Yanai, F | 1 |
| Cavenagh, JD; Dalley, CD; Lister, TA; Rohatiner, AZ | 1 |
| Cottoni, F; Sanna, S; Satta, R | 1 |
| Adriansson, M; Arheden, K; Axelsson, P; Billström, R; Cervin, A; Fioretos, T; Johansson, B; Mitelman, F; Olofsson, T; Strömbeck, B; Tanke, HJ | 1 |
| Feng, S; Han, M; Li, C | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Andresen, S; Elson, P; Hussein, M; Kalaycio, M; Lichtin, A; Pohlman, B; Tripp, B | 1 |
| Hatake, K; Komatsu, N; Matsumoto, Y; Mori, M; Muroi, K; Ohtsuki, T; Ozawa, K | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| Elgie, AW; Lewandowicz, GM; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Bieri, S; Chapuis, B; Helg, C; Miralbell, R | 1 |
| Azuma, A; Huang, P; Matsuda, A; Plunkett, W | 1 |
| Asahara, S; Chinzei, T; Hasuike, N; Maeda, N; Maeda, Y; Okada, Y; Okutani, T; Saigo, K; Satake, S; Takata, M; Tamura, M; Tasaka, K; Tomofuji, Y | 1 |
| Douglas, R; Michael, B; Nabil, S; Thomas, F | 1 |
| Appelbaum, FR; Banker, DE; Garrido, SM; Willman, CL | 1 |
| Berthold, F; Creutzig, U; Gadner, H; Havers, W; Henze, G; Hermann, J; Jürgens, H; Kabisch, H; Kluba, U; Niggli, F; Reinhardt, D; Reiter, A; Ritter, J; Zimmermann, M | 1 |
| Ajchenbaum-Cymbalista, F; Delmer, A; Marie, JP; Radosevic, N; Tang, R | 1 |
| Chang, J; Covelli, A; Isidori, A; Kelsey, S; Leoni, F; Litchman, M; Malagola, M; Marcus, R; Mayer, H; Milligan, D; Pfister, C; Piccaluga, PP; Powles, R; Schey, S; Visani, G | 1 |
| Kuijpers, M; Pieters, R; Sonneveld, P; van den Heuvel-Eibrink, MM; Wiemer, EA | 1 |
| Fukushima, T; Goto, N; Imamura, S; Iwasaki, H; Kawai, Y; Kishi, S; Masada, M; Tsutani, H; Ueda, T; Urasaki, Y; Yamauchi, T; Yoshida, A | 1 |
| Adler, S; Galvez, A; Gezer, S; Gregory, SA; Hsu, WT; Jajeh, A; Larson, A; Manson, S; Preisler, HD; Slvinick, D; Venugopal, P | 1 |
| Friedman, JH; Shetty, N | 1 |
| Bohgaki, T; Kohno, M; Kondo, M; Mukai, M; Notoya, A | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Shen, Y; Thomas, D | 1 |
| Erikson, C; Florschütz, A; Rosahl, W; Schreiber, J; Schumann, HJ; Zugehör, M | 1 |
| Bar-Sef, A; Elis, A; Fabian, I; Lishner, M | 1 |
| Canepa, L; Carrara, S; Cerri, R; Clavio, M; Damasio, E; Gobbi, M; Masoudi, B; Miglino, M; Muner, P; Pierri, I; Quintino, S | 1 |
| Appelbaum, FR; Bennett, CL; Godwin, J; Golub, RM; Hynes, D; Stinson, TJ | 1 |
| Bardy, P; Horvath, N; Hughes, T; Hui, CH; To, LB | 1 |
| Behm, FG; Pritchard, M; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Srivastava, DK; Tong, X | 1 |
| Andreeff, M; Carter, BZ; Estey, E; Estrov, Z; Harris, D; Konopleva, M; Kornblau, SM; Lapillonne, H; Milella, M; Zhao, S | 1 |
| Bowers, DC; Civin, CI; Friedman, AD; Loeb, DM | 1 |
| Ehninger, G; Fiedler, F; Friedrichsen, K; Hänel, A; Hänel, M; Herbst, R; Morgner, A; Neser, S; Nicklisch, M; Teich, M | 1 |
| Bessho, M; Hirashima, K; Kawai, N; Kayano, H; Kusumoto, S; Matsuda, A; Sakata, T; Sugahara, Y; Suzuki, T; Yagasaki, F; Yoshida, K | 1 |
| Höffken, K; Wedding, U | 1 |
| Amadori, S; Archimbaud, E; Aul, C; Boogaerts, M; de Witte, T; Ferrant, A; Gratwohl, A; Hagemeijer, A; Jehn, U; Labar, B; Mandelli, F; Muus, P; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R; Zwierzina, H | 1 |
| Chen, Y; Wang, X; Zhang, X | 1 |
| Du, EZ; Friedman, PJ; Le, DT; Masliah, E; Yi, ES; Yung, GL | 1 |
| Allan, DS; Buckstein, R; Imrie, KR | 1 |
| Gotto, H; Hartmann, F; Jacobs, G; Pfreundschuh, M; Schwamborn, J | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Cobos, E; Keung, YK; Morgan, D | 1 |
| Gadner, H; Mann, G; Trebo, MM | 1 |
| Appelbaum, FR; Doroshow, JH; Dorr, R; Head, DR; Hynes, HE; Karanes, C; Kopecky, KJ; List, AF; Persons, DL; Shurafa, M; Slovak, ML; Willman, CL | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Eguchi, M; Hayashi, Y; Hibi, S; Hongo, T; Imaizumi, M; Ishii, E; Isoyama, K; Kamada, N; Kawasaki, H; Kinukawa, N; Kosaka, Y; Mizutani, S; Nishimura, S; Oda, M; Oda, T; Okamura, T; Okawa, H; Tsukimoto, I | 1 |
| Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S | 1 |
| Hahn, JS; Jang, JH; Ko, YW; Lee, ST; Min, YH; Suh, HC | 1 |
| Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM | 1 |
| Andreeff, M; Chang, S; Estrov, Z; Gribble, G; Harris, D; Honda, T; Jackson, CE; Konopleva, M; Leysath, CE; May, WS; Munsell, M; Ruvolo, P; Sporn, MB; Stiouf, I; Suh, N; Tsao, T; Zhao, S | 1 |
| Bruserud, Ø; Foss, B; Hervig, T; Ulvestad, E | 1 |
| Delgado, J; Garcia-Grande, A; Hernandez-Navarro, F; Jimenez, MC; Morado, M | 1 |
| Iwato, K; Kyo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suetsugu, Y; Sugihara, T; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
| Case, D; Damon, LE; Linker, CA; Navarro, WA; Ries, CA; Wolf, JL | 1 |
| Cañete, A; Carvajal, E; Castel, V; Fernández, JM; Verdeguer, A | 1 |
| Draznin, J; Parisi, E; Porter, D; Schuster, SJ; Sollecito, TP; Stoopler, E | 1 |
| Alkotob, LM; Avery, RK; Chemaly, RF; Eliachar, I; Fox, SB; Procop, GW; Scharpf, J; Schmitt, SK; Smith, M; Sobecks, R | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Bernstein, SH; Jusko, WJ; Krzyzanski, W; Nichol, J; Wetzler, M | 1 |
| Balwierz, W; Bogusławska-Jaworska, J; Dluzniewska, A; Dobaczewski, G; Januszkiewicz-Lewandowska, D; Kowalczyk, J; Kołecki, P; Krenke, K; Matysiak, M; Moryl-Bujakowska, A; Rokicka-Milewska, R; Rola-Kurc, E; Sońta-Jakimczyk, D; Stefaniak, MJ; Tomaszewska, R | 1 |
| Earle, CC; Lang, K; Mallick, R; Menzin, J | 1 |
| Auvrignon, A; Bader-Meunier, B; Baruchel, A; Couillaud, G; Dalle, JH; De Lumley, L; Gandemer, V; Lamagnere, JP; Landman-Parker, J; Leblanc, T; Leverger, G; Michel, G; Nelken, B; Perel, Y; Schaison, G; Schmitt, C; Thuret, I; Vannier, JP | 1 |
| Cline, MJ; Fahey, J; Feig, S; Gale, RP; Opelz, G; Sarna, G; Territo, M; Young, L | 1 |
| Nordquist, RE; Shaw, MT | 1 |
| Haanen, C; Hillen, H; Wessels, J | 1 |
| Chabner, BA; Coleman, CN; Drake, JC; Stoller, RG | 1 |
| Burge, PS; Prankerd, TA; Richards, JD; Sare, M; Thompson, DS; Wright, P | 1 |
| Gürtler, R; Raderecht, C | 1 |
| Bear, RA; Garvey, MB; Ho, M | 1 |
| Cline, MJ; Gale, RP | 1 |
| Bocaccino, CA; Greenberger, JS; Moloney, WC; Szot, SJ | 1 |
| Buchman, VM; Lichinitser, MR; Mkheidze, DM; Svet-Moldavsky, GJ | 1 |
| Preisler, HD; Renick, J; Rustum, YM; Walczak, I | 1 |
| Raich, PC | 1 |
| Hayhoe, FG; Rees, JK | 1 |
| Finklestein, JZ; Hammond, D; Higgins, G; Krivit, W | 1 |
| Alexander, P; Clink, HM; McElwain, TJ; Morgenstern, G; Palu, G; Powles, RL; Selby, PJ | 1 |
| Cassileth, PA; Cooper, RA; Katz, ME; Petrillo, MH | 1 |
| al-Ismail, SA; Whittaker, JA | 1 |
| Anteunis, A; Audebert, AA; Debray, J; Krulik, M; Robineaux, R | 1 |
| Barabash, G; Benjamin, D; Djaldetti, M; Douer, D; Pinkhas, J; Weinberger, A | 1 |
| Carnelli, V; Gargantini, G; Giulotto, P; Masera, G; Porcelli, P; Uderzo, C | 1 |
| Amadori, S; Mastrovincenzo, C; Petti, MC; Testa, MG | 1 |
| Gustavsson, A; Olofsson, T; Olsson, I | 1 |
| Chen, H; Kamimura, O; Nagao, T; Naito, T; Toki, H | 1 |
| Egan, EM; Ensminger, WD; Greenberger, JS; Moloney, WC; Muse, MB | 1 |
| Chabner, BA; Coleman, CN; Johns, DG | 1 |
| Bekesi, JG; Holland, JF | 1 |
| Chabner, BA; Hande, KR | 1 |
| Blaese, RM; Bleyer, WA; Bujak, JS; Graw, RG; Herzig, GP | 1 |
| Durie, BG; Giles, HR | 1 |
| McCredie, KB | 1 |
| Fülle, HH | 2 |
| Elias, L; Embury, SH; Greenberg, PL; Heller, PH; Hood, CE; Schrier, SL | 1 |
| Haanen, C; van der Kleijn, E; van Prooijen, R | 1 |
| Nagao, K; Okuda, K; Yamaguchi, K; Yonemitsu, H | 1 |
| Buskard, NA; Catovsky, D; Costello, C; Galton, DA; Goldman, JM; Spiers, AS | 1 |
| Ho, DH | 2 |
| Catovsky, D; Costello, C; Galton, DA; Goldman, JM; Pitcher, CS; Spiers, AS | 1 |
| Benvenuto, J; Brown, NS; Buckels, D; Freireich, EJ; Ho, DH; McCredie, KB | 1 |
| Barzilai, D; Hazani, A; Tatarsky, I | 1 |
| Castleberry, RP; McCann, WP; Moreno, H | 1 |
| Canellos, GP; Gralnick, HR; Rosenthal, S; Whang-Peng, J | 1 |
| Falcão, R; MacLennan, IC; Sonis, ST | 1 |
| Cowall, DE; Trump, DL | 1 |
| Brand, A; den Ottolander, GJ; Eernisse, JG; Haak, HL; Hartgrink-Groeneveld, CA; Heering, KJ; Jansen, J; Willemze, R; Zwaan, FE | 1 |
| Breuer, AC; Dawson, DM; Pitman, SW; Schoene, WC | 1 |
| Appelbaum, FR; Graw, RG; Herzig, GP; Kramer, BS; Levine, AS | 1 |
| Crowell, EB; Keimowitz, RM; MacKinney, AA; Pisciotta, AV; Schloesser, LL | 1 |
| Challener, J; Hayhoe, FG; Rees, JK; Sandler, RM | 1 |
| Hauptmann, E; Heinz, R; Jaksic, B; Stacher, A | 1 |
| Domján, O; Horváth, A; István, L; Kassai, P; Kemény, P; Koós, R; Laub, MW; Révész, T; Schuler, D; Székely, K; Velkey, L; Vincellér, M; Virág, I | 1 |
| Gjemdal, T; Ly, B; Stavem, P | 1 |
| Delamore, IW; Freeman, CB; Geary, CG; Harris, R; Hull, PJ; MacIver, JE; Taylor, GM; Tooth, JA; Zuhrie, SR | 1 |
| Armitage, JO; Burns, CP | 1 |
| Benestad, HB | 1 |
| Badia, L; Besalduch, J; Marty, ML; Mayans, J; Prieto, F | 1 |
| Dienstl, F; Frisch, H; Gstöttner, M | 1 |
| Lauzon, GJ; Paran, JH; Paterson, AR | 1 |
| Belch, AW; Lauzon, GJ; Paterson, AR | 1 |
| Blackett, NM; Douglas, ID; Gordon, MY | 1 |
| Bukhman, VM; Lichinitser, MR; Mkheidze, DM; Svet-Moldavskiĭ, GIa | 1 |
| Cavalli, F | 1 |
| Pfrimmer, WJ; Sartiano, GP; Turner, AR | 1 |
| Amadori, S; De Lipsis, E; Grignani, F; Liso, V; Mandelli, F; Martelli, M | 1 |
| Bury, RW; Keary, PJ | 1 |
| Ichimiya, M; Ishiguro, J; Kamiya, T; Kawashima, K; Kobayashi, M; Koie, K; Morishima, Y; Murakami, S; Nishiwaki, H; Ogata, K; Ohno, R; Sako, F; Takeyama, H; Uetani, T; Yamada, K; Yamaguchi, H; Yoshikawa, H; Yoshikawa, S | 1 |
| Shaw, D; Tudhope, GR | 1 |
| Humphrey, GB; McMillan, CW; Steuber, CP; Vietti, TJ | 1 |
| Gale, RP; Wolff, L; Zighelboim, J | 1 |
| Preisler, HD; Rustum, YM | 2 |
| Yoshikawa, H | 1 |
| Büchner, T; Hiddemann, W; Kamanabroo, D; Urbanitz, D | 1 |
| Rustum, YM | 1 |
| Aglietta, M; Sonneveld, P | 1 |
| Garratty, G; Morel, PA; Ness, PM; Perkins, HA | 1 |
| Aglietta, M; Colly, L | 1 |
| Riehm, H; Scheer, U; Schellong, G | 1 |
| Beard, ME; Duff, GB; Hamer, JW | 1 |
| Leyden, MJ; Manoharan, A | 1 |
| Baudet, D; Besancenot, JF; Bonhomme, J; Cortet, P; Guy, H; Schadeck, C | 1 |
| Libánský, J; Lukásová, M; Sedlácková, M | 1 |
| Chiyoda, S; Kubota, K; Miura, Y; Mizoguchi, H; Muto, Y; Takaku, F | 1 |
| Flexner, JM; Graber, SE; Stein, RS | 1 |
| Cadman, E; Eiferman, F | 1 |
| Foon, KA; Gale, RP; Naiem, F; Yale, C | 1 |
| Baccarani, M; Tura, S | 1 |
| Madanat, FF; Sullivan, MP | 1 |
| Boutagy, J; Bunch, C; Grahame-Smith, DG; Harris, AL; Harvey, DJ; Potter, C | 1 |
| Glomstein, A; Lie, KK; Lie, SO | 1 |
| Rothenberg, SP; Saponara, EJ; Villamena, D | 1 |
| Fujimoto, T; Hiyoshi, Y; Ito, M; Kim, PY; Sasaki, K; Yanai, M; Yokoyama, T | 1 |
| Kechijian, P; Mariglio, J; Sadick, NS; Schulman, P | 1 |
| Belch, A; Brox, L; Mowles, D | 1 |
| Buchanan, JG; Matthews, JR; Postlewaight, BF; Upsdell, M | 1 |
| Waetzin, GL | 1 |
| Bodey, GP; Dicke, KA; Freireich, EJ; Keating, MJ; McCredie, KB; Smith, T | 1 |
| Curtis, JE; McCulloch, EA; Messner, HA; Sousan, P; Till, JE | 1 |
| Koelmel, HW; Weizsaecker, M | 1 |
| Gahrton, G; Granström, M; Hörnsten, P; Wahren, B | 1 |
| Asherson, GL; Athanassiades, PH; Oliver, RT; Platts-Mills, TA | 1 |
| Rachmilewitz, EA; Shalev, O; Siew, F; Yaar, I | 1 |
| Zighelboim, J | 1 |
| Douglas, ID; Gordon, MY; Powles, RL | 1 |
| Anderton, KJ; Hill, AS; Lilleyman, JS | 1 |
| Mauer, AM | 1 |
| Clarkson, BD | 3 |
| Bodey, GP; Rodriguez, V | 1 |
| Cavalier, J; David, R; Duhamel, G; Gorin, NC; Hirsch Marie, F; Jullien, AM; Leblanc, G; Muller, JY; Najman, A; Parlier, Y; Petit, JC; Salmon, C; Stachowiak, J | 1 |
| Carpenter, JL; Old, CW; Torrington, KG; Urban, ES | 1 |
| Dietrich, BE; Jacobs, P; Miller, JL; Uys, CJ | 1 |
| Cheng, YC; Creaven, P; Mihich, E; Pavelic, Z; Rustum, Y | 1 |
| Brunner, KW; Carey, RW; Cuttner, J; DelDuca, V; Glidewell, OJ; Hoagland, HC; Holland, JF; Kung, FH; Silver, RT; Spurr, CL; Wiernik, PH | 1 |
| Fujiwara, Y; Furukawa, K; Hirota, Y; Nakaide, Y; Tanaka, M | 1 |
| Baccarani, M; Fiacchini, M; Gobbi, M; Guarini, A; Gugliotta, L; Lauria, F; Ricci, P; Ruggero, D; Santucci, MA; Tomasini, I; Tura, S; Zaccaria, A | 1 |
| Delamore, IW; Geary, CG; Milner, GR; Sumner, C; Wilkinson, PM | 1 |
| Davies, JE; Khurshid, M; Whittaker, JA | 1 |
| Bodey, GP; Freireich, EJ; McCredie, KB; Rodriguez, V | 1 |
| Steinberg, D | 1 |
| Bodey, GP; Freireich, EJ; Ho, DH; Loo, TL | 1 |
| Barbui, T; Battista, R; Dini, E | 1 |
| Fennelly, JJ; Gorman, AM; Keane, TJ; O'Connell, LG | 1 |
| Barlogie, B; Büchner, T; Hofschröer, J | 1 |
| Eppinger-Helft, M; Hidalgo, G; Muriel, FS; Pavlovsky, A; Pavlovsky, S; Suarez, A; Vilaseca, G | 1 |
| Ansari, BM; Thompson, EN | 2 |
| Cohen, MM; Eldor, A; Kohn, G; Manny, N | 1 |
| Brincker, H | 4 |
| Eernisse, JG; Hartgrink-Groeneveld, CA; Speck, B; Willemze, R | 1 |
| Hansen, MM | 1 |
| Kremer, WB | 1 |
| Bergsagel, DE; Cowan, DH; Curtis, JE; Hasselback, R; McCulloch, EA | 1 |
| Bleich, HL; Boro, ES | 1 |
| Mandelli, F | 2 |
| Gavosto, F; Masera, P; Pagliardi, GL | 1 |
| Baccarani, M; Tura, S; Zaccaria, A | 1 |
| Cimino, R; Di Girolamo, R; Montuori, R; Quattrin, N | 1 |
| Barbui, T; Battista, R; Cartei, G; Cazzavillan, M; Chisesi, T; Dini, E | 1 |
| Bernard, J | 2 |
| Burchenal, JH; Clarkson, BD; Cunningham, IB; Dowling, MD; Gee, TS | 1 |
| Goodall, PT; Vosti, KL | 1 |
| Kimura, K; Yamada, K | 1 |
| Masi, M; Paolucci, P; Vecchi, V; Vivarelli, F | 2 |
| Bryon, PA; Fière, D; Martin, C; Péaud, PY | 1 |
| Brenning, G; Engstedt, L; Franzén, S; Gahrton, G; Gullbring, B; Höglund, S; Holm, G; Jameson, S; Killander, A; Killander, D; Lockner, D; Mellstedt, H; Palmblad, J; Reizenstein, P; Skårberg, KO; Swedberg, B; Udén, AM; Wadman, B; Wide, L | 1 |
| Curet, LB; Raich, PC | 1 |
| Bateman, CJ; Beard, ME; Crowther, DC; Fairley, GH; Scott, RB; Whitehouse, JM; Wrigley, PF | 1 |
| Ansari, BM; Thompson, EN; Whittaker, JA | 1 |
| Evans, DI; Jones, PH; Morley, CJ | 1 |
| Blom, J; Carey, RW; Cuttner, J; Eagan, RT; Ellison, RR; Glidewell, O; Harley, JB; Haurani, F; Holland, JH; Kyle, R; Lee, ST; Levy, RN; Moon, JH; Ribas-Mundo, M; Silver, R; Spurr, CL | 1 |
| Bruntsch, U; GAllmeier, WM; Osieka, R; Schmidt, CG; Seeber, S | 1 |
| Omine, M; Perry, S; Sarna, G | 1 |
| Hirano, M; Imai, K; Imamura, K; Ishiguro, J; Kamiya, T; Koie, K; Nishiwaki, H; Ohno, R; Sako, F; Uetani, T | 1 |
| di Cato, MA | 1 |
| Henderson, ES; Leventhal, BG; Pizzo, PA | 1 |
| Karle, H; Killmann, SA; Wantzin, GL | 2 |
| Sauter, C | 1 |
| Pelka, R; Sauer, H; Wilmanns, W | 1 |
| Fisher, V; Flessa, HC; Hake, DA; Lampkin, BC; Mauer, AM; McWilliams, NB | 1 |
| McCulloch, EA; Niho, Y; Till, JE | 1 |
| Dunning, AJ | 1 |
| Althof, S; Essers, U; Ewers, M | 1 |
| Amaki, I; Ohshima, T | 1 |
| Javier, G; Ortega, JJ; Sáenz, A; Tusell, J | 1 |
| Bosković, D; Ruvidić, R | 1 |
| Burke, PJ; Karp, JE | 2 |
| Leese, CL; Robins, AB; Smyth, JF | 1 |
| Bodey, GP; Burgess, MA; Frei, E; Freireich, EJ; McCredie, KB; Rodriguez, V | 1 |
| Liong, SK; Uzuka, Y; Yamagata, S | 1 |
| James, PD; Toghill, PJ; Wilcox, RG | 1 |
| Lebowitz, JL; Rubinow, SI | 1 |
| Elbadawi, A; Griner, PF; Packman, CH | 1 |
| Cauchi, MN; Paton, C; Stone, J; Whiteside, MG | 1 |
| Haanen, C; van Egmond, J; van Prooijen, HC; Vierwinden, G; Wessels, JM | 1 |
| Bernard, J; Boiron, M; Chastang, CL; Gemon-Auclerc, MF; Izrael, V; Jacyuillat, CI; Weil, M | 1 |
| Aisner, J; Fortner, C; Lichtenfeld, JL; O'Connell, MJ; Schiffer, CA; Schimpff, SC; Wiernik, PH | 1 |
| Alberto, P; Cavalli, F; Sauter, C; Senn, HJ | 1 |
| Powles, R; Toy, JL | 1 |
| Benedek, S; Fekete, S; Gráf, F; Sréter, L; Takácsi-Nagy, L | 1 |
| Agafonov, VA; Faĭnshteĭn, FE; Kott, TL; Kovaleva, LG; Volkova, MA | 1 |
| Bloomfield, CD; Coccia, PF; Krivit, W; Nesbit, ME; Ramsay, NK | 1 |
| Garwood, FA; Groth, D; Vogler, WR | 1 |
| Bryon, PA; Fiere, D; Martin, C; Revol, L | 2 |
| Greenberg, ML; Waxman, S | 1 |
| Zittoun, R | 2 |
| Jastrzebska, M; Lukowska, K; Pacholska, J; Paciorkiewicz, W; Rokicka-Milewska, R | 1 |
| Heit, W; Maschmeyer, G; Willborn, K | 1 |
| Raymakers, RA; Rustum, YM | 1 |
| Andreeff, M; Bettelheim, P; Geissler, K; Lechner, K; Schulz, G; Sillaber, C; Tafuri, A; Valent, P; Vieder, L | 1 |
| Garewal, HS; Roe, DJ; Shamdas, GJ | 1 |
| Damiani, D; Dinota, A; Fanin, R; Geromin, A; Michelutti, A; Michieli, M; Pileri, S; Raspadori, D; Russo, D; Visani, G | 1 |
| Canty, A; Dyson, PG; Haylock, DN; Juttner, CA; Thorp, D; To, LB | 1 |
| Legrand, O; Marie, JP; Russo, D; Suberville, AM; Zhou, D; Zittoun, R | 1 |
| Brach, MA; Herrmann, F; Mertelsmann, RH | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Camitta, BP; Clavell, LA; Gelber, RD; Grier, HE; Link, MP; Weistein, HJ | 1 |
| Chiba, S; Hanazono, Y; Hirai, H; Miura, Y; Miyagawa, K; Miyazono, K; Piao, YF; Sakamoto, S; Taketazu, F; Yazaki, Y | 1 |
| Alberto, P; Mermillod, B; Zulian, GB | 1 |
| Lou, FD; Meng, FY; Zhou, Q | 1 |
| Cowan, DH; Friedman, S; Nabholtz, JM; Pinkerton, PH; Senn, JS | 1 |
| Bajko, G; Drozdowska, D; Hansz, J; Woźny, T | 2 |
| Imai, Y; Nagata, K; Nara, N; Shiina, S; Suzuki, T; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Sauter, C; Zahner, M | 1 |
| Alvarez, MA; Castillo, D; Gomez, P; Rojas, R; Torres, A; Velasco, F | 1 |
| Ahmed, T; Arlin, Z; Baskind, P; Chun, H; Cook, P; Feldman, E; Mittelman, A; Puccio, C | 1 |
| Brown, RA; Fay, JW; Herzig, GP; Herzig, RH; Phillips, GL; Wolff, SN | 1 |
| Isaev, VG; Kucher, RA; Savchenko, VG | 1 |
| Kaletin, GI; Volkova, MA | 1 |
| Brinch, L; Evensen, SA; Stavem, P; Tjønnfjord, G | 1 |
| Balcar-Boroń, A; Graduszewska-Czerebiej, K; Nowaczyk-Michalak, A | 1 |
| Abakumov, EM; Isaev, VG; Khoroshko, ND; Navashin, SM; Savchenko, VG; Sokolov, AN; Turkina, AG; Viadro, MM | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Braunsteiner, H; Dietze, O; Herold, M; Nachbaur, K; Thaler, J; Vogel, W | 1 |
| Bernstein, EF; Spielvogel, RL; Topolsky, DL | 1 |
| Belin, T; Champlin, R; Gajewski, J; Lee, M; Nimer, S; Schiller, G; Territo, M | 1 |
| el-Mangoush, M; Singh, NK | 1 |
| Grant, S; Jarvis, WD; Pettit, GR; Turner, AJ; Wallace, HJ | 1 |
| Balcar-Boroń, A; Nowaczyk-Michalak, A; Pilecki, O; Trybuś, L; Wysocki, M | 1 |
| Butti, C; Deliliers, GL; Della Volpe, A; Fossati, V; Mozzana, R; Selva, S | 1 |
| Sasaki, A; Tsukaguchi, M | 1 |
| Eguchi, T; Iwahara, Y; Kubonishi, I; Miyagi, T; Muneishi, H; Sugito, S; Taguchi, H; Takehara, N; Tanaka, Y; Uemura, Y | 1 |
| Yue, BB | 1 |
| Kimura, F; Mizukami, H; Motoyoshi, K; Nagata, N; Ohtsuki, T; Takagi, S; Takemura, Y; Yamamoto, K | 1 |
| Di Mario, A; Etuk, B; Leone, G; Pagano, L; Salutari, P; Sica, S | 1 |
| McCauley, DL | 1 |
| Bosco, L; Bufton, MG; Faich, GA; Flynn, B; Gerstman, BB; Jolson, HM; Rinsler, SS; Simmons, WD; Stadel, BV; Williams, E | 1 |
| Grever, MR; Gumbart, CH; Head, D; Hynes, HE; Kopecky, KJ; Lipschitz, DA; Ryan, DH; Shiaer, SM; Veith, RW; Vial, RH | 1 |
| Ahmed, T; Arlin, ZA; Chun, H; Cook, P; Decter, J; Feldman, E; Finger, L; Mittelman, A; Puccio, C | 1 |
| Cersosimo, RJ | 1 |
| Rebora, A; Rongioletti, F | 1 |
| Endo, K; Moriyama, Y | 1 |
| Beran, M; Deisseroth, A; Estey, E; Gutterman, J; Kantarjian, H; Keating, M; Koller, CA; O'Brien, S; Thall, PF | 1 |
| Decter, J; Karetzky, MS; O'Donnell, T | 1 |
| Barletta, JP; Fanous, MM; Margo, CE | 1 |
| Masauji, N; Matsue, K; Tohi, T; Tsukuda, K | 1 |
| de Witte, T; Ferrini, PR; Gattringer, C; Mandelli, F; Petti, MC; Solbu, G; Stryckmans, P; Tura, S; Willemze, R; Zittoun, R | 1 |
| Creutzig, U; Ritter, J; Schellong, G | 5 |
| Babin, A; Béhar, C; Bertrand, Y; Boutard, P; Brock, P; Robert, A; Rubie, H; Solbu, G; Suciu, S; Vilmer, E | 1 |
| Resegotti, L | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Bassan, R; Battista, R; Buelli, M; D'Emillio, A; Lim, J; Love, S; Oza, AM; Rohatiner, AZ; Viero, P; Whelan, JS | 1 |
| Björkholm, M; Gahrton, G; Grimfors, G; Hast, R; Järnmark, M; Juliusson, G; Killander, A; Kimby, E; Paul, C; Tidefelt, U | 1 |
| Amadori, S; Avvisati, G; Cacciola, E; Cantore, N; De Laurenzi, A; De Rosa, C; Fioritoni, G; Mandelli, F; Spadea, A; Vegna, ML | 1 |
| Bosly, A; De Bruyère, M; Delannoy, A; Deneys, V; Doyen, C; Ferrant, A; Martiat, P; Michaux, JL; Sokal, G; Van den Bossche, L | 1 |
| Dainer, PM; Knupp, CL; Sartiano, GP | 1 |
| Hempling, RE; Piver, MS; Sprance, HE | 1 |
| Grimfors, G; Järnmark, M; Lerner, R; Ljungman, P; Lönnqvist, B; Nyström-Rosander, C; Oberg, G; Palmblad, J; Samuelsson, J | 1 |
| Erturk, G; Gümrük, F; Gurgey, A; Hicsönmez, G; Karadeniz, N; Ozsoylu, S; Tuncer, AM; Zamani, VP | 1 |
| Elmhorn-Rosenborg, A; Eriksson, LC; Hao, XY; Mannervik, B; Paul, C; Tidefelt, U | 1 |
| Akerman, S; Arlin, Z; Baskind, P; Budman, DR; DeAngelis, L; Feldman, EJ; Kreis, W; Lesser, M | 1 |
| Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS | 1 |
| Browman, GP; Preisler, HD | 1 |
| Curtis, JE; McCulloch, EA; Minden, MD; Tohda, S | 1 |
| Bisserbe, S; Marie, JP; Wdowik, T; Zittoun, R | 1 |
| Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Chen, GJ; Imai, Y; Murohashi, I; Nagata, K; Nara, N; Shiina, S; Suzuki, T; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Aoki, N; Goto, Y; Kanemoto, N | 1 |
| Banavali, SD; Bokari, SA; Finke, D; Gopal, V; Preisler, HD | 1 |
| Chao, TY; Chen, LM; Hwang, SH; Hwang, WS; Kao, WY; Ko, WS; Lee, WC; Wang, CC | 1 |
| Bonnet, D; Ell, J; Gibson, J; Joshua, D; Paul, M; Pollard, J; Rahme, N | 1 |
| Ross, DD | 1 |
| Auber, ML; Dicke, KA; Horwitz, LJ; Jagannath, S; Spinolo, JA; Spitzer, G; Zander, AR | 1 |
| Gray, RG; Rees, JK | 1 |
| Fiere, D; Haanen, C; Jehn, U; Löwenberg, B; Peetermans, M; Solbu, G; Stryckmans, P; Suciu, S; Willemze, R; Zittoun, R | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Woods, WG | 1 |
| Champlin, R; Gajewski, J; Ho, W; Landaw, E; Nimer, S; Schiller, G; Vollset, S; Winston, D | 1 |
| Bogdanic, V; Hauptmann, E; Jaksic, B; Labar, B; Minigo, H; Nemet, D; Planinc-Peraica, A | 1 |
| Curtis, JE; Lipton, J; Lipton, M; McCulloch, EA; Minkin, S; Wang, YF | 1 |
| Koistinen, P; Lyman, SD; McCulloch, EA; Minden, MD; Wang, C; Wang, YF; Williams, DE; Yang, GS | 1 |
| Curtis, JE; Koistinen, P; McCulloch, EA; Wang, C | 1 |
| Champlin, RE; Gajewski, JL; Ho, WG; Nimer, SD; Schiller, GJ; Territo, MC | 1 |
| Challis, J; Farag, S; Garson, OM; White, J | 1 |
| Arlin, ZA; Banks, PL; Case, DC; Enck, RE; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Kristensen, J; Larsson, R; Nygren, P; Sandberg, C | 1 |
| Capizzi, RL; White, JC; Yang, JL | 1 |
| Jiang, CJ; Liang, DC | 1 |
| Bennett, J; Browman, G; Day, R; Goldberg, J; Gottlieb, A; Larson, RA; Preisler, HD; Raza, A; Vardiman, JW; Vogler, R | 1 |
| Mandelli, F; Meloni, G | 1 |
| Domula, M; Dörffel, W; Eggers, G; Exadaktylos, P; Fuchs, D; Hermann, J; Krause, M; Palme, H; Prager, J; Zintl, F | 1 |
| Cuddy, DP; de Valeriola, DL; Egorin, MJ; Forrest, A; Ross, DD | 1 |
| Intragumtornchai, T; Mahasandhana, S; Sucharitchan, P; Swasdikul, D; Watananukul, P | 1 |
| Brandalise, S; De Bellis, R; Fernández, I; Jiménez-Fonseca, E; Palau, V; Pavlovsky, S; Ruiz-Argüelles, G; Santarelli, MT | 1 |
| Brach, MA; Henschler, R; Herrmann, F; Mertelsmann, R | 1 |
| Bessho, F; Kigasawa, H; Nakazawa, S; Ohkawa, Y; Sugita, K; Tsuchida, M; Tsukimoto, I; Tsunematsu, Y; Yamada, K; Yamamoto, M | 1 |
| Apel, D; Hołowiecki, J; Konecki, R; Lawniczek, T; Maj, S; Mariańska, B; Mazur, J; Pałynyczko, G; Rozmysłowicz, T; Rudzka, E | 1 |
| Ardia, A; Di Pietro, N; Di Raimondo, F; Falconi, E; Ganzina, F; Geraci, E; Ladogana, S; Latagliata, R; Mandelli, F; Petti, MC | 1 |
| Brugnatelli, S; Danova, M; Giordano, M; Girino, M; Mazzini, G; Riccardi, A; Ucci, G | 1 |
| Korycka, A; Robak, T | 1 |
| Brach, M; Kufe, D; Stone, R | 1 |
| Goudsmit, R; Thomas, BL; van der Lelie, H; van Ketel, RJ; van Oers, RH; von dem Borne, AE | 1 |
| Bastida Vila, P; Giralt López, J; Javier Manchón, G; Olivé Oliveras, T; Ortega Aramburu, JJ; Sánchez, C | 1 |
| Browman, G; Goldberg, J; Kukla, C; Larson, R; Preisler, HD; Raza, A | 1 |
| McCulloch, EA; Minden, MD; Minkin, S; Wang, C; Yang, GS | 1 |
| Damon, LE; Linker, CA; Plunkett, W | 1 |
| Black, D; Brown, J; Burck, K; Collins, C | 1 |
| Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C | 1 |
| De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pinto, MR; Testi, AM; Vegna, ML; Vignetti, M | 1 |
| Attal, M; Broustet, A; Corront, B; Gastaut, JA; Hollard, D; Marit, G; Michallet, M; Reiffers, J; Rigal-Huguet, F; Stoppa, AM | 1 |
| Zhang, GZ | 1 |
| Arlin, Z; Bhalla, K; Birkhofer, M; Graham, G; Grant, S; Lutzky, J; Safah, H | 1 |
| Bergmann, OJ | 1 |
| Bonilauri, E; Butturini, A; Castriota Scanderbeg, A; Croci, G; Franchi, F; Izzi, G; Santucci, MA; Tondelli, MT | 1 |
| Gockerman, JP; Higa, GM; Horne, BJ; Hunt, AL; Jones, MR | 1 |
| Carey, M; Goldberg, J; Kukla, C; Larson, R; Preisler, H; Raza, A; Tricot, G | 1 |
| Dölken, G; Fauser, AA; Herbst, EW; Kreisel, W | 1 |
| Ben-Bassat, I; Ra'anani, P; Ramot, B; Shpilberg, O | 1 |
| Feng, CS | 1 |
| Dan, K; Hoshino, S; Kimura, M; Mizoguchi, H; Mutoh, Y; Nomura, T; Ogawa, T; Toyama, K; Urabe, A; Yamaguchi, H | 1 |
| Crocker, I; Dabbs, CK; Kalin, NS; Lopez, PF; Sternberg, P; Vogler, WR | 1 |
| Baccarani, M; Cenacchi, A; Damiani, D; Fanin, R; Fogli, M; Gamberi, B; Revignas, G; Russo, D; Tura, S; Visani, G | 1 |
| Bishop, M; Marks, L; Schulz, WC; Stiff, PJ | 1 |
| Brodsky, I; Bulova, S; Conroy, J; Crilley, P; Gryn, J; Kahn, SB; Topolsky, D; Weiss, J | 1 |
| Civin, C; Culbert, S; Krischer, J; Leventhal, B; Ragab, A; Ravindranath, Y; Ruymann, FB; Steuber, CP; Vietti, TJ; Wilkinson, R | 1 |
| Andreeff, M; Bettelheim, P; Gorischek, C; Haas, O; Haimi, J; Muhm, M; Sillaber, C; Tafuri, A; Valent, P; Vieder, L | 1 |
| Barnett, MJ; Bolwell, BJ; Brown, RA; Frei-Lahr, DA; Herzig, RH; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, S; Kolitz, J; McKenzie, S; Santorsa, J | 1 |
| Barzi, A; Lepri, E; Liberati, M; Menconi, E; Portuese, MG; Santucci, A | 1 |
| Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P | 1 |
| Fujita, N; Gotoh, H; Inaba, T; Itoh, K; Murakami, S; Nakagawa, M; Nakanishi, S; Oku, N; Shimazaki, C | 1 |
| Andoh, K; Kobayashi, N; Kubota, T; Sadakata, H; Tanaka, H | 1 |
| Bandini, G; Barbui, T; Bassan, R; Battista, R; Ciolli, S; D'Emilio, E; Leoni, F; Rosti, G; Todeschini, G; Zuffa, E | 1 |
| Fukawa, H; Harano, H; Hashimoto, Y; Kanamori, H; Kodama, F; Maruta, A; Matsuzaki, M; Miyashita, H; Murata, T; Noguchi, T | 1 |
| Biliczki, F; Bozóky, G | 1 |
| Hiddemann, W | 1 |
| Mansberg, R; Rowlings, PA; Rozenberg, MC; Yip, MY | 1 |
| Amadori, S; Arcese, W; Isacchi, G; Mandelli, F; Meloni, G; Monarca, B; Petti, MC; Testi, AM | 1 |
| Bettelheim, P; Dudczak, R; Hinterberger, W; Kyrle, PA; Lechner, K; Niessner, H; Pabinger, I; Schwarzinger, I; Speiser, W | 1 |
| Dhanapongsathorn, V; Intragumtornchai, T; Laongsiri, P; Mahasandana, S; Rajatapiti, B; Wanakrairoj, P | 1 |
| Boesen, AM; Brincker, H; Christensen, BE; Drivsholm, A; Ellegaard, J; Hansen, OP; Hippe, E; Jans, H; Jensen, KB; Pedersen-Bjergaard, J | 1 |
| Creutzig, U; Ritter, I; Schellong, G | 1 |
| Preĭsler, KhD; Raza, A | 1 |
| Bleher, E; Civin, CI; Ducore, J; Inoue, S; Krischer, J; Pitel, P; Ravindranath, Y; Sexauer, C; Steuber, CP; Vega, R | 1 |
| Potter, MN; Rogers, S; Slade, RR | 1 |
| Akazawa, K; Asano, Y; Harada, M; Morioka, E; Niho, Y; Okamura, S; Shibuya, T | 1 |
| Nagata, K; Nara, N; Suzuki, T; Tohda, S | 1 |
| Ciolli, S; Leoni, F; Morfini, M; Patriarchi, S; Rossi Ferrini, P | 1 |
| Lishner, M; McCulloch, EA; Minden, MD; Wang, C | 1 |
| Berglund, G; Gustafsson, G; Jonmundsson, G; Lie, SO; Siimes, M; Yssing, M | 1 |
| Krulder, JW; Vlasveld, LT; Willemze, R | 1 |
| Hoshino, K; Kageyama, S; Katayama, N; Kobayashi, T; Komada, F; Minami, N; Nishii, K; Nishikawa, M; Shirakawa, S; Tsukada, T | 1 |
| Chen, PM; Chuang, MW; Fan, S; Hsieh, RK; Liu, CJ; Liu, JH; Tzeng, CH | 1 |
| Aul, C; Büchner, T; Heinecke, A; Hiddemann, W; Löffler, H; Ludwig, W; Maschmeyer, G; Nowrousian, M | 1 |
| Arlin, Z; Cartwright, K; Case, DC; Desai, P; Feldman, E; Moore, J; Saletan, S; Sia, L; Wiernik, P | 1 |
| Rolston, KV | 1 |
| Camitta, BM; Clavell, LA; Garcea, MJ; Gelber, RD; Grier, HE; Link, MP; Weinstein, HJ | 1 |
| Ausserer, B; Fink, FM; Gadner, H; Grümayer, ER; Kardos, G; Mutz, I; Revesz, T; Schuler, D; Urban, C | 1 |
| Broccia, G; Caronia, F; Di Raimondo, F; Fioritoni, G; Ladogana, S; Leone, G; Liso, V; Musso, M; Neri, A; Petti, MC | 1 |
| Ehninger, G; Fackler-Schwalbe, E; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Löffler, B; Lösch, A; Mitrou, PS | 1 |
| Blasius, S; Büchner, T; Hiddemann, W; Koch, P; Kuse, R; Ludwig, WD; Maschmeyer, G; Sodomann, H; Thiel, E; Tirier, C | 1 |
| Bennett, JM; Cassileth, PA; Harrington, DP; Hines, JD; Lynch, E; Mazza, JJ; McGlave, P; O'Connell, MJ; Oken, MM | 1 |
| Austein, J; Diedrich, H; Fackler-Schwalbe, E; Freund, M; Henke, M; Hoffmann, R; Link, H; Schlimok, G; Wandt, H; Wilke, H | 1 |
| Appelt, M; Büchner, T; Eichelbaum, M; Grille, W; Hiddemann, W; Hossfeld, DK; Koslowski, B; Kraft, J; Kuse, R; Quabeck, K | 1 |
| Aul, HC; Donhuijsen-Ant, R; Grüneisen, T; Hiddemann, W; Köppler, H; Lathan, B; Ludwig, WD; Maschmeyer, G; Reichle, A; Urbanitz, D | 1 |
| Estey, E; Heinemann, V; Keating, M; Plunkett, W | 1 |
| Abels, J; de Gast, GC; Dekker, AW; Löwenberg, B; Sonneveld, P; van der Lelie, J; van Putten, WL; Verdonck, LF; Willemze, R; Zwaan, FE | 1 |
| Beran, M; Deisseroth, A; Estey, EH; Gutterman, JU; Kantarjian, HM; Keating, MJ; McCredie, KB | 1 |
| Bodey, GP; Deisseroth, AB; Dixon, D; Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; Kurzrock, R; McCredie, K; Talpaz, M | 1 |
| Ben-Ishay, Z; Prindull, G; Sharon, S; Yankelev, S | 1 |
| Bayle, C; el Zimeity, M; Sabbour, MS | 1 |
| Broustet, A; Corront, B; Gastaut, JA; Maraninchi, D; Marit, G; Michallet, M; Montastruc, M; Reiffers, J; Sotto, JJ; Stoppa, AM | 1 |
| Degos, L | 2 |
| Burke, PJ; Geller, RB; Karp, JE; Santos, GW; Saral, R | 1 |
| Burke, PJ; Donehower, RC; Karp, JE | 2 |
| Jacobs, P; Martell, RW; Wilson, EL | 1 |
| Benjamin, DR; Bernstein, ID; Buckley, JD; Feig, SA; Kim, TH; Lampkin, BC; Ruymann, FB; Smithson, WA; Srivastava, AK; Woods, WG | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Kamiya, K; Nakamura, T; Uchida, M; Ueda, T | 1 |
| Brizzi, MF; Clark, SC; Lista, P; Pegoraro, L; Resegotti, L; Rossi, M | 1 |
| Bosly, A; Chatelain, C; Delannoy, A; Doyen, C; Ferrant, A; Ghilain, JM; Martiat, P; Michaux, JL; Sokal, G | 1 |
| Buscarini, L; Cavanna, L; Civardi, G; Di Stasi, M; Fornari, F; Moretto, M; Sbolli, G | 1 |
| Butturini, A; Gale, RP; Perocco, P; Santucci, MA; Tura, S | 1 |
| Chiba, P; Eher, R; Knapp, W; Köller, U; Kraupp, M; Salamon, J; Szekeres, T; Tihan, T | 1 |
| Boyer, D; Gordon, R; Inoue, S | 1 |
| Andreeff, M; Tafuri, A | 1 |
| Gore, M; Helenglass, G; Milan, S; Parikh, P; Pinkerton, R; Powles, R; Rose, M; Smith, C; Talbot, D; Treleaven, J | 1 |
| Daeschner, CW; Heath, DV; Lockhart, LH; McCombs, JL; Rouse, BM | 1 |
| Imai, Y; Maruyama, Y; Nagata, K; Nara, N; Suzuki, T; Tohda, S; Tomiyama, J; Yamashita, Y | 1 |
| Yao, EG; Zhang, RX | 1 |
| Barcos, M; Bennett, J; Browman, G; Day, R; Kukla, C; Lykins, J; Preisler, HD; Raza, A; White, M; Yasin, Z | 1 |
| Bartolucci, A; Cohen, HJ; Raney, MR; Stein, RS; Vogler, WR; Winton, EF | 1 |
| Billström, R; Carneskog, J; Grimfors, G; Hellström, E; Kimby, E; Lindemalm, C; Oberg, G; Robèrt, KH; Samuelsson, J; Winqvist, I | 1 |
| Aul, CH; Büchner, T; Heinecke, A; Hiddemann, W; Maschmeyer, G; Schleyer, E; Uhrmeister, C | 1 |
| Itou, S; Koyama, S; Shibata, A | 1 |
| Brière, J; Desablens, B; Ghandour, C; Harousseau, JL; Milpied, N | 1 |
| Arning, M; Aul, C; Gehrt, A; Hadding, U; Runde, V; Schneider, W | 1 |
| Bordessoule, D; Casassus, P; Castaigne, S; Degos, L; Desablens, B; Henry-Amar, M; Le Prisé, PY; Tertian, G; Tilly, H | 1 |
| Dahl, GV; Johnson, FL; Kalwinsky, DK; Look, AT; Mason, C; Mirro, J; Murphy, SB; Pui, CH; Ruggiero, M; Schell, M | 1 |
| Arentsen-Honders, MW; Colly, LP; Peters, WG; Willemze, R | 1 |
| Estey, EH; Freireich, EJ; Keating, MJ; McCredie, KB; Plunkett, W | 1 |
| Hassan, HT; Rees, JK | 1 |
| Grant, S; Howe, C; Kuczynski, T | 1 |
| Smith, JG; Smith, MA; Taylor, PC | 1 |
| Büchner, T; Heinecke, A; Hiddemann, W; Martin, WR; Sauerland, CM | 1 |
| Bär, BM; de Pauw, BE; de Witte, T; Haanen, C | 1 |
| Björkholm, M; Björnsdottir, J; Grimfors, G; Stenke, L | 1 |
| ten Kate, RW; Wijermans, PW | 1 |
| Kramer, B; Reich, WK; Scheulen, ME; Skorzec, M | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, C; Harousseau, JL; Ifrah, N; Le Prise, PY; Milpied, N | 1 |
| Dekker, AW; Nieuwenhuis, HK; Verdonck, LF; Witteveen, EO | 1 |
| Gattringer, C; Konwalinka, G; Linkesch, W; Thaler, J | 1 |
| Amess, J; Davis, CL; Lim, J; Lister, TA; Rohatiner, AZ | 1 |
| Aul, C; Schneider, W | 1 |
| Büchner, T; Essink, ME; Hiddemann, W; van de Loo, J; von Eiff, M | 1 |
| Havemann, K; Koeppler, H; Pflueger, KH; Weide, R; Wolf, M | 1 |
| Domae, N; Fukushima, T; Kagawa, D; Kamiya, K; Nakamura, T; Tsutani, H; Uchida, M; Ueda, T; Yoshida, W | 1 |
| Cotes, PM; Hellebostad, M; Marstrander, J; Refsum, HE; Slørdahl, SH | 1 |
| Chen, TP; Lin, SF; Liu, HW | 1 |
| Cassileth, PA | 1 |
| Chapuis, B; Grob, JP; Helg, C; Pugin, P | 1 |
| Evans, C; Rosenfeld, CS; Shadduck, RK; Winkelstein, A; Zeigler, ZR | 1 |
| Cosson, A; Estienne, MH; Fenaux, P; Lai, JL; Lepelley, P; Preudhomme, C; Zandecki, M | 1 |
| Carcassonne, Y; Gastaut, JA; Launay, MC; Lejeune, C; Maraninchi, D; Richard, B; Sainty, D; Sebahoun, G; Tubiana, N | 1 |
| Han, P; Kueh, YK; Suri, R; Tan, YO | 1 |
| De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC | 1 |
| Advani, SH; Banavali, SD; Charak, BS; Gopal, R; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Saikia, TK | 1 |
| Bauters, F; Fenaux, P; Gardin, C; Lai, JL | 1 |
| Nooter, K; Sonneveld, P | 1 |
| Dekker, AW; Nieuwenhuis, HK; Verdonck, LF | 1 |
| Boughton, BJ; Franklin, I; Goldstone, AH; Gribben, JG; Leyland, MM; Linch, DC; McMillan, AK; Milligan, DW; Patterson, KG; Richards, JD | 1 |
| Hölzel, D; Nüssler, V; Pelka-Fleischer, R; Sauer, H; Wilmanns, W | 1 |
| De Pauw, B; De Witte, T; Haanen, C; Muus, P | 1 |
| Capizzi, RL; Contento, MM; Craig, JB; Do, KA; Gregory, BW; Kute, TE; Lyerly, ES; Powell, BL | 1 |
| Fountzilas, G; Inoue, S; Ohnuma, T | 1 |
| Saito, Y; Uzuka, Y | 3 |
| Bian, SG; Hao, YS; Wang, ZC | 1 |
| Bishop, JF; Cobcroft, R; Dodds, A; Joshua, D; Kronenberg, H; Lowenthal, RM; Ma, D; Matthews, JP; Todd, D; Whiteside, MG | 1 |
| Cooper, JT; Friedman, DJ; Halvorson, RD; Hurt, MA; Petr, FC | 1 |
| Heimpel, H; Hoelzer, D; Kurrle, E | 1 |
| Nieuwenhuis, HK; Sixma, JJ | 1 |
| Bhalla, K; Gleyzer, M; Grant, S | 1 |
| McCulloch, EA; Wang, C | 1 |
| Burnison, M; Champlin, R; Decker, R; Gale, RP; Greenberg, P; Ho, W; Holly, FE; Winston, D | 1 |
| Gyger, M; Momparler, LF; Momparler, RL; Onetto, N | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Baehner, RL; Buckley, JD; Chard, RL; Hammond, GD; Lampkin, BC; Nesbit, ME; Woods, WG | 1 |
| Archimbaud, E; Fiere, D; Sebban, C | 1 |
| Boschetti, C; Cofrancesco, E; Cortellaro, M; Moreo, G; Pogliani, E; Salvatore, M | 1 |
| Brodzki, LM; Gepner-Woźniewska, M; Pawelski, S | 3 |
| Girasoli, M; Leone, G; Liene, DR; Marra, R; Pagano, L; Storti, S | 1 |
| Hołowiecki, J; Mandecki, M; Wnuk-Wojnar, AM; Wojnar, J | 1 |
| Meyers, PA; Redner, A; Steinherz, PG; Tan, CT | 1 |
| Bender-Götze, C; Haas, RJ; Holler, E; Kolb, HJ; Thierfelder, S; Wilmanns, W | 1 |
| Bernasconi, C; Bernasconi, P; Bonfichi, M; Castagnola, C; Colombo, A | 1 |
| Bentley, DP; Campbell, IA; Green, AR; Poynton, C | 1 |
| Huijgens, PC; Langenhuijsen, MM; Nauta, JJ; Ossenkoppele, GJ; Wijermans, PW | 1 |
| Aso, T; Hino, H; Hirota, Y; Kondou, S; Makuuchi, M; Matsumoto, I; Nishiura, S; Takata, K | 1 |
| Büchner, T; Essink, M; Hiddemann, W; Huhn, D; Jung, M; Koppensteiner, R; Marosi, L; Martin, T; Minar, E; Siegert, W | 1 |
| Bardy, P; Branford, AL; Dart, GD; Dyson, PG; Haylock, DN; Ho, JQ; Horvath, N; Roberts, MM; Thorp, D; To, LB | 1 |
| Bernard, P; Boiron, JM; Marit, G; Reiffers, J; Rice, A; Vezon, G | 1 |
| Jehn, U; Zittoun, R | 1 |
| Cepelák, V; Koza, V; Slechtová, J; Svojgrová, M | 1 |
| Carella, AM; D'Amico, T; Damasio, E; Gaozza, E; Giordano, D; Nati, S; Piatti, G; Pungolino, E; Spriano, M | 1 |
| Bernabei, PA; Dal Pozzo, O; Rossi Ferrini, P; Saccardi, R; Santini, S; Santini, V | 1 |
| Tanaka, M; Yoshida, S | 1 |
| Frenkel', MA; Perilov, AA; Volkova, MA | 1 |
| Cullen, J; Freeman, AI; Hicks, RA; Jackson, MA; Sotiropoulos, SV; Woods, GM | 1 |
| Kyo, T; Maehama, S | 1 |
| Ohshima, T | 1 |
| Huijgens, PC; Langenhuijsen, MM; Ossenkoppele, GJ; van Geel, BM; Wijermans, PW | 1 |
| Avalos, M; Brivet, F; Dommergues, JP; Léonard, C; Miélot, F; Mirica, C; Tchernia, G; Tertian, G | 1 |
| Wahlin, A | 1 |
| Ihle, H; Ihle, R; Matthes, H | 1 |
| Bernhart, M; Fiedler, E; Kasparu, H; Krieger, O; Lutz, D; Weber, E | 1 |
| Gao, RL; Jin, JM; Ma, FS | 1 |
| Dufour, P; Facon, T; Guy, H; Harousseau, JL; Hurteloup, P; Ifrah, N; Milpied, N; Reiffers, J; Rigal-Huguet, F | 1 |
| Bearden, JD; Capizzi, RL; Jackson, DV; Lyerly, ES; Morgan, TM; Muss, HB; Powell, BL; Richards, F; Rosenbaum, DL; White, DR | 1 |
| Amadori, S; Avvisati, G; Covelli, A; De Laurenzi, A; Leone, G; Leoni, P; Liso, V; Mandelli, F; Neri, A; Petti, MC | 1 |
| Champlin, RE; Gajewski, JL; Golde, DW | 1 |
| Abels, J; Bury, J; Fière, D; Haanen, C; Hayat, M; Jehn, U; Löwenberg, B; Peetermans, M; Willemze, R; Zittoun, R | 1 |
| Carr, T; Chang, J; Coutinho, LH; Deakin, DP; Dexter, TM; Morgenstern, GR; Scarffe, JH; Testa, NG | 1 |
| Omura, G; Raney, M; Velez-Garcia, E; Vogler, WR | 1 |
| Aegerter, P; Gorin, NC; Gratwohl, A; Hayat, M; Hermans, J; Stijnen, T; Stryckmans, P; Suciu, S; Zittoun, R; Zwaan, FE | 1 |
| Azarnia, N; Benger, A; Browman, G; Chervenick, P; D'Arrigo, P; Doeblin, T; Goldberg, J; Preisler, H; Raza, A; Syracuse, K | 1 |
| Amadori, S; Ceci, A; Comelli, A; Defazio, D; Madon, E; Mandelli, F; Masera, G; Nespoli, L; Paolucci, G; Zanesco, L | 1 |
| Broccia, G; Carotenuto, M; De Rosa, F; Di Marco, P; Di Raimondo, F; Fioritoni, G; Leone, G; Mandelli, F; Petti, MC; Vegna, ML | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Lazzarino, M; Merante, S; Morra, E | 1 |
| Dicke, KA; Spinolo, JA | 1 |
| Amadori, S; De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pulsoni, A; Sandrelli, A | 1 |
| Goldstone, AH; Gribben, JG; Linch, DC; MacMillan, AK; Richards, JD | 1 |
| Bernasconi, C | 1 |
| Forgeson, G; Gore, M; Goss, G; Lakhani, A; Maitland, J; Milan, S; Nandi, A; Perren, T; Powles, R; Treleaven, J | 1 |
| Morgan, HJ; Schreiner, RD | 1 |
| Cannistra, SA; Griffin, JD; Groshek, P | 1 |
| Düllmann, J; Gerhartz, H; Illinger, H; Keilhauer, R; König, H; Linkesch, W; Michlmayr, G; Moldrzyk, D | 1 |
| Aul, C; Balleisen, L; Donhuijsen-Ant, R; Grüneisen, T; Hiddemann, W; Hoffmann, R; Köppler, H; Lathan, B; Ludwig, WD; Maschmeyer, G | 1 |
| Dohy, H; Kyo, T | 3 |
| Bustelo, P; Freigeiro, D; Jiménez, E; Kohan, R; Kvicala, R; Pavlovsky, S; Richard, L; Sackmann Muriel, F; Santarelli, MT; Scaglione, C | 1 |
| Drozdova, TS; Maiakova, SA; Makhonova, LA | 1 |
| Burke, PJ; Geller, RB; Karp, JE; Vaughan, WP | 1 |
| Braine, HG; Burke, PJ; Fox, MG; Geller, RB; Hall, KL; Humphrey, RL; Karp, JE; Morrell, L; Tucker, RW; Zahurak, M | 1 |
| Bernstein, ID; Buckley, JD; Feig, SA; Hammond, GD; Kersey, JH; Kim, T; Lampkin, BC; Nesbit, ME; Piomelli, S | 1 |
| Bogdanić, V; Hauptman, E; Jaksić, B; Kovacević, J; Labar, B; Minigo, H; Mrsić, M; Nemet, D; Pavletić, Z; Sertić, D | 1 |
| Pretnar, J | 1 |
| Gastineau, DA; Gerstner, JB; Goldberg, RM; Gundlach, WJ; Kardinal, CG; Letendre, L; Mailliard, JA; Niedringhaus, RD; Pierre, RV; Therneau, TM | 1 |
| Estey, E; Heinemann, V; Keating, MJ; Plunkett, W | 1 |
| Ciolli, S; Leoni, F; Rossi Ferrini, P | 1 |
| Andreeff, M; Berman, E; Clarkson, BD; Gabrilove, J; Gee, TS; Gulati, S; Kempin, SJ; Raymond, V; Wiernik, PH; Young, CW | 1 |
| Carella, AM; Cerri, R; Giordano, D; Nati, S; Piatti, G; Pungolino, E; Risso, M | 1 |
| Boughton, BJ; Donohue, SM | 1 |
| Gahrton, G; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U | 1 |
| Dybedal, I; Lamvik, J | 1 |
| Iavorkovskiĭ, LI; Klutse, GK; Shvidel', LM; Zile, MA | 1 |
| Abakumov, EM; Faĭnshteĭn, FE; Isaev, VG; Kucher, RA; Shakhbaian, GP | 1 |
| Bennett, JM; Cassileth, P; Ebrahim, K; Kahn, SB; Knospe, WH; O'Connell, MJ | 1 |
| Kodera, Y; Minami, S; Morishima, Y; Morishita, Y; Nagai, T; Ohno, R; Saito, H; Tanimoto, M; Yokomaku, S | 1 |
| Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Itami, S; Mizunuma, N; Mukaiyama, T; Ogawa, M; Tabata, M | 1 |
| Hassan, FM; Pesce, AJ; Pruemer, JM; Warner, A; Wermeling, JR | 1 |
| Hino, K; Nakamaki, T; Sakashita, A; Sano, M; Suzuki, K; Tomoyasu, S; Tsuruoka, N | 1 |
| Akagi, K; Asou, N; Goto, J; Hamasaki, N; Hidaka, M; Kawano, F; Kurisaki, H; Sawatari, T; Suzushima, H; Takatsuki, K | 1 |
| Alvarez, A; del Potro, E; Díaz Mediavilla, J; Díaz Morfa, M; Guerra, JL; Krsnik, I; Llorente, L; López, JC; Martínez, R; Villegas, A | 1 |
| Brinch, L; Evensen, SA; Wisløff, F | 1 |
| Ozaki, S; Ryo, R; Saigo, K; Tatsumi, E; Ueda, K; Yamaguchi, N | 1 |
| Hoffman, MS; Turnquist, D | 1 |
| Castaman, G; Castronovo, S; Cortesi, S; Dini, E; Quaglio, R; Rodeghiero, F; Soffiati, G | 1 |
| Bagot, M; Cordonnier, C; Jais, JP; Kuentz, M; Landais, P; Oksenhendler, E; Roujeau, JC; Vernant, JP | 1 |
| Kano, Y; Kitagawa, S; Miura, Y; Muto, Y; Sakamoto, S; Sasaki, R; Suda, K; Takaku, F; Tsuboyama, A; Yoshida, M | 1 |
| Hayashi, K; Ito, T; Kamiya, O; Kinoshita, T; Nagata, K; Ohara, K; Ono, Y; Saito, M; Sugiura, I; Yamamoto, K | 1 |
| Damon, LE; Linker, CA; Mass, R | 1 |
| Kelleher, CA; McCulloch, EA; Minkin, S; Miyauchi, J; Wang, C | 1 |
| Deng, CG; Hu, HZ; Li, SQ; Liu, MY; Wang, YJ; Wu, JX; Yao, QX; Zhang, YL; Zhu, S | 1 |
| Champlin, RE; Gajewski, JL; Gekelman, L; Hirji, KF; Ho, WG; Jacobs, AD; Nimer, SD | 1 |
| Ito, T; Komatu, M; Saito, Y; Takahashi, H; Uzuka, Y | 1 |
| Curtis, JE; Lishner, M; McCulloch, EA; Minkin, S | 1 |
| Castaman, G; Rodeghiero, F; Ruggeri, M | 1 |
| Caro, J; Erslev, AJ; Piroso, E | 1 |
| Catovsky, D; Galton, DA; Goldman, JM; Hegde, U; Marcus, RE; Newland, AC; Slocombe, G | 1 |
| Gore, ME; Lwin, KY; Powles, RL; Sloane, JP; Smith, JF | 1 |
| Aul, HC; Büchner, T; Donhuijsen-Ant, R; Hiddemann, W; Kreutzmann, H; Lengfelder, E; Ludwig, WD | 1 |
| Copplestone, JA; Hamblin, TJ; Mufti, GJ; Oscier, DG; Worsley, A | 1 |
| Bayle, J; Cassuto, JP; Dujardin, P; Fuzibet, JG; Gratecos, N; Pesce, A; Raynaud, S | 2 |
| Gray, RG; Hayhoe, FG; Rees, JK; Swirsky, D | 1 |
| Burke, PJ; Dole, GB; Donehower, RC; Enterline, JP; Fox, MG; Karp, JE | 1 |
| Amadori, S; Mandelli, F; Meloni, G; Miniero, R; Papa, G; Petti, MC | 1 |
| Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L | 1 |
| Dua, H; Kochupillai, V; Kumar, L | 1 |
| de Arriba, G; Hernando, L; Oliva, H; Ordi, J; Thomson, M | 1 |
| Burns, CP; Lazarus, HM; Vogler, WR; Winton, EF | 1 |
| Graves, T; Hooks, MA | 1 |
| Anderson, K; Cuttner, J; DuPre, E; Holland, JF; Preisler, HD; Rai, K; Yates, J | 1 |
| Annaloro, C; Cortelezzi, A; Cortellaro, M; Della Volpe, A; Lambertenghi-Deliliers, G; Maiolo, AT; Mozzana, R; Pogliani, E; Polli, EE; Pozzoli, E | 1 |
| Mandelli, F; Petti, MC | 1 |
| Arlin, ZA; Case, DC; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Gerhartz, HH; Kolb, HJ; Mittermüller, J; Wilmanns, W | 2 |
| Li, CW; Li, YS; Zhang, TD | 1 |
| Holt, PJ; Lucas, GS; Shall, L; Whittaker, JA | 1 |
| Gustavsson, A; Kjellén, E; Olofsson, T; Pero, RW | 1 |
| Capizzi, RL; Cooper, MR; Lyerly, ES; Powell, BL | 1 |
| Einhorn, S; Gahrton, G; Hellström, E; Robèrt, KH | 1 |
| Ross, DW | 3 |
| Bennett, TE; Chaplinski, TJ | 1 |
| Oberg, G; Venge, P | 1 |
| Arentsen-Honders, MW; Colly, LP; Peters, WG; Richel, D; Starrenburg, CW; Willemze, R | 1 |
| Kamiyama, T; Katoh, A; Kobayashi, H; Koyama, T; Maruyama, Y; Miura, O; Murakami, N; Nakamura, Y; Suzuki, T; Tohda, S | 1 |
| Dutcher, JP; Wiernik, PH | 1 |
| Burghouts, J; Bury, J; Jager, U; Jehn, U; Löwenberg, B; Solbu, G; Stryckmans, P; Suciu, S; Willemze, R; Zittoun, R | 1 |
| Blankenborg, G; De Witte, T; Haanen, C; Koekman, E; Muus, P; Van der Lely, N; Van der Locht, A; Wessels, J | 1 |
| Firkin, FC; Januszewicz, EH | 1 |
| Advani, SH; Gopal, R; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Rajni, A; Saikia, TK | 1 |
| Brodowski, L; Drzewoski, J; Hołub, A; Krykowski, E; Matusewicz, W; Robak, T | 1 |
| Dong, ZR; Liu, FZ; Xu, SR; Yao, EG | 1 |
| Zhao, SC | 1 |
| Abe, T; Aoki, Y; Hanada, T; Nagasawa, T; Nakazawa, M; Ninomiya, H; Shibuya, A | 1 |
| Fu, Z; Hou, CH; Li, JL; You, XY; Zhang, ZY; Zhu, YF | 1 |
| Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, T; Walters, R | 1 |
| Cai, JR; Chen, SR; Gu, LJ; Huang, ME; Shen, ZX; Wang, ZY; Xie, JX; Ye, YC; Zhao, JC; Zhao, L | 1 |
| Attadia, V; Cimino, R; Colletta, G; Colombatti, A; Pinto, A; Rosati, R | 1 |
| Comelli, A; Cordero di Montezemolo, L; Fiandino, G; Madon, E; Miniero, R; Saracco, P | 1 |
| Colly, LP; Hhlen, K; van der Does-van den Berg, A; Vossen, JM | 1 |
| Blanc, CM; Marie, JP; Rio, B; Zittoun, R | 1 |
| Capizzi, RL; Cooper, MR; Cuttner, J; Davis, R; Dillman, R; Dupre, E; Ellison, RR; Major, WB; McIntyre, OR; Powell, B | 1 |
| Hirai, J; Itoh, K; Kanno, M; Kobayashi, K; Matsuda, TT; Nakamura, S; Ohtake, S; Yoshida, T | 1 |
| Colly, LP; Peters, WG; Willemze, R | 4 |
| Vilpo, JA; Vilpo, LM | 1 |
| Lie, SO; Norum, KR; Petersen, LB; Slørdahl, SH; Wathne, KO | 1 |
| Hirosawa, S | 1 |
| Fujiwara, Y; Murase, T; Nagai, H; Nakaide, Y; Ohkita, T; Tanaka, M | 1 |
| Andersson, B; Beran, M; Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Plunkett, WK; Walters, RS | 1 |
| Adachi, S; Akiyama, Y; Kiriyama, Y; Kubota, Y; Mikawa, H; Takimoto, T; Tanizawa, A | 1 |
| Araszkiewicz, Z; Polubiec, M | 1 |
| Boesen, P; Fallingborg, J; Spaun, E | 1 |
| Daly, KM; Larson, RA; Le Beau, MM; Pape, LH; Rowley, JD; Vardiman, JW; Wernli, M | 1 |
| Larson, R; Le Beau, MM; Leichman, L; Levin, B; Shepard, KV | 1 |
| Lawlor, E; McCann, SR; Murray, M; Sarsfield, P | 1 |
| Bettelheim, P; Haas, O; Hinterberger, W; Jäger, U; Korninger, C; Kyrle, PA; Leitha, T; Neumann, E; Schlappack, O; Schwarzinger, I | 1 |
| Hatae, Y; Hatayama, Y; Nakadate, H; Takeda, T | 1 |
| Cooper, RB; Pezzimenti, J; Provatas, AC | 1 |
| Balaban, EP; Cox, JV; Frenkel, EP; Haley, BB; Harth, CA; Schneider, NR; Sheehan, R | 1 |
| Adachi, Y; Murohashi, I; Nagata, K; Nara, N; Suzuki, T; Yamashita, Y | 1 |
| Dong, ZR; Xu, SR; Yao, EG | 1 |
| Juttner, CA; Kimber, RJ; Roberts, MM; To, LB | 1 |
| Aiba, K; Ichiba, K; Isogai, Y; Kobayashi, T; Kuraishi, Y; Nagata, T; Nakamura, T; Ogawa, M; Usui, N; Yamazaki, H | 1 |
| Furukawa, Y; Inoue, T; Kishida, T; Kojima, K; Sagawa, H; Sannomiya, Y; Sasaki, A; Yamane, T; Yokomatsu, Y; Yoshikawa, T | 1 |
| Marie, JP; Thevenin, D; Zittoun, R | 1 |
| Ishikawa, E; Kawakami, M; Kuraishi, Y; Meguro, S; Tanaka, H | 1 |
| Abe, T; Kobayashi, T; Kondo, I; Sato, Y; Tomiyama, J; Yoda, Y | 1 |
| Masuda, M; Mizoguchi, H; Mori, S; Motoji, T; Osada, K; Oshimi, K; Shimizu, M; Takanashi, M | 1 |
| Kamiyama, T; Kato, A; Koyama, T; Maruyama, Y; Miura, O; Murakami, N; Nagata, K; Nakamura, Y; Suzuki, T; Tohda, S | 1 |
| Gomis, F; Lorenzo, JI; Martín Aragonés, G; Martínez, JA; Rafecas, FJ; Sanz, GF; Sanz, MA | 1 |
| Nara, N | 1 |
| Nakada, H; Takahashi, I | 1 |
| Avanzi, GC; Lista, P; Pegoraro, L; Porcu, P | 1 |
| Arlin, Z; Bhalla, K; Birkhofer, M; Graham, G; Grant, S; Lutzky, J | 1 |
| Bello, C; Carrera, D; Coma, A; Conde, E; Fanjul, E; Garijo, J; Hermosa, V; Iriondo, A; Rayon, C; Richard, C | 1 |
| Büchner, T; Essink, M; Hiddemann, W; Koch, O; Stenzinger, W; van de Loo, J | 1 |
| Jehn, U; Knüppel, W; Wilmanns, W | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS; Ohl, S; Queisser, W; Schlimok, G | 2 |
| Bolwell, BJ; Cassileth, PA; Gale, RP | 2 |
| Arthur, K; Kufe, D; Mayer, RJ; Robbins, G; Spriggs, DR | 1 |
| Büchner, T; Hiddemann, W; Koch, P; Kreutzmann, H; Kuse, R; Maschmeyer, G; Mohr, A; Pielken, HJ; Urbanitz, D; Wendt, F | 1 |
| Bode, U; Creutzig, U; Henze, G; Jürgens, H; Prindull, G; Ritter, J; Schellong, G | 1 |
| Preisler, HD; Sato, H | 1 |
| Cuttner, J; Davis, R; Holland, JF; Mayer, R; McIntyre, OR; Preisler, H; Rai, KR; Yates, J | 1 |
| Büchner, T; Donhuijsen-Ant, R; Fuhr, HJ; Hiddemann, W; Kreutzmann, H; Lengfelder, E; Ludwig, WD; Straif, K | 1 |
| Anders, C; Niederle, N; Nowrousian, MR; Osieka, R; Pfeiffer, R; Schaefer, UW; Schmidt, CG | 1 |
| Alberto, P; Berchtold, W; Fopp, M; Gmür, J; Gratwohl, A; Imbach, P; Maurice, P; Obrecht, P; Sauter, C; Senn, HJ | 1 |
| Fink, FM; Gadner, H; Grümayer, ER; Kardos, G; Revesz, T; Schuler, D | 2 |
| Boiron, M; Bordessoule, D; Desablens, B; Guilhot, F; Guy, H; Harousseau, JL; Lepage, E; Leverger, G; Marty, M; Schaison, G | 1 |
| Büchner, T; Gassmann, W; Hiddemann, W; Kreutzmann, H; Kuse, R; Löffler, H; Maschmeyer, G; Mohr, A; Urbanitz, D; Wendt, F | 1 |
| Büchner, T; Heinecke, A; Koch, P; Ludwig, WD; Maschmeier, G; Pielken, H; Urbanitz, D; van de Loo, J | 1 |
| Budde, M; Creutzig, U; Riehm, H; Ritter, J; Schellong, G | 1 |
| Dörffel, W; Eggers, G; Exadaktylos, P; Fuchs, D; Hermann, J; Hilgenfeld, E; Kotte, W; Malke, H; Plenert, W; Zintl, F | 1 |
| Dahl, GV; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Linch, DC; Singer, CR | 1 |
| Aggarwal, S; Dua, H; Francis, S; Kochupillai, V; Kumar, L; Nanu, A; Sharma, S; Singh, S; Verma, IC | 1 |
| Covelli, A; De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pulsoni, A; Sandrelli, A; Simone, F | 1 |
| Amess, J; Barnett, MJ; Bassan, R; Biruls, R; Gregory, W; Lister, TA; Rohatiner, AZ | 1 |
| Chang, CS; Chen, JR; Lin, SF; Liu, HW; Yen, JH | 1 |
| Archimbaud, E; Coiffier, B; Fiere, D; Guyotat, D; Maupas, J; Sebban, C; Treille-Ritouet, D | 1 |
| Amato, R; Kantarjian, H; Keating, M; Walters, R | 1 |
| Barnett, MJ; Bassan, R; Biruls, R; Ganesan, TS; Gregory, WM; Malik, ST; Richards, MA; Rohatiner, AZ; Tucker, J; Waxman, J | 1 |
| Miura, Y; Owada, N; Sakamoto, S; Sasaki, R; Yoshida, M | 1 |
| Durham, JP; Fontana, JA; Rogers, JS | 1 |
| Bodensteiner, J; Dunton, SF; Krous, HF; Nitschke, R; Spruce, WE | 1 |
| Baquerizo, H; Byrnes, JJ; Gonzalez, M; Hensely, GT | 1 |
| Curtis, JE; McCulloch, EA; Nara, N; Senn, JS; Tritchler, DL | 1 |
| Archimbaud, E; Bryon, PA; Campos, L; Coiffier, B; Extra, JM; Fière, D; Guyotat, D; Milan, JJ; Van, HV; Viala, JJ | 1 |
| Muus, P; Punt, K; Roelofs, JM; van Prooijen, HC | 1 |
| Fisher, RI; Fisher, SG; Messmore, HL; Nand, S; Patel, R | 1 |
| Borit, A; Fields, WS; Hwang, TL; Lee, YY; Yung, WK | 1 |
| Bhandal, AK; Brelvi, ZS; Studzinski, GP | 1 |
| Iacoboni, S; Keating, MJ; Plunkett, W | 1 |
| Hammerstrøm, J; Hoff, JE; Langtind, J; Lødemel, B; Waage, A | 1 |
| Horiuchi, A; Kanamaru, A; Kitani, T; Kohsaki, M; Masaoka, T; Nagai, K; Shibata, H; Tagawa, S; Tsubaki, K; Yasunaga, K | 1 |
| Blaney, C; Lawlor, E; McCann, SR; Murray, M; Sarsfield, P | 1 |
| Durmaz, R; Ucar, K | 1 |
| Cold, S | 1 |
| Abe, T; Aoki, Y; Nagasawa, T; Nakazawa, M; Ninomiya, H; Shibuya, A | 1 |
| Cork, A; Dalton, WT; Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, TL; Trujillo, JM; Walters, RS | 1 |
| Benny, WB; Moir, CR; Scudamore, CH | 1 |
| Abita, JP; Balitrand, N; Chomienne, C; Degos, L | 1 |
| Baer, MR; Ferrin, W; Flexner, JM; Greer, JP; Lenox, R; Stein, RS | 1 |
| Dahl, GV; Dow, LW; Kalwinsky, DK; Mirro, J; Nash, MB; Roberson, PK | 1 |
| Bourguignat, A; Eydoux, P; Floiras, JL; Le Doussal, V; Trassard, M; Turpin, F | 1 |
| Amaki, I; Hayakawa, Y; Horikoshi, A; Kawamura, M; Murakami, J; Ohshima, T; Sakurai, T; Takeo, H; Takeuchi, J | 1 |
| Andersson, BS; Beran, M; Hittelman, WN; McCredie, KB | 1 |
| Hayashi, M; Hozumi, M; Okabe-Kado, J | 1 |
| Aardema, MJ; Preston, RJ | 1 |
| Estey, EH; Freireich, EJ; Iacoboni, S; Kantarjian, HM; Keating, MJ; McCredie, KB; Plunkett, W; Walters, RS | 1 |
| Aoyama, S; Hayashi, N; Inagaki, T; Kobayashi, Y; Nakada, H; Nonaka, K; Ohmoto, E; Sekito, N; Takahashi, I; Uchida, K | 1 |
| Bodey, GP; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Walters, RS | 1 |
| Castellanos, AM; Glass, JP; Keating, MJ; Ventura, GJ | 1 |
| Barnett, MJ; Bragman, K; Dhaliwal, HS; Lister, TA; Malpas, JS; Prentice, HG; Shannon, MS | 1 |
| Compagnoni, G; Falda, M; Genazzani, E; Infelise, V; Lovisone, E; Silvestro, L; Viano, I | 1 |
| Beck, JD | 1 |
| Carter, JM; Dewar, JM; Pease, C | 1 |
| Jacobs, P; Martell, RW | 1 |
| Kato, Y; Minami, S; Morishima, Y; Murase, T; Nagura, E; Ogura, M; Ohno, R; Okumura, M; Suzuki, H; Yamada, H | 1 |
| Fehr, J; Gmür, J; Hofmann, V; Honegger, HP; Morant, R; Sauter, C | 1 |
| Honma, Y; Hozumi, M; Kasukabe, T; Nishii, Y; Suda, T | 1 |
| Kawamura, M; Ohshima, T | 1 |
| Kim, SH; Okabe, T; Okazaki, K; Suzuki, H; Tanaka, N; Tanara, M; Wu, RT | 1 |
| Brito-Babapulle, F; Catovsky, D; Galton, DA; Goldman, JM; Marcus, RE; Newland, AC; Slocombe, G | 1 |
| Arlin, Z; Büchner, T; Donhuijsen-Ant, R; Hiddemann, W; Kreutzmann, H; Lengfelder, E; Ludwig, WD; Mertelsmann, R; Straif, K | 1 |
| Gilbert, RD; Karabus, CD; Mills, AE | 1 |
| Baba, N; Harasawa, N; Ito, H; Kurayashiki, R; Miyawaki, S; Nemoto, K; Tobe, I; Uchida, S; Wakamatsu, R; Yashiro, K | 1 |
| Cararach, V; Carreras, E; Fortuny, A; Grañena, A; Rozman, C; Sierra, J; Urbano Ispizua, A | 1 |
| Burke, PJ; Dole, GB; Donehower, RC; Karp, JE | 1 |
| Freireich, EJ | 1 |
| Drenthe-Schonk, A; Haanen, C; Linssen, P; Muus, P; Wessels, H | 1 |
| Audhuy, B; Barats, JC; Blaise, AM; Boilletot, A; Flesch, M; Herbrecht, R; Pignon, B; Rozenbaum, A | 1 |
| Gomis, F; Javier Rafecas, F; Lorenzo, IJ; Martín-Aragonés, G; Martínez, JA; Marty, ML; Sanz, GF; Sanz, MA; Sayas, MJ | 1 |
| Reilly, IA; Russell, NH; Sadler, J | 1 |
| Adams, TM; Estey, E; Kantarjian, H; Keating, MJ; Liliemark, JO; Nowak, B; Plunkett, W | 1 |
| Aoki, N; Imai, Y; Murohashi, I; Nara, N; Tanikawa, S; Yamashita, Y | 1 |
| Baba, N; Karasawa, M; Miyawaki, S; Nakura, M; Nemoto, K; Takada, M; Tanaka, H; Uchida, S; Wakamatsu, R; Yashiro, K | 1 |
| Finch, LR; Jamieson, GP; Snook, M; Wiley, JS | 1 |
| Berrebi, A; Lotem, J; Sachs, L; Shtalrid, M | 1 |
| Colly, LP; Guiot, HF; Peters, WG; Willemze, R | 1 |
| Bénichou, J; Chastang, C; Lepage, E | 1 |
| Fekete, S; Ihle, R; Kasparu, H; Köller, U; Krieger, O; Lutz, D; Minigo, H; Nowotny, H; Tüchler, H | 1 |
| Griffin, JD; Kufe, DW; Spriggs, DR | 1 |
| Colly, LP; Hagenbeek, A; Martens, AC | 1 |
| de Witte, T; Haanen, C; Muus, P; Raijmakers, R; Salden, M; Wessels, J | 1 |
| Delanian, S; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 1 |
| Gray, R; Rees, JK | 1 |
| Brito-Babapulle, F; Catovsky, D; Galton, DA; Goldman, JM; Newland, AC | 1 |
| Barnett, MJ; Bassan, R; Ganesan, TS; Gregory, W; Lister, TA; Richards, MA; Rohatiner, AZ; Tucker, J; Waxman, J; Willis, L | 1 |
| Estey, E; Freireich, EJ; Keating, MJ; McCredie, KB; Plunkett, W | 1 |
| Arlin, Z; Büchner, T; Donhuijsen-Ant, R; Hiddemann, W; Kreutzmann, H; Lengfelder, E; Ludwig, WD; Mertelsmann, R; Planker, M; Straif, K | 1 |
| Boogaerts, MA; Emonds, MP; Tricot, G; Verwilghen, RL; Vlietinck, R | 1 |
| Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Walters, RS | 1 |
| Camitta, BM; Delorey, MJ; Gelber, RD; Grier, HE; Leavitt, PR; Link, MP; Price, KN; Weinstein, HJ | 1 |
| Merino Moreno, J; Núñez Olarte, JM; Ortega Núñez, A; Pastor Gómez-Cornejo, L; Picó Sambucety, JM | 1 |
| Dudley, JM; Duncombe, AS; Slater, NG; Sturgess, I | 1 |
| Katayama, N; Minami, N; Shirakawa, S; Tanaka, I | 1 |
| Berkowitz, FE; Greeff, M; Ngwenya, ET; Rabson, AR; Wadee, AA; Wehde, S | 1 |
| Bradstock, K; Castaldi, P; Gottlieb, D; Koutts, J; Lee, C; Robertson, T | 1 |
| Champlin, RE; Decker, RW; Ho, WG | 1 |
| Kokenberg, E; Löwenberg, B; Nooter, K; Sonneveld, P; van der Steuijt, K | 1 |
| Bauch, HJ; Pielken, HJ; Preusser, P | 1 |
| Aul, C; Heyll, A; Heyll, U; Schneider, W | 1 |
| Franke, A; Mey, U | 1 |
| Aul, C; Heyll, A | 1 |
| Fülle, HH; Hellriegel, KP | 2 |
| Kubaschinski, G; Nowrousian, MR; Pfeiffer, R; Schaefer, UW; Schmidt, CG | 1 |
| Lie, SO; Slørdahl, SH | 1 |
| Berthold, F; Creutzig, U; Lampert, F | 1 |
| Brilhante, D; Delmer, A; Marie, JP; Zittoun, R | 1 |
| Camitta, B; Delorey, M; Gelber, R; Grier, H; Link, M; Price, K; Weinstein, H | 1 |
| Amadori, S; Ceci, A; Comelli, A; Covelli, A; Madon, E; Mandelli, F; Masera, G; Nespoli, L; Paolucci, G; Zanesco, L | 1 |
| Aoyama, S; Hara, M; Hayashi, N; Inagaki, T; Nakada, H; Nishimura, M; Ohmoto, E; Sekito, N; Takahashi, I; Yorimitu, S | 1 |
| Nakada, H; Nishimura, M; Nonaka, K; Ohmoto, E; Ohnoshi, T; Takahashi, I | 1 |
| Catovsky, D; Dharmasena, F; Drysdale, HC; Englert, H; Galton, DA | 1 |
| Huang, ME; Ye, YC; Zhao, L | 1 |
| Kern, W; Kurrle, E; Vanek, E | 1 |
| Ota, K | 1 |
| Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Háber, J; Klener, P; Kolesková, E | 1 |
| Carpenter, BF; Hsu, E; Katsanis, E; Luke, KH; Mantynen, PR | 1 |
| Jones, RJ; Karp, JE; Roubenoff, R; Stevens, MB | 1 |
| Kufe, D; Ohno, Y; Robbins, G; Spriggs, D | 1 |
| Berney, JJ; Francis, GE; Guimaraes, JE; Hamblin, TJ; Knowles, SM; Mufti, GJ; Secker-Walker, LM | 1 |
| Islam, A | 1 |
| Grasmane, DV; Iavorskiĭ, LI | 1 |
| Elstner, E; Goldschmidt, H; Ihle, R; Wächter, M | 1 |
| Balaian, LN; Kravtsova, VM; Patterson, D; Petrova, EM; Zabelina, TS | 1 |
| Chen, JR; Chien, CH; Lin, SF; Liu, HW | 1 |
| Harrison, P | 1 |
| de Bruïne, FT; Peters, WG; Tham, RT; Willemze, R | 1 |
| Berthold, F; Harbott, J; Lampert, F; Ludwig, WD | 1 |
| Blakley, RL; Jamieson, GP; Lihou, MG; Pemble, LB; Smith, PJ | 1 |
| Hast, R; Reizenstein, P; Stenke, L | 1 |
| Boogaerts, MA; Tricot, G; Verwilghen, RL | 1 |
| Brennan, J; Browman, G; Goldberg, J; Gottlieb, AJ; Grunwald, H; Miller, KB; Preisler, HD; Rai, K; Vogler, WR; Winton, EF | 1 |
| De Cataldo, F; Haanen, C; Hayat, M; Jehn, U; Lowenberg, B; Monconduit, M; Peetermans, M; Stryckmans, P; Willemze, R; Zittoun, R | 1 |
| Frauer, HM; Heil, G; Heimpel, H; Hoelzer, D; Kurrle, E; Link, H; Ostendorf, P; Waller, HD; Wilms, K | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS | 1 |
| Arlin, Z; Büchner, T; Donhuijsen-Ant, R; Hiddemann, W; Kreutzmann, H; Lengfelder, E; Ludwig, WD; Straif, K | 1 |
| Cassileth, PA; Gale, RP | 1 |
| Gassmann, W; Kayser, W; Löffler, H; Schmitz, N | 1 |
| Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P | 1 |
| Curtis, JE; McCulloch, EA; Messner, HA; Minden, MD; Minkin, S | 1 |
| Boiron, M; Gisselbrecht, C; Lenoble, M; Lepage, E; Marty, M | 1 |
| Benavides, M; Delgado, M; Gastiaburu, J; Goldschmidt, E; Machover, D; Mathe, G; Misset, JL; Vandenbulcke, JM | 1 |
| Kufe, DW; Spriggs, DR; Stone, RM | 1 |
| Adeleine, P; Archimbaud, E; Fiere, D; Guyotat, D; Sebban, C; Treille-Ritouet, D; Viala, JJ; Vuvan, H | 1 |
| Preisler, HD; Raza, A; Spiridonidis, C; Zhao, SC | 1 |
| Bierling, P; Brun, B; Cordonnier, C; Duedari, N; Farcet, JP; Heilmann, MG; Imbert, M; Kuentz, M; Rodet, M; Vernant, JP | 1 |
| Gudauskas, G; Rootman, J | 1 |
| Fibbe, WE; Kootte, AM; Lie, R; Peters, WG; Rodenburg, CJ; van Berkel, M; van Hennik, MB; Veltkamp, JJ; Willemze, R | 1 |
| Jusufhodzić, L; Labar, B | 1 |
| Giordano, P; Mazzini, G; Montecucco, C; Riccardi, A; Traversi, E | 1 |
| Lutz, D | 1 |
| Colla, L; Colly, LP; Peters, WG; Willemze, R | 1 |
| Broustet, A; David, B; Marit, G; Reiffers, J | 1 |
| Iizuka, A; Kigasawa, H; Nagao, T; Nishihira, H | 1 |
| Grützmeier, S | 1 |
| Baker, MA; Chang, G; Grant, S; Hindenburg, AA; Taub, RN | 1 |
| Azarnia, N; Barcos, M; Booker, L; Brennan, J; Browman, G; Goldberg, J; Gottleib, A; Preisler, HD; Rakowsky, I; Raza, A | 1 |
| Preisler, HD; Riva, CM; Rustum, YM | 1 |
| Campos, L; Coiffier, B; Extra, JM; Ffrench, M; Fiere, D; Guyotat, D; Huan, VV; Ritouet, D | 1 |
| Barnett, MJ; Bragman, KS; Ganesan, TS; Lister, TA; Richards, MA; Rohatiner, AZ; Waxman, JH | 1 |
| Haanen, C; Marie, JP; Marquet, J; Zittoun, J; Zittoun, R | 1 |
| Lie, SO; Slørdahl, S | 1 |
| Colly, LP; Edelbroek, PM; Honders, W; vd Hoorn, F; Willemze, R | 1 |
| Andersson, B; Beran, M; Estey, E; Freireich, EJ; Iacoboni, S; Kantarjian, H; Keating, MJ; McCredie, KB; Plunkett, W; Walters, R | 1 |
| Amenomori, T; Ichimaru, M; Kuriyama, K; Matsuo, T; Sadamori, N; Shibata, J; Tagawa, M; Tomonaga, M; Yoshida, Y | 1 |
| Ershler, WB; Roberts, JD; Stewart, JA; Tindle, BH | 1 |
| Lin, MF; Lin, XH; Lin, XJ | 1 |
| Imura, H; Ino, T; Matsui, T; Nakamura, K; Okamoto, M; Ono, Y; Saito, M; Shigemura, H; Shimizu, S; Takada, T | 1 |
| Arkavina, EA; Berliner, GB; Mendeleev, IM; Miasnikov, AA; Polezhaev, IuN | 1 |
| Amaki, I; Hattori, K; Hirota, Y; Hoshino, A; Ichimaru, M; Ito, M; Kimura, I; Kimura, K; Maekawa, T; Ohno, R | 1 |
| Hossfeld, DK; von Paleske, A; Weh, HJ; Zschaber, R | 1 |
| Nagai, K; Nakayama, S; Yabe, H; Yoshida, T | 1 |
| Bauters, F; Fenaux, P; Jouet, JP; Pollet, JP; Simon, M | 1 |
| Goldberg, J; Paolozzi, FP | 1 |
| Hayashi, S; Iwane, S; Katsura, T; Ohta, S; Shimada, M | 1 |
| Jensen, JH; Nielsen, HK; Orntoft, T; Petersen, EL | 1 |
| Kulizkowski, K; Preisler, HD; Raza, A; Zhao, SC | 1 |
| Grisold, W; Lutz, D; Mamoli, B; Mokrusa, W; Weber, R | 1 |
| Fujita, N; Haruyama, H; Ijichi, H; Nakagawa, M; Nakanishi, S; Nishio, A; Shimazaki, C | 1 |
| Allen, S; Budman, DR; Chan, K; Chaudhri, F; Deere, M; Freeman, J; Kreis, W; Schulman, P; Vinciguerra, V; Weiselberg, L | 1 |
| Ho, AD; Hunstein, W; Schwarz, CE | 1 |
| Berens, ME; Cogoli, M; Früh, U; Hofmann, V; Kistler, G; Merchant, RE; Moreillon, MC | 1 |
| Pan, QC; Su, YZ | 1 |
| Kuliczkowski, K; Preisler, HD; Raza, A; Raza, AS; Zhao, SC | 1 |
| Bordessoule, D; Brière, J; Castaigne, S; Colombat, P; Donadio, D; Drony, S; Guy, H; Sigaux, F; Solal Celigny, P; Tilly, H | 1 |
| Morley, AA; Wan, JH | 1 |
| Finch, LR; Jamieson, GP; Sawyer, WH; Snook, M; Taupin, J; Wiley, JS | 1 |
| Desforges, J; Johnson, H; Smith, TJ | 1 |
| Cheng, GY; Curtis, JE; McCulloch, EA; Tritchler, D | 1 |
| Champlin, RE; Elashoff, R; Feig, SA; Gale, RP; Ho, WG; Lenarsky, C; Mitsuyasu, R; Selch, M; Winston, D; Zighelboim, J | 1 |
| Brittinger, G; Heidemann, H; Lunscken, C; Meusers, P; Uppenkamp, M; Zou, P | 1 |
| Anders, C; Miller, AA; Nowrousian, MR; Ohl, S; Schmidt, CG; Seeber, S | 1 |
| Brudler, O; Heil, G; Kurrle, E | 1 |
| Dickerhoff, R; Haas, RJ | 1 |
| Breithaupt, H; Pralle, H | 1 |
| Pees, HW; Radtke, H | 1 |
| Gassmann, W; Löffler, H; Schmitz, N | 1 |
| Oken, MM; Perri, RT; Weisdorf, DJ | 1 |
| Jehn, U; Löwenberg, B | 1 |
| Grier, HE; Weinstein, HJ | 1 |
| Amare, M; Balcerzak, SP; Chen, T; Costanzi, JJ; Gutterman, JU; Hewlett, JS | 1 |
| Bodey, GP; Freireich, EJ; Hurtubise, M; Keating, MJ; Leavens, M; Maor, M; McCredie, KB; Smith, TL; Stewart, DJ | 1 |
| Curtis, JE; Messner, HA; Minden, MM | 1 |
| Champlin, R; Feig, SA; Gale, RP; Ho, W; Jacobs, A; Lenarsky, C; Selch, M | 1 |
| Bodenstein, H; Eisert, R; Freund, M; Poliwoda, H | 1 |
| Büchner, T; Heinecke, A; Hiddemann, W; Koch, P; Maschmeier, G; Pielken, HJ; Urbanitz, D; van de Loo, J; Wendt, F | 1 |
| Jehn, U; Löwenberg, B; Zittoun, R | 1 |
| Aul, HC; Büchner, T; Fischer, J; Hiddemann, W; Kuse, R; Ludwig, WD; Rühl, H; Urbanitz, D; Vaupel, HA; Zeile, G | 1 |
| Höcker, P | 1 |
| Francis, S; Gokhale, U; Kochupillai, V; Kumar, S; Mehra, NK; Nanu, A; Sharma, S; Takkar, D; Verma, IC | 1 |
| Berney, JJ; Francis, GE; Guimaraes, JE; Wing, MA | 1 |
| Barnett, MJ; Butler, MG; Ganesan, TS; Lister, TA; Richards, MA; Rohatiner, AZ; Slevin, ML; Smith, BF; Waxman, JH | 1 |
| Kufe, DW; Spriggs, DR | 1 |
| Ishikura, H; Izumi, Y; Mochizuki, T; Okazaki, T; Sawada, H; Tashima, M; Uchino, H | 1 |
| Shan, YD | 1 |
| Carmel, R; Coltman, CA | 1 |
| Mann, JR | 1 |
| Bailey, CC; Brown, MJ; Geary, CG; Israëls, MC; Weatherall, DJ; Whittaker, JA | 1 |
| Canellos, GP; Whang-Peng, J | 1 |
| Keane, WM; Khaleeli, M; Lee, GR | 1 |
| Barkhan, P; Black, PJ; Rose, MS | 1 |
| Demeulenaere, L; Hamers, J; Van Hove, W | 1 |
| Beard, ME; Fairley, GH | 1 |
| Grignani, F; Martelli, M; Tonato, M | 2 |
| Chan, YK; Vogler, WR | 1 |
| McElwain, TJ; Smith, IE | 1 |
| Bodey, GP; Burgess, MA; Freireich, EJ; Gehan, E; Gutterman, JU; Hersh, EM; Mavligit, G; McCredie, KB; Reed, R; Rodriguez, V; Smith, T | 1 |
| Danieli, G | 1 |
| Atkinson, K; Clink, HM; Kay, HE; McElwain, TJ; Powles, R; Wells, DG | 1 |
| Abeloff, MD; Anderson, PN; Bias, WB; Borgaonkar, DS; Braine, HG; Burke, PJ; Davis, TE; Humphrey, RL; Mullins, GM; Santos, GW; Sensenbrenner, LL; Slavin, RE; Tutschka, PJ | 1 |
| Rosner, F; Seligman, BR | 1 |
| Jaenicke, L; Sauer, H; Wilmanns, W; Wilms, K | 1 |
| Almici, C; Inzoli, MR | 1 |
| Speck, B; Zwaan, FE | 1 |
| Bolognesi, DP; Green, RW; Metzgar, RS; Miller, DS; Mohanakumar, T | 1 |
| Rebuck, JW; Van Slyck, EJ | 1 |
| Alexander, P; Bateman, CJ; Beard, ME; Crowther, D; Fairley, GH; Lister, TA; McElwain, TJ; Pike, M; Powles, RL; Russell, J; Whitehouse, JM; Wrigley, PF | 1 |
| Bryan, JH; Johnson, GE; Leventhal, BG | 1 |
| Zubrod, CG | 3 |
| Lampkin, B; Mauer, AM; McWilliams, NB | 1 |
| Komp, DM | 1 |
| Anderson, JC; Henderson, WG; Palmer, CA; Rogers, RT | 1 |
| Ruffner, BW | 1 |
| Ganeshaguru, K; Hoffbrand, AV; Tattersall, MH | 1 |
| Hustinx, TW; Rutten, FJ; Scheres, JM; Wagener, DJ | 1 |
| Bourdarias, H; Caruel, N; Najman, A; Singer, B | 1 |
| Bateman, CJ; Beard, ME; Crowther, D; Malpas, JS; Whitehouse, JM | 1 |
| Labitan, A; Momparler, RL; Rossi, M | 1 |
| Gunz, FW; Levi, JA; Vincent, PC | 2 |
| Giralt, M; Raichs, A; Torres, A | 1 |
| Cheung, WH; Rai, KR; Sawitsky, A | 1 |
| Lampkin, BC; Mauer, AM; McWilliams, NB | 2 |
| Fülle, HH; Pribilla, W | 1 |
| Frei, E | 1 |
| Montuori, R; Quattrin, N | 1 |
| Amar, M; Boivin, P; Hakim, J; Kahn, A | 1 |
| Moloney, WC; Rosenthal, DS; Wiernik, PH | 1 |
| Praga, C | 1 |
| Lee, SL; Parise, F; Rosner, F; Seligman, BR | 1 |
| Abu-Zahra, H; Clarysse, A; Cowan, DH; McCulloch, EA; Senn, JS | 1 |
| Böhnel, J; Höcker, P; Stacher, A | 1 |
| Bauters, F; Goudemand, M; Lerche, B; Samsoen, J | 1 |
| Wilmanns, W; Wilms, K | 1 |
| Bateman, DN; Rose, MS | 1 |
| Bornstein, RS; Kennedy, BJ; Nesbit, M | 1 |
| Fennelly, JJ; Gorman, A; O'Connell, LG | 1 |
| Armentrout, SA; Burns, CP; Stjernholm, RL | 1 |
| Bastrup-Madsen, P; Jensen, KB; Petersen, HS; Thorling, K | 1 |
| Abu-Zahra, H; Bergsagel, DE; Clarysse, A; Cowan, DH; Hasselback, R | 1 |
| Kjeldsberg, CR; Ward, HP | 1 |
| Salvati, A | 1 |
| Au-Yong, R; Collins, P; Young, JA | 1 |
| Granatir, RG; Moquin, RB; Perlin, E; Roche, J | 1 |
| Baker, DH; Berdon, WE; Renert, WA | 1 |
| Basch, A; Dreyfus, B; Gluckman, E; Varet, B | 1 |
| Brodin, A; Gold, J; Steinberg, D | 1 |
| Duttera, MJ; Geelhoed, GW; Graff, KS; Henderson, ES | 1 |
| Bateman, CJ; Beard, ME; Crowther, D; Fairley, GH; Gauci, CL; Malpas, JS; Powles, RL; Scott, RB; Wrigley, PF | 1 |
| Ishii, M; Nishi, H; Sakurai, M | 1 |
| Flieder, J; Gehanno, P; Lallemant, Y | 1 |
| Domańska, B; Lawkowicz, W; Polubiec, A | 1 |
| Infelise, V; Paolino, W; Resegotti, L; Rossi, M | 1 |
| Janele, J; Rosa, L | 1 |
| Gemon, MF; Jacquillat, C; Weil, M | 1 |
| Nagao, T; Tashiro, Y; Toyosaka, H; Tsukimoto, I | 1 |
| Abbrederis, K; Braunsteiner, H; Huber, H; Michlmayr, G; Schmalzl, F | 1 |
| Dublin, P; Leikin, S; Movassaghi, N | 1 |
| Bull, JM; Carbone, PP; Duttera, MJ; Henderson, E; Northup, J; Stashick, ED | 1 |
| Bloomfield, CD; Theologides, A | 1 |
| Buchanan, JG; Casey, TP; Davison, JG; Grigor, RR; Matthews, JR | 1 |
| Mathe, G; Pouillart, P; Schwarzenberg, L | 1 |
| Delamore, IW; Freeman, CB; Geary, CG; Harris, R; Leyland, MJ; MaCiver, JE | 1 |
| Jungi, WF | 1 |
| Gjemdal, T; Stavem, P | 1 |
| Frei, E; Goldin, A; Schabel, FM | 1 |
| Ernst, P; Faille, A; Killmann, SA | 1 |
| Hamblin, TJ; Jones, JV | 1 |
| Clarkson, B; Erichson, R; Finch, S; Flannery, J; Grann, V | 1 |
| Alberto, P; Brunner, KW; Martz, G; Nagel, G; Obrecht, JP; Senn, HJ | 1 |
| Albrecht, M; Fülle, HH | 1 |
| Delamore, IW; Mir, MA | 2 |
| Bickers, JN; Coltman, CA; Freireich, EJ; Gehan, EA; Hewlett, JS; Stuckey, WJ; Van Slyck, EJ; Wilson, HE | 1 |
| Bodey, GP; Bonnet, JD; Coltman, CA; Freireich, EJ; Gehan, EA; Haut, AB; Hewlett, JS; McCredit, KB; Saiki, JH; Wilson, HE | 1 |
| Fleming, I; Jackson, R; Johnson, W; Mason, C; Simone, J; Walters, T | 1 |
| Burchenal, JH; Clarkson, BD; Dowling, MD; Gee, TS | 1 |
| Bodey, GP; Frei, E; Freireich, E; Ho, DH | 1 |
| Bleihöfer, B; Englebert, B; Gerhartz, H; Paulisch, R; Schneider, J | 1 |
| Burchenal, JH; Cole, MT; Dowling, MD | 1 |
| Gahrton, G; Jonasson, J; Lindsten, J; Simonsson-Lindemalm, C; Zech, L | 1 |
| Friend, JH; Giles, C; Richardson, SG | 1 |
| Seip, M | 1 |
| Ernst, P | 1 |
| Brun, B; Dreyfus, B; Gluckman, E; Reyes, F; Rochant, H | 1 |
| Drings, P; Fritsch, H; Moskwa, G; Sefrin, R; von Kaick, G | 1 |
| Ruzicka, F; Weigerstorfer, B | 1 |
| Brincker, H; Hansen, PB | 1 |
| Asseburg, U; Barlogie, B; Büchner, T; Göhde, W; Hiddemann, W; Kamanabroo, D | 1 |
| Abbrederis, K; Michlmayr, G; Schmalzl, F | 1 |
| Buckley, J; Metcalf, D; Moore, MA; Spitzer, G; Williams, N | 1 |
| Sacks, PV; Tavassoli, M | 1 |
| Sakurai, M; Sandberg, AA | 1 |
| Momparler, RL | 1 |
| Amar, M; Bernard, JF; Boivin, P; Garbaz, M; Hakim, J; Kahn, A | 1 |
| Burgess, MA; Freireich, EJ; Gutterman, JU; Hersh, EM; Matthews, A; Mavligit, GM; McCredie, KB | 1 |
| Böhnel, J; Gingold, N; Hermansky, F; Pawlowski, M; Stacher, A | 1 |
| Bax, I; Greenberg, P; Mara, B; Schrier, S | 1 |
| Engstedt, L; Franzén, S; Gahrton, G; Gullbring, B; Höglund, S; Holm, G; Killander, A; Killander, D; Lockner, D; Mellstedt, H; Palmblad, J; Reizenstein, P; Skarberg, KO; Swedberg, B; Udén, AM | 1 |
| Bayrd, ED; Kyle, RA; Pierre, RV | 1 |
| Keating, MJ; Penington, DG | 1 |
| Aye, MT; McCulloch, EA; Niho, Y; Till, JE | 1 |
| Bergna, L; Eppinger-Helft, M; Hidalgo, G; Macchi, A; Pavlovsky, A; Pavlovsky, S; Sackmann Muriel, F; Suarez, A; Vilaseca, G | 1 |
| Brott, W; Green, DC; Treasure, RL; Zumbro, GL | 1 |
| Asseburg, U; Barlogie, B; Büchner, T; Kamanabroo, D | 1 |
| Baroncelli, PG; Cordero di Montezemolo, L; Madon, E; Roberi, PL; Sacerdote, A | 1 |
| Burchenal, JH; Clarkson, BD; Cunningham, B; Dowling, MD; Gee, TS; Haghbin, M; Tan, CT | 1 |
| Amiel, JL; Cattan, A; De Vassal, F; Hayat, M; Jasmin, C; Mathé, G; Pouillart, P; Rosenfeld, C; Schneider, M; Schwarzenberg, L; Weiner, R | 1 |
| Sakai, Y; Sakano, T | 1 |
| Armentrout, SA; Burns, CP | 1 |
| Bricteux, N | 1 |
| Ono, R | 1 |
| Sakano, T | 1 |
| Bertino, JR; DeConti, RC; Hubbard, S; Marsh, JC; Mitchell, MS; Skeel, RT | 1 |
| Cooper, LE; Groth, DP; Vogler, WR | 1 |
| Bernard, J; Jacquillat, C; Weil, M | 2 |
| Pöttgen, W | 1 |
| Delalieux, G; Manaster, J; Stryckmans, P | 1 |
| Brilliant, MD | 1 |
| Powles, R | 2 |
| Buckner, CD; Clift, RA; Fass, L; Fefer, A; Glucksberg, H; Mickelson, EM; Neiman, P; Storb, R; Thomas, ED | 1 |
| Hansen, NE; Karle, H | 1 |
| Schrier, SL; Silvergleid, AJ | 1 |
| Bauters, F; Caulier, MT; Goudemand, M; Mouton, J; Plouvier, B | 1 |
| Hacker, B; Hall, TC; Kessel, D; Nahas, A | 1 |
| Baccarani, M; Lauria, F; Ricci, P; Santucci, MA; Tura, S | 1 |
| Carnelli, V; Masera, G; Uderzo, C | 1 |
| Bernard, J; Faille, A; Najean, Y | 1 |
| Bernard, J; Blom, J; Boiron, M; Cuttner, J; Ellison, RR; Forcier, RJ; Gussoff, B; Haurani, F; Hayes, DM; Holland, JF; Hutchison, JL; Jacquillat, C; Karanas, A; Kyle, R; Leone, LA; Moon, JH; Rosner, F; Sawitsky, A; Silver, RT; Spurr, CL; Weil, M | 1 |
| Jacquillat, C | 1 |
| Bernard, J; Boiron, M; Jacquillat, C; Weil, M | 1 |
| Dano, K; Nissen, NI | 1 |
| Perry, S; Skipper, HE | 1 |
| Bateman, CJ; Crowther, D; Fairley, GH; Malpas, JS; Scott, RB; Vartan, CP; Whitehouse, JM | 1 |
| Clarkson, BD; Fried, J | 1 |
| Fairley, GH | 2 |
| Frei, E; Goldin, A; Henderson, ES; Holland, JF; Newman, JW; Sandberg, JS | 1 |
| Dean, HM; Post, RM | 1 |
| Cline, MJ | 1 |
| Gerhartz, H | 1 |
| Bodey, GP; Freireich, EJ; Harris, JE; Hart, JS | 1 |
| Holland, JF | 1 |
| Lee, SL; Rosner, F | 1 |
| Crosby, WH | 1 |
| Hall, TC; Kessel, D; Rosenthal, D | 1 |
| Hall, TC; Roberts, D; Rosenthal, D | 1 |
| Clarkson, BD; Gee, TS; Yu, KP | 1 |
| Lampkin, BC; Mauer, AM; Nagao, T | 2 |
| Begemann, H; Kreiter, H; Rastetter, J | 1 |
| Bodey, GP; DeJongh, D; Freireich, EJ; Isassi, A | 1 |
| Aoki, Y; Moore, GE | 1 |
| Groth, DP; Horwitz, S; Vogler, WR | 1 |
| Aguercif, M; Dubois-Ferrière, H; Hazeghi, P; Rudhardt, M | 1 |
| Pratt, CB; Wang, JJ | 1 |
| Brodie, GN; Penny, R | 1 |
| Finklestein, JZ; Freedman, MH; Gilchrist, GS; Hammond, GD; Higgins, GR; Hyman, CB; Karon, MR; Shore, NA; Williams, KO | 1 |
| Benesová, E; Friedmann, B; Hermanský, F | 1 |
| Amano, I; Higo, O; Horiuchi, A; Morita, K; Oshima, T | 1 |
| White, LP | 1 |
| Ridell, B; Weinfeld, A; Westin, J | 1 |
| Canova, R; Casalino, C; Fischioni, P; Maroncelli, P | 1 |
| Bryon, PA; Dechavanne, M; Fiere, D; Guyon, JM; Kahi, S; Revol, L | 1 |
| Barry, A; Delage, JM | 1 |
| McLean, FW; Noyes, WD; Pawliger, DF | 1 |
| Bertino, JR; Capizzi, RL; Creasey, WA; Handschumacher, RE; Olayon, C; Peterson, RG; Skeel, RT; Zanes, R | 1 |
| Curci, G; De Pasquale, A; Montero, C; Piccinini, L; Quaglino, D | 1 |
| Frei, E; Freireich, EJ; George, SL; Hart, JS; Trujillo, JM | 1 |
| Crowther, D | 1 |
| Cuesta, MB; Gabriel, FD; Kozinn, PJ; Rosener, F; Taschdjian, C | 1 |
| Colebatch, JH; Ekert, H; Lay, HN | 1 |
| Foadi, M; Shaw, MT | 1 |
| Cork, A; Drewinko, B; Freireich, EJ; Hart, JS; Trujillo, JM | 1 |
| Burke, PJ; Steuart, CD | 1 |
| Gerron, GG; Howard, CH; Rudman, D; Vogler, WR | 1 |
| Baroncelli, PG; Madon, E; Roberi, PL; Sacerdote, A | 1 |
| Das, L; Dohlwitz, A; Hall, TC; Jaffe, N; Moloney, WC; Traggis, DG | 1 |
| Henderson, ES; Leventhal, BG | 1 |
| Burke, PJ; Owens, AH | 1 |
| Cornwell, GG; McIntyre, OR; Mills, RC | 1 |
| Bodey, GP; Freireich, EJ; Hersh, EM; McCredie, KB; Whitecar, JP | 1 |
| Baguley, BC; Falkenhaug, EM | 1 |
| Benirschke, K; Forcier, RJ; Maurer, LH; McIntyre, OR | 1 |
| Cohen, SL; Dodsworth, H; Whitelaw, AG | 1 |
| Hirano, M; Koie, K; Morita, A; Sako, F; Uetani, T | 1 |
| Braunsteiner, H; Schmalzl, F | 1 |
| Bagshawe, KD | 1 |
| Buchanan, JG | 1 |
| Hall, TC | 1 |
| Wilmanns, W | 1 |
| Hitzig, WH; Plüss, HJ | 1 |
| Bodey, GP; Frei, E; Freireich, E; Hart, J; Whitecar, J | 1 |
| Blom, J; Burningham, R; Cuttner, J; Falkson, G; Glidewell, O; Holland, JF; Levy, RN; Moon, JH; Onuma, T; Rosner, F; Silver, RT | 1 |
327 review(s) available for cytarabine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2022 |
The cure of leukemia through the optimist's prism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fusion Proteins, bcr-abl; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2022 |
Is there an optimal adjunct therapy to traditional cytotoxic induction?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
Is the current consolidation regimen for AML evidence-based?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 2021 |
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2022 |
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute | 2023 |
Diagnosis and treatment of therapy-related acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis | 2022 |
Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Cytarabine; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2022 |
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
Topics: Cytarabine; DNA Repair; Humans; Leukemia, Myeloid, Acute; Mutation; Nucleosides | 2022 |
[Research Advance of Gene Mutation and Targeted Drug Therapy in Childhood Acute Myeloid Leukemia --Review].
Topics: Adult; Child; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Myeloproliferative Disorders; Nuclear Proteins; Nucleophosmin; Prognosis | 2022 |
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
The paradox of Myeloid Leukemia associated with Down syndrome.
Topics: Child; Cytarabine; Down Syndrome; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemoid Reaction | 2022 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Nucleosides; Sulfonamides | 2022 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
Central Nervous System Prophylaxis and Treatment in Acute Leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Leukemia, Myeloid, Acute; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2022 |
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation | 2022 |
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Homologous; Young Adult | 2023 |
Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes | 2023 |
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Topics: Core Binding Factors; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Recurrence | 2023 |
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Cytarabine; Humans; Leukemia, Myeloid, Acute; Network Meta-Analysis; Treatment Outcome | 2023 |
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Receptors, Chimeric Antigen; Recurrence; Single-Cell Gene Expression Analysis | 2023 |
Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
[Research Advances on Combination Strategies of Demethylating Agents for Elderly Acute Myeloid Leukemia--Review].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute | 2019 |
CPX-351 (vyxeos) in AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2020 |
Leukemic Vasculitis: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow Transplantation; Colitis, Ulcerative; Cytarabine; Diagnosis, Differential; Erythema; Female; Humans; Idarubicin; Immunohistochemistry; Leg Dermatoses; Leukemia, Myeloid, Acute; Leukemic Infiltration; Mesalamine; Skin Neoplasms; Transplantation Conditioning; Treatment Outcome; Vasculitis | 2019 |
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Pharmaceutical Preparations; Remission Induction | 2020 |
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Topics: Allografts; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precision Medicine; Remission Induction | 2019 |
Single-agent and combination biologics in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Neoplasm Proteins; Sulfonamides; Survival Rate | 2019 |
How to address second and therapy-related acute myelogenous leukaemia.
Topics: Age Factors; Allografts; Antibodies, Bispecific; Antineoplastic Agents, Immunological; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation | 2020 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cladribine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
A User's Guide to Novel Therapies for Acute Myeloid Leukemia.
Topics: Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Stem Cell Transplantation; United States; United States Food and Drug Administration | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
AML: New Drugs but New Challenges.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines | 2020 |
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Ireland; Leukemia, Myeloid, Acute; Liposomes | 2020 |
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Safety; Survival Analysis; Topoisomerase II Inhibitors; Treatment Outcome; United States; Young Adult | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Roles of hsa-miR-12462 and SLC9A1 in acute myeloid leukemia.
Topics: 3' Untranslated Regions; Animals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Regulation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasm Proteins; RNA, Neoplasm; Sodium-Hydrogen Exchanger 1; Tumor Burden; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays | 2020 |
AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2020 |
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Topics: Administration, Oral; Allografts; Antineoplastic Agents; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Risk Assessment; Stem Cell Transplantation; Survival Rate | 2020 |
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Sulfonamides; United States | 2020 |
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Topics: Age Factors; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Mutation; Myelodysplastic Syndromes | 2020 |
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Calicheamicins; Chlorides; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Middle Aged; Multicenter Studies as Topic; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Tretinoin | 2020 |
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds | 2020 |
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Quinuclidines; Sulfonamides | 2020 |
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Cell Line, Tumor; Clinical Trials as Topic; Cytarabine; Drug Approval; Drug Evaluation, Preclinical; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mice; Phenylurea Compounds; Signal Transduction; Smoothened Receptor; United States | 2021 |
Glasdegib in newly diagnosed acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds | 2021 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
New Treatment Options for Older Patients with Acute Myeloid Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Patient Selection; Stem Cell Transplantation; Sulfonamides | 2021 |
Which novel agents will have a clinically meaningful impact in AML at diagnosis?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2021 |
Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.
Topics: Animals; Cell Death; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Models, Biological | 2021 |
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Core binding factor acute myelogenous leukemia-2021 treatment algorithm.
Topics: Algorithms; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human; Core Binding Factors; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Neoplasm, Residual; Translocation, Genetic | 2021 |
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Risk Assessment; Staurosporine | 2021 |
Systematic review and meta-analysis of clinical efficacy of drug therapy for acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2021 |
Acute myeloid leukemia with t (3;8) (q26.2;q24), a simple variant of 3q26.2/EVI1 translocation.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 8; Cytarabine; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Male; MDS1 and EVI1 Complex Locus Protein; Proto-Oncogenes; Transcription Factors; Translocation, Genetic | 2017 |
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature.
Topics: Abortion, Therapeutic; Adult; Cesarean Section; Child; Cytarabine; Daunorubicin; Female; Fetal Death; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic | 2017 |
Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Young Adult | 2017 |
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Treatment Outcome | 2017 |
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Pharmacogenetics; Polymorphism, Genetic | 2018 |
Do cytogenetics affect the post-remission strategy for older patients with AML in CR1?
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2017 |
How can one optimize induction therapy in AML?
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Gemtuzumab; History, 20th Century; History, 21st Century; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute | 2017 |
The role of targeted therapy in the management of patients with AML.
Topics: Cytarabine; Daunorubicin; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute | 2017 |
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Carriers; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Liposomes; Prognosis; Survival Rate; Treatment Outcome | 2018 |
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Combinations; Drug Interactions; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes | 2018 |
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Patient Selection; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2018 |
Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bone Marrow; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease Management; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Risk Assessment; RUNX1 Translocation Partner 1 Protein; Sequence Analysis, DNA | 2018 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
Advances in treatment formulations for acute myeloid leukemia.
Topics: Animals; Anthracyclines; Cytarabine; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Pharmaceutical Preparations | 2018 |
Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myelodysplastic Syndromes; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
BCL-2 inhibition in AML: an unexpected bonus?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Acute myeloid leukaemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Gemtuzumab; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Patient Selection; Recurrence; Remission Induction; Risk Assessment; Risk Factors; Staurosporine | 2018 |
[Advances of Targeting Therapy in Acute Myeloid Leukemia--Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Recurrence | 2018 |
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines | 2018 |
A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Bayes Theorem; Cytarabine; Disease-Free Survival; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Neoplasm Recurrence, Local; Odds Ratio; Pyrazoles; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles | 2018 |
A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Publication Bias; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
Is the overall survival for older adults with AML finally improving?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Survival Rate | 2018 |
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Heart Diseases; Hematologic Diseases; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liposomes; Meta-Analysis as Topic; Mucositis; Multicenter Studies as Topic; Neoplasms, Second Primary; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Tubes; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Vascular Access Devices | 2018 |
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Approval; Europe; Humans; Leukemia, Myeloid, Acute; Liposomes; Remission Induction; United States | 2018 |
Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Sulfonamides | 2019 |
The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Tumor Suppressor Protein p53 | 2019 |
Glasdegib: First Global Approval.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Drug Approval; Europe; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Signal Transduction; United States | 2019 |
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Randomized Controlled Trials as Topic | 2019 |
Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.
Topics: Adult; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Nucleophosmin; Remission Induction; Survival Rate | 2019 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Excessive Toxicity After Treatment of Congenital Acute Myeloid Leukemia.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute | 2019 |
Choosing induction chemotherapy in therapy-related acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Neoplasms, Second Primary | 2019 |
[Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2019 |
Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles.
Topics: Animals; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Carriers; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Liposomes; Nanoparticles | 2019 |
Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Topics: Aged; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Survival Rate | 2019 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines | 2019 |
[Novel therapies for acute myeloid leukemia based on genomic aberrations].
Topics: Cytarabine; Enzyme Inhibitors; Genomics; Humans; Japan; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2019 |
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genome-Wide Association Study; Genotype; Humans; Leukemia, Myeloid, Acute; Phenotype; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Development of a curative treatment within the AML-BFM studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thioguanine; Vincristine | 2013 |
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
Topics: Aged; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib | 2013 |
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cytarabine; Daunorubicin; Humans; Immunoconjugates; Immunologic Factors; Leukemia, Myeloid, Acute; Prognosis; Purine Nucleosides; Risk Factors; Stem Cell Transplantation; Transplantation, Autologous | 2013 |
Important milestones in acute leukemia in 2013.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; History, 20th Century; History, 21st Century; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Proteins; Remission Induction; Survival Analysis | 2013 |
Relapsed acute myeloid leukemia: why is there no standard of care?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Salvage Therapy; Standard of Care; Survival Analysis; Transplantation, Homologous | 2013 |
The euphoria of hypomethylating agents in MDS and AML: is it justified?
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; Endpoint Determination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Topics: Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Chromosome Inversion; Chromosomes, Human; Cytarabine; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-kit; Translocation, Genetic | 2013 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Discovery; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Mutation; Recurrence; Tretinoin; Vincristine | 2014 |
Hypomethylating agents and chemotherapy in MDS.
Topics: Allografts; Anthracyclines; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Stem Cell Transplantation | 2013 |
Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.
Topics: Adenine Nucleotides; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Humans; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult | 2014 |
Asymmetric anterior uveitis as a delayed complication of treatment with systemic high-dose cytosine-arabinoside: a case report and literature review.
Topics: Adult; Cytarabine; Diagnosis, Differential; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Uveitis, Anterior | 2014 |
Decitabine. Acute myeloid leukaemia: no progress.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Patient Selection; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demyelinating Diseases; Disease-Free Survival; Drug Evaluation, Preclinical; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pteridines; Randomized Controlled Trials as Topic | 2014 |
GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Disease-Free Survival; Female; Gene Deletion; Genotype; Glutathione Transferase; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Odds Ratio; Pharmacogenetics; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemtuzumab; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Odds Ratio; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Rate; Treatment Outcome | 2014 |
Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Brain; Cerebral Hemorrhage; Cytarabine; Fatal Outcome; Humans; Hydroxamic Acids; Idarubicin; Interleukin-2 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mast Cells; Middle Aged; Neoplasms, Second Primary; Neoplastic Stem Cells; Opportunistic Infections; Prostatectomy; Prostatic Neoplasms; Vorinostat | 2014 |
Prognosis and management of acute myeloid leukemia in patients with Down syndrome.
Topics: Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Child; Cytarabine; Down Syndrome; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Prognosis | 2014 |
High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.
Topics: Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2014 |
The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2015 |
Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; ATP Binding Cassette Transporter, Subfamily B; Child; Child, Preschool; Cohort Studies; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Observational Studies as Topic; Polymorphism, Genetic; Treatment Outcome; Young Adult | 2015 |
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Core Binding Factors; Cytarabine; Histone Deacetylase Inhibitors; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Treatment Outcome | 2015 |
Minimal residual disease-directed therapy in acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein | 2015 |
Translocation t(11;19)(q23;q13.1) without MLL Rearrangement in Acute Myeloid Leukemia: Heterogeneity of the 11q23 Breakpoints.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 19; Cytarabine; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Translocation, Genetic | 2015 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Recurrence; Thiazoles; Topoisomerase Inhibitors; Treatment Failure | 2015 |
Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomarkers, Pharmacological; Biotransformation; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Myeloid, Acute; Precision Medicine; Prodrugs | 2016 |
Chemotherapy options for previously untreated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Remission Induction | 2015 |
Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Remission Induction; Signal Transduction | 2015 |
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Young Adult | 2016 |
The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2015 |
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Genetic Association Studies; Humans; Leukemia, Myeloid, Acute; Observational Studies as Topic; Polymorphism, Single Nucleotide; Survival Analysis; WT1 Proteins | 2016 |
[Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Remission Induction; Sagittal Sinus Thrombosis | 2016 |
[Drug treatment of acute myelogenous leukaemia. Current options and future perspectives].
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Induction Chemotherapy; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Middle Aged; Molecular Targeted Therapy; Quality of Life; Survival Analysis; Treatment Outcome | 2016 |
What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Cytarabine; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Prognosis; Remission Induction; Survival Rate | 2016 |
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Haplorhini; Humans; Leukemia, Myeloid, Acute; Mice; Middle Aged; Naphthyridines; Quinolones; Rats; Thiazoles | 2016 |
HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Intussusception: a rare complication in a patient with acute leukaemia after consolidation chemotherapy.
Topics: Abdominal Pain; Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Female; Humans; Ileal Diseases; Intussusception; Leukemia, Myeloid, Acute; Middle Aged | 2017 |
Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Treatment Outcome | 2008 |
[Klinefelter syndrome and acute myeloblastic leukaemia].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 8; Cytarabine; Cytogenetics; Genetic Predisposition to Disease; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Karyotyping; Klinefelter Syndrome; Leukemia, Myeloid, Acute; Male; Trisomy | 2009 |
Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature.
Topics: Adult; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Cytarabine; Echinocandins; Female; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lipopeptides; Liver Diseases; Radiography; Splenic Diseases; Tomography Scanners, X-Ray Computed | 2009 |
Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Hyperammonemia; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Mutation; Nuclear Proteins; Nucleophosmin | 2009 |
[Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacillaceae Infections; Bacillus cereus; Cytarabine; Fatal Outcome; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Opportunistic Infections; Remission Induction; Sepsis; Subarachnoid Hemorrhage | 2009 |
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Topics: Core Binding Factors; Cytarabine; Dose-Response Relationship, Drug; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis | 2009 |
Dermatomyositis associated with acute myelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow Examination; Cytarabine; Daunorubicin; Dermatomyositis; Electromyography; Fatal Outcome; Female; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Paraneoplastic Syndromes; Prednisolone; Quadriceps Muscle; Treatment Failure | 2010 |
Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Time Factors; Young Adult | 2009 |
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Synergism; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Monosomy; Neoplasms, Second Primary; Translocation, Genetic; Tretinoin | 2009 |
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic | 2009 |
Genetic factors influencing cytarabine therapy.
Topics: 5'-Nucleotidase; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Forecasting; Genetic Variation; Humans; Leukemia, Myeloid, Acute; Nucleoside Deaminases; Pharmacogenetics; Ribonucleotide Reductases | 2009 |
[History, current status, and future prospects in clinical study of myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Design; Drug Therapy, Combination; Gene Targeting; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Precision Medicine; Pyrimidines; Remission Induction; Risk; Tretinoin | 2009 |
[Combination chemotherapy for acute myeloid leukemia].
Topics: Aged; Aged, 80 and over; Aminoglycosides; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy | 2009 |
[Characteristics of elderly patients with acute myelogenous leukemia].
Topics: Age Distribution; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Hospitals, Municipal; Humans; Japan; Leukemia, Myeloid, Acute; Remission Induction; Spouses | 2009 |
[Standard therapies for acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Remission Induction | 2009 |
[Acute myeloid leukemia trials by Japan Adult Leukemia Study Group (JALSG)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Evidence-Based Medicine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Young Adult | 2009 |
Current and emerging therapies for acute myeloid leukemia.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid, Acute | 2009 |
Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: case report and review of literature.
Topics: Abdominal Neoplasms; Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 6; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Sarcoma, Myeloid; Translocation, Genetic | 2010 |
Therapy of acute myelogenous leukemia in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Clinical Trials as Topic; Combined Modality Therapy; Core Binding Factors; Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 2010 |
Chemotherapy for patients with acute myeloid leukemia in first remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Remission Induction | 2006 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
[Acute myelogenous leukemia developed at the 26th week of gestation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Cytarabine; Female; Humans; Idarubicin; Infant, Low Birth Weight; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, Second; Remission Induction | 2011 |
Granulocytic sarcoma of palate. Case report and review of literature.
Topics: Adolescent; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Hand; Humans; Leukemia, Myeloid, Acute; Palatal Neoplasms; Sarcoma, Myeloid | 2011 |
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic | 2012 |
Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia.
Topics: Antineoplastic Agents; Cytarabine; Drug Delivery Systems; Drug Discovery; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy | 2011 |
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2011 |
Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Child; Cytarabine; Disease Management; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2011 |
What is the optimal induction strategy for older patients?
Topics: Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Disease Management; Drug Resistance, Neoplasm; Humans; Karyotype; Leukemia, Myeloid, Acute; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome; United States | 2011 |
Is a nadir bone marrow required and, if so, what to do with residual disease?
Topics: Anthracyclines; Antineoplastic Agents; Biopsy; Bone Marrow; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Practice Guidelines as Topic; Prognosis; Remission Induction; Retrospective Studies; Sensitivity and Specificity; Survival Rate; United States | 2011 |
New induction and postinduction strategies in acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
[A systematic review of MA versus IA regimen for patients with acute myelogenous leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Young Adult | 2011 |
Pediatric acute myeloid leukemia.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Complementary Therapies; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Neoplasm, Residual; Secondary Prevention; Survival Rate; Therapies, Investigational; Transplantation, Homologous; Treatment Outcome | 2012 |
Relapse of acute myeloid leukemia at the pituitary gland: a case report and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Diabetes Insipidus; Etoposide; Female; Humans; Hypopituitarism; Idarubicin; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Methotrexate; Pituitary Neoplasms; Radiotherapy; Recurrence; Remission Induction; Vision Disorders | 2012 |
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Tract; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile | 2012 |
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.
Topics: Anthracyclines; Cytarabine; DNA-Binding Proteins; Farnesyltranstransferase; Glutathione Transferase; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Nuclear Proteins; Pharmacogenetics; Precision Medicine | 2012 |
Current treatment of acute myeloid leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Precision Medicine; Stem Cell Transplantation | 2012 |
A tetraploid minimally differentiated acute myeloblastic leukemia with extensive erythrophagocytosis: a case report and literature review.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Differentiation; Cytarabine; Cytophagocytosis; Erythrocytes; Fatal Outcome; Female; HLA-DR Antigens; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Middle Aged; Mitomycin; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prognosis; Tetraploidy | 2012 |
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Cytarabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Idarubicin; Leukemia, Myeloid, Acute; Vorinostat | 2012 |
Is it time to revisit standard post-remission therapy?
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 2012 |
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Treatment Outcome | 2013 |
Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Delivery Systems; Drug Discovery; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy | 2013 |
Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation.
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 13; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Vidarabine | 2002 |
What is the optimal therapy for childhood AML?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Humans; Immunotherapy; Leukemia, Myeloid, Acute | 2002 |
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; France; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome.
Topics: Abnormalities, Multiple; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Cytokines; Female; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Menorrhagia; Neoplasm Proteins; Platelet Count; Proto-Oncogene Proteins; Radius; Receptors, Cytokine; Receptors, Thrombopoietin; Recurrence; Remission Induction; Risk; Syndrome; Thrombocytopenia | 2003 |
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia].
Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin | 2003 |
[Hematologic tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Mechlorethamine; Prednisone; Procarbazine; Vinblastine; Vincristine | 2003 |
Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger?
Topics: Actinomycetales; Actinomycetales Infections; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Translocation; Cefepime; Cephalosporins; Clostridium Infections; Colistin; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Fatal Outcome; Hemoptysis; Humans; Hydroxyurea; Immunocompromised Host; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Metronidazole; Middle Aged; Neutropenia; Pneumonia, Bacterial; Superinfection; Teicoplanin; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Acute myeloid leukemia with t(8;21)(q22;q22) manifesting as granulocytic sarcomas in the rhinopharynx and external acoustic meatus at relapse after high-dose cytarabine: case report and review of the literature.
Topics: Adult; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Ear; Female; Humans; Leukemia, Myeloid, Acute; Nasopharynx; Peripheral Blood Stem Cell Transplantation; Radiotherapy; Recurrence; Remission Induction; Sarcoma, Myeloid; Translocation, Genetic | 2004 |
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
Granulocytic sarcoma of the testis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleolus; Chemotherapy, Adjuvant; Chromatin; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Orchiectomy; Radiotherapy, Adjuvant; Sarcoma, Myeloid; Testicular Neoplasms | 2004 |
Acute myeloblastic leukemia in pregnancy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third | 2004 |
Assessment of drug resistance in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Vault Ribonucleoprotein Particles | 2004 |
A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Treatment Outcome | 2004 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).
Topics: Adult; Cytarabine; Deoxyribonucleotides; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Models, Biological; Substrate Cycling | 2005 |
Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cytarabine; Cytogenetic Analysis; Etoposide; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2005 |
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 2005 |
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Helicases; Etoposide; Exodeoxyribonucleases; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; RecQ Helicases; Werner Syndrome; Werner Syndrome Helicase | 2005 |
Treatment of older patients with AML.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Stem Cell Transplantation; Thioguanine; Transplantation, Homologous | 2005 |
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
Topics: Adolescent; Adult; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Randomized Controlled Trials as Topic | 2006 |
Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction | 2007 |
[Current therapeutic strategies in the management of acute myeloid leukemia].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Retreatment | 2007 |
[Treatment for acute myeloid leukemia: introduction].
Topics: Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Randomized Controlled Trials as Topic; Remission Induction | 2007 |
Infections with viridans group streptococci in children with cancer.
Topics: Antibiotic Prophylaxis; Child; Child, Preschool; Cytarabine; Humans; Incidence; Leukemia, Myeloid, Acute; Myocarditis; Nervous System Diseases; Neutropenia; Practice Guidelines as Topic; Respiratory Distress Syndrome; Shock, Septic; Stem Cell Transplantation; Streptococcal Infections; Viridans Streptococci | 2007 |
Long-term propylthiouracil use and acute myeloid leukemia: a case report and review of the literature.
Topics: Adult; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 21; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Iodide Peroxidase; Leukemia, Myeloid, Acute; Peroxidase; Propylthiouracil; Remission Induction; Time Factors; Translocation, Genetic; Transplantation, Homologous | 2008 |
Acute myeloid leukemia.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Pharmacogenetics; Prognosis; Remission Induction; Risk Factors; Stem Cell Transplantation | 2008 |
Consolidation therapy: what should be the standard of care?
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2008 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Treatment of relapsed acute myeloid leukaemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Cytarabine; Etoposide; Humans; Immunity, Innate; Immunologic Factors; Leukemia, Myeloid, Acute; Mitoxantrone; Randomized Controlled Trials as Topic; Secondary Prevention | 2006 |
[Acute promyelocytic leukemia. Review of the literature].
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Heparin; Humans; Inclusion Bodies; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Neoplastic Stem Cells; Thioguanine; Translocation, Genetic | 1984 |
Adult acute nonlymphocytic leukemias.
Topics: Acute Disease; Aged; Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Blood Transfusion; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Resistance; Female; Hemorrhage; Humans; Immunotherapy; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Spinal Cord; Syndrome | 1980 |
[The clinical significance of the Philadelphia chromosome in acute leukaemia (author's transl)].
Topics: Acute Disease; Adult; Blood Transfusion; Chromosomes, Human, 21-22 and Y; Cytarabine; Female; Glucocorticoids; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Vincristine | 1980 |
Biochemical pharmacological determinants of drug action in cancer therapeutics.
Topics: Animals; Biotransformation; Cytarabine; Humans; Leukemia L1210; Leukemia, Myeloid, Acute; Methotrexate; Mice; Rats | 1980 |
Renewal and determination in leukemic blast populations.
Topics: Antibodies, Monoclonal; Cell Differentiation; Cell Division; Cells, Cultured; Cytarabine; Doxorubicin; Genes; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Models, Biological; Phytohemagglutinins; Transfection | 1982 |
The treatment of acute myelogenous leukemia in adults.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Naphthacenes; Prednisolone; Prognosis; Regression Analysis; Thioguanine; Time Factors; Vincristine | 1982 |
[Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
Topics: Aclarubicin; Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 7; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Recombinant Proteins; Remission Induction | 1995 |
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasms, Second Primary; Oncogenes; Topoisomerase II Inhibitors; Translocation, Genetic | 1995 |
rHuGM-CSF after high-dose chemotherapy in post-remission acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins | 1995 |
Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?
Topics: Age Factors; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Remission Induction | 1995 |
Toxic megacolon complicating chemotherapy for acute myeloid leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Megacolon, Toxic | 1994 |
[Progress of chemotherapy in adult acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Remission Induction; Survival Rate | 1995 |
[A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Mercaptopurine; Prednisolone; Recurrence; Remission Induction; Uterus; Vincristine | 1994 |
Epipodophyllotoxins in the treatment of childhood cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Second Primary; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teniposide | 1994 |
Poor prognosis acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Cell Division; Cytarabine; Daunorubicin; Drug Resistance; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Neoplasms, Second Primary; Neoplastic Stem Cells; Preleukemia; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Failure | 1993 |
Fludarabine for treatment of adult acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Acute myelogenous leukemia associated with a mediastinal tumor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Mediastinal Neoplasms; Mercaptopurine; Middle Aged; Prednisolone; Radiography, Thoracic; Remission Induction; Time Factors; Tomography, X-Ray Computed | 1993 |
Clinical review on features and cytogenetic patterns in adult acute myeloid leukemia with lymphoid markers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aneuploidy; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosome Aberrations; Cytarabine; DNA Nucleotidylexotransferase; Etoposide; Female; Gene Rearrangement; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Vindesine | 1993 |
Two additional cases of acute myeloid leukemia with t(7;11)(p15;p15) having low neutrophil alkaline phosphatase scores.
Topics: Acute Disease; Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Neutrophils; Prednisolone; Primary Myelofibrosis; Remission Induction; Translocation, Genetic | 1993 |
Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthalenes; Peroxidase; Prednisolone; Remission Induction | 1993 |
Filamentous degeneration of neurons. A possible feature of cytosine arabinoside neurotoxicity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cell Nucleus; Cytarabine; Humans; Intermediate Filaments; Kidney Tubular Necrosis, Acute; Leukemia, Myeloid, Acute; Male; Motor Neurons; Nerve Degeneration; Neurons; Spinal Cord | 1993 |
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine | 1993 |
Is intensive treatment beneficial to elderly patients with ANLL?
Topics: Acute Disease; Aged; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction | 1993 |
[Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Hematopoietic Cell Growth Factors; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Vidarabine | 1995 |
Postremission therapy of acute myeloid leukemia in older adults.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction | 1996 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Procarbazine; Recurrence; Remission Induction; Vinblastine | 1996 |
Primary extramedullary leukemia of the prostate: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Diagnostic Errors; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prostatectomy; Prostatic Neoplasms; Radioisotope Teletherapy; Remission Induction; Urinary Retention; Vincristine | 1996 |
Haemopoietic growth factors, the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cytarabine; Cytokines; Drug Screening Assays, Antitumor; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Recombinant Proteins | 1996 |
The management of acute myeloid leukaemia (AML) in human immunodeficiency virus (HIV) infection: a case report and review.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; HIV Infections; Humans; Leukemia, Myeloid, Acute; Male; Thioguanine; Zidovudine | 1997 |
[Recent advances on the treatment of acute childhood leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 1997 |
[Progress in the treatment of adult acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Tretinoin | 1997 |
Mitoxantrone in the treatment of acute myelogenous leukemia: a review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Randomized Controlled Trials as Topic | 1997 |
[Update on malignant hematologic diseases].
Topics: Antineoplastic Agents; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Multiple Myeloma | 1998 |
[The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cyclosporine; Cyclosporins; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate | 1998 |
Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC).
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carrier Proteins; Cytarabine; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Gene Expression; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Membrane Proteins; Microscopy, Confocal; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purine Nucleosides | 1998 |
Down syndrome and acute myeloid leukemia. Lessons learned from experience with high-dose Ara-C containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Deoxycytosine Nucleotides; Disease-Free Survival; Dose-Response Relationship, Drug; Down Syndrome; Humans; Leukemia, Myeloid, Acute | 1999 |
New developments in the treatment of acute myeloid leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colony-Stimulating Factors; Cytarabine; Drug Resistance, Multiple; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Remission Induction | 1999 |
Fatal disseminated infection by Scedosporium prolificans during induction therapy for acute leukemia: a case report and literature review.
Topics: Aged; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Microbial; Fatal Outcome; Female; Fungemia; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Mycetoma; Pseudallescheria | 1999 |
High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis | 2000 |
[Prognostic factors in chemotherapies for acute myeloid leukemia].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Prognosis; Risk Factors; Survival Analysis; Tretinoin | 2000 |
[Acute myelogenous leukemia in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quality of Life; Remission Induction | 2000 |
New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients.
Topics: Adult; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation, Autologous | 2000 |
Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Topics: Animals; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor alpha Subunits; Cytarabine; Diagnosis, Differential; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Analysis; Transcription Factor AP-2; Transcription Factors; Translocation, Genetic; Treatment Outcome | 2000 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Therapeutic options for acute myelogenous leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Prognosis; Topotecan; Vidarabine | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
[Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Esophageal Stenosis; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2002 |
Acute myelogenous leukemia: advances and limitations of treatment.
Topics: Adult; Aminoglycosides; Anthracyclines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Case-Control Studies; Cytarabine; Fatal Outcome; Gemtuzumab; Gingiva; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Immunotoxins; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Piperazines; Pyrimidines; Remission Induction; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Consequences of acute myelogenous leukemia in early pregnancy.
Topics: Abortion, Therapeutic; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant Mortality; Infant, Newborn; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Risk; Teratogens; Thioguanine; Vincristine | 1977 |
Current concepts of leukemia and results of recent treatment programs.
Topics: Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute | 1978 |
Approaches to the treatment of acute leukemia and lymphoma in adults.
Topics: Acute Disease; Adult; Animals; BCG Vaccine; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Environment, Controlled; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Mice; Prednisone; Vincristine | 1978 |
Advances in the treatment of acute myelogenous leukemia.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Hemorrhage; Humans; Immunotherapy; Infections; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Meningeal Neoplasms; Preleukemia; Prognosis; Remission, Spontaneous; Transplantation, Homologous | 1979 |
Early consolidation chemotherapy for adults with acute leukemia in remission.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Cytarabine; Enterocolitis, Pseudomembranous; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Necrosis; Prednisone; Remission, Spontaneous; Vincristine | 1976 |
1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview.
Topics: Animals; Clinical Trials as Topic; Cytarabine; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute | 1992 |
Hematopoietins in combination with 1-beta-D-arabinofuranosylcytosine: a possible strategy for improved treatment of myeloid disorders.
Topics: Acute Disease; Antineoplastic Agents; Cytarabine; Drug Synergism; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Leukemia, Myeloid; Leukemia, Myeloid, Acute; S Phase | 1992 |
High-dose cytosine arabinoside for the treatment of acute myeloid leukemia. Studies of the North American Marrow Transplant Group.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute | 1992 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Vincristine | 1992 |
Treatment of adult acute leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Prognosis; Remission Induction; United States | 1992 |
Improving the "quality of remission induction" therapy: a necessary step for increasing the cure rate in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Idarubicin: an anthracycline antineoplastic agent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Cytarabine; Drug Labeling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
New drugs in acute myelogenous leukemia: a review.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Isomerism; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction; Survival Rate; Tretinoin | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Resistance; Gene Amplification; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Neoplastic Stem Cells; Retrospective Studies | 1991 |
To overcome pharmacologic and cytokinetic resistance to cytarabine in the treatment of acute myelogenous leukemia by using recombinant interleukin-3?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Differentiation; Cytarabine; Drug Resistance; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Recombinant Proteins | 1991 |
CSFs in combination with cytosine arabinoside, an inhibitor of DNA synthesis: potential strategies for the treatment of myeloid disorders.
Topics: Cell Differentiation; Colony-Stimulating Factors; Cytarabine; DNA, Neoplasm; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; In Vitro Techniques; Interleukin-3; Leukemia, Myeloid, Acute | 1991 |
Gelatinous transformation of marrow in a case of acute myelogenous leukemia post-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrophy; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Hyaluronic Acid; Leukemia, Myeloid, Acute; Middle Aged | 1991 |
[Therapeutic possibilities in the treatment of the myelodysplasia syndrome].
Topics: Age Factors; Anemia, Sideroblastic; Antineoplastic Agents; Blastomeres; Bone Marrow Transplantation; Cytarabine; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 1991 |
Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.
Topics: Cytarabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Recurrence | 1991 |
Pharmacologically directed design of leukemia therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Evaluation; Humans; Leukemia; Leukemia, Myeloid, Acute; Mitoxantrone | 1990 |
Differentiating agents in the treatment of leukemia.
Topics: Cell Differentiation; Cytarabine; Humans; Interferon Type I; Leukemia; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Tretinoin | 1990 |
Differentiating agents in the treatment of leukemia and myelodysplastic syndromes.
Topics: Cell Differentiation; Cell Division; Cytarabine; Humans; Interferon Type I; Leukemia; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Tretinoin | 1990 |
Cure of acute myelocytic leukemia in adults: a reality.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction | 1990 |
Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
Topics: Arabinofuranosylcytosine Triphosphate; Biological Transport; Cytarabine; Deamination; Drug Administration Schedule; Drug Resistance; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Phosphorylation; Recurrence | 1990 |
Eccrine squamous syringometaplasia. A cutaneous sweat gland reaction in the histologic spectrum of 'chemotherapy-associated eccrine hidradenitis' and 'neutrophilic eccrine hidradenitis'.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Cytarabine; Eccrine Glands; Humans; Inflammation; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Sweat Glands | 1990 |
Treatment of acute myelogenous leukemia in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Remission Induction | 1989 |
Treatment of relapsed and refractory acute myeloid leukemia in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction | 1989 |
High dose therapy and autologous bone marrow transplant (ABMT) in acute leukemia: is purging necessary?
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Preoperative Care; Transplantation, Autologous; Whole-Body Irradiation | 1989 |
High dose cytarabine in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 1989 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lomustine; Melphalan; Mitoxantrone | 1989 |
[Progress in the treatment of acute myelogenous leukemia].
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Heart; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Prognosis; Remission Induction; Vincristine | 1989 |
High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.
Topics: Adult; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute | 1989 |
Mitoxantrone in the treatment of refractory and relapsed non-lymphoblastic acute leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone | 1989 |
[Acute pericarditis caused by daunorubicin in acute myelocytic leukemia].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Pericarditis | 1988 |
Differentiation in acute myeloid leukemia and myelodysplastic disorders. Is differentiation-induction therapy possible?
Topics: Cell Differentiation; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Tretinoin | 1988 |
High-dose cytosine arabinoside: pharmacological and clinical aspects.
Topics: Animals; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1988 |
High dose cytarabine: a review.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pancytopenia | 1988 |
Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
Topics: Age Factors; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 1987 |
[Clinical observations of 30 patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disseminated Intravascular Coagulation; Female; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Remission Induction | 1986 |
Treatment of patients with myelodysplastic syndromes: a review.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Cell Differentiation; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Tretinoin; Vitamin D | 1986 |
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Humans; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma | 1986 |
[Ultrahigh-dosage cytostatics--their possible use in acute leukemias?].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Recurrence | 1987 |
The treatment of myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Agents; Blood Transfusion; Bone Marrow Transplantation; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Preleukemia; Prognosis | 1986 |
Leukemic cell maturation.
Topics: Cell Differentiation; Cell Line; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Dimethyl Sulfoxide; Genotype; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Neutrophils; Oncogenes; Phenotype; Tetradecanoylphorbol Acetate; Vitamin A | 1985 |
Acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Aberrations; Cytarabine; Doxorubicin; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Nervous System Neoplasms; Prednisolone; Prognosis; Recurrence; Risk; Vincristine | 1985 |
Biochemical and cellular pharmacology of cytosine arabinoside.
Topics: Animals; Aphidicolin; Arabinofuranosylcytosine Triphosphate; Binding, Competitive; Cell Line; Cell Survival; Centrifugation, Density Gradient; Cytarabine; Diterpenes; DNA; DNA Repair; DNA Replication; Fibroblasts; Granulocytes; Humans; Kinetics; Leukemia L1210; Leukemia, Myeloid, Acute; Nucleic Acid Synthesis Inhibitors; Templates, Genetic; Vidarabine | 1985 |
Acute leukemia in adults.
Topics: Adult; Alkaline Phosphatase; BCG Vaccine; Blood Transfusion; Bone Marrow Examination; Central Nervous System Diseases; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Combinations; Drug Therapy, Combination; Esterases; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Meningitis; Microscopy, Electron; Neutrophils; Staining and Labeling; Subarachnoid Hemorrhage; Thioguanine | 1974 |
Treatment of acute leukemia.
Topics: Asparaginase; Bacterial Infections; Central Nervous System Diseases; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Hemorrhage; Humans; Immunotherapy; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Mitosis; Neoplasms, Nerve Tissue; Prednisone; Remission, Spontaneous; Testicular Neoplasms; Uric Acid; Vincristine | 1972 |
[Progress in the chemotherapy of acute leukemias].
Topics: Adult; Age Factors; Antineoplastic Agents; Child; Cyclophosphamide; Cytarabine; Follow-Up Studies; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Time Factors; Vincristine | 1972 |
[Treatment of acute leukemia. Controlled clinical trials and experimental data with a view to a more rational administration of anti-leukemic drugs].
Topics: Clinical Trials as Topic; Cytarabine; Daunorubicin; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisolone; Vincristine | 1973 |
[Treatment of acute leukemias].
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methods; Methotrexate; Prednisolone; Recurrence; Remission, Spontaneous; Vincristine | 1973 |
Treatment of acute granulocytic leukemias.
Topics: Adult; Age Factors; Antineoplastic Agents; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Heart; Hemorrhage; Humans; Hydrazones; Injections, Intravenous; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count | 1974 |
Present treatment of acute leukemias.
Topics: Asparaginase; Blood Transfusion; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Meninges; Mercaptopurine; Methotrexate; Prednisone; Remission, Spontaneous | 1973 |
[Lysozyme and leukemia. Diagnostic, prognostic and pathogenic significance of lysozyme measurements].
Topics: Cytarabine; Evaluation Studies as Topic; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methods; Muramidase; Neutrophils; Thioguanine | 1974 |
[Treatment of acute leukemias].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Infant, Newborn; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1968 |
[New principles of treatment in acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Central Nervous System Diseases; Child; Cyclophosphamide; Cytarabine; Female; Guanidines; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Male; Mercaptopurine; Methotrexate; Middle Aged; Nitroso Compounds; Prednisone; Thrombocytopenia; Urea; Uric Acid; Vincristine | 1970 |
Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Division; Cytarabine; Hematopoietic System; Humans; Kinetics; Leukemia; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; Mice; Neoplasm Transplantation; Thymidine; Time Factors; Tritium | 1970 |
Changing concepts of treatment in acute leukemia.
Topics: Acute Disease; Animals; Antineoplastic Agents; Asparaginase; Cell Differentiation; Cell Division; Cytarabine; DNA; Erythropoiesis; Hematopoiesis; Humans; Immunosuppressive Agents; Kinetics; Leukemia; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice; Mitosis; Models, Biological; Oncogenic Viruses; Prednisone; Remission, Spontaneous; Time Factors | 1971 |
The treatment of acute myeloblastic leukaemia.
Topics: Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Meningitis; Mercaptopurine; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1971 |
The chemotherapy of human and animal acute leukemia.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Azaserine; Cell Division; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Disease Models, Animal; Drug Combinations; Humans; Kinetics; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Neoplasms; Prednisone; Remission, Spontaneous; RNA, Neoplasm; Vincristine | 1971 |
Combination chemotherapy in malignant diseases.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carmustine; Child; Cyclophosphamide; Cytarabine; Cytosine; Daunorubicin; Drug Therapy, Combination; Hodgkin Disease; Humans; Immunotherapy; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Procarbazine; Remission, Spontaneous; Vincristine | 1971 |
823 trial(s) available for cytarabine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cyclophosphamide; Cytarabine; Daunorubicin; Down-Regulation; Drug Eruptions; Hidradenitis; Homoharringtonine; Humans; Incidence; Leukemia, Myeloid, Acute; Mercaptopurine; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neutrophils; Protein Kinase Inhibitors; Sweat Glands | 2021 |
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Glycolipids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 2022 |
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Topics: Aged; Benzothiazoles; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds | 2021 |
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate | 2021 |
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2022 |
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines | 2021 |
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; NF-kappa B; Phosphorylation; Transcription Factor RelA | 2022 |
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute | 2021 |
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Remission Induction; Vidarabine | 2022 |
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Lymphoma; Vorinostat | 2022 |
Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Cytoreduction Surgical Procedures; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Transplantation Conditioning | 2022 |
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Sulfides; Treatment Outcome | 2022 |
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; para-Aminobenzoates; Pyrrolidines | 2022 |
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Finland; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prospective Studies; Remission Induction; Thioguanine | 2022 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Topics: Aged; Cytarabine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation | 2023 |
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Vidarabine; Vorinostat | 2022 |
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles | 2022 |
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Vidarabine | 2022 |
Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Remission Induction | 2022 |
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nuclear Proteins; Quality of Life; Standard of Care | 2022 |
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Indoles; Leukemia, Myeloid, Acute | 2023 |
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arginase; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Polyethylene Glycols | 2023 |
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 2023 |
A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Aclarubicin; Adult; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Myelodysplastic Syndromes; Recurrence | 2023 |
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local | 2023 |
Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Eukaryotic Initiation Factor-4E; Glucuronosyltransferase; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Ribavirin; Uridine Diphosphate; Zinc Finger Protein GLI1 | 2023 |
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Tumor Lysis Syndrome | 2023 |
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; United Kingdom | 2023 |
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Nuclear Proteins; Treatment Outcome; Tretinoin; Young Adult | 2023 |
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Topics: Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Sorafenib | 2023 |
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Proteomics; Tumor Suppressor Protein p53; Young Adult | 2023 |
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Sorafenib | 2023 |
Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Consolidation Chemotherapy; Cytarabine; Decitabine; Disease-Free Survival; Female; Fetal Blood; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Rate | 2019 |
Glasdegib in the treatment of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Phenylurea Compounds; Prognosis; Survival Rate | 2019 |
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2020 |
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Poland; Prospective Studies; Remission Induction | 2020 |
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese".
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Palonosetron; Treatment Failure; Vomiting; Young Adult | 2020 |
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Filgrastim; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Middle Aged; Remission Induction; Treatment Outcome; Triazoles; Young Adult | 2020 |
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2020 |
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prodrugs; Prognosis; Treatment Outcome | 2019 |
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Etoposide; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondria; Mitoxantrone | 2020 |
Gemtuzumab Ozogamicin in
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Progression-Free Survival; Prospective Studies; Tretinoin; Young Adult | 2020 |
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Immunoconjugates; Induction Chemotherapy; Ki-1 Antigen; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate | 2020 |
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
Topics: Aged; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Nucleophosmin; Remission Induction | 2020 |
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Treatment Outcome | 2020 |
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
Topics: Adult; Aged; Cytarabine; Dasatinib; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2020 |
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Sulfonamides; Survival Rate | 2020 |
Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
Topics: Aged; Allografts; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Risk Factors | 2020 |
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Sulfonamides; Treatment Outcome | 2020 |
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diphosphates; Drug Resistance, Neoplasm; Drug Synergism; Feasibility Studies; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prodrugs; Respiratory Distress Syndrome; Salvage Therapy; Stilbenes; Treatment Outcome; Young Adult | 2020 |
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine | 2020 |
Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Remission Induction; Retreatment; Retrospective Studies; Risk Factors; Salvage Therapy; Single-Blind Method; Time Factors; Treatment Failure | 2021 |
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Recurrence; Survival Rate | 2020 |
A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherap
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Phenylurea Compounds; Survival Analysis | 2020 |
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Topics: Adult; Cytarabine; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Indazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Ecotropic Viral Integration Site 1 Protein; Pyrazines; Syk Kinase | 2020 |
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Topics: Aclarubicin; Adolescent; Adult; Aminopyridines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome; Young Adult | 2020 |
An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzimidazoles; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Time Factors; Treatment Outcome; United States | 2020 |
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.
Topics: Aged; Allografts; Compassionate Use Trials; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2020 |
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Female; Genomics; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Precision Medicine; Survival Analysis; Treatment Outcome | 2020 |
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Drug Interactions; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Pharmacists; Phenylurea Compounds; Physicians | 2021 |
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peptides; Receptors, CXCR4; Recurrence; Remission Induction | 2021 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; para-Aminobenzoates; Prognosis; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Remission Induction; Tissue Distribution; Young Adult | 2021 |
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nucleophosmin; Prognosis; Survival Rate; Young Adult | 2021 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Remission Induction | 2021 |
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
Topics: Adult; Allografts; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Fusion Proteins | 2021 |
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Retrospective Studies; Survival Rate; Vidarabine; Vincristine | 2021 |
Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Topics: Adult; Autografts; Chromosome Aberrations; Chromosomes, Human; Consolidation Chemotherapy; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Remission Induction; Survival Rate | 2021 |
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes | 2021 |
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Phenylurea Compounds; Survival Analysis; Treatment Outcome | 2021 |
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinate Synthase; Cytarabine; Drug Administration Schedule; Female; Humans; Hydrolases; Injections, Intramuscular; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Polyethylene Glycols; Thrombocytopenia; Treatment Outcome | 2021 |
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Azacitidine; Benzothiazoles; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Survival Rate | 2021 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis | 2021 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Topics: Adolescent; Anthracyclines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cytarabine; Female; Gemtuzumab; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Myeloid-Lymphoid Leukemia Protein; Progression-Free Survival; Recurrence; Risk Assessment; Risk Factors; Time Factors; United States | 2021 |
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Thionucleotides | 2021 |
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quality of Life; Survival Analysis | 2021 |
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2021 |
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm, Residual; Treatment Outcome | 2017 |
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult | 2017 |
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Filgrastim; Humans; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Polyethylene Glycols; Survival Rate | 2017 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Everolimus; Humans; Leukemia, Myeloid, Acute; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Cytarabine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pteridines; Tissue Distribution | 2018 |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2017 |
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Vidarabine | 2017 |
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult | 2017 |
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.
Topics: Adult; Aged; Alleles; Anthracyclines; Bone Marrow; Cytarabine; Exome; Female; Hematopoiesis; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Phenotype; Prognosis; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Checkpoint Kinase 1; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazoles; Pyrimidines | 2017 |
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Transcriptome; Treatment Outcome | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis | 2018 |
Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Male | 2018 |
Acute Myeloid Leukemia With Central Nervous System Involvement in Children: Experience From the French Protocol Analysis ELAM02.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; France; Humans; Infant; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukocyte Count; Prognosis; Recurrence; Survival Analysis | 2018 |
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2017 |
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Physical Fitness; Survival Analysis; Treatment Outcome | 2018 |
Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Autografts; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Treatment Outcome; Young Adult | 2018 |
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 2018 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cohort Studies; Combined Modality Therapy; Cytarabine; Cytogenetic Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pravastatin; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Remission Induction; Signal Transduction; Sirolimus | 2018 |
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Recurrence; Thiazoles | 2018 |
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pteridines; Salvage Therapy | 2019 |
Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II-III Randomized Trial (JPLSG AML-12).
Topics: Child; Cytarabine; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Japan; Leukemia, Myeloid, Acute | 2018 |
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Topics: Adult; Aged; Cytarabine; Disease-Free Survival; Female; Humans; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nucleophosmin; Remission Induction; Survival Rate | 2018 |
Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.
Topics: Adult; Cytarabine; Female; Follow-Up Studies; Genetic Association Studies; Glucuronosyltransferase; Humans; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Treatment Outcome | 2018 |
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary | 2018 |
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dopamine D2 Receptor Antagonists; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioridazine | 2018 |
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Risk Factors | 2018 |
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Young Adult | 2018 |
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Retrospective Studies; Risk Factors; Time Factors; Vidarabine | 2018 |
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Vidarabine; Young Adult | 2019 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction | 2018 |
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Theoretical; Quality-Adjusted Life Years; Staurosporine; Survival Rate; Treatment Outcome; United States | 2019 |
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase B; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors | 2019 |
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Approval; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; United States; United States Food and Drug Administration | 2019 |
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Cytarabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Phenylurea Compounds; Prognosis; Survival Rate | 2019 |
c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Febrile Neutropenia; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Respiratory Tract Infections; Retrospective Studies; Risk Factors | 2019 |
Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
Topics: Anthracyclines; China; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Remission Induction | 2019 |
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine | 2019 |
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Decitabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2019 |
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Sulfonamides | 2019 |
Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Risk; Single-Blind Method; Treatment Failure; Vidarabine | 2019 |
Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Female; Follow-Up Studies; Genotype; Histone-Lysine N-Methyltransferase; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2019 |
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Patient Safety; Remission Induction; Salvage Therapy; Treatment Outcome | 2019 |
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Comorbidity; Cytarabine; Dose-Response Relationship, Drug; Drug Approval; Drug Labeling; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Smoothened Receptor; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2019 |
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Combinations; Female; Half-Life; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Treatment Outcome | 2019 |
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Decitabine; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pilot Projects; Protein Kinase Inhibitors; Pyrimidines | 2020 |
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2019 |
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Survival Rate | 2019 |
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Retrospective Studies; Sorafenib; Survival Rate; Tandem Repeat Sequences | 2019 |
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Resistance, Neoplasm; Female; Galectins; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; T-Lymphocyte Subsets; Treatment Failure; Triazoles | 2019 |
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytarabine; Etoposide; Female; Gene Expression Regulation, Leukemic; Humans; Hydroxamic Acids; Karyotype; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Recurrence; Translational Research, Biomedical; Treatment Outcome; Tumor Necrosis Factor Decoy Receptors; Vorinostat; Young Adult | 2013 |
Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Failure; Treatment Outcome; Young Adult | 2013 |
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genome-Wide Association Study; Genotype; Humans; Leukemia, Myeloid, Acute; Phenotype; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2013 |
Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Heart Diseases; Homoharringtonine; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Young Adult | 2013 |
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Cytarabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Organophosphates; Protein Serine-Threonine Kinases; Quinazolines; Stomatitis; Treatment Outcome | 2013 |
Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Mass Index; Coronary Artery Disease; Cytarabine; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Rate | 2013 |
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Infant; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Single-Cell Analysis; Thioguanine; Treatment Outcome | 2013 |
Outcome of older patients with acute myeloid leukemia in first relapse.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2013 |
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Organophosphates; Quinazolines; Treatment Outcome | 2013 |
Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Obesity; Retrospective Studies; Survival Rate | 2013 |
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Treatment Outcome | 2013 |
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Drug Eruptions; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Nausea; Pilot Projects; Remission Induction; Survival Analysis; Young Adult | 2013 |
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Survival Analysis; Treatment Outcome | 2013 |
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodeoxyribonucleotides | 2014 |
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Comorbidity; Cytarabine; Drug Eruptions; Female; Humans; Leukemia, Myeloid, Acute; Liver Failure; Male; Mucositis; Prospective Studies; Remission Induction | 2014 |
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Survival Analysis; Vidarabine; Young Adult | 2014 |
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BRCA1 Protein; Checkpoint Kinase 1; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Agonism; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Heterografts; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Panobinostat; Protein Kinases; Rad51 Recombinase; U937 Cells | 2013 |
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2014 |
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cholesterol; Cytarabine; Drug Administration Schedule; Electrocardiography; Female; Heart; Humans; Leukemia, Myeloid, Acute; Lipoproteins; Male; Middle Aged; Recurrence; Treatment Outcome | 2014 |
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Thalidomide | 2014 |
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Signal Transduction; Stem Cell Niche; Tumor Cells, Cultured | 2014 |
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetic Analysis; Decitabine; Female; Humans; Internationality; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Risk Factors; Treatment Outcome | 2014 |
Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome; Vidarabine; Young Adult | 2014 |
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Young Adult | 2014 |
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Critical Care; Cytarabine; Disease-Free Survival; Drug Synergism; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Survival Rate; Tretinoin; Valproic Acid | 2014 |
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Female; Humans; Hyperbilirubinemia; Hypercholesterolemia; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Treatment Failure | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pteridines; Treatment Outcome | 2014 |
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; RNA, Messenger; Treatment Outcome; WT1 Proteins | 2014 |
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2014 |
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fibroblast Growth Factor 7; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Stomatitis | 2014 |
Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.
Topics: Adolescent; Adult; Chemotherapy-Induced Febrile Neutropenia; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Risk Factors; Survival Analysis; Thioguanine; Treatment Outcome | 2014 |
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mitoxantrone; Russia | 2014 |
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis | 2015 |
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Young Adult | 2015 |
A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-4E; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Ribavirin; Salvage Therapy; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Young Adult | 2015 |
Re-induction with L-DNR/FLAG improves response after AML relapse, but not long-term survival.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Female; Follow-Up Studies; Germany; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Polyethylene Glycols; Remission Induction; Retreatment; Selection Bias; Survival Rate; Vidarabine; Young Adult | 2014 |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Young Adult | 2015 |
Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Asian People; ATP Binding Cassette Transporter, Subfamily B; Cytarabine; Female; Genotype; Haplotypes; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Recurrence; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cytarabine; Cytosine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate | 2015 |
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pravastatin; Risk Factors; Survival Rate | 2015 |
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Assessment; Survival Rate; United Kingdom | 2015 |
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2015 |
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Young Adult | 2015 |
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thiazoles | 2015 |
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome | 2015 |
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2015 |
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azocines; Benzhydryl Compounds; Cytarabine; Cytokines; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged | 2015 |
A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2015 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies.
Topics: Adolescent; Adult; Allografts; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Family; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Whole-Body Irradiation | 2015 |
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2016 |
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2015 |
Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2015 |
Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Prognosis; Survival Rate | 2015 |
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Flavonoids; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Survival Rate | 2015 |
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Induction Chemotherapy; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Pilot Projects; Remission Induction; Survival Analysis; Thrombocytopenia | 2015 |
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Idarubicin; Indoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Neoplasm, Residual; Panobinostat; Prognosis; Recurrence; Treatment Outcome | 2015 |
Family History and Relapse in Pediatric Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Rate | 2015 |
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Remission Induction; Thiazoles; Treatment Outcome | 2015 |
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 2015 |
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis | 2016 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Vincristine | 2016 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
Topics: Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Stem Cell Transplantation; Survival Rate; Tamoxifen; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Thalidomide | 2016 |
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2016 |
[Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drugs, Chinese Herbal; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Medicine, Chinese Traditional; Phytotherapy; Yin Deficiency | 2016 |
Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - Study protocol of a randomized placebo-controlled trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bicycling; Cognitive Dysfunction; Cytarabine; Executive Function; Exercise Therapy; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neuropsychological Tests; Spatial Memory; Treatment Outcome | 2016 |
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cohort Studies; Cord Blood Stem Cell Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Young Adult | 2016 |
SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytarabine; Equilibrative Nucleoside Transporter 1; Female; Genetic Association Studies; Genetic Variation; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Remission Induction; Treatment Outcome; Young Adult | 2016 |
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-mdm2; Salvage Therapy; Survival Analysis; Treatment Outcome | 2016 |
[Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction | 2016 |
CHK1 as a therapeutic target to bypass chemoresistance in AML.
Topics: Checkpoint Kinase 1; Cytarabine; DNA Replication; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Pyrazoles; Pyrimidines | 2016 |
Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Prospective Studies; Proto-Oncogene Proteins c-kit; Translocation, Genetic; Vidarabine; Young Adult | 2017 |
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Female; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors | 2016 |
Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Random Allocation; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2017 |
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Cytarabine; Female; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2017 |
Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Remission Induction | 2017 |
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2017 |
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Stem Cell Transplantation | 2017 |
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Oligodeoxyribonucleotides; Oligonucleotides, Antisense; Ribonucleotide Reductases; Treatment Outcome | 2008 |
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Genes, ras; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Remission Induction; Statistics, Nonparametric; Survival Rate | 2008 |
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Survival Rate | 2008 |
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors | 2008 |
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Remission Induction | 2008 |
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Vidarabine; Young Adult | 2008 |
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid; Survival Rate; Treatment Outcome | 2008 |
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine | 2009 |
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Salvage Therapy | 2008 |
Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 2008 |
Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Outcome | 2009 |
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Remission Induction; Survival Rate | 2008 |
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; France; Gemtuzumab; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Time Factors; Treatment Failure; Treatment Outcome | 2008 |
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Vidarabine | 2008 |
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Quinolones; Remission Induction | 2009 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Daunorubicin; Dibenzocycloheptenes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolines; Time Factors | 2009 |
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Societies, Medical; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Tretinoin; Vidarabine | 2009 |
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
[Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2009 |
Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.
Topics: Adult; Aged; ATP-Binding Cassette Transporters; Blast Crisis; Cell Membrane; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; LLC-PK1 Cells; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stem Cells; Survival Rate | 2009 |
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Cytogenetic Analysis; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate | 2009 |
[A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Young Adult | 2009 |
Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia.
Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Down Syndrome; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Erythrocytes; Etoposide; Female; Guanine Nucleotides; Humans; Infant; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Registries; Scandinavian and Nordic Countries; Thioguanine; Thionucleotides; Treatment Outcome | 2009 |
[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2009 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
[Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Young Adult | 2009 |
[Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 2009 |
Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberrations; Cytarabine; Daunorubicin; Drugs, Chinese Herbal; Etoposide; Female; Humans; Immunophenotyping; Integrative Medicine; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Treatment Outcome; Young Adult | 2009 |
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Candida; Cladribine; Cytarabine; Daunorubicin; Female; Fungemia; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Treatment Outcome; Young Adult | 2010 |
Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Agranulocytosis; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Nausea; Recurrence; Remission Induction; Young Adult | 2009 |
Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Disease Progression; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Treatment Outcome; Young Adult | 2009 |
[Clinical research of modified CAG regimen for the treatment of relapsed acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2009 |
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides; Young Adult | 2009 |
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult | 2009 |
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged | 2010 |
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Remission Induction; Risk Factors; Treatment Outcome; Young Adult | 2010 |
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gemtuzumab; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Topotecan | 2010 |
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epidemiologic Methods; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Treatment Outcome | 2010 |
[Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine; Young Adult | 2009 |
[Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Topotecan; Young Adult | 2009 |
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Flavonoids; Follow-Up Studies; Heart Diseases; Humans; Hyperkalemia; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Polyamines; Premedication; Remission Induction; Risk; Sepsis; Sevelamer; Transplantation, Homologous; Treatment Outcome; Tumor Lysis Syndrome; Young Adult | 2010 |
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2010 |
[FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thioguanine; Treatment Outcome; Tretinoin; Young Adult | 2010 |
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Precision Medicine; Prognosis; Remission Induction; Treatment Outcome; Young Adult | 2010 |
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
Topics: Adolescent; Adult; Age Distribution; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Risk Factors; Survival Analysis; Transplantation, Homologous | 2010 |
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Changes of serum growth factors (IGF-I & IGFBP-2) and prediction of response to chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor I; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Prognosis; Remission Induction; Treatment Outcome; Young Adult | 2008 |
[Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Invasive Pulmonary Aspergillosis; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pulse Therapy, Drug; Recurrence; Remission Induction; Treatment Outcome | 2010 |
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Adjustment; Risk Factors; Survival Rate; Tretinoin | 2010 |
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; STAT5 Transcription Factor | 2010 |
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Confidence Intervals; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2010 |
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Nuclear Proteins; Nucleophosmin; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Risk Factors | 2010 |
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Remission Induction; Survival Rate; Young Adult | 2010 |
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Cytarabine; Female; Gene Frequency; Genotype; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Remission Induction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Young Adult | 2010 |
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 2010 |
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Young Adult | 2011 |
Brain perfusion in adult patients with acute myeloblastic leukemia before and after cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Brain; Cerebrovascular Circulation; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Perfusion; Tomography, Emission-Computed, Single-Photon; Young Adult | 2011 |
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alpha Particles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bismuth; Cytarabine; Drug Administration Schedule; Female; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Male; Middle Aged; Radioimmunotherapy; Radioisotopes; Remission Induction | 2010 |
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Progenitor Cells; Oligonucleotides; Recurrence; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2011 |
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Neoplasm Staging; Quinolones; Remission Induction; Risk; Young Adult | 2011 |
Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Salvage Therapy; Translocation, Genetic; Young Adult | 2011 |
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Nucleophosmin; Prognosis; Recurrence; Stem Cell Transplantation; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome | 2011 |
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2011 |
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Cytarabine dose for acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Female; Humans; Intention to Treat Analysis; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Stem Cell Transplantation; Survival Analysis; Young Adult | 2011 |
Prophylactic treatment for cytosine arabinoside-induced keratoconjunctivitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppressive Agents; Keratoconjunctivitis; Leukemia, Myeloid, Acute; Male; Middle Aged; Ophthalmic Solutions; Prednisolone; Treatment Outcome; Young Adult | 2011 |
Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.
Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytochrome P-450 CYP2D6; Daunorubicin; Drug Interactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Oxidation-Reduction; Phenotype; Young Adult | 2011 |
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Down-Regulation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; STAT3 Transcription Factor | 2011 |
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarabine; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome; Valproic Acid | 2011 |
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome | 2011 |
Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Doxorubicin; Female; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Survival Rate; Vincristine | 2011 |
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Prospective Studies; Remission Induction; Risk; Treatment Outcome | 2011 |
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Therapy; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleophosmin; Prospective Studies; Remission Induction; Young Adult | 2011 |
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Treatment Failure | 2012 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2011 |
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2012 |
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Risk; Salvage Therapy; Young Adult | 2011 |
Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycophenolic Acid; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Survival Analysis; Thioguanine; Treatment Outcome | 2011 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Apoptosis; Cytarabine; Female; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neurons; Neurotoxicity Syndromes; NM23 Nucleoside Diphosphate Kinases; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Young Adult | 2012 |
[Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2011 |
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 2012 |
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cytarabine; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Myeloid, Acute; Male; Primary Cell Culture; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid | 2012 |
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Ribosomal Protein S6; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
Topics: Adolescent; Adult; Age Factors; Antigens, CD34; Chromosome Aberrations; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2012 |
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Chromatography, High Pressure Liquid; Creatinine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Prospective Studies; Tissue Distribution; Young Adult | 2012 |
Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytarabine; Female; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Young Adult | 2012 |
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Recurrence; Treatment Outcome | 2012 |
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2012 |
A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction; Vinblastine; Vincristine; Young Adult | 2012 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Receptors, CXCR4; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2012 |
[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Topics: Aclarubicin; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate | 2012 |
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytokines; Female; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Palliative Care; Prognosis; Theophylline; Tretinoin; Tumor Cells, Cultured; Valproic Acid | 2012 |
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Treatment Outcome | 2012 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
High Dose Cytosine Arabinoside in the consolidation of adult acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2012 |
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome | 2012 |
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Placebos; Recurrence | 2012 |
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolones; Survival Analysis; Treatment Outcome | 2012 |
Treatment outcome in older patients with childhood acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Transplantation, Autologous; Young Adult | 2012 |
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Decision Making; Decitabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Palliative Care; Patient Participation; Remission Induction; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Referral and Consultation; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Treatment Outcome | 2012 |
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Etoposide; Exons; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
[The clinical comparison of FLAG regimen versus IA regimen for newly diagnosed acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Survival Rate | 2012 |
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Tract; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Internationality; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome | 2013 |
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Leukocytosis; Male; Survival Rate | 2012 |
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Gemtuzumab; Humans; Immunotoxins; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Remission Induction; Secondary Prevention; Treatment Outcome | 2012 |
Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytarabine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Indicators and Reagents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Vidarabine | 2012 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Japan; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Recurrence; Treatment Outcome | 2012 |
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Grading; Prognosis; Remission Induction; Survival Rate | 2013 |
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
[The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Russia; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Survival Rate; Time Factors; Vidarabine | 2013 |
Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Cell Count; Bone Marrow Cells; Comorbidity; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hemoglobins; Humans; Immunophenotyping; Kaplan-Meier Estimate; Karyotyping; Kidney Function Tests; Leukemia, Myeloid, Acute; Liver Function Tests; Logistic Models; Male; Middle Aged; Prognosis; Remission Induction; Risk Factors; Treatment Outcome | 2012 |
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Checkpoint Kinase 1; Cytarabine; Drug Resistance, Neoplasm; Female; Histones; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2012 |
High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Streptococcal Infections; Viridans Streptococci | 2013 |
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Survival Analysis; Treatment Outcome | 2012 |
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Odds Ratio; Remission Induction; Research Design; Treatment Outcome; Vidarabine | 2013 |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Core Binding Factors; Cytarabine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Genes, Neoplasm; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Prognosis; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Everolimus; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2013 |
High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Risk Factors; Survival Rate | 2013 |
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Female; Humans; Idarubicin; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Survivin; Treatment Outcome | 2013 |
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Remission Induction | 2002 |
Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate; Thioguanine; Time Factors | 2002 |
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction | 2002 |
Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Tretinoin | 2003 |
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
Topics: Adolescent; Adult; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prospective Studies; Quinine; Rhodamine 123 | 2003 |
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2003 |
A homoharringtonine-based regimen for childhood acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Cytarabine; Disease-Free Survival; Etoposide; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2003 |
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Pilot Projects; Remission Induction; Salvage Therapy; Treatment Outcome | 2003 |
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Survival Rate; Treatment Outcome | 2003 |
Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2003 |
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Survival Rate | 2003 |
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis | 2003 |
Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Child; Cytarabine; Etoposide; fas Receptor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes, Mononuclear; Lymphocyte Depletion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Outcome | 2003 |
[Modified FLAG regimen in the management of refractory acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2003 |
Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Treatment Outcome | 1996 |
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by seq
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Survival Analysis; Thioguanine | 2003 |
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Patient Selection; Recurrence; Statistics, Nonparametric; Survival Rate; Thioguanine; Time Factors | 2004 |
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2004 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2004 |
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate; Vidarabine | 2004 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine | 2004 |
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Topotecan; Treatment Outcome | 2004 |
Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM data.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins | 2004 |
Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Stem Cell Transplantation; Survival Analysis; Thioguanine | 2004 |
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Microcirculation; Middle Aged; Mitoxantrone; Recombinant Proteins; Recurrence; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2004 |
Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Probability; Prospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning | 2004 |
A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Treatment Outcome | 2004 |
Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Incidence; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Siblings; Stem Cell Transplantation; Stem Cells; Tissue and Organ Harvesting; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Models, Chemical; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Nucleosides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2004 |
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2005 |
Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Patient Selection; Pilot Projects; Prognosis; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Recurrence; Remission Induction; Risk Factors; Survival Analysis | 2005 |
High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Interleukin-11; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis | 2005 |
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Survival Rate; Treatment Outcome | 2005 |
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Topics: Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Helicases; Etoposide; Exodeoxyribonucleases; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; RecQ Helicases; Werner Syndrome; Werner Syndrome Helicase | 2005 |
Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Salvage Therapy | 2006 |
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diarrhea; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vomiting, Anticipatory | 2005 |
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cytarabine; Daunorubicin; Etoposide; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Recurrence | 2006 |
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult L
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Probability; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine; Vindesine | 2005 |
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Cycle; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cytarabine; DNA Damage; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Protein v-akt; Pharmacokinetics; Phosphorylation; Pilot Projects; Protein Kinases; Salvage Therapy; Staurosporine; Tumor Cells, Cultured | 2006 |
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cattle; Cell Proliferation; Cohort Studies; Cytarabine; Endothelium, Vascular; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; U937 Cells; Vascular Endothelial Growth Factor A | 2005 |
Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Tretinoin | 2006 |
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
Topics: Aged; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sepsis; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Time Factors | 2006 |
Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors; Treatment Outcome | 2006 |
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cytarabine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Safety | 2007 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucositis; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 2006 |
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 2007 |
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Treatment Outcome | 2007 |
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 2007 |
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Flavonoids; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Piperidines; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2007 |
Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
Topics: Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Matched-Pair Analysis; Middle Aged; Thioguanine | 2008 |
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Ethnicity; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Time Factors; Treatment Outcome; United States | 2007 |
Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Neoplasms, Second Primary; Prognosis; Remission Induction; Risk | 2008 |
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retrospective Studies; Time Factors | 2007 |
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Poland; Remission Induction; Vidarabine | 2008 |
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Monitoring; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Methemoglobinemia; Middle Aged; Pyridines; Recurrence; Thiosemicarbazones | 2008 |
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome | 2008 |
Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome | 2008 |
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Topotecan | 2008 |
Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
Topics: Adolescent; Adult; Child; Child, Preschool; Cytarabine; Humans; Hydroxyurea; Infections; Leukemia; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid, Acute; Liver; Skin; Survival Analysis | 2008 |
Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.
Topics: Acyclovir; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biological Availability; Cross-Over Studies; Cytarabine; Daunorubicin; Drug Interactions; Female; Humans; Intestinal Absorption; Leukemia, Myeloid, Acute; Male; Middle Aged | 2008 |
Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Clinical Trials as Topic; Cytarabine; Evaluation Studies as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Prognosis; Random Allocation; Thioguanine; Thrombocytopenia; Vincristine | 1984 |
Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol.
Topics: Adolescent; Adult; Aged; Ancitabine; Antineoplastic Agents; Bacterial Vaccines; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Pseudomonas aeruginosa; Random Allocation; Thioguanine | 1981 |
A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BCG Vaccine; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyguanosine; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Thioguanine; Thionucleosides; United States | 1984 |
Cooperative randomized studies on the treatment of adult acute leukemia in Poland. A comparison of two remission induction regimes and two maintenance regimes for AML.
Topics: Adult; Animals; Blood Transfusion; Cattle; Cytarabine; Doxorubicin; Granulocytes; Humans; Leukemia, Myeloid, Acute; Middle Aged; Platelet Transfusion; Poland; Prospective Studies; Random Allocation; Thioguanine; Thymus Gland; Tissue Extracts | 1984 |
Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group.
Topics: Adolescent; Adult; Ancitabine; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Delayed-Action Preparations; Female; Humans; Infant; Injections, Intraperitoneal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Lomustine; Male; Podophyllotoxin | 1984 |
[New agents in the treatment of leukemia and lymphoma].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cytarabine; Doxorubicin; Drug Evaluation; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Lymphoma; Middle Aged; Naphthacenes | 1983 |
Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients.
Topics: Adult; Aged; Bone Marrow; Clinical Trials as Topic; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male | 1983 |
Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Risk | 1983 |
Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as Topic; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Thioguanine; Time Factors; Vincristine | 1984 |
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prednisone; Vincristine | 1984 |
Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia. A Southeastern Cancer Study Group study.
Topics: Age Factors; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Fever; Humans; Infections; Leukemia, Myeloid, Acute; Lithium; Lithium Carbonate; Male; Middle Aged; Neutropenia; Random Allocation; Thrombocytopenia | 1984 |
Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Amphotericin B; Anti-Bacterial Agents; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Pneumonia | 1982 |
[Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Clinical Trials as Topic; Cytarabine; Drug Synergism; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1982 |
Immunotherapy for remission maintenance in acute myeloblastic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Mycobacterium bovis | 1982 |
Short-term treatment for acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1982 |
Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
Topics: Adolescent; Adult; BCG Vaccine; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Thioguanine; Time Factors | 1980 |
Intensive chemotherapy for acute myelogenous leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Thioguanine | 1981 |
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.
Topics: Acute Disease; Adolescent; Adult; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Time Factors | 1981 |
Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia.
Topics: Adolescent; Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Thioguanine; Vincristine | 1981 |
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Colitis, Ulcerative; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Stomatitis | 1982 |
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1982 |
Chemotherapy of the myeloid leukaemias.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Remission, Spontaneous; Thioguanine | 1980 |
Androgen therapy during myeloblastic leukemia remission induced by two drug combinations.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Stanozolol; Vincristine | 1981 |
[Results of a clinical study of the preparation Lenvis in leukemias in children and adults].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Drug Therapy, Combination; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Thioguanine | 1981 |
Maintenance chemoimmunotherapy of nonlymphoblastic acute leukemias.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes; Male; Middle Aged; Mycobacterium bovis; Thioguanine | 1982 |
Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Probability; Random Allocation; Thioguanine; Vincristine | 1982 |
Progress in acute myelogenous leukemia.
Topics: Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Graft vs Host Reaction; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine; Time Factors | 1981 |
A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins | 1995 |
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Europe; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pilot Projects; Prognosis; Prospective Studies; Survival Analysis | 1995 |
High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 1995 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects | 1995 |
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence | 1995 |
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Remission Induction; Thioguanine | 1995 |
[Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1995 |
[Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1995 |
Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recombinant Proteins | 1995 |
Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient r
Topics: Aged; Antineoplastic Agents; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Double-Blind Method; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Outpatients; Randomized Controlled Trials as Topic; Recombinant Proteins | 1995 |
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Topics: Administration, Oral; Antineoplastic Agents; Arabinofuranosyluracil; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Dose-Response Relationship, Drug; Half-Life; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Statistics, Nonparametric | 1995 |
Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Adducts; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prednisolone; Recurrence; Survival Analysis; Thioguanine; Vincristine | 1995 |
Fractionated total-body irradiation preceding high-dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Whole-Body Irradiation | 1995 |
In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Remission Induction | 1995 |
All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Tretinoin | 1995 |
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1993 |
Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Thioguanine; United States | 1995 |
Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cell Cycle; Cytarabine; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1995 |
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
Topics: Aged; Aged, 80 and over; Cytarabine; Daunorubicin; Double-Blind Method; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Regression Analysis; Remission Induction; Treatment Outcome | 1995 |
[Treatment results of acute nonlymphocytic leukemia in childhood--Kyushu Yamaguchi Children's Cancer Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Recurrence; Remission Induction; Survival Rate; Vincristine | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 1995 |
The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukemia. Australian Leukemia Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Myeloid, Acute; Life Tables; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Treatment Outcome | 1994 |
[High-dose cytarabine as intensive postremission therapy in acute myelogenous leukemia: effect on long-term disease-free survival].
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1994 |
Improved survival for patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; United States | 1995 |
Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cytarabine; DNA Adducts; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Organoplatinum Compounds; Predictive Value of Tests; Recurrence; Remission Induction | 1994 |
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Thioguanine | 1994 |
Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy | 1994 |
A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Survival Analysis | 1994 |
[Role of double induction in the treatment of acute myeloblastic leukemia in the adult: intermediate results of protocol LAM90].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction | 1994 |
[Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1994 |
Salvage therapy with low-dose cytosine arabinoside in refractory or relapsed acute non-lymphocytic leukaemia: a report on 25 patients.
Topics: Adolescent; Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1994 |
Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Survival Analysis | 1994 |
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetics; Dose-Response Relationship, Drug; Doxorubicin; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recurrence; Survival Analysis; Time Factors; Translocation, Genetic | 1994 |
A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Time Factors | 1994 |
Phase II-trial of double-consolidation following intensive induction treatment for improvement of survival in elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 1994 |
Effects of bone marrow transplantation on myocardial function in children.
Topics: Adolescent; Adult; Blood Pressure; Bone Marrow Transplantation; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Echocardiography; Female; Heart; Humans; Infant; Leukemia, Myeloid, Acute; Male; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radionuclide Angiography; Time Factors; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1993 |
Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: results of a randomized, controlled study.
Topics: Adolescent; Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 1993 |
Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
Topics: Adult; Aged; Blast Crisis; Cytarabine; Deoxycytidine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia | 1993 |
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 1994 |
Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate | 1993 |
Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Analysis | 1993 |
[Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute | 1993 |
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Conjunctivitis; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1993 |
Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Treatment Outcome | 1993 |
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Chemical and Drug Induced Liver Injury; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Time Factors | 1993 |
Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Recombinant Proteins | 1993 |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1993 |
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence | 1993 |
[Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1993 |
Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prospective Studies; Remission Induction; Survival Rate; Thioguanine | 1993 |
[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of
Topics: Actuarial Analysis; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Survival Analysis; Transplantation, Autologous | 1993 |
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Topics: Adenosine Triphosphate; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Base Sequence; Biotransformation; Cladribine; Cytarabine; DNA Replication; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Neoplasm Proteins; Neoplastic Stem Cells; Prodrugs; Ribonucleotide Reductases; Salvage Therapy | 1996 |
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neutropenia; Pilot Projects; Remission Induction; Survival Rate | 1996 |
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Platelet Count; Recombinant Proteins; Recurrence; Remission Induction | 1996 |
MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate | 1995 |
Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Remission Induction | 1995 |
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Survival Rate | 1996 |
[Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome | 1996 |
In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Regression Analysis; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation | 1996 |
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 1996 |
Heterogeneous effects of G-CSF and GM-CSF on cell growth and ara-C cytotoxicity in childhood leukemias which express myeloid markers.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cell Division; Child; Child, Preschool; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunophenotyping; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thymidine; Tritium | 1996 |
[Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quality of Life; Recurrence; Remission Induction; Survival Rate | 1996 |
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence | 1996 |
BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 1996 |
[Treatment results for unselected patients with acute myelogenous leukemia. During a 10-year period, August 1984 to July 1994].
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Patient Selection; Prednisolone; Remission Induction; Retrospective Studies; Treatment Outcome | 1996 |
A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Topics: Adolescent; Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Data Interpretation, Statistical; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1996 |
Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Taiwan | 1996 |
Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction | 1996 |
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Prospective Studies; Remission Induction | 1997 |
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 1996 |
[Myelogenous leukemia in children. ANLL9205 study by Children's Cancer and Leukemia Study Group (CCLSG)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Risk Factors; Vincristine | 1997 |
[Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Time Factors; Vinblastine; Vincristine | 1997 |
Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Prospective Studies | 1997 |
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Topics: Age Factors; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Double-Blind Method; Drug Resistance, Multiple; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recombinant Proteins | 1997 |
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Preleukemia; Prognosis; Risk Factors; Treatment Outcome | 1997 |
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Ondansetron; Phenothiazines; Pilot Projects; Serotonin Antagonists; Vomiting | 1997 |
Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Agranulocytosis; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Nausea; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
[Treatment results in childhood acute myeloblastic leukemia--a report of clinical trials of a past decade from the Japanese children's Cancer and Leukemia Study Group (CCLSG)].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Tretinoin | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission.
Topics: Adult; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Survival Analysis; Transplantation, Autologous | 1997 |
Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction | 1997 |
Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects | 1997 |
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1998 |
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy | 1998 |
Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C.
Topics: Aged; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Analysis | 1998 |
Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Transplantation, Autologous | 1998 |
Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients.
Topics: Aclarubicin; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male | 1998 |
[Treatment of children with non-Hodgkin's lymphoma with CCLSG NHL 855/890 protocols long-term outcome and incidence of secondary malignancies].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hydrocortisone; Infant; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Prednisolone; Remission Induction; Treatment Outcome; Vincristine | 1998 |
Chemotherapy of acute myeloblastic leukaemia with DAM regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1997 |
[A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Time Factors | 1998 |
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Vincristine | 1998 |
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemotherapy, Adjuvant; Creatinine; Cyclosporine; Cytarabine; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1998 |
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Cytarabine; Diarrhea; Distamycins; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Mice; Mice, SCID; Middle Aged; Nausea; Nitrogen Mustard Compounds; Transplantation, Heterologous; Tumor Cells, Cultured; Vomiting | 1997 |
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Blast Crisis; Cell Cycle; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Pilot Projects; Vidarabine | 1995 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study.
Topics: Adult; Aged; Amsacrine; Chromatography, High Pressure Liquid; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Time Factors | 1998 |
[A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
Topics: Adolescent; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Cytarabine; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vomiting | 1998 |
[Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Topics: Adult; Aged; Anorexia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Vincristine; Vomiting, Anticipatory | 1999 |
Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Drug Synergism; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1999 |
FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 1999 |
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Humans; Karyotyping; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Thioguanine; Treatment Outcome | 1999 |
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Vidarabine | 1999 |
A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Central Nervous System Diseases; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1999 |
Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukopenia; Prospective Studies | 1999 |
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Disease Progression; Female; Genes, MDR; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Phenotype; Quinine; Remission Induction; Survival Analysis | 1999 |
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis; Remission Induction; Salvage Therapy | 1999 |
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Danazol; Drug Screening Assays, Antitumor; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Tamoxifen; Vidarabine | 1999 |
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Analysis; Translocation, Genetic | 1999 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Female; Genes, bcl-2; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Recurrence; Survival Analysis; Treatment Outcome; Tretinoin | 2000 |
[A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Prognosis; Prospective Studies; Remission Induction; Vincristine | 2000 |
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Probability; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2000 |
Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Survival Rate; Treatment Outcome | 2000 |
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine).
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prognosis; Radiation-Protective Agents; Treatment Outcome | 2000 |
[Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
Topics: Adolescent; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prospective Studies | 2000 |
High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Thioguanine; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Patient Selection; Recurrence; Ventricular Function, Left | 2000 |
Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: a report from the Kyushu-Yamaguchi Children's Cancer Study group in Japan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 2000 |
Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutrophils | 2001 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Risk Factors; Survival Rate | 2001 |
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 2001 |
High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cytarabine; Cytogenetic Analysis; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Treatment Outcome | 2001 |
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Carriers; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Recurrence; Treatment Outcome | 2001 |
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Costs and Cost Analysis; Cytarabine; Daunorubicin; Disease-Free Survival; Fever; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Infections; Leukemia, Myeloid, Acute; Middle Aged; Placebos; Southwestern United States | 2001 |
Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Rate; Thioguanine; Time Factors; Treatment Outcome | 2001 |
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Rate; Vidarabine | 2001 |
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2001 |
Outpatient supportive care following chemotherapy for acute myeloblastic leukemia.
Topics: Adult; Aged; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Feasibility Studies; Female; Growth Substances; Humans; Inpatients; Leukemia, Myeloid, Acute; Male; Middle Aged; Outpatients; Patient Discharge; Patient Readmission; Remission Induction; Retrospective Studies; Safety; Social Support; Survival Rate; Time Factors; Treatment Outcome | 2001 |
Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Survival Rate | 2001 |
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Cytarabine; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Prognosis; Proto-Oncogenes; Remission Induction; Survival Rate; Transcription Factors; Translocation, Genetic; Treatment Outcome; Vincristine | 2001 |
Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cell Count; Cytarabine; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Middle Aged; Thrombopoietin; Time Factors | 2002 |
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Infusions, Intravenous; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Treatment Outcome | 2002 |
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Mitoxantrone; Prospective Studies; Recurrence; Treatment Outcome | 2002 |
Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1979 |
Active immunotherapy in leukemia with neuraminidase-modified leukemic cells.
Topics: Animals; Antigens, Neoplasm; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Hypersensitivity, Delayed; Immunization; Immunotherapy; Leukemia Virus, Murine; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Mice, Inbred AKR; Mice, Inbred C57BL; Mice, Inbred DBA; Neuraminidase; Tumor Virus Infections | 1977 |
Age and treatment response in acute nonlymphoblastic leukemia.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Marrow; Cytarabine; Depression, Chemical; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Thioguanine; Time Factors; Vincristine | 1978 |
Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1978 |
Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia.
Topics: Agranulocytosis; Bacterial Infections; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Lithium; Neutropenia; Remission, Spontaneous | 1979 |
The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous; Thioguanine | 1979 |
Chemotherapy and immunotherapy interspersion: clinical studies in acute myeloblastic leukaemia.
Topics: Adult; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Skin Tests | 1977 |
Chemotherapy of acute myeloid leukaemia in adults: Medical Research Council.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Random Allocation; Thioguanine; Vincristine | 1979 |
Design of adjuvant chemotherapy based on target cell determinants of drug action: possibilities and limitations.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Drug Evaluation; Humans; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Neoplasms; Research Design | 1979 |
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Remission, Spontaneous; Thioguanine | 1979 |
Interhospital differences in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group.
Topics: Acute Disease; Adult; Aged; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Finland; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous | 1979 |
[Revaluation of the two step DCMP chemotherapy for acute leukemias (author's transl)].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1979 |
Early consolidation chemotherapy for adults with acute leukemia in remission.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Cytarabine; Enterocolitis, Pseudomembranous; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Necrosis; Prednisone; Remission, Spontaneous; Vincristine | 1976 |
L-asparaginase and prednisolone pretreatment followed by rubidomycin and cytosine arabinoside for induction of remission in adult patients with acute myeloblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Nausea; Prednisolone; Remission, Spontaneous; Vomiting | 1975 |
Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors | 1975 |
Acute myelogenous leukemia in children: a preliminary report of combination chemotherapy.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Prednisolone; Remission, Spontaneous; Vincristine | 1976 |
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Bone Marrow; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Guanazole; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Meninges; Middle Aged; Pyrimethamine; Remission, Spontaneous; Skin Tests; Thioguanine | 1976 |
The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1976 |
Cell kinetics in leukemia. Correlation with clinical features and response to chemotherapy.
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Therapy, Combination; Humans; Kinetics; Leucovorin; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methotrexate; Mitotic Index; Thioguanine | 1975 |
[Letter: Acute myeloblastic leukemia: prevision of the efficiency by the combination of daunorubicin-cytosine-arabinoside].
Topics: Cells, Cultured; Clinical Trials as Topic; Cytarabine; Daunorubicin; DNA; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Thymidine | 1975 |
[Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis].
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Drug Evaluation; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male | 1975 |
AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Heart Diseases; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome | 1992 |
Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Monitoring, Physiologic; Recombinant Proteins; Remission Induction; Survival Rate | 1992 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Prednisolone; Survival Analysis; Vincristine | 1992 |
Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction | 1992 |
[Effectiveness of empirical antibiotic therapy in the control of infections in patients with acute leukemia during severe neutropenia].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Daunorubicin; Female; Humans; Immune Tolerance; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1992 |
High-dose cytosine arabinoside for the treatment of acute myeloid leukemia. Studies of the North American Marrow Transplant Group.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute | 1992 |
[The first Russian trial of treating patients with acute nonlymphoblastic leukemias with novantrone combined with cytosar].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Tolerance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pancytopenia; Remission Induction; Russia; Time Factors | 1992 |
[Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1992 |
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors | 1992 |
Use of high-dose cytarabine in autologous bone marrow transplantation in acute myeloid leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation, Autologous | 1992 |
[Effects of alternating as well as long-term intensive polychemotherapy in the remission-maintaining treatment of patients with acute myelocytic leukemia].
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine; Time Factors | 1992 |
Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1992 |
Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous | 1992 |
Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Germany, West; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction; Survival Rate | 1992 |
Mitoxantrone and high dose Ara-C for the treatment of ANLL in childhood: a pilot study of the EORTC CLCG (EORTC 58 872).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pilot Projects; Remission Induction; Survival Analysis | 1992 |
Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Drug Administration Schedule; Feasibility Studies; Humans; Idarubicin; Infusions, Intravenous; Italy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Thioguanine | 1992 |
Short term therapy (STT) for acute myelogenous leukaemia (AML).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Thioguanine; Whole-Body Irradiation | 1992 |
DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA; DNA Adducts; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Prednisone; Survival Analysis; Thioguanine; Vincristine | 1992 |
A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Thioguanine; Time Factors | 1992 |
Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Leukemia Group of Middle Sweden.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Ceftazidime; Cytarabine; Daunorubicin; Female; Fever; Fever of Unknown Origin; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Thioguanine | 1992 |
High remission rate in acute myeloblastic leukemia in children treated with high-dose methylprednisolone.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liver; Male; Methylprednisolone; Mitoxantrone; Remission Induction; Spleen; Thioguanine; Vincristine | 1992 |
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1992 |
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1992 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Belgium; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine; Vincristine | 1990 |
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1990 |
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Survival Analysis | 1990 |
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytosis; Male; Middle Aged; Remission Induction | 1992 |
[Autotransplantation in acute nonlymphoid leukemia].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1991 |
[Therapy of acute myeloid leukemia in children--results of the AML II/87 multicenter study].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Survival Analysis; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Treatment of adult acute myelogenous leukemia: a pilot study at Chulalongkorn Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cause of Death; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Thailand; Treatment Outcome | 1991 |
Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 1991 |
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence | 1991 |
Improved prognosis of acute nonlymphocytic leukemia in children: results of the 12th-ANLL protocol of Tokyo Children's Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Prognosis; Survival Rate; Treatment Outcome | 1991 |
[Preliminary results of the treatment of acute leukemia with mitoxantrone].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1991 |
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 1991 |
The effect of lithium on haematopoiesis of patients with acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Lithium Carbonate | 1991 |
BAVC regimen in CR AML patients.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Etoposide; Follow-Up Studies; Graft Survival; Humans; Infant; Italy; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Transplantation, Autologous | 1991 |
Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 1991 |
The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.
Topics: Adult; Aged; Conjunctivitis; Cytarabine; Dexamethasone; Double-Blind Method; Female; Humans; Keratitis; Leukemia, Myeloid, Acute; Male; Middle Aged; Ophthalmic Solutions; Prednisolone | 1991 |
Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Cycle; Cell Division; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 1991 |
High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1991 |
A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; DNA Nucleotidylexotransferase; Female; Fever; Humans; Infant; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Random Allocation; Receptors, Glucocorticoid; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thioguanine; Tumor Cells, Cultured; Vincristine | 1991 |
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cytarabine; Daunorubicin; DNA; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neutrophils; Recombinant Proteins | 1991 |
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Probability | 1991 |
Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Thioguanine; Vindesine | 1991 |
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Denmark; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Regression Analysis; Remission Induction; Survival Rate | 1991 |
[Intensification of chemotherapy of acute myeloid leukemia in children: report on the studies of the AML-BFM 78 and AML-BFM 83 protocols].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Prognosis; Remission Induction; Thioguanine; Time Factors; Vincristine | 1991 |
[Treatment of acute nonlymphocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Time Factors | 1991 |
High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cross-Sectional Studies; Cytarabine; Down Syndrome; Doxorubicin; Humans; Iceland; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Multicenter Studies as Topic; Preleukemia; Remission Induction; Scandinavian and Nordic Countries; Survival Rate; Thioguanine | 1990 |
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Remission Induction; Survival Rate | 1990 |
Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Multicenter Studies as Topic; Remission Induction; Thioguanine | 1990 |
Intensive sequential chemotherapy for children with acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Doxorubicin; Humans; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Multicenter Studies as Topic; Prednisolone; Remission Induction; Survival Rate; United States; Vincristine | 1990 |
Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84.
Topics: Aclarubicin; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Austria; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Hungary; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Multicenter Studies as Topic; Prednisone; Prospective Studies; Remission Induction; Thioguanine; Vincristine | 1990 |
Therapy of acute myelogenous leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Italy; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine | 1990 |
Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Survival Rate | 1990 |
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine | 1990 |
Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Thioguanine; United States | 1990 |
Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Remission Induction; Survival Rate | 1990 |
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cytarabine; Daunorubicin; Hemodynamics; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Thioguanine; Verapamil | 1990 |
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-H
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Child; Cytarabine; Daunorubicin; Drug Resistance; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prospective Studies; Randomized Controlled Trials as Topic; Thioguanine | 1990 |
Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Netherlands; Prospective Studies; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1990 |
Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Multivariate Analysis; Prognosis; Risk Factors | 1990 |
Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol).
Topics: Aclarubicin; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Survival Rate | 1990 |
Cure of acute myelocytic leukemia in adults: a reality.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction | 1990 |
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
Topics: Adult; Aged; Clinical Trials as Topic; Cytarabine; Delayed-Action Preparations; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Recurrence; Remission Induction; Time Factors | 1990 |
Chemotherapy of adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitolactol; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Tamoxifen | 1990 |
The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Pilot Projects; Random Allocation; Remission Induction; Thioguanine | 1990 |
High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prospective Studies; Survival Rate | 1990 |
High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1990 |
Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Thioguanine; United States | 1990 |
Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
Topics: Aged; Aged, 80 and over; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Tretinoin | 1990 |
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence | 1990 |
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Random Allocation; Remission Induction | 1990 |
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Survival Analysis | 1990 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prednisolone; Prognosis; Remission Induction; Thioguanine; Vincristine | 1989 |
[Treatment of acute myeloblastic leukemia in aged patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Palliative Care; Prognosis | 1989 |
Bone marrow transplantation for the treatment of leukaemia-results of the Munich Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Germany, West; Graft vs Host Disease; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; Whole-Body Irradiation | 1989 |
[AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients.
Topics: Aged; Aging; Clinical Trials as Topic; Cytarabine; Drug Administration Schedule; Female; Granulocytes; Hemorrhage; Humans; Infections; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Prospective Studies; Remission Induction; Thrombocytopenia | 1989 |
High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinical Trials as Topic; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Random Allocation; Remission Induction | 1989 |
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Remission Induction | 1989 |
Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study.
Topics: Adult; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Remission Induction; Time Factors | 1989 |
Results of the Italian AIEOP/LAM 8204 study for the treatment of childhood AML: an update.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Infant; Italy; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Remission Induction; Thioguanine | 1989 |
A randomized comparison of post-consolidation therapy in acute non-lymphoid leukaemia: a study of the Italian cooperative group GIMEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Humans; Italy; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Random Allocation; Remission Induction; Thioguanine | 1989 |
High dose cytarabine in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 1989 |
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Random Allocation; Thioguanine | 1989 |
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary res
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Random Allocation | 1989 |
[Advances in the treatment of acute myeloid leukemia in children. Experience of the Argentinian Group of Acute Leukemia Treatment and the Latin American Group of Malignant Hemopathies Treatment 1967-1987].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Evaluation Studies as Topic; Humans; Infant; Leukemia, Myeloid, Acute; Methotrexate; Prednisolone; Prednisone; Thioguanine; Vincristine | 1989 |
[Complete 8-year remission of acute myeloblastic leukemia in 2 children].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Prednisone; Remission Induction; Time Factors; Vincristine | 1989 |
A two-step timed sequential treatment for acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1989 |
Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Survival Analysis | 1989 |
High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.
Topics: Adult; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute | 1989 |
Idarubicin in acute leukemia: results of US trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1989 |
Results of chemotherapy for unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results. The Toronto Leukemia Study Group.
Topics: Administration, Oral; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Evaluation Studies as Topic; Humans; Infusions, Parenteral; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Prognosis; Random Allocation; Thioguanine | 1986 |
Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Diseases; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Infant; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Random Allocation; Thioguanine | 1986 |
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Topics: Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Prognosis; Thioguanine | 1989 |
Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Random Allocation; Remission Induction | 1989 |
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
[Results of the treatment of non-lymphoblastic leukemia with small doses of cytosine arabinoside].
Topics: Adult; Aged; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1988 |
Extension of remission in acute nonlymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Thioguanine | 1988 |
[Results of treating acute myeloid leukemia resistant to conventional chemotherapy with moderately large doses of cytarabine and etoposide].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Drug Resistance; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1988 |
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosyluracil; Asparaginase; Cytarabine; Humans; Leukemia, Myeloid, Acute | 1988 |
Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: a prospective controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Probability; Prospective Studies; Remission Induction | 1988 |
High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects | 1988 |
Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytosine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Random Allocation; Vincristine | 1988 |
A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Infections; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia | 1988 |
Prolonged high dose ARA-C infusions in acute leukemia.
Topics: Adult; Aged; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 1988 |
[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Random Allocation; Remission Induction | 1987 |
[High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Mitoxantrone | 1987 |
Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfamethoxazole; Time Factors; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 1987 |
Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Drug Administration Schedule; Germany, West; Humans; Leukemia, Myeloid, Acute; Mitoxantrone | 1987 |
Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine | 1987 |
Long-term results of two Swiss AML studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Immunization; Leukemia, Myeloid, Acute; Male; Switzerland; Vincristine | 1987 |
Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes; Prospective Studies; Remission Induction | 1987 |
Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Random Allocation; Remission Induction; Time Factors | 1987 |
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Random Allocation; Remission Induction; Thioguanine | 1987 |
Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Immunization; Leukemia, Myeloid, Acute; Neuraminidase; Prospective Studies; Random Allocation; Remission Induction; Thioguanine | 1987 |
The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Prognosis; Remission Induction; Risk; Thioguanine; Vincristine | 1987 |
Improved treatment results in childhood acute nonlymphoblastic leukemia with the BFM-AML protocol 78 in a multicenter study in the GDR.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Germany, East; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
A comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vincristine | 1987 |
The treatment of acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Random Allocation; Thioguanine | 1987 |
Short-term therapy for acute myelogenous leukemia.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1988 |
Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Thioguanine; Vincristine | 1987 |
Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Middle Aged | 1986 |
Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Bone Marrow; Clinical Trials as Topic; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Random Allocation | 1986 |
[Risk groups in acute, non-lymphatic leukemia in childhood. Analysis of the results of the cooperative therapeutic studies AML-BFM 78 and 83].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Risk; Thioguanine | 1986 |
A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Doxorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prospective Studies; Random Allocation; Testosterone Congeners; Thioguanine; Time Factors; Vincristine | 1986 |
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Humans; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma | 1986 |
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Cytarabine; Doxorubicin; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Phenotype; Remission Induction; Statistics as Topic; Sulfamethoxazole; Thioguanine; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Tumor Stem Cell Assay | 1987 |
Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Statistics as Topic; Thioguanine | 1987 |
Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine | 1985 |
Low-dose ARA-C fails to enhance differentiation of leukaemic cells.
Topics: Adult; Aged; Bone Marrow; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[AML-7 study of the value of intensive remission induction in aged patients with acute myelocytic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Vincristine | 1985 |
High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Random Allocation; Sex Factors; Time Factors; Vincristine | 1985 |
Treatment of acute myelocytic leukemia with a daunorubicin-cytarabine-6 thioguanine regimen without maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1985 |
Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Prospective Studies; Random Allocation; Thioguanine | 1985 |
[AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients].
Topics: Adult; Age Factors; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azaguanine; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Middle Aged; Pilot Projects; Random Allocation; Thioguanine; Time Factors | 1985 |
Fetal liver infusion: an adjuvant in the therapy of acute myeloid leukemia (AML).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cell Survival; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Erythrocyte Transfusion; Female; Fetus; Humans; Leukemia, Myeloid, Acute; Liver; Liver Transplantation; Male; Middle Aged; Pregnancy | 1985 |
Central nervous system toxicity of high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Central Nervous System Diseases; Cerebellar Diseases; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Epilepsy, Tonic-Clonic; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Nystagmus, Pathologic; Syndrome; Tremor | 1985 |
Prolonging remission in myeloblastic leukemia by tice-strain bacillus Calmette-Guérin.
Topics: Administration, Oral; Adolescent; Adult; BCG Vaccine; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Immunotherapy; Injections, Intravenous; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1974 |
Immunotherapy for acute myelogenous leukaemia.
Topics: Adolescent; Adult; BCG Vaccine; Cytarabine; Daunorubicin; Female; Histocompatibility Testing; Humans; Immunity; Immunotherapy; Injections, Intradermal; Leukemia, Myeloid, Acute; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Plicamycin; Remission, Spontaneous; Statistics as Topic; Time Factors | 1973 |
Management of adult acute myelogenous leukaemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; BCG Vaccine; Blood Cell Count; Blood Platelets; Child; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Thioguanine | 1973 |
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Amidines; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Evaluation Studies as Topic; Glyoxal; Humans; Hydrazones; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous; Thioguanine | 1973 |
Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response.
Topics: Acute Disease; Adult; Blood Cell Count; Blood Platelets; Cytarabine; Female; Hemoglobinometry; Humans; Infusions, Parenteral; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Regression, Spontaneous; Remission, Spontaneous; Sex Factors; Time Factors | 1974 |
Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Anemia; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Male; Middle Aged; Nausea; Prednisone; Time Factors; Vincristine; Vomiting | 1974 |
Combination chemotherapy of acute leukaemia in adults. Comparison of two schedules.
Topics: Administration, Oral; Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis | 1974 |
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
Topics: Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Guanidines; Humans; Intensive Care Units; Leukemia, Myeloid, Acute; Leukocyte Count; Mitoguazone; Remission, Spontaneous; Thioguanine; Time Factors | 1974 |
[Treatment of acute leukemia. Controlled clinical trials and experimental data with a view to a more rational administration of anti-leukemic drugs].
Topics: Clinical Trials as Topic; Cytarabine; Daunorubicin; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisolone; Vincristine | 1973 |
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party on Leu
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Blood Platelets; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocytes; Male; Mercaptopurine; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous; Thioguanine; Thrombocytopenia | 1974 |
[Results in the treatment of acute granulocytic leukemias using a combination of daunorubicine-cytosine arabinoside-cyclophosphamide. Apropos of 35 cases].
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glycosides; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged | 1974 |
Combination of arabinosyl cytsone, methylglyoxal bis (guanylhydrazone), 6-mercaptopurine and prednisone in the treatment of acute myelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Cytarabine; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisone | 1969 |
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Asparaginase; Blood Cell Count; Clinical Trials as Topic; Cytarabine; Daunorubicin; Edema; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Serum Albumin; Vomiting | 1970 |
Clinical trials of 1-beta-D-arabinofuranosyl cytosine and 1,3-bis-(2-chloroethyl)-1-nitrosourea combination in metastatic cancer and acute leukemia.
Topics: Age Factors; Blood Cell Count; Blood Platelets; Blood Urea Nitrogen; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Hemoglobins; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Nitrogen Mustard Compounds; Nitroso Compounds; Nitrosourea Compounds; Remission, Spontaneous; Reticulocytes; Sex Factors; Urea; Uric Acid | 1971 |
The chemotherapy of human and animal acute leukemia.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Azaserine; Cell Division; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Disease Models, Animal; Drug Combinations; Humans; Kinetics; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Neoplasms; Prednisone; Remission, Spontaneous; RNA, Neoplasm; Vincristine | 1971 |
2739 other study(ies) available for cytarabine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Guanosine diphosphate-L-fucose plasma: N-acetylglucosaminide fucosyltransferase as in index of bone marrow hyperplasia after chemotherapy.
Topics: Antineoplastic Agents; Bone Marrow; Guanosine Diphosphate Fucose; Hexosyltransferases; Humans; Hyperplasia; Leukemia, Myeloid, Acute; Lymphoma; Remission, Spontaneous | 1978 |
Levels of two plasma fucosyltransferases as an index of disease status in acute myelogenous leukemias.
Topics: Acetylglucosamine; Antineoplastic Agents; Bone Marrow; Galactose; Guanosine Diphosphate Fucose; Hexosyltransferases; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous | 1978 |
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Leukemia, Myeloid, Acute | 2010 |
Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia.
Topics: Amines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Molecular Structure; Reactive Oxygen Species; Structure-Activity Relationship | 2013 |
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Tria
Topics: Amides; Animals; Cell Line, Tumor; Halogenation; Humans; Leukemia, Myeloid, Acute; Mice; Models, Molecular; Picolinic Acids; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1 | 2015 |
Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.
Topics: Amides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Discovery; fms-Like Tyrosine Kinase 3; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2018 |
Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nucleophosmin; Sorafenib | 2022 |
Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Comet Assay; Cytarabine; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mesenchymal Stem Cells; Micronucleus Tests; Middle Aged; Pilot Projects | 2021 |
MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Proliferation; Cytarabine; DNA Repair Enzymes; Doxorubicin; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Neoplastic Stem Cells; Phosphoric Monoester Hydrolases; Prognosis; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2022 |
Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Feasibility Studies; Humans; Leukemia, Myeloid, Acute; Outpatients; Retrospective Studies | 2022 |
A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Transplantation Conditioning | 2021 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies | 2022 |
CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1.
Topics: ADP-ribosyl Cyclase; Adult; Aged; Aged, 80 and over; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Female; GPI-Linked Proteins; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Thiophenes; THP-1 Cells | 2021 |
CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
Topics: Adolescent; Aged; Child; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Prospective Studies | 2022 |
Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2022 |
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Registries; Remission Induction | 2021 |
Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Etoposide; Fluconazole; Humans; Kenya; Leukemia, Myeloid, Acute; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
Topics: Animals; Antineoplastic Agents; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mice; Nanoconjugates; Prodrugs | 2022 |
Ultraviolet recall due to cytarabine chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2021 |
Coculture in vitro with endothelial cells induces cytarabine resistance of acute myeloid leukemia cells in a VEGF-A/VEGFR-2 signaling-independent manner.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line; Cell Movement; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Endothelial Cells; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HL-60 Cells; Humans; Indoles; Jurkat Cells; K562 Cells; Leukemia, Myeloid, Acute; Models, Biological; Neovascularization, Pathologic; Phosphorylation; Signal Transduction; U937 Cells; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |
Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Topics: Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Risk Assessment | 2022 |
Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression.
Topics: Animals; Cytarabine; Drug Resistance, Neoplasm; Hematopoiesis; Humans; Laminin; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Mice; Mice, Knockout; Reactive Oxygen Species | 2022 |
The "7+3" regimen in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2022 |
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gemtuzumab; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Young Adult | 2022 |
Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy.
Topics: Biomarkers; Cytarabine; Humans; Leukemia, Myeloid, Acute; Progression-Free Survival; United States; United States Food and Drug Administration | 2022 |
Toward Personalization of Cytarabine Dosing in Acute Myeloid Leukemia.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2022 |
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Topics: Animals; Azacitidine; Cytarabine; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-hck | 2022 |
Neutropenia in the First Cycle of Consolidation Chemotherapy with High-Dose Cytarabine Is Not Associated with the Incidence of Relapse in Adult Acute Myeloid Leukemia Patients in First Complete Remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Humans; Incidence; Leukemia, Myeloid, Acute; Neutropenia; Recurrence; Remission Induction | 2022 |
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Curcumin; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Gastrointestinal Microbiome; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Metabolomics; Metagenomics; Mice; Xenograft Model Antitumor Assays | 2022 |
Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2022 |
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Topics: Adult; Aged; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Sulfonamides | 2022 |
Retreatment with full-dose cytarabine in a patient with previous neurological toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retreatment | 2022 |
Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13.
Topics: Cell Line; Cell Line, Tumor; Cell Proliferation; Clustered Regularly Interspaced Short Palindromic Repeats; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2022 |
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells.
Topics: Animals; Cytarabine; Diabetes Mellitus, Type 2; Humans; Leukemia, Myeloid, Acute; Metformin; Mice; Mice, Nude; Mice, SCID; Mitochondria; Stromal Cells; Tumor Microenvironment | 2022 |
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2022 |
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis | 2022 |
Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases.
Topics: Abnormal Karyotype; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberrations; Chromosome Deletion; Cytarabine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2022 |
The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Diamines; Leukemia, Myeloid, Acute; Mice; Oxadiazoles; Pyrazines; Reactive Oxygen Species | 2022 |
Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation.
Topics: Adult; Aged; Aminopyridines; Antimetabolites, Antineoplastic; Benzamides; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
Is acute myeloid leukaemia maintenance therapy necessary?
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute | 2022 |
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides | 2022 |
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
Topics: CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Proteins; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Prognosis; Receptors, Colony-Stimulating Factor; Retrospective Studies | 2022 |
Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients.
Topics: Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Proteomics; Recurrence; Stem Cells | 2022 |
Cytarabine-induced TNFα promotes the expansion and suppressive functions of myeloid-derived suppressor cells in acute myeloid leukaemia.
Topics: Cytarabine; Humans; Interleukin-6; Leukemia, Myeloid, Acute; Myeloid-Derived Suppressor Cells; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2022 |
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Patient Acceptance of Health Care; Retrospective Studies | 2022 |
Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
Topics: Anthracyclines; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2022 |
Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML).
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Apoptosis; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2022 |
IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia.
Topics: Animals; Cytarabine; Drug Resistance, Neoplasm; Fatty Acids; Humans; Interleukin-6; Leukemia, Myeloid, Acute; Mice; Mice, Knockout; Receptors, Interleukin-6 | 2022 |
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2022 |
[Influence of Serum TGF-β1 and EGFR Levels on the Therapeutic Effect of High-Dose AraC in Patients with Acute Myeloid Leukemia Based on the Decision Curve].
Topics: Cytarabine; ErbB Receptors; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transforming Growth Factor beta1 | 2022 |
[Influence of Serum TGF-β1 and EGFR Levels on the Therapeutic Effect of High-Dose AraC in Patients with Acute Myeloid Leukemia Based on the Decision Curve].
Topics: Cytarabine; ErbB Receptors; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transforming Growth Factor beta1 | 2022 |
Effect of Chemotherapy Cytarabine and Acute Myeloid Leukemia on the Development of Spermatogenesis at the Adult Age of Immature Treated Mice.
Topics: Adult; Animals; Child; Cytarabine; Glial Cell Line-Derived Neurotrophic Factor; Humans; Interleukin-6; Leukemia, Myeloid, Acute; Male; Mice; RNA; Seminiferous Tubules; Spermatogenesis; Spermatogonia; Testis; Tumor Microenvironment | 2022 |
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytoreduction Surgical Procedures; Genomics; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2022 |
The favorable prognostic value of the loss of sex chromosomes in patients with t(8;21) acute myeloid leukemia: an exploratory study.
Topics: Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Retrospective Studies; Sex Chromosomes | 2022 |
Single-dose (4.5 mg/m
Topics: Adult; Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Vidarabine | 2022 |
Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Topics: Aged; Animals; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Fatigue; Humans; Leukemia, Myeloid, Acute; Quality of Life; Sulfonamides | 2022 |
Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity.
Topics: Animals; Cytarabine; Disease Models, Animal; Disease Progression; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasm, Residual | 2022 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
Topics: Adult; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Transplantation, Autologous | 2022 |
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Vidarabine; Young Adult | 2022 |
Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure.
Topics: ATP Binding Cassette Transporter, Subfamily B; Calcium; Calcium Signaling; Cell Line; Cytarabine; Humans; Leukemia, Myeloid, Acute; ORAI1 Protein; Stromal Interaction Molecule 1 | 2022 |
[Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2022 |
[The efficacy and safety of CLAG-M/I regimen for relapsed or refractory acute myeloid leukemia in children].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Recurrence; Treatment Outcome | 2022 |
[Establishment of Drug-Resistant Cell Lines of Acute Myeloid Leukemia and Correlation of Sirt1 and PGC-1α Expression Levels with Drug Resistance].
Topics: Cell Line; Cytarabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; RNA, Messenger; Sirtuin 1 | 2022 |
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Emulsions; Feasibility Studies; Fish Oils; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2 | 2022 |
Granulocytic sarcoma of cervix: A rare case report.
Topics: Cervix Uteri; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Sarcoma, Myeloid | 2022 |
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Sulfonamides | 2022 |
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2022 |
A multiparametric niche-like drug screening platform in acute myeloid leukemia.
Topics: Anthracyclines; Cytarabine; Drug Evaluation, Preclinical; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Neoplastic Stem Cells | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Retrospective Studies | 2022 |
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2022 |
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype.
Topics: Cytarabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Phenotype; RNA, Small Interfering | 2022 |
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Retrospective Studies | 2022 |
Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
Topics: Cell Differentiation; Checkpoint Kinase 1; Cytarabine; Dihydroorotate Dehydrogenase; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Pyrimidines | 2022 |
Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
Topics: Cytarabine; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; RNA-Binding Proteins; SAM Domain and HD Domain-Containing Protein 1 | 2022 |
Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.
Topics: Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; NF-kappa B | 2022 |
Exosomes from bone marrow mesenchymal stem cells decrease chemosensitivity of acute myeloid leukemia cells via delivering miR-10a.
Topics: Bone Marrow Cells; Cell Cycle Proteins; Cell Proliferation; Cytarabine; Exosomes; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; MicroRNAs; Repressor Proteins; Tumor Microenvironment | 2022 |
Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders | 2022 |
Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation.
Topics: Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Humans; Leukemia, Myeloid, Acute; Recurrence; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Tumor Lysis Syndrome | 2023 |
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
Topics: Adenosine Triphosphate; Anthracyclines; Antibiotics, Antineoplastic; ATP-Binding Cassette Transporters; Cytarabine; Daunorubicin; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute | 2022 |
Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pneumocystis carinii; Pneumonia, Pneumocystis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Topics: 5'-Nucleotidase; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytidine Deaminase; Cytogenetic Analysis; Genotype; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction | 2022 |
Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Ceramides; Cytarabine; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies | 2023 |
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute | 2022 |
Treatment of myeloid neoplasia with doxorubicin and cytarabine in 11 dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Subclones of bone marrow CD34
Topics: Anthracyclines; Antigens, CD34; Bone Marrow; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute | 2022 |
[Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2022 |
Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Leukemia, Myeloid, Acute; Mice; Mitochondria; Phosphatidylinositol 3-Kinases | 2022 |
Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Monitoring; Humans; Itraconazole; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Pruritic papules after induction chemotherapy with daunorubicin and cytarabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Exanthema; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Pruritus; Triamcinolone | 2022 |
Isolated myeloid sarcoma with pericardial and pleural effusions as first manifestation: A case report.
Topics: Adult; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Pleural Effusion; Sarcoma, Myeloid | 2022 |
Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy.
Topics: Aged; Canada; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Retrospective Studies | 2022 |
Exosomal miR92a Promotes Cytarabine Resistance in Myelodysplastic Syndromes by Activating Wnt/β-catenin Signal Pathway.
Topics: beta Catenin; Cytarabine; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Wnt Signaling Pathway | 2022 |
[Acute myeloid leukemia harboring NUP98::DDX10].
Topics: Cytarabine; DEAD-box RNA Helicases; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Nuclear Pore Complex Proteins; Prognosis; Recurrence | 2022 |
Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
Topics: Anthracyclines; Biopsy; Bone Marrow; Bone Marrow Cells; Cytarabine; Humans; Leukemia, Myeloid, Acute; Transcriptome; Tumor Microenvironment | 2023 |
Early changes in gene expression profiles in AML patients during induction chemotherapy.
Topics: Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; NF-kappa B; Pilot Projects; Transcriptome | 2022 |
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Topics: Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2023 |
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Topics: Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Prospective Studies; Retrospective Studies | 2023 |
Topics: Apoptosis; Artesunate; Caspase 3; Caspase 9; Cell Line; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Myeloid, Acute; Mutation; Retrospective Studies | 2022 |
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Eukaryotic Initiation Factor-4A; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2 | 2022 |
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Optimizing outcomes in secondary AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mitoxantrone; Respiratory Tract Infections; Sepsis | 2023 |
Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine.
Topics: Apoptosis; Cell Nucleus; Cytarabine; DNA Glycosylases; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Proto-Oncogene Proteins c-akt | 2023 |
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Vidarabine | 2023 |
Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Retrospective Studies | 2023 |
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Effectiveness Analysis; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Italy; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; State Medicine; Treatment Outcome | 2023 |
Exposure to cytarabine causes side effects on adult development and physiology and induces intestinal damage via apoptosis in Drosophila.
Topics: Animals; Apoptosis; Cytarabine; Drosophila; Drosophila melanogaster; Drug-Related Side Effects and Adverse Reactions; Leukemia, Myeloid, Acute | 2023 |
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia.
Topics: Arabinofuranosylcytosine Triphosphate; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Polymorphism, Single Nucleotide; SAM Domain and HD Domain-Containing Protein 1 | 2023 |
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prognosis; Remission Induction | 2023 |
Quantitative Profiling of Alpha-Subunit of IL-3 Receptor on Single Acute Myeloid Leukemia Cells by Super-Resolution Imaging.
Topics: Cell Line, Tumor; Cytarabine; Flow Cytometry; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Receptors, Interleukin-3 | 2023 |
[A comparative clinical study of modified IA "3+4" regimen and intermediate-dose cytarabine regimen in the consolidation treatment of low-risk acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2022 |
[Analysis of the efficacy of azacitidine combined with homoharringtonine and cytarabine in induction and salvage therapy of acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Treatment Outcome | 2022 |
Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.
Topics: Amsacrine; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Heart Diseases; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2023 |
Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Macrocyclic Compounds; Myeloid Cell Leukemia Sequence 1 Protein | 2023 |
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2023 |
Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenotype | 2023 |
Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; U937 Cells | 2023 |
Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods.
Topics: Child; Cytarabine; Cytoreduction Surgical Procedures; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytosis | 2023 |
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.
Topics: Cell Line, Tumor; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation | 2023 |
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
Topics: Aged; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Nuclear Proteins; Nucleophosmin; Panobinostat | 2023 |
Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridge Therapy; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2023 |
Bewersdorf JP, Patel KK, Goshua G, et al. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood. 2022;139(11):1766-1770.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2023 |
Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Leukemia, Myeloid, Acute; Mice; Receptors, Transferrin | 2023 |
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.
Topics: Apoptosis; Cell Death; Cell Line, Tumor; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mannose | 2023 |
Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2023 |
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Treatment Outcome | 2023 |
Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
Topics: Aged; Anthracyclines; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2023 |
Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prognosis; Retrospective Studies | 2023 |
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies | 2023 |
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Obesity; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction | 2023 |
Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience.
Topics: Adult; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2023 |
Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Treatment Outcome | 2023 |
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2023 |
Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).
Topics: Child; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction | 2023 |
Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progression.
Topics: Animals; Cystine; Cytarabine; Glutamate Dehydrogenase; Glutamine; Glutathione; Leukemia, Myeloid, Acute; Mice | 2023 |
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Leukemia, Myeloid, Acute; Mice; Sulfonamides | 2023 |
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase I as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2023 |
Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Transplants | 2023 |
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies | 2023 |
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Staurosporine | 2023 |
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning | 2023 |
Treatment outcomes of pediatric acute myeloid leukemia in Western Kenya before and after the implementation of the SIOP PODC treatment guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Kenya; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2023 |
Development of Real-world Data-based Medication Instruction Sheet for Acute Myeloid Leukemia Patients Receiving High-dose Cytarabine Consolidation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
[Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Topics: Aged; Aged, 80 and over; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Prognosis; Retrospective Studies | 2023 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2023 |
The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemia.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Methyltransferases; Recurrence; Tumor Microenvironment | 2023 |
HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia.
Topics: Aged; Cytarabine; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Transplantation, Autologous | 2023 |
Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; RNA Splicing; Sulfonamides | 2023 |
FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines".
Topics: Adult; Anthracyclines; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Vidarabine | 2023 |
Prolonged Survival Using Outpatient Palliative Chemotherapy in Two Children With Refractory Acute Myelogenous Leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Outpatients; Quality of Life | 2023 |
Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2023 |
Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Interleukin-10; Leukemia, Myeloid, Acute; Male; Mice; Semen; Spermatogenesis | 2023 |
Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
Topics: Chromosomes, Human, Pair 16; Core Binding Factors; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Prognosis | 2023 |
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; United Kingdom | 2023 |
A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia.
Topics: Apoptosis; Carcinogenesis; Carcinogens; Cell Cycle; Cytarabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-6 | 2023 |
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Outpatients; Prospective Studies; Remission Induction; Retrospective Studies | 2023 |
E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
Topics: Cytarabine; E2F1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Polymorphism, Single Nucleotide; Prognosis; Remission Induction | 2023 |
[Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy].
Topics: Adult; Cesarean Section; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pregnancy; Translocation, Genetic | 2023 |
Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1-Mediated Mitochondrial Fusion.
Topics: Animals; Cytarabine; Drug Resistance, Neoplasm; Humans; Interleukin-6; Leukemia, Myeloid, Acute; Mice; Mitochondrial Dynamics | 2023 |
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mice; Quinolones | 2023 |
Distinct and targetable role of calcium-sensing receptor in leukaemia.
Topics: Calcium; Cytarabine; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-myc; Receptors, Calcium-Sensing; Signal Transduction; Tumor Microenvironment | 2023 |
Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.
Topics: Artesunate; Cytarabine; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Signal Transduction; STAT3 Transcription Factor | 2023 |
Research on the preparation process of the cytarabine/daunorubicin dual-encapsulation liposome and its physicochemical properties and performances in vitro/vivo.
Topics: Copper; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes | 2023 |
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Core Binding Factors; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2023 |
Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia.
Topics: Area Under Curve; Cellular Senescence; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Tumor Microenvironment | 2023 |
A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
Topics: Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning | 2023 |
Spatiotemporal evolution of AML immune microenvironment remodeling and RNF149-driven drug resistance through single-cell multidimensional analysis.
Topics: Bone Marrow; Cytarabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2023 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment.
Topics: Apoptosis; Cell Line, Tumor; Cytarabine; Gene Expression; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation | 2023 |
Non-allogeneic immunotherapy in acute myeloid leukaemia.
Topics: Cytarabine; Humans; Idarubicin; Immunotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nivolumab | 2019 |
Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cell Line, Tumor; Cytarabine; Female; Gene Expression Regulation, Leukemic; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Biological; Mutation; Oncogene Proteins, Fusion; Treatment Outcome | 2019 |
Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Chromatography, High Pressure Liquid; Cytarabine; Drug Monitoring; Humans; Leukemia, Myeloid, Acute; Linear Models; Pilot Projects; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2019 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
Topics: Cell Line, Tumor; Cytarabine; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Oxidative Phosphorylation; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction | 2019 |
Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Salvage Therapy | 2020 |
Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; Cytarabine; Drug Approval; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2019 |
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Discharge; Young Adult | 2020 |
Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Eruptions; Female; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes | 2020 |
Acute Pancreatitis Associated With Cytarabine During the Treatment of Pediatric Acute Myeloid Leukemia.
Topics: Child; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Pancreatitis | 2020 |
Muscle aches and pains: do I have leukemia?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Lower Extremity; Male; Myalgia | 2020 |
Benzyl butyl phthalate (BBP) triggers the malignancy of acute myeloid leukemia cells via upregulation of PDK4.
Topics: 5' Untranslated Regions; Adenosine Triphosphate; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinogens; Cell Line, Tumor; Cell Proliferation; Cytarabine; Daunorubicin; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Phthalic Acids; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA, Small Interfering; Up-Regulation | 2020 |
An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Cost Savings; Cytarabine; Drug Costs; Drug Stability; Drug Storage; Humans; Leukemia, Myeloid, Acute; Medication Adherence; Nuclear Magnetic Resonance, Biomolecular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solutions | 2020 |
Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Apoptosis; Carbenoxolone; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gap Junctions; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
Topics: Aclarubicin; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2020 |
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2020 |
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Topics: Aged; Aged, 80 and over; Amino Acids; Cytarabine; Drug Therapy; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Lipid Metabolism; Male; Mercaptopurine; Metabolomics; Middle Aged; Treatment Outcome; Tretinoin; Valproic Acid | 2019 |
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Topics: Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Sulfonamides | 2019 |
Translesion synthesis DNA polymerases η, ι, and ν promote mutagenic replication through the anticancer nucleoside cytarabine.
Topics: Antimetabolites, Antineoplastic; Cytarabine; DNA Replication; DNA-Directed DNA Polymerase; Fibroblasts; Humans; Leukemia, Myeloid, Acute; Nucleic Acid Conformation | 2019 |
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine | 2021 |
Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Retrospective Studies; Y Chromosome | 2020 |
Improved chemotherapy modeling with RAG-based immune deficient mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Doxorubicin; Drug Administration Schedule; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mice; Mice, SCID; Models, Theoretical; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Retreatment; Retrospective Studies | 2020 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma | 2020 |
Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Topics: Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Daunorubicin; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Postoperative Complications; Programmed Cell Death 1 Receptor; Protoporphyria, Erythropoietic; Recurrence; Remission Induction; Virus Activation; Young Adult | 2020 |
Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia.
Topics: Core Binding Factors; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 2020 |
Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Thioguanine; Treatment Outcome | 2020 |
Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; Drug Interactions; Equilibrative Nucleoside Transporter 1; Female; Humans; Leukemia, Myeloid, Acute; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Organic Cation Transport Proteins; Symporters; Thioinosine | 2019 |
Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Neoplasms, Second Primary; Treatment Outcome | 2019 |
Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Nucleosides | 2021 |
Bilateral ovarian granulocytic sarcoma as the primary manifestation of acute myelogenous leukemia treated with allogenic stem cell transplantation: A case report.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Ovarian Neoplasms; Sarcoma, Myeloid; Stem Cell Transplantation | 2019 |
The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation.
Topics: Adolescent; Adult; Aged; Anthracyclines; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Young Adult | 2020 |
Pregnancy exposure to midostaurin in the first trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Compassionate Use Trials; Cytarabine; Female; Fetal Growth Retardation; fms-Like Tyrosine Kinase 3; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Protein Kinase Inhibitors; Recurrence; Staurosporine; Tandem Repeat Sequences | 2020 |
Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
Topics: Cytarabine; Fusion Proteins, bcr-abl; GATA2 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Protein Kinase Inhibitors; Repressor Proteins | 2020 |
HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cytarabine; Gene Knockdown Techniques; Glycolysis; Humans; Leukemia, Myeloid, Acute; Phosphofructokinase-1, Type C; RNA, Long Noncoding; Signal Transduction; Wnt Signaling Pathway | 2020 |
Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia.
Topics: Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Retrospective Studies; X Chromosome | 2020 |
Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytarabine; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Ribosomal Protein S6 Kinases, 70-kDa; Xenograft Model Antitumor Assays | 2020 |
Acute cerebellar toxicity induced by high dose of cytarabine (HiDAC): A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellum; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Remission Induction; Young Adult | 2020 |
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Cytarabine; Leukemia, Myeloid, Acute; Mice; Pyrophosphatases; Ribonucleotide Reductases; SAM Domain and HD Domain-Containing Protein 1 | 2020 |
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Recurrent Isolated Hyperbilirubinemia From Drug-Induced Impaired Hepatic Bilirubin Uptake.
Topics: Antimetabolites, Antineoplastic; Bilirubin; Chemical and Drug Induced Liver Injury; Cytarabine; Diagnosis, Differential; Female; Gilbert Disease; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Liver; Medication Therapy Management; Patient Care Management; Young Adult | 2020 |
Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Young Adult | 2020 |
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes | 2020 |
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2020 |
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Topics: Adolescent; Adult; Aged; Alleles; Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Progression-Free Survival; Recurrence; Risk Assessment; Young Adult | 2020 |
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2020 |
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2020 |
Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Rate; Vidarabine | 2020 |
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.
Topics: Antineoplastic Agents, Alkylating; Child; Cytarabine; Female; Fetal Blood; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Shwachman-Diamond Syndrome; Transplantation Conditioning; Vidarabine | 2021 |
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Preoperative Care; Prognosis; Recurrence; Treatment Outcome | 2020 |
UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cause of Death; Cytarabine; Female; Genotype; Glucuronosyltransferase; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome | 2020 |
Venetoclax for paediatric acute myeloid leukaemia: a step forward.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Child; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Cohort Studies; Cytarabine; Daunorubicin; DNA Topoisomerases, Type II; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Poly-ADP-Ribose Binding Proteins; RNA, Messenger; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2020 |
[Successful delivery after chemotherapy for acute myeloid leukemia diagnosed in the second trimester].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Cytarabine; Daunorubicin; Female; Humans; Japan; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Remission Induction; Retrospective Studies | 2020 |
Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Consolidation Chemotherapy; Cytarabine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2020 |
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Feasibility Studies; Female; Gemtuzumab; Geriatric Assessment; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Outcome Assessment, Health Care; Survival Analysis | 2020 |
Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Survival; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Array Analysis; SUMO-1 Protein; Sumoylation; Treatment Outcome; Ubiquitin; Young Adult | 2020 |
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Cytarabine; Female; Hospital Mortality; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; United States; Young Adult | 2020 |
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Trisomy | 2020 |
Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Cytarabine; Deoxyglucose; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Genetic Heterogeneity; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Mesenchymal Stem Cells; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Proteomics; Sulfonamides; Survival Analysis; Young Adult | 2020 |
[Clinical outcome of CAG regimen in 26 children with aucte myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2019 |
Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow; Consolidation Chemotherapy; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Linezolid; Male; Middle Aged; Platelet Count; Retrospective Studies; Thrombocytopenia | 2020 |
Model-Based Optimal AML Consolidation Treatment.
Topics: Bone Marrow; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute | 2020 |
Venetoclax is safe and efficacious in relapsed/refractory AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Retrospective Studies; Sulfonamides | 2020 |
TUG1 weakens the sensitivity of acute myeloid leukemia cells to cytarabine by regulating miR-655-3p/CCND1 axis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cells, Cultured; Cyclin D1; Cytarabine; Humans; Leukemia, Myeloid, Acute; MicroRNAs; RNA, Long Noncoding | 2020 |
Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Prognosis; RNA, Small Interfering; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2021 |
Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzothiazoles; Biosynthetic Pathways; Cell Line, Tumor; Cell Proliferation; Cholesterol; Cytarabine; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Space; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Rosuvastatin Calcium; Translational Research, Biomedical; Young Adult | 2020 |
Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
Topics: Aldehyde Oxidoreductases; Aldehydes; Animals; Carbolines; Cell Line, Tumor; Cyclohexylamines; Cytarabine; Doxorubicin; Ferroptosis; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Lipid Peroxidation; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Oleic Acid; Oncogene Proteins, Fusion; Oxidation-Reduction; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase | 2020 |
A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Consolidation Chemotherapy; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles | 2020 |
Diffuse alveolar hemorrhage during induction therapy for acute myeloid leukemia with inv(16)(p13.1q22).
Topics: Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Diagnosis, Differential; Hemorrhage; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged; Pulmonary Alveoli; Tomography, X-Ray Computed | 2020 |
FLAG-Ida is back in.
Topics: Anthracyclines; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2020 |
Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Disorders; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Dexamethasone; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Translocation, Genetic; Tretinoin | 2021 |
[Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Survival Rate; Treatment Outcome | 2020 |
[Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2020 |
Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Glucose Transporter Type 1; Humans; Leukemia, Myeloid, Acute | 2021 |
Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.
Topics: Adult; Busulfan; Cladribine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Melphalan; Mitoxantrone; Salvage Therapy; Transplantation Conditioning | 2020 |
Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Aprepitant; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Cytarabine; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasms, Experimental | 2020 |
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; SARS-CoV-2 | 2020 |
Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia.
Topics: Antigens, CD; Apyrase; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondria | 2020 |
Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2020 |
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Blood Transfusion; Cause of Death; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Multicenter Studies as Topic; Phenylurea Compounds; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2020 |
A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Proteome activity landscapes of tumor cell lines determine drug responses.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Computer Simulation; Cytarabine; Drug Development; Genomics; Humans; Leukemia, Myeloid, Acute; Neoplasms; Proteome; Proteomics; Raloxifene Hydrochloride; Receptors, Progesterone; Signal Transduction | 2020 |
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Sulfonamides; Tumor Lysis Syndrome | 2021 |
Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzothiazoles; Biomarkers, Tumor; Cell Cycle; Cell Movement; Cell Proliferation; Cytarabine; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mutation; Phenylurea Compounds; Prognosis; Survival Rate; Tumor Cells, Cultured | 2020 |
Immunosuppressive role of CD11b
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytarabine; Cytotoxicity, Immunologic; Female; Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Phenotype; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes, Cytotoxic; Treatment Outcome; Tumor Escape | 2020 |
Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins c-abl; Trans-Activators; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2020 |
Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2β.
Topics: Anthracyclines; Antineoplastic Agents; Cytarabine; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Poly-ADP-Ribose Binding Proteins; SAM Domain and HD Domain-Containing Protein 1 | 2021 |
Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Young Adult | 2021 |
Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dasatinib; Daunorubicin; Female; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Core Binding Factors; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Infant; Japan; Leukemia, Myeloid, Acute; Male; Mutation; Prognosis; Remission Induction; Retrospective Studies; Societies, Medical; Stem Cell Transplantation; Survival Rate | 2020 |
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Child; Clinical Trials, Phase III as Topic; Cytarabine; Datasets as Topic; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenetic Repression; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Organic Cation Transport Proteins; Progression-Free Survival; Randomized Controlled Trials as Topic; Symporters; Young Adult | 2021 |
BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Self Renewal; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Indoles; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-6; Radiation Chimera; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Thiazolidinediones; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2021 |
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms.
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous | 2020 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2020 |
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine | 2021 |
Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Compassionate Use Trials; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2021 |
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Consensus; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myeloproliferative Disorders; Neoplasm Grading; Predictive Value of Tests; Severity of Illness Index; Survival Rate; Young Adult | 2020 |
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Clofarabine; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines; Sulfonamides | 2020 |
Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2020 |
A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome.
Topics: Antineoplastic Agents; Autistic Disorder; Child; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Intellectual Disability; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 3; Myeloid-Lymphoid Leukemia Protein; Vault Ribonucleoprotein Particles | 2021 |
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Ginsenosides; Humans; Leukemia, Myeloid, Acute; Mitochondria | 2020 |
[Curative Efficacy and Survival Analysis of Low-Intensity Traditional Chemotherapy Regimen in the Elderly Patients with Acute Myeloid Leukemia (non-M
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Survival Analysis | 2020 |
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Microarray Analysis; Transcriptome | 2020 |
MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Autophagy-Related Protein 7; Autophagy-Related Proteins; Caspase 3; Caspase 9; Cytarabine; Dose-Response Relationship, Drug; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Signal Transduction; U937 Cells; Vesicular Transport Proteins | 2020 |
Diagnosis of oesophageal mucormycosis managed with medical therapy alone.
Topics: Amphotericin B; Antifungal Agents; Cytarabine; Esophageal Diseases; Esophagus; Humans; Idarubicin; Immunocompromised Host; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucormycosis; Rhizopus; Triazoles | 2020 |
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Retrospective Studies; Tumor Suppressor Protein p53 | 2020 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic; Sulfonamides | 2021 |
Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cell Line, Tumor; Computer Simulation; Cytarabine; Datasets as Topic; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Ontology; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Nonlinear Dynamics; Precision Medicine; Prognosis; Real-Time Polymerase Chain Reaction; Renin-Angiotensin System; Tretinoin | 2020 |
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Fluid Therapy; Humans; Hydroxyurea; Incidence; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukocytosis; Male; Middle Aged; Phosphate-Binding Proteins; Phosphorus; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Sulfonamides; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2021 |
miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers, Tumor; Cell Line, Tumor; Cytarabine; Female; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; MicroRNAs; Piperazines; Proto-Oncogene Proteins c-mdm2 | 2021 |
miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Mutation; Nuclear Proteins; Nucleophosmin; Principal Component Analysis; RNA, Small Interfering | 2021 |
Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Sulfonamides | 2020 |
Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; COVID-19; Cytarabine; Extracorporeal Membrane Oxygenation; Female; Humans; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Prospective Studies; Receptors, Immunologic; Survival Rate; Young Adult | 2021 |
Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes | 2021 |
Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Tumor Suppressor Protein p53 | 2020 |
Polyserositis as a primary clinical manifestation of CD7+ acute myelogenous leukemia with myeloid sarcoma: A case report.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Pericardial Effusion; Pleural Effusion; Positron-Emission Tomography; Sarcoma, Myeloid; Tomography, X-Ray Computed | 2020 |
Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
Role of CD19 and specific KIT-D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities.
Topics: Adolescent; Adult; Aged; Antigens, CD19; Antimetabolites, Antineoplastic; Biomarkers, Tumor; China; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-kit; Remission Induction; Retrospective Studies; Risk Assessment; Survival Rate; Translocation, Genetic; Young Adult | 2021 |
Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2.
Topics: Adult; Aged; Animals; Apoptosis; Cell Line, Tumor; Cytarabine; DNA Damage; DNA Repair; Female; Heterografts; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; MutS Homolog 2 Protein; NF-E2-Related Factor 2; THP-1 Cells; Young Adult | 2021 |
Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Panniculitis; Sulfonamides; Withholding Treatment | 2021 |
HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient.
Topics: Acyclovir; Adult; Antimetabolites, Antineoplastic; Antiviral Agents; Cytarabine; Encephalitis, Viral; Female; Herpesvirus 6, Human; Humans; Leukemia, Myeloid, Acute | 2021 |
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; RUNX1 Translocation Partner 1 Protein; Young Adult | 2021 |
Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Erythema; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2022 |
Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2021 |
Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Analysis | 2021 |
Evaluation of Empiric Vancomycin for Fevers During High-dose Cytarabine Administration.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Bacteremia; Burkitt Lymphoma; Child; Child, Preschool; Cytarabine; Female; Fever; Follow-Up Studies; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Male; Prognosis; Retrospective Studies; Vancomycin; Young Adult | 2021 |
Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Obesity; Retrospective Studies; Young Adult | 2021 |
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2021 |
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Remission Induction; Sulfonamides; Treatment Outcome | 2021 |
Recognizing the potential for copper-related toxicities from liposomal daunorubicin--cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Copper; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2021 |
Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.
Topics: Cladribine; Cytarabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Mitoxantrone | 2021 |
Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cytarabine; Hemoglobins; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Magnetic Iron Oxide Nanoparticles; Mice, Inbred NOD; Mice, SCID; NADPH Oxidase 2; Neoplastic Stem Cells; Reactive Oxygen Species; Superoxide Dismutase; Xenograft Model Antitumor Assays | 2021 |
Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; MicroRNAs; RNA, Long Noncoding | 2021 |
Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Chloroquine; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 2021 |
GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinases; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Glycogen Synthase Kinase 3; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Mice, Nude; Phosphatidylinositol 3-Kinase; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; THP-1 Cells; Tumor Burden; U937 Cells; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2021 |
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Retrospective Studies; Treatment Outcome | 2021 |
AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance.
Topics: Adult; Aged; Basic Helix-Loop-Helix Transcription Factors; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Receptors, Aryl Hydrocarbon; Signal Transduction; THP-1 Cells; U937 Cells | 2021 |
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction | 2021 |
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Sulfonamides | 2021 |
Evaluation of the Anticancer Activity of pH-Sensitive Polyketal Nanoparticles for Acute Myeloid Leukemia.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Drug Carriers; Female; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; Mice; Nanoparticles; Polymers; Tissue Distribution | 2021 |
Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cycle Proteins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Microfilament Proteins; Neoplasm Proteins; Prognosis; Protein-Tyrosine Kinases; Survival Rate | 2021 |
Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia.
Topics: Animals; Cytarabine; Flavonoids; Leukemia, Myeloid, Acute; Liposomes; Mice; Piperidines | 2021 |
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pancytopenia; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2021 |
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2021 |
Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomal Proteins, Non-Histone; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins; Poly-ADP-Ribose Binding Proteins; Treatment Outcome | 2021 |
Prognostic factors and their importance in relapsed and refractory AML: Comments on "Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia" by Linch et al.
Topics: Cytarabine; Genotype; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Prognosis | 2021 |
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2021 |
Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antimetabolites, Antineoplastic; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Cytarabine; DNA Glycosylases; DNA Repair; Humans; Leukemia, Myeloid, Acute; RNA, Messenger | 2021 |
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Treatment Outcome | 2021 |
Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants.
Topics: Allografts; Bone Marrow Transplantation; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Infant; Injections, Spinal; Leukemia, Myeloid, Acute; Myeloablative Agonists; Recurrence; Transplantation Conditioning | 2022 |
Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clofarabine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleophosmin; Treatment Outcome | 2021 |
Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Registries; Retrospective Studies; Survival Analysis; Taiwan; Treatment Outcome | 2021 |
Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2021 |
Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
Topics: Adult; Anti-Allergic Agents; Antimetabolites, Antineoplastic; Cornea; Corneal Diseases; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Loteprednol Etabonate; Male; Microscopy, Confocal; Ophthalmic Solutions | 2021 |
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2021 |
[A Case of Descending Colon and Rectal Cancer with Acute Myeloid Leukemia Performed Robot‒Assisted Hartmann's Procedure].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Descending; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Rectal Neoplasms; Remission Induction; Robotics | 2021 |
Zwitterion-functionalized hollow mesoporous Prussian blue nanoparticles for targeted and synergetic chemo-photothermal treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Ferrocyanides; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Nanoparticles; Particle Size; Photothermal Therapy; Polyethyleneimine; Porosity; Surface Properties | 2021 |
[The Relationship between Body Mass Index and Adult Acute Myeloid Leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Young Adult | 2021 |
Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine‑resistant myeloid leukemia cells.
Topics: Adolescent; Apoptosis; Cell Line, Tumor; Child; Curcumin; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Indoles; Ketoglutaric Acids; Leukemia, Myeloid, Acute; Male; Purines; Signal Transduction; TOR Serine-Threonine Kinases; Transaminases | 2021 |
Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cytarabine; Drug Synergism; Female; Glucose; Glucosephosphate Dehydrogenase; Glutamate-Cysteine Ligase; Glycolysis; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Liver; Mice, Inbred BALB C; Mice, Nude; NF-E2-Related Factor 2; Quassins; THP-1 Cells; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Intracranial myeloid sarcoma presentation in distant acute myeloid leukemia remission.
Topics: Adult; Aminopyridines; Brain Neoplasms; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Sarcoma, Myeloid; Triazines | 2021 |
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.
Topics: Antigens, Surface; Cell Cycle Proteins; Cytarabine; Fatty Acids; HL-60 Cells; Humans; Immunity; Jurkat Cells; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteome; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Quinazolines | 2021 |
CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2021 |
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Vidarabine | 2021 |
Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies | 2022 |
Second Transplant for Relapsed AML, Learning from Defeat.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local | 2021 |
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Propensity Score; Sulfonamides | 2021 |
[Lineage switch from T-lymphoblastic leukemia to myeloid leukemia at relapse].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2021 |
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Topics: Adult; Aged; Biomarkers, Tumor; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Prognosis; Retrospective Studies; Young Adult | 2021 |
RSPO2 inhibits BMP signaling to promote self-renewal in acute myeloid leukemia.
Topics: Animals; Autocrine Communication; Bone Morphogenetic Proteins; Cell Differentiation; Cell Self Renewal; Cytarabine; HEK293 Cells; Hematopoietic Stem Cells; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Prognosis; Risk Factors; Signal Transduction; Survival Analysis; Xenograft Model Antitumor Assays | 2021 |
Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Dactinomycin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Salvage Therapy; Sulfonamides; Survival Rate | 2021 |
Xeroderma pigmentosum and acute myeloid leukemia: a case report.
Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Skin Neoplasms; Xeroderma Pigmentosum | 2021 |
A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia.
Topics: Aged; Cytarabine; Decitabine; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Stem Cells | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
FLT3 Mutation Testing in Acute Myeloid Leukemia.
Topics: Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Genetic Testing; Headache; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukostasis; Male; Middle Aged; Segmental Duplications, Genomic; Tandem Repeat Sequences; Vision Disorders | 2017 |
A three-dimensional
Topics: Benzylamines; Biomarkers; Cell Communication; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cyclams; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Receptors, CXCR4; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Proportional Hazards Models; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Diagnosis, Differential; Eosinophilia; Eosinophils; Exanthema; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Skin; Translocation, Genetic; Treatment Outcome; Young Adult | 2017 |
DNA Methyltransferases Demonstrate Reduced Activity against Arabinosylcytosine: Implications for Epigenetic Instability in Acute Myeloid Leukemia.
Topics: Antimetabolites, Antineoplastic; Cytarabine; DNA Modification Methylases; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute | 2017 |
Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Transplantation, Homologous | 2017 |
Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cytarabine; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Phosphatidylserines; Tetrahydronaphthalenes; Thrombomodulin; Thromboplastin | 2017 |
Escalated anthracycline dose in adult AML.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
Topics: Animals; CD36 Antigens; Cell Line, Tumor; Cell Lineage; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Neoplastic Stem Cells; Oxidative Phosphorylation; Xenograft Model Antitumor Assays | 2017 |
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Cytarabine; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mitosis; Polo-Like Kinase 1; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cytarabine; Drug Synergism; fms-Like Tyrosine Kinase 3; G1 Phase; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Mutation; Resting Phase, Cell Cycle; Signal Transduction | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
[Efficacy Comparison of Different Salvage Treatment Regimens for Patients with Refractory/Relapsed Acute Myeloid Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2017 |
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |
[Long-term safety and efficacy of high-dose cytarabine consolidation in patients with acute myeloid leukemia].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2017 |
Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Computational Biology; Cytarabine; Databases, Genetic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Ontology; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Annotation | 2017 |
Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Kelch-Like ECH-Associated Protein 1; Leukemia, Myeloid, Acute; Mutation; NF-E2-Related Factor 2; Protein Transport; Response Elements; Tumor Cells, Cultured | 2017 |
Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction; Retrospective Studies; Young Adult | 2017 |
Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Drug Therapy, Combination; Enterocolitis, Neutropenic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Minocycline; Mortality; Remission Induction; Tigecycline; Treatment Outcome; Ultrasonography; Workflow; Young Adult | 2017 |
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Disease-Free Survival; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Polymorphism, Single Nucleotide; Young Adult | 2017 |
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Topics: Adolescent; Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Cytarabine; Female; Genotype; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Metabolic Networks and Pathways; Middle Aged; Pharmacogenomic Variants; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2017 |
Looking up for AML in Down syndrome.
Topics: Cytarabine; Down Syndrome; Etoposide; Humans; Leukemia, Myeloid, Acute | 2017 |
Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.
Topics: Autophagy; Cell Death; Cell Differentiation; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Metabolic Networks and Pathways; Oncogene Protein v-akt; Time Factors; TOR Serine-Threonine Kinases; U937 Cells | 2017 |
Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells.
Topics: Animals; Bone Marrow Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Oxidative Phosphorylation | 2017 |
Release of Danger-Associated Molecular Patterns following Chemotherapy Does Not Induce Immunoparalysis in Leukemia Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cells, Cultured; Cholesterol, LDL; Cytarabine; Cytokines; DNA; DNA, Mitochondrial; Female; HLA-DR Antigens; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukocytes; Lipopolysaccharides; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2017 |
JNK1 as a signaling node in VDR-BRAF induction of cell death in AML.
Topics: Antimetabolites, Antineoplastic; Cell Death; Cytarabine; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Proto-Oncogene Proteins B-raf; Receptors, Calcitriol; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2018 |
Unexpected diagnosis of appendicitis in a paediatric patient with febrile neutropaenia and acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Febrile Neutropenia; Humans; Incidental Findings; Leukemia, Myeloid, Acute; Male; Tomography, X-Ray Computed | 2017 |
JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML).
Topics: Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Genetic Therapy; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Societies, Medical | 2017 |
Acute myeloid leukaemia masquerading as a primary CNS tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Sarcoma, Myeloid; Treatment Outcome | 2017 |
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Young Adult | 2017 |
Systemic mastocytosis associated with acute myeloid leukaemia.
Topics: Adult; Biopsy, Needle; Bone Marrow; Cytarabine; Humans; Idarubicin; Immunohistochemistry; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit | 2017 |
Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Binding Factor; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Myosin Heavy Chains; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Transplantation, Autologous | 2017 |
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Analysis; Vascularized Composite Allotransplantation; Vidarabine | 2017 |
A case report of acute myelogenous leukemia with Turner Syndrome.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Incidental Findings; Karyotype; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Turner Syndrome | 2017 |
Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2018 |
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine | 2017 |
Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Pericarditis | 2018 |
Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2018 |
Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cytarabine; Drug Repositioning; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, SCID; Middle Aged; Quinacrine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.
Topics: Cell Line, Tumor; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Peptides; Tumor Suppressor Protein p53 | 2018 |
TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Biomarkers; Bone Marrow; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chemokine CXCL12; Chromosome Aberrations; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Mesenchymal Stem Cells; Mice; Middle Aged; Neoplasm Grading; Transforming Growth Factor beta1 | 2018 |
Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Biomarkers, Tumor; Cytarabine; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Metabolic Networks and Pathways; MicroRNAs; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; U937 Cells; Xenograft Model Antitumor Assays | 2017 |
Anthracycline-induced acute myocarditis and ventricular fibrillation arrest.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cardiopulmonary Resuscitation; Chest Pain; Combined Modality Therapy; Cytarabine; Defibrillators, Implantable; Echocardiography; Etoposide; Heart Arrest; Humans; Idarubicin; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Myocarditis; Ventricular Fibrillation | 2018 |
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Propensity Score; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
[Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Topics: Alzheimer Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2017 |
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Case-Control Studies; Chemical and Drug Induced Liver Injury; Clofarabine; Cohort Studies; Combined Modality Therapy; Cost Savings; Costs and Cost Analysis; Cytarabine; Granulocyte Colony-Stimulating Factor; Hospital Costs; Humans; Incidence; Induction Chemotherapy; Length of Stay; Leukemia, Myeloid, Acute; Michigan; Middle Aged; Neutropenia; Propensity Score; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Vidarabine | 2018 |
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.
Topics: Adult; Aged; Aged, 80 and over; Cell Line; Cytarabine; Cytogenetics; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance; Epigenesis, Genetic; Exome; Exome Sequencing; Female; Histone Demethylases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Remission Induction; Young Adult | 2018 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
Acute myeloid leukemia presenting as erythema nodosum: A case report.
Topics: Antineoplastic Agents; Bone Marrow Examination; Cytarabine; Daunorubicin; Erythema Nodosum; Fatal Outcome; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 2017 |
[Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Minnesota; Progression-Free Survival; Remission Induction; Retrospective Studies; Salvage Therapy | 2018 |
Ara-C ears: an actual drug-induced reaction or a distinctive manifestation of a neutrophilic dermatosis?
Topics: Adult; Biopsy; Cytarabine; Drug Therapy, Combination; Ear Diseases; Ear, External; Erythema; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Sweet Syndrome | 2018 |
Effect of NPM1 type B mutation on the proliferation, invasion and chemosensitivity of THP-1 leukemia cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Invasiveness; Nuclear Proteins; Nucleophosmin; Prognosis | 2017 |
Can we forecast induction failure in acute myeloid leukemia?
Topics: Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute | 2018 |
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2018 |
High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction; Salvage Therapy; Survival Analysis; United Kingdom; Vidarabine | 2018 |
Consolidation Chemotherapy Prevents Relapse by Indirectly Regulating Bone Marrow Adipogenesis in Patients with Acute Myeloid Leukemia.
Topics: Adipocytes; Adipogenesis; Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Cells, Cultured; Consolidation Chemotherapy; Cytarabine; Female; Growth Differentiation Factor 15; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Secondary Prevention | 2018 |
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2018 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
Topics: Adult; Aged; Animals; Autophagy; Cell Line, Tumor; Cell Survival; Chemokine CXCL12; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Neoplasm Transplantation; Receptors, CXCR4; Signal Transduction; Sirtuin 1 | 2018 |
Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells.
Topics: Cell Survival; Cells, Cultured; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzazepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytarabine; Drug Synergism; Enzyme Inhibitors; Female; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrimidines; RNA, Messenger; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2018 |
Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Topics: Adolescent; Adult; Aged; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Proteins; Nucleotides; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Quantitative Trait Loci; Remission Induction; Young Adult | 2018 |
In brief: Two new drugs for AML.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Mutation; Treatment Outcome; Triazines | 2018 |
Acute Onset Unilateral Proptosis.
Topics: Aged; Antineoplastic Agents; Cytarabine; Exophthalmos; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Radiotherapy; Sarcoma, Myeloid | 2018 |
[Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2018 |
Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Down Syndrome; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Vidarabine; Vorinostat | 2019 |
An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.
Topics: Animals; CRISPR-Cas Systems; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Regulatory Networks; Genome, Human; HEK293 Cells; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; Mice; Pharmacogenetics; Proteins; RNA; RNA, Long Noncoding; RNA, Messenger; Signal Transduction | 2018 |
Genital ulcers as diagnostic clue for acute myeloid leukaemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Fissure in Ano; Genitalia; Gingival Hyperplasia; Humans; Leukemia, Myeloid, Acute; Treatment Outcome; Young Adult | 2018 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Cystitis; Cytarabine; Cytomegalovirus Infections; Drug Therapy, Combination; Epstein-Barr Virus Infections; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Leukocytes; Male; Prospective Studies; Transplantation Conditioning; Young Adult | 2018 |
Connecting the Dots: A Case of Myeloid Sarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cladribine; Cytarabine; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Sarcoma, Myeloid | 2018 |
Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chromosome Inversion; Chromosomes, Human, Pair 16; Core Binding Factor beta Subunit; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocytosis; Longitudinal Studies; Male; Middle Aged; Morocco; Myosin Heavy Chains; Oncogene Proteins, Fusion; Prognosis; Young Adult | 2018 |
[Comparison of the efficacy of decitabine combined with micro-transplantation or priming regimen as consolidation treatment for older patients with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Treatment Outcome | 2018 |
Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Sulfonamides | 2018 |
Congenital acute myeloid leukaemia with KMT2A rearrangement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Exanthema; Female; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein | 2018 |
Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Survival Rate | 2018 |
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult | 2018 |
Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome | 2019 |
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
Topics: Apoptosis; Biomarkers; Biomarkers, Tumor; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Computational Biology; Cytarabine; Drug Discovery; Drug Screening Assays, Antitumor; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Neoplastic Stem Cells; Transcriptome | 2018 |
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-pim-1; Signal Transduction | 2018 |
Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Neurotoxicity Syndromes | 2018 |
[Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Treatment Outcome | 2018 |
Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia.
Topics: Aged; Allografts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Drug Evaluation; Fatal Outcome; Female; Genes, sry; Histocompatibility; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Peripheral Blood Stem Cell Transplantation; Transplantation Chimera | 2018 |
[Impact of KIT D816 mutation on salvage therapy in relapsed acute myeloid leukemia with t(8;21) translocation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Retrospective Studies; Salvage Therapy | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
Benefit of nanomedicine confirmed in sAML.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Nanomedicine | 2018 |
Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Cytarabine; Cytidine Triphosphate; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Polymorphism, Single Nucleotide; Young Adult | 2018 |
Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Topics: Animals; Apoptosis; Caspases; Cell Survival; Cytarabine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Emodin; Extracellular Signal-Regulated MAP Kinases; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
[The Clinical Efficacy of Small Dose CAG Program in Comparison with MA Program in Senile Patients with Acute Myeloid Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; THP-1 Cells; Vidarabine | 2018 |
n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cytarabine; Energy Metabolism; Fatty Acids, Omega-3; Fish Oils; Glycolysis; Humans; Leukemia, Myeloid, Acute; Mitochondria; NF-E2-Related Factor 2; Signal Transduction | 2018 |
Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.
Topics: Cell Line, Tumor; Cell Survival; Cytarabine; DNA; DNA Adducts; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mass Spectrometry | 2018 |
Drug Shortage Impacts Patient Receipt of Induction Treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Induction Chemotherapy; Insurance Claim Review; Leukemia, Myeloid, Acute; Male; Medicare; Retrospective Studies; SEER Program; United States | 2018 |
Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzylamines; Cell Line, Tumor; Cyclams; Cytarabine; Disease Models, Animal; Heterocyclic Compounds; Humans; Immunomodulation; Immunotherapy; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Receptors, CXCR4; Tumor Microenvironment | 2019 |
Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients.
Topics: Aclarubicin; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotaxis; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; NF-kappa B; Prognosis; Receptors, CXCR4; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Smad4 Protein; Stem Cell Niche; Tumor Microenvironment; Up-Regulation | 2018 |
Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.
Topics: Adult; Aged; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
Sequential reduced-intensity chemotherapy for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia with rare cytogenetic abnormalities transformed from Fanconi anemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Fanconi Anemia; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetics; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation | 2018 |
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine.
Topics: Absorption, Physiological; Administration, Oral; Animals; Antineoplastic Agents; Berberine; Cell Death; Cell Line, Tumor; Cell Survival; Cytarabine; Drug Interactions; Drug Liberation; Emulsions; Leukemia, Myeloid, Acute; Mice; Nanoparticles; Permeability; Phase Transition; Rabbits; Xenograft Model Antitumor Assays | 2018 |
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; CD47 Antigen; Cell Cycle; Cytarabine; Depsipeptides; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Phenotype; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.
Topics: Adult; Antiviral Agents; Cytarabine; Cytomegalovirus Infections; Diagnosis, Differential; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Meningitis, Viral; Recurrence; Treatment Outcome | 2019 |
Lomustine in older patients with acute myeloid leukaemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2018 |
Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Exosomes; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Recurrence; Young Adult | 2018 |
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Red-Cell Aplasia, Pure; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Female; Gene Expression Regulation, Leukemic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Proportional Hazards Models; SAM Domain and HD Domain-Containing Protein 1; Young Adult | 2018 |
Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Purines; Remission Induction; RNA, Long Noncoding; Vidarabine | 2018 |
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2019 |
Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Topics: Adenine; Animals; Apoptosis; Caspases; Cell Cycle Checkpoints; Cytarabine; DNA Damage; Drug Compounding; Drug Resistance, Neoplasm; Drug Synergism; Female; Histones; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Organophosphonates; Poly(ADP-ribose) Polymerases; Transplantation, Heterologous; Tumor Cells, Cultured | 2018 |
Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocytosis; Lomustine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine.
Topics: Activating Transcription Factor 4; Adenylate Kinase; Adipocytes; Adult; Bone Marrow; Cell Death; Cell Survival; Coculture Techniques; Cytarabine; Drug Synergism; Fatty Acids; Glycolysis; Humans; Leukemia, Myeloid, Acute; Middle Aged; Models, Biological; Oxidation-Reduction; Signal Transduction; THP-1 Cells; TOR Serine-Threonine Kinases; Young Adult | 2018 |
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2018 |
The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Autophagy; Basigin; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Glycoproteins; Humans; Leukemia, Myeloid, Acute; Phenols; Prognosis; Signal Transduction; Small Molecule Libraries; Survival Rate; Tumor Cells, Cultured | 2019 |
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Monitoring; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Precision Medicine; Prognosis; Remission Induction; ROC Curve; Treatment Outcome; Workflow; Young Adult | 2019 |
Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen.
Topics: Abietanes; Antineoplastic Agents; Antioxidants; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cytarabine; Ergocalciferols; Humans; Leukemia, Myeloid, Acute; MAP Kinase Kinase Kinase 5; Mitogen-Activated Protein Kinase 8; Signal Transduction; Vitamins | 2019 |
Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cladribine; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Recurrence; Survival Rate; Treatment Outcome | 2019 |
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Vidarabine | 2019 |
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Europe; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Platelet Count; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Rate; Young Adult | 2019 |
Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Renal Insufficiency; Treatment Outcome | 2019 |
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Proliferation; Cyclin-Dependent Kinase 9; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Phosphorylation; Protein Biosynthesis; Proteome; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Nucleophosmin; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 2019 |
Acute Myeloid Leukemia Affects Mouse Sperm Parameters, Spontaneous Acrosome Reaction, and Fertility Capacity.
Topics: Acrosome Reaction; Animals; Cytarabine; Fertility; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Sperm Motility; Spermatozoa; Survival Analysis | 2019 |
Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis.
Topics: Administration, Oral; Biopsy; Bone Marrow Transplantation; Chronic Disease; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Psoriasis; Skin; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2019 |
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Time Factors | 2019 |
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Russia; Survival Rate; Young Adult | 2018 |
In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Proliferation; Computer Simulation; Cytarabine; Disease Progression; Humans; Leukemia, Myeloid, Acute; Systems Biology; Time Factors | 2019 |
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 2019 |
Health state utilities associated with treatment options for acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hospitalization; Humans; Induction Chemotherapy; Infusions, Intravenous; Interviews as Topic; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Economic; Patient Preference; Pilot Projects; Quality of Life; Socioeconomic Factors; Time Factors; United Kingdom | 2019 |
Clinical Reasoning: A pregnant woman with chin numbness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chin; Consolidation Chemotherapy; Cytarabine; Emergency Service, Hospital; Fatigue; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypesthesia; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Paresthesia; Pregnancy; Pregnancy Complications, Neoplastic; Spinal Puncture; Sweating; Upper Extremity | 2019 |
Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Salvage Therapy; Sulfonamides; Young Adult | 2019 |
Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Topics: Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Structure-Activity Relationship | 2019 |
ARA-C RELATED RED EAR SYNDROME.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Dermatitis, Exfoliative; Diagnosis, Differential; Ear Auricle; Ear Diseases; Female; Humans; Leukemia, Myeloid, Acute; Patient Care Management; Treatment Outcome | 2019 |
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.
Topics: Apoptosis; Cell Proliferation; Checkpoint Kinase 1; Cytarabine; Daunorubicin; G2 Phase Cell Cycle Checkpoints; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2019 |
Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cation Transport Proteins; Cell Proliferation; Cytarabine; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Prognosis; Survival Rate; Tumor Cells, Cultured | 2019 |
Meningitis in a patient with neutropenia due to Rothia mucilaginosa: a case report.
Topics: Actinomycetales Infections; Aged; Antimetabolites, Antineoplastic; Cytarabine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Meningitis; Neutropenia; Opportunistic Infections | 2019 |
Cytarabine-Resistant
Topics: Anilides; Apoptosis Regulatory Proteins; Biomarkers; Cell Line, Tumor; Cell Survival; Cytarabine; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Deletion; Humans; Leukemia, Myeloid, Acute; Metabolic Networks and Pathways; Mutation; Pyridines; Tandem Repeat Sequences; Tumor Suppressor Protein p53 | 2019 |
Acute myeloid leukaemia: an unusual cause of biliary strictures.
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bile Ducts, Extrahepatic; Cholangiography; Cholangitis; Cholestasis; Constriction, Pathologic; Cytarabine; Daunorubicin; Drug Therapy; Humans; Jaundice, Obstructive; Leukemia, Myeloid, Acute; Male; Treatment Outcome | 2019 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Siblings; Transplantation, Haploidentical; Treatment Outcome | 2019 |
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Europe; Gemtuzumab; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Sialic Acid Binding Ig-like Lectin 3 | 2019 |
Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.
Topics: Bone Marrow; Bone Marrow Cells; Cell Line; Cell Line, Tumor; Cytarabine; Cytochrome P-450 CYP3A; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Stromal Cells; Tumor Microenvironment; Up-Regulation | 2019 |
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
Topics: Affect; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Anxiety; Cytarabine; Depression; Female; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Quality of Life | 2019 |
Autologous hematopoetic cell transplantation: preferred consolidation treatment in low-risk AML?
Topics: Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation, Autologous | 2019 |
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.
Topics: Acid Ceramidase; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Survival; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Flow Cytometry; HEK293 Cells; HL-60 Cells; Humans; In Vitro Techniques; Lentivirus; Leukemia, Myeloid, Acute; Mitoxantrone; NF-kappa B; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Tandem Mass Spectrometry | 2019 |
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
Topics: Alleles; Animals; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cytarabine; DNA Damage; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; Heterozygote; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Transgenic; Mutation; Myeloid-Lymphoid Leukemia Protein; Neoplasm Recurrence, Local; Nuclear Proteins; Phenotype; Signal Transduction | 2019 |
MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Gene Knockdown Techniques; Humans; Leukemia, Myeloid, Acute; MicroRNAs; RNA, Long Noncoding; Up-Regulation | 2019 |
FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cytarabine; DNA Repair Enzymes; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Pyrazoles; Pyrimidines; rac1 GTP-Binding Protein; Tandem Repeat Sequences; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; T-Lymphocytes, Cytotoxic; Young Adult | 2019 |
MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytarabine; DCMP Deaminase; Deoxycytidine Kinase; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Regulatory Networks; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Networks and Pathways; MicroRNAs; Nucleosides; THP-1 Cells | 2019 |
Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction | 2019 |
Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Translocation, Genetic | 2019 |
Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Polymorphism, Single Nucleotide; Prognosis; Survival; Systematic Reviews as Topic | 2019 |
Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2020 |
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 2020 |
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cell Line, Tumor; Child; Child, Preschool; Cytarabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; High-Throughput Screening Assays; Humans; Infant; Janus Kinase Inhibitors; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Taxoids; Whole-Body Irradiation; Xenograft Model Antitumor Assays; Young Adult | 2019 |
Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine Kinase; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Histones; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Ubiquitination; Zidovudine | 2019 |
Cytarabine ears - A side effect of cytarabine therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug-Related Side Effects and Adverse Reactions; Ear; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2020 |
Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
Topics: Abnormal Karyotype; Adolescent; Allografts; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression Regulation, Leukemic; Genes, Mitochondrial; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mitochondrial Proteins; Neoplasm Proteins; Prognosis; Progression-Free Survival; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2019 |
The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Cytarabine; Interleukin-3 Receptor alpha Subunit; Isatin; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Nucleophosmin | 2020 |
FLAI induction regimen in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Sex Factors; Time Factors; Transplantation, Homologous; Vidarabine | 2019 |
[Intermediate-high dose cytarabine consolidation therapy in younger adults with acute myeloid leukemia and favorable-intermediate cytogenetic risk: a retrospective study of 124 patients in a single Chinese hospital].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Treatment Outcome | 2019 |
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Young Adult | 2019 |
A delayed diagnosis of acute myeloid leukaemia during pregnancy using an old blood cell analyser.
Topics: Adult; Blood Cell Count; Cesarean Section; Cytarabine; Delayed Diagnosis; Female; Gestational Age; Humans; Isoflavones; Leukemia, Myeloid, Acute; Obstetric Labor, Premature; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy, Twin; Remission Induction; Ritodrine | 2019 |
SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
Topics: Acetylation; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice, SCID; Middle Aged; Mitochondria; Oxidative Phosphorylation; Reactive Oxygen Species; Sirtuin 3; Superoxide Dismutase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation.
Topics: Abietanes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antioxidants; Apoptosis; Cell Line, Tumor; Cytarabine; Ergocalciferols; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Reactive Oxygen Species; Receptors, Calcitriol; RNA Interference; RNA, Small Interfering; U937 Cells; Vitamin D | 2020 |
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.
Topics: Cell Proliferation; Cytarabine; Humans; Leukemia, Myeloid, Acute; Models, Biological | 2019 |
Clofarabine and cytarabine for acute myeloid leukaemia.
Topics: Arabinonucleosides; Clofarabine; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2019 |
Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Interleukin-8; Leukemia, Myeloid, Acute; Models, Molecular; Structure-Activity Relationship | 2019 |
Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells.
Topics: Cell Line, Tumor; Cells, Cultured; Clinical Trials as Topic; Cytarabine; Humans; Immunosuppressive Agents; Immunotherapy; Killer Cells, Natural; Leukemia, Myeloid, Acute; NK Cell Lectin-Like Receptor Subfamily K; Receptors, KIR; Signal Transduction | 2019 |
Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds | 2019 |
Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Genes, Modifier; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Salvage Therapy; Survival Rate | 2019 |
Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Hypochlorous Acid; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Oxidation-Reduction; Oxidative Stress; Peroxidase; Reactive Oxygen Species; RNA, Neoplasm; RNA, Small Interfering; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Cell Count; Bone Marrow; Clofarabine; Cytarabine; Filgrastim; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors; Treatment Outcome | 2019 |
A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Benzimidazoles; Cell Proliferation; Cell Survival; Cytarabine; DNA Damage; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 2019 |
Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival.
Topics: Anilides; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzothiazoles; Bone Density Conservation Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Child; Cytarabine; Daunorubicin; Drug Repositioning; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Pamidronate; Phenylurea Compounds; Primary Cell Culture; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; ras Proteins | 2019 |
Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Young Adult | 2013 |
Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cohort Studies; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Health Resources; Hospitals, Pediatric; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Logistic Models; Male; Odds Ratio; Poisson Distribution; Risk Assessment; Risk Factors; Thioguanine; Treatment Outcome; United States | 2013 |
Core binding factor acute myeloid leukaemia and c-KIT mutations.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Core Binding Factors; Cytarabine; Disease-Free Survival; Etoposide; Exons; Female; Humans; Idarubicin; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Retrospective Studies; Stem Cell Transplantation; Young Adult | 2013 |
Dermatic Scedosporium apiospermum infection after autologous bone marrow transplantation.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dermatomycoses; Drugs, Chinese Herbal; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Opportunistic Infections; Postoperative Complications; Pyrimidines; Scedosporium; Skin Ulcer; Transplantation Conditioning; Transplantation, Autologous; Triazoles; Voriconazole; Young Adult | 2013 |
[A man with neutropenic fever].
Topics: Adult; Cytarabine; Dermatomycoses; Fatal Outcome; Fusarium; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Neutropenia; Opportunistic Infections | 2013 |
Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
Topics: Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Remission Induction | 2013 |
Florid skin rash in acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Drug Eruptions; Exanthema; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2013 |
Resident rounds. Part III: Neutrophilic eccrine hidradenitis in the setting of acute myelogenous leukemia treated with cytarabine.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cytarabine; Female; Hidradenitis; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutrophil Infiltration; Skin | 2013 |
Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Cell Division; Cell Line, Tumor; Cytarabine; Histones; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Organophosphates; Phosphorylation; Quinazolines; U937 Cells | 2013 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
[Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2013 |
Accidental overdose of intrathecal cytarabine in children.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child, Preschool; Cytarabine; Drug Overdose; Female; Glucocorticoids; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Medication Errors; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2013 |
Consolidation chemotherapy for adults with AML in first remission: is there a best choice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male | 2013 |
[Refractory acute myeloid leukemia developed malignancy-associated hemophagocytic lymphohistiocytosis during treatment of invasive fungal infection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Fungal Infections; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Mitoxantrone | 2013 |
[Acute myeloid leukemia with monosomy 7 and inv(3)(q21q26.2) complicated with central diabetes insipidus].
Topics: Chromosome Deletion; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Cytarabine; Diabetes Insipidus, Neurogenic; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Treatment Outcome; Young Adult | 2013 |
CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; bcl-X Protein; Cell Line, Tumor; Chemokine CXCL12; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Receptors, CXCR4; Signal Transduction; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays; YY1 Transcription Factor | 2013 |
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Busulfan; Chromosome Mapping; Cytarabine; Disease-Free Survival; DNA; Etoposide; Female; Follow-Up Studies; Genetic Loci; Genotype; Glutathione Transferase; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Membrane Transport Proteins; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Remission Induction; Young Adult | 2013 |
D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged; Mitoxantrone; Neutropenia; Neutrophils; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2014 |
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine | 2013 |
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2013 |
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Neoplasm Transplantation; Receptors, CXCR4; Transforming Growth Factor beta; Tumor Microenvironment | 2013 |
[Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
Topics: Animals; Antibodies, Monoclonal; CD47 Antigen; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prognosis | 2013 |
Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Topics: 5'-Nucleotidase; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine Kinase; DNA Methylation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Inactivation, Metabolic; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Survival Analysis; Tandem Repeat Sequences; Topoisomerase I Inhibitors; Young Adult | 2013 |
Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.
Topics: Cytarabine; Drug Approval; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[IAG regimen for patients with refractory/relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2013 |
Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Arterial Occlusive Diseases; Bone Marrow Examination; Combined Modality Therapy; Cyanosis; Cytarabine; Diagnosis, Differential; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Humans; Idarubicin; Ischemia; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Shoes; Thrombectomy; Thrombocytopenia; Thrombosis; Toes; Ultrasonography | 2013 |
Post-chemotherapeutic resolution of acute myeloid leukaemia-induced gingival enlargement: a case report.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Early Detection of Cancer; Female; Follow-Up Studies; Gingiva; Gingival Hemorrhage; Gingival Overgrowth; Gingivitis, Necrotizing Ulcerative; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Remission Induction | 2012 |
The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytarabine; Disease Progression; Female; Fibronectins; HL-60 Cells; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Young Adult | 2013 |
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Topics: Cell Line, Tumor; Cladribine; Cytarabine; Genetic Association Studies; HapMap Project; Humans; Leukemia, Myeloid, Acute; Linkage Disequilibrium; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prevalence; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Bacteremia; Canada; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Streptococcal Infections; Treatment Outcome; Viridans Streptococci | 2014 |
Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: a biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia.
Topics: Arabinofuranosylcytosine Triphosphate; Biomarkers, Tumor; Biosensing Techniques; Cytarabine; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Luminescent Measurements | 2014 |
BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biomarkers; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Peptide Fragments; Proto-Oncogene Proteins; Remission Induction; ROC Curve; Treatment Outcome; Young Adult | 2013 |
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Statistical; Neoplasms, Second Primary; Patient Outcome Assessment; Prognosis; Risk Factors; Treatment Outcome | 2014 |
Medical image. A rare complication of cytarabine therapy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Female; Hand Dermatoses; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2013 |
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Young Adult | 2014 |
Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Fungal; Fatal Outcome; Female; Fever; Fusariosis; Fusarium; Humans; Idarubicin; Leukemia, Myeloid, Acute; Triazoles; Young Adult | 2014 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomimetics; Blotting, Western; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Mitochondrial Proteins; Oligopeptides | 2014 |
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Salvage Therapy; Vidarabine | 2014 |
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Secondary Prevention; Survival Analysis; Vidarabine | 2014 |
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2014 |
Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission.
Topics: Adolescent; Adult; Biomarkers; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Binding Sites; Cell Transformation, Neoplastic; Combined Modality Therapy; Cytarabine; DNA-Binding Proteins; Doxorubicin; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Myeloid Ecotropic Viral Integration Site 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorothioate Oligonucleotides; Pre-B-Cell Leukemia Transcription Factor 1; Protein Binding; Proto-Oncogene Proteins; Regulatory Sequences, Nucleic Acid; Transcription Factors; Transcriptome; Xenograft Model Antitumor Assays | 2014 |
Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Clone Cells; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Risk | 2014 |
Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Nerve Tissue Proteins; Phosphatidylinositol 3-Kinases; Signal Transduction | 2014 |
Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
[Cytarabine and skin reactions in acute myeloid leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Drug Eruptions; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Young Adult | 2013 |
Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C.
Topics: Antineoplastic Agents; Cell Proliferation; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Hyaluronan Receptors; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc | 2014 |
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Trials; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Methylprednisolone; Middle Aged; Neutropenia; Nucleophosmin; Recombinant Proteins; Remission Induction; Salvage Therapy; Thrombocytopenia | 2014 |
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Young Adult | 2014 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Severity of Illness Index | 2014 |
Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Blood Cell Count; Critical Care; Cyclophosphamide; Cytarabine; Daunorubicin; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunocompromised Host; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Retrospective Studies; Young Adult | 2014 |
Crucial role of heme oxygenase-1 in the sensitivity of acute myeloid leukemia cell line Kasumi-1 to ursolic acid.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Heme Oxygenase-1; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasm Transplantation; Protoporphyrins; Triterpenes; Ursolic Acid | 2014 |
Laryngeal chloroma heralding relapse of acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Dose Fractionation, Radiation; Fatal Outcome; Humans; Laryngeal Neoplasms; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Respiratory Insufficiency; Sarcoma, Myeloid; Stem Cell Transplantation; Tomography, X-Ray Computed | 2014 |
The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2014 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antigens, CD7; Antimetabolites, Antineoplastic; CCAAT-Enhancer-Binding Proteins; Cytarabine; Female; Fucosyltransferases; HLA-DR Antigens; Humans; Immunophenotyping; Kaplan-Meier Estimate; Karyotype; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Lewis X Antigen; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult | 2014 |
Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Dexamethasone; Erythroid Cells; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Megakaryocytes; Mitoxantrone; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2014 |
Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factors; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Translocation, Genetic; Treatment Outcome; Young Adult | 2014 |
Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hospitals, University; Humans; Infant; Infusions, Intravenous; Injections, Spinal; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Methotrexate; Mexico; Middle Aged; Mitoxantrone; Proportional Hazards Models; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Mutational Analysis; Doxorubicin; Female; Genetic Association Studies; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prognosis; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2014 |
Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Hemorrhage; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Palliative Care; Pneumonia; Retrospective Studies; Survival Analysis | 2014 |
HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Graft Survival; Graft vs Leukemia Effect; Histocompatibility; HLA Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Male; Middle Aged; Remission Induction; Tissue Donors | 2014 |
[Observation of low-dose HA/HAA regimen as induction chemotherapy on elderly patients with acute myeloid leukemia].
Topics: Aged; Aged, 80 and over; Cytarabine; Female; Harringtonines; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged | 2014 |
c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.
Topics: Antimetabolites, Antineoplastic; Cell Death; Cells, Cultured; Cytarabine; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; GPI-Linked Proteins; HL-60 Cells; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid, Acute; Ligands; NK Cell Lectin-Like Receptor Subfamily K; Proto-Oncogene Proteins c-myc | 2014 |
Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Cell Proliferation; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; Intracellular Space; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Phosphotransferases (Alcohol Group Acceptor) | 2014 |
MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Differentiation; Cell Proliferation; Cytarabine; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Mutation; Neoplasm Proteins; Signal Transduction; Survival Analysis; Tumor Cells, Cultured | 2014 |
Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Survival Analysis; Treatment Outcome | 2015 |
Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 2014 |
An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromatin; Chromosome Aberrations; Chromosomes; Core Binding Factor Alpha 2 Subunit; Cytarabine; DNA; Enhancer Elements, Genetic; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Exome; Gene Expression Regulation, Leukemic; HeLa Cells; Hematologic Neoplasms; Humans; K562 Cells; Leukemia, Myeloid, Acute; Mutation; Polycomb Repressive Complex 2; Promoter Regions, Genetic; RNA, Long Noncoding; Translocation, Genetic | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
Topics: 3' Untranslated Regions; Adolescent; Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; HL-60 Cells; HMGB1 Protein; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Young Adult | 2014 |
Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Differentiation; Cytarabine; DNA-Binding Proteins; Drug Synergism; Histone-Lysine N-Methyltransferase; Histones; Humans; Leukemia, Myeloid, Acute; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Trans-Activators; Transcriptional Activation; Transcriptional Elongation Factors; Tretinoin | 2014 |
[Contribution of PET/CT for the management of hepatosplenic candidiasis in hematology].
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candidiasis, Invasive; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Daunorubicin; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hepatitis; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Splenic Diseases; Tomography, X-Ray Computed | 2014 |
The first Korean case of Moraxella osloensis bacteremia in a patient with acute myeloid leukemia.
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Asian People; Cytarabine; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Moraxella; Moraxellaceae Infections; Republic of Korea; Respiratory Tract Infections; RNA, Ribosomal, 16S; Sequence Analysis, RNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulbactam | 2014 |
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Chromosome Aberrations; Consolidation Chemotherapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prognosis; RUNX1 Translocation Partner 1 Protein; Young Adult | 2014 |
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy.
Topics: Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Salvage Therapy | 2014 |
Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Drug Costs; Female; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Victoria; Young Adult | 2014 |
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Topics: Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Gene Deletion; Glucuronic Acid; Glucuronosyltransferase; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Ribavirin; Signal Transduction; Transcription Factors; Zinc Finger Protein GLI1 | 2014 |
Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
Topics: Adolescent; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Injections, Spinal; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies | 2015 |
Critical considerations on the utility of FDG-PET/CT for posttreatment restaging of the bone marrow in diffuse large B-cell lymphoma.
Topics: Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Salvage Therapy | 2014 |
Critical considerations on the utility of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for posttreatment restaging of the bone marrow in diffuse large B-cell lymphoma.
Topics: Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Salvage Therapy | 2014 |
Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Skin Diseases | 2014 |
The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cytarabine; Daunorubicin; Disease Models, Animal; Etoposide; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Microarray Analysis; Reactive Oxygen Species; SUMO-1 Protein; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
Acute basophilic leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antigens, CD; Antimetabolites, Antineoplastic; Asthenia; Azacitidine; Basophils; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Leukemia, Basophilic, Acute; Leukemia, Myeloid, Acute | 2014 |
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Cytarabine; Etoposide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; Cytarabine; Down Syndrome; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Vidarabine | 2014 |
Acquired factor VII deficiency associated with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bacteremia; Cytarabine; Daunorubicin; Factor VII; Factor VII Deficiency; Fatal Outcome; Granulocytes; Hematoma; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pseudomonas Infections | 2015 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.
Topics: 5'-Nucleotidase; Antimetabolites, Antineoplastic; Cytarabine; Female; Genetic Association Studies; Genetic Variation; Genotype; Glycoproteins; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Polymorphism, Single Nucleotide; Republic of Korea; Treatment Outcome | 2014 |
Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Alleles; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cytarabine; Cytochrome P-450 CYP2D6; Drug Resistance; Female; Haplotypes; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Polymorphism, Single Nucleotide; Vomiting; Young Adult | 2014 |
[Effect of intermediate-dose cytarabine on mobilization of peripheral blood hematopoietic stem cell in acute myeloid leukemia].
Topics: Adolescent; Adult; Child; Cytarabine; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
[Efficacy of FLAG as initial induction chemotherapy followed by autologous hematopoietic stem cell transplantation after IBu conditioning regimen in acute myeloid leukemia with FLT3 mutations].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Odds Ratio; Prognosis; Risk Factors; Survival Analysis; Young Adult | 2015 |
Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; Cytarabine; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Leukemia, Myeloid, Acute; Mice; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Sequence Analysis, RNA | 2014 |
When the eye gives it all: diagnosis of relapsing acute myeloblastic leukemia with anterior chamber tap of a chronic hypopyon.
Topics: Adult; Anterior Chamber; Antimetabolites, Antineoplastic; Cytarabine; Humans; Iridectomy; Iris; Karyotyping; Leukemia, Myeloid, Acute; Male; Recurrence | 2014 |
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Microarray Analysis; MicroRNAs; Middle Aged; Prognosis; Survival Analysis | 2015 |
Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Whole-Body Irradiation; Young Adult | 2014 |
Rapid in-vitro testing for chemotherapy sensitivity in leukaemia patients.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Biological Assay; Biosensing Techniques; Cell Line, Tumor; Cytarabine; Drug Screening Assays, Antitumor; Escherichia coli; Genes, Reporter; Genetic Engineering; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Luciferases, Bacterial; Luminescent Measurements; Operon; Phosphorylation | 2014 |
Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Consolidation Chemotherapy; Cytarabine; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Takotsubo Cardiomyopathy; Treatment Outcome | 2014 |
Chemotherapy drug shortages in the United States revisited.
Topics: Antineoplastic Agents; Cytarabine; Drug Industry; Health Care Rationing; Health Services Accessibility; Leukemia, Myeloid, Acute; Medicare; United States; United States Food and Drug Administration | 2014 |
Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia.
Topics: Algorithms; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytarabine; DNA Mutational Analysis; Humans; Leukemia, Myeloid, Acute; Monte Carlo Method; Mutation; Neoplasm Recurrence, Local; Remission Induction | 2015 |
[Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mast Cells; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Vidarabine | 2015 |
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2015 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Haploidentical peripheral blood stem cell infusion in combination with chemotherapy for acute myeloid leukaemia in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Prospective Studies; Treatment Outcome | 2014 |
Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Male; Middle Aged; Retrospective Studies; Young Adult | 2015 |
Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Feasibility Studies; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Homologous; Treatment Failure | 2015 |
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
Topics: Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; DNA Damage; Female; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Pyrroles; U937 Cells | 2015 |
Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Biphenyl Compounds; Cell Line, Tumor; Cytarabine; Disease Models, Animal; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Profiling; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Nitrophenols; Piperazines; Sulfonamides; Survival Rate; Transplantation, Homologous; Up-Regulation | 2014 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
[Clinical curative efficacy of inducing remission for the newly diagnosed aged AML patients by chemotherapy with IA and DA regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2014 |
[Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML].
Topics: Adolescent; Adult; Allografts; Cytarabine; Disease-Free Survival; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2014 |
Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia.
Topics: Adult; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Humans; Leukemia, Myeloid, Acute; Male | 2015 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
[The comparative study of the effects between modified FLAG and CAG on relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Recurrence | 2014 |
Eccrine poromatosis in a patient with acute myeloid leukemia following chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Poroma; Stem Cell Transplantation; Sweat Gland Neoplasms | 2014 |
The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Cytarabine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Leukemia, Myeloid, Acute; Phorbol Esters; Protein Kinase C; Proto-Oncogene Proteins c-myc; Tumor Cells, Cultured | 2015 |
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Monitoring; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Survival Analysis; Transcription Factors; Translocation, Genetic | 2015 |
Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Vidarabine; Young Adult | 2014 |
Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cause of Death; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Multivariate Analysis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
Topics: ADP-ribosyl Cyclase 1; Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Apoptosis; Cells, Cultured; Coculture Techniques; Cytarabine; Humans; Immunophenotyping; Interleukin-3; Karyotyping; Leukemia, Myeloid, Acute; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Knockout; Neoplastic Stem Cells; Stem Cell Factor | 2015 |
Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Survival; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Proteolysis; Signal Transduction; Time Factors | 2015 |
[Progress of study on drug therapy in adults patients with acute myeloid leukemia (non APL) after remission].
Topics: Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2014 |
[Characteristics and treatment outcomes in 822 adult patients with acute myeloid leukemia:a single center experience].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Proteins, Fusion; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Female; Follow-Up Studies; Hospitalization; Humans; Idarubicin; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients.
Topics: Adult; Alleles; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; China; Cytarabine; Disease Susceptibility; Female; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Osteopontin; Polymorphism, Single Nucleotide; Transfection | 2015 |
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2015 |
Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; India; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2015 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Topics: Adolescent; Adult; Allografts; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infections; Kaplan-Meier Estimate; Keratitis; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Xerophthalmia; Young Adult | 2016 |
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome; Vidarabine | 2015 |
Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside.
Topics: Antimetabolites, Antineoplastic; Arsenites; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Real-Time Polymerase Chain Reaction; Sodium Compounds | 2015 |
CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.
Topics: Adult; Aged; Antineoplastic Agents; Case-Control Studies; Cell Lineage; Cytarabine; Daunorubicin; Female; Gene Expression; Humans; Immunity, Innate; Immunophenotyping; Interferon-gamma; Interleukin-7 Receptor alpha Subunit; Interleukins; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.
Topics: Adolescent; Aged; Animals; Antimetabolites, Antineoplastic; Arginase; Arginine; Child; Child, Preschool; Cytarabine; Enzyme Therapy; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mice, SCID; Middle Aged; Recombinant Proteins; Tumor Cells, Cultured; Young Adult | 2015 |
Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Female; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome; Young Adult | 2015 |
INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Chemoradiotherapy; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Nucleophosmin; Phosphoric Monoester Hydrolases; Prognosis; Radiation, Ionizing; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tumor Cells, Cultured; Young Adult | 2015 |
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytarabine; DNA Damage; DNA Replication; HEK293 Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridines; S Phase; Transcription, Genetic; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation; Young Adult | 2015 |
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child Health Services; Child, Preschool; Comparative Effectiveness Research; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Health Information Systems; Hospitals, Pediatric; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Outcome and Process Assessment, Health Care; Young Adult | 2015 |
Evolving treatments in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy | 2015 |
[The relationship between induction chemotherapy cycles and prognosis in patients with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction | 2015 |
Cytarabine, venous catheter removal, sepsis, diagnosis of malignancy, and takotsubo syndrome.
Topics: Consolidation Chemotherapy; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Takotsubo Cardiomyopathy | 2015 |
"Cup-like" blasts in acute myeloid leukemia with FLT3 and NPM1 mutations.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin | 2015 |
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Risk factors for cytarabine-induced cutaneous toxicity in patients with haematological malignancies.
Topics: Cytarabine; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Risk Factors; Skin Diseases | 2014 |
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide | 2015 |
[Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction | 2015 |
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cytarabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Doxorubicin; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; GATA2 Transcription Factor; Gene Expression Regulation, Neoplastic; Gene Silencing; Haploinsufficiency; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins | 2015 |
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fluconazole; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Pre-Exposure Prophylaxis; Remission Induction; Retrospective Studies; Survival Analysis; Triazoles | 2016 |
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Proto-Oncogene Proteins c-akt; Triazoles | 2015 |
Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
Topics: Aminoacridines; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytarabine; Doxorubicin; Drug Synergism; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; RNA, Small Interfering; Signal Transduction; Survivin | 2015 |
Two cases of cytarabine syndrome successfully resolved by desensitization.
Topics: Aged; Antimetabolites, Antineoplastic; Chills; Cytarabine; Desensitization, Immunologic; Drug-Related Side Effects and Adverse Reactions; Female; Fever; Humans; Hypotension; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Shivering; Syndrome | 2015 |
Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Topics: Aged; Cell Differentiation; Cell Line, Tumor; Cohort Studies; Cytarabine; Female; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Homeodomain Proteins; Humans; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Mutation; Myeloid Cells; Myeloid Ecotropic Viral Integration Site 1 Protein; Neoplasm Proteins; Oncogene Proteins, Fusion; ras Proteins | 2015 |
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cohort Studies; Cytarabine; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocytes; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Thrombocytopenia | 2015 |
[Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cytarabine; Dactinomycin; Humans; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Recurrence; Remission Induction; Salvage Therapy | 2015 |
Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Membrane Transport Proteins; Middle Aged; Survival Analysis; Translocation, Genetic; Treatment Outcome; Up-Regulation; Young Adult | 2015 |
Cytarabine, venous catheter removal, sepsis, diagnosis of malignancy, and takotsubo syndrome. Reply by Baumann et al.
Topics: Consolidation Chemotherapy; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Takotsubo Cardiomyopathy | 2015 |
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine; Young Adult | 2015 |
Development and molecular characterization of polymeric micro-nanofibrous scaffold of a defined 3-D niche for in vitro chemosensitivity analysis against acute myeloid leukemia cells.
Topics: Biphenyl Compounds; Cell Adhesion; Cell Proliferation; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fibronectins; Humans; Lactic Acid; Leukemia, Myeloid, Acute; Nanocomposites; Nanofibers; Nitrophenols; Piperazines; Polyesters; Polymers; Polyurethanes; Sulfonamides; Tissue Scaffolds | 2015 |
Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Delivery, Obstetric; Female; Humans; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic | 2015 |
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine Kinase; Disease-Free Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2015 |
MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cytarabine; Down-Regulation; Drug Synergism; G1 Phase; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; U937 Cells | 2015 |
Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Case-Control Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Endostatins; Female; Fibroblast Growth Factors; Gene Expression; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; ROC Curve; Treatment Outcome | 2015 |
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
Topics: Adoptive Transfer; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Gene Expression; Humans; Immunocompromised Host; Immunoglobulin Fc Fragments; Interleukin-3 Receptor alpha Subunit; Killer Cells, Natural; Leukemia, Myeloid, Acute; Mice; Survival Analysis; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2015 |
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2015 |
SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cytarabine; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Necrosis; Osteonectin; Protein Kinases | 2015 |
Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa | 2015 |
Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
Topics: Animals; Anthracyclines; Bone Marrow; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Cytarabine; Cytogenetic Analysis; DNA Mutational Analysis; Exome; Humans; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplasm, Residual; Xenograft Model Antitumor Assays | 2015 |
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine | 2015 |
Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Endothelial Cells; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sulfonamides; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzothiazoles; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Deoxyglucose; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Glycolysis; Glycosylation; Humans; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Phenylurea Compounds; Piperazines; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Death; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydroxychloroquine; Leukemia, Myeloid, Acute; U937 Cells | 2015 |
Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; U937 Cells | 2015 |
N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia.
Topics: Acrylamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cytarabine; Daunorubicin; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Pyrimidines | 2016 |
Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Cohort Studies; Cytarabine; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Obesity; Overweight; Recurrence; Remission Induction; Retrospective Studies; Young Adult | 2015 |
Vosaroxin in acute myeloid leukaemia.
Topics: Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Naphthyridines; Neoplasm Recurrence, Local; Thiazoles | 2015 |
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Autoantigens; Cell Line, Tumor; Cytarabine; Daunorubicin; DNA Breaks, Double-Stranded; Female; Humans; Leukemia, Myeloid, Acute; Mi-2 Nucleosome Remodeling and Deacetylase Complex; Mice, Inbred NOD; Mice, SCID; RNA Interference; Tumor Cells, Cultured | 2015 |
Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcumin; Cytarabine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Real-Time Polymerase Chain Reaction; Structure-Activity Relationship; Vault Ribonucleoprotein Particles | 2016 |
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).
Topics: Aged; Alternative Splicing; Anthracyclines; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Exons; Gene Expression Profiling; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins; Oncogenes; Poly-ADP-Ribose Binding Proteins; RNA Interference; RNA, Small Interfering; WT1 Proteins | 2016 |
Bone Marrow MicroRNA-335 Level Predicts the Chemotherapy Response and Prognosis of Adult Acute Myeloid Leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Genome, Human; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mutation; Outcome Assessment, Health Care; Polymorphism, Genetic; Prognosis; Recurrence; RNA, Messenger; Sequence Analysis, RNA | 2015 |
Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Proliferation; Cytarabine; Drug Delivery Systems; Enzyme Activation; Female; Fingolimod Hydrochloride; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipids; Mice; Mice, Transgenic; Nanoparticles; Nanotechnology; Propylene Glycols; Sphingosine | 2015 |
Limited efficacy of HLA-haploidentical peripheral blood stem cell infusion in treatment of elderly patients with acute myelogenous leukaemia.
Topics: Aged; Cytarabine; Daunorubicin; Female; Histocompatibility Testing; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation | 2017 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.
Topics: Abietanes; Annexin A5; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Differentiation; Comet Assay; Cytarabine; DNA Damage; Ergocalciferols; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Propidium; U937 Cells | 2016 |
Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Cytogenetic Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Thioguanine; Young Adult | 2015 |
The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mitoxantrone; Pilot Projects; Real-Time Polymerase Chain Reaction; Remission Induction; RNA, Neoplasm; Transcriptome | 2015 |
Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.
Topics: Adolescent; Adult; Aged; Cytarabine; Cytidine Deaminase; Disease-Free Survival; Female; Haplotypes; Humans; Karyotype; Leukemia, Myeloid, Acute; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Genetic; Survival Rate | 2015 |
Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Male; Reproducibility of Results; RNA Interference; RNA, Small Interfering; Transcriptome; Treatment Outcome | 2016 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Fertility After Treatment With High Dose Melphalan in Women With Acute Myelogenous Leukemia.
Topics: Adolescent; Adult; Anthracyclines; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Fertility; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Survivors; Transplantation Conditioning; Young Adult | 2016 |
STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia patients to Ara-C-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; STAT5 Transcription Factor; Treatment Outcome | 2016 |
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cytarabine; Decitabine; Disease-Free Survival; Female; Harringtonines; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2015 |
Knockdown of homeobox A5 by small hairpin RNA inhibits proliferation and enhances cytarabine chemosensitivity of acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Homeodomain Proteins; Humans; Leukemia, Myeloid, Acute; RNA Interference; RNA, Small Interfering; U937 Cells | 2015 |
A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzylamines; Bone Marrow Cells; Cell Movement; Chemokine CXCL12; Cyclams; Cytarabine; Female; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Neoplasms, Experimental; Neoplastic Stem Cells; Receptors, CXCR4; Tumor Microenvironment | 2015 |
Cytarabine syndrome despite corticosteroid premedication in an adult undergoing induction treatment for acute myelogenous leukemia.
Topics: Adrenal Cortex Hormones; Adult; Antimetabolites, Antineoplastic; Cytarabine; Dexamethasone; Female; Fever; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Pain; Premedication; Syndrome | 2016 |
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Young Adult | 2015 |
Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2015 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
[Clinical features and survival analysis of patients with CD56 expression in de- novo acute myeloid leukemia with t（8;21）].
Topics: Bone Marrow; CD56 Antigen; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis | 2015 |
Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Treatment Outcome | 2016 |
A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Remission Induction | 2015 |
FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
Topics: Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Cytarabine; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Tandem Repeat Sequences; Transcription, Genetic; Transduction, Genetic | 2015 |
Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Synergism; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Female; Granulocyte Colony-Stimulating Factor; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Malate Dehydrogenase; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Salvage Therapy; Translocation, Genetic; Vidarabine | 2015 |
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Karyotype; Leukemia, Myeloid, Acute; Treatment Outcome | 2016 |
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Disease-Free Survival; Etoposide; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Induction Chemotherapy; International Cooperation; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Proto-Oncogene Proteins c-kit; ras Proteins; Retrospective Studies; Translocation, Genetic; Transplantation, Homologous; Treatment Outcome | 2015 |
Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Neoplastic Stem Cells | 2016 |
Interactions Between Nutraceutical Supplements and Standard Acute Myeloid Leukemia Chemotherapeutics.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cytarabine; Daunorubicin; Dietary Supplements; Drug Interactions; Humans; Leukemia, Myeloid, Acute; U937 Cells | 2015 |
Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1).
Topics: Animals; Anthracyclines; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Cytidine Deaminase; DNA, Complementary; Gene Expression Regulation, Leukemic; Gene Transfer Techniques; Genetic Vectors; Hematopoietic Stem Cells; Humans; Lentivirus; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; RNA Splice Sites | 2015 |
Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cohort Studies; Cytarabine; DNA; Female; Genetic Linkage; Genetic Variation; Humans; Leukemia, Myeloid, Acute; Liver-Specific Organic Anion Transporter 1; Male; Mice; Mice, Knockout; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2016 |
The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; China; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-kit; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
[Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion].
Topics: Aged, 80 and over; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Remission Induction | 2015 |
[Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Topics: Cyclophosphamide; Cytarabine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Recurrence; Remission Induction; Transplantation, Homologous; Transplants; Whole-Body Irradiation | 2015 |
Cerebral embolism through hematogenous dissemination of pulmonary mucormycosis complicating relapsed leukemia.
Topics: Aged; Autopsy; Cytarabine; Fatal Outcome; Female; Humans; Injections, Spinal; Intracranial Embolism; Invasive Pulmonary Aspergillosis; Leukemia, Myeloid, Acute; Lung; Methotrexate; Mucormycosis | 2015 |
[Infliximab therapy for Crohn's-like gastrointestinal lesions after allogeneic bone marrow transplantation].
Topics: Bone Marrow Transplantation; Cytarabine; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Infliximab; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation, Homologous | 2015 |
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
Topics: Adenine; Cytarabine; Daunorubicin; Leukemia, Myeloid, Acute; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Topics: Antimetabolites; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Cytarabine; Drug Delivery Systems; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Lipids; Polymers; Receptors, CXCR4; RNA, Small Interfering; Stromal Cells | 2016 |
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cohort Studies; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retreatment; Treatment Outcome | 2016 |
Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Time Factors; Treatment Failure; Young Adult | 2016 |
[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Retrospective Studies | 2015 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies | 2016 |
Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Topics: Adolescent; Adult; Anthracyclines; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; China; Consolidation Chemotherapy; Cytarabine; Female; Humans; Incidence; Infant; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prospective Studies; Survival Rate; Vidarabine; Young Adult | 2016 |
Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Cell Line; Cytarabine; Epithelial-Mesenchymal Transition; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Polycomb Repressive Complex 1; Prognosis; Twist-Related Protein 1 | 2015 |
ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression.
Topics: Animals; Biological Transport; Cell Death; Cell Line, Tumor; Child, Preschool; Cytarabine; Gene Knockdown Techniques; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Multidrug Resistance-Associated Proteins; Myeloid Progenitor Cells | 2016 |
Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Time Factors | 2016 |
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Virus Diseases | 2016 |
[Clinic Outcome of FLAG Regimen treating Patients with Refractory and Relapse Acute Myeloid Leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2016 |
Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance.
Topics: Antimetabolites, Antineoplastic; Autophagy; Blotting, Western; Cytarabine; Drug Resistance, Neoplasm; Genes, Reporter; Green Fluorescent Proteins; Humans; Hydroxychloroquine; Leukemia, Myeloid, Acute; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Microtubule-Associated Proteins; U937 Cells | 2016 |
Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oncogene Proteins, Fusion; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Survival Rate; Translocation, Genetic; Young Adult | 2016 |
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Topics: Cytarabine; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
[Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
Wernicke's Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Thiamine; Vidarabine; Wernicke Encephalopathy | 2016 |
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2016 |
[Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].
Topics: Aclarubicin; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Nucleophosmin; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Guideline Adherence; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Practice Guidelines as Topic | 2016 |
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Bone Marrow Cells; Cell Line; Cell Proliferation; Cytarabine; Disease Models, Animal; Drug Combinations; Drug Synergism; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Mice; Monocytes; Primary Cell Culture; Signal Transduction; Survival Analysis; Valproic Acid | 2016 |
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Interleukin-2; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Thalidomide | 2016 |
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
Topics: Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Protein Stability; Sulfonamides | 2016 |
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Vidarabine; Young Adult | 2016 |
Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine Kinase; Doxorubicin; Equilibrative Nucleoside Transporter 1; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Evaluation of artemisinins for the treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Survival; Cytarabine; High-Throughput Screening Assays; Humans; Leukemia, Myeloid, Acute; Lysosomes; Mice, Inbred Strains; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |
Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Daunorubicin; Echinocandins; Febrile Neutropenia; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipopeptides; Male; Micafungin; Middle Aged; Mycoses; Prospective Studies; Young Adult | 2016 |
The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts.
Topics: Abietanes; Adult; Aged; Aged, 80 and over; Apoptosis; Bcl-2-Like Protein 11; Cytarabine; Drug Synergism; Ergocalciferols; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, Calcitriol; RNA Interference; Tumor Cells, Cultured; U937 Cells | 2016 |
[Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia].
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thrombocytopenia; Topotecan; Young Adult | 2016 |
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib; Treatment Outcome | 2016 |
CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2016 |
Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Cytarabine; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2016 |
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Remission Induction | 2016 |
Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Middle Aged; Renal Dialysis | 2016 |
Granulocyte infusion: benefit beyond neutrophils?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Middle Aged; Pulmonary Aspergillosis | 2016 |
AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Biomimetic Materials; Cell Adhesion; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cyclams; Cytarabine; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Leukemia, Myeloid, Acute; Polystyrenes; Receptor Cross-Talk; Receptors, CXCR4; Stromal Cells | 2016 |
[Role of Rheb in Human Acute Myeloid Leukemia].
Topics: Adult; Apoptosis; Bone Marrow; Cytarabine; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Monomeric GTP-Binding Proteins; Neuropeptides; Ras Homolog Enriched in Brain Protein; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spleen | 2016 |
[Comparison of Curative Effects of HAG and CAG Regimens for Patients with AML and Medium/High-Risk MDS].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Remission Induction | 2016 |
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Cytarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Oxidative Stress; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Reactive Oxygen Species; Signal Transduction; Thiazolidines; Topoisomerase II Inhibitors | 2016 |
Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Real-Time Polymerase Chain Reaction; Recurrence; Remission Induction; Retrospective Studies; Sequence Analysis, DNA | 2016 |
Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Cytarabine; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondrial Proteins; Mutation; NF-kappa B; Nucleophosmin; Receptors, Tumor Necrosis Factor, Type I; Signal Transduction; Treatment Outcome; Young Adult | 2016 |
Successful Cytoreduction with CAG (cytarabine, Aclarubicin and G-CSF) Therapy in Refractory Acute Myelogenous Leukemia before Allogeneic Stem Cell Transplantation.
Topics: Aclarubicin; Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Peripheral Blood Stem Cell Transplantation; Remission Induction | 2001 |
[A Case of a Multidisciplinary Team Approach to Serious Hand-Foot Syndrome Induced by High-Dose Cytarabine Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Erythema; Female; Hand-Foot Syndrome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Patient Care Team; Treatment Outcome | 2016 |
Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Self Renewal; Cell Transformation, Neoplastic; Cytarabine; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Profiling; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Copper-Transporting ATPases; Cytarabine; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Phosphorylation; RNA, Small Interfering; Signal Transduction | 2016 |
The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies | 2016 |
Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Cytarabine; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplastic Stem Cells; Signal Transduction | 2016 |
Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Pilot Projects; Remission Induction; Risk; Young Adult | 2016 |
Severe palmar-plantar erythrodysesthesia and aplasia in an adult undergoing re-induction treatment with high-dose cytarabine for acute myelogenous leukemia: a possible drug interaction between posaconazole and cytarabine.
Topics: Cytarabine; Drug Interactions; Erythema; Female; Hand-Foot Syndrome; Humans; Leukemia, Myeloid, Acute; Triazoles; Young Adult | 2017 |
[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Young Adult | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
[High-intensity chemotherapy versus palliative chemotherapy in patients over 60 years with acute myeloid leukemia].
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Palliative Care; Retrospective Studies; Treatment Outcome | 2016 |
Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cytarabine; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorescein; Fluorescent Dyes; Heterocyclic Compounds, 4 or More Rings; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Small Molecule Libraries; Spectrometry, Fluorescence; Tetrazoles; Tumor Cells, Cultured | 2016 |
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cause of Death; Clofarabine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 2017 |
BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents.
Topics: Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Cytarabine; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins B-raf; Signal Transduction; Vitamin D | 2017 |
Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Topics: Adult; Aged; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction | 2017 |
AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Benzothiazoles; Cytarabine; Disease Models, Animal; DNA Mutational Analysis; fms-Like Tyrosine Kinase 3; Gene Duplication; Genotype; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Tandem Repeat Sequences; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Safety; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential.
Topics: Animals; Cell Line, Tumor; Cytarabine; Drug Synergism; Fructose; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glucose Transporter Type 5; Humans; Leukemia, Myeloid, Acute; Mannitol; Mice; Prognosis; Treatment Outcome; Up-Regulation | 2016 |
Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Gene Silencing; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Mice; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Microenvironment | 2017 |
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cytarabine; Dacarbazine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Iodobenzenes; Leukemia, Myeloid, Acute; Male; Paraganglioma; Radiation Tolerance; Temozolomide | 2017 |
Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
Topics: Animals; Base Sequence; Cell Line; Clone Cells; Clustered Regularly Interspaced Short Palindromic Repeats; Cytarabine; Deoxycytidine Kinase; Dexamethasone; DNA, Complementary; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gene Library; Genetic Loci; Genetic Testing; Genome, Human; Glucocorticoids; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mice; Mutation; Prednisolone; Receptors, Glucocorticoid; Reproducibility of Results; RNA, Guide, Kinetoplastida; U937 Cells | 2016 |
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Topics: Adult; Cytarabine; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Young Adult | 2017 |
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Thioguanine; Tumor Suppressor Protein p53 | 2017 |
NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
Topics: Animals; Cell Line, Tumor; Cytarabine; DNA (Cytosine-5-)-Methyltransferase 1; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Polycomb Repressive Complex 1; Sorafenib | 2016 |
NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Daunorubicin; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Mutation; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Prednisone; Prognosis; Translocation, Genetic; Up-Regulation; Vincristine | 2017 |
Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Prognosis; Survival Analysis | 2017 |
Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity.
Topics: Aniline Compounds; Antimetabolites, Antineoplastic; Benzodiazepinones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cytarabine; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 7; Phosphorylation; Proto-Oncogene Proteins c-bcl-2 | 2017 |
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Blotting, Western; Bortezomib; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin-Dependent Kinases; Cytarabine; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Homeodomain Proteins; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Immunoprecipitation; Indoles; Leukemia, Myeloid, Acute; Male; Mass Spectrometry; Mice; Middle Aged; Neoplasm Transplantation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proteomics; Pyridones; Young Adult | 2017 |
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Melphalan; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phenylalanine; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Communication; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Lysosomes; Male; Microscopy, Fluorescence; Middle Aged; Nanotubes; NF-kappa B; Signal Transduction; THP-1 Cells; Tumor Cells, Cultured | 2017 |
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Disease Models, Animal; Female; Flow Cytometry; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Male; Middle Aged; Monomeric GTP-Binding Proteins; Prognosis; Retrospective Studies; SAM Domain and HD Domain-Containing Protein 1; Young Adult | 2017 |
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
[Analysis of Therapy and Efficacy after Remission of Acute Myeloid Leukemia].
Topics: Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2016 |
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; Cell Cycle; Checkpoint Kinase 1; Cytarabine; Daunorubicin; DNA Damage; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Rad51 Recombinase; RNA Interference; Signal Transduction; THP-1 Cells; Transfection | 2017 |
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.
Topics: Amino Acid Motifs; Base Sequence; Cytarabine; fms-Like Tyrosine Kinase 3; Gene Expression; Genetic Variation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Domains; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Tandem Repeat Sequences | 2017 |
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Disease Models, Animal; Female; Humans; In Vitro Techniques; Infant; Leukemia, Myeloid, Acute; Male; Mice; Molecular Targeted Therapy; Monomeric GTP-Binding Proteins; Prognosis; SAM Domain and HD Domain-Containing Protein 1; Viral Regulatory and Accessory Proteins | 2017 |
De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
Topics: Antimetabolites, Antineoplastic; Bone Marrow; Bone Marrow Cells; Case-Control Studies; Cell Line; Cell Proliferation; Cellular Microenvironment; Chemotaxis; Cytarabine; Cytokines; Female; Gene Expression Regulation; Gene Silencing; Humans; Immunomodulation; Leukemia, Myeloid, Acute; Male; MicroRNAs; Mitogen-Activated Protein Kinases; Myelodysplastic Syndromes; NF-kappa B; RNA Interference; Signal Transduction; T-Lymphocyte Subsets; Tumor Microenvironment | 2017 |
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Topics: Antibodies; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclodextrins; Cytarabine; Down-Regulation; Humans; K562 Cells; Leukemia, Myeloid, Acute; Nanoparticles; Neoplastic Stem Cells; Receptors, Interleukin-3; RNA, Small Interfering; Transcription Factors | 2017 |
Monkey business: Repurposing a protein from the simian immunodeficiency virus to enhance cytotoxic chemotherapy.
Topics: Animals; Cytarabine; Hematologic Neoplasms; Leukemia, Myeloid, Acute; SAM Domain and HD Domain-Containing Protein 1; Simian Immunodeficiency Virus | 2017 |
Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.
Topics: Bone Marrow; Bone Marrow Cells; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Humans; Leukemia, Myeloid, Acute; Patient Outcome Assessment; Stromal Cells | 2017 |
Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Proliferation; Child; Cytarabine; Drug Combinations; Drug Interactions; Drug Synergism; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Morpholines; Prognosis; Pyrimidines; Tumor Cells, Cultured; Young Adult | 2017 |
Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Histocompatibility; HLA Antigens; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation | 2017 |
Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target.
Topics: Adult; Aged; Aged, 80 and over; Animals; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Neoplastic Stem Cells; Receptors, Serotonin, 5-HT1; Serotonin Antagonists; Young Adult | 2017 |
OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.
Topics: Animals; Antimetabolites, Antineoplastic; Child; CHO Cells; Cohort Studies; Cricetulus; Cytarabine; Deoxycytidine; Dipyridamole; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; HEK293 Cells; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Organic Cation Transport Proteins; Symporters | 2017 |
Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mortality; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Core Binding Factors; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Japan; Leukemia, Myeloid, Acute; Mitoxantrone; Proto-Oncogene Proteins c-kit; Recurrence; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2017 |
Clofarabine-based consolidation therapy in AML.
Topics: Adenine Nucleotides; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Disease Progression; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Young Adult | 2017 |
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Bone Marrow; Cell Line, Tumor; Cytarabine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Nanoparticles; Organophosphates; Polyploidy; Protein Kinase Inhibitors; Quinazolines; Rats; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Topics: Cell Count; Cell Death; Cell Survival; Cyclopentanes; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines | 2017 |
Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.
Topics: ADP-ribosyl Cyclase 1; Antigens, CD34; Cell Line, Tumor; Cell Survival; Cytarabine; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Neoplastic Stem Cells; Phenotype; Receptors, Interleukin-3; Tyrphostins | 2008 |
[HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2008 |
Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.
Topics: Adult; Bone Marrow; Cytarabine; Humans; Kinetics; Leukemia, Myeloid, Acute; Probability; Remission Induction | 2008 |
Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Burkitt Lymphoma; Cerebrospinal Fluid; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Liposomes; Male; Middle Aged; Remission Induction; Reproducibility of Results | 2008 |
Induction therapy for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Female; Health Services for the Aged; Humans; Leukemia, Myeloid, Acute; Male | 2008 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
Topics: Acrylonitrile; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow; Cell Differentiation; Cell Proliferation; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Point Mutation; Signal Transduction; Styrenes; Tissue Distribution; Tumor Cells, Cultured | 2008 |
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Busulfan; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Prognosis; Proportional Hazards Models; Statistics, Nonparametric | 2008 |
Localized small-bowel infarction caused by Aspergillus during chemotherapy for acute myeloid leukemia: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Cytarabine; Humans; Ileal Diseases; Immunocompromised Host; Intestinal Perforation; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 2008 |
Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
Topics: Adolescent; Adrenal Cortex Hormones; Antimetabolites, Antineoplastic; Cytarabine; Dexamethasone; Female; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Liposomes; Male; Papilledema; Remission Induction | 2008 |
Relapse of acute myeloid leukemia as isolated bilateral testicular granulocytic sarcoma in an adult.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Orchiectomy; Recurrence; Remission Induction; Sarcoma, Myeloid; Testicular Neoplasms | 2008 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning | 2009 |
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2008 |
Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Folliculitis; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sweet Syndrome | 2008 |
[The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2008 |
Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cytarabine; Down-Regulation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Ligands; Signal Transduction; Up-Regulation | 2009 |
Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Cohort Studies; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Liposomes; Lymphoma; Male; Meningitis; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Transplantation, Homologous | 2008 |
Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Drug Evaluation; Epidemiologic Methods; Female; Gemtuzumab; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Treatment Outcome | 2008 |
Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.
Topics: 5'-Nucleotidase; Alleles; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gene Expression; Gene Expression Regulation, Neoplastic; Glycoproteins; Heterozygote; Homozygote; Humans; Leukemia, Myeloid, Acute; Polymorphism, Single Nucleotide; Tumor Suppressor Protein p53 | 2008 |
[Loeys-Dietz syndrome with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Marfan Syndrome; Middle Aged; Mutation, Missense; Receptors, Transforming Growth Factor beta; Remission Induction; Translocation, Genetic | 2008 |
The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 2009 |
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Databases, Factual; Emergency Medical Services; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Remission Induction; Risk Factors; Survival Analysis; Time Factors; Young Adult | 2009 |
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Cytarabine; Female; Half-Life; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Male; Middle Aged; Neurotoxicity Syndromes | 2008 |
Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epoxy Compounds; Humans; I-kappa B Proteins; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Phenanthrenes; X-Linked Inhibitor of Apoptosis Protein | 2008 |
[Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2008 |
Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Injections, Spinal; Leukemia, Myeloid, Acute; Liposomes; Longitudinal Studies; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Registries; Spain | 2008 |
Human leukocyte antigen-DR negative de novo acute myeloid leukemia with Philadelphia chromosome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Philadelphia Chromosome; Remission Induction | 2008 |
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Case-Control Studies; Child; Child, Preschool; Cytarabine; Cytosine Deaminase; Ethnicity; Genotype; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Survival Rate; Young Adult | 2009 |
[Granulocytic sarcoma of the prostate presenting with urinary obstruction which progressed to acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Dysuria; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Remission Induction; Sarcoma, Myeloid | 2008 |
Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 2008 |
[Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Topics: Antimetabolites, Antineoplastic; Child; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Gene Expression; Humans; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2008 |
Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Fatal Outcome; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Mitoxantrone; Oncogene Proteins, Fusion; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic | 2009 |
Inappropriate antidiuretic hormone production by leukaemic blasts in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Cytarabine; Fatty Liver; Female; Granulocyte Precursor Cells; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Liver; Tomography, X-Ray Computed; Vasopressins | 2009 |
The effect of cantharidins on leukemic stem cells.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Arylamine N-Acetyltransferase; Basic-Leucine Zipper Transcription Factors; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Caspases; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Enzyme Inhibitors; Female; Fetal Blood; Humans; Leukemia, Myeloid, Acute; Luminescence; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Phosphorylation; Proto-Oncogene Proteins c-myc; Snail Family Transcription Factors; STAT5 Transcription Factor; Stromal Cells; Survival Rate; Transcription Factors; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2009 |
Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Cohort Studies; Comorbidity; Cytarabine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Wnt Proteins | 2009 |
Life-threatening conjunctival presentation of myeloid sarcoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Conjunctival Neoplasms; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Sarcoma, Myeloid; Skin Neoplasms | 2008 |
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Factor VIIa; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Recombinant Proteins; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Acute myelogenous leukemia presenting as acute infectious meningitis in a 7-year-old boy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Ceftriaxone; Child; Chromosomes, Human, Pair 10; Cytarabine; Daunorubicin; Diagnosis, Differential; Escherichia coli Infections; Etoposide; Flow Cytometry; Gemtuzumab; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Meningitis, Bacterial; Patient Transfer; Spinal Puncture; Trisomy | 2009 |
Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome.
Topics: Cytarabine; Diphenhydramine; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Immunosuppressive Agents; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Methylprednisolone; Premedication; Ranitidine; Syndrome; Treatment Outcome | 2009 |
Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxins; Cytarabine; Daunorubicin; Electrocardiography; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Monitoring, Physiologic | 2009 |
[Relapsed acute myeloid leukemia with Down syndrome showing long disease-free survival after bone marrow transplantation].
Topics: Adolescent; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Chromosomes, Human, Pair 7; Cytarabine; Disease-Free Survival; Down Syndrome; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Male; Monosomy; Mutation; Recurrence; Remission Induction; Risk; Time Factors | 2009 |
Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytarabine; Deoxycytidine Kinase; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Models, Biological; Oligonucleotide Array Sequence Analysis; Phenotype | 2009 |
Auto-SCT for AML in second remission: CALGB study 9620.
Topics: Adult; Aged; Aging; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ideal Body Weight; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation, Autologous; Treatment Outcome; Treatment Refusal; Young Adult | 2009 |
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
Topics: Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Line, Tumor; Chromatography, Liquid; Cytarabine; Humans; Leukemia; Leukemia, Myeloid, Acute; Linear Models; Nucleotides; Oligodeoxyribonucleotides; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Cytarabine-associated lymphoid dyscrasia with atypical T CD30+ infiltrate in a patient suffering from acute nonlymphoblastic leukaemia.
Topics: Chronic Disease; Cytarabine; Female; Humans; Immunosuppressive Agents; Ki-1 Antigen; Leukemia, Myeloid, Acute; Middle Aged; Skin Diseases | 2009 |
Laromustine: the return of alkylators to non-myeloablative therapy of AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cytarabine; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies | 2009 |
Severe Henoch-Schönlein purpura induced by cytarabine.
Topics: Adult; Cytarabine; Humans; IgA Vasculitis; Leukemia, Myeloid, Acute; Male; Severity of Illness Index | 2009 |
Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Topics: 5'-Nucleotidase; Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Predictive Value of Tests; RNA, Messenger | 2009 |
An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma.
Topics: Antineoplastic Agents; Cytarabine; Female; Humans; Idarubicin; Intestinal Obstruction; Intestine, Small; Leukemia, Myeloid, Acute; Middle Aged; Sarcoma, Myeloid; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Survival Analysis; Translocation, Genetic | 2009 |
pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
Topics: Acrylamides; Acrylic Resins; Alkylation; Antibodies, Monoclonal; Antibody Affinity; Antibody Specificity; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biological Availability; Cell Line, Tumor; Cell Survival; Cold Temperature; Cytarabine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Stability; Endocytosis; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Immunoconjugates; Leukemia, Myeloid, Acute; Liposomes; Polymethacrylic Acids; Sialic Acid Binding Ig-like Lectin 3 | 2009 |
Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Blast Crisis; Blotting, Western; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Young Adult | 2009 |
SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nucleoside Deaminases; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Myeloid disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders | 2009 |
Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Harringtonines; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Young Adult | 2009 |
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2009 |
Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.
Topics: Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Cytarabine; DNA Damage; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; Histones; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases | 2009 |
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.
Topics: Animals; Antifungal Agents; Antimetabolites, Antineoplastic; Apoptosis; Cells, Cultured; Ciclopirox; Cytarabine; Drug Synergism; Electron Spin Resonance Spectroscopy; Fibroblasts; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Luciferases; Lung; Mice; Mice, Inbred NOD; Mice, SCID; Microtubule-Associated Proteins; Multiple Myeloma; Promoter Regions, Genetic; Pyridones; Ribonucleotide Reductases; Survivin | 2009 |
Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Transplantation, Homologous | 2009 |
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Proliferation; Cytarabine; Daunorubicin; Drug Synergism; Flow Cytometry; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines | 2009 |
A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Drug Administration Schedule; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis | 2009 |
Acute myeloid leukemia and Langerhans' cell histiocytosis: multiple theories for an unusual presentation.
Topics: Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 8; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Trisomy | 2010 |
Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Multiple Myeloma; Remission Induction; Thioguanine | 2009 |
Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Cytarabine; Cytotoxins; Daunorubicin; Drug Evaluation, Preclinical; Drug Synergism; Etoposide; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Models, Biological; Nitrophenols; Peptide Initiation Factors; Piperazines; Protein Biosynthesis; Protein Synthesis Inhibitors; Sulfonamides; Triterpenes; U937 Cells | 2010 |
A new pattern of cytosine-arabinoside-induced lung toxicity.
Topics: Adult; Alveolitis, Extrinsic Allergic; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tomography, X-Ray Computed; Young Adult | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Successful treatment of congenital acute myeloid leukemia (AML-M6) in a premature infant.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Remission Induction | 2009 |
Severe anterior uveitis as a complication of high-dose cytosine-arabinoside.
Topics: Administration, Topical; Adult; Antimetabolites, Antineoplastic; Cytarabine; Dexamethasone; Drug Administration Schedule; Female; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Mydriatics; Uveitis, Anterior | 2009 |
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2009 |
Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Cryoelectron Microscopy; Cytarabine; Down-Regulation; Drug Delivery Systems; Genetic Therapy; Humans; Hydrogen-Ion Concentration; K562 Cells; Leukemia, Myeloid, Acute; Nanoparticles; Oligodeoxyribonucleotides; Oligodeoxyribonucleotides, Antisense; Receptors, Transferrin; Ribonucleotide Reductases; RNA, Messenger; RNA, Neoplasm; Transferrin; Tumor Cells, Cultured | 2010 |
FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytarabine; Down-Regulation; Equilibrative Nucleoside Transporter 1; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Promoter Regions, Genetic | 2009 |
Successful treatment of Hodgkin lymphoma and acute leukemia.
Topics: Adult; Biopsy; Bone Marrow Cells; Cytarabine; Hodgkin Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Remission Induction | 2010 |
Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cell Cycle; Cell Survival; Cytarabine; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Time Factors | 2009 |
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cellular Senescence; Cytarabine; Daunorubicin; Etoposide; Genes, ras; Humans; Leukemia, Myeloid, Acute; Mutation; ras Proteins; Tumor Suppressor Protein p53 | 2009 |
Molecular identification of phaeohyphomycosis due to Alternaria infectoria in a patient with acute myeloid leukemia--a case report.
Topics: Adolescent; Alternaria; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Mycoses; Nasal Cavity; Polymerase Chain Reaction; Rhinitis; Vidarabine | 2010 |
Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Recurrence; Time Factors; Translocation, Genetic | 2010 |
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine | 2009 |
Mees lines and Beau lines after chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytarabine; Daunorubicin; Docetaxel; Female; Humans; Leukemia, Myeloid, Acute; Nail Diseases; Taxoids | 2010 |
Multiple hepatocellular carcinomas developed 15 months after commencement of chemotherapy for elderly acute myelogenous leukemia.
Topics: Aclarubicin; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cytarabine; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Hemochromatosis; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Time Factors | 2009 |
"I am older, not elderly," said the patient with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mercaptopurine | 2010 |
Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Republic of Korea; Retrospective Studies; Survival Analysis; Thioguanine; Young Adult | 2010 |
Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Male; Meninges; Middle Aged; Mitoxantrone; Testis; Young Adult | 2010 |
Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Digestive System Surgical Procedures; Enterococcus faecium; Fatal Outcome; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mucormycosis; Neutropenia; Rhinitis; Shock, Septic; Sinusitis; Typhlitis | 2010 |
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides | 2010 |
Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence | 2010 |
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Female; Genes, Wilms Tumor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Time Factors; Transcription, Genetic; Treatment Outcome; WT1 Proteins; Young Adult | 2010 |
Brucellosis: a rare cause of febrile neutropenia in acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brucellosis; Cytarabine; Diagnosis, Differential; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neutropenia; Prognosis; Remission Induction | 2011 |
[Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Erythroblasts; Female; Humans; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Mitoxantrone; Remission Induction; Survival Rate | 2010 |
Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Stem Cell Transplantation; Survival Rate; Young Adult | 2010 |
Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.
Topics: Adult; Aged; Animals; Azo Compounds; Cells, Cultured; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycogen Synthase Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Middle Aged; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; RNA, Small Interfering; Stem Cells | 2010 |
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Toxic shock syndrome caused by hospital-acquired methicillin-resistant Staphylococcus aureus in a patient with pancytopenia.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Methicillin-Resistant Staphylococcus aureus; Multiple Organ Failure; Pancytopenia; Shock, Septic; Staphylococcal Infections | 2010 |
[Distribution of WHO subtypes, initial treatment outcomes and prognosis study of 623 unselected adult patients with acute myeloid leukaemia in Shanghai.].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Treatment Outcome | 2010 |
Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Corneal Diseases; Cytarabine; Epithelium, Corneal; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Microscopy, Confocal; Middle Aged; Models, Biological; Prospective Studies | 2010 |
Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Flavonoids; Follow-Up Studies; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Risk; Treatment Outcome; Tumor Lysis Syndrome | 2010 |
Orbital mass as a presenting sign of acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Orbital Neoplasms | 2010 |
Central line-associated bacteremia caused by drug-resistant Staphylococcus caprae after chemotherapy for acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Staphylococcus | 2010 |
Neurological complications during treatment of childhood cancer: mind Wernicke encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Mercaptopurine; Methotrexate; Prednisone; Radiography; Vincristine; Wernicke Encephalopathy | 2010 |
Advances in the management of acute myeloid leukemia in older adult patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Practice Guidelines as Topic; Prognosis; Quality of Life; Social Support; Stem Cell Transplantation | 2010 |
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Cell Line; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Cytarabine; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Drug Resistance; Female; HCT116 Cells; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombination, Genetic; Sister Chromatid Exchange; Young Adult | 2010 |
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Leukemia cutis limited to the needle puncture sites.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cytarabine; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Skin Neoplasms | 2010 |
Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytarabine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Leukemia, Myeloid, Acute; Mice | 2010 |
Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antibodies, Viral; Antigens, Viral; Antineoplastic Agents; Antiviral Agents; Cytarabine; Cytomegalovirus; Cytomegalovirus Infections; Daunorubicin; Female; Humans; Hydroxyurea; Incidence; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Monitoring, Physiologic; Phosphoproteins; Treatment Outcome; Viral Matrix Proteins; Young Adult | 2010 |
Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Child; Child, Preschool; Cytarabine; Cytokines; Daunorubicin; Drug Resistance, Neoplasm; Elafin; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinases; Prognosis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Remission Induction; RNA, Messenger; Signal Transduction; Young Adult | 2009 |
[Prognostic factors and therapeutic strategies for acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis | 2010 |
Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe.
Topics: Apoptosis; Aurora Kinases; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Cytarabine; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Mitochondria; Mitosis; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Transfection | 2010 |
Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteria; Blood; Cytarabine; Female; Finland; Humans; Idarubicin; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Prospective Studies; Sepsis; Thioguanine; Young Adult | 2010 |
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheterization; Cytarabine; Female; Hospital Mortality; Hospitalization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Admission; Quality of Health Care; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy.
Topics: Adrenal Insufficiency; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hydrocortisone; Immunosuppressive Agents; Injections, Spinal; Leukemia, Myeloid, Acute; Methotrexate; Recurrence | 2010 |
Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Trisomy; Young Adult | 2010 |
An unusual case of acute myeloid leukemia: late isolated testicular relapse followed by isolated central nervous system relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Cytarabine; Daunorubicin; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Testicular Neoplasms; Thioguanine; Treatment Outcome | 2010 |
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2.
Topics: Chromosome Aberrations; Cytarabine; Daunorubicin; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Middle Aged; Translocation, Genetic | 2010 |
Questions regarding frontline therapy of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Retreatment | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Systemic mastocytosis associated with acute myeloid leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Cells; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mast Cells; Mastocytosis, Systemic | 2010 |
Acute intraoperative tumour lysis syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Postoperative Complications; Risk Factors; Time Factors; Tumor Lysis Syndrome | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Risk Factors; Survival Rate | 2010 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Race and intensity of post-remission therapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black People; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Time Factors; Treatment Outcome; White People; Young Adult | 2011 |
Extramedullary tumors presenting double vision in patients with t(8;21)(q22;q22) acute myeloid leukemia lacking mutations in the receptor tyrosine kinase genes KIT or FLT3.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blast Crisis; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Diplopia; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Paranasal Sinus Neoplasms; Proto-Oncogene Proteins c-kit; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous | 2010 |
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2010 |
FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Ulcerated plaque under a ruby ring in an immunosuppressed patient.
Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Candida; Candidiasis, Cutaneous; Clofarabine; Cytarabine; Dermatologic Agents; Dermatomycoses; Fusarium; Humans; Immunocompromised Host; Itraconazole; Jewelry; Leukemia, Myeloid, Acute; Male; Pyrimidines; Skin Ulcer; Treatment Outcome; Triazoles; Voriconazole | 2010 |
[A case of del(16)(q22) in a patient with acute myeloid leukemia with complex karyotype].
Topics: Antimetabolites, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Monocyte-Macrophage Precursor Cells; Prognosis | 2010 |
Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cytarabine; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Survival Rate; Treatment Outcome; Young Adult | 2011 |
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Trans-Activators; Transcriptional Regulator ERG; Treatment Outcome | 2010 |
Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Gene Expression Profiling; Humans; I-kappa B Proteins; Leukemia, Myeloid, Acute; Lymphocytes; Oligonucleotide Array Sequence Analysis; Pyrimidines | 2011 |
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure; Young Adult | 2010 |
Dorsolateral midbrain MRI abnormalities and ocular motor deficits following cytarabine-based chemotherapy for acute myelogenous leukemia.
Topics: Antimetabolites, Antineoplastic; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Mesencephalon; Ocular Motility Disorders; Time | 2011 |
Anterior uveitis associated with high-dose cytosine arabinoside.
Topics: Adolescent; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Prednisolone; Treatment Outcome; Uveitis, Anterior | 2010 |
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
Topics: Apoptosis; Caspase 3; Caspase 9; Cytarabine; DNA Damage; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Male; Structure-Activity Relationship; Tumor Cells, Cultured; Valproic Acid | 2010 |
A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
Topics: Antimetabolites, Antineoplastic; Biosensing Techniques; Bone Marrow Cells; Cell Line, Tumor; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Escherichia coli; Humans; Intracellular Space; Leukemia, Myeloid, Acute; Luminescent Measurements; Mutation; Nucleoside Deaminases; Phosphorylation | 2010 |
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cytarabine; Cytosine; Daunorubicin; Etoposide; Female; Flavonoids; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Vidarabine; Young Adult | 2011 |
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Staging; Recurrence; Retrospective Studies; Risk; Salvage Therapy; Treatment Outcome; Young Adult | 2011 |
Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Nitrosourea Compounds; Treatment Outcome | 2010 |
Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
Topics: Adult; Antifungal Agents; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Female; Fluconazole; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Neutropenia; Racial Groups; Reproducibility of Results; Risk Assessment | 2010 |
Salvaging AML with CLAG: novel option, or more of the same?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine | 2011 |
Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs.
Topics: Adult; Aged; Ambulatory Care; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Opportunistic Infections; Patient Discharge; Patient Readmission; Retrospective Studies; Young Adult | 2010 |
New agents in post-remission therapy.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous | 2010 |
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Germany; Humans; Internet; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Predictive Value of Tests; Prognosis; Regression Analysis; Remission Induction; Risk Assessment; Risk Factors; Surveys and Questionnaires; Time Factors | 2010 |
The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Topics: Apoptosis; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytarabine; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Deletion; Genes, p53; Humans; Lethal Dose 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Naphthyridines; Thiazoles; Topoisomerase II Inhibitors | 2011 |
The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells.
Topics: Apoptosis; Cytarabine; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction | 2010 |
Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
Topics: Adult; Aminopeptidases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cytarabine; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Cells, Cultured; Young Adult | 2011 |
Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, CXCR4; Recurrence | 2011 |
Acquired protein C deficiency in a child with acute myelogenous leukemia, splenic, renal, and intestinal infarction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cholecystectomy; Cytarabine; Etoposide; Fibrin Fibrinogen Degradation Products; Fibrinogen; Gallbladder; Heparin, Low-Molecular-Weight; Humans; Idarubicin; Infarction; Kidney; Lebanon; Leukemia, Myeloid, Acute; Male; Protein C; Protein C Deficiency; Remission Induction; Splenectomy; Splenic Infarction; Thrombosis; Tretinoin | 2011 |
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle; Cells, Cultured; Cyclin-Dependent Kinases; Cytarabine; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxazoles; Phosphorylation; Thiazoles | 2011 |
[Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies | 2010 |
Images in clinical medicine. Palmar-plantar rash with cytarabine therapy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Erythema; Foot; Foot Dermatoses; Hand; Hand Dermatoses; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2011 |
C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice; Mice, Transgenic; Mutation; NIH 3T3 Cells; Oncogene Proteins, Fusion; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic | 2011 |
Blood consult: acute myeloid leukemia and the t(8;21)(q22;22).
Topics: Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Topics: Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Child; Cytarabine; Drug Synergism; Gene Knockdown Techniques; Histone Deacetylase 1; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; RNA, Small Interfering; Up-Regulation | 2011 |
Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2011 |
Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Female; Follow-Up Studies; Humans; Immunophenotyping; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
[The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Siblings presenting with progressive congenital aleukemic leukemia cutis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Siblings; Skin Neoplasms; Thioguanine | 2011 |
[FLAG regimen in the treatment of refractory and relapsed acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Comorbidity; Critical Care; Cytarabine; Decision Making; Humans; Leukemia, Myeloid, Acute; Risk Assessment; Survival Analysis; Sweden; Treatment Outcome; Validation Studies as Topic | 2011 |
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Networks and Pathways; Phenotype; Prognosis; Treatment Outcome; Young Adult | 2011 |
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clinical Trials, Phase II as Topic; Cytarabine; Drug Synergism; Eukaryotic Initiation Factor-4E; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Ribavirin; RNA Caps; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2011 |
What's up with down syndrome and leukemia-A lot!
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Doxorubicin; Female; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Survival Rate; Vincristine | 2011 |
A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Area Under Curve; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Theoretical; Remission Induction; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cytarabine; Disease Models, Animal; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tandem Mass Spectrometry; Time Factors; Transplantation, Heterologous; Treatment Outcome | 2011 |
Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Clinical Chemistry Tests; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Harringtonines; Hematologic Tests; Hepatitis B; Homoharringtonine; Humans; Infant; Leukemia, Myeloid, Acute; Liver Failure; Male; Pancreatitis; Remission Induction; Secondary Prevention | 2011 |
Smoking adversely affects survival in acute myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Smoking; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Utility of myeloperoxidase stain in the differential diagnosis of leukemia cutis vs. hystiocitoid Sweet syndrome.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Peroxidase; Skin; Skin Neoplasms; Staining and Labeling; Sweet Syndrome; Treatment Outcome | 2011 |
Treatment of acute myeloid leukemia in children: experience from a tertiary care hematology centre in India.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; India; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Stem Cell Transplantation | 2011 |
An inexpensive way to treat elderly patients with high-risk MDS or AML.
Topics: Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Treatment Outcome; Valproic Acid | 2011 |
Cytarabine dose for acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Monosomy; Regression Analysis; Survival Analysis; Treatment Outcome | 2011 |
Cytarabine dose for acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; fms-Like Tyrosine Kinase 3; Genes, Duplicate; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2011 |
Cytarabine dose for acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2011 |
Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Infections; Leukemia, Myeloid, Acute; Recurrence; Treatment Failure | 2011 |
Targeting PIM kinase activity significantly augments the efficacy of cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Drug Synergism; Humans; Imidazoles; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines | 2012 |
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Differentiation; Cytarabine; Decitabine; DNA Damage; Electrophoresis, Polyacrylamide Gel; Epigenesis, Genetic; Genes, p53; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Transplantation, Heterologous | 2011 |
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2011 |
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Topics: 5'-Nucleotidase; Antimetabolites, Antineoplastic; Base Sequence; Blotting, Western; Cell Line; Cell Line, Tumor; Child; Cytarabine; Cytosol; DNA; Electrophoretic Mobility Shift Assay; Exons; Genetic Variation; Humans; Leukemia, Myeloid, Acute; Luciferases; Methylation; Molecular Sequence Data; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors | 2011 |
Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Retrospective Studies; Transplantation, Homologous | 2012 |
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Risk Assessment; Risk Factors | 2012 |
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years.
Topics: Aged; Aged, 80 and over; Comorbidity; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis | 2012 |
Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Pancytopenia; Pyoderma Gangrenosum; Wound Healing | 2011 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Beau's lines.
Topics: Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Nail Diseases; Nails; Treatment Outcome | 2011 |
Therapy-related leukemia cutis with histopathologic changes resembling xanthogranuloma.
Topics: Adult; Biopsy, Needle; Cytarabine; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Granuloma; Humans; Immunohistochemistry; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemic Infiltration; Lymphoma, T-Cell; Risk Assessment; Xanthomatosis | 2011 |
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Young Adult | 2012 |
Prompt and definitive diagnosis of acute invasive Aspergillus rhinosinusitis in a patient with acute myeloid leukaemia using in situ hybridization: a case report.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Cytarabine; Humans; Idarubicin; In Situ Hybridization; Itraconazole; Leukemia, Myeloid, Acute; Male; Mycological Typing Techniques; Rhinitis; Sinusitis | 2012 |
Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?
Topics: Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cytarabine; Cytogenetic Analysis; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes; Leukocytosis; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome | 2011 |
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Remission Induction; Sorafenib; Survival Rate | 2011 |
Reversal of leukostasis-related pulmonary distress syndrome after leukapheresis and low-dose chemotherapy in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Male; Respiratory Distress Syndrome | 2011 |
Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML.
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Proportional Hazards Models; Risk Factors | 2012 |
Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk | 2011 |
Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cohort Studies; Cytarabine; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; RNA, Neoplasm | 2011 |
Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Reactive Oxygen Species | 2011 |
Is obesity a prognostic factor for acute myeloid leukemia outcome?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Clinical Trials, Phase I as Topic; Cytarabine; Databases, Factual; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Obesity; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Predictive Value of Tests; Prognosis; Retrospective Studies; Treatment Outcome; WT1 Proteins; Young Adult | 2011 |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents; Child; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factors; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Predictive Value of Tests; Recurrence; Translocation, Genetic; Treatment Outcome | 2011 |
Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Erythropoiesis; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Pancytopenia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Translocation, Genetic; Vincristine | 2012 |
Eccrine hidradenitis sine neutrophils: a toxic response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Eccrine Glands; Female; Hidradenitis; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Neutrophils; Staphylococcal Skin Infections; Staphylococcus epidermidis | 2011 |
Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.
Topics: Anthracyclines; Child; Child, Preschool; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Infant; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Myeloid-Lymphoid Leukemia Protein; Salvage Therapy; Treatment Outcome | 2012 |
Necrotic intramuscular chloroma with infection: magnetic resonance imaging features.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Child; Contrast Media; Cytarabine; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Gentamicins; Humans; Image Enhancement; Klebsiella Infections; Klebsiella pneumoniae; Leg; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Meropenem; Muscle Neoplasms; Necrosis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sarcoma, Myeloid; Teicoplanin; Thienamycins; Treatment Outcome | 2011 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis | 2012 |
Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Endostatins; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Prognosis; Salvage Therapy; Treatment Outcome | 2012 |
Acute isolated transmural neutropenic gastritis.
Topics: Acute Disease; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Daunorubicin; Factor VII Deficiency; Female; Furans; Gastritis; Granulocyte Colony-Stimulating Factor; Humans; Incidental Findings; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Pharmacogenomics of cytarabine in childhood leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Pharmacological; Child; Child, Preschool; Cytarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gene Expression Regulation, Leukemic; Genetic Variation; Humans; Infant; Leukemia, Myeloid, Acute; Signal Transduction | 2011 |
Diffuse osteosclerosis-associated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Middle Aged; Osteosclerosis; Remission Induction; Treatment Outcome | 2012 |
Evaluation of prognostic factors in AML. Preface.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Cytarabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Europe; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Prognosis; Survival Analysis; United States | 2011 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles | 2011 |
Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Tandem Repeat Sequences; WT1 Proteins | 2012 |
De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Mutation, Missense; Polycythemia Vera | 2012 |
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2012 |
Renaissance of autologous stem cell transplantation for AML?
Topics: Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male | 2012 |
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Retrospective Studies; Translocation, Genetic; Vidarabine | 2012 |
Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Posterior Leukoencephalopathy Syndrome; Young Adult | 2012 |
Cutaneous myeloid sarcoma presenting as grey pigmented macules.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 7; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Sarcoma, Myeloid; Skin; Skin Neoplasms; Skin Pigmentation; Translocation, Genetic; Treatment Outcome | 2012 |
Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Cycle Proteins; Cytarabine; Gene Expression Profiling; Genome, Human; Genomics; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Protein-Tyrosine Kinases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; S Phase; Tumor Cells, Cultured | 2012 |
Phospho-specific flow: fixating on the target.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Adolescent; Adult; Aged; Base Sequence; Case-Control Studies; Cell Line, Tumor; Cytarabine; Cytidine Deaminase; Drug Resistance, Neoplasm; Female; Gene Expression; Haplotypes; Humans; Introns; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Sequence Data; Polymorphism, Single Nucleotide; RNA, Messenger; U937 Cells; Young Adult | 2012 |
Nine years interval between first and second bone marrow transplantations and subsequent long-term survival--a case of acute myeloid leukemia with MLL-AF6 fusion gene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clone Cells; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Mercaptopurine; Myeloid-Lymphoid Leukemia Protein; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prednisolone; Recurrence; Remission Induction; Reoperation; Time Factors; Transplantation, Homologous; Vincristine | 2012 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Fatal Outcome; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Multiple Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor beta; Stem Cell Transplantation | 2012 |
FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Salvage Therapy; Survival Rate; Vidarabine | 2012 |
Myeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Retrospective Studies; Young Adult | 2012 |
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Aurora Kinase A; Aurora Kinases; Azepines; Bcl-2-Like Protein 11; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mice, SCID; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines; Xenograft Model Antitumor Assays | 2012 |
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Child; Child, Preschool; Clofarabine; Cytarabine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Infant; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured; Valproic Acid | 2012 |
Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Topics: Aclarubicin; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2012 |
Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Valproic Acid | 2012 |
Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cyclosporine; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Induction Chemotherapy; Karyotype; Leukemia, Myeloid, Acute; Lymphoid Progenitor Cells; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Statistics, Nonparametric; Young Adult | 2012 |
Bilateral ear swelling and erythema after chemotherapy: a case of ara-C ears.
Topics: Cytarabine; Ear Diseases; Ear, External; Edema; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2012 |
[GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Down Syndrome; Female; Follow-Up Studies; GATA1 Transcription Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Mosaicism; Mutation; Myelopoiesis; Myeloproliferative Disorders | 2012 |
Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Flow Cytometry; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin | 2012 |
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Genes, ras; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Proteomics; ras Proteins; Remission Induction; Retrospective Studies; Signal Transduction; Young Adult | 2012 |
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Topotecan | 2012 |
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine | 2013 |
[Percutaneous coronary intervention in a patient with acute myeloid leukemia].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Coronary Angiography; Cytarabine; Female; Heart Failure; Humans; Leukemia, Myeloid, Acute; Lymph Nodes; Middle Aged; Mitoxantrone; Mitral Valve Insufficiency; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Transfusion; Remission Induction; Stents; Thrombocytopenia | 2012 |
High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Cell Line, Tumor; Cytarabine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Poly-ADP-Ribose Binding Proteins; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome | 2012 |
Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Equilibrative Nucleoside Transporter 1; Humans; Leukemia, Myeloid, Acute; Mice; Stromal Cells; Tumor Cells, Cultured | 2012 |
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells.
Topics: Animals; Antineoplastic Agents; Cytarabine; Dopamine Antagonists; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Mefloquine; Mice; Neoplastic Stem Cells; Pluripotent Stem Cells; Pyrans; Thioridazine | 2012 |
Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Fungal; Etoposide; Fatal Outcome; Female; Fusariosis; Fusarium; Humans; Immunocompromised Host; Itraconazole; Leukemia, Myeloid, Acute; Mitoxantrone; Neutropenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Premedication; Pyrimidines; Recurrence; Salvage Therapy; Transplantation, Homologous; Triazoles; Voriconazole | 2013 |
Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Genome-Wide Association Study; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Republic of Korea; Survival Analysis; Young Adult | 2012 |
Be quick, but don't hurry.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male | 2012 |
Drug shortages delay cancer clinical trials.
Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Child; Clinical Trials as Topic; Clofarabine; Cytarabine; Daunorubicin; Drug Approval; Drug Industry; Drugs, Generic; Europe; Humans; Leukemia, Myeloid, Acute; National Cancer Institute (U.S.); Patient Selection; Survival Analysis; Time Factors; United States; United States Food and Drug Administration | 2012 |
Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Quality of Life; Treatment Outcome; Young Adult | 2012 |
Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cytarabine; Daunorubicin; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Hepatomegaly; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Multivariate Analysis; Muscle Proteins; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-bcl-2; Splenomegaly; Treatment Outcome; Up-Regulation; Young Adult | 2012 |
[Lethal pulmonary hemorrhage caused by Stenotrophomonas maltophilia pneumonia in a patient with acute myeloid leukemia].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fatal Outcome; Gram-Negative Bacterial Infections; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged; Pneumonia, Bacterial; Stenotrophomonas maltophilia | 2012 |
Acute myeloid leukaemia with abnormal eosinophil precursors without inversion 16.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Eosinophilia; Eosinophils; Granulocyte Precursor Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins, Fusion | 2012 |
Probable cytarabine-induced acral erythema: report of 2 pediatric cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Etoposide; Female; Hand-Foot Syndrome; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis | 2013 |
[Role of high-dose cytarabine as consolidation therapy for cytogenetically intermediate AML: a single center analysis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Treatment Outcome; Young Adult | 2012 |
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2012 |
[Genetic prognostic factors in childhood acute myeloid leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Cytarabine; DNA Mutational Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Genetic Markers; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Translocation, Genetic | 2012 |
Favorable outcome in a patient with vulvar mucormycosis during acute myeloid leukemia induction with medical management alone.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Mucormycosis; Vulvar Diseases | 2012 |
Successful importation of cytarabine into the United States during a critical national drug shortage.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Drug Approval; Drug Costs; Drug Industry; Humans; Informed Consent; International Cooperation; Leukemia, Myeloid, Acute; Minnesota; Organizational Case Studies; Pharmacy Service, Hospital; Risk Assessment; Switzerland; United States; United States Food and Drug Administration | 2012 |
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cytarabine; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines | 2012 |
Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Female; Gene Frequency; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Young Adult | 2012 |
Fatal palmar-plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Fatal Outcome; Hand-Foot Syndrome; Humans; Leukemia, Myeloid, Acute | 2012 |
[Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cytarabine; Female; Granisetron; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Retrospective Studies; Vomiting; Young Adult | 2012 |
Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Histiocytosis, Langerhans-Cell; Humans; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Palatine Tonsil; Remission Induction | 2013 |
Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Cytarabine; Disease Models, Animal; Doxorubicin; Gene Expression Regulation, Leukemic; Histones; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oncogene Proteins; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Trans-Activators; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Influence of chemotherapy on the lipid peroxidation and antioxidant status in patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cytarabine; Daunorubicin; Female; Glutathione Peroxidase; Humans; Leukemia, Myeloid, Acute; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Superoxide Dismutase | 2012 |
[Effects of IAT and MAT chemotherapeutic regimens in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Vidarabine; Young Adult | 2012 |
Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Cytarabine; Female; Genetic Loci; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Networks and Pathways; Middle Aged; Multilocus Sequence Typing; Polymorphism, Single Nucleotide; Treatment Outcome; Young Adult | 2013 |
[Comparative evaluation of CHAG and CAG priming regimen for treatment of refractory and relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Glutethimide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2012 |
[Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
Topics: Adolescent; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Transplantation, Homologous; Treatment Outcome | 2012 |
Gemtuzumab ozogamicin: time to resurrect?
Topics: Age Factors; Aged; Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Drug Approval; Gemtuzumab; Humans; Immunotoxins; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Treatment Outcome; United States; United States Food and Drug Administration | 2012 |
High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Risk Factors | 2012 |
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Core Binding Factors; Cytarabine; Disease-Free Survival; Exons; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Korea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Point Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic; Treatment Outcome; Young Adult | 2013 |
An unusual initial manifestation of acute leukemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bone Marrow; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Paraneoplastic Syndromes; Skin Diseases, Papulosquamous | 2012 |
Complete remission following chemotherapy with low-dose cytosine arabinoside and macrophage colony-stimulating factor/granulocyte colony-stimulating factor in a patient with relapsed acute myeloid leukemia after stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Recurrence; Remission Induction; Stem Cell Transplantation | 2012 |
Cytarabine toxicity of the corneal endothelium.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Endothelium, Corneal; Eye Diseases; Humans; Leukemia, Myeloid, Acute; Male; Vision Disorders | 2013 |
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cytarabine; Frameshift Mutation; Gene Expression Regulation, Leukemic; Humans; Immunologic Factors; K562 Cells; Lenalidomide; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; Point Mutation; Promoter Regions, Genetic; Protein Isoforms; Protein Structure, Tertiary; Recombinant Fusion Proteins; RNA, Neoplasm; Thalidomide; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
An extreme example of focal bone marrow involvement in acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; Humans; Ilium; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sternum | 2013 |
Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Retrospective Studies; Tandem Repeat Sequences; Treatment Failure | 2013 |
What is better for older patients with acute myeloid leukemia?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Palliative Care; Patient Participation | 2013 |
When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Palliative Care; Patient Participation | 2013 |
A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Case Management; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Dogs; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Forecasting; France; Haplorhini; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia, Myeloid, Acute; Male; Medical Oncology; Mercaptopurine; Middle Aged; National Institutes of Health (U.S.); Rats; Remission Induction; United States | 2013 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2012 |
Outcome of poor response paediatric AML using early SCT.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Early Medical Intervention; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloablative Agonists; Thioguanine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2013 |
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
Topics: Adult; Animals; Antineoplastic Agents; Cytarabine; Gene Expression Profiling; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Myeloid-Lymphoid Leukemia Protein | 2013 |
Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; CD11c Antigen; Cell Line, Tumor; Cytarabine; Fluorescent Dyes; Green Fluorescent Proteins; HL-60 Cells; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Luminescent Measurements; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Optical Imaging; Tretinoin; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Cell Cycle Proteins; Cell Proliferation; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Molecular Targeted Therapy; Neoplastic Stem Cells; Nuclear Proteins; RNA, Messenger; Transcription Factors; Triazoles; Tumor Cells, Cultured; U937 Cells; Young Adult | 2012 |
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; RNA, Messenger | 2013 |
Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |
A case report of acute myeloid leukemia after liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Hepatitis B; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mitoxantrone; Oxides; Tretinoin | 2013 |
Neutrophilic eccrine hidradenitis induced by cytarabine.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Eccrine Glands; Female; Hidradenitis; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged | 2012 |
Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Cytarabine; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Thiazoles | 2013 |
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Doxorubicin; Drug Administration Routes; Drug Resistance, Neoplasm; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Topics: Adult; Aged; Aged, 80 and over; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; I-kappa B Kinase; Isoxazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Resorcinols; Signal Transduction; Tumor Cells, Cultured; Young Adult | 2013 |
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Time-to-Treatment; Treatment Outcome; Young Adult | 2013 |
CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2013 |
Enhancing the efficacy of Ara-C through conjugation with PAMAM dendrimer and linear PEG: a comparative study.
Topics: Arabinofuranosyluracil; Cell Line, Tumor; Chemical Phenomena; Chromatography, High Pressure Liquid; Cytarabine; Cytidine Deaminase; Dendrimers; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; Magnetic Resonance Spectroscopy; Particle Size; Polyethylene Glycols; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
A case of acantholytic dermatosis and leukemia cutis: cause or effect?
Topics: Acantholysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Skin; Skin Neoplasms; Treatment Outcome | 2002 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 11; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pelvis; Pregnancy; Pregnancy Complications, Neoplastic; Transplantation, Autologous | 2002 |
Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytarabine; Female; Humans; Idarubicin; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Retrospective Studies; Treatment Outcome | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
Acute myelogenous leukemia following treatment with cyclosporin A in a nephrotic patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclosporine; Cytarabine; Daunorubicin; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Nephrotic Syndrome; Treatment Outcome | 2002 |
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Rate; Treatment Outcome; Trisomy | 2002 |
Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia | 2002 |
Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Ploidies; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neutrophils; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
High-dose cytosine arabinoside-induced cutaneous reactions.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Drug Eruptions; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies | 2002 |
Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).
Topics: Adolescent; Adult; Antineoplastic Agents; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Female; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Lysis Syndrome | 2002 |
[WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; WT1 Proteins | 2002 |
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Acute myelogenous leukaemia presenting as a conjunctival lesion and red eye.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Conjunctiva; Conjunctival Neoplasms; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2002 |
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Recurrence | 2003 |
A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13).
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 16; Cytarabine; Female; Gene Rearrangement; Histone Acetyltransferases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae Proteins; Sequence Analysis, DNA; Translocation, Genetic | 2003 |
Long-term outcomes of acute myeloid leukemia in adults in Pakistan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pakistan; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
[The effect of interferon alone, cytosine arabinoside alone and their combined effect on hematopoietic progenitors of chronic myeloid leukemia in vitro].
Topics: Adult; Cell Division; Cytarabine; Drug Synergism; Female; Hematopoietic Stem Cells; Humans; Interferons; K562 Cells; Leukemia, Myeloid, Acute; Male; Middle Aged | 2002 |
[Effects of small-dose cytarabine on the course of atheromatosis in over 60 years of age patients with acute myeloblastic leukemia (description of 2 cases)].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Arteriosclerosis; Cell Division; Cytarabine; Female; Humans; Hypertension; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 2002 |
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacillaceae Infections; Bacillus cereus; Cytarabine; Enterocolitis; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Diseases; Male; Neutropenia; Sepsis | 2003 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Severe hyperglycemia as a complication of big ICE chemotherapy in a patient with acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cytarabine; Etoposide; Female; Humans; Hyperglycemia; Idarubicin; Insulin; Leukemia, Myeloid, Acute; Recurrence; Time Factors | 2002 |
Sweet's syndrome masquerading as facial cellulitis.
Topics: Antineoplastic Agents; Cellulitis; Cytarabine; Diagnosis, Differential; Face; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Sweet Syndrome; Treatment Outcome | 2003 |
The comprehensive evaluation on four indices of drug resistance in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Cell Division; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Harringtonines; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Stem Cell Assay | 1999 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
Effects of TNFalpha on the growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia with special reference to the role of NF-kappaB.
Topics: Adult; Aged; Blast Crisis; Cell Division; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; NF-kappa B; Tumor Necrosis Factor-alpha | 2003 |
[High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2003 |
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.
Topics: Animals; Antibodies; Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance, Neoplasm; Fibronectins; Humans; Integrin alpha4beta1; Integrin alpha5beta1; Leukemia; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm, Residual; Phosphatidylinositol 3-Kinases; Predictive Value of Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stromal Cells; Survival Rate; Time Factors; Tumor Cells, Cultured | 2003 |
[Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival].
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leucine; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Rate | 2003 |
[Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Time Factors | 2003 |
Acute myeloid leukemia presenting as non-neutropenic colitis in an infant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis; Colon; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; Infant; Leukemia, Myeloid, Acute; Leukemic Infiltration; Leukocyte Common Antigens; Peroxidase; Sigmoidoscopy; Thioguanine | 2003 |
[Intensive multi-drug chemotherapy for acute myeloid leukemia in a renal allograft recipient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kidney Transplantation; Leukemia, Myeloid, Acute; Male; Middle Aged; Postoperative Complications | 2003 |
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Salvage Therapy; Transplantation, Autologous | 2003 |
[Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Lysis Syndrome | 2003 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
Biphasic acute myeloid leukemia with near-tetraploidy and immunophenotypic transformation.
Topics: Adult; Aneuploidy; Antigens, CD; Antigens, CD7; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; CD56 Antigen; Cell Size; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; DNA, Neoplasm; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Transplantation, Homologous | 2004 |
Lack of effect of the human GM-CSF analog E21R on the survival of primary human acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Binding, Competitive; Cell Death; Cell Division; Cell Survival; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Recombinant Proteins | 2004 |
Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Count; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute | 2004 |
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
Topics: Adult; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Neoplasms; Proto-Oncogene Proteins; Transcription Factors; Translocation, Genetic | 2004 |
Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells.
Topics: Biological Transport; Cholesterol, LDL; Coenzyme A Ligases; Cytarabine; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Synthase; Leukemia, Myeloid, Acute; Lovastatin; Receptors, LDL; RNA, Messenger; Tumor Cells, Cultured | 2004 |
Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Immunotoxins; Leukemia, Myeloid, Acute; Salvage Therapy; Treatment Outcome | 2004 |
A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Treatment Outcome | 2004 |
Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Recombinant Proteins; Remission Induction; Skin; Sweet Syndrome | 2004 |
Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report.
Topics: Antimetabolites, Antineoplastic; Blood Cell Count; Chemical and Drug Induced Liver Injury; Cytarabine; Dipyridamole; Drug Interactions; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Liver Function Tests; Male; Middle Aged; Multiple Organ Failure; Platelet Aggregation Inhibitors | 2004 |
Isolated recurrence of granulocytic sarcoma manifesting as extra- and intracranial masses--case report.
Topics: Adult; Antineoplastic Agents; Biopsy, Needle; Brain Injuries; Brain Neoplasms; Core Binding Factor Alpha 2 Subunit; Cytarabine; DNA-Binding Proteins; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Sarcoma, Myeloid; Transcription Factors | 2004 |
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2004 |
A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytokines; Diphtheria Toxin; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Recombinant Fusion Proteins | 2004 |
Teaching cases from the Royal Marsden and St Mary's Hospitals case 28: a patient with acute leukemia with rare leukemic cells of unusual morphology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Middle Aged; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2004 |
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chi-Square Distribution; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Logistic Models; Male; Mitoxantrone; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Survival Rate | 2004 |
An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF.
Topics: Antineoplastic Agents; Blood Cells; Blood Coagulation; Cell Death; Cells, Cultured; Cytarabine; Daunorubicin; Granulocyte Precursor Cells; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Thromboplastin | 2004 |
Cytarabine-induced neurotoxicity responding to methyl prednisolone.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Fatal Outcome; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Methylprednisolone; Neurotoxicity Syndromes | 2004 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ecthyma; Female; gamma-Globulins; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pseudomonas aeruginosa; Pseudomonas Infections; Scalp; Sepsis; Treatment Outcome | 2004 |
[Infection control in neutropenia induced by high-dose cytarabine chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Laryngeal Mucosa; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Retrospective Studies; Risk; Streptococcal Infections | 2004 |
Complex t(8;14;21)(q22;q13;q22), a variant of t(8;21), with t(15;21)(q15;p11) in a patient with acute myelogenous leukemia (M1).
Topics: Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Therapy, Combination; Female; Genetic Variation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Middle Aged; Oncogene Proteins, Fusion; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Secondary Prevention; Transcription Factors; Translocation, Genetic | 2004 |
A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin | 2004 |
Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Survival Analysis | 2005 |
Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Line, Tumor; Cell Survival; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; Signal Transduction | 2005 |
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.
Topics: Aniline Compounds; Apoptosis; Caspases; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Topics: Antimetabolites, Antineoplastic; Benzoquinones; Checkpoint Kinase 1; Cytarabine; Drug Synergism; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Protein Kinases; Rifabutin; RNA, Small Interfering; S Phase | 2005 |
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA-Binding Proteins; Etoposide; GTPase-Activating Proteins; Histone-Lysine N-Methyltransferase; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogenes; RNA, Messenger; Transcription Factors | 2005 |
Trying to improve clinical outcome in AML: lessons from negative trials.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Interleukin-11; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Curing acute myelogenous leukemia: still a major challenge.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Risk Factors; Survival Analysis | 2005 |
Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts.
Topics: Antimetabolites, Antineoplastic; Bone Marrow Cells; Cytarabine; HeLa Cells; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenotype; Prognosis; ras Proteins; Signal Transduction; Survival Analysis; Treatment Outcome | 2005 |
GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recombinant Proteins; Retrospective Studies; Risk Assessment; Risk Factors | 2005 |
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Topics: Butyrates; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Enzyme Inhibitors; Etoposide; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Valproic Acid | 2005 |
Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Female; Humans; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Spectrometry, Fluorescence; Tetrazolium Salts; Thiazoles | 2005 |
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Treatment Outcome; Vidarabine | 2005 |
[Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Respiratory Tract Infections; Treatment Outcome; Vidarabine | 2005 |
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2005 |
Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Heart Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Sarcoma, Myeloid; Transplantation, Homologous | 2005 |
Cytarabine-induced lung injury: case report.
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Cytarabine; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Male; Prednisolone; Respiratory Distress Syndrome | 2005 |
[Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vincristine | 2005 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |
Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Survival; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Progenitor Cells; Neoplastic Stem Cells; Pilot Projects; Predictive Value of Tests; Treatment Outcome; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2005 |
Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; DNA-Binding Proteins; DNA, Complementary; Drug Resistance, Neoplasm; Electroporation; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Proteins; Phenotype; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; Tumor Cells, Cultured | 2005 |
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Biomarkers, Tumor; Blast Crisis; Cell Line, Tumor; Chromosome Aberrations; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Receptors, Cytokine; Stem Cell Factor; Treatment Outcome | 2006 |
Medical ethics collides with public policy: LVAD for a patient with leukemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cost-Benefit Analysis; Cytarabine; Health Care Rationing; Heart-Assist Devices; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Public Policy; United States | 2005 |
Methotrexate-induced status epilepticus.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Humans; Injections, Intraventricular; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Status Epilepticus; Treatment Outcome | 2005 |
Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Methylprednisolone; Neutropenia; Recombinant Proteins; Recurrence; Sweet Syndrome; Vidarabine | 2006 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Proliferation; Cytarabine; Daunorubicin; DNA; Etoposide; Flow Cytometry; Fluorescent Dyes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocarbons, Chlorinated; Leukemia; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Oligopeptides; Organic Chemicals; Radiation-Protective Agents | 2005 |
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2005 |
Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Aphidicolin; Azacitidine; Child; Cyclin-Dependent Kinases; Cytarabine; Decitabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Nucleic Acid Synthesis Inhibitors; Ribonucleotide Reductases | 2005 |
Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy.
Topics: Adult; Antimetabolites, Antineoplastic; Cesarean Section; Cytarabine; Female; Fetal Monitoring; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Recombinant Proteins; Stem Cells | 2005 |
Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum.
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Central Nervous System; Cytarabine; Disease Progression; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Mediastinum; Polyploidy; Prognosis; Stem Cell Transplantation; Tomography, X-Ray Computed | 2005 |
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzhydryl Compounds; Benzoquinones; Combined Modality Therapy; Cytarabine; Drug Synergism; Etoposide; HL-60 Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Mitochondria; Protein Conformation; Pyrrolidinones; Rifabutin; RNA, Small Interfering | 2005 |
Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as Topic; Cytarabine; Drug Administration Schedule; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 1989 |
Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 1989 |
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Survival; Coculture Techniques; Cytarabine; Endothelial Cells; Humans; Leukemia, Myeloid, Acute; Proteasome Inhibitors; Pyrazines | 2005 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Central Nervous System; Chromosome Aberrations; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Radiography; Recurrence; Registries; Transplantation, Autologous; Transplantation, Homologous | 2006 |
Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Female; Health Services for the Aged; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Palliative Care; Quality of Life; Retrospective Studies; Survival Analysis; Thioguanine | 2006 |
Acute leukaemia presenting as vulvar ulcers in an adolescent girl.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Risk Assessment; Treatment Outcome; Ulcer; Vulvar Diseases | 2005 |
A cat with acute myeloblastic leukemia without maturation (M1) treated with combination chemotherapy.
Topics: Animals; Blood Transfusion; Bone Marrow Cells; Cat Diseases; Cats; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Fatal Outcome; Leukemia, Myeloid, Acute; Peroxidase; Prednisolone; Vincristine | 2006 |
Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Caspofungin; Combined Modality Therapy; Cytarabine; Debridement; Diplopia; Drug Therapy, Combination; Echinocandins; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Lipopeptides; Male; Middle Aged; Mitoxantrone; Opportunistic Infections; Orbital Diseases; Peptides, Cyclic; Sinusitis; Zygomycosis | 2005 |
Developmental clinical trials: building one step at a time.
Topics: Antineoplastic Agents; Apoptosis; Clinical Trials, Phase I as Topic; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Neural Tube Defects; Pyridines; Research Design; Thiosemicarbazones | 2006 |
Roles of protein C, protein S, and antithrombin III in acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Asparaginase; Cyclophosphamide; Cytarabine; Disseminated Intravascular Coagulation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Myocardial Infarction; Peripheral Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prednisone; Protein C; Protein S; Thrombosis; Vincristine | 2006 |
Unrelated cord blood transplantation after myeloablative conditioning in patients with acute leukemia aged between 50 and 55 years.
Topics: Acute Disease; Body Weight; Cord Blood Stem Cell Transplantation; Cytarabine; Female; Fetal Blood; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning | 2006 |
Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 2006 |
Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Cells, Cultured; Coculture Techniques; Cytarabine; Female; Flow Cytometry; Gene Expression Profiling; Granulocyte-Macrophage Colony-Stimulating Factor; HSC70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2006 |
[Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Harringtonines; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome | 2005 |
The role of post-remission chemotherapy for older patients with acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Cells; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Treatment Outcome | 2006 |
Excretion of cytosine arabinoside in saliva after its administration at high doses.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Saliva; Time Factors | 2006 |
Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Structure-Activity Relationship; Thiazolidinediones; Troglitazone; U937 Cells | 2006 |
[Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Asparagine; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Tumor Cells, Cultured; Vincristine | 2005 |
Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2006 |
Acute myeloblastic leukemia in a patient with hereditary protein C deficiency.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enterocolitis, Pseudomembranous; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein C Deficiency | 2006 |
Ex vivo activity of thalidomide in childhood acute leukemia.
Topics: Angiogenesis Inhibitors; Cell Cycle; Child; Child, Preschool; Cytarabine; Female; Humans; Immunophenotyping; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Tetrazolium Salts; Thalidomide; Thiazoles | 2006 |
Treatment of acute myeloid leukemia in older adults: time to reflect?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Cells; Cytarabine; Disease-Free Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction; Treatment Outcome | 2006 |
Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CD56 Antigen; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Transplantation, Homologous | 2007 |
Acute myelogenous leukemia associated with Ollier disease.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 21; Cytarabine; Daunorubicin; Enchondromatosis; Etoposide; Gemtuzumab; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplastic Syndromes, Hereditary; Translocation, Genetic | 2008 |
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Topics: Acrylamides; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Combinations; Humans; K562 Cells; Leukemia, Myeloid, Acute; Melphalan; Methylnitronitrosoguanidine; Monocytes; NAD; Piperidines | 2006 |
Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2006 |
Neutrophilic eccrine hidradenitis masquerading as facial cellulitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cellulitis; Cytarabine; Diagnosis, Differential; Facial Dermatoses; Female; Follow-Up Studies; Hidradenitis; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Risk Assessment | 2007 |
Increased mortality with FLA compared with ADE chemotherapy in high-risk AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2006 |
Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Humans; In Situ Hybridization; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prostatic Neoplasms | 2007 |
Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report.
Topics: Adolescent; Antimetabolites, Antineoplastic; Cerebellar Diseases; Cerebrospinal Fluid; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male | 2006 |
Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Diterpenes; Diterpenes, Kaurane; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Neoplasms, Experimental; Oncogene Proteins, Fusion; Plant Extracts; Plants, Medicinal; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; U937 Cells | 2007 |
A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.
Topics: Amyloid beta-Protein Precursor; Antimetabolites, Antineoplastic; Cytarabine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-bcl-2 | 2007 |
Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Vidarabine | 2007 |
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
Topics: Apoptosis; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Down-Regulation; Etoposide; HL-60 Cells; Humans; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2007 |
Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2).
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Cytogenetic Analysis; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Nucleic Acid Hybridization; Oncogene Proteins, Fusion; Polymerase Chain Reaction; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic | 2008 |
"Flushing out" cytosine arabinoside from CSF to reverse neurotoxicity.
Topics: Adolescent; Antimetabolites, Antineoplastic; Cerebellar Diseases; Cerebrospinal Fluid; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male | 2007 |
Diffuse alveolar damage and hemorrhage in acute myelogenous leukemia treated with corticosteroids.
Topics: Adrenal Cortex Hormones; Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lung Diseases; Pulmonary Alveoli; Radiography | 2007 |
[The standard treatments for patients with hematological malignancies in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Rituximab; Survival Rate; Vincristine | 2007 |
Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Jehovah's Witnesses; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Organic Chemicals; Remission Induction; Severity of Illness Index | 2007 |
[Acute myelogenous leukemia with multilineage myelodysplasia, positive direct Coombs test, and elevated levels of platelet-associated IgG].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Coombs Test; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulin G; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pancytopenia; Prednisolone; Treatment Outcome | 2007 |
Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: a case report.
Topics: Antimetabolites, Antineoplastic; Bradycardia; Cytarabine; Electrocardiography; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2007 |
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2007 |
Biphenotypic acute leukaemia: a case series.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Immunophenotyping; Leukemia; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vincristine | 2007 |
Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Bone Marrow; Cell Differentiation; Clone Cells; Cytarabine; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Methotrexate; Middle Aged; Monocytes; Neoplasm Proteins; Neoplastic Stem Cells | 2008 |
Acute myeloid leukaemia presenting as recurrent generalized urticaria in infancy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Urticaria | 2008 |
Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disseminated Intravascular Coagulation; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Partial Thromboplastin Time; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Remission Induction; Vincristine | 2007 |
Modulation of cell apoptosis by AIR.
Topics: Antibodies; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cytarabine; DNA, Complementary; Endogenous Retroviruses; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Maleates; Oligodeoxyribonucleotides, Antisense; RNA, Messenger; Thionucleotides; Transfection | 2007 |
Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Leukemic Infiltration; Liposomes; Male; Meninges; Middle Aged; Retrospective Studies; Spain; United Kingdom | 2007 |
Trisomy 21 as a sole acquired abnormality in an adult Omani patient with CD7- and CD9-positive acute myeloid leukemia.
Topics: Adult; Antigens, CD; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Cytogenetic Analysis; Daunorubicin; Down Syndrome; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Remission Induction; Tetraspanin 29; Treatment Outcome | 2007 |
Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Therapy, Combination; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Lewis X Antigen; Multidrug Resistance-Associated Proteins; Receptors, IgG; Up-Regulation | 2007 |
The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis | 2008 |
Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Retrospective Studies; Treatment Outcome | 2008 |
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Proliferation; Cell Survival; Cytarabine; Drug Design; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Stromal Cells; Tumor Cells, Cultured | 2008 |
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 3; Cohort Studies; Cytarabine; Danazol; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Tamoxifen; Translocation, Genetic | 2007 |
Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia.
Topics: Chromosomes, Human, Pair 3; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Philadelphia Chromosome; Syndrome; Time Factors | 2008 |
[Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].
Topics: Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 2007 |
Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Adhesion; Cell Line, Tumor; Cytarabine; Drug Resistance; Drug Therapy, Combination; Fibronectins; Humans; Integrin beta1; Leukemia, Myeloid, Acute; Mice; Neoplasm, Residual; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2008 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Child; Cytarabine; Disease Progression; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Military Medicine; Military Personnel; Pakistan; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin | 2007 |
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Topics: Adolescent; Adult; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2008 |
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Odds Ratio; Poland; Recurrence; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome | 2008 |
[Effects of FLAG protocol in treatment of the first time induced non-remission acute myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Vidarabine; Young Adult | 2007 |
[Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Tretinoin; Young Adult | 2007 |
Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1).
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Oncogene Proteins, Fusion; Prednisone; Thioguanine; Translocation, Genetic; Treatment Outcome; Vincristine | 2007 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2008 |
Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Child; Child, Preschool; Coloring Agents; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles; Treatment Outcome | 2007 |
[Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia].
Topics: ABO Blood-Group System; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2008 |
Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Cytarabine; Disease Models, Animal; Female; Flow Cytometry; Gene Transfer Techniques; Granulocyte-Macrophage Colony-Stimulating Factor; Immunologic Memory; Immunotherapy; Injections, Intraperitoneal; Leukemia, Myeloid, Acute; Luciferases; Lymphopenia; Mice; Mice, Congenic; Mice, Inbred C57BL; Neoplasm Transplantation; Phenotype; Survival Rate; Time Factors; Treatment Outcome | 2008 |
Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis | 2008 |
Two cases of post-liver transplant acute myeloid leukemia in Korean adults: review of bibliographies and comparison with post-renal transplant acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fatal Outcome; Female; Humans; Kidney Transplantation; Korea; Leukemia, Myeloid, Acute; Liver Transplantation; Male; Middle Aged; Treatment Outcome; Tretinoin | 2008 |
Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia.
Topics: Aged; Allopurinol; Anti-Infective Agents; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Eruptions; Exanthema Subitum; Female; Fever; Hematopoiesis; Herpesvirus 6, Human; Histiocytosis; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Middle Aged; Skin; Virus Activation | 2008 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Tandem Repeat Sequences | 2008 |
Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Indomethacin; Leukemia, Myeloid, Acute; Multidrug Resistance-Associated Proteins; Phenotype | 2008 |
Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Cell Death; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Middle Aged; Neoplasm Proteins; Signal Transduction; Tumor Cells, Cultured | 2008 |
Relapse and death during first remission in acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Risk; Survival Analysis; Treatment Outcome | 2008 |
[Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 2008 |
[A rare complication of immunosuppression: digestive aspergillosis].
Topics: Aspergillosis; Cytarabine; Duodenitis; Duodenoscopy; Enteritis; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Jejunal Diseases; Leukemia, Myeloid, Acute; Middle Aged; Opportunistic Infections | 2008 |
Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Marrow; Cell Nucleus; Cytarabine; Cytoplasm; Daunorubicin; Electrophoretic Mobility Shift Assay; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Leukemic; Humans; Immunoprecipitation; Leukemia, Myeloid, Acute; Mutation; NF-kappa B; Nuclear Proteins; Nucleophosmin; Tumor Cells, Cultured | 2008 |
Acute myeloid leukemia presenting as one-and-a-half syndrome.
Topics: Adult; Antineoplastic Agents; Brain Stem Infarctions; Cytarabine; Diagnosis, Differential; Female; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Ocular Motility Disorders; Syndrome | 2008 |
The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Chromosome Aberrations; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression; Gene Rearrangement; Genes, p53; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Polymerase Chain Reaction; Recurrence; Tumor Suppressor Proteins | 2008 |
Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lenograstim; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Tissue and Organ Harvesting | 2008 |
Unexpected CNS localization in M2 acute myeloid leukemia: a link with past heroin addiction?
Topics: Central Nervous System Neoplasms; Cytarabine; Heroin Dependence; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Premedication | 2008 |
Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Saudi Arabia; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary | 2009 |
Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by inducing proliferative responses in them.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Culture Media, Serum-Free; Cytarabine; Humans; Immunoglobulin Heavy Chains; Ki-67 Antigen; Leukemia, Myeloid, Acute; p38 Mitogen-Activated Protein Kinases; Stress, Physiological | 2008 |
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lenograstim; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2008 |
CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Cell Proliferation; Cytarabine; Daunorubicin; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Phenylenediamines; Rats; Rats, Inbred BN | 2008 |
Successful combination therapy with infusion of allogenetic bone marrow mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute myelogenous leukemia.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cell Transplantation; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Transplantation, Homologous | 2008 |
Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Topics: Cell Division; Cell Line; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance; Humans; Kinetics; Leukemia, Myeloid, Acute; Mutation; Phosphotransferases; Pyrimidines; Thymidine Kinase | 1984 |
Disturbances of desmofibrinogenesis in pateints suffering from acute myeloblastic leukemia.
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Factor XIII; Fibrinogen; Free Radicals; Humans; Leukemia, Myeloid, Acute; Middle Aged; Solubility | 1980 |
[Individual chemotherapy in blastic leukemias (AML)].
Topics: Adult; Cyclophosphamide; Cytarabine; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Methods; Platelet Transfusion; Prednisolone; Vincristine | 1981 |
[Experiences in the induction of remission and in maintenance therapy in acute myeloblastic leukemia in adults with the RAMPO scheme].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Vincristine | 1981 |
8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, 6-12 and X; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Staining and Labeling; Thioguanine; Translocation, Genetic | 1984 |
Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1983 |
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine; Time Factors | 1984 |
Hemopoietic stem cells: their roles in human leukemia and certain continuous cell lines.
Topics: Azacitidine; Cell Differentiation; Cell Line; Clone Cells; Colony-Forming Units Assay; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1984 |
Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Cells, Cultured; Cytarabine; Cytidine Triphosphate; Cytosine Nucleotides; Gene Expression Regulation; Histocompatibility Antigens Class II; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute | 1984 |
[Treatment of acute myeloid leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Delayed-Action Preparations; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Prednisone; Recurrence; Thioguanine; Vincristine | 1984 |
Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia.
Topics: Cytarabine; Drug Eruptions; Humans; Inflammation; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Skin; Sweat Gland Diseases | 1984 |
Prognostic factors in adult patients with acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Chromosome Aberrations; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prednisolone; Prognosis; Vincristine; Zinostatin | 1983 |
Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells.
Topics: Bone Marrow; Cells, Cultured; Cytarabine; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Phosphotransferases; Tetrahydrouridine; Uridine | 1980 |
[Ring-shaped inclusions in an uncommon variety of acute myeloid leukemia (author's transl)].
Topics: Adolescent; Cytarabine; Daunorubicin; Female; Humans; Inclusion Bodies; Leukemia, Myeloid, Acute; Microscopy, Electron; Vincristine | 1981 |
Histomorphologic study of bone marrow in acute leukemia following chemotherapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Thioguanine; Time Factors; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 1983 |
Experience with intermediate and high dose cytosine arabinoside in refractory acute leukaemia.
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male | 1983 |
Haemopoietic patterns of acute leukaemia in remission: CFU-E and CFU-GM colony formation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Therapy, Combination; Erythrocytes; Female; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Macrophages; Thioguanine; Time Factors | 1983 |
[ACNP therapy for DCMP-resistant acute leukemia (author's transl)].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Zinostatin | 1981 |
Idiopathic refractory sideroachrestic anemia (IRSA) progressing to acute mixed lymphoblastic-myelomonoblastic leukemia. Case report and review of the literature.
Topics: Aged; Anemia, Sideroblastic; Bone Marrow Examination; Cerebrospinal Fluid; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Pneumonia; Prednisone; Thioguanine; Tuberculosis, Miliary; Vincristine | 1983 |
Extensive pulmonary infiltration by leukemic blast cells treated with irradiation.
Topics: Adult; Cerebral Hemorrhage; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Lung; Thioguanine | 1983 |
Acute cerebellar dysfunction with high-dose ARA-C therapy.
Topics: Aged; Brain Diseases; Cerebellum; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Purkinje Cells | 1983 |
Ocular toxicity from high-dose cytosine arabinoside.
Topics: Cornea; Corneal Opacity; Cytarabine; DNA; Drug Administration Schedule; Eye Diseases; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Visual Acuity | 1983 |
Acute myelomonocytic leukemia in a dog.
Topics: Animals; Antineoplastic Agents; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Drug Therapy, Combination; Female; Leukemia, Myeloid, Acute; Thioguanine; Vincristine | 1983 |
Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytosis; Middle Aged | 1983 |
Plasma fibronectin deficiency during chemotherapy of acute myeloid leukaemia.
Topics: Adult; Aged; Bronchopneumonia; Cytarabine; Daunorubicin; Female; Fever; Fibronectins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1983 |
Acute nonlymphocytic leukemia and acute aplastic anemia. The simultaneous occurrence in marital partners.
Topics: Adult; Anemia, Aplastic; Animals; Antilymphocyte Serum; Cats; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Marriage; Time Factors | 1983 |
Pericarditis as presenting manifestation of acute nonlymphocytic leukemia in a young child.
Topics: Acute Disease; Child, Preschool; Cytarabine; Diagnosis, Differential; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Pericarditis; Thioguanine | 1983 |
Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside.
Topics: Blood Proteins; Cytarabine; Humans; Leukemia, Myeloid, Acute; Protein Binding; Saliva | 1983 |
[Changes of therapy results in acute leukemia under different treatment schedules with special reference to gnotobiotic measures].
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Isolation; Prednisolone; Thioguanine; Vincristine | 1983 |
[Drug sensitivity of human acute myelocytic leukemia cells (HL-60) and normal human myelocytes (CFU-C) in a co-culture].
Topics: Adult; Cells, Cultured; Cytarabine; Daunorubicin; Drug Resistance; Female; Head and Neck Neoplasms; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vincristine | 1983 |
[Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1983 |
Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update.
Topics: Adult; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prednisolone; Vincristine | 1983 |
High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
Topics: Arabinofuranosyluracil; Child; Chromatography, High Pressure Liquid; Cytarabine; Cytidine; Deoxycytidine; Humans; Infusions, Parenteral; Kinetics; Leukemia, Myeloid, Acute; Uridine | 1983 |
[Chemotherapeutic approach to acute myeloid leukemia in adults].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Naphthacenes | 1983 |
[Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Child; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged | 1983 |
Remission of acute myelogenous leukemia in elderly patients with prior refractory dysmyelopoietic anemia.
Topics: Age Factors; Aged; Anemia, Hemolytic; Bone Marrow; Cytarabine; Doxorubicin; Drug Therapy, Combination; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Pancytopenia; Thioguanine | 1983 |
Cytosine arabinoside induced liver damage: histopathologic demonstration.
Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Liver; Middle Aged | 1983 |
[Reduced dosage of cytosine arabinoside in the treatment of acute myelocytic leukemia. Apropos of 3 cases].
Topics: Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male | 1983 |
Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Topics: Antineoplastic Agents; Biological Transport; Cell Division; Cell Line; Cell Survival; Clone Cells; Cytarabine; Deoxyribonucleosides; DNA Replication; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Pyrazoles | 1983 |
Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia.
Topics: Adult; Aged; Anemia; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myeloproliferative Disorders; Preleukemia | 1983 |
Quantitation of chemosensitivity in acute myelocytic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Thioguanine; Time Factors; Tumor Stem Cell Assay | 1983 |
[Small dose of ARA-C in the treatment of an elderly patient with acute myeloblastic leukemia].
Topics: Aged; Cerebral Infarction; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Myocardial Infarction | 1983 |
In vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: growth pattern and drug sensitivity.
Topics: Bone Marrow; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Humans; Leukemia, Myeloid, Acute | 1983 |
Urinary excretion of beta-aminoisobutyrate and pseudouridine in acute and chronic myeloid leukemia.
Topics: Adult; Aminoisobutyric Acids; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Pseudouridine; Uridine | 1983 |
Long term follow-up of remission patients in adult acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Time Factors; Vincristine | 1983 |
Low-dose cytarabine therapy in hypoplastic acute leukemia.
Topics: Aged; Bone Marrow; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Pancytopenia | 1983 |
Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Topics: Aged; Bone Marrow Diseases; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pancytopenia | 1983 |
Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male | 1983 |
Graft-versus-host reaction in 3 adult leukaemia patients after transfusion of blood cell products.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Methotrexate; Middle Aged; Neutropenia; Prednisolone; Prednisone; Thioguanine; Transfusion Reaction; Vincristine | 1983 |
Acute myeloid leukemia in adults: experience at AIIMS.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Vincristine | 1983 |
Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Risk; Sepsis; Statistics as Topic; Thioguanine | 1984 |
[Clinical studies of BH-AC-DMP in adult acute nonlymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1983 |
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
Topics: Cytarabine; Drug Administration Schedule; Humans; Kinetics; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma | 1983 |
[Low dose Ara-C for remission induction in aged patients with atypical nonlymphocytic leukemia and refractory anemia with excess blasts].
Topics: Aged; Anemia, Aplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1983 |
Chemotherapy for acute leukemia during pregnancy. Five case reports.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Vinblastine; Vincristine; Vindesine | 1984 |
Primary colonic plasmacytoma associated with acute myelogenous leukemia.
Topics: Adult; Colon; Colonic Neoplasms; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Plasmacytoma; Prednisolone | 1984 |
Low-dose Ara-C in the treatment of acute leukemia. Cytotoxicity or differentiation induction?
Topics: Adult; Cell Differentiation; Colony-Forming Units Assay; Cytarabine; Cytotoxins; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1984 |
Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Bone Marrow Diseases; Bone Marrow Examination; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polycythemia Vera | 1984 |
[Central nervous system involvement in adult acute leukemia].
Topics: Acute Disease; Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged | 1984 |
A stage classification for prognosis in adult acute myelogenous leukaemia based upon patients' age, bone marrow karyotype and clinical features.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Thioguanine | 1984 |
High-dose cytosine arabinoside: advances in clinical pharmacology and therapeutic results.
Topics: Biotransformation; Cytarabine; DNA Replication; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1983 |
Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia.
Topics: Anemia, Aplastic; Blood Cell Count; Cell Differentiation; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Primary Myelofibrosis; Thrombocytopenia | 1984 |
Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells.
Topics: Cell Cycle; Cell Differentiation; Cell Line; Cycloheximide; Cytarabine; Dactinomycin; Daunorubicin; DNA Replication; Humans; Kinetics; Leucine; Leukemia, Myeloid, Acute; Protein Biosynthesis; Thymidine; Transcription, Genetic; Tretinoin; Tritium; Uridine | 1984 |
In vitro suppression of DNA synthesis by a remission induction agent and its correlation with response in adult acute leukemia.
Topics: Adolescent; Adult; Aged; Cells, Cultured; Cytarabine; DNA; Doxorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Thymidine; Time Factors | 1984 |
Progressive cutaneous herpes simplex infection in acute myeloblastic leukemia. Successful treatment with interferon and cytarabine.
Topics: Acute Disease; Adult; Appendectomy; Appendicitis; Cytarabine; Drug Therapy, Combination; Herpes Simplex; Humans; Interferon Type I; Leukemia, Myeloid, Acute; Male; Skin; Skin Diseases, Infectious; Surgical Wound Infection | 1984 |
Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction.
Topics: Adult; Aged; Animals; Cell Count; Cell Differentiation; Cell Line; Cells, Cultured; Clone Cells; Cytarabine; Female; Humans; Injections, Subcutaneous; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Middle Aged | 1984 |
Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cell Survival; Cytarabine; DNA; Humans; Leukemia, Myeloid, Acute; Tumor Stem Cell Assay | 1984 |
[Combination chemotherapy of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-MP, and prednisolone (BH-AC. AMP therapy) for adult acute non-lymphocytic leukemia].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1984 |
Acute myelogenous leukemia in pregnancy.
Topics: Adult; Cesarean Section; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Recurrence | 1984 |
High-dose cytarabine for high blast counts.
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male | 1984 |
Successful remission induction in acute myelomonocytic leukaemia using low-dose cytosine arabinoside following failure of intensive chemotherapy.
Topics: Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1984 |
Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Daunorubicin; DNA Replication; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Thioguanine | 1984 |
Oral complications in adult leukemic patients undergoing chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mouth Diseases; Naphthacenes | 1984 |
Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine.
Topics: Cell Differentiation; Cell Division; Cell Line; Cell Survival; Clone Cells; Cytarabine; Heme; Hemoglobins; Humans; Hydroxyurea; Kinetics; Leukemia, Myeloid, Acute | 1984 |
[Treatment of adult acute promyelocytic leukemia during the period of 1974-1982].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Deoxycytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1984 |
[Differentiation induction of leukemic cells in acute myeloid leukemia].
Topics: Anemia, Aplastic; Cell Differentiation; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Prednisolone | 1984 |
[A case of refractory acute myeloblastic leukemia who achieved partial remission by high dose cytosine arabinoside].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Vincristine | 1984 |
Acute leukaemia in a defined geographic area--incidence, clinical history and prognosis.
Topics: Adolescent; Adult; Age Factors; Aged; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Preleukemia; Sweden; Thioguanine; Vincristine | 1984 |
[Differential cell growth inhibition and terminal differentiation induction by chemotherapeutic agents of a human acute myelogenous leukemia cell line (HL-60) in vitro].
Topics: Anthraquinones; Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cytarabine; Dactinomycin; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Phagocytes; Thioguanine; Vincristine | 1984 |
Bronchopleural fistula followed by massive fatal hemoptysis in a patient with pulmonary mucormycosis. A case report.
Topics: Adult; Bronchial Fistula; Bronchoscopy; Cytarabine; Hemoptysis; Humans; Leukemia, Myeloid, Acute; Male; Mucormycosis; Pneumonia; Pulmonary Edema; Radiography | 1983 |
Non-cardiotoxic anthracycline regimens in the treatment of acute myeloblastic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1984 |
Thrombin generation in acute promyelocytic leukemia.
Topics: Adult; Cytarabine; Disseminated Intravascular Coagulation; Doxorubicin; Female; Fibrinopeptide A; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Thrombin; Vincristine | 1984 |
Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
Topics: Cell Line; Cytarabine; DNA, Neoplasm; Drug Administration Schedule; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Thymidine; Tumor Stem Cell Assay | 1984 |
[Double minute chromosomes (DMs) in a case of acute myelocytic leukemia (M2: FAB classification)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Vincristine | 1984 |
[Analysis of the effect of cellular morphology on obtaining a complete remission in 99 cases of acute leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Middle Aged; Platelet Count; Prognosis | 1984 |
Treatment of myeloblastic sarcoma in the sacral canal with high-dose cytosine arabinoside.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sacrum | 1984 |
[Results of treatment with 2 chemotherapeutic protocols (TAPA and VAPA) in acute myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prednisone; Thioguanine; Vincristine | 1984 |
Cell differentiation and therapeutic effect of low doses of cytosine arabinoside in human myeloid leukemia.
Topics: Aged; Cell Differentiation; Cells, Cultured; Cytarabine; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male | 1984 |
Low-dose cytarabine in acute myeloid leukaemia.
Topics: Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1984 |
Experimental approaches to outcome prediction in acute myeloblastic leukemia.
Topics: Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Clone Cells; Colony-Forming Units Assay; Culture Techniques; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Time Factors; Tumor Stem Cell Assay | 1984 |
[Low-dose cytosine arabinoside in the treatment of myeloblastic leukemia].
Topics: Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute | 1984 |
Reversible hepatotoxicity related to amphotericin B.
Topics: Amphotericin B; Chemical and Drug Induced Liver Injury; Cytarabine; Humans; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Mycoses; Pneumonia; Thioguanine | 1984 |
Bone marrow fibre content in acute myeloid leukaemia before and after treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Collagen; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Primary Myelofibrosis; Reticulin; Thioguanine | 1984 |
Vitamin A and/or high-dose Ara-C in the maintenance of remission in acute myelogenous leukaemia in children?
Topics: Child; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Vitamin A | 1984 |
Bone marrow stromal deficiency in acute myeloid leukemia in mice.
Topics: Animals; Bone Marrow; Culture Media; Cytarabine; Fibroblasts; Hematopoietic Stem Cells; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL | 1984 |
Cell kinetic studies after high dose Ara-C and adriamycin treatment in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia.
Topics: Animals; Cell Cycle; Cytarabine; Disease Models, Animal; Doxorubicin; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Rats; Rats, Inbred BN | 1984 |
Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia.
Topics: Animals; Cell Cycle; Cytarabine; Doxorubicin; Hematopoietic Stem Cells; Leukemia, Myeloid, Acute; Mice; Mice, Inbred Strains; Neoplastic Stem Cells; Rats; Rats, Inbred BN | 1984 |
[Low-dose cytosine arabinoside treatment in acute myeloid leukemia].
Topics: Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1984 |
Treatment of acute non-lymphocytic leukemia with DCMP intensive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1984 |
[Small-dose cytarabine (Ara-C) in the treatment of myelodysplastic syndrome].
Topics: Anemia, Aplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Preleukemia | 1984 |
[Low-dose cytosine arabinoside (ARA-C) in the treatment of acute myeloid leukemia].
Topics: Adult; Aged; Cytarabine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1984 |
Phase I and early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies.
Topics: Adolescent; Adult; Child; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged | 1984 |
Treatment of acute myelogenous leukemia in aged patients with low-dose Ara-C (arabinosyl cytosine).
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1984 |
[Possibilities for the cure of acute myeloblastic leukemia with the modified VAPA regimen: preliminary results].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prognosis; Vincristine | 1984 |
A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents.
Topics: Aclarubicin; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow; Cell Division; Cell Survival; Cells, Cultured; Colony-Stimulating Factors; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Methods; Naphthacenes; Thymidine; Tumor Stem Cell Assay | 1983 |
High-dose cytosine arabinoside: clinical response to therapy in acute leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Child; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1982 |
Life-threatening hypophosphatemia in a patient with acute myelogenous leukemia.
Topics: Acetazolamide; Cytarabine; Daunorubicin; Female; Glucose; Humans; Leukemia, Myeloid, Acute; Middle Aged; Phosphates; Sepsis; Sodium Chloride; Starvation | 1980 |
An unusual case of acute leukaemia.
Topics: Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine; Vincristine | 1981 |
Hypoparathyroidism and hypocalcaemia during treatment for acute leukaemia.
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Doxorubicin; Female; Humans; Hypocalcemia; Hypoparathyroidism; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Magnesium; Male; Middle Aged; Parathyroid Hormone | 1982 |
Retrospective analysis of treatment of acute myeloblastic leukemia in patients more than 55 years old.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thioguanine | 1982 |
Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis.
Topics: Aphidicolin; Cell Line; Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Depression, Chemical; Diterpenes; DNA; DNA-Directed DNA Polymerase; Humans; Leukemia, Myeloid, Acute; Nucleosides | 1982 |
[Treatment of acute myeloid leukemia with a protocol combining intensive induction chemotherapy, early consolidation treatment, splenectomy and long-term maintenance chemotherapy. Preliminary study].
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Long-Term Care; Middle Aged; Pancytopenia; Prognosis; Splenectomy; Vincristine | 1982 |
[Acute leukaemia during pregnancy: favourable course of pregnancy in two patients treated with cytosine arabinoside and anthracyclines (author's transl)].
Topics: Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Fetus; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications; Remission, Spontaneous; Risk; Vincristine | 1980 |
Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization.
Topics: Aged; Anaphylaxis; Cytarabine; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Leukemia, Myeloid, Acute; Male | 1980 |
The efficiency of strict reverse isolation and antimicrobial decontamination in remission induction therapy of acute leukemia.
Topics: Acute Disease; Adult; Cytarabine; Daunorubicin; Decontamination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Patient Isolation; Retrospective Studies | 1980 |
Myeloblastic leukemia and leukemic meningitis in a dog.
Topics: Animals; Cytarabine; Dog Diseases; Dogs; Female; Leukemia; Leukemia, Myeloid, Acute; Meningitis; Thioguanine | 1980 |
High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Stanozolol; Vincristine; Virilism | 1980 |
Acute myeloblastic leukemia in elderly patients: treatment and prognostic factors.
Topics: Aged; Aldehydes; Cytarabine; Daunorubicin; Female; Humans; Infections; Infusions, Parenteral; Injections, Intravenous; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Pyruvaldehyde; Sex Factors | 1980 |
Predicting response to combination chemotherapy in acute myeloblastic leukemia--- a way to individualize treatment.
Topics: Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute | 1980 |
Treatment of acute myelogenous leukemia in children and adults.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Blood Transfusion; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocytes; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Middle Aged; Vincristine | 1980 |
[Study of the blast cell sensitivity to cytostatic agents in acute leukemia by the radioisotope method].
Topics: Adolescent; Adult; Asparaginase; Bone Marrow; Cytarabine; DNA, Neoplasm; Female; Glucocorticoids; Humans; Hydrocortisone; In Vitro Techniques; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Vincristine | 1980 |
Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia: update of an ongoing trial.
Topics: Agranulocytosis; Bacterial Infections; Cytarabine; Daunorubicin; Fever; Humans; Leukemia, Myeloid, Acute; Lithium; Middle Aged; Neutropenia; Thrombocytopenia; Time Factors | 1980 |
A seven year laboratory and clinical experience with lithium carbonate as an adjuvant to cancer chemotherapy.
Topics: Bone Marrow Cells; Cells, Cultured; Cytarabine; Daunorubicin; Drug Therapy, Combination; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocytosis; Lithium; Lymphoma, Non-Hodgkin; Methotrexate | 1980 |
Prediction of response to chemotherapy in acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow Cells; Cell Division; Child; Clone Cells; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis | 1980 |
Acute promyelocytic leukemia--clinical management of 15 patients.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Doxorubicin; Female; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1980 |
Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Hepatitis B; Humans; Infant; Leukemia, Myeloid, Acute; Liver Function Tests; Male; Middle Aged; Prognosis; Retrospective Studies; Thioguanine | 1980 |
[Cytosine arabinoside in the treatment of herpes simplex and chickenpox].
Topics: Chickenpox; Child; Cytarabine; Herpes Simplex; Humans; Infant, Newborn; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute | 1980 |
Treatment of psoriasis with daunorubicin and cytarabine.
Topics: Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Psoriasis | 1980 |
Sensitivity of normal and acute myelogenous leukaemia marrow cells to inhibition by cytosine arabinoside.
Topics: Bone Marrow; Cells, Cultured; Cytarabine; DNA; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute | 1980 |
Variation in sensitivity of DNA synthesis to ara-C in acute myeloid leukaemia.
Topics: Arabinofuranosylcytosine Triphosphate; Bone Marrow; Cells, Cultured; Cytarabine; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute | 1980 |
Selective use of daunorubicin for remission-induction chemotherapy in acute non-lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1980 |
[Results of treatment of exacerbation of myelocytic leukemia according to the TRAMPCO program].
Topics: Adult; Aged; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Prednisone; Thioguanine; Vincristine | 1980 |
[Results of complex treatment of adults with myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Vincristine | 1980 |
Acute leukemia during pregnancy.
Topics: Adult; Cytarabine; Drug Administration Schedule; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, Second; Thioguanine | 1980 |
Cytokinetic changes in the peripheral blood of leukemic patients during cytostatic therapy. VI. Effect of arabinosylcytosine.
Topics: Adult; Aged; Blood Cells; Cytarabine; DNA; Female; Humans; Interphase; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Primary Myelofibrosis | 1980 |
[Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)].
Topics: Acute Disease; Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1980 |
Absence of the influence of age on remission rate and duration of remission in a group of thirty-four patients with acute myeloid leukaemia.
Topics: Adult; Age Factors; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1980 |
Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Bone Marrow; Cytarabine; Humans; Leukemia, Myeloid, Acute; Lymphocytes | 1980 |
Blast colony formation in myelogenous leukemia: drug sensitivity and renewal capacity of the leukemic clone.
Topics: Antineoplastic Agents; Cell Division; Cell Survival; Clone Cells; Cytarabine; Doxorubicin; Drug Evaluation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Methylcellulose; Phytohemagglutinins | 1980 |
Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
Topics: 3-Deazauridine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cells, Cultured; Chromatography, High Pressure Liquid; Cytarabine; Cytidine Triphosphate; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Uracil Nucleotides; Uridine; Uridine Triphosphate | 1980 |
Acute leukemia: early recognition can spell survival.
Topics: Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1981 |
Re-induction of complete remissions in adults with acute non-lymphocytic leukemia.
Topics: Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Thioguanine | 1981 |
The heritable nature of clonal characteristics in acute myeloblastic leukemia.
Topics: Clone Cells; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Drug Resistance; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1981 |
Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Bone Marrow; Cells, Cultured; Cytarabine; Deamination; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Tetrahydrouridine | 1981 |
[The trials of determination of acute leukemia blasts sensitivity against cytostatics (author's transl)].
Topics: Adult; Antineoplastic Agents; Asparaginase; Cells, Cultured; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Lymphocytes; Methotrexate; Middle Aged; Vincristine | 1981 |
1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
Topics: Bone Marrow; Cells, Cultured; Cytarabine; Deamination; Humans; Leukemia, Myeloid, Acute; Tetrahydrouridine | 1981 |
Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.
Topics: Cell Division; Cell Line; Cell Survival; Cells, Cultured; Clone Cells; Cytarabine; DNA Replication; Humans; Leukemia, Myeloid, Acute | 1981 |
Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Female; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Platelet Transfusion; Thioguanine; Time Factors | 1981 |
Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP).
Topics: Aged; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pneumonia; Prednisone; Sepsis; Time Factors; Vincristine | 1981 |
Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1980 |
A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycosides; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Prednisone; Vincristine | 1981 |
Double minute chromosomes in a case of acute myelogenous leukemia resistant to chemotherapy.
Topics: Aged; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute | 1981 |
Acute myeloblastic leukemia presenting as progressive hepatic failure.
Topics: Adult; Child, Preschool; Cytarabine; Humans; Leukemia, Myeloid, Acute; Liver Diseases; Male | 1981 |
[Case of full remission of a blast crisis in myelocytic leukemia].
Topics: Blood Transfusion; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Remission, Spontaneous | 1981 |
Graft-versus-host disease in consecutive patients with acute myeloid leukaemia treated with blood cells from normal donors.
Topics: Cytarabine; Doxorubicin; Graft vs Host Reaction; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transfusion Reaction; Transplantation Immunology | 1981 |
[Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)].
Topics: Aclarubicin; Adult; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1981 |
Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Topics: Animals; Cell Division; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia L1210; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Rats | 1981 |
Bone marrow biopsy.
Topics: Bone Marrow; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 1981 |
DNA damage in AML cell exposed to adriamycin; correlations with clinical response to therapy.
Topics: Cells, Cultured; Cytarabine; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prognosis | 1981 |
The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.
Topics: Adult; Cytarabine; Drug Administration Schedule; Humans; Infusions, Parenteral; Injections, Intravenous; Injections, Subcutaneous; Kinetics; Leukemia, Myeloid, Acute | 1981 |
Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival.
Topics: Adult; Cytarabine; Daunorubicin; Histocytochemistry; Humans; Leukemia, Myeloid, Acute; Nervous System Neoplasms; Prognosis; Thioguanine; Vincristine | 1981 |
Self-renewal capacity of leukemic blast progenitor cells.
Topics: Aminoacridines; Amsacrine; Cell Division; Clone Cells; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Prognosis | 1981 |
Dose-dependent suppression of DNA synthesis in vitro as a predictor of clinical response in adult acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Cells, Cultured; Cytarabine; Depression, Chemical; DNA, Neoplasm; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thymidine | 1981 |
Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy.
Topics: Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Daunorubicin; DNA, Neoplasm; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Thymidine | 1981 |
VAPA10: a treatment program for acute myelocytic leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Infant; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Probability; Recurrence; Vincristine | 1981 |
Leukemic infiltration of the cerebellum in acute myelomonocytic leukemia.
Topics: Adult; Cerebellar Ataxia; Cerebellar Neoplasms; Cerebellum; Cytarabine; Drug Therapy, Combination; Female; Humans; Injections, Intraventricular; Leukemia, Myeloid, Acute; Methotrexate; Neoplasm Recurrence, Local; Tomography, X-Ray Computed | 1982 |
Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Binding Sites; Bone Marrow Cells; Carrier Proteins; Cell Transformation, Neoplastic; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Middle Aged; Nucleosides; Thioinosine; Time Factors | 1982 |
[Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
Topics: Aclarubicin; Adult; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes | 1981 |
The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia (AML).
Topics: Analysis of Variance; Cell Transformation, Neoplastic; Cells, Cultured; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Regression Analysis; Risk | 1982 |
A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Topics: Adolescent; Adult; Aged; Blood; Bone Marrow; Brain; Brain Neoplasms; Child; Cytarabine; Drug Evaluation; Eye; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Pilot Projects | 1982 |
Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.
Topics: Aclarubicin; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Naphthacenes; Recurrence | 1982 |
Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?
Topics: Aged; Cell Differentiation; Cytarabine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1982 |
Treatment of acute myeloid leukaemia in children.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Thioguanine | 1982 |
Causes of initial remission induction failure in acute myelogenous leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Bacterial Infections; Cytarabine; Daunorubicin; Doxorubicin; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Mycoses; Pneumonia; Prednisone; Vincristine | 1982 |
Case report: acute leukemia after semustine (methyl-CCNU) therapy.
Topics: Adenocarcinoma; Aged; Cecal Neoplasms; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrosourea Compounds; Semustine | 1982 |
Treatment of refractory acute leukaemia with high dose cytosine arabinoside.
Topics: Adolescent; Adult; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1982 |
Brachial plexus neuritis and fatal hemorrhage following Aspergillus infection of a Hickman catheter.
Topics: Antineoplastic Agents; Aspergillosis; Brachial Plexus; Catheters, Indwelling; Cytarabine; Female; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neuritis; Thioguanine | 1982 |
Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Bone Marrow; Cell Line; Cells, Cultured; Cytarabine; DNA Replication; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Organophosphorus Compounds; Phosphonoacetic Acid | 1982 |
Prognostic factors in response to anthracyclines.
Topics: Age Factors; Antibiotics, Antineoplastic; Body Temperature; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Metaphase; Middle Aged; Naphthacenes; Precancerous Conditions; Prognosis; Prospective Studies; Regression Analysis; Retrospective Studies | 1981 |
Vincristine and prednisolone therapy in blast crisis of chronic myelogenous leukaemia in childhood.
Topics: Adolescent; Child; Cyclophosphamide; Cytarabine; DNA Nucleotidylexotransferase; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Prednisolone; Prognosis; Vincristine | 1981 |
Acute leukaemia in pregnancy. A case report and discussion on modern management.
Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Thioguanine | 1982 |
Retrospective analysis of 158 cases of adult acute leukaemia: factors influencing prognosis and treatment response.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Karyotyping; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Prognosis; Regression Analysis; Retrospective Studies; Thioguanine; Vincristine | 1982 |
Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation.
Topics: Cell Cycle; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cytarabine; Dimethyl Sulfoxide; Humans; Hydroxyurea; Kinetics; Leukemia, Myeloid, Acute | 1982 |
Improved prospects for long-term survival in adults with acute myelogenous leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Cytarabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Prognosis; Time Factors | 1982 |
High dose cytosine arabinoside in the management of refractory acute leukaemia.
Topics: Adolescent; Adult; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1982 |
The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.
Topics: Arabinofuranosyluracil; Bone Marrow Cells; Cytarabine; Cytidine Triphosphate; Deamination; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Time Factors | 1982 |
[Treatment of acute promyelocytic leukemia: comparison of the therapeutic effect of daunorubicin and "DCMP" regimen in remission induction treatment].
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone | 1982 |
Totally implanted system for intravenous chemotherapy in patients with cancer.
Topics: Antineoplastic Agents; Blood Transfusion; Cytarabine; Doxorubicin; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Middle Aged; Vena Cava, Superior; Vincristine | 1982 |
[Treatment of acute myeloid leukemia with an intense chemotherapeutic regimen and variable reduction of the dosage for elderly patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1982 |
Acute myelogenous leukemia: successful treatment of relapse with cytosine arabinoside, VP 16-213, vincristine and vinblastine (A-triple-V).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thrombocytopenia; Vinblastine; Vincristine | 1982 |
Multicentre study on intensified remission induction therapy for acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Time Factors | 1982 |
Introduction to the symposium on high-dose cytosine arabinoside.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute | 1982 |
The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy.
Topics: Cytarabine; Dose-Response Relationship, Drug; Humans; Kinetics; Leukemia, Myeloid, Acute | 1982 |
Use of cytosar in pediatric acute myelocytic leukemia and leukemic meningitis.
Topics: Age Factors; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Hydrocortisone; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Meningitis; Methotrexate | 1982 |
A comparison of two schedules of cytosine arabinoside used in combination with adriamycin and 6-thioguanine in the treatment of acute myelogenous leukemia.
Topics: Adult; Bone Marrow; Cytarabine; Digestive System; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Thioguanine | 1982 |
High doses of cytosine arabinoside (HD-Ara-C) as reinforcement during remission of acute myeloid leukemia.
Topics: Adult; Cytarabine; Digestive System; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1982 |
In vitro sensitivity of CFU-L to cytosine arabinoside (Ara-C).
Topics: Bone Marrow; Cells, Cultured; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1982 |
[Treatment of acute leukemias].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Prognosis; Vincristine | 1982 |
Whether or not to administer Amphotericin to an immunosuppressed patient with hematologic malignancy and undiagnosed fever.
Topics: Agranulocytosis; Amphotericin B; Cytarabine; Daunorubicin; Decision Making; Esophagitis; Fever of Unknown Origin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses | 1981 |
[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Random Allocation | 1982 |
Variations of the phosphorylation of 1-beta-D-arabinofuranosylcytosine (ARA-C) in human myeloid leukemic cells related to the cell cycle.
Topics: Cell Cycle; Cell Separation; Cytarabine; DNA Replication; Humans; Leukemia, Myeloid, Acute; Phosphorylation | 1982 |
The treatment of acute myelocytic leukemia in patients 30 years of age and younger.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Combinations; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Sulfamethoxazole; Thioguanine; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1982 |
Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Cytarabine; Drug Therapy, Combination; Female; Hepatic Veins; Humans; Leukemia, Myeloid, Acute; Liver; Liver Diseases; Male; Radiotherapy; Transplantation, Autologous; Transplantation, Homologous; Vascular Diseases | 1980 |
[Effect on peripheral blood cells in children with acute leukemia during remission by intramuscular injected of arabinosyl-cytosine (author's transl)].
Topics: Blood Cell Count; Blood Cells; Child; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1980 |
Treatment of early acute nonlymphatic leukemia with low dose cytosine arabinoside.
Topics: Adult; Aged; Animals; Bone Marrow; Bone Marrow Transplantation; Cell Division; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Rats | 1981 |
Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Division; Cells, Cultured; Cytarabine; Daunorubicin; DNA Polymerase II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Thioguanine | 1995 |
Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Treatment Outcome | 1995 |
Acute nonlymphocytic leukemia complicated by Garcin's syndrome.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cranial Nerve Neoplasms; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Paralysis; Prednisolone; Recurrence; Syndrome; Zinostatin | 1995 |
[A case of acute myeloblastic leukemia invaded uterine cervix-diagnosed by changes in peripheral blood after G-CSF administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Mercaptopurine; Middle Aged; Neoplasm Invasiveness; Prednisolone; Prednisone; Recombinant Proteins; Uterine Cervical Neoplasms; Vincristine | 1993 |
Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Cell Cycle; Child, Preschool; Cytarabine; Female; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Stem Cell Factor; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
[Complete remission during administration of rhG-CSF in acute myeloblastic leukemia with pneumonia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Pancytopenia; Pneumonia; Prednisolone; Recombinant Proteins; Remission Induction | 1994 |
Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
Topics: Antineoplastic Agents; Cell Cycle; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured | 1994 |
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
Topics: Adult; Aged; Base Sequence; Blotting, Southern; Codon; Cytarabine; Deoxycytidine Kinase; DNA Mutational Analysis; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; RNA, Neoplasm | 1994 |
Successful second autologous blood stem cell transplantation after G-CSF-combined conditioning for the treatment of high-risk acute myelogenous leukemia.
Topics: Adult; Blood Transfusion, Autologous; Combined Modality Therapy; Cytarabine; DNA, Neoplasm; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Recurrence; Remission Induction; Risk Factors; Thymidine; Tritium | 1994 |
In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.
Topics: Adolescent; Adult; Aged; Cell Division; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Cells, Cultured | 1994 |
Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
Topics: Adult; Aged; Bromodeoxyuridine; Cytarabine; DNA, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cytarabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Vidarabine | 1994 |
All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Megakaryocytes; Tretinoin | 1994 |
[Continuation of complete remission by oral administration of cytarabine ocfosfate in a patient with M0, who achieved remission by small doses of cytosine arabinoside with G-CSF].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 1995 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine | 1995 |
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Topics: Animals; Antineoplastic Agents; Azacitidine; Base Sequence; Chromosome Aberrations; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Rats; Translocation, Genetic; Tumor Cells, Cultured | 1995 |
Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia.
Topics: Adolescent; Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytokines; Dacarbazine; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Interleukin-2; Interleukin-6; Interleukin-8; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Nimustine; Prospective Studies; Sialoglycoproteins; Tumor Necrosis Factor-alpha; Vincristine | 1995 |
[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 1995 |
Dose-intensive treatment of acute myelogenous leukemia: improved survival?
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Patient Selection; Prognosis; Remission Induction; Sex Factors | 1995 |
Oral Fusarium infection in a granulocytopenic patient with acute myelogenous leukemia: a case report.
Topics: Acute Kidney Injury; Aged; Agranulocytosis; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Epirubicin; Etoposide; Fatal Outcome; Fusarium; Gingival Diseases; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Maxillary Diseases; Mercaptopurine; Mycoses; Necrosis; Prednisolone; Ulcer; Vindesine | 1995 |
Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Dacarbazine; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid, Acute; Male; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Pilot Projects; Temozolomide | 1995 |
[Detection of the resistance to Ara-C blast cells in acute myeloid leukemia using flow cytometry].
Topics: Adolescent; Adult; Aged; Cell Cycle; Clone Cells; Cytarabine; DNA, Neoplasm; Drug Resistance; Female; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; S Phase; Tumor Cells, Cultured | 1995 |
Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Neutrophils; Remission Induction; Survival Analysis | 1995 |
Sensitivity of hematopoietic progenitors of acute myeloblastic leukemia to new compounds derived from marine organisms.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Cytarabine; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tumor Cells, Cultured; Urochordata | 1995 |
Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Interleukin-6; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphoma, Non-Hodgkin; Macrophage Colony-Stimulating Factor; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
Enhancement of cytosine arabinoside cytotoxicity by granulocyte/macrophage colony-stimulating factor and granulocyte colony-stimulating factor in a human myeloblastic leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cell Division; Child; Cytarabine; DNA, Neoplasm; Drug Synergism; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; RNA, Neoplasm; Solubility; Subcellular Fractions; Tumor Cells, Cultured | 1993 |
Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
Topics: Adult; Aged; Antineoplastic Agents; Cell Division; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
[Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].
Topics: Adult; Aged; Cell Cycle; Cytarabine; Drug Screening Assays, Antitumor; Drug Synergism; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Factor; Tumor Cells, Cultured | 1993 |
Recombinant human granulocyte colony-stimulating factor in combination with continuous infusion of cytosine arabinoside for the treatment of refractory acute myelogenous leukemia.
Topics: Bone Marrow; Cell Cycle; Cytarabine; Drug Therapy, Combination; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Remission Induction | 1993 |
Effects of mast cell growth factor on Ara-C mediated acute myeloid leukemia cell killing.
Topics: Cell Cycle; Cell Death; Cell Division; Cytarabine; Drug Synergism; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptors, Colony-Stimulating Factor; Recombinant Fusion Proteins; Recombinant Proteins; Stem Cell Factor; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
Re: Pseudorelapse in acute myelomonocytic leukemia after high dose methylprednisolone.
Topics: Child; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute | 1995 |
[Acute right ventricular insufficiency reversible following anthracycline treatment].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Time Factors; Ventricular Dysfunction, Right | 1995 |
Posttransfusion hepatitis after induction chemotherapy in acute nonlymphoblastic leukemia: implications for long-term management and outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hepatitis; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Transfusion Reaction; Treatment Outcome | 1995 |
[Ischemic hepatitis due to anthracycline-induced cardiac insufficiency in a patient with acute myelocytic leukemia (M0)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cytarabine; Doxorubicin; Etoposide; Female; Hepatitis; Humans; Ischemia; Leukemia, Myeloid, Acute; Liver; Remission Induction | 1995 |
Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
Topics: Acetylcysteine; Antioxidants; Base Sequence; Blotting, Northern; Cytarabine; Down-Regulation; Drug Interactions; Drug Screening Assays, Antitumor; Free Radicals; Gene Expression Regulation, Leukemic; Humans; Hydrocortisone; Hydrogen Peroxide; Leukemia, Myeloid, Acute; Lymphocyte Activation; Lymphocytes; Molecular Sequence Data; Polymerase Chain Reaction; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured | 1995 |
Encephalopathy with parkinsonian features in children following bone marrow transplantations and high-dose amphotericin B.
Topics: Adolescent; Amphotericin B; Antineoplastic Agents; Aspergillosis; Bone Marrow Transplantation; Brain Diseases; Child; Cyclophosphamide; Cytarabine; Humans; Leukemia, Myeloid, Acute; Lung Diseases; Male; Methotrexate; Parkinson Disease; Radiation Injuries | 1995 |
Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 1995 |
Fluorescence-labeling of nicks in DNA from leukemic blast cells as a measure of damage following cytosine arabinoside. Application to the study of regulated drug sensitivity.
Topics: Cytarabine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorescence; Genetic Techniques; Humans; Hydrocortisone; Kinetics; Leukemia, Myeloid, Acute; Tretinoin; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
Topics: Adult; Aged; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Genetic Techniques; Humans; Hydrocortisone; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Tretinoin; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
[Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside].
Topics: Age Factors; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 1994 |
Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia.
Topics: Cell Cycle; Cell Division; Cytarabine; Daunorubicin; Gene Expression; Genes, myc; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myb; Proto-Oncogene Proteins c-myc; Tritium; Tumor Stem Cell Assay | 1994 |
Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C.
Topics: Apoptosis; Base Sequence; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1995 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Humans; Idarubicin; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Tretinoin; Vincristine | 1994 |
Low expression of the deoxycytidine kinase (dCK) gene in a 1-beta-D-arabinofuranosylcytosine-resistant human leukemic cell line KY-Ra.
Topics: Base Sequence; Blotting, Northern; Cytarabine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance; Gene Expression; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; RNA, Messenger; Tumor Cells, Cultured | 1994 |
Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carrier Proteins; Child; Child, Preschool; Cytarabine; Drug Evaluation; Drug Resistance; Female; Gene Expression; Humans; Infant; Leukemia; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Mitoxantrone; Molecular Sequence Data; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1994 |
Acute myelogenous leukemia in pregnancy: fetal blood sampling and early effects of chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fetal Blood; Fetal Growth Retardation; Fetus; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Ultrasonography, Prenatal | 1994 |
1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrophoresis, Agar Gel; Genome, Human; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Paclitaxel; Tumor Cells, Cultured | 1994 |
Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Tissue Donors | 1994 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluoresceins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1994 |
Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia--neonatal and infantile course.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Craniosynostoses; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Phenotype; Pregnancy; Pregnancy Complications, Neoplastic; Thioguanine | 1994 |
[Acute leukemia in the elderly--a death sentence?].
Topics: Age Factors; Aged; Aged, 80 and over; Cytarabine; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 1994 |
Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute | 1994 |
Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Time Factors | 1994 |
Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Manitoba; Middle Aged; Multivariate Analysis; Neutropenia; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 1994 |
GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy.
Topics: Bone Marrow Diseases; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1994 |
Bone marrow purging in acute leukemia with alkyl-lysophospholipids: a new family of anticancer drugs.
Topics: Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Phospholipid Ethers; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Analysis; Whole-Body Irradiation | 1994 |
Infection of elderly patients receiving high dose cytarabine-based chemotherapy for induction treatment of acute myelogenous leukemia (AML)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 1994 |
[Acute febrile neutrophilic dermatitis (Sweet's syndrome) during therapeutic agranulocytosis in acute myeloblastic leukemia].
Topics: Agranulocytosis; Cytarabine; Female; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Middle Aged; Sweet Syndrome | 1993 |
[Therapy-related acute non-lymphocytic leukemia (M2) with 7;11 chromosome translocation induced into complete remission by low dose cytosine arabinoside and cytarabine ocfosfate therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Remission Induction; Translocation, Genetic | 1994 |
[High-dose chemoradiotherapy combined with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by autologous peripheral blood stem cell transplantation (PBSCT) in a case of refractory acute myelogenous leukemia (AML)].
Topics: Adult; Blood Cell Count; Combined Modality Therapy; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Recombinant Proteins | 1993 |
Vitamin D3 administration and multidrug resistance in acute nonlymphoblastic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cytarabine; Drug Resistance; Female; Humans; Hydroxycholecalciferols; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Remission Induction | 1993 |
The multiface morphology of acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Daunorubicin; Fatal Outcome; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1993 |
Case report: hypercalcemia in acute myeloblastic leukemia is caused by osteoclast activation.
Topics: Biopsy; Bone and Bones; Bone Marrow; Cytarabine; Etidronic Acid; Humans; Hypercalcemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Osteoclasts | 1993 |
Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients.
Topics: Antineoplastic Agents; Arabinofuranosyluracil; Chromatography, High Pressure Liquid; Cytarabine; Half-Life; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Treatment of refractory undifferentiated acute myelogenous leukemia with all-trans-retinoic acid.
Topics: Aged; Base Sequence; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Remission Induction; Tretinoin | 1994 |
Combination chemotherapy with DATV regimen in treatment of adult acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine; Vincristine | 1993 |
Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Chromosome Banding; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Peroxidase; Remission Induction; Thioguanine; Treatment Outcome | 1993 |
Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cell Cycle; Cytarabine; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Recurrence; Treatment Outcome | 1993 |
Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model.
Topics: Acute Disease; Aged; Aged, 80 and over; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Survival Rate | 1994 |
[Preliminary evaluation of adverse effects after administration of arabinoside cytosine (Ara-C) in high doses to children with acute myelogenous leukemia].
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Female; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male | 1994 |
[Combined therapy with mitoxantrone and cytosine arabinoside as a first-line treatment in ANLL: preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Treatment Outcome | 1993 |
[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Hematopoiesis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisolone; Remission Induction; Time Factors; Vincristine | 1993 |
Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients.
Topics: Adult; Aged; Blood Cells; Bone Marrow; Clone Cells; Cytarabine; Gene Expression Regulation, Leukemic; Genes, myc; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Oncogenes; Recombinant Proteins; S Phase; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Proteins; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Protein Binding; Serum Albumin; Topoisomerase II Inhibitors | 1993 |
Handling punctate keratitis resulting from systemic cytarabine.
Topics: Adult; Chloramphenicol; Corneal Opacity; Cytarabine; Glucocorticoids; Humans; Keratitis; Leukemia, Myeloid, Acute; Male; Ointments; Premedication; Visual Acuity | 1993 |
Translocation (2;4)(p23;q25): an additional case of a new recurrent anomaly in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Translocation, Genetic | 1993 |
[Treatment of myelodysplastic syndrome by combined traditional Chinese medicine and Western medicine therapy].
Topics: Adolescent; Adult; Aged; Cell Transformation, Neoplastic; Cytarabine; Drugs, Chinese Herbal; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyridoxine; Stanozolol; Tretinoin | 1993 |
Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
Topics: Adolescent; Adult; Anthracenes; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Follow-Up Studies; Heart Diseases; Hematologic Diseases; Humans; Infant; Kidney Diseases; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1994 |
Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Topics: Adolescent; Adult; Aged; Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine Kinase; DNA Polymerase II; DNA-Directed DNA Polymerase; DNA, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; S Phase; Thymidine Kinase; Tumor Cells, Cultured | 1994 |
[Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vinblastine; Vincristine | 1994 |
A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Methylcellulose; Vidarabine | 1993 |
Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
Topics: Arabinofuranosylcytosine Triphosphate; Bone Marrow; Bone Marrow Cells; Cytarabine; Deoxycytosine Nucleotides; DNA, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Intracellular Fluid; Kinetics; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Recombinant Proteins; S Phase; Tritium; Tumor Cells, Cultured | 1993 |
Dynamics of interaction between DNA-specific antitumor agents and serum-contained cytokines in the initiation of ML-1 human myeloblastic leukemia cell differentiation.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Differentiation; Cytarabine; Cytokines; Dactinomycin; Daunorubicin; DNA, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Monocytes; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1993 |
Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Coloring Agents; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Tetrazolium Salts; Thiazoles | 1993 |
Changes in the oral microflora during cytotoxic chemotherapy in children being treated for acute leukemia.
Topics: Adolescent; Analysis of Variance; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Candida albicans; Candidiasis, Oral; Chi-Square Distribution; Child; Child, Preschool; Chlorhexidine; Colony Count, Microbial; Cytarabine; Daunorubicin; Etoposide; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Mouth; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Streptococcus mutans; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prospective Studies; Recurrence; Salvage Therapy; Tumor Stem Cell Assay | 1993 |
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Tumor Stem Cell Assay | 1993 |
Orbito-ocular granulocytic sarcoma (OOGS) and acute myeloblastic leukemia (AML) with duplication of Philadelphia chromosome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Eye Neoplasms; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Multigene Family; Neoplasms, Multiple Primary; Orbital Neoplasms; Philadelphia Chromosome; Thioguanine | 1993 |
Prognostic significance of myeloperoxidase containing blast cells in acute myelogenous leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Prognosis; Recurrence; Remission Induction | 1993 |
Malignant fibrous histiocytoma following bone marrow transplantation for acute leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Combined Modality Therapy; Cytarabine; Daunorubicin; Graft vs Host Disease; Histiocytoma, Benign Fibrous; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Radiography | 1993 |
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 1993 |
Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1993 |
On the interaction between cytosine arabinoside and etoposide in vivo and in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Interactions; Etoposide; Humans; In Vitro Techniques; Kinetics; Leukemia, Myeloid, Acute; Phosphorylation | 1993 |
High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Life Tables; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Risk; Vincristine | 1993 |
All-trans retinoic acid plus low doses of cytarabine for the treatment of "poor-risk" acute myeloid leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Tretinoin | 1993 |
[Alterations in morphological and phenotypical features of leukemic cells relapse 7 years after onset in a case of acute non-lymphocytic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Neoplasms, Second Primary; Prednisolone | 1993 |
Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction | 1993 |
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Topics: Adult; Aged; Arabinofuranosylcytosine Triphosphate; Clinical Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 1993 |
Disseminated subcutaneous Nocardia asteroides abscesses in a patient after bone marrow transplantation.
Topics: Abscess; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Immunocompromised Host; Incidence; Leukemia, Myeloid, Acute; Mercaptopurine; Neutropenia; Nocardia asteroides; Nocardia Infections; Opportunistic Infections; Prednisolone; Remission Induction; Skin Diseases, Infectious | 1993 |
Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate | 1993 |
[Effect of 2-chlorodeoxyadenosine, arabinoside cytosine and doxorubicin on acute myeloid leukemia clonogenic cell proliferation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cladribine; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1995 |
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cyclosporine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mathematical Computing; Monitoring, Physiologic; Probability; Remission Induction; Research Design | 1996 |
Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Fungemia; Fungi; Humans; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mycoses; Remission Induction; Retrospective Studies | 1995 |
[Acute myelogenous leukemia with diabetes insipidus without desmopression administration by anti-leukemic chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Deamino Arginine Vasopressin; Diabetes Insipidus; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Renal Agents | 1995 |
Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1995 |
Cutaneous eruption of lymphocyte recovery mimicking mycosis fungoides in a patient with acute myelocytic leukemia.
Topics: CD4 Antigens; Cytarabine; Diagnosis, Differential; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Mycosis Fungoides; Skin | 1995 |
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Recurrence; Translocation, Genetic | 1996 |
Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Medical Futility; Probability; Survival Rate; Treatment Outcome | 1996 |
A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.
Topics: Alkaline Phosphatase; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cell Line; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Radioimmunoassay; Sensitivity and Specificity; Tumor Cells, Cultured | 1996 |
Translocation (2;3)(p13;q26) in two cases of myeloid malignancies. Acute myeloblastic leukemia (M2) and blastic phase of chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Prednisolone; Prednisone; Translocation, Genetic; Vincristine | 1996 |
Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate | 1995 |
Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy.
Topics: Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blotting, Northern; Blotting, Western; Cytarabine; Daunorubicin; Down-Regulation; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Remission Induction; RNA, Messenger; Transcription, Genetic; Transcriptional Activation; Tretinoin; Tumor Cells, Cultured | 1996 |
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mitoxantrone | 1996 |
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Topics: Antineoplastic Agents; Cell Cycle; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Binding; Tumor Cells, Cultured; Vidarabine | 1996 |
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Logistic Models; Middle Aged; Prognosis; Remission Induction; Risk Factors | 1996 |
[A case of acute myelocytic leukemia in relapse controlled by continuous home administration of Ara-C].
Topics: Antimetabolites, Antineoplastic; Cytarabine; Home Care Services, Hospital-Based; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quality of Life | 1996 |
Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blast Crisis; Calcium; Cell Membrane; Cytarabine; Flow Cytometry; Glutathione; Humans; Leukemia, Myeloid, Acute; Lipid Peroxidation; Neoplastic Stem Cells; Oxidation-Reduction; Oxidative Stress; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Remission Induction; Risk Factors | 1996 |
Bilateral submandibular salivary gland enlargement during chemotherapy for acute myeloid leukaemia--beneficial effect of propranolol.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Propranolol; Submandibular Gland | 1996 |
Clonality switch in acute myeloid leukemia.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Clone Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Dosage Compensation, Genetic; Female; Hematopoiesis; Heterozygote; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Prednisolone; Remission Induction; Thioguanine; Vincristine | 1996 |
Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Eosinophilia; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Translocation, Genetic | 1996 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1996 |
Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; DNA Damage; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2 | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disease; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Female; Hepatic Encephalopathy; Hepatitis B; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1996 |
A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: preclinical cell culture studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Paclitaxel; Tretinoin; Tumor Cells, Cultured | 1996 |
[Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leu
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Myelodysplastic Syndromes; Phosphorylation; Tyrosine | 1996 |
[8;21 translocation acute myelocytic leukemia developing in the second trimester of pregnancy with successful delivery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Female; Humans; Infant, Newborn; Labor, Obstetric; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Translocation, Genetic | 1996 |
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Camptothecin; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topotecan | 1997 |
Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1996 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prednisolone; Recombinant Fusion Proteins; RNA, Messenger; Translocation, Genetic | 1997 |
[Early establishment of bone marrow hypoplasia by antileukemic chemotherapy with concurrent rhG-CSF in a case of acute myelogenous leukemia complicated with intestinal perforation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Duodenal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Intestinal Perforation; Karyotyping; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Recombinant Proteins; Remission Induction | 1997 |
Acute abdomen due to endometriosis as a diagnostic and therapeutic challenge in the treatment of acute myelocytic leukemia.
Topics: Abdomen, Acute; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Endometriosis; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged | 1997 |
[Growth inhibitory effects of ubenimex on leukemic cell lines resistant to chemotherapeutic agents].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Cytarabine; Daunorubicin; Depression, Chemical; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leucine; Leukemia, Myeloid, Acute; Mercaptopurine; Tumor Cells, Cultured | 1996 |
Complete remission following donor PBSC after low-dose cytarabine chemotherapy for early relapse of acute myelogenous leukemia after allogeneic stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Transplantation, Homologous | 1997 |
Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vincristine | 1997 |
Retreatment with low-dose cytarabine in patients with previous central nervous system toxicity.
Topics: Cerebellar Diseases; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Spontaneous remission in acute myelogenous leukemia: a case report.
Topics: Antimetabolites, Antineoplastic; Blood Component Transfusion; Cytarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Regression, Spontaneous; Remission Induction | 1997 |
Angioimmunoblastic lymphadenopathy with disseminated human herpesvirus 6 infection in a patient with acute myeloblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Cytarabine; DNA, Viral; Fatal Outcome; Fever; Herpesviridae Infections; Herpesvirus 6, Human; Humans; Hypergammaglobulinemia; Idarubicin; Immunoblastic Lymphadenopathy; Immunophenotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Middle Aged; Pericarditis; Polymerase Chain Reaction; Remission Induction; Tumor Virus Infections | 1997 |
Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity.
Topics: Calcium; Cytarabine; Flow Cytometry; Humans; Intracellular Membranes; Leukemia, Myeloid, Acute; Membrane Potentials; Mitochondria; Oxidative Stress; Permeability; Phosphatidylserines; Reactive Oxygen Species; Time Factors; Tumor Cells, Cultured | 1997 |
Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Philadelphia Chromosome | 1997 |
[Treatment of acute myelogenous leukemia in patients more than 80 years old].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Quality of Life; Remission Induction | 1997 |
Disseminated tuberculosis treated with amikacin in a patient with acute myelocytic leukemia.
Topics: Abscess; Adrenal Gland Diseases; Aged; Amikacin; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Tuberculosis; Tuberculosis, Hepatic; Tuberculosis, Pulmonary | 1997 |
Acute myeloblastic leukemia in adults.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Treatment Outcome | 1995 |
[Observation and care in high-dose cytarabine treatment of acute myelogenous leukemia].
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nursing Assessment | 1996 |
Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Erythema; Female; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence | 1997 |
[Acute myeloblastic leukemia showing pronounced skin infiltration during administration of low-dose cytarabine and etoposide with granulocyte colony-stimulating factor].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Skin | 1997 |
FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Vidarabine | 1997 |
[IL-2 post-autologous transplant of hematopoietic stem cells].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lymphoma, AIDS-Related; Male; Neoplasms, Second Primary; Viral Load | 1998 |
High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia.
Topics: Adult; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Candidiasis; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Risk Factors | 1997 |
Cytosine arabinoside-induced vasculitis.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Vasculitis | 1998 |
Cranial irradiation and permeability of blood-brain barrier to cytosine arabinoside in children with acute leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Blood-Brain Barrier; Brain Neoplasms; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1998 |
[Giant platelet-like cell fragments produced from abnormal promyelocytes in acute myelogenous leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocytes; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Platelet Count; Prednisolone; Remission Induction | 1998 |
[Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; DNA; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Retrospective Studies; Vincristine | 1998 |
Follicular mucinosis as a presenting sign of acute myeloblastic leukemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytarabine; Doxorubicin; Follow-Up Studies; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucinosis, Follicular; Mycosis Fungoides; Paraneoplastic Syndromes; Remission Induction; Skin Neoplasms; T-Lymphocytes | 1998 |
[Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged | 1996 |
Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Treatment Outcome; Trisomy | 1998 |
Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis?
Topics: Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Erythema; Hand Dermatoses; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Necrosis | 1998 |
Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Marrow Cells; Child, Preschool; Cytarabine; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Karyotyping; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Treatment Outcome | 1998 |
Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia, Myeloid, Acute; Uridine Triphosphate | 1998 |
Multiple inflammatory pseudotumors of the liver associated with acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cytarabine; Daunorubicin; Diagnosis, Differential; Granuloma, Plasma Cell; Humans; Leukemia, Myeloid, Acute; Liver Abscess; Liver Diseases; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mercaptopurine; Prednisolone; Tomography, X-Ray Computed | 1998 |
Evidence for sinoatrial blockade associated with high dose cytarabine therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Leukemia, Myeloid, Acute; Sinoatrial Block | 1998 |
[Petechiae, suffusions and cytarabine-induced erythema in treatment of acute myeloid leukemia].
Topics: Aged; Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Drug Eruptions; Female; Humans; Leukemia, Myeloid, Acute; Purpura | 1998 |
Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Topics: Bone Marrow Transplantation; Cytarabine; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Transplantation, Autologous; Treatment Outcome | 1998 |
[Low-dose oral etoposide and subcutaneous injection of low-dose cytosine arabinoside (Et-A non i.v.) with or without minimum anthracycline for refractory acute non-lymphoblastic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Vindesine | 1998 |
[Prognostic significance of CD7 expression in adult acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antigens, CD7; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Prognosis; Survival Rate; Thioguanine; Tretinoin | 1998 |
[Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Translocation, Genetic; Treatment Outcome | 1998 |
Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bone Marrow Purging; Bone Marrow Transplantation; Crohn Disease; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Thioguanine; Transplantation, Homologous | 1998 |
An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Calcium; Cytarabine; Flow Cytometry; Gamma Rays; Genes, bcl-2; Glutathione; Humans; Lasers; Leukemia, Myeloid, Acute; Membrane Potentials; Mitochondria; Oxidative Stress; Phosphatidylserines; Reactive Oxygen Species; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
[Cytarabine-induced pericarditis].
Topics: Aged; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pericarditis | 1998 |
Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Survival Rate; Treatment Outcome | 1999 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Combined Modality Therapy; Cytarabine; Doxorubicin; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematoma; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Puerperal Disorders; Remission Induction; Rupture, Spontaneous; Shock; Splenic Rupture; Thioguanine | 1999 |
Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Agents; Brain; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Radiography; Seizures | 1999 |
Chemotherapy-induced inflammation in seborrheic keratoses mimicking disseminated herpes zoster.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Eruptions; Female; Herpes Zoster; Humans; Keratosis, Seborrheic; Leukemia, Myeloid, Acute; Skin; Substance Withdrawal Syndrome | 1999 |
Transient effusive-constrictive pericarditis due to chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Echocardiography; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pericarditis, Constrictive; Tomography, X-Ray Computed | 1999 |
Bacteremia caused by a novel isolate resembling leptotrichia species in a neutropenic patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Gram-Negative Anaerobic Straight, Curved, and Helical Rods; Gram-Negative Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Microscopy, Electron; Middle Aged; Neutropenia; Phylogeny | 1999 |
Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Salvage Therapy; Survival Analysis; Time Factors | 1999 |
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Autologous | 1999 |
Acute myeloblastic leukemia (M0) with an unusual chromosomal abnormality: translocation (1;14)(p13;q32).
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Cytarabine; Female; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Peroxidase; Translocation, Genetic | 1999 |
Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Treatment Failure; Treatment Outcome | 1999 |
Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Multiple; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 1999 |
Thiamine deficiency in a patient receiving chemotherapy for acute myeloblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Thiamine Deficiency | 1999 |
Pseudotumor cerebri secondary to intermediate-dose cytarabine HCl.
Topics: Acetazolamide; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Child; Cytarabine; Diuretics; Humans; Leukemia, Myeloid, Acute; Male; Prednisone; Pseudotumor Cerebri | 1999 |
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine | 1999 |
Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-), and CD33(-).
Topics: Adult; Antibiotics, Antineoplastic; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Bone Marrow Cells; CD13 Antigens; Cell Adhesion Molecules; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Lipopolysaccharide Receptors; Male; Membrane Glycoproteins; Peroxidase; Phenotype; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic | 1999 |
[The use of the nucleolar apparatus indices of the leukemic cells in patients with acute myeloblastic leukemia for the early detection of resistant clones].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Cell Nucleolus; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Middle Aged; Prednisolone; Time Factors | 1999 |
De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Translocation, Genetic | 1999 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Potassium; Sodium | 1999 |
Skin toxicity after administration of low-dose cytarabine.
Topics: Antimetabolites, Antineoplastic; Child; Cytarabine; Erythema Nodosum; Exanthema; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Skin Diseases; Urticaria | 1999 |
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Idarubicin; Immunohistochemistry; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Survival Rate; Tretinoin; Vault Ribonucleoprotein Particles | 1999 |
Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML.
Topics: Apoptosis; bcl-2-Associated X Protein; Blast Crisis; Bone Marrow Cells; Cytarabine; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Thioguanine | 1999 |
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxorubicin; Drug Screening Assays, Antitumor; Erythrocytes; Etoposide; Humans; Leukemia, Myeloid, Acute; Recurrence; Scandinavian and Nordic Countries; Thioguanine | 1999 |
Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aphidicolin; Blast Crisis; Bone Marrow Cells; Cell Survival; Cytarabine; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1999 |
Effects of CSFS and their combinations with chemotherapeutic agents (CH) on leukemic blasts (LB) in children (MTT-assay).
Topics: Adolescent; Adult; Antineoplastic Agents; Blast Crisis; Bone Marrow Cells; Child; Child, Preschool; Colony-Stimulating Factors; Cytarabine; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1999 |
Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34.
Topics: Antibodies; Antigens, CD34; Cell Count; Cytarabine; Dactinomycin; Flow Cytometry; Fluorescent Dyes; Humans; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Light; Myelodysplastic Syndromes; Scattering, Radiation; Sensitivity and Specificity; Stem Cells; Tumor Cells, Cultured | 1999 |
Modulation of in vitro chemosensitivity in acute myelogenous leukemia cell line by GM-CSF: opposing effects observed with different cytotoxic drugs and time exposure.
Topics: Antimetabolites, Antineoplastic; Cell Death; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Methotrexate; Time Factors; Tumor Cells, Cultured | 1999 |
[Necrotizing fasciitis in sacrococcygeal pilonidal sinus in a patient with bone marrow aplasia. Treatment by large excision and closing by local flaps].
Topics: Adult; Anemia, Aplastic; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Fasciitis, Necrotizing; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Pilonidal Sinus; Sacrococcygeal Region; Surgical Flaps | 1999 |
Pulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Ascomycota; Cytarabine; Drug Resistance, Microbial; Female; Humans; Idarubicin; Itraconazole; Leukemia, Myeloid, Acute; Lung Diseases, Fungal; Midwestern United States; Mycological Typing Techniques | 2000 |
Extramedullary myeloid cell tumour: presentation as anterior chest wall mass during AML relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Soft Tissue Neoplasms; Thoracic Neoplasms | 1999 |
Regulation of drug sensitivity by ribosomal protein S3a.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cryopreservation; Cytarabine; DNA Replication; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Gene Targeting; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel; Phosphorylation; Phosphoserine; Protein Processing, Post-Translational; Rats; Ribosomal Proteins; Tissue Preservation; Treatment Outcome; Tretinoin | 2000 |
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm, Residual; Prognosis; Prospective Studies; Recurrence; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Typhlitis as a presenting manifestation of acute myelogenous leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Ileal Diseases; Laparotomy; Leukemia, Myeloid, Acute; Tomography, X-Ray Computed | 2000 |
[Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases].
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Retrospective Studies | 1998 |
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2000 |
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
Topics: Antineoplastic Agents; Blast Crisis; Cell Survival; Child; Cytarabine; Dexamethasone; Down Syndrome; Doxorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2000 |
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cerebellar Diseases; Cytarabine; Death, Sudden, Cardiac; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Thrombocytopenia; Treatment Outcome | 2000 |
Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Neoplasms; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Prednisolone; Remission Induction; Reoperation | 2000 |
[Retrospective study of acute myelogenous leukemia in elderly patients: treatment and outcome of 83 consecutive patients].
Topics: Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Therapy, Combination; Gene Deletion; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2000 |
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Neoplasms, Second Primary; Survival Rate; Treatment Outcome | 2000 |
Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Erythroblasts; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Middle Aged; Prognosis; Treatment Outcome | 2000 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine | 2000 |
[In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes; Tumor Cells, Cultured | 2000 |
Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Genes, rel; Humans; Leukemia, Myeloid, Acute; NF-kappa B; Oligodeoxyribonucleotides; Tumor Cells, Cultured | 2000 |
[Study on combined chemosensitivity test in acute non-lymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1998 |
Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin.
Topics: Antigens, CD34; Antineoplastic Agents; Cell Survival; Coumarins; Cytarabine; Cytotoxicity Tests, Immunologic; Daunorubicin; DNA, Antisense; Edetic Acid; Etoposide; Flow Cytometry; Granzymes; HeLa Cells; Humans; Isocoumarins; Jurkat Cells; K562 Cells; Leukemia, Myeloid, Acute; Magnesium Chloride; Membrane Glycoproteins; Perforin; Pore Forming Cytotoxic Proteins; Serine Endopeptidases; Tumor Cells, Cultured; U937 Cells | 2000 |
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Regression Analysis; Retrospective Studies; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2000 |
Visual loss following high-dose cytosine arabinoside (ARA-C)
Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Nervous System Diseases; Vision Disorders | 2000 |
Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Treatment Outcome | 2000 |
[Childhood acute myeloblastic leukemias. Report of 21 cases].
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis | 2000 |
High dose ara-C combined with autologous peripheral blood stem cell transplantation in the treatment of acute myelogenous leukemia: the question is still not answered.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation, Autologous | 2000 |
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Rate | 2000 |
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic l
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Clone Cells; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vidarabine | 2000 |
Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multivariate Analysis | 2001 |
Madurella infection in an immunocompromised host.
Topics: Aged; Antifungal Agents; Antimetabolites, Antineoplastic; Cytarabine; Humans; Immunocompromised Host; Itraconazole; Leukemia, Myeloid, Acute; Madurella; Male; Mycetoma | 2000 |
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
Topics: Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Isochromosomes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Remission Induction; Thioguanine | 2001 |
[Outcome of autologous bone marrow transplantation in 73 patients with acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1998 |
[Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2001 |
Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
Topics: Antimetabolites, Antineoplastic; Aphidicolin; Cell Survival; Cytarabine; DNA; Drug Resistance; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fetal Blood; Formazans; Humans; Lethal Dose 50; Leukemia, Myeloid, Acute; Tetrazolium Salts; Tumor Cells, Cultured | 2001 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Chromosome Breakage; Cyclin B; Cyclin B1; Cytarabine; Deoxycytidine; DNA, Neoplasm; G2 Phase; Gemcitabine; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Phosphorylation; RNA; Tumor Cells, Cultured | 2001 |
[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neural Tube Defects; Tretinoin | 2001 |
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Homosexuality, Male; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, AIDS-Related; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Neoplasm Metastasis; Neoplasms, Second Primary; Topoisomerase II Inhibitors | 2001 |
Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Cycle; Cell Division; Coculture Techniques; Colony-Forming Units Assay; Culture Media, Conditioned; Cytarabine; Daunorubicin; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Stromal Cells; Tumor Cells, Cultured | 2001 |
Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure.
Topics: Apoptosis; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cyclin D; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Cytarabine; Daunorubicin; DNA Damage; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Microtubule-Associated Proteins; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Stem Cell Factor; Tumor Suppressor Proteins | 2001 |
Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML).
Topics: Cytarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mutation; Recurrence | 2001 |
Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
Topics: Adult; Aged; Aged, 80 and over; Arabinofuranosylcytosine Triphosphate; Cytarabine; Female; Half-Life; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged | 2001 |
Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
Topics: Adult; Antimetabolites, Antineoplastic; Atrophy; Cerebellar Ataxia; Cerebellum; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Videotape Recording | 2001 |
Leukemia cutis in an elderly patient treated with low dose cytosine arabinoside and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Exanthema; Humans; Immunophenotyping; Leukemia; Leukemia, Myeloid, Acute; Male | 2001 |
[Primary pulmonary manifestation of extramedullary acute myelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bronchoalveolar Lavage Fluid; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Middle Aged; Prednisolone; Radiography; Thioguanine; Vincristine | 2001 |
Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines.
Topics: Anticholesteremic Agents; Antimetabolites, Antineoplastic; Cell Division; Cytarabine; Drug Synergism; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Myeloid, Acute; Simvastatin; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cytarabine; Drug Costs; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Treatment Outcome; Vidarabine | 2001 |
Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Cladribine; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Prognosis; Treatment Outcome | 2001 |
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cytarabine; Enzyme Inhibitors; Flavonoids; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Proteins; X-Linked Inhibitor of Apoptosis Protein | 2001 |
[CD7(+) acute myeloid leukemia (M0) associated with a mediastinal bulky mass lesion].
Topics: Adult; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Neoplasms, Multiple Primary; Remission Induction | 2001 |
[Therapy of acute myeloid leukemia in the elderly patient].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Geriatric Assessment; Germany; Humans; Infant; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Rate | 2001 |
[Experimental study of cord blood plasma enhancing the anti-leukemia effect of Ara-C].
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Cell Cycle; Cytarabine; Drug Resistance, Neoplasm; Female; Fetal Blood; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Plasma; Recombinant Proteins; Tumor Cells, Cultured | 1999 |
Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a lung allograft recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Alveolar Proteinosis; Tomography, X-Ray Computed; Vidarabine | 2001 |
Cocaine-contaminated allogeneic bone marrow transplantation.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Cocaine-Related Disorders; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Graft Survival; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Marijuana Abuse; Middle Aged; Recurrence; Salvage Therapy; Thrombocythemia, Essential; Tissue and Organ Procurement; Tissue Donors; Transplantation, Homologous | 2001 |
And the sun keeps shining.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Etoposide; Female; Hair Follicle; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2001 |
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Topics: Benzamides; Cell Division; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interleukin-3; Kinetics; Leukemia, Myeloid, Acute; Leukocyte Count; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Signal Transduction; Stem Cell Factor | 2001 |
Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2001 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; Cytarabine; Down Syndrome; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Thioguanine; Vincristine | 2002 |
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
Topics: Annexin A5; Apoptosis; bcl-2-Associated X Protein; Blast Crisis; Caspase 3; Caspases; Cell Differentiation; Cell Survival; Cytarabine; DNA Fragmentation; Drug Interactions; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Potentials; Mitogen-Activated Protein Kinases; Oleanolic Acid; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retinoids; Tretinoin; Tumor Cells, Cultured | 2002 |
Effects of cytarabine and various anthracyclins on platelet activation: characterization of in vitro effects and their possible clinical relevance in acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antigens, CD; Antimetabolites, Antineoplastic; Cell Adhesion; Cytarabine; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Neoplastic Cells, Circulating; P-Selectin; Platelet Activation; Platelet Membrane Glycoproteins; Tetraspanin 30; Tumor Cells, Cultured | 2002 |
CD56 expression in myeloperoxidase-negative FAB M5 acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; CD56 Antigen; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cytarabine; Fatal Outcome; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Recurrence; Remission Induction | 2002 |
Autologous stem cell transplantation for advanced acute myeloid leukemia.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Count; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Translocation, Genetic; Transplantation, Autologous | 2002 |
Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Encephalitis, Viral; Etoposide; Fatal Outcome; Female; Fetal Blood; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Herpesvirus 6, Human; Humans; Immunocompromised Host; Korsakoff Syndrome; Leukemia, Myeloid, Acute; Recurrence; Roseolovirus Infections; Transplantation Conditioning; Transplantation, Homologous; Virus Activation | 2001 |
Treatment and outcome of infants with acute myeloid leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Survival Rate; Time Factors; Treatment Outcome | 2002 |
A case of zygomycosis and invasive candidiasis involving the epiglottis and tongue in an immunocompromised patient.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Candida; Candidiasis; Cytarabine; Epiglottis; Fungi; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Neutropenia; Tongue; Tongue Diseases; Zygomycosis | 2002 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
[Intermediate doses of cytosine arabinoside in the treatment of acute non-lymphoblastic leukaemia in children].
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Poland; Prednisone; Remission Induction; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Bone marrow transplantation in acute leukemia using intensive chemoradiotherapy (SCARI--UCLA).
Topics: ABO Blood-Group System; Adolescent; Adult; Bone Marrow Cells; Bone Marrow Transplantation; Candidiasis; Child; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Daunorubicin; Graft vs Host Reaction; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Radiation Chimera; Thioguanine; Transplantation, Homologous | 1976 |
Bone marrow transplantation with intensive combination chemotherapy/radiation therapy (SCARI) in acute leukemia.
Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Graft vs Host Reaction; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Time Factors; Transplantation, Homologous | 1977 |
"Pure" monocytic or histiomonocytic leukemia: a revised concept.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Bone Marrow; Bone Marrow Cells; Child, Preschool; Cytarabine; Doxorubicin; Esterases; Female; Glucuronidase; Histiocytes; Histocytochemistry; Humans; Infant; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Microscopy, Electron; Monocytes; Peroxidases; Prednisone; Remission, Spontaneous; Staining and Labeling; Vincristine | 1975 |
Bone-marrow-profileration patterns in acute myeloblastic leukaemia determined by pulse cytophotometry.
Topics: Autoradiography; Bone Marrow; Bone Marrow Cells; Cell Count; Cell Division; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Photometry; Remission, Spontaneous; Thioguanine; Tritium | 1975 |
Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes.
Topics: Azacitidine; Blood Proteins; Cell Separation; Cell-Free System; Cytarabine; Cytidine Deaminase; Deoxycytidine; Granulocytes; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Molecular Weight; Phosphates; Phosphotransferases; Tissue Extracts; Uridine Kinase | 1975 |
Quality and quantity of survival in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Allopurinol; Bacterial Infections; Cytarabine; Daunorubicin; Drug Therapy, Combination; Focal Infection, Dental; Follow-Up Studies; Humans; Length of Stay; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Philosophy; Quality of Life; Remission, Spontaneous | 1975 |
[Problems in maintenance therapy in acute myeloid leukemias in adults].
Topics: Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Vincristine | 1975 |
Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia.
Topics: Adult; Azacitidine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Phosphates; Prednisone; Pregnancy; Pregnancy Complications; Thioguanine; Vincristine | 1976 |
High remission-induction rate in acute myeloid leukaemia.
Topics: Administration, Oral; Adult; Age Factors; Aged; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors | 1977 |
Chemotherapeutic remissions in Wistar Furth rat acute myelogenous leukemia: a model for human AML.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Dexamethasone; Disease Models, Animal; Doxorubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Methotrexate; Rats; Remission, Spontaneous; Vinblastine; Vincristine | 1977 |
Deoxycytidine and lethal doses of cytarabine in advanced murine leukaemia.
Topics: Administration, Oral; Animals; Cytarabine; Deoxycytidine; Drug Antagonism; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mice | 1977 |
Prolonged maintained remissions of adult acute non-lymphocytic leukaemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cytarabine; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors | 1977 |
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation.
Topics: Azacitidine; Bone Marrow; Cell Division; Cell Separation; Centrifugation; Cytarabine; Humans; In Vitro Techniques; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Thymidine | 1977 |
Prediction of therapeutic response in acute leukaemia.
Topics: Adult; Aged; Cells, Cultured; Cyclophosphamide; Cytarabine; Depression, Chemical; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous; Thymidine; Tritium; Vincristine | 1978 |
D.A.T. (daunorubicin, cytarabine, 6-thioguanine) in acute myeloid leukaemia.
Topics: Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Thioguanine | 1978 |
Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors.
Topics: Adolescent; Ancitabine; Child; Child, Preschool; Cytarabine; Drug Evaluation; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Neoplasms | 1979 |
The nature of remission in acute myeloblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous; Thioguanine; Transplantation, Homologous | 1979 |
Synchronisation of cell phase in treatment of leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytological Techniques; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; S Phase | 1977 |
Acute eosinophilic leukemia. An ultrastructural study.
Topics: Adult; Bone Marrow; Cytarabine; Daunorubicin; Eosinophils; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Prednisone; Recurrence | 1978 |
A 13-years remission in chronic myelocytic leukemia after a single course of busulfan.
Topics: Adult; Busulfan; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Remission, Spontaneous; Time Factors | 1978 |
[Low-dose cytosine arabinoside in the therapy of varicella in childhood leukaemia (author's transl)].
Topics: Chickenpox; Child; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1978 |
Drug-induced kinetic perturbations of the marrow blasts in acute leukemia. Effects of the daunorubicin, cytosine arabinoside and 6-thioguanine combination.
Topics: Adolescent; Adult; Bone Marrow; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitotic Index; Thioguanine | 1979 |
Oscillations of marrow culture growth in acute myeloid leukemia during remission induction and remission.
Topics: Adult; Bone Marrow; Colony-Forming Units Assay; Culture Techniques; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Thioguanine | 1979 |
[Statistical studies on therapy of leukemia with tumor formation (author's transl)].
Topics: Adolescent; Adult; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Statistics as Topic; Vincristine; Zinostatin | 1975 |
Technique for preclinical evaluation of continuous infusion chemotherapy with the use of WF rat acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Infusions, Parenteral; Injections, Intravenous; Leukemia, Experimental; Leukemia, Myeloid, Acute; Rats; Rats, Inbred WF; Thymidine; Zinostatin | 1979 |
Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Cytidine Deaminase; Deoxycytidine; Drug Resistance; Erythrocytes; Granulocytes; Humans; Kinetics; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Nucleoside Deaminases; Phosphotransferases; Tetrahydrouridine | 1975 |
Pyrimidine nucleoside monophosphate kinase from human leukemic blast cells.
Topics: Animals; Cell Line; Cytarabine; Deoxycytidine Monophosphate; Humans; In Vitro Techniques; Kinetics; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Molecular Weight; Nucleoside-Phosphate Kinase; Phosphotransferases; Pyrimidine Nucleotides; Sulfhydryl Reagents | 1978 |
Long-term remission from acute myelogenous leukemia after bone marrow transplantation and recovery from acute graft-versus-host reaction and prolonged immunoincompetence.
Topics: ABO Blood-Group System; Adolescent; Adult; Anti-Bacterial Agents; Antilymphocyte Serum; B-Lymphocytes; Bacterial Infections; Blood Group Incompatibility; Bone Marrow Cells; Bone Marrow Transplantation; Candidiasis; Cyclophosphamide; Cytarabine; Graft vs Host Reaction; Histocompatibility Antigens; Humans; Immunity, Maternally-Acquired; Immunologic Deficiency Syndromes; Leukemia, Myeloid, Acute; Male; Nitrosourea Compounds; Opsonin Proteins; T-Lymphocytes; Thioguanine; Transplantation, Homologous; Virus Diseases | 1975 |
Successful treatment of acute leukemia during pregnancy. Combination therapy in the third trimester.
Topics: Adult; Birth Weight; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Karyotyping; Leukemia, Myeloid, Acute; Prednisone; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, Third; Remission, Spontaneous; Vincristine | 1977 |
Current concepts in acute leukemia.
Topics: Acute Disease; Adult; Age Factors; BCG Vaccine; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Vincristine | 1977 |
[Induction and maintenance treatment of acute myelogenous leukemia in adults by sequential use of combination chemotherapy (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1977 |
Remission maintenance therapy in acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous; Thioguanine | 1977 |
Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia.
Topics: Adult; Aged; Cytarabine; Deamination; Female; Glomerular Filtration Rate; Humans; Infusions, Parenteral; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1977 |
A case of acute myeloblastic leukemia with Ph1 chromosome showing translocation 9q+;22q-.
Topics: Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, 6-12 and X; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Nuclear Warfare; Prednisolone; Translocation, Genetic | 1977 |
Multiple-drug chemotherapy for acute leukemia The TRAMPCOL regimen: results in 86 patients.
Topics: Adolescent; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Methotrexate; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1977 |
Potential advances in the clinical use of arabinosyl cytosine.
Topics: Adult; Cytarabine; Delayed-Action Preparations; Drug Resistance; Humans; In Vitro Techniques; Infusions, Parenteral; Leukemia, Myeloid, Acute; Tetrahydrouridine | 1977 |
Prolonged remission maintenance in acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1977 |
Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system.
Topics: Arabinofuranosyluracil; Cytarabine; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Methods | 1977 |
Prolonged remission of leukemia associated with polycythemia vera.
Topics: Aged; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Polycythemia Vera; Prednisone; Remission, Spontaneous; Time Factors; Vincristine | 1977 |
Cytosine arabinoside and 6-thioguanine in the treatment of childhood acute myeloblastic leukemia.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Recurrence; Remission, Spontaneous; Thioguanine; Time Factors | 1977 |
Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications.
Topics: Adult; Bone Marrow; Carmustine; Cytarabine; Diploidy; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Male; Maryland; Middle Aged; Prednisone; Retrospective Studies; Splenectomy; Vincristine | 1977 |
Assessment of drug sensitivity of human leukaemic myeloblasts. II. The toxic effects of cytosine arabinoside on 125IUdR-labelled human leukaemic myeloblasts in mice.
Topics: Animals; Blood Cells; Bone Marrow Cells; Cell Survival; Cells, Cultured; Cytarabine; Drug Evaluation, Preclinical; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Mice | 1977 |
Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease.
Topics: Adult; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Male; Mechlorethamine; Prednisone; Procarbazine; Radiotherapy; Thrombocytopenia; Vinblastine; Vincristine | 1977 |
[Treatment of acute myelogenous leukemia in adults; an account of the years 1968 to 1975].
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Remission, Spontaneous; Thioguanine; Vincristine | 1977 |
Paraparesis following intrathecal cytosine arabinoside: a case report with neuropathologic findings.
Topics: Aged; Cytarabine; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Muscle Spasticity; Spinal Cord | 1977 |
Treatment of refractory acute leukemia with high-dose chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Semustine; Thioguanine | 1977 |
Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous; Thioguanine | 1977 |
Treatment of acute non-lymphoid leukemias: comparison of two protocols.
Topics: Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Prognosis; Thioguanine; Vincristine | 1977 |
[Results and problems in the treatment of childhood leukaemia (author's transl)].
Topics: Age Factors; Child; Cytarabine; Daunorubicin; Humans; Hungary; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Thioguanine; Vincristine | 1978 |
[Long term remission in acute myelogenous leukemia in adults].
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Prognosis; Remission, Spontaneous; Vincristine | 1978 |
Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
Topics: BCG Vaccine; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Remission, Spontaneous; Time Factors | 1978 |
Maintenance therapy of adult acute nonlymphoblastic leukemia: an argument against the need for central nervous system prophlyaxis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1978 |
Treatment of acute leukaemia: implications of recent findings in cell biology.
Topics: Animals; Antiviral Agents; Asparaginase; Cell Cycle; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1978 |
[Trysomy of chromosome 1 long arms plus chromosome 9 inversion in leukaemic cells (author's transl)].
Topics: Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Trisomy | 1978 |
[Delivery of a normal child after chemotherapy of acute promyelocytic leukaemia during pregnancy (author's transl)].
Topics: Cesarean Section; Cytarabine; Daunorubicin; Female; Humans; Infant, Newborn; Infant, Premature; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Remission, Spontaneous | 1978 |
Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
Topics: 3-Deazauridine; Animals; Cell Division; Cells, Cultured; Choline; Cytarabine; Cytidine Diphosphate Choline; Drug Synergism; Humans; Hydrolysis; Leukemia, Experimental; Leukemia, Myeloid, Acute | 1978 |
Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
Topics: 3-Deazauridine; Animals; Choline; Cytarabine; Cytidine Diphosphate Choline; Drug Synergism; Female; HeLa Cells; Leukemia L1210; Leukemia, Experimental; Leukemia, Myeloid, Acute; Liver; Lymphocytes; Mice; Mice, Inbred Strains | 1978 |
Effect of medium conditioned by acute myeloid leukaemia cells on normal marrow colony-forming ability and sensitivity to cytosine arabinoside.
Topics: Bone Marrow; Bone Marrow Cells; Cell Survival; Clone Cells; Culture Media; Cytarabine; Humans; Leukemia, Myeloid, Acute | 1978 |
[Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Topics: Administration, Oral; Animals; Cytarabine; Deoxycytidine; Drug Evaluation; Drug Therapy, Combination; Injections, Intraperitoneal; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice | 1978 |
[Progress in the treatment of acute leukemias].
Topics: Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1978 |
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Remission, Spontaneous; Thioguanine; Vincristine | 1978 |
Therapy of acute myelogeneous leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinogen; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Prognosis; Regression Analysis; Remission, Spontaneous; Time Factors; Vincristine | 1978 |
Determination of cytosine arabinoside in human plasma by high-pressure liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Cytarabine; Humans; Leukemia, Myeloid, Acute; Methods | 1978 |
[Treatment of therapy-resistant acute non-lymphocytic leukemia with PADOC (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Vincristine | 1978 |
Razoxane in treatment of acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous | 1978 |
Razoxane in treatment of acute myeloid leukaemia.
Topics: Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Razoxane | 1978 |
Remission induction in acute myelogenous leukemia using cytosine arabinoside synchronization: a Southwest Oncology Group Study.
Topics: Adolescent; Bone Marrow; Cell Cycle; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Humans; Infant; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous | 1978 |
Paraplegia following intrathecal cytosine arabinoside.
Topics: Adult; Cytarabine; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Paraplegia | 1979 |
Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.
Topics: Adult; Aged; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Bone Marrow; Cytarabine; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1979 |
[PADOC therapy of aged patients with acute non-lymphocytic leukemia (author's transl)].
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Vincristine | 1978 |
[Therapy of adult myeloblastic leukemia in complete remission with modified TRAP, COAP and POMP cycles].
Topics: Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Thioguanine; Vincristine | 1978 |
[Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine].
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine | 1978 |
Multiple determinants of antimetabolite action in humans.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Deamination; DNA; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Neoplasms, Experimental | 1979 |
The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML).
Topics: Animals; Bone Marrow Cells; Cell Division; Cytarabine; Drug Administration Schedule; Kinetics; Leukemia, Myeloid, Acute; Liver; Male; Methotrexate; Organ Size; Rats; Spleen; Time Factors | 1978 |
The relationship of cytosine arabinoside phosphorylation to inhibition of DNA synthesis in human leukaemic myeloblasts [proceedings].
Topics: Cytarabine; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Phosphorylation | 1979 |
Tn polyagglutination preceding acute leukemia.
Topics: Aged; Cytarabine; Daunorubicin; Hemagglutination; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Splenectomy; Thioguanine; Thrombocytopenia | 1979 |
Relevance of recruitment-synchronization in the scheduling of 1-beta-D-arabinofuranosylcytosine in a slow-growing acute myeloid leukemia of the rat.
Topics: Animals; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Hematopoietic Stem Cells; Interphase; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation | 1979 |
[Prognosis improvements in children with acute myelocytic leucemia after more intensive induction therapy (author's transl)].
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Thioguanine | 1979 |
Pregancy complicated by acute myeloid leukaemia.
Topics: Adult; Blood Transfusion; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Platelet Transfusion; Pregnancy; Pregnancy Complications; Thioguanine | 1979 |
Acute non-lymphocytic leukaemia in the third trimester of pregnancy.
Topics: Adult; Cytarabine; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Thioguanine | 1979 |
[Treatment of myeloblastic leukemia after 65 years. Results in 9 cases].
Topics: Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous | 1979 |
[Occurrence of infectious complications during therapy for acute leukemia].
Topics: Antineoplastic Agents; Bacterial Infections; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Neutropenia; Prednisone; Thioguanine | 1979 |
Serial studies on in vitro colony formation in patients with acute leukemia in relation to the maintenance of remission.
Topics: Acute Disease; Adult; Child; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous | 1978 |
Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Cell Survival; Cells, Cultured; Cytarabine; Deoxyribonucleotides; Drug Synergism; Humans; In Vitro Techniques; Leukemia L1210; Leukemia, Myeloid, Acute; Methotrexate; Mice | 1979 |
Acute myelogenous leukemia: morphologic classification and response to therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Platinum; Thioguanine | 1979 |
Differentiation of myeloid leukaemic cells: new possibilities for therapy.
Topics: Anemia, Aplastic; Cell Differentiation; Cytarabine; Humans; Leukemia, Myeloid, Acute; Leukocytes; Mitosis | 1979 |
Improved survival in young children with acute granulocytic leukemia treated with combination therapy using cyclophosphamide, oncovin, cytosine arabinoside, and prednisone.
Topics: Adolescent; Age Factors; Antineoplastic Agents; Bone Marrow; Central Nervous System Diseases; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prednisone; Remission, Spontaneous; Time Factors; Vincristine | 1979 |
Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Female; Half-Life; Humans; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 1979 |
Clinical and pharmacologic studies with adriamycin-DNA complex in children with malignant disease.
Topics: Child; Cytarabine; DNA; Doxorubicin; Evaluation Studies as Topic; Fibroblasts; Humans; Leukemia, Myeloid, Acute; Neoplasms | 1979 |
Cytarabine and thioguanine for acute nonlymphocytic leukemia. Another look.
Topics: Adolescent; Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Thioguanine | 1979 |
[Treatment of acute myelogenous leukemia in children with a multiple-drug protocol (MINI-COAP regimen) (author's transl)].
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Vincristine | 1979 |
Cytarabine-induced inflammation in the seborrheic keratoses of Leser-Trélat.
Topics: Aged; Cytarabine; Erythema; Female; Humans; Keratosis; Leukemia, Myeloid, Acute; Skin Manifestations | 1979 |
Inhibition by arabinosylcytosine of DNA synthesis in bone marrows of relapsed AML patients.
Topics: Adult; Aged; Bone Marrow; Cell Survival; Cytarabine; DNA, Neoplasm; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Thymidine | 1979 |
The proliferative activity of leukaemic myeloblasts following the intravenous infusion of cytarabine.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cell Division; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis | 1979 |
Effect of cytosine arabinoside on nuclear labelling of leukaemic myeloblasts with tritiated thymidine triphosphate.
Topics: Adult; Aged; Bone Marrow; Cell Nucleus; Cytarabine; Deoxycytosine Nucleotides; DNA Replication; DNA, Neoplasm; Female; Humans; Isotope Labeling; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Thymidine; Thymine Nucleotides | 1979 |
Treatment of adult acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Prognosis; Time Factors; Vincristine | 1979 |
Prediction of therapeutic response in acute myelocytic leukemia.
Topics: Arabinofuranosylcytosine Triphosphate; Benzimidazoles; Biological Transport; Cytarabine; DNA, Neoplasm; Doxorubicin; Drug Therapy, Combination; Fluorescence; Fluorescent Dyes; Humans; Leukemia, Myeloid, Acute; Phosphorylation | 1979 |
Comparison of outcomes and prognostic factors for two groups of patients with acute myeloblastic leukemia.
Topics: Adult; Blood Cell Count; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quality of Life; Vincristine | 1979 |
Meningeal involvement in leukemias and malignant lymphomas of adults: incidence, course of disease, and treatment for prevention.
Topics: Adult; Cytarabine; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Meningeal Neoplasms; Methotrexate; Prognosis; Retrospective Studies; Time Factors | 1979 |
Prognostic value of colony-stimulating and colony-forming cells in peripheral blood in acute non-lymphoblastic leukemia.
Topics: Adult; Aged; Cell Division; Cells, Cultured; Clone Cells; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes; Male; Middle Aged; Prognosis; Remission, Spontaneous | 1977 |
Effect of antileukaemic chemotherapy on helper and suppressor activity of T cells on immunoglobulin production by B cells.
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunoglobulin G; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Lymphocyte Cooperation; Middle Aged; T-Lymphocytes; Thioguanine | 1978 |
Intracerebral tumor and diffuse central nervous system infiltration complicating acute myelogenous leukemia.
Topics: Adult; Brain Neoplasms; Central Nervous System Diseases; Cytarabine; Female; Humans; Injections, Intraventricular; Leukemia, Myeloid, Acute; Meningeal Neoplasms; Tomography, Emission-Computed | 1979 |
Deficiency of antibody-dependent cellular cytotoxicity and mitogen-induced cellular cytotoxicity effector cell function in patients with acute myelogenous leukemia in remission.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cytarabine; Cytotoxicity, Immunologic; Daunorubicin; Drug Therapy, Combination; Humans; Immunity, Cellular; Immunoglobulin Fc Fragments; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Middle Aged; Phytohemagglutinins; Remission, Spontaneous; T-Lymphocytes; Thioguanine; Time Factors | 1979 |
Colony-forming ability of marrow from patients receiving immunotherapy during chemotherapy-induced remission in acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Cell Division; Clone Cells; Cytarabine; Female; Granulocytes; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycobacterium bovis; Remission, Spontaneous | 1977 |
Current treatment of acute leukemia.
Topics: Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Methotrexate; Neoplasm Metastasis; Prednisone; Vincristine | 1978 |
[High dose combination chemotherapy with and without autologous bone marrow transplantation in patients with solid tumors and acute leukemias. Kinetics of recovery of peripheral bloods cells (author's transl)].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Hematopoiesis; Humans; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Neoplasms; Remission, Spontaneous; Thioguanine; Transplantation, Autologous | 1978 |
Transurethral passage of Aspergillus fungus balls in acute myelocytic leukemia.
Topics: Aspergillosis; Aspergillus fumigatus; Cytarabine; Daunorubicin; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Urethra; Urine | 1979 |
Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia.
Topics: Adolescent; Bone Marrow Transplantation; Budd-Chiari Syndrome; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liver; Lymph Nodes; Remission, Spontaneous; Transplantation, Homologous | 1979 |
Acute promyelocytic leukemia: results of therapy and analysis of 13 cases.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Cytarabine; Daunorubicin; Doxorubicin; Female; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous | 1977 |
Granulocyte function in myeloblastic leukaemia.
Topics: BCG Vaccine; Candida albicans; Cytarabine; Daunorubicin; Granulocytes; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Leukocytes; Mycobacterium bovis; Phagocytosis | 1975 |
The effect of cytotoxic drugs on neutrophil phagocytosis in vitro and in patients with acute myelogenous leukaemia.
Topics: Antineoplastic Agents; Candida albicans; Cell Survival; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Methotrexate; Neutrophils; Phagocytosis | 1976 |
Perspectives and prospectives in the management of acute leukemia.
Topics: BCG Vaccine; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Life Expectancy; Mycobacterium bovis; Nucleotides, Cyclic; Prednisone; Remission, Spontaneous; Vincristine | 1976 |
The management of acute myelogenous leukemia.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Blood Transfusion; Cell Division; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Infection Control; Kinetics; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Mycoses; Prednisone; Pseudomonas Infections; Remission, Spontaneous; Thioguanine; Vincristine | 1975 |
Pharmacological and clinical studies of some nucleoside analogs.
Topics: Allopurinol; Cytarabine; Guanosine; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Nucleosides; Uridine | 1975 |
[Hematologic intensive care units for cancer patients. Their role in the efficacy of cytostatic chemotherapy].
Topics: Antineoplastic Agents; Blood Transfusion; Bone Marrow Cells; Bone Marrow Transplantation; Cross Infection; Cytarabine; Daunorubicin; Hemorrhage; Humans; Immunosuppression Therapy; Infection Control; Intensive Care Units; Leukemia, Myeloid, Acute; Patient Isolators; Thioguanine | 1975 |
Fibrinogen survival with 75-seleniomethionine in acute myeloblastic leukemia during polychemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Prednisolone; Selenomethionine | 1976 |
epsilon-Amino-caproic acid in the management of acute promyelocytic leukaemia.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Cytarabine; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Vincristine | 1976 |
[Use of pulse cytophotometry in hematology].
Topics: Aneuploidy; Blood Cells; Bone Marrow; Cell Cycle; Cytarabine; Cytological Techniques; DNA, Neoplasm; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Photometry | 1976 |
Sequential therapy for induction and maintenance of remission in acute myeloblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Time Factors; Vincristine | 1975 |
Methoxy-9-ellipticine lactate in refractory acute myeloid leukaemia.
Topics: Administration, Oral; Adolescent; Alkaloids; Antineoplastic Agents; Carbazoles; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Methyl Ethers; Prednisone; Remission, Spontaneous; Time Factors | 1975 |
De novo appearance of the ph-1 chromosome in a previously monosomic bone marrow (45,XX,-6): conversion of a myeloproliferative disorder to acute myelogenous leukemia.
Topics: Adult; Alkaline Phosphatase; Blood Transfusion; Bone Marrow Cells; Bone Marrow Examination; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, 6-12 and X; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocytes; Myeloproliferative Disorders; Prednisone; Vincristine | 1975 |
Treatment of therapy-resistant acute myeloid leukaemia with 7 and 8 cytostatics.
Topics: Adolescent; Adult; Aged; Candidiasis; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Esophagitis, Peptic; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Stomach Ulcer; Thioguanine; Vincristine | 1975 |
Treatment of acute myelogenous leukaemia in adults. A retrospective study of 70 patients (1968-1973).
Topics: Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thioguanine | 1975 |
[Treatment of acute myeloblastic leukemia. Experiences with "conventional" single-drug therapy, 1968-70, and intensive combination chemotherapy, 1971-73].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Vincristine | 1975 |
Drugs five years later: cytarabine.
Topics: Acute Disease; Adult; Animals; Bone Marrow Diseases; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine; Virus Diseases | 1975 |
Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Clone Cells; Culture Media; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocytes; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Vincristine | 1975 |
Cell kinetics and practical consequences for therapy of acute leukemia.
Topics: Adrenal Cortex Hormones; Asparaginase; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Cytarabine; Daunorubicin; DNA; DNA, Neoplasm; Drug Therapy, Combination; Humans; Kinetics; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Mitosis; Prognosis; Vincristine | 1975 |
[Therapy of non-lymphoid acute leukemias].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Body Weight; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous; Thioguanine; Vincristine | 1975 |
[Cytokinetics, chemotherapy and clinical course of acute leukemias].
Topics: Animals; Antineoplastic Agents; Cytarabine; Humans; Kinetics; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice; Mitosis; Prognosis | 1975 |
[Evolution and therapy of blastic crises].
Topics: Bone Marrow; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Spleen | 1975 |
[Our recent therapeutic experiences in acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Prednisone; Vincristine | 1975 |
[Treatment of 17 cases of non-lymphoblastic acute leukemia with a combination of daunorubicin, cytosine and arabinoside].
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged | 1975 |
[General remarks on the treatment of acute leukemias].
Topics: Asparaginase; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Thioguanine; Vincristine | 1975 |
Treatment of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Asparaginase; Carmustine; Child; Cytarabine; Daunorubicin; Female; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Thioguanine; Vincristine | 1975 |
Fever in acute myelogenous leukemia.
Topics: Agranulocytosis; Anti-Bacterial Agents; Candidiasis; Cytarabine; Daunorubicin; Fever; Humans; Klebsiella Infections; Leukemia, Myeloid, Acute; Pseudomonas Infections; Thioguanine | 1975 |
Cyclocytidine study in the treatment of acute leukemia.
Topics: Cytarabine; Drug Evaluation; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Prednisolone | 1975 |
[Clinical use of cytosine arabinoside in childhood. II. Cytosine arabinoside in the prevention and therapy of leukemic meningosis].
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous | 1975 |
[Letter: New combination drug therapy of acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoguazone; Remission, Spontaneous; Vincristine | 1975 |
Letter: Cytarabine: therapeutic trials and editorial standards.
Topics: Cytarabine; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous | 1975 |
Treatment of acute leukemia during pregnancy.
Topics: Adult; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, Second; Thioguanine | 1975 |
Hypoplastic acute myelogenous leukaemia.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1975 |
A comparative study of acute myeloblastic leukaemia in children and adults.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Cell Count; Blood Platelets; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1975 |
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.
Topics: Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Remission, Spontaneous; Thioguanine | 1975 |
[Results of combined chemotherapy in treatment-resistant leukaemia of adults (author's transl)].
Topics: Acute Disease; Adolescent; Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1975 |
Cytokinetics of human acute leukemia before and after chemotherapy.
Topics: Adolescent; Adult; Asparaginase; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Child; Cytarabine; DNA, Neoplasm; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Male; Thioguanine; Thymidine | 1975 |
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults.
Topics: Adolescent; Adult; Age Factors; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Inosine; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission, Spontaneous; Thioinosine | 1975 |
Acute myeloid leukemia in the adult.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Thioguanine | 1975 |
Cell proliferation and protein synthesis in human leukaemic myeloblasts after cytosine arabinoside therapy.
Topics: Adult; Bone Marrow; Bone Marrow Cells; Cytarabine; Depression, Chemical; Female; Humans; Injections, Intravenous; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis; Neoplasm Proteins; Time Factors | 1976 |
[The therapy of acute myelogenous leukemia].
Topics: Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Lomustine; Thioguanine | 1975 |
[Pharmakokinetics of hydroxy-urea. Therapy of acute myeoblastic leukemias using synchronization and recruitment effects (author' transl)].
Topics: Administration, Oral; Adult; Cell Division; Cytarabine; DNA, Neoplasm; Half-Life; Humans; Hydroxyurea; Kinetics; Leukemia, Myeloid, Acute; Middle Aged; Time Factors | 1976 |
Manipulation of the mitotic cycle in the treatment of acute myelogenous leukaemia.
Topics: Adolescent; Adult; Bone Marrow Examination; Child; Child, Preschool; Cytarabine; Daunorubicin; DNA; Doxorubicin; Female; Humans; Infant; Infant, Newborn; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis; Remission, Spontaneous; Time Factors | 1976 |
Effect of arabinosyl cytosine on granulopoietic colony formation by marrow cells from leukemic and non-leukemic patients.
Topics: Bone Marrow; Bone Marrow Cells; Cell Division; Cell Survival; Clone Cells; Cytarabine; Cytidine Deaminase; Granulocytes; Hematopoiesis; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Remission, Spontaneous | 1976 |
Nuclear DNA-polymerase estimation in human leukaemic myeloblasts.
Topics: Bone Marrow; Bone Marrow Cells; Cell Nucleus; Cell Transformation, Neoplastic; Cytarabine; DNA Nucleotidyltransferases; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Methotrexate; Neoplasm Proteins; Thymidine; Thymine Nucleotides; Tritium | 1976 |
[A patient with anemia].
Topics: Aged; Anemia; Blood Cell Count; Bone Marrow Examination; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Thioguanine | 1976 |
[Experiences in the treatment of acute myeloblastic leukemia and acute monocytic leukemia using cytosine arabinoside and 6-thioguanine].
Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1975 |
Serial quantitative observations of leukemic and normal hematopoietic cells in the bone marrow of acute leukemia under chemotherapy.
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Remission, Spontaneous; Vincristine | 1976 |
[Neonatal leukemia. Report of seven cases (author's transl)].
Topics: Cytarabine; Daunorubicin; Humans; Infant, Newborn; Infant, Newborn, Diseases; Leukemia, Myeloid, Acute | 1976 |
[Results in the treatment of acute leukemias at the Internal Clinic B in the period 1970-1975].
Topics: Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Hospitals, University; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Prednisone; Remission, Spontaneous; Vincristine | 1976 |
Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.
Topics: Bone Marrow; Bone Marrow Cells; Cell Count; Cell Division; Cell Survival; Cells, Cultured; Cytarabine; Humans; Leukemia, Myeloid, Acute; Thymidine | 1976 |
The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia.
Topics: Adult; Aged; Cells, Cultured; Cytarabine; Deamination; Female; Freezing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phosphates; Remission, Spontaneous | 1976 |
Combinations of arabinosyl cytosine and 6-thioguanine for treatment of adults with acute leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow; Cytarabine; DNA; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1975 |
Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous | 1976 |
Endomyocardial fibrosis associated with daunorubicin therapy.
Topics: Adult; Cytarabine; Daunorubicin; Endomyocardial Fibrosis; Female; Humans; Leukemia, Myeloid, Acute | 1976 |
A mathematical model of the chemotherapeutic treatment of acute myeloblastic leukemia.
Topics: Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mathematics; Models, Biological; Thioguanine | 1976 |
Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.
Topics: Acute Disease; Adolescent; Aged; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Cytarabine; Hepatic Veins; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver; Male; Thioguanine | 1976 |
Chemoimmunotherapy for maintenance in acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors | 1976 |
Sequencing of cytosine arabinoside (NSC-63878) and daunorubicin (NSC-82151) in acute myelogenous leukemia.
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1976 |
A sensitive bio-assay for pharmacokinetic studies of cytosine arabinoside in man.
Topics: Animals; Biological Assay; Bone Marrow; Bone Marrow Cells; Cytarabine; DNA; Half-Life; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Rats; Thymidine; Time Factors | 1976 |
Acute granulocytic leukemia: treatment of the disease.
Topics: Adolescent; Adult; Age Factors; Blood Transfusion; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Lomustine; Meningitis; Middle Aged; Prognosis; Thioguanine | 1976 |
[The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination].
Topics: Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Thioguanine; Vincristine | 1976 |
Comparative observations in the treatment of acute leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1976 |
[Treatment of acute leukemia in adults by the OAP regimen].
Topics: Adult; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Prednisolone; Remission, Spontaneous; Time Factors; Vincristine | 1976 |
Vinblastine, procarbazine, and cytosine arabinoside in combination for reinduction of childhood acute myelocytic leukemia.
Topics: Child; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Procarbazine; Vinblastine | 1976 |
Short induction treatment in acute granulocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Fever; Hemorrhage; Humans; Leucovorin; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Pyruvaldehyde; Remission, Spontaneous; Sepsis | 1975 |
Sequential use of methotrexate, folinic acid, and cytosine arabinoside in the treatment of acute leukemia.
Topics: Adult; Bone Marrow; Bone Marrow Cells; Child; Cytarabine; Deoxyuridine; DNA; Drug Administration Schedule; Female; Humans; In Vitro Techniques; Leucovorin; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Mitosis; Thymidine; Thymine | 1976 |
Cytomegalovirus infection in children with blood diseases.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Daunorubicin; Female; gamma-Globulins; Humans; Immune Tolerance; Immunization, Passive; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Thioguanine; Vincristine | 1992 |
Usefulness of bone-marrow biopsy during induction therapy for acute myeloid leukemia.
Topics: Biopsy, Needle; Bone Marrow Examination; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Time Factors | 1992 |
Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cytarabine; Daunorubicin; Drug Resistance; Gene Expression; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction | 1992 |
A discrepancy between the instantaneous and the overall collection efficiency of the Fenwal CS3000 for peripheral blood stem cell apheresis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Blood Component Removal; Blood Transfusion, Autologous; Bone Marrow Diseases; Cyclophosphamide; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Neoplasms; Thioguanine | 1992 |
Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Neoplasm Proteins; Remission Induction | 1992 |
ABEP as primary chemotherapy for Hodgkin's disease.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Prednisone; Procarbazine; Vincristine | 1992 |
[Countermeasure for treatment of leukemia in the aged].
Topics: Aged; Chromosome Aberrations; Creatinine; Cytarabine; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1992 |
A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia.
Topics: Aged; Aged, 80 and over; Anemia, Sideroblastic; Bone Marrow; Chromosome Aberrations; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Platelet Count; Predictive Value of Tests | 1992 |
[Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 1992 |
[A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Thioguanine; Vincristine | 1992 |
Progress and survival factors in acute non lymphocytic leukemia. A 15 year analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Survival Rate | 1992 |
Comparison of the proliferative activity and sensitivity to cytosine arabinoside of leukemic blast progenitors in acute myeloblastic leukemia at diagnosis and in relapse.
Topics: Blast Crisis; Cell Division; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Recurrence; Tumor Cells, Cultured | 1992 |
Acute myelogenous leukemia: proliferation stop or cell lysis during the first hours of treatment?
Topics: Cell Death; Cell Division; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 1992 |
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Child; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peptide Hydrolases; Plasminogen Activator Inhibitor 2; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1992 |
["Small doses" of cytosar in the therapy of acute nonlymphoblastic leukemias].
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Time Factors | 1992 |
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Cause of Death; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Norway; Recurrence; Remission Induction; Survival Analysis; Survival Rate; Thioguanine | 1992 |
[Cure of acute myeloblastic leukemia in a child with Down syndrome and tetralogy of Fallot].
Topics: Abnormalities, Multiple; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Down Syndrome; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Tetralogy of Fallot; Thioguanine | 1992 |
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1992 |
Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Failure, Acute; Mitoxantrone; Necrosis; Recurrence; Thioguanine | 1992 |
Recurrent neutrophilic eccrine hidradenitis.
Topics: Adult; Cytarabine; Eccrine Glands; Female; Hidradenitis; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Methylprednisolone; Mitoxantrone; Recurrence; Skin | 1992 |
Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes.
Topics: Aged; Bone Marrow Examination; Cytarabine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Treatment Failure | 1992 |
Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-beta-D-arabinofuranosylcytosine in human leukaemic myeloblasts.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Bryostatins; Cytarabine; Drug Interactions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lactones; Leukemia, Myeloid, Acute; Macrolides; Recombinant Proteins; Time Factors | 1992 |
Low-dose combination remission induction therapy for acute myeloid leukaemia in elderly patients--a pilot study.
Topics: Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction | 1992 |
Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia.
Topics: Administration, Oral; Cytarabine; Drug Administration Schedule; Female; Humans; Hyperbilirubinemia; Infant; Jaundice; Leukemia, Myeloid, Acute; Remission Induction; Remission, Spontaneous; Time Factors | 1992 |
[Evaluation of 58 patients with acute leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 1992 |
[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction; Sepsis; Survival Rate | 1992 |
[High dose cinobufocini in attenuation and treatment of infection and granulocytopenia during combined chemotherapy of malignant blood diseases].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Cyclophosphamide; Cytarabine; Female; Humans; Infection Control; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 1992 |
Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Macrophage Colony-Stimulating Factor; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Predictive Value of Tests; Prednisone; Remission Induction; Vindesine | 1992 |
Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine.
Topics: Adolescent; Adult; Aged; Cerebellar Diseases; Cerebellum; Cohort Studies; Creatinine; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors | 1992 |
Eccrine squamous syringometaplasia in chemotherapy-induced acral erythema.
Topics: Cytarabine; Eccrine Glands; Epithelium; Erythema; Foot Dermatoses; Hand Dermatoses; Humans; Leukemia, Myeloid, Acute; Metaplasia | 1992 |
Leukemic cell death during heating is well fitted with the Gompertz-Makeham's formula--a law of human mortality.
Topics: Bone Marrow Transplantation; Cell Death; Cytarabine; Dose-Response Relationship, Drug; Hot Temperature; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Mathematics; Regression Analysis; Tumor Cells, Cultured | 1992 |
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Survival Rate | 1992 |
Pulmonary complications of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mitoxantrone; Tomography, X-Ray Computed | 1992 |
Corneal and conjunctival toxicity with low-dose cytosine arabinoside.
Topics: Conjunctiva; Cornea; Cytarabine; Dexamethasone; Humans; Keratoconjunctivitis; Leukemia, Myeloid, Acute; Male; Middle Aged; Visual Acuity | 1992 |
[Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Testicular Neoplasms | 1992 |
High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age.
Topics: Aged; Aged, 80 and over; Cytarabine; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thrombocytopenia | 1992 |
Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses.
Topics: Adolescent; Adult; Christianity; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged | 1992 |
Leukemia following cisplatin-based chemotherapy for ovarian carcinoma at Roswell Park.
Topics: Adult; Carcinoma, Papillary; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Neoplasms, Second Primary; Ovarian Neoplasms; Thrombocytopenia | 1992 |
Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Glutathione Transferase; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Thioguanine; Time Factors | 1992 |
Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arabinofuranosyluracil; Cytarabine; Deamination; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Serum Albumin, Bovine; Sex Factors | 1992 |
Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia.
Topics: Bone Marrow; Bone Marrow Examination; Cytarabine; Humans; Leukemia, Myeloid, Acute; Likelihood Functions; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction | 1992 |
Comparison of the effects of all-trans and cis-retinoic acid on the blast stem cells of acute myeloblastic leukemia in culture.
Topics: Cell Survival; Cytarabine; Drug Administration Schedule; In Vitro Techniques; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Stereoisomerism; Tretinoin; Tumor Cells, Cultured | 1992 |
Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mitoxantrone | 1992 |
[Short-term intensive consolidation chemotherapy in the treatment of acute non-lymphocytic leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Remission Induction; Survival Rate | 1992 |
The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Blast Crisis; Cell Division; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cells | 1992 |
Electrical alternans of the T-U wave without change in the QRS complex.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Cytarabine; Daunorubicin; Electrocardiography; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged | 1992 |
Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents.
Topics: Animals; Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cell Nucleus; Cell Survival; Cells, Cultured; Chickens; Cytarabine; DNA Replication; DNA, Neoplasm; G1 Phase; G2 Phase; Interferon alpha-2; Interferon-alpha; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mitosis; Propidium; Recombinant Proteins; S Phase; Tretinoin; Tumor Cells, Cultured | 1992 |
Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Remission Induction | 1991 |
Fatal peripheral neuropathy associated with axonal degeneration after high-dose cytosine arabinoside in acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axons; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Peripheral Nervous System Diseases; Sural Nerve | 1991 |
Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Vindesine | 1990 |
High dose ARA-C as induction therapy of acute myeloid leukaemia.
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 1990 |
Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Tumor Cells, Cultured | 1991 |
OCI/AML-4 an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside.
Topics: Antigens, CD; Blotting, Northern; Cell Division; Cell Survival; Cytarabine; Gene Expression; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Hydrocortisone; In Vitro Techniques; Interleukin-3; Interleukin-6; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Receptor, Macrophage Colony-Stimulating Factor; Stem Cell Factor; Tretinoin; Tumor Cells, Cultured | 1991 |
Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity.
Topics: Adult; Aged; Cell Survival; Cytarabine; DNA, Neoplasm; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Thymidine; Tumor Cells, Cultured | 1991 |
Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Homologous | 1992 |
Novel translocation (2;4) with consistent involvement of 2p23 in acute nonlymphocytic leukemia (M2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Translocation, Genetic | 1992 |
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA).
Topics: Antineoplastic Agents; Cytarabine; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorometry; Humans; Leukemia, Experimental; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1992 |
Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole.
Topics: Biological Transport; Cytarabine; Dipyridamole; Drug Interactions; Humans; Leukemia, Myeloid, Acute; Models, Biological; Tumor Cells, Cultured | 1992 |
Epirubicin and cytosine arabinoside for the induction therapy of childhood acute nonlymphocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Epirubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction | 1991 |
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Middle Aged; Pilot Projects; Prognosis; Remission Induction; Time Factors | 1991 |
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Deoxycytidine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Tumor Cells, Cultured | 1991 |
Cell kinetics with in vivo bromodeoxyuridine and flow cytometry: clinical significance in acute non-lymphoblastic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bromodeoxyuridine; Cells; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Vincristine | 1991 |
Incidence and clinical epidemiology of streptococcal septicemia during treatment of acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Sepsis; Streptococcal Infections | 1991 |
[Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Northern; Bone Marrow; Cytarabine; Daunorubicin; Gene Expression; Humans; Interleukin-1; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Transcription, Genetic | 1991 |
Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.
Topics: Blast Crisis; Cell Survival; Cytarabine; DNA; Dose-Response Relationship, Drug; Doxorubicin; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Thymidine; Time Factors; Tritium; Tumor Cells, Cultured | 1991 |
Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Topics: Adult; Arabinofuranosyluracil; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Regression Analysis | 1991 |
Treatment of cytarabine acral erythema with corticosteroids.
Topics: Adult; Cytarabine; Erythema; Facial Dermatoses; Foot Dermatoses; Hand Dermatoses; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Prednisone | 1991 |
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Myeloid, Acute; Myocardium; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Stroke Volume | 1991 |
[Combination treatment of acute non-lymphocytic leukemia with HOAP and AA--preliminary report of 14 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Vincristine | 1991 |
Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
Topics: Bone Marrow; Cytarabine; Deoxycytosine Nucleotides; DNA; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Recombinant Proteins | 1991 |
Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Candidiasis; Cytarabine; Enterobacteriaceae; Enterococcus faecalis; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mouth; Mouth Diseases; Prospective Studies; Remission Induction; Saliva | 1991 |
Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Humans; Interferon-gamma; Interleukin-2; Leukemia, Myeloid, Acute; Male; Neutrophils | 1991 |
[Gastroenterologic findings in graft versus host disease after allogenic bone marrow transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Infant, Newborn; Intestinal Mucosa; Leukemia, Myeloid, Acute; Liver; Pregnancy; Pregnancy Complications, Neoplastic; Sigmoidoscopy | 1991 |
Recurrent bilateral parotitis in acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Parotitis; Recurrence | 1991 |
Bone marrow transplant retinopathy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Incidence; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Retinal Diseases; Visual Acuity | 1991 |
Granulocyte-macrophage colony-stimulating factor in acute non-lymphocytic leukemia before and after chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Time Factors | 1991 |
Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Separation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Humans; Immunotherapy; In Vitro Techniques; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; Tumor Stem Cell Assay | 1991 |
High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1991 |
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prognosis; Remission Induction | 1991 |
In vitro chemosensitivity of newly diagnosed and relapsing acute non-lymphoid leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Idoxuridine; Iodine Radioisotopes; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1991 |
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction | 1991 |
[Successful pregnancy after 6 years complete remission in patient with acute myeloblastic leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Pregnancy; Remission Induction | 1991 |
Tissue factor released from leukemic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Endotoxins; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Thromboplastin; Tumor Cells, Cultured | 1991 |
[Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate | 1991 |
First and second complete remissions in a HIV positive patient following remission induction therapy for acute non-lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; HIV Seropositivity; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Remission Induction; Substance Abuse, Intravenous | 1991 |
Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 1991 |
Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Factor X; Factor X Deficiency; Female; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1991 |
Necrotizing fasciitis of previous surgical wound complicating intensive postremission chemotherapy.
Topics: Adolescent; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Cytarabine; Doxorubicin; Escherichia coli Infections; Fasciitis; Humans; Leukemia, Myeloid, Acute; Male; Surgical Wound Infection | 1991 |
High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Pilot Projects; Prognosis; Recurrence; Remission Induction; Survival Rate | 1991 |
Aspergillus appendicitis in acute myeloid leukaemia.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Appendix; Aspergillosis; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Ileal Diseases; Iliac Vein; Intestinal Perforation; Ischemia; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neutropenia; Thrombosis | 1990 |
Drug sensitivity test for acute myeloblastic leukemia by an efficient leukemic blast colony assay using 5637-conditioned medium as a stimulator.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Culture Media; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Stem Cell Assay | 1990 |
Comparative effects of busulfan, cytosine arabinoside and adriamycin on different maturation stages of normal human bone marrow cells.
Topics: Bone Marrow; Bone Marrow Cells; Busulfan; Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1990 |
Etoposide in remission induction of adult acute myeloid leukemia.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Thioguanine; Time Factors | 1990 |
The effects of leukemia inhibitory factor (LIF) on the blast stem cells of acute myeloblastic leukemia.
Topics: Cell Cycle; Cytarabine; Growth Inhibitors; Humans; Interleukin-6; Leukemia Inhibitory Factor; Leukemia, Myeloid, Acute; Lymphokines; Neoplastic Stem Cells; Recombinant Proteins; Thymidine; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Erythema and swelling of ears after treatment with cytarabine for leukemia.
Topics: Cytarabine; Ear Diseases; Erythema; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1990 |
[Aplastic anemia which terminated in hypoplastic leukemia 10 years after diagnosis].
Topics: Anemia, Aplastic; Bone Marrow; Cholecalciferol; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1990 |
Remission induction of ANLL with low dose cytosine arabinoside combined with retinoic acid.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etretinate; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1990 |
How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate; Thioguanine | 1990 |
Management of febrile episodes during neutropenia caused by chemotherapy.
Topics: Adult; Agranulocytosis; Cytarabine; Fever; Humans; Klebsiella Infections; Klebsiella pneumoniae; Leukemia, Myeloid, Acute; Male; Neutropenia | 1990 |
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
Topics: Aged; Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recombinant Proteins; Remission Induction | 1990 |
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recombinant Proteins | 1990 |
Cumulative bone marrow stromal damage caused by X-irradiation and cytosine-arabinoside in leukemic mice.
Topics: Animals; Bone Marrow; Cells, Cultured; Cytarabine; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Whole-Body Irradiation | 1990 |
Immunologic and morphologic typing as prognostic factor in M1 acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cytarabine; Daunorubicin; Female; Histocytochemistry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Vincristine | 1990 |
Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity.
Topics: Adult; Aged; Biotransformation; Bone Marrow; Cell Division; Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Tumor Cells, Cultured | 1990 |
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
[Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C].
Topics: Arabinofuranosylcytosine Triphosphate; Biological Transport, Active; Biotransformation; Cytarabine; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1990 |
Different sensitivity of normal and leukaemic progenitor cells to Ara-C and IL-3 combined treatment.
Topics: Cell Division; Cytarabine; Drug Synergism; Growth Substances; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Interleukin-3; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Recombinant Proteins; Tumor Cells, Cultured | 1990 |
Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 1990 |
GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy.
Topics: Cytarabine; DNA, Neoplasm; Doxorubicin; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1990 |
Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo.
Topics: Adolescent; Adult; Arabinofuranosylcytosine Triphosphate; Cytarabine; DCMP Deaminase; Deoxycytidine Kinase; Deoxycytosine Nucleotides; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Pyrimidines; Thymine Nucleotides | 1990 |
Interstitial pneumonia and alpha-hemolytic Streptococcus sepsis in a child with malignancy who recently received cytosine arabinoside.
Topics: Adolescent; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Pulmonary Fibrosis; Streptococcal Infections | 1990 |
Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Survival; Cytarabine; Cytokines; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Recombinant Proteins; Tumor Cells, Cultured | 1990 |
A complex chromosomal rearrangement and congenital anomalies in the progeny of a mother treated for childhood leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 12; Cytarabine; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prednisone; Vincristine | 1990 |
Effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on blast progenitors of acute myeloblastic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Cytarabine; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged | 1990 |
Flow cytometry DNA measurement for prediction of effect of therapy in acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; DNA, Neoplasm; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis | 1990 |
Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study.
Topics: Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cytarabine; Daunorubicin; Female; Humans; Kinetics; Leukemia, Myeloid, Acute; Male; S Phase | 1990 |
[Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Remission Induction | 1990 |
Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction | 1990 |
Septicemia due to Streptococcus mitis in neutropenic patients with acute leukemia.
Topics: Adult; Cytarabine; Disseminated Intravascular Coagulation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Penicillin G; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinolines; Respiratory Distress Syndrome; Sepsis; Streptococcal Infections | 1990 |
Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Doxorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Methotrexate; Neoplasm Recurrence, Local; Prednisolone; Probability; Remission Induction; Vincristine | 1990 |
Cell kinetics after high dose cytosine arabinoside in patients with acute myelocytic leukemia.
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 1990 |
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Topics: Amsacrine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Chromosome Deletion; Chromosome Inversion; Cytarabine; Drug Resistance; Humans; Karyotyping; Leukemia, Myeloid, Acute | 1990 |
Triple combination of retinoic acid, low concentration of cytarabine and dimethylformamide induces differentiation of human acute myeloid leukaemic blasts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Dimethylformamide; Humans; Leukemia, Myeloid, Acute; Tretinoin | 1990 |
Selective eradication of leukemic (L-CFU) versus normal (CFU-GM) myeloid progenitors in suspension culture utilizing a prolonged exposure to 1-B-D arabinofuranosylcytosine (Ara-C) and deoxycytidine (dCyd).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cells, Cultured; Cytarabine; Deoxycytidine; Granulocytes; Humans; Leukemia, Myeloid, Acute; Macrophages; Neoplastic Stem Cells; Stem Cells; Tumor Cells, Cultured | 1990 |
Cytosine arabinoside does not cause differentiation in vitro of CFU-GM in marrow from normal, myelodysplastic or ANLL subjects.
Topics: Alkaline Phosphatase; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cytarabine; Granulocytes; Histocytochemistry; HLA-DR Antigens; Humans; Immunohistochemistry; In Vitro Techniques; Leukemia, Myeloid, Acute; Macrophages; Myelodysplastic Syndromes; Stem Cells | 1990 |
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Rate; Thioguanine | 1990 |
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Time Factors | 1990 |
Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 1990 |
Successful chemotherapy for acute myeloid leucaemia in HIV-infected patients.
Topics: CD4 Antigens; Cytarabine; HIV Antibodies; HIV Infections; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Zidovudine | 1990 |
Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Thioguanine; Tumor Cells, Cultured | 1990 |
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; France; Humans; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Neutropenia; Survival Rate | 1990 |
Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Middle Aged; Netherlands; Remission Induction; Survival Rate; Thioguanine | 1990 |
Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Austria; Blast Crisis; Cytarabine; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Treatment of recurrent acute myelogenous leukaemia at a single centre over a 10-year period.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Evaluation; Humans; Interferon Type I; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Thioguanine; United Kingdom | 1990 |
Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Preleukemia; Remission Induction; Thioguanine | 1990 |
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Topics: Agranulocytosis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Depression, Chemical; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Mitoxantrone; Mycoses; Thioguanine; Thrombocytopenia | 1990 |
High-dose chemotherapy with noncryopreserved autologous bone marrow transplantation for acute myeloid leukemia in first complete remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Transplantation, Autologous | 1990 |
[Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences].
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Middle Aged | 1990 |
Serum immunoreactive erythropoietin in children with acute leukaemia at various stages of disease--and the effects of treatment.
Topics: Adolescent; Anemia; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Erythropoietin; Female; Hemoglobins; Humans; Infant; Leukemia, Myeloid, Acute; Longitudinal Studies; Lymphoma, Non-Hodgkin; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
Topics: Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1990 |
Intensive therapy in elderly patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Remission Induction | 1990 |
[Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1990 |
High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 1990 |
Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients.
Topics: Adolescent; Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Cytarabine; Daunorubicin; Female; Hemoglobins; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Remission Induction; Survival Rate | 1990 |
High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
Topics: Adolescent; Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Chemotherapy of adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 1990 |
BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis | 1990 |
Acute non-lymphoblastic leukemia in children: prognostic factors and results of chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction | 1990 |
Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly.
Topics: Aged; Cytarabine; Female; Gene Rearrangement; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged | 1990 |
Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured | 1990 |
Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1990 |
High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Transplantation, Autologous; Transplantation, Homologous | 1990 |
Clinical, biochemical and cytokinetic parameters for distinguishing smouldering and rapidly proliferating variants of acute leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cytarabine; DNA; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thymidine Kinase | 1990 |
Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
Topics: Adult; Age Factors; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Retrospective Studies | 1990 |
Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cell Division; Cytarabine; DNA, Neoplasm; Drug Administration Schedule; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction | 1990 |
Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
[Individualized chemotherapy of adult acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction | 1990 |
[Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Female; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Rate; Thioguanine | 1990 |
[Therapeutic results in acute myelogenous leukemia in the years from 1970 to 1982].
Topics: Adolescent; Adult; Blood Transfusion; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Prednisone; Retrospective Studies; Thioguanine; Vincristine | 1985 |
Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chondroitin Sulfates; Cytarabine; Daunorubicin; Dermatan Sulfate; Disseminated Intravascular Coagulation; Drug Evaluation; Glycosaminoglycans; Heparinoids; Heparitin Sulfate; Humans; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine; Time Factors | 1986 |
Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.
Topics: Azacitidine; Cell Division; Cell Line; Colony-Forming Units Assay; Cytarabine; Decitabine; Deoxycytidine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1986 |
Sensitivity to 5-azacytidine of blast progenitors in acute myeloblastic leukemia.
Topics: Azacitidine; Cell Survival; Cells, Cultured; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Tumor Stem Cell Assay | 1987 |
Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Whole-Body Irradiation | 1987 |
In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
Topics: Adult; Azacitidine; Cells, Cultured; Child; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Replication; DNA, Neoplasm; Drug Resistance; Humans; In Vitro Techniques; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Thymidine Kinase | 1987 |
Alpha-2 antiplasmin in acute nonlymphoblastic leukemia.
Topics: alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Cytarabine; Disseminated Intravascular Coagulation; Fibrinolysis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Plasminogen; Prognosis; Remission Induction | 1989 |
The results of treatment of selected patients with ANLL with low-dose Ara-C.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
OAP combination in the treatment of elderly leukaemic patients with preexisting severe internal disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Prednisone; Risk Factors; Vincristine | 1989 |
Clinical studies on aclacinomycin A cardiotoxicity in adult patients with acute non lymphoblastic leukaemia.
Topics: Aclarubicin; Adult; Arrhythmias, Cardiac; Cytarabine; Electrocardiography; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male | 1989 |
Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia.
Topics: Adolescent; Ancitabine; Antineoplastic Agents; Aziridines; Benzoquinones; Bone Marrow; Cell Survival; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male | 1989 |
Acute nonlymphocytic leukemia: evidence of clonogenic cells in peripheral blood in early complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Remission Induction; Translocation, Genetic | 1989 |
Acute myeloid leukaemia presenting with pleural effusions.
Topics: Antigens, Differentiation; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Histocompatibility Antigens; Humans; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Lymph Nodes; Lymphoma; Male; Middle Aged; Mitoxantrone; Pleural Effusion; Remission Induction | 1989 |
Maturation induction in freshly isolated human myeloid leukemic cells, 1.25 (OH)2 vitamin D3 being the most potent inducer.
Topics: Adult; Aged; Cell Differentiation; Cell Separation; Cholecalciferol; Cytarabine; Dimethyl Sulfoxide; Female; Granulocytes; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monocytes; Neoplastic Stem Cells; Tretinoin; Tumor Cells, Cultured | 1989 |
[Hepatocellular carcinoma treated with a curative segmentectomy five years after complete remission of acute myeloblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Cytarabine; Daunorubicin; Embolization, Therapeutic; Hepatectomy; Hepatitis B Surface Antigens; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Male; Mercaptopurine; Middle Aged; Neoplasms, Multiple Primary; Prednisolone; Remission Induction | 1989 |
Accidental overdose of mitoxantrone in three patients.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Small Cell; Cytarabine; Drug Overdose; Drug Tolerance; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 1989 |
The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Bone Marrow Diseases; Cell Count; Combined Modality Therapy; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thioguanine; Transplantation, Autologous | 1989 |
The role of peripheral blood stem cells as rescue after myeloablative therapy.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Combined Modality Therapy; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Transplantation, Autologous | 1989 |
Leukaemia Research Fund international research symposium on cytotoxic drug resistance in leukemia and other malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Cisplatin; Congresses as Topic; Cytarabine; DNA; Drug Resistance; Gene Amplification; Glutathione Transferase; Humans; Leukemia; Leukemia, Myeloid, Acute; Neoplasms; Nucleosides; Oxygen; Phenotype; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1989 |
[Intensive post-remission therapy of acute myeloid leukemia with high doses of cytosine arabinoside].
Topics: Adolescent; Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 1989 |
Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
A comparison of two assays for the in vitro chemosensitivity testing of human acute non-lymphoblastic leukemia cells.
Topics: Adult; Aged; Colorimetry; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tetrazolium Salts; Thymidine; Tumor Cells, Cultured | 1989 |
Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antigens, CD; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Humans; Interphase; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone | 1989 |
[Late results of the treatment of acute granulocytic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Evaluation; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prednisone; Remission Induction; Vincristine | 1989 |
Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside.
Topics: Anti-Bacterial Agents; Child; Cytarabine; Humans; Immune Tolerance; Leukemia, Myeloid, Acute; Pulmonary Fibrosis; Retrospective Studies; Sepsis; Shock, Septic; Streptococcal Infections | 1989 |
[Chemotherapy of adult ANLL].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction; Survival Rate; Vincristine | 1989 |
[The curative treatment of adult acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction | 1989 |
[Comparison of conventional chemotherapy and short-term intensive chemotherapy in adult acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction; Survival Rate | 1989 |
Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies | 1989 |
Low-dose arabinosyl cytosine therapy of AML may be effective after failure of high or conventional doses.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Remission Induction | 1989 |
Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1989 |
Phenotype switch in acute leukemia patients after intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
Preliminary results of an induction combination regimen including fractionated anthracycline.
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
[Leukemic clonogenic assay and drug sensitivity test of homoharringtonine and cytarabine in acute myeloid leukemia].
Topics: Alkaloids; Bone Marrow; Colony-Forming Units Assay; Cytarabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Prognosis; Tumor Stem Cell Assay | 1989 |
The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: an update.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cells, Cultured; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Pilot Projects; Remission Induction; Risk; Thioguanine; Transplantation, Autologous | 1989 |
Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 1989 |
Autologous bone marrow transplantation in patients with AML in second complete remission (CR).
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation, Autologous | 1989 |
Double autologous bone marrow transplantation in acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Evaluation Studies as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Methods; Middle Aged; Myelodysplastic Syndromes; Thioguanine; Transplantation, Autologous | 1989 |
Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1989 |
Therapeutic medical reasoning.
Topics: Adolescent; Cesarean Section; Cytarabine; Daunorubicin; Decision Making; Decision Support Techniques; Female; Humans; Judgment; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic | 1989 |
Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.
Topics: Blast Crisis; Cell Division; Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1989 |
Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 1989 |
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside.
Topics: Age Factors; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation | 1989 |
Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
Low dose cytosine arabinoside in adult acute non-lymphoid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1989 |
Idarubicin in combination with etoposide and cytarabine in adult acute non-lymphoblastic leukaemia (ANLL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 1989 |
Fractionated anthracycline therapy in acute myeloblastic leukaemia in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Cytarabine; Daunorubicin; Drug Administration Schedule; Heart Ventricles; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine | 1989 |
Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA; DNA Adducts; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Metabolic Clearance Rate | 1989 |
Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans.
Topics: Acute Disease; Adult; Cytarabine; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Insufficiency; Sepsis; Streptococcal Infections | 1989 |
[Treatment of patients with acute nonlymphoblastic leukemia with low doses of cytarabine].
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1989 |
[Low doses of cytarabine in the treatment of acute non-lymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
Attenuated high-dose cytosine arabinoside in the treatment of the elderly patient with acute nonlymphocytic leukemia. An Eastern Cooperative Oncology Group Pilot Study.
Topics: Aged; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Pilot Projects; Remission Induction | 1989 |
[Cancer curable by chemotherapy: acute myelogenous leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Evaluation; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Mercaptopurine; Prednisolone; Prognosis; Remission Induction | 1989 |
[4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukopenia; Male; Middle Aged; Prednisolone; Remission Induction; Thioguanine; Thrombocytopenia | 1989 |
Liquid-chromatographic monitoring of cytosine arabinoside and its metabolite, uracil arabinoside, in serum.
Topics: Aged; Arabinofuranosyluracil; Chromatography, High Pressure Liquid; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Spectrophotometry, Ultraviolet; Uridine | 1989 |
[Differentiation induction of myeloid leukemia cells by glucocorticoid--the differentiation induction effect in vitro and in vivo].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cell Survival; Cytarabine; Dexamethasone; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission Induction; Tumor Cells, Cultured | 1989 |
["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Vinblastine; Vincristine; Vindesine | 1989 |
[Remission induction treatment in adults with acute myeloid leukemia. 8-year experience with 2 successive protocols].
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prednisolone; Prognosis; Remission Induction; Vincristine | 1989 |
[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local | 1989 |
[An aged patient with acute myelogenous leukemia complicated with liver cirrhosis: successful treatment with low-dose cytosine arabinoside].
Topics: Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Remission Induction | 1989 |
Necrotizing fasciitis of the vulva during chemotherapy.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fasciitis; Female; Humans; Leukemia, Myeloid, Acute; Necrosis; Thioguanine; Vulva; Vulvar Diseases | 1989 |
Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Fibrinogen; Fibrinopeptide A; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radioimmunoassay; Thioguanine; Time Factors | 1989 |
Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Prognosis; Remission Induction | 1989 |
Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1989 |
[The continuous-DCMP therapy for acute nonlymphocytic leukemia in elderly patients--comparison with younger patients].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1989 |
The association between high-dose cytarabine neurotoxicity and renal insufficiency.
Topics: Acute Kidney Injury; Alcoholism; Cytarabine; Female; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Nervous System Diseases; Risk Factors | 1989 |
Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture.
Topics: Adult; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Colony-Stimulating Factors; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1989 |
[Low-dose cytosine arabinoside in treatment of 17 patients with acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.
Topics: Age Factors; Anemia, Aplastic; Anemia, Refractory, with Excess of Blasts; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Multivariate Analysis; Neural Tube Defects; Preleukemia; Prognosis; Regression Analysis; Survival Rate; Thioguanine | 1989 |
[Neutropenic enterocolitis in adults with acute leukemia].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Enterocolitis, Pseudomembranous; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Neutropenia; Prednisolone | 1989 |
Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia.
Topics: Cell Survival; Cytarabine; DNA; Doxorubicin; Drug Interactions; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Tretinoin; Tumor Cells, Cultured | 1989 |
Increased proteolysis of antithrombin III Vicenza during disseminated intravascular coagulation in acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Antithrombin III Deficiency; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Thioguanine; Thrombin; Thrombophlebitis | 1989 |
Inappropriate increase in erythropoietin titers during chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Erythropoietin; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 1989 |
Mitozantrone and high-dose cytarabine in adult acute myeloid leukaemia.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone | 1985 |
Disturbance of blood-brain barrier after bone-marrow transplantation.
Topics: Adult; Blood-Brain Barrier; Bone Marrow Transplantation; Brain; Child; Cyclosporins; Cytarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male | 1985 |
Mitozantrone and high-dose cytarabine in refractory adult acute myeloid leukaemia.
Topics: Adult; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone | 1985 |
Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukaemia in the elderly.
Topics: Aged; Cytarabine; Female; Humans; Infusions, Parenteral; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
Very-low-dose cytarabine for elderly patients.
Topics: Adult; Age Factors; Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1986 |
In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.
Topics: Adult; Aged; Bone Marrow; Cell Division; Cytarabine; DNA; Humans; Interphase; Intracellular Fluid; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 1989 |
Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia.
Topics: Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 1989 |
Low-dose cytosine arabinoside in acute non-lymphoblastic leukemia.
Topics: Adolescent; Adult; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thrombocytopenia | 1989 |
Acute myelogenous leukemia treated with daunomycin associated with nephrotic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kidney; Leukemia, Myeloid, Acute; Male; Nephrotic Syndrome | 1989 |
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1989 |
Drug-induced toxicities associated with high-dose cytosine arabinoside infusions.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Central Nervous System Diseases; Cytarabine; Eye Diseases; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Skin Diseases | 1989 |
The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Time Factors | 1989 |
Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
[Treatment of acute myeloblastic leukemia with low-dose cytarabine].
Topics: Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
In vivo differentiation of leukaemic blasts and effect of low dose Ara-C in a marrow grafted patient with leukaemic relapse.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Cell Differentiation; Cytarabine; Female; Humans; Isoenzymes; Leukemia, Myeloid, Acute; Phosphoglucomutase | 1986 |
[Clinical observation on the effect of an AOAP regimen in acute non-lymphatic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Middle Aged; Plant Extracts; Plants, Medicinal; Prednisone; Vincristine | 1986 |
Painful red hands: a side-effect of leukaemia therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Leukemia, Myeloid, Acute; Middle Aged; Pain; Thioguanine | 1988 |
Adenosine diphosphate ribosyl transferase in marrow cells of patients with acute myeloid leukemia is related to differentiation and drug sensitivity.
Topics: Bone Marrow; Cell Differentiation; Cell Division; Clinical Enzyme Tests; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nucleotidyltransferases; Poly(ADP-ribose) Polymerases; Prognosis; Tumor Stem Cell Assay | 1985 |
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System Diseases | 1986 |
Acute myelogenous leukemia of unfavourable prognosis treated with retinoic acid, vitamin D3, alpha-interferon and low doses of cytosine arabinoside.
Topics: Aged; Bone Marrow; Child; Cholecalciferol; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Interferon Type I; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Tretinoin | 1986 |
Measurement of myeloid maturation by flow cytochemistry in HL-60 leukemia: esterase is inducible, myeloperoxidase is not.
Topics: Cell Line; Cell Survival; Cytarabine; Dimethyl Sulfoxide; Enzyme Induction; Esterases; Flow Cytometry; Granulocytes; Histocytochemistry; Humans; Leukemia, Myeloid, Acute; Monocytes; Peroxidase; Vitamin A | 1986 |
Study of differentiation of fresh myeloid leukemic cells by physiologic agents that induce a human promyelocytic leukemic line (HL-60) to differentiate.
Topics: Bucladesine; Cell Cycle; Cell Differentiation; Cell Line; Cells, Cultured; Cytarabine; Dinoprostone; Esterases; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Nitroblue Tetrazolium; Prostaglandins E; Receptors, Formyl Peptide; Receptors, Immunologic; Theophylline; Vitamin D | 1986 |
Bone-marrow regeneration after therapy-induced hypoplasia monitored by serum measurements of lactoferrin, lysozyme and myeloperoxidase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Doxorubicin; Hematopoiesis; Humans; Lactoferrin; Lactoglobulins; Leukemia, Myeloid, Acute; Leukocyte Count; Muramidase; Neutrophils; Peroxidase; Prednisolone; Thioguanine; Time Factors; Vincristine | 1986 |
Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Age Factors; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleoside Deaminases; Phosphotransferases | 1987 |
Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction | 1988 |
GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
Topics: Bone Marrow; Cell Survival; Colony-Forming Units Assay; Colony-Stimulating Factors; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukemia, Myeloid, Acute; Placenta; Pregnancy; Recombinant Proteins; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1988 |
Long term results in acute non-lymphocytic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male | 1988 |
Low-dose ARA-C in acute leukemias. Analysis of 30 cases.
Topics: Adolescent; Adult; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged | 1986 |
[Chemotherapy of medium-to-large doses in the treatment of acute leukemia: report of 16 cases].
Topics: Adolescent; Adult; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged | 1987 |
Immunological erythroblastopenia induced by HCO-60 as a solvent of enocitabine (BH-AC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Castor Oil; Cytarabine; Erythroblasts; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Red-Cell Aplasia, Pure; Solvents | 1987 |
Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
Topics: Adult; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Harringtonines; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Vincristine | 1987 |
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisone; Prognosis; Prospective Studies; Recurrence; Regression Analysis; Retrospective Studies; Vincristine | 1987 |
All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases.
Topics: Adult; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tretinoin | 1987 |
Differentiation of human leukaemic cell lines and fresh leukaemia cells by low dose Ara-C: monitoring by expression of c-myc and c-fos oncogenes.
Topics: Cell Differentiation; Cell Line, Transformed; Cytarabine; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Nucleic Acid Hybridization; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-myc; Proto-Oncogenes; Transcription, Genetic; Tumor Cells, Cultured | 1988 |
Second long-term remission achieved with low-dose Ara-C in children with relapsed acute nonlymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine | 1987 |
Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Doxorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Netherlands; Pilot Projects; Remission Induction; Thioguanine | 1988 |
Cytotoxic action of low dose Ara-C. Investigations in a marrow grafted patient with relapse.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Combined Modality Therapy; Cytarabine; Female; Humans; Isoenzymes; Leukemia, Myeloid, Acute; Phosphoglucomutase | 1985 |
[Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
Topics: Adult; Aged; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Bone Marrow; Bone Marrow Cells; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1988 |
Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors | 1988 |
Metabolism, incorporation into DNA, and interactions with 1-beta-D-arabinofuranosylcytosine of 5-hydroxymethyl-2'-deoxyuridine in human promyelocytic leukemia cells (HL-60).
Topics: Cell Line; Cell Survival; Cytarabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Kinetics; Leukemia, Myeloid, Acute; Thymidine | 1988 |
High-dose retinol in children with acute myelogenous leukemia in remission.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine; Vitamin A | 1988 |
[Effect of low-dose Ara-C regimen on myelodysplastic syndrome (MDS)].
Topics: Aged; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1988 |
[Pharmacokinetic studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) by 30-minute infusion with acute nonlymphocytic leukemia--the possibility of administration for outpatients].
Topics: Adult; Ambulatory Care; Antineoplastic Agents; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1988 |
[Acute leukemia subsequent to sideroblastic anemia: response to low dose cytosine arabinoside].
Topics: Adult; Anemia, Sideroblastic; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute | 1988 |
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 1988 |
[Aclarubicin-related pancreatitis in a child with AML].
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Naphthacenes; Pancreatitis; Vincristine | 1988 |
[Coexistence of tuberculosis of the lymph nodes and myeloblastic leukemia].
Topics: Antitubercular Agents; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Tuberculosis, Lymph Node | 1988 |
Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy.
Topics: Adult; Cerebellar Diseases; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Purkinje Cells | 1988 |
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine.
Topics: Adult; Aged; Biopsy, Needle; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1988 |
Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU.
Topics: Adenocarcinoma; Antineoplastic Agents; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrosourea Compounds; Rectal Neoplasms; Translocation, Genetic | 1988 |
Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.
Topics: Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis | 1988 |
[High dosage and intermediate dosage cytosine arabinoside in the treatment of secondary leukemias].
Topics: Adult; Alkylating Agents; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Male; Middle Aged; Remission Induction | 1988 |
[BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
Topics: Aclarubicin; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Male; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction | 1988 |
Acute adult leukemia. The Danbury Hospital experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Thioguanine | 1988 |
Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside.
Topics: Adult; Aged; Bone Marrow; Cell Count; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction | 1988 |
Relationship between the in vitro sensitivity to cytosine arabinoside of blast progenitors and the outcome of treatment in acute myeloblastic leukaemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged | 1988 |
[Low-dose ARA-C and HOAAP regimen in the treatment of adult acute nonlymphocytic leukemia: analysis of 59 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Harringtonines; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Vincristine | 1988 |
Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Remission Induction; Thioguanine | 1988 |
[DCTP(II) combination chemotherapy of adult acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission Induction; Thioguanine | 1988 |
[Differentiating effect of the oral administration of vitamin D and vitamin A in acute myelocytic leukemia after BHAC-DMP therapy].
Topics: Administration, Oral; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Vitamin A; Vitamin D | 1988 |
In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Clone Cells; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1988 |
A comparative pathological study of liver injury after different combination chemotherapies for leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Liver; Melphalan; Prednisolone; Prednisone; Thioguanine | 1988 |
[Abnormal karyotype, t(9;13)(q34;q12) in a patient with acute myelocytic leukemia].
Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 1988 |
[Acute graft-versus-host disease in a patient with acute myeloblastic leukemia following consolidation therapy and platelet transfusions].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Platelet Transfusion; Prednisolone; Transfusion Reaction | 1988 |
[Dissociation between the effect on myeloblastoma and the hematologic effect of Ara-C therapy: report of an autopsied myeloblastic leukemia case with around five-year course].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Remission Induction; Tumor Cells, Cultured; Uterine Neoplasms | 1988 |
[Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Remission Induction; Thioguanine; Vincristine | 1988 |
Results of aggressive chemotherapy for myelodysplastic syndromes.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine | 1988 |
Association between the secondary colony-plating efficiency of blast progenitors and the remission induction outcome of acute myeloblastic leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Neoplastic Stem Cells; Prednisolone; Prognosis; Remission Induction; Tumor Stem Cell Assay | 1988 |
Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Prognosis; Remission Induction; Vincristine | 1988 |
[Chemotherapeutic effects in hypoplastic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Drug Evaluation; Humans; Immunoglobulin G; Immunotoxins; Infusions, Intravenous; Leukemia, Myeloid, Acute; Melphalan; Middle Aged; Preleukemia | 1988 |
Interleukin 3 enhances the cytotoxic activity of 1-beta-D-arabinofuranosylcytosine (ara-C) on acute myeloblastic leukaemia (AML) cells.
Topics: Cell Survival; Cytarabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Interleukin-1; Interleukin-3; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1988 |
Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells.
Topics: Bone Marrow; Cell Division; Colony-Stimulating Factors; Cytarabine; Deoxycytosine Nucleotides; Drug Synergism; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Macrophages; Neoplastic Stem Cells; Recombinant Proteins | 1988 |
[Induction and intensive combined therapy of acute myeloid leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dacarbazine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Nimustine; Nitrosourea Compounds; Vincristine | 1988 |
Proto-oncogene expression in HL-60 cells exposed to ara-C.
Topics: Cell Cycle; Cell Differentiation; Cell Line; Cell Survival; Cytarabine; Gene Expression Regulation; Histones; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogenes; RNA, Messenger; Triose-Phosphate Isomerase | 1987 |
Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Cell Survival; Clone Cells; Cyclophosphamide; Cytarabine; Etoposide; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation, Autologous; Tumor Cells, Cultured | 1987 |
Fetal liver infusion in acute myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fetus; Humans; Leukemia, Myeloid, Acute; Liver; Liver Transplantation | 1987 |
Autologous bone marrow transplantation for patients with acute myelogenous leukemia in complete remission.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Postoperative Complications; Remission Induction; Transplantation, Autologous | 1987 |
Treatment of acute myeloid leukemia in elderly patients. A retrospective study.
Topics: Aged; Antineoplastic Agents; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies | 1988 |
Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Prednisone; Vincristine | 1988 |
[A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Topics: Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1986 |
The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia.
Topics: Adult; Cell Differentiation; Cytarabine; Humans; In Vitro Techniques; Isotretinoin; Leukemia, Myeloid, Acute; Male; Tretinoin | 1986 |
Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain; Cytarabine; Female; Humans; Injections, Intravenous; Injections, Spinal; Leukemia, Myeloid, Acute; Lung; Muscles; Paralysis; Spinal Cord; Time Factors | 1986 |
Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy.
Topics: Antineoplastic Agents; Blood Transfusion; Cytarabine; Daunorubicin; Erythrocyte Transfusion; Female; Humans; Leukemia, Myeloid, Acute; Microcirculation; Mitomycins; Platelet Transfusion; Purpura; Thrombocytopenia | 1986 |
The sensitivity to cytosine arabinoside of the blast progenitors of acute myeloblastic leukemia.
Topics: Adult; Aged; Cell Survival; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Methylcellulose; Middle Aged; Suspensions; Tumor Stem Cell Assay | 1986 |
Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias.
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy?
Topics: Adult; Arabinofuranosyluracil; Biological Transport; Blood-Brain Barrier; Cytarabine; Half-Life; Humans; Kinetics; Leukemia, Myeloid, Acute; Male; Uridine | 1986 |
Neurotoxicity associated with systemic high-dose cytosine arabinoside.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Nervous System Diseases | 1986 |
High dose Ara-C related leukoencephalopathy.
Topics: Adult; Brain; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Time Factors; Tomography, X-Ray Computed | 1986 |
Potentiation by 1-alpha,25-dihydroxyvitamin D3 of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea.
Topics: Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cytarabine; DNA, Neoplasm; Drug Synergism; Humans; Hydroxyurea; Leukemia, Myeloid, Acute | 1986 |
Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Biotransformation; Chromatography, High Pressure Liquid; Cytarabine; Humans; Kinetics; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1986 |
[Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
Topics: Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
[Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Parenteral; Injections, Subcutaneous; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
Treatment of TdT+ myeloid blast crisis of chronic granulocytic leukemia with low dose cytosine arabinoside.
Topics: Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1986 |
High-dose chemotherapy regimens.
Topics: Cerebellar Diseases; Cytarabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Oxygen Inhalation Therapy | 1986 |
Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemia.
Topics: Cerebellar Diseases; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1986 |
Successful treatment of acute megakaryoblastic leukaemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Thioguanine | 1986 |
Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Doxorubicin; Female; Hemorrhage; Hospitals, Teaching; Hospitals, University; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Risk; Texas; Time Factors; Vincristine | 1986 |
Typhlitis: selective surgical management.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Child; Colitis; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Risk | 1986 |
1-B-D arabinofuranosyl cytosine and all-trans retinoic acid in combination accelerates and increases monocyte differentiation of myeloid leukemic cells.
Topics: Antibodies, Monoclonal; Cell Differentiation; Cell Line; Cells, Cultured; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Isomerism; Leukemia, Myeloid, Acute; Nitroblue Tetrazolium; Tretinoin | 1986 |
Clinical experience with amphotericin B in acute myelogenous leukemia.
Topics: Aged; Amphotericin B; Anti-Bacterial Agents; Aspergillosis; Cytarabine; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Lung Diseases, Fungal; Male; Middle Aged; Neutropenia; Pneumonia; Retrospective Studies; Time Factors | 1986 |
Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Tumor Stem Cell Assay | 1986 |
Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
Topics: Animals; Cell Survival; Cytarabine; Female; Hematopoietic Stem Cells; Injections; Intestines; Leukemia, Myeloid, Acute; Mice; Mice, Inbred Strains; Rats; Rats, Inbred BN; Time Factors | 1986 |
[An unusual way of manifesting acute granulocytic leukemia: granulocytic sarcoma of the breast. Apropos of a case with trisomy 22].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, 21-22 and Y; Cytarabine; Daunorubicin; Female; Granulocytes; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms, Multiple Primary; Trisomy | 1986 |
Relapsing process in FAB subtypes of adult acute leukemia and its relationship to treatment regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Time Factors | 1986 |
Induction of differentiation in human myeloid leukemia cells with cytosine arabinoside.
Topics: Bone Marrow Cells; Cell Differentiation; Cytarabine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count | 1986 |
Inducibility of terminal differentiation in daunomycin- and cytosine arabinoside-resistant mouse myeloid leukemia M1 cells.
Topics: Animals; Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cytarabine; Daunorubicin; Dexamethasone; Drug Resistance; Leukemia, Myeloid, Acute; Methylnitronitrosoguanidine; Mice; Organophosphorus Compounds; Poly I; Pyridinium Compounds | 1986 |
DNA-repair kinetics and the sensitivity of cells to X-ray-induced chromosome aberrations: a mouse myeloid leukemia cell line and normal mouse bone marrow cells.
Topics: Animals; Bone Marrow; Cell Cycle; Cell Line; Chromosome Aberrations; Cytarabine; DNA Repair; Leukemia, Myeloid, Acute; Mice; X-Rays | 1986 |
Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
Topics: Adolescent; Adult; Aged; Brain Diseases; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged | 1986 |
[Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Vincristine | 1986 |
Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy.
Topics: Adult; Cerebellar Diseases; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Ophthalmoplegia | 1986 |
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Topics: Aged; Amsacrine; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1986 |
A short-term chemosensitivity test with different labeled precursors of DNA or protein synthesis: correlation with clinical response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leucine; Leukemia, Myeloid, Acute; Protein Biosynthesis; Thioguanine; Thymidine | 1986 |
[Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes; Thioguanine | 1986 |
Interstitial pneumonitis due to leukaemic cell necrosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lung; Necrosis; Pulmonary Fibrosis | 1986 |
Surgery for the acute abdomen in adults with leukaemia.
Topics: Abdomen, Acute; Adolescent; Adult; Appendectomy; Colectomy; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 1986 |
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Prognosis; Statistics as Topic | 1986 |
[Effectiveness and toxicity of high-dosage Ara-C. Clinical observations in 10 cases and review of the literature].
Topics: Adolescent; Adult; Aged; Alopecia; Bone Marrow Diseases; Brain Diseases; Conjunctivitis; Cytarabine; Digestive System Diseases; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cell Differentiation; Cell Division; Cytarabine; Dactinomycin; Daunorubicin; Dexamethasone; Hydroxycholecalciferols; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Time Factors | 1987 |
[High-dose cytarabine therapy in acute myeloid leukemia].
Topics: Adolescent; Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
Topics: Anti-Bacterial Agents; Cell Division; Cell Line; Cell Survival; Cytarabine; Drug Synergism; Guanosine; Humans; Kinetics; Leukemia, Myeloid, Acute; Tritium | 1987 |
Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 1987 |
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prognosis; Thioguanine | 1987 |
Acute promyelocytic leukemia. A childhood cluster.
Topics: Bone Marrow; Child; Child, Preschool; Cytarabine; Epidemiologic Methods; Humans; Infant; Leukemia, Myeloid, Acute; Microscopy, Electron; South Africa; Tranexamic Acid | 1987 |
[Multiple liver abscesses successfully treated by intraportal administration of amphotericin B in a case of AML (M2)].
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liver Abscess; Male; Mercaptopurine; Portal System; Prednisolone | 1986 |
[Diagnosis and intensive treatment of acute leukemia in pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Thioguanine; Vincristine | 1987 |
[Preliminary results of the treatment of various forms of non-lymphoblastic leukemia with small doses of cytosine arabinoside].
Topics: Adult; Aged; Blood Cell Count; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
Topics: Arabinofuranosylcytosine Triphosphate; Bone Marrow; Bone Marrow Cells; Cell Cycle; Cells, Cultured; Cytarabine; DNA, Neoplasm; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Prognosis | 1987 |
Arabinosyl cytosine: a 20-year update.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute | 1987 |
In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells.
Topics: Bone Marrow; Cytarabine; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Phosphorylation | 1987 |
[Acute myeloblastic leukemias and myelodysplasias: treatment with low doses of aracytine].
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes | 1986 |
[Treatment of acute adult myeloblastic leukemia with intensive chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Mercaptopurine; Methotrexate; Middle Aged; Mitoguazone; Prednisone; Thioguanine; Vincristine | 1986 |
Hypoplastic acute leukemia: cytogenic evidence for differentiation in vivo in response to low-dose ara-C.
Topics: Cell Differentiation; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Metabolic Clearance Rate | 1987 |
Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin.
Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Clone Cells; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Kinetics; Leukemia, Myeloid, Acute; Mice; Naphthacenes | 1987 |
["A-triple-V" in refractory or relapsed acute myelocytic leukemia].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vinblastine; Vincristine | 1987 |
Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DCMP Deaminase; Guanosine; Half-Life; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphocytes; Phosphorylation; Thioinosine; Thionucleosides | 1987 |
Review of clinical and haematological response to low-dose cytosine arabinoside in acute myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
Side effects of intermediate- and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute leukaemia and non-Hodgkin's lymphoma.
Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1987 |
[Termination rules in therapeutic trials. Application of sequential methods in 2 clinical trials in hematology].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Random Allocation; Research Design | 1987 |
Different response rates to low-dose cytosine arabinoside in acute myeloid leukemia subtypes.
Topics: Age Factors; Antigens, Neoplasm; Antigens, Surface; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Prognosis | 1987 |
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.
Topics: Adult; Aged; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; DNA Replication; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Replicon; Thrombocytopenia | 1987 |
An in vitro model to predict clinical response in adult acute myelogenous leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Blood; Bone Marrow; Cell Cycle; Cells, Cultured; Culture Media; Cytarabine; DNA, Neoplasm; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Time Factors | 1987 |
In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia.
Topics: Animals; Cell Line; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance; Leukemia, Experimental; Leukemia, Myeloid, Acute; Nucleoside Deaminases; Rats | 1987 |
Influence of dose and duration of exposure on the cytotoxic effect of cytarabine toward human hematopoietic clonogenic cells.
Topics: Bone Marrow Cells; Cell Cycle; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells | 1987 |
Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Prognosis | 1987 |
Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Time Factors | 1987 |
Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Time Factors | 1987 |
Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Time Factors; Translocation, Genetic; Vincristine | 1987 |
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Thioguanine | 1987 |
The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Time Factors | 1987 |
Intensive treatment of acute leukemia in adults 70 years of age and older.
Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Vincristine | 1987 |
Prognostic factors in childhood acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Prednisolone; Remission Induction; Risk; Time Factors; Vincristine | 1987 |
[Granulocytic sarcoma (chloroma) with bladder and breast localizations preceding acute myeloblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Drug Combinations; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Multiple Primary; Prednisone; Time Factors; Urinary Bladder Neoplasms; Vincristine | 1987 |
C-reactive protein and cytosine arabinoside.
Topics: C-Reactive Protein; Cytarabine; Drug Hypersensitivity; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow; Cytarabine; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Time Factors | 1987 |
Anaphylactic shock due to cytarabine in a leukemic child.
Topics: Anaphylaxis; Child, Preschool; Cytarabine; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin E; Leukemia, Myeloid, Acute | 1987 |
The neurotoxicity of high-dose cytosine arabinoside is age-related.
Topics: Activities of Daily Living; Adolescent; Adult; Age Factors; Ataxia; Brain; Cerebellum; Coma; Confusion; Cytarabine; Dysarthria; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sleep Stages | 1987 |
Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kinetics; Leukemia, Myeloid, Acute; Vincristine | 1987 |
Pharmacokinetic study of cytosine arabinoside in patients with acute myelogeneous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Humans; Kinetics; Leukemia, Myeloid, Acute; Mitoxantrone; Thioguanine | 1987 |
Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Remission Induction; Time Factors | 1987 |
Low-dose Ara-C treatment in elderly patients with acute myeloblastic leukemia.
Topics: Aged; Blast Crisis; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1987 |
Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Thioguanine; Tumor Stem Cell Assay | 1987 |
4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male | 1987 |
Acute myelocytic leukemia in adults: a long-term analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors | 1987 |
High-dose cytosine arabinoside and retinol in the treatment of acute myelogenous leukemia in childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Diterpenes; Humans; Leukemia, Myeloid, Acute; Retinyl Esters; Vitamin A | 1987 |
Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors | 1987 |
Prediction of induction and duration of complete remission in acute myelogenous leukemia: value of clonogenic cell properties.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Tumor Stem Cell Assay | 1987 |
Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Prednisolone; Prognosis; Remission Induction; Thioguanine; Time Factors; Vincristine | 1987 |
Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine | 1987 |
[Treatment of hypoplastic leukemia--clinical effects of low-dose 4N-behenoyl-beta-D-arabinofuranosylcytosine (BH-AC) therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1987 |
[Influences of aging on clinical pictures of hematological diseases: hypoplastic leukemia in the aged].
Topics: Aged; Aging; Antineoplastic Agents; Cytarabine; Humans; Leukemia, Myeloid, Acute | 1987 |
Incomplete Reiter's syndrome following chemotherapy of acute myeloid leukaemia.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Reactive; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Thioguanine | 1986 |
[Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases].
Topics: Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Tretinoin | 1987 |
High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.
Topics: Adolescent; Adult; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Microbial Sensitivity Tests; Middle Aged; Remission Induction; Risk Factors; Sepsis; Streptococcal Infections; Streptococcus | 1987 |
[Cytarabine].
Topics: Animals; Antineoplastic Agents; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; Structure-Activity Relationship | 1987 |
Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Time Factors; Tumor Cells, Cultured | 1987 |
Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Diarrhea; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Nausea; Vomiting | 1987 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
[High doses of cytosine arabinoside in the treatment of refractory leukemia].
Topics: Blast Crisis; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1987 |
Neutrophilic eccrine hidradenitis in acute myelomonocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Eccrine Glands; Female; Humans; Inflammation; Leukemia, Myeloid, Acute; Prednisolone; Remission Induction; Sweat Gland Diseases; Sweat Glands; Vincristine | 1987 |
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 1987 |
Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.
Topics: Adult; Aged; Cell Line; Chromatography, High Pressure Liquid; Cytarabine; DNA; Female; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; Male; Middle Aged; Radioimmunoassay; Tumor Cells, Cultured | 1987 |
Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Differentiation; Cytarabine; Drug Synergism; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Thioguanine; Tretinoin; Tumor Cells, Cultured; Vincristine | 1987 |
Pattern of bone marrow regeneration following chemotherapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Regeneration; Thioguanine | 1987 |
[Acute leukemia with blasts in the shape of a hand mirror].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Histocytochemistry; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Spiro Compounds; Vincristine | 1987 |
Sensitivity of stromal elements from human bone marrow cells to cytosine arabinoside in vitro.
Topics: Anemia, Aplastic; Bone Marrow; Cytarabine; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute | 1987 |
[Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1987 |
[Bone marrow changes in acute non-lymphocytic leukemia patients treated with low-dose Ara-C--implications of therapeutic mechanism].
Topics: Aged; Bone Marrow; Cell Differentiation; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1987 |
Few genetic mutations, many cancers, say experts.
Topics: Acute Disease; Child; Cytarabine; Eye Neoplasms; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasms; Oncogenes; Retinoblastoma; T-Lymphocytes, Cytotoxic | 1986 |
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lung; Lymphoma, Non-Hodgkin; Prednisone; Radiography; Remission Induction; Respiratory Insufficiency | 1987 |
Alteration of blast phenotype after low-dose cytarabine in children with acute myeloid leukemia.
Topics: Antigens, Ly; Antigens, Surface; Bone Marrow; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenotype; T-Lymphocytes | 1987 |
Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells.
Topics: Cell Line; Cytarabine; Cytidine Deaminase; Demecolcine; Deoxyadenosines; Deoxycytidine Kinase; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1987 |
Treatment of poor prognosis acute myeloid leukemia with aggressive and non-aggressive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis | 1987 |
TAD-induction therapy for 175 adults with acute myeloid leukemia, followed by consolidation and maintenance therapy. The joint study of Ulm and Tübingen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Prednisolone; Prednisone; Thioguanine; Vincristine | 1986 |
Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Prognosis | 1986 |
High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study.
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis | 1986 |
Idarubicin in refractory acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Parenteral; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Aclacinomycin-A in the induction treatment of childhood AML.
Topics: Aclarubicin; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Naphthacenes; Thioguanine | 1986 |
[Therapy of acute leukemia in the adult. Role of anthracyclines].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1987 |
[Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes | 1987 |
Ara-C incorporation into DNA.
Topics: Cytarabine; DNA; Humans; Leukemia, Myeloid, Acute | 1985 |
Acute promyelocytic leukemia in 57 previously untreated patients.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Prognosis; Respiratory Insufficiency; Time Factors | 1985 |
Treatment of ocular leukemia with local chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Conjunctiva; Cytarabine; Eye Neoplasms; Female; Humans; Injections; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate | 1985 |
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fever; Humans; Intercalating Agents; Intestinal Obstruction; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Middle Aged; Nausea; Time Factors; Vomiting | 1985 |
Differences in cell cycle kinetics during induced granulocytic versus monocytic maturation of HL-60 leukemia cells.
Topics: Cell Count; Cell Cycle; Cell Line; Cytarabine; Dimethyl Sulfoxide; DNA, Neoplasm; Granulocytes; Humans; Leukemia, Myeloid, Acute; Monocytes; Neoplasm Proteins | 1985 |
Adriamycin and cytosine arabinoside contribute equally to prediction of response in acute myelocytic leukemia with improved confidence level.
Topics: Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Interphase; Leukemia, Myeloid, Acute; Time Factors; Tumor Stem Cell Assay | 1985 |
[The effect of cytostatic therapy on pyruvate kinase activity in the erythrocytes of patients with acute myelocytic leukemia].
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Erythrocytes; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyruvate Kinase | 1985 |
Cytokinetic studies in acute leukemia during early induction therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Division; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Peptichemio; Prednisone; Time Factors; Vincristine | 1985 |
[Various induction therapies in older patients with acute myeloid leukemias].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Tamoxifen | 1985 |
Prediction of response of acute non-lymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Topics: Adult; Aged; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[ACMP two-step therapy for children with acute nonlymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone | 1985 |
Myxoedema in a case of acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Myxedema; Thioguanine; Thyroxine | 1985 |
Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells.
Topics: 3-Deazauridine; Agglutination; Antimetabolites, Antineoplastic; Cell Line; Cytarabine; Cytidine Triphosphate; Doxorubicin; Glucosamine; Humans; Isoxazoles; Lectins; Leukemia, Myeloid, Acute; N-Acetylneuraminic Acid; Pyrimidines; Sialic Acids | 1985 |
Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy.
Topics: Aged; Bone Marrow; Cytarabine; DNA, Neoplasm; Humans; Interphase; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Time Factors | 1985 |
Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leukemia; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice; Mice, Inbred DBA | 1985 |
Intensive timed chemotherapy for 51 acute myeloid leukemia patients with poor prognosis.
Topics: Adult; Aged; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Time Factors | 1985 |
High-dose cytosine arabinoside in the initial treatment of acute leukemia.
Topics: Adolescent; Adult; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1985 |
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Humans; Hydroxyurea; Interphase; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Thymidine | 1985 |
High-dose cytosine arabinoside in the treatment of childhood malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child; Child, Preschool; Cytarabine; Diterpenes; Doxorubicin; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Pancytopenia; Recurrence; Retinyl Esters; Vitamin A; Vomiting | 1985 |
In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
Topics: Animals; Arabinofuranosyluracil; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Disease Models, Animal; Half-Life; Humans; Kinetics; Leukemia, Myeloid, Acute; Nucleoside Deaminases; Rats; Uridine | 1985 |
Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Division; Cytarabine; Daunorubicin; DNA; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1985 |
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
Topics: Arabinofuranosylcytosine Triphosphate; Chromosome Aberrations; Cytarabine; Drug Evaluation; Drug Resistance; Half-Life; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prognosis; Time Factors | 1985 |
Low-dose cytosine arabinoside regimen induced a complete remission with normal karyotypes in a case with hypoplastic acute myeloid leukaemia with No. 8-trisomy: in vitro and in vivo evidence for normal haematopoietic recovery.
Topics: Chromosomes, Human, 6-12 and X; Colony-Forming Units Assay; Cytarabine; Female; Hematopoiesis; Humans; Infusions, Parenteral; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Time Factors; Trisomy | 1985 |
Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia.
Topics: Adult; Aged; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukopenia; Male; Myeloproliferative Disorders; Thrombocytopenia | 1985 |
[Small doses of Ara-C in the treatment of acute myeloid leukaemia].
Topics: Adolescent; Adult; Cytarabine; Female; Humans; Injections, Subcutaneous; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[Treatment of acute myelogenous leukemia with concurrent administration of N4-behenoyl-ara-C, aclacinomycin A, 6-mercaptopurine and prednisolone].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1985 |
[Use of cytosar (cytosine arabinoside) in the control of herpetic complications in patients with acute leukemia and lymphogranulomatosis].
Topics: Adolescent; Aged; Chickenpox; Child, Preschool; Cytarabine; Female; Herpes Zoster; Hodgkin Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male | 1985 |
Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Agents; Cytarabine; Diarrhea; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Skin Diseases | 1985 |
Treatment of acute myeloid leukemia and myelodysplastic syndrome by low dose cytosine arabinoside.
Topics: Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloproliferative Disorders | 1985 |
[A trial administration of small doses of Ara-C as a second step in remission induction in patients with acute non-lymphocytic leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Male | 1985 |
[Cytosine-arabinoside in high doses in refractory acute granulocytic leukemia. Apropos of 17 cases].
Topics: Adolescent; Adult; Cytarabine; Drug Resistance; Eye Diseases; Female; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged | 1985 |
Acute granulocytic leukemia following systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aspirin; Cyclophosphamide; Cytarabine; Humans; Immunosuppression Therapy; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lupus Erythematosus, Systemic; Male | 1985 |
[Leukocytosis induced by BH-AC administration--allergic reaction to Casteo oil HCO-60. A case report].
Topics: Adolescent; Antineoplastic Agents; Castor Oil; Cytarabine; Drug Hypersensitivity; Female; Humans; Leukemia, Myeloid, Acute; Leukocytosis; Solvents | 1985 |
Effects of chemotherapy on bone marrow stroma in mice with acute myelogenous leukemia. Correlation with CFU-C and CFU-D.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cytarabine; Diffusion; Doxorubicin; Fibroblasts; Granulocytes; Hematopoietic Stem Cells; Hydroxyurea; Leukemia, Experimental; Leukemia, Myeloid, Acute; Macrophages; Male; Mice; Mice, Inbred C57BL; Time Factors | 1985 |
Plasma fibronectin in acute myeloid leukaemia.
Topics: Adult; Aged; Blood Transfusion; Cytarabine; Daunorubicin; Female; Fibronectins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precipitin Tests; Thioguanine | 1985 |
Treatment of acute myelogenous leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisolone; Prednisone; Risk; Thioguanine; Vincristine | 1985 |
Effects of cytosine arabinoside on DNA synthesis and mitotic activity of HL-60 cells.
Topics: Autoradiography; Cell Count; Cell Line; Cytarabine; Demecolcine; DNA Replication; Humans; Interphase; Leukemia, Myeloid, Acute; Mitosis; Thymidine; Time Factors | 1985 |
[Acute myelomonocytic and monoblastic leukemia with polyradicular symptoms].
Topics: Abducens Nerve; Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebral Hemorrhage; Cerebrospinal Fluid; Cranial Nerve Diseases; Cytarabine; Danazol; Demyelinating Diseases; Facial Paralysis; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Meningism; Methotrexate; Middle Aged; Spinal Nerve Roots; Tamoxifen | 1985 |
[Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
Topics: Adult; Asparaginase; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged | 1985 |
Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
Topics: Aged; Cytarabine; Female; Humans; Injections, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Preleukemia | 1985 |
Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine.
Topics: Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1985 |
Effects of 13-cis retinoic acid and Ara-C on differentiation and proliferation of non-promyelocytic acute myelogenous leukemia.
Topics: Adult; Aged; Alkaline Phosphatase; Cell Differentiation; Cell Division; Cytarabine; Female; Humans; Isotretinoin; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Thymidine; Tretinoin; Tritium | 1985 |
The cytarabine syndrome in adults.
Topics: Adolescent; Adult; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Syndrome | 1985 |
[Chemosensitivity assay in acute leukemia].
Topics: Colony-Forming Units Assay; Cytarabine; Harringtonines; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Tumor Stem Cell Assay | 1985 |
Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias.
Topics: Animals; Autoradiography; Bone Marrow; Cells, Cultured; Cytarabine; DNA Replication; DNA, Neoplasm; Doxorubicin; Flow Cytometry; Humans; Interphase; Leukemia; Leukemia P388; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Mice | 1985 |
Treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating vindesine-prednisolone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Vindesine | 1985 |
[Treatment of malignant hemopathies with aracytine in low doses. Analysis of 159 cases].
Topics: Aged; Aging; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myeloproliferative Disorders; Retrospective Studies | 1985 |
[The response of cells to anti-tumour drugs estimated by limiting dilution in microwell culture].
Topics: Antineoplastic Agents; Cell Line; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Thioguanine; Tumor Stem Cell Assay | 1985 |
Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.
Topics: Adolescent; Adult; Aged; Arabinofuranosylcytosine Triphosphate; Biological Transport, Active; Biotransformation; Child; Child, Preschool; Cytarabine; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Middle Aged; T-Lymphocytes | 1985 |
Cytosine-arabinoside-induced colitis and peritonitis: nonoperative management.
Topics: Abdomen; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colitis; Cryptococcosis; Cytarabine; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Myeloid, Acute; Male; Nausea; Pain; Pancytopenia; Peritonitis; Radiography | 1985 |
Response to hydrocortisone of blast progenitors in acute myeloblastic leukemia: an aspect of lineage infidelity.
Topics: Adolescent; Adult; Aged; Cell Differentiation; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Middle Aged; Phenotype; T-Lymphocytes | 1985 |
[High-dose cytarabine treatment: a promising therapy modality in acute resistant myeloid leukemias in recurrence].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Middle Aged | 1985 |
[High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Middle Aged | 1985 |
[Experiences with HD-Ara C treatment in leukemia patients].
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia; Leukemia, Myeloid, Acute | 1985 |
[High-dose cytosine arabinoside in the treatment of recurrent or acute refractory myeloid leukemias].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[Therapeutic experiences with high-dose ARA-C and L-ASP].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Testicular Neoplasms | 1985 |
[Results of therapy with high-dose cytosine arabinoside].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[High-dose cytarabine treatment with asparaginase (Capizzi schedule) in recurrent or refractory AML in the adult].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[Results of high-dose cytarabine therapy. A review].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma | 1985 |
Remission from central nervous system involvement in adults with acute leukemia. Effect of intensive therapy and prognostic factors.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Humans; Hydrocortisone; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Meningeal Neoplasms; Methotrexate; Prognosis; Radiotherapy Dosage | 1985 |
The combined use of cytosine arabinoside, cyclophosphamide, and total body irradiation as preparative regimen for bone marrow transplantation in patients with AML and CML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Infections; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pulmonary Fibrosis; Whole-Body Irradiation | 1985 |
High-dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with acute leukemia: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Graft vs Host Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Fibrosis; Recurrence; T-Lymphocytes; Thioguanine; Whole-Body Irradiation | 1985 |
[Thrombocyte replacement in hematologic diseases].
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Blood Platelets; Blood Transfusion; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Doxorubicin; Fever; Hematologic Diseases; Hemorrhage; Histocompatibility; HLA Antigens; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Plateletpheresis | 1985 |
Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Bone Marrow; Bone Marrow Diseases; Cell Differentiation; Cells, Cultured; Cytarabine; Diterpenes; DNA; Drug Synergism; Formamides; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Preleukemia; Syndrome; Tretinoin | 1985 |
Effect of antimetabolites and thymidine blockage on the induction of differentiation of HL-60 cells by retinoic acid or 1 alpha,25-dihydroxyvitamin D3.
Topics: Antibiotics, Antineoplastic; Aphidicolin; Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cytarabine; Diterpenes; DNA Replication; Humans; Hydroxyurea; Kinetics; Leukemia, Myeloid, Acute; Tretinoin | 1985 |
[HOAP/HOAGP in the treatment of acute non-lymphocytic leukemia: an analysis of 68 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Thioguanine; Vincristine | 1985 |
Serum vitamin B12-binding capacity and muramidase changes with cyclic neutropenia induced by cytosine arabinoside.
Topics: Adult; Agranulocytosis; Alpha-Globulins; Beta-Globulins; Blood Cell Count; Blood Protein Electrophoresis; Bone Marrow Examination; Cobalt Isotopes; Cytarabine; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Muramidase; Periodicity; Protein Binding; Vitamin B 12 | 1971 |
Cytosine arabinoside and herpes zoster.
Topics: Acute Disease; Adolescent; Adult; Child, Preschool; Cytarabine; Herpes Zoster; Herpesvirus 3, Human; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous; Time Factors | 1971 |
Cytosine arabinoside in the treatment of acute myeloblastic leukaemia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Amino Sugars; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Drug Synergism; Female; Follow-Up Studies; Glycosides; Humans; Injections, Intravenous; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Pregnancy; Remission, Spontaneous; Time Factors | 1971 |
Philadelphia-chromosome-positive preleukaemic state.
Topics: Adult; Blood Cell Count; Bone Marrow Cells; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetics; Daunorubicin; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Prednisone; Thioguanine; Vincristine | 1972 |
Sideroblastic anemia in multiple myeloma: a preleukemic change.
Topics: Anemia, Sideroblastic; Bone Marrow Examination; Cytarabine; Female; Humans; Immunodiffusion; Immunoelectrophoresis; Immunoglobulins; Iron; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Melphalan; Mercaptopurine; Middle Aged; Multiple Myeloma; Muramidase; Precancerous Conditions; Prednisone; Staining and Labeling; Vincristine | 1973 |
Fatal outcome after combined therapy for myeloblastic leukaemia and toxoplasmosis.
Topics: Autopsy; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Humans; Leucovorin; Leukemia, Myeloid, Acute; Pyrimethamine; Toxoplasmosis | 1973 |
Fatal outcome after combined therapy for myeloblastic leukaemia and toxoplasmosis.
Topics: Aged; Antineoplastic Agents; Bone Marrow Diseases; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Pyrimethamine; Sulfamethazine; Toxoplasmosis | 1973 |
Acute leukaemia in myeloma.
Topics: Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Mercaptopurine; Middle Aged; Multiple Myeloma | 1973 |
Editorial: Immunotherapy for acute myeloid leukaemia.
Topics: Antibodies, Neoplasm; Antibody Formation; Antigen-Antibody Complex; Antigens, Neoplasm; BCG Vaccine; Cell Transformation, Neoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunologic Deficiency Syndromes; Immunotherapy; Leukemia, Myeloid, Acute; Remission, Spontaneous; Thioguanine | 1974 |
[Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II].
Topics: Antimetabolites; Azacitidine; Azaguanine; Azauridine; Cell Membrane Permeability; Cytarabine; DNA, Neoplasm; Fluorouracil; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Purines; Pyrimidines | 1974 |
Letter: Adriamycin in acute leukaemia.
Topics: Adolescent; Adult; Child; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Humans; Infusions, Parenteral; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous | 1974 |
Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G.
Topics: Administration, Oral; Adult; Antibody Formation; BCG Vaccine; Bone Marrow; Bone Marrow Cells; Cytarabine; Drug Therapy, Combination; Humans; Hypersensitivity, Delayed; Immunotherapy; In Vitro Techniques; Injections, Intravenous; Leukemia, Myeloid, Acute; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Middle Aged; Prednisone; Remission, Spontaneous; Skin Tests; Time Factors; Vincristine | 1974 |
[1973 treatment of acute leukemias].
Topics: Chlorambucil; Colchicine; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Vinblastine; Vincristine | 1974 |
Adult acute leukaemia.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Remission, Spontaneous; Staining and Labeling; Thioguanine; Vincristine | 1974 |
Allogeneic marrow grafts in man using cyclophosphamide.
Topics: Amidines; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Cytomegalovirus; Graft vs Host Disease; Graft vs Host Reaction; Herpesviridae; Histocompatibility Testing; Humans; Immunologic Deficiency Syndromes; Injections, Spinal; Karyotyping; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Culture Test, Mixed; Methotrexate; Phenyl Ethers; Pneumonia; Prednisone; Transplantation Immunology; Transplantation, Homologous | 1974 |
Varicella and cytosine arabinoside.
Topics: Chickenpox; Child; Child, Preschool; Cytarabine; Female; Herpesvirus 3, Human; Humans; Leukemia, Myeloid, Acute; Male | 1970 |
[Activity of methionine synthetase (5-methyl-5,6,7,8-tetrahydrofolate: homocysteine methyltransferase) as a proliferation parameter in growing cells].
Topics: Cell Division; Cells, Cultured; Cytarabine; DNA Nucleotidyltransferases; Folic Acid; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Methionine; Methyltransferases; Prednisolone; Tetrahydrofolates; Thioguanine; Thymidine Kinase; Vincristine | 1973 |
[Therapy of acute leukosis with cytarabine].
Topics: Cyclophosphamide; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous | 1973 |
Acute myelomonocytic leukemia in a patient with Hodgkin's disease.
Topics: Adult; Bone Marrow Examination; Cobalt Isotopes; Cytarabine; Female; Hodgkin Disease; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Lymph Nodes; Radiation Injuries | 1973 |
Human leukemia antigens: partial isolation and characterization.
Topics: Animals; Antigens, Neoplasm; Cell Line; Cell Membrane; Centrifugation; Chromatography, Gel; Cycloheximide; Cytarabine; Cytotoxicity Tests, Immunologic; Dactinomycin; Haplorhini; Histocompatibility Antigens; Humans; Immune Sera; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; Microscopy, Electron; Neuraminidase; Papain; Potassium Chloride; Pronase; Puromycin; Rabbits; Subcellular Fractions; Temperature; Trypsin | 1974 |
Pseudo-Chediak-Higashi anomaly in acute leukemia. A significant morphologic corollary?
Topics: Adult; Aged; Blood Transfusion; Carbenicillin; Cephalothin; Chediak-Higashi Syndrome; Cyclophosphamide; Cytarabine; Escherichia coli; Female; Gentamicins; Hepatitis B; Humans; Klebsiella; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukoencephalopathy, Progressive Multifocal; Lung Abscess; Male; Prednisone; Pseudomonas aeruginosa; Sepsis; Urinary Tract Infections; Vincristine | 1974 |
The effect of autologous serum on lymphocyte response to human leukemia cells.
Topics: Adolescent; Adult; Asparaginase; Child; Child, Preschool; Cytarabine; Female; Humans; Immune Sera; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocytes; Male; Mercaptopurine; Methotrexate; Middle Aged; Nitrosourea Compounds; Prednisolone; Prognosis; Thioguanine; Vincristine | 1974 |
Acute leukemias and Burkitt's lymphoma. Present status of therapy.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Choriocarcinoma; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Female; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Mercaptopurine; Methotrexate; Prednisone; Pregnancy; Vincristine; Wilms Tumor | 1968 |
Cytocentrifugation in the management of central nervous system leukemia.
Topics: Arachnoiditis; Central Nervous System Diseases; Centrifugation; Cytarabine; Humans; Hydrocortisone; Injections, Spinal; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Neoplasms, Nerve Tissue | 1972 |
Septicaemia due to Pasteurella pneumotropica.
Topics: Ampicillin; Cephaloridine; Chloramphenicol; Culture Media; Cytarabine; Daunorubicin; Erythromycin; Gentamicins; Humans; Kanamycin; Leukemia, Myeloid, Acute; Male; Microbial Sensitivity Tests; Middle Aged; Pasteurella Infections; Polymyxins; Sepsis; Tetracycline | 1973 |
Letter: Androgen role in erythroleukemia after treatment with alkylating agents.
Topics: Adult; Alkylating Agents; Androgens; Carcinoma, Intraductal, Noninfiltrating; Chlorambucil; Cytarabine; Female; Fluoxymesterone; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasm Metastasis; Thiotepa | 1974 |
Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside.
Topics: Adult; Aminohydrolases; Bone Marrow; Bone Marrow Cells; Cytarabine; Deoxycytidine; Deoxyribonucleosides; Drug Resistance; Humans; Kinetics; Leukemia, Myeloid, Acute; Phosphotransferases; Tritium | 1974 |
Trisomy-9 in the bone marrow of a patient with acute myelomonoblastic leukaemia.
Topics: Adult; Autopsy; Bone Marrow Cells; Chromosomes, Human, 6-12 and X; Cytarabine; Dactinomycin; Hemorrhage; Histocytochemistry; Humans; Kidney Neoplasms; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasm Metastasis; Radiotherapy; Trisomy; Wilms Tumor | 1974 |
[A case of spinal chloroma revealing acute leukemia].
Topics: Adult; Asparaginase; Betamethasone; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Spinal Cord Compression; Spinal Neoplasms | 1974 |
[Difficulties of remission induction treatment of acute myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1974 |
Adriamycin in the treatment of acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission, Spontaneous | 1972 |
Enzymatic estimation and metabolism of 1- -D-arabinofuranosylcytosine in man.
Topics: Adenosine Triphosphate; Adult; Chemistry, Clinical; Chromatography, DEAE-Cellulose; Chromatography, Thin Layer; Cytarabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Male; Methods; Phosphorus Isotopes; Phosphotransferases | 1972 |
Combination chemotherapy of adult acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Drug Synergism; Female; Humans; Hydroxyurea; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission, Spontaneous; Thioguanine; Vomiting | 1972 |
[Therapeutic trials in acute myeloblastic leukosis. Analysis of a group of 51 patients treated with daunomycin].
Topics: Cytarabine; Daunorubicin; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisone; Remission, Spontaneous | 1972 |
Characteristics of cell proliferation in acute leukemia.
Topics: Adolescent; Adult; Autoradiography; Bone Marrow Cells; Cell Division; Child; Child, Preschool; Cytarabine; Daunorubicin; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Thymidine; Tritium; Vincristine | 1972 |
Cell kinetics and chemotherapy in acute leukemia.
Topics: Asparaginase; Autoradiography; Bone Marrow; Bone Marrow Cells; Bone Marrow Examination; Cells, Cultured; Cyclophosphamide; Cytarabine; DNA; Drug Combinations; Exchange Transfusion, Whole Blood; Humans; Hydrocortisone; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Methylprednisolone; Mitosis; Prednisone; Thymidine; Tritium; Vincristine | 1972 |
[Treatment of acute myeloid leukaemia in adults with cytarabine and thioguanine].
Topics: Adult; Age Factors; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Thioguanine; Time Factors | 1972 |
The treatment of acute granulocytic leukemia in adults.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors; Vincristine | 1972 |
Acute granulocytic leukemia in adults.
Topics: Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1972 |
[Experience in the therapy of acute leukemia in the period from March, 1959 to February, 1971].
Topics: Adolescent; Adult; Asparaginase; Child; Child, Preschool; Cytarabine; Evaluation Studies as Topic; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Vincristine | 1972 |
[Cytosine arabinoside in the polychemotherapy of acute leukemia].
Topics: Adolescent; Adult; Asparaginase; Child; Child, Preschool; Cytarabine; Drug Synergism; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisone; Recurrence; Thioguanine; Vincristine | 1972 |
[Should acute myeloblastic leukemias be treated in elderly patients?].
Topics: Age Factors; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Combinations; Drug Tolerance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission, Spontaneous | 1972 |
Treatment of acute granulocytic leukemia in adults.
Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Vincristine | 1972 |
[Research on optimal dosage schemes in clinical experimentation with antineoplastic agents].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Combinations; Glycosides; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Naphthacenes; Neoplasms | 1972 |
Serum muramidase levels in acute leukemia.
Topics: Adult; Aged; Blood Cell Count; Bone Marrow Cells; Bone Marrow Examination; Child; Cytarabine; Densitometry; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Muramidase; Remission, Spontaneous; Thioguanine; Vincristine | 1972 |
The effect of remission induction in acute myeloblastic leukemia on efficiency of colony formation in culture.
Topics: Asparaginase; Bone Marrow; Bone Marrow Cells; Bone Marrow Examination; Cells, Cultured; Cyclophosphamide; Cytarabine; Humans; Kinetics; Leukemia, Myeloid, Acute; Remission, Spontaneous; Suspensions; Vincristine | 1972 |
[Effect of daunomycin and adriamycin in cytostatic combination therapy of acute leukoses of the adult].
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Blood Coagulation Disorders; Bone Marrow Diseases; Carbenicillin; Cytarabine; Daunorubicin; Drug Synergism; Female; Glycosides; Hair; Heart Diseases; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission, Spontaneous; Skin Diseases; Vincristine | 1972 |
[Trial treatment of acute myeloblastic leukemia with the cytosine arabinoside-cyclophosphamide association. (Apropos of 30 cases)].
Topics: Adolescent; Adult; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1972 |
DNA synthesis in normal and leucemic cells as related to therapy with cytotoxic drugs.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; DNA; DNA Nucleotidyltransferases; DNA, Neoplasm; Doxorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Methotrexate; Prednisolone; Tetrahydrofolate Dehydrogenase; Thymidine Kinase; Thymine Nucleotides | 1972 |
Pyrexia with cytosine arabinoside.
Topics: Aged; Cytarabine; Fever; Humans; Leukemia, Myeloid, Acute; Male | 1972 |
Chronic myelogenous leukemia presenting in blastic crisis.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, 21-22 and Y; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Vincristine | 1972 |
Intensive chemotherapy of acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Vincristine | 1972 |
Prediction of the response of patients with acute nonlymphocytic leukemia to cytosine arabinoside (NSC-63878) therapy.
Topics: Adult; Aged; Cytarabine; Female; Humans; Kinetics; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes; Male; Middle Aged; Remission, Spontaneous; Thymidine; Tritium | 1972 |
[Treatment of acute myeloblastic leukemia with daunorubicin and cytosine-arabinoside].
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1972 |
The outlook for the adult with acute leukaemia, 1972.
Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Cytarabine; Drug Combinations; Female; Hemorrhage; Humans; Hydroxyurea; Length of Stay; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Isolators; Prednisone; Remission, Spontaneous; Thioguanine | 1972 |
Treatment of acute myeloblastic leukemia in adults: remission induction with a combination of cyclophosphamide, cytarabine and vincristine.
Topics: Adult; Age Factors; Cyclophosphamide; Cytarabine; Evaluation Studies as Topic; Female; Hepatitis; Hepatitis B Antigens; Hospitalization; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Muramidase; Remission, Spontaneous; Vincristine | 1972 |
Acute myelocytic leukemia in adults.
Topics: Adult; Age Factors; Antineoplastic Agents; Cell Transformation, Neoplastic; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prognosis; Remission, Spontaneous; Thioguanine; United States | 1972 |
Leukemia in arsenic poisoning.
Topics: Aged; Anemia, Aplastic; Arsenic; Arsenic Poisoning; Autopsy; Biopsy; Bone Marrow Cells; Cytarabine; Environmental Exposure; Humans; Klebsiella Infections; Leukemia, Myeloid, Acute; Male; Oxymetholone; Penicillamine; Pesticides; Poisoning; Prednisone; Recurrence; Sepsis; Thioguanine | 1972 |
Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination.
Topics: Adult; Aged; Aspergillosis; Bacterial Infections; Candidiasis; Cytarabine; Daunorubicin; Female; Humans; Infant; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1972 |
[Therapy of acute leukemia. Opinion of Prof. Franco Mandelli].
Topics: Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Synergism; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Prognosis; Remission, Spontaneous; Thioguanine; Vincristine | 1973 |
Acute myeloblastic leukemia during pregnancy.
Topics: Acute Disease; Cytarabine; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Thioguanine | 1972 |
Remission of leukemia associated with polycythemia vera.
Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Phosphorus Isotopes; Polycythemia Vera; Remission, Spontaneous; Thioguanine; Vincristine | 1973 |
Hemorrhagic cystitis and vesicoureteral reflux secondary to cytotoxic therapy for childhood malignancies.
Topics: Child, Preschool; Cyclophosphamide; Cystitis; Cytarabine; Eye Neoplasms; Female; Ganglioneuroma; Hematuria; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasms; Radiography; Retinoblastoma; Stomach Neoplasms; Urinary Bladder; Vesico-Ureteral Reflux | 1973 |
Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemia.
Topics: Adult; Aged; Anemia, Aplastic; Cerebral Hemorrhage; Child; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1973 |
Necrotizing enterocolitis in leukemia.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Cecum; Colon; Cytarabine; Enterocolitis, Pseudomembranous; Female; Humans; Ileum; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Necrosis; Prednisone; Radiography | 1973 |
Acute leukemia presenting as a breast mass.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Biopsy, Needle; Breast Neoplasms; Child; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Menarche; Mercaptopurine; Methotrexate; Prednisolone; Sulfates; Vincristine | 1973 |
Optimism in leukemia treatment.
Topics: Acute Disease; Adult; Child; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisolone; Thioguanine; Vincristine | 1973 |
[Cytosine arabinoside therapy of varicella, complicated in children with acute leukemia].
Topics: Chickenpox; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male | 1973 |
[Otitis and leukemia].
Topics: Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Ear Neoplasms; Gentamicins; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Otitis; Otitis Externa; Punctures | 1973 |
[Combined treatment of myeloid leukemia with cytosine arabinoside and 6-mercaptopurine].
Topics: Cytarabine; Drug Synergism; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine | 1973 |
Refractory leukemia treated with cytosine arabinoside and cyclophosphamide.
Topics: Adolescent; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Prednisone; Remission, Spontaneous; Vincristine | 1973 |
Treatment of acute myeloid leukaemia according to the Hammersmith protocol: preliminary report.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; London; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine | 1973 |
Effects of chemotherapeutic agents on cell cycle and cellular proliferation: basic and clinical considerations.
Topics: Autoradiography; Bone Marrow Cells; Cell Division; Cyclophosphamide; Cytarabine; DNA; Drug Antagonism; Drug Combinations; Hodgkin Disease; Humans; Hydrocortisone; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Mitosis; Thymidine; Tritium; Vincristine | 1973 |
Our experience with cytosine arabinoside in the treatment of acute haemoblastoses.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Evaluation Studies as Topic; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Time Factors; Vincristine | 1973 |
[Treatment of acute myeloblastic leukemia].
Topics: Antineoplastic Agents; Asparaginase; Blood Platelets; Blood Transfusion; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous | 1973 |
[The effects of cytosine arabinoside and daunomycin on cell kinetics in childhood acute myeloblastic leukemia].
Topics: Bone Marrow; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Humans; In Vitro Techniques; Kinetics; Leukemia, Myeloid, Acute; Leukocytes; Mitosis | 1973 |
[Acute myelogenous leukaemia of adults: diagnosis, prognosis and treatment (author's transl)].
Topics: Adult; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Evaluation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Muramidase; Prognosis; Remission, Spontaneous; Thymidine; Tritium | 1973 |
Letter: Leukemic infiltration of the testes in acute myelocytic leukemia during bone marrow remission.
Topics: Bone Marrow; Child, Preschool; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Metastasis; Remission, Spontaneous; Testicular Neoplasms | 1973 |
Serial in vitro marrow culture in acute myelocytic leukemia.
Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Examination; Cell Count; Cell Division; Child; Clone Cells; Culture Techniques; Cytarabine; Daunorubicin; Drug Therapy, Combination; Embryo, Mammalian; Female; Humans; Kidney; Leukemia, Myeloid, Acute; Leukocytes; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1973 |
Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse.
Topics: Aminohydrolases; Animals; Bone Marrow; Bone Marrow Cells; Cytarabine; Deoxycytidine; Humans; Kidney; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Liver; Mice; Phosphotransferases; Spleen; Uridine | 1973 |
Acute granulocytic leukemia in elderly patients.
Topics: Adult; Age Factors; Aged; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous; Retrospective Studies; Time Factors | 1973 |
Treatment of acute myeloid leukemia of adults with cytosine arabinoside in combination with 6-mercaptopurine.
Topics: Administration, Oral; Adult; Aged; Child; Cytarabine; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Remission, Spontaneous | 1973 |
[A new approach to chemotherapeutic combinations in the treatment of solid tumors: trail synchronization, recruitement].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Methotrexate; Mitosis; Neoplasms; Vincristine | 1973 |
Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Bone Marrow Examination; Cytarabine; Daunorubicin; Female; Humans; Immunization; Immunotherapy; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Radiation Effects; Recurrence; Remission, Spontaneous; Time Factors | 1973 |
[Therapy of acute leukemias].
Topics: Adrenal Cortex Hormones; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Thioguanine; Vincristine | 1973 |
Acute leukemia in adults.
Topics: Adult; Agranulocytosis; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Thrombocytopenia; Time Factors | 1973 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluorouracil; Hodgkin Disease; Humans; Leukemia; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Mechlorethamine; Melphalan; Mice; Mice, Inbred AKR; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Vinblastine; Vincristine | 1974 |
Perturbation of cell cycle of human leukaemic myeloblasts in vivo by cytosine arabinoside.
Topics: Adult; Aged; Autoradiography; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Survival; Cytarabine; Depression, Chemical; DNA; Erythrocytes; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Mitosis; Spectrophotometry; Thymidine; Time Factors; Tritium | 1973 |
Adult acute leukaemia--a suitable case for treatment?
Topics: Acute Disease; Adult; Aged; Agranulocytosis; Anemia; Blood Platelet Disorders; Blood Transfusion; Bone Marrow Diseases; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mouth Diseases; Ulcer | 1973 |
The therapy of acute granulocytic leukemia in patients more than fifty years old.
Topics: Age Factors; Aged; Antineoplastic Agents; Connecticut; Cytarabine; Drug Combinations; Hospitals, Community; Hospitals, Special; Hospitals, Teaching; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms; New York City; Prognosis; Remission, Spontaneous; Thioguanine | 1974 |
[Therapy of acute leukemia. Results of the Swiss study group for clinical cancer research (SAKK)].
Topics: Age Factors; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Mercaptopurine; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1974 |
[Morphology of megakaryocytes in hematologic diseases].
Topics: Anemia, Pernicious; Blood Cell Count; Bone Marrow Cells; Cytarabine; Cytoplasm; Follow-Up Studies; Hematologic Diseases; Humans; In Vitro Techniques; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Megakaryocytes; Mercaptopurine; Plasmacytoma; Polycythemia; Thioguanine; Thrombocytopenia | 1974 |
Hyponatraemia syndrome in acute myeloid leukaemia.
Topics: Adult; Ampicillin; Blood Cell Count; Body Weight; Bone Marrow Cells; Chlorides; Cloxacillin; Cytarabine; Daunorubicin; Diet; Female; Fever; Food Analysis; Gentamicins; Humans; Hyponatremia; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrogen; Osmolar Concentration; Potassium; Sodium; Syndrome; Urea | 1974 |
Proceedings: Splenectomy and chemotherapy in acute myelocytic leukemia of childhood.
Topics: Adolescent; Adult; Age Factors; Azauridine; Child; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Hepatomegaly; Humans; Leukemia, Myeloid, Acute; Liver; Lymph Nodes; Male; Mercaptopurine; Remission, Spontaneous; Spleen; Splenectomy; Splenomegaly; Vincristine | 1974 |
Treatment of acute myeloblastic leukemia.
Topics: Administration, Oral; Adult; Bone Marrow Examination; Cytarabine; DNA; Drug Therapy, Combination; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Mitosis; Remission, Spontaneous; Thioguanine | 1973 |
Pharmacologic and cytokinetic studies of arabinosyl cytosine.
Topics: Adolescent; Adult; Animals; Antibody Formation; Cell Migration Inhibition; Child; Child, Preschool; Cyclophosphamide; Cytarabine; DNA; DNA Nucleotidyltransferases; Drug Therapy, Combination; Humans; Leukemia, Experimental; Leukemia, Myeloid, Acute; Lymphocyte Activation; Macrophages; Mice; Mitosis; Multiple Myeloma; Prednisone; Vincristine | 1973 |
Combined chemotherapy of acute myeloblastic leukemia.
Topics: Adult; Age Factors; Asparaginase; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous; Vincristine | 1973 |
Eventual control of clinical leukemia.
Topics: Administration, Oral; Africa; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Injections, Spinal; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; United States; Vincristine | 1973 |
Clinical classification and evaluation of treatment response in acute myeloid leukaemia on the basis of differences of leukaemic cell differentiation.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Division; Cell Survival; Cytarabine; Daunorubicin; Depression, Chemical; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Activation; Male; Middle Aged; Prognosis; Stimulation, Chemical; Thioguanine; Vincristine | 1973 |
Trisomy 8 in acute myeloblastic leukemia and sideroachrestic anemia.
Topics: Aged; Anemia, Myelophthisic; Anemia, Sideroblastic; Bone Marrow Examination; Cells, Cultured; Chromosomes, Human, 6-12 and X; Cytarabine; Daunorubicin; Female; Folic Acid; Humans; Karyotyping; Lectins; Leukemia, Myeloid, Acute; Leukocytes; Middle Aged; Prednisolone; Pyridoxal Phosphate; Pyridoxine; Thioguanine; Trisomy | 1974 |
The treatment of acute myeliod leukaemia.
Topics: Adolescent; Adult; Blood Cell Count; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous | 1974 |
[Treatment of leukemia in children].
Topics: Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Time Factors | 1974 |
[Kinetic effect of cytostatic drugs on the generation cycle of human leukaemic blast cells in vivo. A review].
Topics: Antineoplastic Agents; Asparaginase; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; DNA Nucleotidyltransferases; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Methotrexate; Mitosis; Prednisone; Thymidine; Time Factors; Vincristine | 1974 |
Treating acute leukaemia in special centres.
Topics: Antineoplastic Agents; Cytarabine; Hospitals, Special; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisolone; Prognosis | 1973 |
[Treatment of acute myeloblastic leukemia. 79 cases treated by cytosine-rubidomycin combination].
Topics: Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission, Spontaneous; Statistics as Topic; Time Factors | 1974 |
[Results of cytarabine and 6-thioguanine combination chemotherapy in acute leukemia].
Topics: Adult; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1973 |
[Electron microscopic bone marrow changes in acute leukemias before and after cytosin-arabinoside therapy].
Topics: Bone Marrow; Cytarabine; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron | 1973 |
Development of pulmonary aspergillomas coinciding with induction of remission in acute myeloid leukaemia.
Topics: Aged; Aspergillosis; Autopsy; Cytarabine; Daunorubicin; Diagnosis, Differential; Humans; Leukemia, Myeloid, Acute; Lung; Male; Radionuclide Imaging; Remission, Spontaneous; Strontium Radioisotopes | 1974 |
Accumulation of S-phase cells in the bone marrow of patients with acute leukemia by cytosine arabinoside.
Topics: Bone Marrow; Bone Marrow Examination; Cell Division; Cytarabine; DNA; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Photometry; Ribonucleases; RNA | 1974 |
[Acute lymphatic leukemia in adults. Therapy and prognosis in comparison with acute myelogenous leukemia].
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Asparaginase; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Middle Aged; Paresis; Prognosis; Radiotherapy Dosage; Remission, Spontaneous; Vincristine | 1974 |
[Antimetabolites in the therapy of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. I].
Topics: Aminopterin; Antimetabolites; Azaguanine; Cytarabine; DNA, Neoplasm; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Purines; Quinazolines; RNA, Neoplasm | 1974 |
Agar culture studies in 127 cases of untreated acute leukemia: the prognostic value of reclassification of leukemia according to in vitro growth characteristics.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Child; Clone Cells; Cytarabine; Daunorubicin; Densitometry; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission, Spontaneous; Vincristine | 1974 |
Letter: Leukemia in the elderly.
Topics: Age Factors; Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Thioguanine | 1974 |
Chromosomes and causation of human cancer and leukemia. IX. Prognostic and therapeutic value of chromosomal findings in acute myeloblastic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis; Nitrosourea Compounds; Prednisone; Prognosis; Thioguanine; Time Factors; Vincristine | 1974 |
A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine.
Topics: Adult; Cell Division; Cell Survival; Chromosomes; Cytarabine; DNA Replication; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Male; Models, Biological; Oncogenic Viruses; RNA Viruses | 1974 |
[Treatment of acute myeloblastic leukemia in patients over 60. Apropos of 22 cases].
Topics: Cytarabine; Daunorubicin; Drug Synergism; Glyoxal; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Remission, Spontaneous | 1974 |
Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia.
Topics: Adolescent; Adult; Aged; Antibody Formation; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypersensitivity, Delayed; Immunotherapy; In Vitro Techniques; Lectins; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphocyte Activation; Lymphocytes; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous; Skin Tests; Streptolysins; Vincristine | 1974 |
[Cytosine-arabinoside in the treatment of acute leukemias].
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polycythemia | 1972 |
Alterations of granulopoiesis following chemotherapy.
Topics: Adult; Aged; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Cell Division; Clone Cells; Cytarabine; DNA; Doxorubicin; Female; Glycoproteins; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Mitosis; Muramidase; Thioguanine; Thymidine; Tritium | 1974 |
Induction of remission with l-Asparaginase, cyclophosphamide, cytosine arabinoside, and prednisolone in adult patients with acute leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Blood Cell Count; Child; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Liver Function Tests; Male; Middle Aged; Remission, Spontaneous; Sex Factors | 1974 |
Primary amyloidosis and acute leukemia associated with melphalan therapy.
Topics: Amyloidosis; Blood Cell Count; Blood Platelets; Blood Transfusion; Bone Marrow Examination; Cephalothin; Cytarabine; Erythrocytes; Gentamicins; Hemoglobins; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Proteinuria; Thioguanine | 1974 |
Prognosis of acute leukaemia in adults.
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Prognosis; Remission, Spontaneous; Thioguanine; Vincristine | 1974 |
Studies of leukemic cell populations in culture.
Topics: Autoradiography; Bone Marrow Cells; Cell Adhesion; Cell Division; Cell Separation; Cells, Cultured; Culture Media; Cytarabine; Daunorubicin; Freezing; Humans; Lectins; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Mercaptopurine; Middle Aged; Prednisone; Radiation Effects; Thymidine; Tritium; Ultrafiltration | 1974 |
[Treatment of acute myeloblastic leukemia. Evaluation of six years of cooperative studies in Argentina (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Infant; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisone; Remission, Spontaneous; Vincristine | 1974 |
Hypouricaemia and proximal renal tubular dysfunction in acute myeloid leukaemia.
Topics: Amino Acids; Calcium; Creatinine; Cytarabine; Daunorubicin; Female; Humans; Hydrogen-Ion Concentration; Kidney Diseases; Kidney Tubules, Proximal; Leukemia, Myeloid, Acute; Middle Aged; Muramidase; Phosphates; Phosphorus; Pyrazinamide; Uric Acid | 1974 |
Pulmonary sequestration with spontaneous intrapleural hemorrhage.
Topics: Adult; Bronchopulmonary Sequestration; Cytarabine; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Lung Diseases; Male; Pneumonectomy; Thioguanine | 1974 |
[Cytokinetic effect of cytosine arabinoside in clinical tests].
Topics: Adult; Animals; Bone Marrow Cells; Cell Division; Cytarabine; DNA; Female; Humans; Infusions, Parenteral; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Care Planning; Rats; Time Factors | 1974 |
[Our experience in the treatment of acute myeloblastic leukemia].
Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Thioguanine; Vincristine | 1974 |
Comparative results obtained in the treatment of acute leukemia.
Topics: Antineoplastic Agents; Asparaginase; Carmustine; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Meningitis; Methotrexate; Prednisone; Thioguanine; Vincristine | 1973 |
Comparative results obtained in the treatment of acute lymphoid leukemia, acute myleoid leukemia, and acute monocytoid leukemia.
Topics: Adult; Antineoplastic Agents; Asparaginase; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1973 |
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine.
Topics: Age Factors; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1973 |
Chemotherapy of acute myelocytic leukemia in adults.
Topics: Adolescent; Adult; Aged; Anhydrides; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1974 |
Cytosine arabinoside as a single agent in the therapy of adult acute leukemia.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Anemia; Child; Cytarabine; DNA, Neoplasm; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Muramidase; Nausea; Remission, Spontaneous; Sex Factors; Thioguanine; Thrombocytopenia; Time Factors; Vomiting | 1974 |
[Treatment of complications induced by chemotherapy of acute leukemias].
Topics: Agranulocytosis; Anemia, Aplastic; Anti-Bacterial Agents; Antineoplastic Agents; Asparaginase; Blood Platelets; Blood Transfusion; Cytarabine; Daunorubicin; Drug Therapy, Combination; Hemorrhage; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Mercaptopurine; Methotrexate; Prednisone; Thrombocytopenia; Vincristine | 1974 |
[Treatment of acute myelogenous leukemia in adults].
Topics: Adult; Cyclophosphamide; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone | 1972 |
[Combination chemotherapy for acute myelogenous leukemia in adults (author's transl)].
Topics: Adolescent; Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous; Thioinosine | 1974 |
[Clinical evaluation of new antileukemic agent. 1) Cyclocytidine (author's transl)].
Topics: Adult; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous | 1974 |
Development of a combination chemotherapy program for adult acute leukemia: CAM and CAM-L.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Evaluation Studies as Topic; Female; Humans; Leucovorin; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Time Factors | 1973 |
Correlation of cytosine arabinoside-induced increment in growth fraction of leukemic blast cells with clinical response.
Topics: Adult; Aged; Bone Marrow; Bone Marrow Cells; Cell Division; Cytarabine; DNA, Neoplasm; Drug Therapy, Combination; Female; Humans; Leucovorin; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Mitosis; Thymidine; Time Factors; Tritium | 1974 |
Treatment of the acute leukemias.
Topics: Adjuvants, Immunologic; Asparaginase; Bacterial Vaccines; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Mycobacterium bovis; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1972 |
[Treatment of acute myeloid leukemia in adults with a combination of daunomycin and cytosine-arabinoside].
Topics: Adult; Aged; Bone Marrow Cells; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1972 |
Immunotherapy of acute myelogenous leukemia in man.
Topics: Antigens, Neoplasm; BCG Vaccine; Cross Reactions; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Humans; Immunity, Cellular; Immunization; Leukemia, Myeloid, Acute; Mycobacterium bovis; Remission, Spontaneous | 1973 |
Marrow grafting and immunotherapy in identical twins with hematologic malignancies.
Topics: Adolescent; Adult; Antigens, Neoplasm; Bone Marrow Cells; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Diseases in Twins; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Transplantation, Homologous | 1973 |
Active specific immunotherapy for acute myelogenous leukaemia.
Topics: Adjuvants, Immunologic; Antigens, Bacterial; Antigens, Neoplasm; BCG Vaccine; Cytarabine; Daunorubicin; Freezing; Humans; Immunization; Immunotherapy; Leukemia, Myeloid, Acute; Leukocytes; Mycobacterium bovis; Neoplasm Transplantation; Radiation Effects; Remission, Spontaneous; Thioguanine; Time Factors; Transplantation, Homologous | 1974 |
Acute myelogenous leukemia in two patients treated with azathioprine for nonmalignant diseases.
Topics: Adult; Azathioprine; Blood Cell Count; Blood Platelets; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Graft Rejection; Hepatitis; Humans; Immunosuppression Therapy; Kidney Transplantation; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prednisone; Thioguanine; Transplantation, Homologous | 1974 |
Biochemical techniques for classification of leukemic cell types.
Topics: Cytarabine; Cytological Techniques; DNA, Neoplasm; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Phosphorus | 1973 |
[Cytosine arabinoside alone and in association to other drugs in the therapy of acute myeloblastic leukemia].
Topics: Cyclophosphamide; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid, Acute; Vincristine | 1972 |
[Cytosine arabinoside in the treatment of acute childhood leukemia: clinical contribution].
Topics: Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Prednisone; Vincristine | 1972 |
[Kinetics of human leukemic myeloblasts after use of cytosine-arabinoside].
Topics: Adolescent; Adult; Child; Child, Preschool; Cytarabine; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Thymidine; Tritium | 1973 |
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Bone Marrow Examination; Cell Nucleus; Cytarabine; Drug Tolerance; Erythrocytes; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone | 1968 |
Fatal infection with Aeromonas hydrophila in a patient with acute myelogenous leukemia.
Topics: Adolescent; Aeromonas; Cyclophosphamide; Cytarabine; Female; Humans; Immunosuppressive Agents; Joint Diseases; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Sepsis; Vincristine | 1967 |
Prediction of in vivo cytotoxicity of chemotherapeutic agents by their effect on malignant leukocytes in vitro.
Topics: Blood Cell Count; Cytarabine; DNA; Humans; In Vitro Techniques; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Mercaptopurine; Multiple Myeloma; Prednisone; RNA; Tritium; Uridine; Vincristine | 1967 |
[Chemotherapy of acute leukemia].
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Thrombocythemia, Essential; Vincristine | 1967 |
Treatment of the acute leukemias.
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Nitroso Compounds; Prednisone; Urea; Vincristine | 1967 |
Therapy for acute granulocytic leukemia.
Topics: Cytarabine; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Mercaptopurine | 1967 |
Summary: recent advances in the treatment of acute leukemia and Burkitt's tumor.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Nitroso Compounds; Prednisone; Urea; Vincristine | 1967 |
Treatment of acute leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Burkitt Lymphoma; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Thioguanine; Time Factors; Vincristine | 1968 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Pipobroman; Prednisolone; Vincristine | 1968 |
Treatment of AGL.
Topics: Adult; Afibrinogenemia; Aged; Anemia; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Humans; Hydroxyzine; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukopenia; Mercaptopurine; Methotrexate; Middle Aged; Polycythemia Vera; Prednisone; Primary Myelofibrosis; Splenomegaly; Vincristine | 1969 |
Treatment of AGL.
Topics: Aminopterin; Cortisone; Cytarabine; Daunorubicin; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Infections; Leukemia, Myeloid, Acute; Patient Isolators; Steroids; Transfusion Reaction | 1969 |
Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro.
Topics: Blood Platelets; Cell Membrane Permeability; Cytarabine; Cytosine Nucleotides; Erythrocytes; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Oxidative Phosphorylation; Temperature; Tritium | 1969 |
Coordinated changes in biochemical patterns: the effect of cytosine arabinoside and methotrexate on leukocytes from patients with acute granulocytic leukemia.
Topics: Acute Disease; Cytarabine; Deoxyuridine; DNA; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Ligases; Methotrexate; Phosphotransferases; Tetrahydrofolate Dehydrogenase; Thymidine; Thymidine Kinase | 1969 |
Treatment of adult acute leukemia with arabinosylcytosine and thioguanine.
Topics: Adolescent; Adult; Aged; Cytarabine; Dosage Forms; Female; Humans; Injections, Intravenous; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1969 |
Drug effect in acute leukemia.
Topics: Adolescent; Bone Marrow; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; DNA, Neoplasm; Humans; Hydrocortisone; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mitosis; Prednisone; Thymidine; Tritium; Vincristine | 1969 |
[Experiences with daunomycin and cytosine arabinoside in the therapy of acute myeloid leukemias].
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1968 |
Hypersplenism due to disseminated candidiasis in a patient with acute leukemia.
Topics: Acute Disease; Adult; Amphotericin B; Blood Cell Count; Blood Platelets; Candida; Candidiasis; Cytarabine; Feces; Fever; Humans; Hypersplenism; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Nose; Pharynx; Prednisone; Skin; Spleen | 1969 |
Comparative sensitivity to various antimetabolites of several established cell lines derived from the buffy coat of normal humans and patients with neoplastic diseases.
Topics: Antimetabolites; Blood Cells; Cell Line; Culture Techniques; Cytarabine; Fluorouracil; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Mitosis; Neoplasms | 1969 |
Studies on the effects of hydroxyurea and other anticancer drugs upon pyrimidine metabolism.
Topics: Amidohydrolases; Animals; Antineoplastic Agents; Ascites; Carbon Isotopes; Cyclophosphamide; Cytarabine; Deoxyuridine; DNA; Fluorouracil; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukocytes; Methotrexate; Mice; Neoplasms, Experimental; Orotic Acid; Pyrimidines; Transferases; Triazines | 1969 |
Review of recent studies of cellular proliferation in acute leukemia.
Topics: Adolescent; Adult; Autoradiography; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Nucleus; Cytarabine; DNA, Neoplasm; Female; Humans; Karyometry; Leukemia, Myeloid, Acute; Male; Mitosis; Thymidine; Tritium | 1969 |
[Abnormalities of the erythropoiesis at the beginning of remission in acute promyelocytic leukemia treated with arabinoside-cytosine].
Topics: Anemia, Aplastic; Bone Marrow Examination; Cell Nucleus; Child; Cytarabine; Erythrocytes; Erythropoiesis; Humans; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Methotrexate; Mitosis; Reticulocytes; Thioguanine | 1970 |
Intrathecal arabinosyl cytosine in meningeal leukemia.
Topics: Adolescent; Brain Neoplasms; Cerebrospinal Fluid; Child; Child, Preschool; Cytarabine; Female; Humans; Injections, Spinal; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Meninges; Time Factors | 1970 |
Experience with the use of cytosine arabinoside in adult acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Cyclophosphamide; Cytarabine; Female; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1970 |
Preliminary evaluation of cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in acute leukemia of children.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male | 1969 |
The treatment of acute lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; Asparaginase; Blood Platelets; Bone Marrow Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Synergism; Hemorrhage; Humans; Infections; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Mice; Prednisone; Prognosis; Thrombocytopenia; Vincristine | 1970 |
[Effect of cytosine-arabinoside in hemoblastoses].
Topics: Bone Marrow Diseases; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Monocytes; Polycythemia | 1970 |
[Treatment of acute myeloid leukemia by the combination therapy of 6-mercaptopurine and cytosine arabinoside--evaluation of twenty-two cases].
Topics: Adolescent; Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged | 1970 |
Treatment of acute myeloblastic leukaemia.
Topics: Acute Disease; Adult; Child; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 1970 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Prednisone; Vincristine | 1970 |
[Therapy of acute myeloblastic leukemia. Thoughts after preliminary results].
Topics: Acute Disease; Adult; Cyclophosphamide; Cytarabine; Female; Humans; Intensive Care Units; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Vincristine | 1970 |
[Cytosine-arabinoside in the treatment of acute myeloblastic leukemias].
Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male | 1971 |
[Therapeutic evolution of 63 cases of recent acute myeloblastic leukemias].
Topics: Acute Disease; Aged; Antineoplastic Agents; Asparaginase; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1971 |
[Treatment of acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antilymphocyte Serum; Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Synergism; Female; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Prednisone; Vincristine | 1970 |
Normal fetus after cytosine arabinoside therapy.
Topics: Adult; Birth Weight; Cytarabine; Female; Fetus; Gestational Age; Humans; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Thioguanine; Vincristine | 1971 |
L-asparaginase: clinical, biochemical, pharmacological, and immunological studies.
Topics: Adolescent; Adult; Antibody Formation; Antineoplastic Agents; Asparaginase; Asparagine; Bone Marrow Examination; Child; Child, Preschool; Cytarabine; Drug Hypersensitivity; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Remission, Spontaneous | 1971 |
[Cytosine arabinoside in the therapy of acute leukoses].
Topics: Adolescent; Adult; Child; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone | 1971 |
Cytarabine.
Topics: Acute Disease; Amino Sugars; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Cyclophosphamide; Cytarabine; Glycosides; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukopenia; Lymphoma; Prednisone; Remission, Spontaneous; Thioguanine; Thrombocytopenia; Vincristine | 1971 |
Cytogenetic studies and their clinical correlates in adults with acute leukemia.
Topics: Adolescent; Adult; Age Factors; Aneuploidy; Bone Marrow Cells; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, 13-15; Chromosomes, Human, 16-18; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, 6-12 and X; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Recurrence; Remission, Spontaneous; Vincristine | 1971 |
Treatment of acute myelogenous leukaemia in adults.
Topics: Adult; BCG Vaccine; Cell Division; Cytarabine; Daunorubicin; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Neoplasm Transplantation; Transplantation, Autologous; Transplantation, Homologous | 1971 |
Serologic diagnosis of systemic candidiasis in patients with acute leukemia.
Topics: Adult; Agglutination Tests; Amphotericin B; Anti-Bacterial Agents; Candida; Candidiasis; Child; Cyclophosphamide; Cytarabine; Evaluation Studies as Topic; False Negative Reactions; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Nitrosourea Compounds; Precipitin Tests; Prednisone; Serologic Tests; Vinblastine; Vincristine | 1971 |
Experiences with cytosine arabinoside in childhood leukaemia and lymphoma.
Topics: Acute Disease; Adolescent; Central Nervous System Diseases; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Injections, Intravenous; Injections, Spinal; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Neoplasm Regression, Spontaneous | 1971 |
The disappearance of ring sideroblasts in myeloblastic leukaemia in remission.
Topics: Adult; Asparaginase; Blood Transfusion; Bone Marrow; Cytarabine; Daunorubicin; Erythrocytes; Erythrocytes, Abnormal; Female; Humans; Iron; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisone; Remission, Spontaneous | 1971 |
Case report: tetraploid leukemia.
Topics: Aged; Antifungal Agents; Bone Marrow Examination; Candida; Cyclophosphamide; Cytarabine; Gentamicins; Hematopoietic Stem Cells; Humans; Karyotyping; Klebsiella; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Polyploidy; Prednisone; Urine; Vincristine | 1971 |
Cytidine deaminase and the development of resistance to arabinosyl cytosine.
Topics: Adult; Aminohydrolases; Bone Marrow; Bone Marrow Cells; Carbon Isotopes; Cyclophosphamide; Cytarabine; Cytidine; Drug Resistance; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Spectrum Analysis; Time Factors | 1971 |
Observations on the plasma amino acids of patients with acute leukemia.
Topics: Acute Disease; Alanine; Amino Acids; Asparaginase; Cytarabine; Glucocorticoids; Glutamine; Histidine; Humans; Indicators and Reagents; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Methionine; Methotrexate; Nitrogen; Proline; Threonine; Vincristine | 1971 |
[Treatment of acute leukemias in the infancy with cytosine arabinoside].
Topics: Acute Disease; Child, Preschool; Cytarabine; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous | 1971 |
Cytosine arabinoside in acute leukemia of childhood.
Topics: Child; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Remission, Spontaneous; Thrombocytopenia; Vomiting | 1971 |
Therapy of acute leukemia with drug combinations which include asparaginase.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Azaserine; Child; Child, Preschool; Cytarabine; Female; Glutamine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Remission, Spontaneous; Vincristine | 1971 |
Attempted recruitment of leukemic myeloblasts to proliferative activity by sequential drug treatment.
Topics: Adult; Autoradiography; Bone Marrow; Bone Marrow Cells; Culture Techniques; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mitosis; Models, Biological; Remission, Spontaneous; Thymidine; Tritium; Vincristine | 1971 |
Remission of leukemia associated with multiple myeloma.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Remission, Spontaneous | 1971 |
Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia.
Topics: Adult; Aged; Antibodies; Antigens; Cyclophosphamide; Cytarabine; Female; Hemocyanins; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Immunologic Deficiency Syndromes; Immunosuppression Therapy; Lectins; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Activation; Lymphocytes; Male; Mercaptopurine; Methotrexate; Prednisone; Prognosis; Remission, Spontaneous; Skin Tests; Thioguanine; Vincristine | 1971 |
Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia.
Topics: Animals; Culture Techniques; Cytarabine; DNA; Half-Life; Humans; Injections, Intravenous; L Cells; Leukemia, Myeloid, Acute; Male; Methods; Mice; Spleen; Thymidine; Tritium | 1971 |
Synchronization and recruitment in acute leukemia.
Topics: Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Bone Marrow Cells; Child; Culture Techniques; Cyclophosphamide; Cytarabine; Deoxyuridine; Depression, Chemical; DNA, Neoplasm; Exchange Transfusion, Whole Blood; Humans; Hydrocortisone; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Methotrexate; Mitosis; Thymidine; Tritium; Vincristine | 1971 |
Fetal group C trisomy after cytosine arabinoside and thioguanine.
Topics: Abnormalities, Drug-Induced; Abortion, Therapeutic; Adult; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, 6-12 and X; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Mosaicism; Pregnancy; Pregnancy Complications, Hematologic; Thioguanine; Trisomy | 1971 |
Leukaemia on myeloma.
Topics: Adult; Bronchopneumonia; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Multiple Myeloma; Plasmacytoma; Thioguanine | 1971 |
[Therapy of acute leukemia. 4. Remission induction and remission maintenance therapy].
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Vincristine | 1971 |
[Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Allopurinol; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Blood Transfusion; Cytarabine; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Muramidase; Nausea; Prednisolone; Thrombocytopenia; Vincristine | 1971 |
Advances in the chemotherapy of malignant disease.
Topics: Antibiotics, Antineoplastic; Asparaginase; Cytarabine; Drug Combinations; Hodgkin Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Medication Systems, Hospital; Neoplasms | 1971 |
Cytosine arabinoside therapy for acute myeloid leukaemia in adults.
Topics: Abdomen; Adolescent; Adult; Aged; Alopecia; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Cytarabine; Diarrhea; Erythrocytes; Female; Fever; Humans; Infusions, Parenteral; Injections, Intravenous; Kidney Diseases; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ulcer; Vomiting | 1971 |
Selecting drug regimens in human leukemia.
Topics: Antineoplastic Agents; Cell Membrane Permeability; Child; Cyclophosphamide; Cytarabine; Drug Combinations; Drug Resistance; Follow-Up Studies; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Nucleotides; Prednisone; Prognosis; Vincristine | 1971 |
DNA synthesis in leukemic cells under the action of cytotoxic agents in vitro and in vivo.
Topics: Adult; Aged; Antineoplastic Agents; Cells, Cultured; Cytarabine; Daunorubicin; DNA, Neoplasm; Female; Glucocorticoids; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Male; Methotrexate; Middle Aged; Prognosis; Thymine Nucleotides; Tritium | 1971 |
[Treatment of acute leukosis in children with arabinosyl cytosine].
Topics: Adolescent; Anti-Bacterial Agents; Asparaginase; Blood Platelets; Blood Transfusion; Bone Marrow Diseases; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Remission, Spontaneous | 1971 |
Advances in the chemotherapy of acute leukemia.
Topics: Adult; Animals; Blood Platelets; Blood Transfusion; Carbenicillin; Child; Cyclophosphamide; Cytarabine; Folic Acid Antagonists; Glucocorticoids; Humans; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Nitrogen Mustard Compounds; Patient Isolators; Purines; Remission, Spontaneous | 1970 |
Treatment of adult leukemia with L-asparaginase (NSC-109229).
Topics: Adolescent; Adult; Aged; Allopurinol; Anaphylaxis; Asparaginase; Blood Coagulation Disorders; Cytarabine; Daunorubicin; Drug Hypersensitivity; Female; Fever; Gastrointestinal Hemorrhage; Hallucinations; Humans; Hyperglycemia; Injections, Intravenous; Jaundice; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Liver; Male; Mercaptopurine; Methotrexate; Middle Aged; Oral Hemorrhage; Prednisone; Thioguanine; Uremia; Vincristine; Vomiting | 1971 |